RowID,Outcome,Comparator,Intervention,Answer,Reasoning,xml_offsets,XML,PMID,Location
 59610 ,Recurrent venous thromboembolism,LMWH,Unfractionated heparin,No significant difference,Recurrent venous thromboembolism	96/2212 (4.3%)	115/2235 (5.1%)	0.85 (0.65-1.12)	0.20,20409:20586, 59610 ,11714421,Unavailable
 59610 ,Major haemorrhage,LMWH,Unfractionated heparin,No significant difference,Major haemorrhage 33/2212 (1.5%) 57/2235 (2.5%) 0.63 (0.37-1.05) 0.08,20617:20778, 59610 ,11714421,Unavailable
 59610 ,Total mortality,LMWH,Unfractionated heparin,Significantly decreased,Total mortality	98/2006 (4.9%)	132/2027 (6.5%)	0.76 (0.59-0.98)	0.03,20809:20969, 59610 ,11714421,Unavailable
 59610 ,recurrent episodes of venous thromboembolism,tinzaparin,unfractionated heparin,Significantly decreased,"here were no recurrent episodes of venous thromboembolism in the group of patients treated with tinzaparin, and seven new episodes (four pulmonary embolisms) in the unfractionated heparin group (95% confidence interval for the difference 1.9% to 11.7%; P = 0.01). Death occurred in 6.2% and 8.7% of patients, respectively;",19122:19462, 59610 ,11714421,Unavailable
 30713 ,the ratio of partial pressure of arterial oxygen to fractional inspired oxygen concentration (PaO2/FIO2),continuous lateral rotation (CLR),routine turning every 2 h from the left to right lateral position,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",17455:17595, 30713 ,11299066,Unavailable
 30713 , the ratio of deadspace to tidal volume (Vd/Vt) ,continuous lateral rotation (CLR),routine turning every 2 h from the left to right lateral position,No significant difference,"Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",17455:17595, 30713 ,11299066,Unavailable
 30713 ,sputum volume,continuous lateral rotation (CLR),routine turning every 2 h from the left to right lateral position,Significantly increased,There were statistically significant increases in sputum volume during the periods of CLR (Table 3).,17455:17595, 30713 ,11299066,Unavailable
 32174 ,happiness with the recovery,patient-held record (PHR),control,Significantly increased,"PHR group patients were happier with the recovery they had made (79% vs. 59%, p=0.04)",17528:17614, 32174 ,11257719,Unavailable
 32174 ,satisfaction with ability to talk to staff about problems,patient-held record (PHR),control,Significantly decreased,"they were significantly less satisfied that they could talk to staff about problems (61% vs. 82%, p=0.02).",24519:24623, 32174 ,11257719,Unavailable
 32174 ,number of patients who has fear to ask questions to doctors,patient-held record (PHR),control,Significantly increased,"However, PHR group patients were significantly more afraid to ask questions of doctors than control group patients (21% vs. 4%, p=0.01).",24519:24623, 32174 ,11257719,Unavailable
 32174 ,number of patients who felt ready to go home at the point of discharge,patient-held record (PHR),control,No significant difference,"More PHR than control group patients felt ready to go home at the point of discharge (82% vs. 60%, p=0.14),",24519:24623, 32174 ,11257719,Unavailable
 32174 ,number of patients who know how to cope at home,patient-held record (PHR),control,No significant difference,"but control group patients were more likely to have been instructed in how to cope at home (49% vs. 33%, p=0.11).",24519:24623, 32174 ,11257719,Unavailable
 32174 ,number of patients felt that they had made a complete recovery from the stroke,patient-held record (PHR),control,Significantly increased,"Significantly more PHR than control group patients felt that they had made a complete recovery from the stroke (38% vs. 14%, p=0.01),",24519:24623, 32174 ,11257719,Unavailable
 32174 ,"number of patient that felt that they had ""got their lives back together again""",patient-held record (PHR),control,No significant difference,"and a higher proportion felt that they had ""got their lives back together again"" (48% VS. 31%, P=0.08).",24519:24623, 32174 ,11257719,Unavailable
 32174 ,number of patients receiving explanations about their condition,patient-held record (PHR),control,No significant difference,"PHR group patients reported receiving fewer explanations about their condition (18% vs. 33%, p=0.12)",4910:5047, 32174 ,11257719,Unavailable
 32174 ,number of patients receiving explanations about their treatment,patient-held record (PHR),control,No significant difference,"PHR group patients reported receiving fewer explanations about their condition (18% vs. 33%, p=0.12) and treatment (26% vs. 45%, p=0.07),",4910:5047, 32174 ,11257719,Unavailable
 88884 ,Knowledge that smoking causes bad breath,tobacco-use prevention programs,control,No significant difference,(1) Smoking causes bad breath ....................	98.4	100	N.S.,23272:23405, 88884 ,11897014,Unavailable
 88884 ,Knowledge that smokers have yellow teeth and fingers ,tobacco-use prevention programs,control,Significantly increased,(2) Smokers have yellow teeth and fingers ............	72.0	96.5	p = 0.0313,23492:23636, 88884 ,11897014,Unavailable
 88884 ,Knowledge that Low tar cigarettes are safe,tobacco-use prevention programs,control,No significant difference,(3) Low tar cigarettes are safe .....................	88.2	92.6	N.S.,23729:23866, 88884 ,11897014,Unavailable
 88884 ,Knowledge that smokers have clean smelling clothes,tobacco-use prevention programs,control,No significant difference,(4) Smokers have clean smelling clothes ............	89.2	91.6	N.S.,23953:24089, 88884 ,11897014,Unavailable
 88884 ,Knowledge that Smoking decreases the amount of air that gets into your lungs ,tobacco-use prevention programs,control,No significant difference,(5) Smoking decreases the amount of air that gets into your lungs ........................	86.5	89.6	N.S.,24176:24350, 88884 ,11897014,Unavailable
 88884 ,Knowledge that Smoking 1 pack of cigarettes a day costs several hundred dollars per year,tobacco-use prevention programs,control,Significantly increased,(6) Smoking 1 pack of cigarettes a day costs several hundred dollars per year.................	81.5	91.8	p = 0.0313,24437:24621, 88884 ,11897014,Unavailable
 88884 ,Attitude about tobacco use: People who use tobacco are popular and glamorous,tobacco-use prevention programs,control,No significant difference,(7) People who use tobacco are popular and glamorous . .	93.2	91.3	N.S,24869:25008, 88884 ,11897014,Unavailable
 88884 ,Attitude about tobacco use: Some people start to use tobacco because their friends do ,tobacco-use prevention programs,control,No significant difference,(8) Some people start to use tobacco because their friends do ............................	93.4	95.9	N.S.,25096:25270, 88884 ,11897014,Unavailable
 88884 ,Attitude about tobacco use: Smoking is relaxing,tobacco-use prevention programs,control,No significant difference,(9) Smoking is relaxing ........................ . .	87.2	90.2	N.S.,25357:25493, 88884 ,11897014,Unavailable
 88884 ,Attitude about tobacco use: Advertising tells the truth about the effects of tobacco use. ,tobacco-use prevention programs,control,No significant difference,(10) Advertising tells the truth about the effects of tobacco use. ............................	73.1	81.0	N.S.,25580:25759, 88884 ,11897014,Unavailable
 88884 ,Knowledge of tobacco use prevalence: What percentage of kids your age (5th graders) use tobacco every week,tobacco-use prevention programs,control,No significant difference,(11) What percentage of kids your age (5th graders) use tobacco every week ....	30.6	45.2	N.S.,28727:28901, 88884 ,11897014,Unavailable
 88884 ,Knowledge of tobacco use prevalence: What percentage of high school students (9th graders) use tobacco every week,tobacco-use prevention programs,control,No significant difference,(12) What percentage of high school students (9th graders) use tobacco every week .......	20.3	31.1	N.S.,28988:29172, 88884 ,11897014,Unavailable
 88884 ,Knowledge of tobacco use prevalence: What percentage of adults use tobacco every week ,tobacco-use prevention programs,control,Significantly increased,(13) What percentage of adults use tobacco every week ..................	4.8	33.9	p = 0.0313,29259:29420, 88884 ,11897014,Unavailable
 60660 ,folate levels,UVA radiation,control,No significant difference,We did not observe significant differences of folate levels between UV exposed and non-exposed volunteers (P &gt; 0.05).,10547:10664, 60660 ,11737876,Unavailable
 65676 ,produced data on a number of patients,postal questionnaires; Patient self-report (PSR),hospital records; Physiotherapy department records (PDR),Significantly increased,Data Collection Method PDR Mean (sd) PSR Mean (sd) pOverall n = 52 4.3 (2.8) 5.6 (3.9) 0.006,NaN:16068, 65676 ,11825347,Unavailable
 65045 ,self reported confidence scores,a 3 ½ hour workshop on Evidence Based Medicine (EBM),a workshop on bioethics (control intervention),No significant difference,"The 2nd phase of the study revealed no differences in test scores (p = 0.74) or self reported confidence scores (p = 0.36),",17707:17831, 65045 ,11818036,Unavailable
 65045 ,The Likert scale (1–10) to determine student's self-perceived confidence in reading medical research.,a 3 ½ hour workshop on Evidence Based Medicine (EBM),a workshop on bioethics (control intervention),No significant difference,"Student self-perception of confidence tended to increase slightly during the trial, although not to a level that was statistically significant (See Table 4).",18504:18700, 65045 ,11818036,Unavailable
 59604 ,Mortality and hospitalization,losartan 50 mg once daily,captopril 50 mg three times daily,Significantly decreased,"Mortality and hospitalization were secondary endpoints, and there was an unexpected 46% lower (P &lt; 0.05) mortality from all causes as well as significantly fewer hospitalizations in the losartan group.",5692:5910, 59604 ,11714415,Unavailable
 59604 ,sudden deaths or resuscitated cardiac arrests,losartan 50 mg once daily,captopril 50 mg three times daily,No significant difference,"There were 142 and 115 sudden deaths or resuscitated cardiac arrests in the losartan and captopril groups, respectively (hazard ratio 1.24, 95% CI 0.97-1.59, P = 0.08).",7244:7429, 59604 ,11714415,Unavailable
 59604 ,mortality and hospitalization from all causes,losartan 50 mg once daily,captopril 50 mg three times daily,No significant difference,"The corresponding figures for the composite of mortality and hospitalization from all causes were 752 and 707 events, respectively (hazard ratio 1.07, 95% CI 0.96-1.18, P = 0.21).",7430:7626, 59604 ,11714415,Unavailable
 59604 ,tolerance,losartan 50 mg once daily,captopril 50 mg three times daily,Significantly increased,"Losartan was better tolerated than captopril in that significantly fewer patients discontinued prematurely owing to adverse events, excluding deaths, in the losartan group (9.7% compared with 14.7%, P = 0.001).",7626:7854, 59604 ,11714415,Unavailable
 1382202 ,systolic and diastolic blood pressure after 6 months ,reducing salt intake,control (no reducing salt intake),Significantly decreased,"At six months the intervention group showed a reduction in systolic (2.54 mmHg [-1.45 to 6.54]) and diastolic (3.95 mmHg [0.78 to 7.11], p = 0.015) BP when compared to control.",26542:26720, 1382202 ,16433927,Unavailable
 1382202 , urinary sodium,reducing salt intake,There was no significant change in UNa.,No significant difference,This effect was not consistent with the effect observed on urinary sodium excretion (Table 3 and 4).,26542:26720, 1382202 ,16433927,Unavailable
 29050 ,predicting shock and organ failure up to 7 days in advance,the Systemic Mediator Associated Response Test (SMART) model,baseline plus serial data predictions,No significant difference,"ROC AUC values above 0.700 were achieved in 30 out of 49 (61%) of SMART baseline models in predicting shock and organ failure up to 7 days in advance, and in 30 out of 54 (56%) of baseline plus serial data models.",3929:4143, 29050 ,11056759,Unavailable
 1865086 ,visceral fat area,growth hormone (GH),placebo,Significantly decreased,"After 40 wk of treatment, visceral fat area declined 23.9 ± 7.4 cm2, a mean difference of −28.1 cm2 compared with placebo (95% confidence interval [CI] −49.9 cm2 to −6.3 cm2; p = 0.02) (Table 3).",33423:33734, 1865086 ,17479164,Unavailable
 1865086 ,visceral adipose tissue (VAT),"Recombinant human growth hormone (GH), pioglitazone (PIO)",placebo,Significantly decreased,"A similar decline in VAT was seen in the GH + PIO group versus placebo, with a mean difference of −31.4 cm2 (95% CI −56.5 cm2 to −6.3 cm2; p = 0.02).",33733:33933, 1865086 ,17479164,Unavailable
 1865086 ,Steady-State Plasma Glucose Response (SSPG),"Recombinant human growth hormone (GH), pioglitazone (PIO)",placebo,Significantly decreased,"Similarly, SSPG declined when both GH and PIO were combined, with a mean difference compared with placebo of −55.3 mg/dl (95% CI −103.9 to −6.7 mg/dl; p = 0.02).",35514:35693, 1865086 ,17479164,Unavailable
 1865086 ,glycohemoglobin levels,"Recombinant human growth hormone (GH) , pioglitazone (PIO)",baseline,No significant difference,"However, mean glycohemoglobin levels for all groups did not change significantly during follow-up.",39023:39121, 1865086 ,17479164,Unavailable
 1820788 ,The Kaplan-Meier survival curve,amodiaquine plus placebo,amodiaquine plus artesunate,No significant difference,The Kaplan-Meier survival estimates were similar in the two study groups for both crude (P = 0.9) and PCR-corrected (P = 0.3) results.,-1:-1, 1820788 ,17328806,Unavailable
 1820788 ,"gametocyte carriage on Day 4, 7, 14, 21",amodiaquine plus artesunate,amodiaquine plus placebo,Significantly decreased,"The differences in gametocyte carriage between groups was statistically significant on Day 4 (OR = 0.1 95%CI 0.02–0.6), Day 7 (OR = 0.2 95%CI 0.04–0.9), Day 14 (OR = 0.09 95%CI 0–0.8), and Day 21 (OR 95% CI 0–0.9) (Figure 2).",24351:24614, 1820788 ,17328806,Unavailable
 111183 ,peak tidal expiratory flow (PTEF),nebulized albuterol (0.15 mg/kg in 3 ml saline),saline (3 ml),No significant difference,PTEF increased significantly both after albuterol and saline treatments but the difference between the two treatments was not significant (P = 0.6).,4503:4669, 111183 ,11983043,Unavailable
 111183 ,tidal expiratory flows at 10% (TEF10),nebulized albuterol (0.15 mg/kg in 3 ml saline),saline (3 ml),Significantly decreased,Both TEF10 and the ratio of the tidal expiratory flow at 25% of the remaining tidal volume to PTEF (25/PT) decreased significantly (P &lt; 0.05) after administration of albuterol.,4669:4862, 111183 ,11983043,Unavailable
 111183 ,ratio of the tidal expiratory flow at 25% of the remaining tidal volume to PTEF (25/PT),nebulized albuterol (0.15 mg/kg in 3 ml saline),saline (3 ml),Significantly decreased,Both TEF10 and 25/PT significantly decreased after albuterol administration (P &lt; 0.05).,16679:16785, 111183 ,11983043,Unavailable
 111183 ,fraction of tidal volume exhaled at peak tidal expiratory flow (PTEF) to total tidal volume (VPTEF/VE) and the fraction of exhaled time at PTEF to total expiratory time (tPTEF/tE),nebulized albuterol (0.15 mg/kg in 3 ml saline),saline (3 ml),No significant difference,There were no significant changes in VPTEF/VEand tPTEF/tE either with albuterol or with saline (Table 3).,16785:17044, 111183 ,11983043,Unavailable
 1794625 ,sleep latency,autoadjusting CPAP (APAP) and Expiratory pressure relief (C-Flex),standard CPAP,No significant difference,"Pressure was 11 ± 2&nbsp;cm/H2O. APAP with C-Flex was as effective as CPAP, with no differences detected in sleep latency (17 ± 5 vs 12.3 ± 3&nbsp;min, p = 0.4),",4022:4201, 1794625 ,17053928,Unavailable
 1794625 ,respiratory indices,autoadjusting CPAP (APAP) and Expiratory pressure relief (C-Flex),standard CPAP,No significant difference,"Pressure was 11 ± 2&nbsp;cm/H2O. APAP with C-Flex was as effective as CPAP, with no differences detected in sleep latency (17 ± 5 vs 12.3 ± 3&nbsp;min, p = 0.4), or respiratory indices (AHI of 4.2 ± 2 vs 2.4 ± 0.7&nbsp;events/h, p = 0.1).",4022:4291, 1794625 ,17053928,Unavailable
 1794625 ,patient satisfaction,autoadjusting CPAP (APAP) and Expiratory pressure relief (C-Flex),standard CPAP,No significant difference,"However, when Mean VAS scores were calculated for individual patients and compared using a paired t test, a trend towards an increased score was noted in the C-Flex group (7.9 vs 7.2, p = 0.07, Fig.&nbsp;4a). Fig.&nbsp;3",18404:18709, 1794625 ,17053928,Unavailable
 1865087 ,resistin concentration and ascorbic acid level,2 g of ascorbic acid orally,baseline,Significantly decreased,"In the experimental group, vitamin C supplementation was significantly associated with both resistin concentration reduction (from 4.3 ± 1.5 to 2.9 ± 0.8 ng/ml; 95% confidence interval [CI] −1.87, −1.03) and ascorbic acid level increase (from 9.4 ± 2.9 to 19.0 ± 5.2 mg/l; 95% CI 7.9, 11.2).",6312:6396, 1865087 ,17479165,Unavailable
 1865087 ,"ascorbic acid level, resistin concentration",no supplementation,baseline,No significant difference,"In the control group, resistin levels did not change significantly (from 4.2 ± 1.0 to 4.3 ± 0.9 ng/ml; 95% CI −0.07, 0.37).",6187:6312, 1865087 ,17479165,Unavailable
 1865087 ,resistin concentration,2 g of ascorbic acid orally,no supplementation,Significantly decreased,The between-group differences were highly significant (p &lt; 0.001).,6312:6396, 1865087 ,17479165,Unavailable
 1783850 ,"Non apoptotic non necrotic cells (annexin negative, PI negative) (%)",moderate hypothermic (ModHT group),mild hypothermic (MiHT group),Significantly decreased,"Non apoptotic non necrotic cells (annexin negative, PI negative) (%)	73.86 ± 18.49/67.28 ± 16.40	51.20 ± 23.88/71.71 ± 11.35 a 0.002/0.307",22521:22744, 1783850 ,17241480,Unavailable
 1783850 ,"Early apoptotic cells (annexin positive, PI negative) (%)",moderate hypothermic (ModHT group),mild hypothermic (MiHT group),Significantly increased,"Early apoptotic cells (annexin positive, PI negative) (%)	16.45 ± 13.36/20.70 ± 12.21	33.21 ± 17.85/17.62 ± 8.06 a	0.003/0.180",22521:22744, 1783850 ,17241480,Unavailable
 1326200 ,"systolic and diastolic blood pressure, oxygen saturation, heart rate, and respiratory rate",mannitol (M),hypertonic (4.5%) saline (HS),No significant difference,"There were no statistically significant carryover effects for any of the baseline, end challenge, or recovery values for systolic and diastolic blood pressure, oxygen saturation, heart rate, and respiratory rate, either at the end of challenge or at recovery (p &gt; 0.2) (Table 5).",44232:44553, 1326200 ,16336673,Unavailable
 59901 ,questions previously rated as mis-specified,"brief explanation of proper formulation, written instructions, and diagrammatic examples",baseline,Significantly decreased,"On follow-up, 7/14 questions previously rated as mis-specified in the Intervention Group had all dimensions described at follow-up (p = 0.008) while the Control Group did not show any changes from baseline.",4940:5163, 59901 ,11716797,Unavailable
 59901 ,questions previously rated as mis-specified, no instruction,baseline,No significant difference,"On follow-up, 7/14 questions previously rated as mis-specified in the Intervention Group had all dimensions described at follow-up (p = 0.008) while the Control Group did not show any changes from baseline.",4940:5164, 59901 ,11716797,Unavailable
 59901 ,"explicitly describe patients , comparisons, and outcomes","brief explanation of proper formulation, written instructions, and diagrammatic examples",no instructions,Significantly decreased,"On the other hand, participants in the Intervention Group were statistically significantly more likely to explicitly describe patients (p = 0.028), comparisons (p = 0.014), and outcomes (p = 0.008) on follow-up.",33258:33521, 59901 ,11716797,Unavailable
 1810369 ,headache status (HIT),program of Tai Chi instruction,wait-list control group,Significantly increased,"Statistically significant (P &lt; 0.05) improvements in favor of the intervention were present for the HIT score and the SF-36 pain, energy/fatigue, social functioning, emotional well-being and mental health summary scores.",3910:4147, 1810369 ,17342248,Unavailable
 1810369 ,"physical functioning , role limitations due to physical health , vitality , social functioning  and the PCS",program of Tai Chi instruction at the baseline,wait-list control group at the baseline,Significantly decreased,"There were five significant differences in which the control group scored higher at baseline than the intervention group (see Fig. 2): physical functioning (t = 2.98, P = 0.0083, df = 17), role limitations due to physical health (t = 4.21, P = 0.002, df = 28), vitality (t = 2.57, P = 0.0157, df = 28), social functioning (t = 2.59, P = 0.0151, df = 28) and the PCS (t = 3.24, P = 0.0031, df = 28).",17138:17744, 1810369 ,17342248,Unavailable
 1784583 ,The median time to first relief of symptoms ,butoconazole nitrate 2% Site Release vaginal cream (Gynazole-1),oral fluconazole 150 mg tablets (Diflucan),Significantly decreased,The median time to first relief of symptoms occurred at 17.5 h for butoconazole patients as compared to 22.9 h for fluconazole patients (p &lt; 0.001).,2587:2736, 1784583 ,16338779,Unavailable
 1784583 ,number of patients reported first relief of symptoms by 12- and 24-h post-treatment,butoconazole nitrate 2% Site Release vaginal cream (Gynazole-1),oral fluconazole 150 mg tablets (Diflucan),Significantly increased,"By 12- and 24-h post-treatment, 44.4% and 72.8% of patients in the butoconazole treatment group reported first relief of symptoms versus 29.1% and 55.7% of patients in the fluconazole group (p = 0.044 and p = 0.024 respectively).",3379:3546, 1784583 ,16338779,Unavailable
 1784583 ,time to total relief of symptoms or reoccurrence of infection within 30 days of treatment,butoconazole nitrate 2% Site Release vaginal cream (Gynazole-1),oral fluconazole 150 mg tablets (Diflucan),No significant difference,There were no significant differences between the two groups with respect to time to total relief of symptoms or reoccurrence of infection within 30 days of treatment.,3379:3546, 1784583 ,16338779,Unavailable
 1794254 ,urine sodium excretion ,Urodilatin,baseline,Significantly increased,URO transiently increased urine sodium excretion from 22 ± 16 μmol/min (mean ± SD) to 78 ± 41 μmol/min (P &lt; 0.05) and there was no effect of placebo (29 ± 14 to 44 ± 32).,14241:14361, 1794254 ,17257428,Unavailable
 1794254 ,urine sodium excretion,placebo,baseline,No significant difference,there was no effect of placebo (29 ± 14 to 44 ± 32).,14241:14361, 1794254 ,17257428,Unavailable
 1794254 ,urine flow and blood pressure,Urodilatin,baseline,No significant difference,URO had no effect on urine flow or on blood pressure.,4333:4386, 1794254 ,17257428,Unavailable
 1794254 ,urine sodium excretion ,Urodilatin,placebo,No significant difference,"At the end of the study, there was no difference between URO and placebo (fig. 2).",14241:14361, 1794254 ,17257428,Unavailable
 1794254 ,serum cGMP,Urodilatin,baseline,Significantly increased,URO infusion markedly increased serum cGMP (P &lt; 0.01) (fig. 5).,15410:15530, 1794254 ,17257428,Unavailable
 1190216 ,ovulation rate,2 ml of alpaca seminal plasma intramuscularly,2 ml of alpaca seminal plasma intrauterine ,Significantly increased,"The ovulation rate in the intramuscular group (93%) was higher (P &lt; 0.01) than in the intrauterine group (41%),",15335:15446, 1190216 ,16018817,Unavailable
 1190216 ,follicle in diameter ,2 ml of alpaca seminal plasma intramuscularly,2 ml of alpaca seminal plasma intrauterine ,No significant difference,"Of the alpacas that ovulated, the diameter of the CL did not differ among groups.",15509:15590, 1190216 ,16018817,Unavailable
 1914073 ,improvement of GHbA1c after three months,paroxetine 20 mg per day,baseline,Significantly increased,"After three months there was a statistically significant improvement in GHbA1c in the paroxetine group (mean change from baseline = 0.69%-units, p = 0.001) but not in the placebo group (mean change = 0.11%-units, p = 0.33) (Figure 2).",17903:18186, 1914073 ,17570858,Unavailable
 1914073 ,improvement of GHbA1c after three months,placebo,baseline,No significant difference,"After three months there was a statistically significant improvement in GHbA1c in the paroxetine group (mean change from baseline = 0.69%-units, p = 0.001) but not in the placebo group (mean change = 0.11%-units, p = 0.33) (Figure 2).",17903:18186, 1914073 ,17570858,Unavailable
 1914073 ,improvement of GHbA1c after six months,paroxetine 20 mg per day,placebo,No significant difference,"At the end of the trial the change from baseline was no longer significant in the paroxetine group (mean change = 0.38%-units, p = 0.10) and there was no significant difference between groups (Table 2).",18368:18609, 1914073 ,17570858,Unavailable
 1914073 ,anxiety and depressive symptoms according to the HADS,paroxetine 20 mg per day,placebo,No significant difference,"However, no statistically significant difference between paroxetine- and placebo-treated participants was detected at any time point (Table 3).",27478:27660, 1914073 ,17570858,Unavailable
 1914073 ,"body weight, BMI, serum glucose, serum c-peptide , and serum SHBG",paroxetine 20 mg per day,placebo,No significant difference,"There was no significant difference between the groups regarding body weight or BMI. Neither was any difference detected in serum glucose, serum c-peptide or serum SHBG.",27661:27830, 1914073 ,17570858,Unavailable
 1976842 ,The relapse free survival (RFS),"mantle radiotherapy followed by 6 courses of adjuvant chemotherapy with mustine, vinblastine, prednisolone and procarbazine- MVPP",mantle radiotherapy alone,Significantly increased,The relapse free survival (RFS) was 81%; 69% for radiotherapy alone and 93% for adjuvant chemotherapy (P = 0.002).,2862:2976, 1976842 ,6375711,Unavailable
 1976842 ,The overall 5 year survival,"mantle radiotherapy followed by 6 courses of adjuvant chemotherapy with mustine, vinblastine, prednisolone and procarbazine- MVPP",mantle radiotherapy alone,No significant difference,The overall 5 year survival was 93% with no statistically significant difference between the two treatment groups (P = 0.54).,3390:3516, 1976842 ,6375711,Unavailable
 1177952 ,creatinine kinase MB-fraction (CK-MB),glucose-insulin-potassium infusion (GIK),no infusion,No significant difference,There were no differences between the two groups in the time course or magnitude of CK-MB release: the peak CK-MB level was 249 ± 228 U/L in the GIK group and 240 ± 200 U/L in the control group (NS).,6376:6576, 1177952 ,15932638,Unavailable
 1177952 ,mean left ventricular ejection fraction (LVEF),glucose-insulin-potassium infusion (GIK),no infusion,No significant difference,The mean LVEF was 43.7 ± 11.0 % in the GIK group and 42.4 ± 11.7% in the control group (P = 0.12).,25784:25882, 1177952 ,15932638,Unavailable
 1177952 ,frequency of a LVEF ≤ 30%,glucose-insulin-potassium infusion (GIK),no infusion,Significantly decreased,"Treatment with GIK was associated with a lower frequency of a LVEF ≤ 30% (51 patients (12%) compared to 74 patients (18%), P = 0.01).",26156:26290, 1177952 ,15932638,Unavailable
 57750 ,Death or myocardial infarction,eptifibatide,placebo,Significantly decreased,Overall	14.2	15.7	0.042	13.3	14.9	0.021,28238:28415, 57750 ,11806794,Unavailable
 57750 ,Myocardial infarction,eptifibatide,placebo,No significant difference,Overall	12.6	13.6	0.137	11.6	12.7	0.08,29423:29599, 57750 ,11806794,Unavailable
 1887535 ,Gametocyte prevalence on day 21,sulphadoxine-pyrimethamine combination (AQ+SP) or artesunate plus amodiaquine combination (AQ+AS),sulphadoxine-pyrimethamine (SP),Significantly decreased,"On day-21, gametocyte prevalence in SP group was significantly higher than the two combinatory treatments (AQ+SP and AQ+AS).",29257:29381, 1887535 ,17519010,Unavailable
 1887535 ,Gametocyte prevalence on day 7 and 14,sulphadoxine-pyrimethamine combination (AQ+SP) or artesunate plus amodiaquine combination (AQ+AS) or chloroquine (CQ) or amodiaquine (AQ),sulphadoxine-pyrimethamine (SP),Significantly decreased,"CQ	4.7 (2/42)	12.5 (3/24)*	4.2 (1/24)*	6.6 (1/15)	0 (0/15)AQ	12.8 (5/39)	13.1 (5/38)*	10.5 (4/38)*	9.6 (3/31)	0 (0/30)SP	10.2 (4/39)	44.4 (16/36)	33.3 (12/36)	17.1 (6/35)	6.1 (2/33)AQ+SP	2.4 (2/83)	3.8 (3/80)*	6.3 (5/80)*	1.3 (1/75)¶	1.3 (1/75)AQ+AS	3.6 (3/83)	2.5 (2/80)*	1.2 (1/79)*	1.5 (1/64)¶	0 (0/64)CQ, Chloroquine, AQ, amodiaquine; SP, Sulphadoxine-Pyrimethamine; AS, artesunate; 95% CI, 95% confidence interval.* On day 7 and day 14, significant difference to SP group (P &lt; 0.05)",30190:31460, 1887535 ,17519010,Unavailable
 1887535 ,"On day-28, the extent of haematological recovery (median of individual increases in Hb)",sulphadoxine-pyrimethamine combination (AQ+SP) or artesunate plus amodiaquine combination (AQ+AS) or chloroquine (CQ) or amodiaquine (AQ),sulphadoxine-pyrimethamine (SP),No significant difference,"On day-28, the extent of haematological recovery (median of individual increases in Hb) did not differ significantly between the five groups (CQ, 0.8 g/dl, -0.8 to 3.4; SP, 1.2 g/dl, -1.0 to 5.8; AQ, 0,9 g/dl, -3.6 to 4.1; AQ+SP, 0.5 g/dl, -4.4 to 5.8; AQ+AS, 1.1 g/dl, -2.6 to 5.2).",28535:28818, 1887535 ,17519010,Unavailable
 1887535 ,adequate clinical and parasitological response at 14-day follow-up,sulphadoxine-pyrimethamine combination (AQ+SP) or artesunate plus amodiaquine combination (AQ+AS) or sulphadoxine-pyrimethamine (SP) or amodiaquine (AQ),chloroquine (CQ) ,Significantly increased,ACPR (%) 25/39 (64.1) 38/38 (100)* 37/38 (97.4)* 80/81 (98.8)* 80/80 (100)*,22355:NaN, 1887535 ,17519010,Unavailable
 1887535 ,adequate clinical and parasitological response at 28-day follow-up,sulphadoxine-pyrimethamine combination (AQ+SP) or artesunate plus amodiaquine combination (AQ+AS) or sulphadoxine-pyrimethamine (SP) or amodiaquine (AQ),chloroquine (CQ) ,Significantly increased,ACPR (%)		20/36 (55.6)		35/36 (97.2)*		37/38 (97.4)*		76/79 (96.2)*		70/76 (92.1)*,25402:NaN, 1887535 ,17519010,Unavailable
 1166569 ,aerobic endurance,12-week exercise program,Baseline,Significantly increased,"The training program resulted in a significant increase in aerobic endurance (pre-training: 322 ± 104 m vs. post-training: 501 ± 99 m, p &lt; 0.05) and leg-press strength (pre-training: 48 ± 16 kg. vs. post-training: 78 ± 27 kg, p &lt; 0.05).",5173:5409, 1166569 ,15918901,Unavailable
 1166569 ,leg-press strength,12-week exercise program,Baseline,Significantly increased,"The training program resulted in a significant increase in aerobic endurance (pre-training: 322 ± 104 m vs. post-training: 501 ± 99 m, p &lt; 0.05) and leg-press strength (pre-training: 48 ± 16 kg. vs. post-training: 78 ± 27 kg, p &lt; 0.05).",5173:5409, 1166569 ,15918901,Unavailable
 1805771 ,I believe this treatment would decrease my low back pain,High Velocity Low Amplitude (HVLA),"placebo light touch (LT), and placebo sub-therapeutic ultrasound (ULTRA)",No significant difference,Repeated measures ANOVA revealed no significant differences for statements 2 and 4.,4686:4769, 1805771 ,17371579,Unavailable
 1805771 ,This seems like a logical way to treat low back pain.,High Velocity Low Amplitude (HVLA),"placebo light touch (LT), and placebo sub-therapeutic ultrasound (ULTRA)",No significant difference,Repeated measures ANOVA revealed no significant differences for statements 2 and 4.,4686:4769, 1805771 ,17371579,Unavailable
 1805771 ,1)I believe this treatment would allow me to get better quicker;,High Velocity Low Amplitude (HVLA),placebo light touch (LT),Significantly increased,"For both statements 1 (p = 0.025) and 3 (p = 0.039), post hoc analysis revealed a difference between HVLA and LT.",4769:4884, 1805771 ,17371579,Unavailable
 1805771 ,3)I believe this treatment would make me more able to do the things I want to do;,High Velocity Low Amplitude (HVLA),placebo light touch (LT),Significantly increased,"For both statements 1 (p = 0.025) and 3 (p = 0.039), post hoc analysis revealed a difference between HVLA and LT.",4769:4884, 1805771 ,17371579,Unavailable
 28991 ,peak inspiratory pressure (PIP),new mode of ventilation (pressure-regulated volume control; PRVC),conventional volume control (VC) ventilation,Significantly decreased,There was a significantly lower PIP in the PRVC group (P &lt; 0.0001).,9366:9451, 28991 ,11056699,Unavailable
 1931598 ,analyses the area under the curves (AUC),with hot compresses on the right upper abdomen over 40 minutes, without hot compresses on the right upper abdomen over 40 minutes,Significantly decreased,"In total, the area under the curve (AUC) was 22.8% (95% confidence interval (CI): 5.1–37.3%) smaller with hot compresses (p = 0.0320).",14491:14626, 1931598 ,17623067,Unavailable
 1931598 ,Second process half lifes,with hot compresses on the right upper abdomen over 40 minutes, without hot compresses on the right upper abdomen over 40 minutes,No significant difference,"Second process half lifes were smaller with hot compresses, although not significant (p = 0.127).",14280:14379, 1931598 ,17623067,Unavailable
 1087853 ,Hearing threshold levels (HTL),genuine exposure of electromagnetic fields (EMF) ,sham exposure of electromagnetic fields (EMF) ,No significant difference,The analysis of means of HTL of the PTA with the Repeated Measures Analysis of Variance and Exact Friedman Test did not reveal any statistically significant differences between pre/post genuine and pre/post sham exposure groups (p &gt; 0.05).,17528:17763, 1087853 ,15840162,Unavailable
 1087853 , transient evoked otoacoustic emissions (TEOAE's),genuine exposure of electromagnetic fields (EMF) ,sham exposure of electromagnetic fields (EMF) ,No significant difference,Statistical analysis with the Repeated Measures Analysis of Variance and Exact Friedman Test did not reveal any statistically significant differences in mean TEOAEs amplitude shifts between genuine and sham exposure groups (p &gt; 0.05).,17528:17763, 1087853 ,15840162,Unavailable
 1216327 ,The mean body weight gain,White Grape Juice (WGJ),colored and flavored water (WA),No significant difference,The mean body weight gain was greater among patients receiving WGJ (+ 50.7 gm) as compared with the patients in the AJ group (+ 18.3 gm) or the patients fed WA (- 0.7 gm) (p = 0.08).,4730:4913, 1216327 ,16091146,Unavailable
 1216327 ,The duration of the illness,White Grape Juice (WGJ),colored and flavored water (WA),Significantly increased,"The duration of the illness was longer in the infants fed juice as compared with those given WA (p = 0.006), the mean +/- SD duration in hours was 49.4 ± 32.6, 47.5 ± 38.9 and 26.5 ± 27.4 in patients fed AJ, WGJ and WA respectively.",4913:5145, 1216327 ,16091146,Unavailable
 1216327 ,The fecal losses,White Grape Juice (WGJ),colored and flavored water (WA),Significantly increased,The fecal losses were also increased among the juice fed patients (p = 0.001);,5371:5449, 1216327 ,16091146,Unavailable
 1175919 ,the time to first defibrillation,semiautomatic  external defibrillators,automated external defibrillators (AEDs),Significantly decreased,Shock was administered safely by 94.1%. In the second evaluation the time to first defibrillation decreased significantly to 56.8 ± 9.9 s (range 35–95 s; P ≤ 0.01).,14222:14403, 1175919 ,15774042,Unavailable
 1175919 ,time to first shock,semiautomatic  external defibrillators with pre-existing medical education ,automated external defibrillators (AEDs) with pre-existing medical education ,Significantly decreased,"Students with pre-existing medical education were significant faster at both times (first evaluation: 73.0 ± 17.1 s versus 83.0 ± 19.1 s, P ≤ 0.01; second evaluation: 51.8 ± 9.2 s versus 58.3 ± 10.1 s, P ≤ 0.01). All other findings are summarized in Table 2.",15182:15513, 1175919 ,15774042,Unavailable
 1925104 ,accuracy,forced-choice vibrotactile frequency discrimination task,without distractor,Significantly decreased,"In the presence of a simultaneous distractor, the accuracy decreased (47%, F(1,11) = 23.90, p &lt; 0.001) and the response time increased significantly (1369 ms, F(1,5) = 13.08, p &lt; 0.05).",8823:9008, 1925104 ,17610721,Unavailable
 1925104 ,response time,forced-choice vibrotactile frequency discrimination task,without distractor,Significantly increased,"In the presence of a simultaneous distractor, the accuracy decreased (47%, F(1,11) = 23.90, p &lt; 0.001) and the response time increased significantly (1369 ms, F(1,5) = 13.08, p &lt; 0.05).",8823:9008, 1925104 ,17610721,Unavailable
 1925104 ,the accuracy of vibrotactile discrimination,Delayed presentation of the probe (ISI = 8 s),presentation of the probe (ISI = 2 s) ,Significantly decreased,"Delayed presentation of the probe (ISI = 8 s) significantly reduced the accuracy of vibrotactile discrimination compared to an ISI of 2 s (54% vs. 59%, F(1,11) = 6.29, p &lt; 0.05). The chance level in this forced choice two-alternative decision task was 50%.",9009:9265, 1925104 ,17610721,Unavailable
 1968186 ,Response rates,Cyclophosphamide Methotrexate Flourouracil ,low dose Epirubicin,Significantly increased,"Response rates were 58% for CMF and 29% for epirubicin (chi 2 = 3.51, 1 d.f., P &gt; 0.05).",1973:2062, 1968186 ,8431375,Unavailable
 1968186 ,Median time to treatment failure,Cyclophosphamide Methotrexate Flourouracil ,low dose Epirubicin,Significantly increased,"Median time to treatment failure was 24 weeks for CMF, 7 weeks for epirubicin (P &lt; 0.05) but survival was similar in both groups.",2062:2192, 1968186 ,8431375,Unavailable
 1968186 ,"alopecia , nausea and vomiting and haematological toxicity",Cyclophosphamide Methotrexate Flourouracil ,low dose Epirubicin,Significantly increased,"CMF caused more objective alopecia (P &lt; 0.001), nausea and vomiting (P &lt; 0.001) and haematological toxicity (P &lt; 0.02).",2288:2409, 1968186 ,8431375,Unavailable
 1079947 ,The average of tcCO2 ,medroxyprogesterone acetate (MPA),baseline,No significant difference,"Three weeks after cessation of MPA, the SaO2 mean remained 1.4 ± 1.8 %-units higher than at baseline, the difference being not significant (95% CI -0.03, 2.8). SaO2 nadir was 2.7 %-units (IQR 4.9; 95% CI 0.06, 18.7) higher than at baseline.",26882:27076, 1079947 ,15807890,Unavailable
 1079947 ,The median of maximum inspiratory slope,medroxyprogesterone acetate (MPA),baseline,Significantly increased,"The median of maximum inspiratory slope increased from 10.7 (IQR 4.6; 95% CI 6.5, 30.0) U/50-1 at baseline to 16.8 (IQR 30.7) U/50-1 with MPA (95% CI 11.8, 59.0; p = 0.042) during stage 4 sleep.",26882:27076, 1079947 ,15807890,Unavailable
 111061 ,postural response (horizontal),Backpacks positioned at T7,baseline (unloaded),Significantly increased,"There was a significant effect of backpack position at tragus of ear, spinous process C7, mid acromion of the shoulder and lateral superior iliac crest.. Table 5 and Figure 3 illustrate that positioning the centre of the backpack on the upper spine (T7) produced the largest horizontal displacement at all anatomical points except shoulder and fibula.",35783:36210, 111061 ,11960561,Unavailable
 111061 ,"Gender, age, and effect of order of testing",Backpacks,baseline (unloaded),No significant difference,"Gender, year level and effect of order of testing did not significantly influence postural response at any anatomical point (illustrated by the non-significant higher order interaction effects in Table 4).",35783:36210, 111061 ,11960561,Unavailable
 57751 ,Total cholesterol,bezafibrate 400 mg/day,placebo,Significantly decreased,Bezafibrate significantly reduced total cholesterol by approximately 8.0%,3439:3513, 57751 ,11806795,Unavailable
 57751 ,HDL-cholesterol,bezafibrate 400 mg/day,placebo,Significantly increased,"increased high-density lipoprotein (HDL)-cholesterol by approximately 11.0% initially, falling to about 6.0% at 3 years.",3585:3707, 57751 ,11806795,Unavailable
 57751 ,LDL-cholesterol,bezafibrate 400 mg/day,placebo,Significantly decreased,"Bezafibrate significantly reduced total cholesterol by approximately 8.0% and low-density lipoprotein (LDL)-cholesterol by approximately 9.0%,",3439:3582, 57751 ,11806795,Unavailable
 57751 ,Triglycerides,bezafibrate 400 mg/day,placebo,Significantly decreased,Triglycerides were significantly reduced by about 23.0% and fibrinogen by about 14.0%.,3707:3794, 57751 ,11806795,Unavailable
 57751 ,Creatinine,bezafibrate 400 mg/day,placebo,Significantly increased,Plasma creatinine rose by approximately 11% in those on active treatment.,3794:3867, 57751 ,11806795,Unavailable
 1974799 ,pain relief (PR) within 2 h after dosing,rizatriptan 10 mg,usual-care oral triptans,Significantly increased,Significantly more patients taking rizatriptan (88.1%) achieved PR within 2 h after dosing than patients taking other oral triptans (81.9%; p = 0.0003).,31058:31288, 1974799 ,17537184,Unavailable
 1974799 ,pain freedom (PF) within 2 h after dosing,rizatriptan 10 mg,usual-care oral triptans,Significantly increased,"With regard to PF, significantly more patients taking rizatriptan achieved PF within 2 h after dosing (60.9%), than patients taking other oral triptans (49.9%; p &lt; 0.0001) (see Table 2).",31058:31288, 1974799 ,17537184,Unavailable
 1974799 ,Median time to pain relief (PR)  ,rizatriptan 10 mg,usual-care oral triptans,Significantly increased,"Median time to PR was statistically shorter for rizatriptan (45 min) than other oral triptans (52 min, p &lt; 0.0001).",39664:39795, 1974799 ,17537184,Unavailable
 1974799 ,Median time to pain freedom (PF) ,rizatriptan 10 mg,usual-care oral triptans,Significantly increased,"Likewise, the median time to PF was statistically shorter for rizatriptan (100 min) than other oral triptans (124 min, p &lt; 0.0001).",39664:39795, 1974799 ,17537184,Unavailable
 1974799 ,Satisfaction and preference,rizatriptan 10 mg,usual-care oral triptans,Significantly increased,"In the cumulative logit multivariate model, patients were 52% more satisfied when treating their attack with rizatriptan than when treating with another oral triptan (odds ratio 1.52, 95% CI: 1.25–1.85; p &lt; 0.0001), after adjusting for treatment sequence, treatment order and the use of rescue medications.",45559:45866, 1974799 ,17537184,Unavailable
 1891438 ,median percentage of days of diarrhea,1250 IU of vitamin A; vitamin A and 10 mg of zinc;," vitamin A, zinc, vitamins B1, B2, B6, B12, C, D, E, and K and copper, iodine, iron, and niacin",No significant difference,"Among HIV-uninfected children born to HIV-uninfected mothers, median percentage of days of diarrhea was 2.4% in 56 children in the vitamin A group; 1.8% in 57 children in the vitamin A and zinc group; and 2.7% in 52 children in the multiple micronutrient group (P = 0.857).",8764:9038, 1891438 ,17593956,Unavailable
 1240403 ,The ratio of highly credible gastroenteritis (HCG) episode rates,real water treatment units (WTUs),sham water treatment units (WTUs),No significant difference,"The ratio of HCG episode rates for the real WTU group compared to the sham WTU group was 0.99 (95% confidence interval, 0.85-1.15, p = 0.85).",2284:2425, 1240403 ,11564611,Unavailable
 29018 ,Scores indicating undersedation,intermittent diazepam,continuous midazolam,Significantly increased,Scores indicating undersedation were more common with diazepam (P &lt;0.01);,2937:3028, 29018 ,11056728,Unavailable
 29018 ,overall adequate sedation,intermittent diazepam,continuous midazolam,Significantly increased,"overall adequate sedation midazolam 64.7%, diazepam 35.7% (P =0.21).",3028:3116, 29018 ,11056728,Unavailable
 1797029 ,the treatment response rate,paclitaxel for patients with HER2 status,paclitaxel for patients with p53 status,No significant difference,The response rate was 23% among women with HER2-positive tumors and 24% among those with HER2-negative tumors (P = 0.96); the respective response rates for tumors with and for those without p53 over-expression were 23% and 21% (P = 0.79).,26028:26301, 1797029 ,17129383,Unavailable
 1797029 ,median time to treatment failure,paclitaxel for patients with HER2 status,paclitaxel for patients with p53 status,No significant difference,There was a trend toward a shorter median time to treatment failure among women with HER2-positive tumors (2.3 versus 4.2 months; P = 0.067).,6931:7089, 1797029 ,17129383,Unavailable
 102323 ,visual analog scale (VAS),electroacupuncture ,placebo and diclofenac,Significantly decreased,VAS -22.86 (4.02) -32.99 (3.94) -48.24 (3.59) -35.59 (2.74) &lt;0.05,30820:31013, 102323 ,11914160,Unavailable
 102323 ,Pain index,diclofenac plus electroacupuncture ,placebo,Significantly decreased,Pain index	-3.31 (0.68)	-4.90 (0.53)	-5.65 (0.59)	-6.28 (0.77)	&lt;0.05††,30820:31013, 102323 ,11914160,Unavailable
 102323 ,Lequesne's functional index,electroacupuncture ,placebo,Significantly decreased,Lequesne's functional index	-3.82 (0.51)	-4.80 (0.61)	-6.44 (0.59)	-5.39 (0.52)	&lt;0.05†††,31706:31917, 102323 ,11914160,Unavailable
 1766476 ,IRR incidence rate ratio among all patients,"intervention program, including systematic assessment and treatment of fall risk factors, active prevention, detection, and treatment of postoperative complication",control group,Significantly decreased,IRR (95% CI) 0.38 (0.20–0.76)a 1.00 (Ref.) 0.006,30195:30313, 1766476 ,17061151,Unavailable
 1766476 ,the fall risk,"intervention program, including systematic assessment and treatment of fall risk factors, active prevention, detection, and treatment of postoperative complication",control group,Significantly decreased,"the fall risk was significantly lower in the intervention group, HRR 0.41 (95% CI: 0.20–0.82, p = 0.012).",31824:31946, 1766476 ,17061151,Unavailable
 1766476 ,Number of fallers with injuries due to falls,"intervention program, including systematic assessment and treatment of fall risk factors, active prevention, detection, and treatment of postoperative complication",control group,Significantly decreased,Number of fallers with injuries due to falls	3	15	0.002,30059:30177, 1766476 ,17061151,Unavailable
 1766476 ,Number of fallers with fractures due to falls,"intervention program, including systematic assessment and treatment of fall risk factors, active prevention, detection, and treatment of postoperative complication",control group,No significant difference,Number of fallers with fractures due to falls	0	4	0.055,30195:30313, 1766476 ,17061151,Unavailable
 1766476 ,IRR incidence rate ratio among patients with dementia,"intervention program, including systematic assessment and treatment of fall risk factors, active prevention, detection, and treatment of postoperative complication",control group,Significantly decreased,"The incidence rate ratio was 0.38 [95% confidence interval (CI): 0.20 – 0.76, p = 0.006] for the total sample and 0.07 (95% CI: 0.01–0.57, p=0.013) among patients with dementia",4495:4705, 1766476 ,17061151,Unavailable
 1863514 ,general adverse events,400 mg capsules of Sutherlandia leaf powder twice daily (800 mg/d),placebo,No significant difference,"There were no significant differences in general adverse events or physical, vital, blood, and biomarker indices between the treatment and placebo groups (p &gt; 0.05).",5988:6170, 1863514 ,17476314,Unavailable
 1863514 ,appetite,400 mg capsules of Sutherlandia leaf powder twice daily (800 mg/d),placebo,Significantly increased,"However, participants consuming Sutherlandia reported improved appetite compared to those in the placebo group (p = 0.01).",6171:6331, 1863514 ,17476314,Unavailable
 1863514 ,"respiration rate, platelet count, MCH, MCHC, total protein, and albumin",400 mg capsules of Sutherlandia leaf powder twice daily (800 mg/d),placebo,No significant difference,"Although the treatment group exhibited a lower respiration rate (p &lt; 0.04) and higher platelet count (p = 0.03), MCH (p = 0.01), MCHC (p = 0.02), total protein (p = 0.03), and albumin (p = 0.03), than the placebo group, these differences remained within the normal physiological range, and were not clinically relevant.",6331:6756, 1863514 ,17476314,Unavailable
 1797029 ,median time to treatment failure,"paclitaxel at a dose of 175, 210, 250 mg/m2  2.3 months","paclitaxel at a dose of 175, 210, 250 mg/m2 4.2 months",No significant difference,There was a trend toward a shorter median time to treatment failure among women with HER2-positive tumors (2.3 versus 4.2 months; P = 0.067).,27314:27501, 1797029 ,17129383,Unavailable
 1797029 ,overall survival in estrogen receptor (ER) positive females,"paclitaxel at a dose of 175, 210, 250 mg/m2 2.3 months","paclitaxel at a dose of 175, 210, 250 mg/m2 4.2 months",Significantly increased,"Although TTF did not differ by ER status (P = 0.13) in the biomarker subset, OS was significantly better in this group of ER-positive tumors (P = 0.003).",27314:27501, 1797029 ,17129383,Unavailable
 1797029 ,Time to treatment failure (TTF),"paclitaxel at a dose of 175, 210, 250 mg/m2 2.3 months","paclitaxel at a dose of 175, 210, 250 mg/m2 4.2 months",No significant difference,"This observation was also true of ER status in the entire cohort of patients from CALGB 9342, in which TTF did not differ by ER status (P = 0.27), whereas ER positivity was associated with more favorable OS (P = 0.0003).",7284:7450, 1797029 ,17129383,Unavailable
 1797029 ,overall survival in women with p53 over-expression,"paclitaxel at a dose of 175, 210, 250 mg/m2 11.5 months","paclitaxel at a dose of 175, 210, 250 mg/m2 14.4 months",Significantly decreased,"In contrast, women with p53 over-expression had significantly shorter OS than those without p53 over-expression (11.5 versus 14.4 months; P = 0.002).",7284:7450, 1797029 ,17129383,Unavailable
 1175098 ,impact of the order of presentation on the assessment of cancer patients' quality of life,"EORTC QLQ-C30 and FACT-G, FACT-G and EORTC QLQ-C30, EORTC QLQ-C30 and FLIC, FLIC and EORTC QLQ-C30, FACT-G and FLIC, and FLIC and FACT-G","EORTC QLQ-C30 and FACT-G, FACT-G and EORTC QLQ-C30, EORTC QLQ-C30 and FLIC, FLIC and EORTC QLQ-C30, FACT-G and FLIC, and FLIC and FACT-G",No significant difference,"There is no evidence of any major impact of the order of presentation on the assessment of cancer patients' quality of life when two of the three questionnaires – FLIC, FACT-G and EORTC QLQ-C30 – are used together.",42712:42926, 1175098 ,15927054,Unavailable
 1540413 ,the percent of seroconversion rate,40 μg HB vaccine intramuscularly,20 μg HB vaccine intradermally,No significant difference,"Although the percent of seroconversion rate was lower in the group A than the group B (60% vs. 70%), it was not significant statistically.",12118:12256, 1540413 ,16734912,Unavailable
 1540413 ,antibody titers,Levamizol to intramuscular  vaccinations,baseline,Significantly increased,"Thus, addition of Levamizol to intramuscular and intradermal vaccinations increased the antibody titers, 514.2 IU/L (p = 0.001) and 176.1 IU/L (p = 0.01), respectively.",12524:12692, 1540413 ,16734912,Unavailable
 1540413 ,antibody titers,Levamizol to intradermal vaccinations,baseline,Significantly increased,"Thus, addition of Levamizol to intramuscular and intradermal vaccinations increased the antibody titers, 514.2 IU/L (p = 0.001) and 176.1 IU/L (p = 0.01), respectively.",12524:12692, 1540413 ,16734912,Unavailable
 1550405 ,total FSH dose,recombinant FSH (r-FSH),"highly-purified, urinary FSH (HP-uFSH)",Significantly decreased,"The only parameter that differed significantly between the two study groups was the total FSH dose, that was significantly lower using r-FSH (p &lt; 0.0003; Table 2).",23705:23910, 1550405 ,16848893,Unavailable
 1550405 ,Delivery rate/started cycle,recombinant FSH (r-FSH),"highly-purified, urinary FSH (HP-uFSH)",No significant difference,Delivery rate/started cycle (%)	11.5	10.0 (95%CI: 4.5–15.2)	13.1 (95%CI: 7.3–18.9)	ns,23312:23489, 1550405 ,16848893,Unavailable
 1550405 ,Delivery rate/ovulatory cycle,recombinant FSH (r-FSH),"highly-purified, urinary FSH (HP-uFSH)",No significant difference,Delivery rate/ovulatory cycle (%)	13.6	12.0	15.2	ns,23520:23663, 1550405 ,16848893,Unavailable
 1915612 ,neck pain intensity,botulinum toxin (maximum 100 units),placebo (saline),No significant difference,"After 12 weeks there was no significant difference between the two treatment groups in decrease of neck pain intensity on VAS (−7.0 mm, 95% confidence interval (CI) [−20.7 to +6.7])",3212:3393, 1915612 ,17345052,Unavailable
 1915612 ,mean number of neck pain days,botulinum toxin (maximum 100 units),placebo (saline),No significant difference,mean number of neck pain days (−1%; 95% CI [−15% to +13%]),3395:3453, 1915612 ,17345052,Unavailable
 1915612 ,neck pain hours per day,botulinum toxin (maximum 100 units),placebo (saline),No significant difference,"neck pain hours per day (−0.14; 95% CI [−3.0 to +2.7]),",3455:3510, 1915612 ,17345052,Unavailable
 1915612 ,number of analgesics taken per day,botulinum toxin (maximum 100 units),placebo (saline),No significant difference,number of analgesics taken per day (−0.14; 95% CI [−0.6 to +0.4]),3588:3653, 1915612 ,17345052,Unavailable
 1915612 ,total cervical range of motion,botulinum toxin (maximum 100 units),placebo (saline),No significant difference,total cervical range of motion (−11 degrees; 95% CI [−40 to +17]),3657:3723, 1915612 ,17345052,Unavailable
 1888710 ,moderate-to-vigorous activity (MVPA) (% recess),moderate-to-vigorous (MVPA) Girls,control girls,Significantly increased,MVPA (% recess)	30.8 ± 11.7	33.1 ± 13.7	21.9 ± 9.9^	27 ± 10.4^,27822:27999, 1888710 ,17517136,Unavailable
 1888710 , vigorous physical activity (VPA) (% recess),moderate-to-vigorous (MVPA) Girls,control girls,Significantly increased,VPA (% recess)	4.5 ± 4.1#	7 ± 5.7#	2.9 ± 3.6^ 6.5 ± 4.9^,27822:27999, 1888710 ,17517136,Unavailable
 1705535 ,incidence of psoriatic arthropathy per patient-year,"efalizumab, 1&nbsp;mg/kg once weekly",placebo,No significant difference,Analysis of first treatment phase data from one study (n&nbsp;=&nbsp;793) showed that the incidence of psoriatic arthropathy per patient-year was lower in efalizumab-treated patients (0.10; 95% CI 0.05–0.18) than in those given placebo (0.17; 95% CI 0.08–0.30).,4187:4455, 1705535 ,17021768,Unavailable
 1705535 ,the incidence of arthropathy during the extended treatment phase,"efalizumab, 1mg/kg once weekly",placebo,No significant difference,Analysis of first treatment phase data from one study (n&nbsp;=&nbsp;793) showed that the incidence of psoriatic arthropathy per patient-year was lower in efalizumab-treated patients (0.10; 95% CI 0.05–0.18) than in those given placebo (0.17; 95% CI 0.08–0.30).,4187:4455, 1705535 ,17021768,Unavailable
 1794452 ,number of infections,"copper 2.5 to 3.1 mg/day, selenium 315 to 380 μg/day, and zinc 26.2 to 31.4 mg/day",placebo,Significantly decreased,"A significant reduction in number of infections was observed in the supplemented patients, which decreased from 3.5 ± 1.2 to 2.0 ± 1.0 episodes per patient in placebo group (p &lt; 0.001).",6046:6249, 1794452 ,17081282,Unavailable
 1794452 ,cases of nosocomial pneumonia,"copper 2.5 to 3.1 mg/day, selenium 315 to 380 μg/day, and zinc 26.2 to 31.4 mg/day",placebo,Significantly decreased,"This was related to a reduction of nosocomial pneumonia, which occurred in 16 (80%) patients versus seven (33%) patients, respectively (p &lt; 0.001)",6250:6416, 1794452 ,17081282,Unavailable
 1794452 ,ventilator-associated pneumonia,"copper 2.5 to 3.1 mg/day, selenium 315 to 380 μg/day, and zinc 26.2 to 31.4 mg/day",placebo,Significantly decreased,"This was related to a reduction of nosocomial pneumonia, which occurred in 16 (80%) patients versus seven (33%) patients, respectively (p &lt; 0.001), and of ventilator-associated pneumonia from 13 to six episodes, respectively (p = 0.023).",6249:6527, 1794452 ,17081282,Unavailable
 1794452 ,The number of days of antibiotherapy,"copper 2.5 to 3.1 mg/day, selenium 315 to 380 μg/day, and zinc 26.2 to 31.4 mg/day",placebo,Significantly decreased,The number of days of antibiotherapy was significantly lower in the supplemented group (p = 0.021).,16879:16996, 1794452 ,17081282,Unavailable
 1794452 ,The length of stay,"copper 2.5 to 3.1 mg/day, selenium 315 to 380 μg/day, and zinc 26.2 to 31.4 mg/day",placebo,Significantly decreased,"The length of stay was significantly reduced in the supplemented patients, with a median of 0.63 days versus 0.99 days per percentage of burned BSA (p = 0.002).",16996:17174, 1794452 ,17081282,Unavailable
 1501010 , Personal and Social Functioning Scale (FPS) scores after 6 months (T1) and after 1 year (T2),VADO (Valutazione delle Abilità e Definizione degli Obiettivi – in english: Skills Assessment and Definition of Goals),Routine(Control group),Significantly increased,"At T1, the FPS increased in both (46.6 ± 13.1 versus 39.8 ± 14.5; t = -1.887, df = 57, p = 0.06). At T2, a the experimental group showed further improvement compared to no further improvement in the control group (49.0 ± 14.3 versus 39.9 ± 14.3; t = -2.360, df = 53, p &lt; 0.05) (Figure 1).",33101:33264, 1501010 ,16584543,Unavailable
 1501010 ,Brief Psychiatric Rating Scale  global score after 6 months (T1) and after 1 year (T2),VADO (Valutazione delle Abilità e Definizione degli Obiettivi – in english: Skills Assessment and Definition of Goals),Routine(Control group),Significantly decreased,"Significant differences between groups were found at T1 (chi square = 11.077, p &lt; 0.01) and T2 (chi square = 7.513, p &lt; 0.05).",33101:33264, 1501010 ,16584543,Unavailable
 1501010 ,Brief Psychiatric Rating Scale  positive symptoms  after 6 months (T1) and after 1 year (T2),VADO (Valutazione delle Abilità e Definizione degli Obiettivi – in english: Skills Assessment and Definition of Goals),Routine(Control group),Significantly decreased,"Significant differences between groups were found at T1 (chi square = 9.890, p &lt; 0.01), and T2 (chi square = 5.692, p &lt;0.05).",33101:33264, 1501010 ,16584543,Unavailable
 1501010 ,Brief Psychiatric Rating Scale  negative symptoms  after 6 months (T1) and after 1 year (T2),VADO (Valutazione delle Abilità e Definizione degli Obiettivi – in english: Skills Assessment and Definition of Goals),Routine(Control group),Significantly decreased,"Significant differences between groups were found at T1 (chi square = 5.713, p &lt; 0.05), and T2 (chi square = 6.432, p &lt;0.05).",33101:33264, 1501010 ,16584543,Unavailable
 1501010 ,Brief Psychiatric Rating Scale  mania/hostility  after 6 months (T1) and after 1 year (T2),VADO (Valutazione delle Abilità e Definizione degli Obiettivi – in english: Skills Assessment and Definition of Goals),Routine(Control group),Significantly decreased,"Significant difference between groups was found at T1 (chi square = 9.890, p &lt; 0.01), but not at T2.",32942:33042, 1501010 ,16584543,Unavailable
 1501010 ,Brief Psychiatric Rating Scale anxiety/depression  after 6 months (T1) and after 1 year (T2),VADO (Valutazione delle Abilità e Definizione degli Obiettivi – in english: Skills Assessment and Definition of Goals),Routine(Control group),Significantly decreased,"Significant difference between groups was found at T1 (chi square = 6.092, p &lt; 0.05), and at T2, difference approached significance (chi square = 4.174, p = 0.07).",33101:33264, 1501010 ,16584543,Unavailable
 1915628 ,Pain intensity,ambulant myofeedback training including ergonomic counselling (Mfb),baseline,Significantly decreased,"Post Hoc comparisons revealed that the VAS score was significantly reduced at T0 (t&nbsp;=&nbsp;4.37, p&nbsp;&lt;&nbsp;.01), T3 (t&nbsp;=&nbsp;5.10, p&nbsp;&lt;&nbsp;.01), and T6 (t&nbsp;=&nbsp;3.54, p&nbsp;&lt;&nbsp;.01) compared to Baseline but also the reduction between T0 and T3 was significant (t&nbsp;=&nbsp;2.85, p&nbsp;=&nbsp;.01).",27681:28077, 1915628 ,17260162,Unavailable
 1915628 ,Pain Disability Index score,ambulant myofeedback training including ergonomic counselling (Mfb),baseline,No significant difference,"No additional effects were found for intervention type (F&nbsp;=&nbsp;.86, p&nbsp;=&nbsp;.35) nor the interaction terms (F&nbsp;≤&nbsp;1.97, p&nbsp;≥&nbsp;.12).",28958:29146, 1915628 ,17260162,Unavailable
 1794469 ,Average access time and number of attempts,ultrasound-guided cannulation of the internal jugular vein,the landmark technique was used,Significantly decreased,Average access time and number of attempts were both significantly reduced using ultrasound compared with the landmark technique (p &lt; 0.001) (Table 2).,22581:22792, 1794469 ,17112371,Unavailable
 1794469 ,the rate of mechanical complications,ultrasound-guided cannulation of the internal jugular vein,the landmark technique was used,Significantly decreased,The success rate was significantly lower and the rate of mechanical complications was significantly higher in the landmark group of patients as compared with the ultrasound group (p &lt; 0.001) (Table 2).,22793:23053, 1794469 ,17112371,Unavailable
 1794469 ,number of CVC-associated blood stream infection (CVC-BSI),ultrasound-guided cannulation of the internal jugular vein,the landmark technique was used,Significantly decreased,"Interestingly, the present data showed a significantly increased number of CVC-BSIs in the landmark group compared with those documented in the ultrasound group (p &lt; 0.001) (Table 2).",23259:23502, 1794469 ,17112371,Unavailable
 1794469 ,incidence of coagulase-negative Staphylococci,ultrasound-guided cannulation of the internal jugular vein,the landmark technique was used,Significantly decreased,"However, the incidence of coagulase-negative Staphylococci was significantly higher in the landmark group of patients compared with the ultrasound group (p &lt; 0.05).",24288:24487, 1794469 ,17112371,Unavailable
 1702540 ,hungry,  glycemic levels determined by standard blood glucose monitors and to eat only when glycemia was &lt; 85 mg/dL (trained),estimate their blood glucose at meal times by associating feelings of hunger  (untrained),Significantly increased,Fewer subjects in the trained group were hungry than those in the control group (p = 0.001).,3861:3954, 1702540 ,17156448,Unavailable
 1702540 ,glucose levels,  glycemic levels determined by standard blood glucose monitors and to eat only when glycemia was &amp;lt; 85 mg/dL (trained),estimate their blood glucose at meal times by associating feelings of hunger  (untrained),Significantly decreased,The 18 hungry subjects of the trained group had significantly lower glucose levels (80.1 ± 6.3 mg/dL) than the 42 hungry control subjects (89.2 ± 10.2 mg/dL; p = 0.01).,3954:4122, 1702540 ,17156448,Unavailable
 1702540 ,accurate estimation of glycemia,  glycemic levels determined by standard blood glucose monitors and to eat only when glycemia was &amp;amp;lt; 85 mg/dL (trained),estimate their blood glucose at meal times by associating feelings of hunger  (untrained),Significantly increased,"Moreover, the trained hungry subjects estimated their glycemia (78.1 ± 6.7 mg/dL; estimation error: 3.2 ± 2.4% of the measured glycemia) more accurately than the control hungry subjects (75.9 ± 9.8 mg/dL; estimation error: 16.7 ± 11.0%; p = 0.0001).",4123:4372, 1702540 ,17156448,Unavailable
 1702540 ,estimation error,  glycemic levels determined by standard blood glucose monitors and to eat only when glycemia was &amp;amp;amp;lt; 85 mg/dL (trained),estimate their blood glucose at meal times by associating feelings of hunger  (untrained),Significantly decreased,Also the estimation error of the entire trained group (4.7 ± 3.6%) was significantly lower than that of the control group (17.1 ± 11.5%; p = 0.0001).,4373:4522, 1702540 ,17156448,Unavailable
 1936359 ,time to leukemic transformation,methyl transferase inhibitor 5 Azacytidine,best supportive care,Significantly increased,"After 6 months of treatment significantly less (3%) patients treated with Azacytidine transformed to AML when compared to those in the supportive care arm (3% vs 24%, p&lt;0.0001).",35595:35774, 1936359 ,18360650,Unavailable
 1936359 ,complete cytogenetic remission,methyl transferase inhibitor 5 Azacytidine,best supportive care,Significantly increased,These translated into a longer survival if complete cytogenetic remission was achieved (p=0.02) (Lubbert et al 2001).,47392:47548, 1936359 ,18360650,Unavailable
 1936359 ,platelet counts,methyl transferase inhibitor 5 Azacytidine,best supportive care,Significantly increased,Increased platelet counts after the first course of decitabine therapy occurred in 58% of thrombocytopenic patients and significantly (p&lt;0.0001) predicted overall survival (van den Bosch et al 2004).,47789:48030, 1936359 ,18360650,Unavailable
 1779263 ,ability to concentrate,fluorescent light sources with a high correlated colour temperature (17000 K),control group,Significantly increased,Individuals in the intervention arm of the study showed a significant improvement in self-reported ability to concentrate at study end as compared to those within the control arm (p &lt; 0.05).,4498:4689, 1779263 ,17217543,Unavailable
 1779263 ,vitality and mental health,fluorescent light sources with a high correlated colour temperature (17000 K),baseline,Significantly increased,"In addition, the intervention population showed significant improvements in two of the five investigated SF-36 scales at study end (vitality and mental health) compared to baseline scores, which for vitality was highly significant (p &lt; 0.001).",35023:35267, 1779263 ,17217543,Unavailable
 1779263 ,vitality and mental health,Control group,baseline,No significant difference,"In contrast, the control group only showed borderline significant improvement on the social functioning scale (Table 4).",35268:35430, 1779263 ,17217543,Unavailable
 1084341 ,electrical pain threshold,ketamine,baseline,No significant difference,"While a ketamine serum concentration of 30 ng/ml did not result in a change in electrical pain threshold when administered alone (P = 0.32; two-way ANOVA), when it was added to a fentanyl serum concentration of 0.4 ng/ml the combination resulted in greater increase in pain threshold than that of fentanyl administered alone (P &lt; 0.01; two-way ANOVA).",25727:26116, 1084341 ,15804361,Unavailable
 1084341 ,electrical pain threshold,fentanyl  with ketamine,fentanyl,Significantly increased,"While a ketamine serum concentration of 30 ng/ml did not result in a change in electrical pain threshold when administered alone (P = 0.32; two-way ANOVA), when it was added to a fentanyl serum concentration of 0.4 ng/ml the combination resulted in greater increase in pain threshold than that of fentanyl administered alone (P &lt; 0.01; two-way ANOVA).",25727:26116, 1084341 ,15804361,Unavailable
 1472695 ,prescribing of thiazides,Thiazides,control group,No significant difference,"Thus, prescribing of thiazides was significantly higher in the experimental group (relative risk 1.94; 95% confidence interval [CI]1.49–2.49).",32428:32570, 1472695 ,16737346,Unavailable
 1626393 ,symptom days,"household repairs, including reduction of water infiltration, removal of water-damaged building materials, and heating/ventilation/air-conditioning alterations",only home cleaning information,Significantly decreased,"The remediation group had a significant decrease in symptom days (p = 0.003, as randomized; p = 0.004, intent to treat) after remodeling, whereas these parameters in the control group did not significantly change.",6166:6413, 1626393 ,17035145,Unavailable
 1626393 ,rate of exacerbations,"household repairs, including reduction of water infiltration, removal of water-damaged building materials, and heating/ventilation/air-conditioning alterations",only home cleaning information,Significantly decreased,"In the postremediation period, the remediation group had a lower rate of exacerbations compared with control asthmatics (as treated: 1 of 29 vs. 11 of 33, respectively, p = 0. 003; intent to treat: 28.1% and 10.0%, respectively, p = 0.11).",6413:6687, 1626393 ,17035145,Unavailable
 1936284 ,duration of respiratory infections (RI),Bacillus clausii,control group,Significantly decreased,Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049).,4132:4373, 1936284 ,18360611,Unavailable
 1936284 ,duration of respiratory infections (RI),Bacillus clausii (allergic treated children),control group (allergic treated children),Significantly decreased,"Moreover, allergic treated children had shorter durations of RI (7.72 ± 2.9) than allergic nontreated (13.1 ± 5.3) (p=0.039).",15548:15673, 1936284 ,18360611,Unavailable
 1586021 ,The proportion of men with presumed early recanalization,vas occlusion by ligation and excision with   fascial interposition (FI),vas occlusion by ligation and excision without  fascial interposition (FI),Significantly decreased,"The proportion of men with presumed early recanalization was 25% (95% CI 21%–30%) with ligation and excision without FI, 10% (95% CI 7%–13%) with ligation and excision with FI, 9% (95% CI 5%–13%)",22153:22348, 1586021 ,16984640,Unavailable
 1586021 ,The proportion of men with presumed early recanalization,vas occlusion by ligation and excision with   fascial interposition (FI)  with thermal cautery,vas occlusion by ligation and excision without  fascial interposition (FI) with electrocautery,Significantly increased,"The proportion of men with presumed early recanalization was 25% (95% CI 21%–30%) with ligation and excision without FI, 10% (95% CI 7%–13%) with ligation and excision with FI, 9% (95% CI 5%–13%) with electrocautery without FI, and 0% (95% CI 0%–2%) with thermal cautery with FI.",22153:22432, 1586021 ,16984640,Unavailable
 1586021 ,adverse event,vas occlusion by ligation and excision with   fascial interposition (FI)  with thermal cautery,vas occlusion by ligation and excision without  fascial interposition (FI) with electrocautery,No significant difference,"The risk of early recanalization was similar whether or not the men experienced a vasectomy related adverse event (without FI 32% vs 24%, p = 0.15; with FI 10% vs 11%, p = 0.83).",26610:26789, 1586021 ,16984640,Unavailable
 1913056 ,Median urinary lactulose/rhamnose excretion ratio (g/g),indomethacin plus placebo,control condition,Significantly increased,"Compared to the control condition, lactulose/rhamnose ratio after ingestion of indomethacin plus placebo was significantly increased to 0.039 (0.035–0.068); P &lt; 0.01).",6114:6282, 1913056 ,17578566,Unavailable
 1913056 ,Median urinary lactulose/rhamnose excretion ratio (g/g) between the conditions," indomethacin plus placebo,","indomethacin + ATP, indomethacin + adenosine",No significant difference,"Differences in L/R ratios between the conditions with indomethacin plus placebo, ATP or adenosine were not significant.",25438:25621, 1913056 ,17578566,Unavailable
 1913056 ,Median urinary lactulose/rhamnose excretion ratio, indomethacin plus ATP ,placebo,No significant difference,"Median L/R ratio after ingestion of indomethacin plus ATP was 0.047 (0.033–0.065; P = 0.22 vs. placebo),",NaN:NaN, 1913056 ,17578566,Unavailable
 1913056 ,Basal urinary recovery of L-rhamnose,"indomethacin + ATP,  indomethacin + adenosine",indomethacin + placebo,No significant difference,"Basal urinary recovery of L-rhamnose was not significantly affected by ingestion of indomethacin plus placebo, ATP or adenosine (Table 1).",25438:25621, 1913056 ,17578566,Unavailable
 58836 ,reducing cardiovascular risk at 12 month follow up,an absolute risk level (AR),the number needed to treat to prevent an adverse event (NNT),No significant difference,"Presenting cardiovascular risk as either an AR or NNT had no impact reducing cardiovascular risk at 12 month follow up, adjusted odds ratio 1.53 (95%CI 0.76 to 3.08).",3871:4037, 58836 ,11686857,Unavailable
 58836 ,systolic or diastolic  blood pressure,an absolute risk level (AR),the number needed to treat to prevent an adverse event (NNT),No significant difference,"There was no difference between the two groups in systolic (adjusted difference 0.97 mmHg, 95%CI -2.34 mmHg to 4.29 mmHg) or diastolic (adjusted difference 0.70 mmHg, 95%CI -1.05 mmHg to 2.45 mmHg) blood pressure.",4038:4252, 58836 ,11686857,Unavailable
 58836 ,Intensity of prescribing of blood pressure lowering drugs,an absolute risk level (AR),the number needed to treat to prevent an adverse event (NNT),No significant difference,Intensity of prescribing of blood pressure lowering drugs was not significantly different between the two groups at six months follow up.,4252:4389, 58836 ,11686857,Unavailable
 1524987 ,The mean level of the double product, C - 40 mcg/kg/min of dobutamine, B -  20 mcg/kg/min of dobutamine,Significantly decreased,The mean level of the double product was significantly lower in the group C patients when compared to group B patients (p = 0.002).,4767:4966, 1524987 ,16569248,Unavailable
 1524987 ,The mean test time, C - 40 mcg/kg/min of dobutamine," B -  20 mcg/kg/min of dobutamine A - 10 mcg/kg/min of dobutamine,",Significantly increased,The mean test time (12.8 ± 3.1 and 18.7 ± 3.4 p= 0.0001) and the mean total dose of dobutamine (14 × 18 × 25 mg p = 0.008) were significantly higher in group C patients than in group A &amp; B patients.,4767:4966, 1524987 ,16569248,Unavailable
 1524987 ,the mean total dose of dobutamine, C - 40 mcg/kg/min of dobutamine," B -  20 mcg/kg/min of dobutamine A - 10 mcg/kg/min of dobutamine,",Significantly increased,The mean test time (12.8 ± 3.1 and 18.7 ± 3.4 p= 0.0001) and the mean total dose of dobutamine (14 × 18 × 25 mg p = 0.008) were significantly higher in group C patients than in group A &amp; B patients.,4767:4966, 1524987 ,16569248,Unavailable
 59899 ,morbidity and mortality,needlescopic appendectomy,laparoscopic appendectomy,No significant difference,No postoperative morbidity or mortality occurred in either group.,4429:4495, 59899 ,11716795,Unavailable
 59899 ,mean operative time,needlescopic appendectomy,laparoscopic appendectomy,Significantly decreased,"The mean operative time was 55 minutes (range, 45–65 minutes) for the needlescopic group and 74 minutes (range, 38–120 minutes) for the laparoscopic group, statistically significantly less (p = 0.02) operative time for the needlescopic group.",12392:12634, 59899 ,11716795,Unavailable
 59899 ,The mean in-hospital use of narcotic analgesia,needlescopic appendectomy,laparoscopic appendectomy,Significantly decreased,The mean in-hospital use of narcotic analgesia as measured in MSO4 equivalent was 11 mg in the patients who underwent needlescopic appendectomy compared with 34 mg in the laparoscopic group (p = 0.05).,13662:13863, 59899 ,11716795,Unavailable
 59899 ,Mean days to return to work or normal activities,needlescopic appendectomy,laparoscopic appendectomy,Significantly decreased,"Mean days to return to work or normal activities	8 (range, 5–14)	17 (range, 7–21)	P = 0.03 *",14769:NaN, 59899 ,11716795,Unavailable
 59899 ,Mean length of hospital stay (days),needlescopic appendectomy,laparoscopic appendectomy,Significantly decreased,"Mean length of hospital stay (days)	1.3 (range, 1–4)	3.2 (range, 1–7)	P = 0.04 *",14545:14693, 59899 ,11716795,Unavailable
 535900 ,systolic and diastolic blood pressures,C -  natural mineral water,baseline,Significantly decreased,"Table 3 shows the blood pressure before and after intervention. Among persons consuming water C, both the systolic and diastolic blood pressures decreased significantly at 2 and 4 weeks.",14757:14982, 535900 ,15571635,Unavailable
 535900 ,calcium/creatinine and magnesium/creatinine in the urine,"C -  natural mineral water, B-  magnesium enriched water",baseline,No significant difference,It is seen that persons consuming waters B and C had significantly higher amounts of magnesium in the urine after the intervention. No significant effects of the waters on serum levels of magnesium could be detected (data not shown).,12961:13194, 535900 ,15571635,Unavailable
 546184 ,depressive symptom severity,duloxetine (40–120 mg/d) for melancholic and non-melancholic patients,placebo for melancholic and non-melancholic patients,Significantly decreased,"Duloxetine demonstrated significantly greater improvement in depressive symptom severity, compared with placebo, within both melancholic and non-melancholic cohorts (p ≤ .001 for HAMD17 total score, CGI-S and PGI-I).",5659:5913, 546184 ,15631624,Unavailable
 546184 ,the magnitude of improvement in efficacy outcomes,duloxetine (40–120 mg/d) male  melancholic patients,duloxetine (40–120 mg/d) female  melancholic patients,No significant difference,"When analyzed by gender, the magnitude of improvement in efficacy outcomes did not differ significantly between duloxetine-treated male and female melancholic patients.",5659:5913, 546184 ,15631624,Unavailable
 546184 ,"severity of symptoms according to Hamilton Rating Scale for Depression (HAMD17) total score,  the Clinical Global Impression of Severity (CGI-S) and Patient Global Impression of Improvement (PGI-I) scales",duloxetine (60 mg/d) for melancholic patients,placebo for melancholic patients,Significantly decreased,"In the two studies that assessed duloxetine 60 mg once-daily dosing, duloxetine-treated melancholic patients had significantly greater improvement compared with placebo on HAMD17 total score, CGI-S, PGI-I, 3 of 4 subscales of the HAMD17, and VAS overall pain severity (p &lt; .01).",5659:5913, 546184 ,15631624,Unavailable
 546184 ,Estimated probabilities of response and remission,duloxetine (60 mg/d)  for melancholic patients,placebo for melancholic patients,Significantly increased,"Estimated probabilities of response and remission were significantly greater for melancholic patients receiving duloxetine 60 mg QD compared with placebo (response 74.7% vs. 42.2%, respectively, p &lt; .001; remission 44.4% vs. 24.7%, respectively, p = .002",5659:5913, 546184 ,15631624,Unavailable
 1562427 ,"total physical activity (min/d),total moderate activity (min/d), Time spent sitting (min/d), total counts per day, counts per minute",1) resistance training; 2) all-round functional-skills training;,3) both;  4) an 'educational' control condition.,No significant difference,There were no between-group differences for changes in habitual physical activity or constipation over 6-months.,4139:4251, 1562427 ,16875507,Unavailable
 29012 ,radioactivity,"cisapride (10 mg, via nasogastric tube)",placebo,Significantly decreased,The difference in radioactivity during cisapride and placebo administration became statistically significant after the third hour (P &lt; 0.05).,18951:19118, 29012 ,11056722,Unavailable
 29012 ,The cumulative bronchial secretion radioactivity,"cisapride (10 mg, via nasogastric tube)",placebo,Significantly decreased,"The cumulative bronchial secretion radioactivity obtained when patients received cisapride was significantly lower than when patients received a placebo: 7540 ± 5330 and 21965 ± 16080 cpm, respectively (P &lt;0.05).",3932:4173, 29012 ,11056722,Unavailable
 1550875 ,length of stay in the intensive care unit after infection,"cefepime (C group), cefepime with amikacin (C-A group)",cefepime with levofloxacin (C-L group),No significant difference,"The length of ICU stay after the occurrence of infection was not different between the three groups: the medians (and 25th to 75th percentile in parentheses) were 15 (7.5 to 24.75), 16 (9 to 21) and 14 days (9.5 to 21.5) for groups C, C-A and C-L, respectively.",17106:17367, 1550875 ,16569261,Unavailable
 1550875 ,ventilator free days,"cefepime (C group), cefepime with amikacin (C-A group)",cefepime with levofloxacin (C-L group),No significant difference,"There was also no difference between VFDs within 28 days after infection: the number of VFDs for each group was 16.1 ± 8.3 VFDs after C treatment, 12.6 ± 8.1 VFD after C-A treatment and 12.6 ± 10.4 VFD after C-L treatment (p &gt; 0.05).",17368:17618, 1550875 ,16569261,Unavailable
 1550875 ,"the time course of temperature, leukocytosis or C-reactive protein level","cefepime (C group), cefepime with amikacin (C-A group)",cefepime with levofloxacin (C-L group),No significant difference,"No significant difference was observed regarding the time course of temperature, leukocytosis or C-reactive protein level.",5030:5152, 1550875 ,16569261,Unavailable
 1513247 ,"diarrhoea, bloating and flatulence",Dietary nucleotides,placebo,No significant difference,"The differences between conditions for diarrhoea, bloating and flatulence were not significant at the p &lt; .05 level.",4680:4797, 1513247 ,16762076,Unavailable
 1513247 ,"anxiety, depression, illness intrusiveness and general health",Dietary nucleotides,placebo,No significant difference,There were no significant differences between the conditions for any of the psychological measures.,4797:4896, 1513247 ,16762076,Unavailable
 1193545 ,pain level,The blood-nourishing and hard-softening (BNHS) capsule,(chondroprotection drug/Viartril-s) - control,No significant difference,"As assessed by the WOMAC index, pain level of the BNHS group decreased by 57% [95% confidence interval (CI) = 50, 63], stiffness by 63% (95% CI = 55, 71) and functional ability increased by 56% (95% CI = 50, 63).",5037:5250, 1193545 ,16136214,Unavailable
 1193545 ,stiffness and functional ability,The blood-nourishing and hard-softening (BNHS) capsule,(chondroprotection drug/Viartril-s) - control,No significant difference,No significant differences were found in any of the outcome measures between the BNHS group and either of the comparison groups.,5251:5380, 1193545 ,16136214,Unavailable
 1193545 ,severe adverse effects,The blood-nourishing and hard-softening (BNHS) capsule,(chondroprotection drug/Viartril-s) - control,No significant difference,No severe adverse effects were reported.,5380:5420, 1193545 ,16136214,Unavailable
 1936363 ,survival,Erlotinb in combination with gemcitabine,gemcitabine monotherapy,Significantly increased,"Certainly in the NCIC Phase III study in pancreatic cancer, sub-group analysis also suggested an association with skin rash and survival; median survival for patients with grade 0 skin rash (n=79) was 5.29 months, with grade 1 skin rash (n=108) was 5.75 months and with grade 3 skin rash (n=103) was 10.51 months (Moore et al 2005). The difference in survival between patients who developed grade 2 rash compared with grade 0/1 was statistically significant (p&lt;0.0001).",44606:45114, 1936363 ,18360654,Unavailable
 57749 ,the incidence of death or MI,eptifibatide,placebo,Significantly decreased,Eptifibatide reduced the incidence of death or MI in the PURSUIT trial by 1.5% (15.7% versus 14.2%; P = 0.042) at 30 days [6].,18155:18336, 57749 ,11806793,Unavailable
 60658 ,gestational age birthweight (SGA,beta-blockers (βb),non-βb drugs,No significant difference,"A higher risk for SGA was observed among the offspring of women who received a βb agent (OR 2.3, 95% CI 1.3–3.4), a non-βb agent (OR 2.1, 95% CI 1.3–3.4), or both (OR 2.7, 95% CI 1.8–3.9) (Table 4).",27606:27844, 60658 ,11737873,Unavailable
 60658 ,The rate of preterm delivery before 32 weeks,beta-blockers (βb),non-βb drugs,No significant difference,"The rate of preterm delivery before 32 weeks was also higher with βb use than with no active treatment (14.7% versus 1.9%, respectively; OR 7.6, 95% CI 4.1–14.1), rising to 20.7% with non-βb therapies (OR 13.4, 95% CI 6.8–26.2) and to 34.7% with combined therapy (OR 21.1, 95% CI 11.6–38.3).",27844:28136, 60658 ,11737873,Unavailable
 1968524 ,The overall response rate,continuous infusion (CI) pump,bolus therapy,No significant difference,The overall response rate was 64% (18% complete response-CR) and 69% (30% CR) respectively (P = 0.13).,2393:2496, 1968524 ,8390287,Unavailable
 1968524 ,The median WHO score for haematological toxicity,continuous infusion (CI) pump,bolus therapy,Significantly increased,The median WHO score for haematological toxicity was 4 for bolus therapy and 3 for CI therapy (P = 0.0007).,2497:2604, 1968524 ,8390287,Unavailable
 1968524 ,myelotoxicity,continuous infusion (CI) pump,bolus therapy,Significantly increased,There were fewer treatment delays due to myelotoxicity in the CI arm (P = 0.04).,2776:2857, 1968524 ,8390287,Unavailable
 1968524 ,nausea,continuous infusion (CI) pump,bolus therapy,Significantly decreased,There was significantly less nausea (P = 0.037) but more mucositis (P = 0.01) in the CI arm.,2943:3036, 1968524 ,8390287,Unavailable
 1968524 ,mucositis,continuous infusion (CI) pump,bolus therapy,Significantly increased,There was significantly less nausea (P = 0.037) but more mucositis (P = 0.01) in the CI arm.,2943:3036, 1968524 ,8390287,Unavailable
 1974808 ,The average total direct costs ,caspofungin,liposomal amphotericin B,No significant difference,The average total direct costs with caspofungin was £9763 (6955–12 577; 95% CI) compared with £11 795 (8902–14 724; 95% CI) for L-Amb.,39597:39732, 1974808 ,17419744,Unavailable
 1513142 ,times at which individual children fell asleep,aromatherapy massage with lavender oil,massage without lavender oil,Significantly decreased,"There was however a significant participant effect suggesting that there were systematic differences in the times at which individual children fell asleep (F = 59.83; df = 1, 10; P &lt; 0.001; meansleep onset time range 9:30 p.m. and 11:40 p.m. Table 1).",11683:12012, 1513142 ,16951722,Unavailable
 1513142 ,The length of time the children were asleep,aromatherapy massage with lavender oil,massage without lavender oil,No significant difference,"The length of time the children were asleep was also subject to a repeated measures analysis of variance which showed that there was no significant difference between the nights with and without aromatherapy (F = 0.59; df = 16, 160; P = 0.89).",12479:12756, 1513142 ,16951722,Unavailable
 1513142 ,sleep durations,aromatherapy massage with lavender oil,massage without lavender oil,Significantly increased,"There was however a statistically significant child effect suggesting that different children had significantly different sleep durations (F = 1411.4; df = 1, 10; P &lt; 0.001; Table 1). The average number of hours slept per child ranged between 6.85 and 8.88 h.",12870:13207, 1513142 ,16951722,Unavailable
 1578590 ,double product,"A or B (early protocol when atropine was administered at 10 and 20 mcg/kg/min of dobutamine, respectively)",group who were not Beta-blocked,Significantly decreased,Beta-blocked patients who received early atropine (Group A&amp;B) had a significantly lower double product (p = 0.008),4832:5106, 1578590 ,16848911,Unavailable
 1578590 ,mean test time,"A or B (early protocol when atropine was administered at 10 and 20 mcg/kg/min of dobutamine, respectively)",group who were not Beta-blocked,Significantly increased,"Beta-blocked patients who received early atropine (Group A&amp;B) had a significantly lower double product (p = 0.008), a higher mean test time (p = 0.010) and required a higher dose of atropine (p = 0.0005) when compared to the patients in this group who were not Beta-blocked.",4832:5106, 1578590 ,16848911,Unavailable
 1578590 ,dose of atropine,"A or B (early protocol when atropine was administered at 10 and 20 mcg/kg/min of dobutamine, respectively)",group who were not Beta-blocked,Significantly increased,"Beta-blocked patients who received early atropine (Group A&amp;B) had a significantly lower double product (p = 0.008), a higher mean test time (p = 0.010) and required a higher dose of atropine (p = 0.0005) when compared to the patients in this group who were not Beta-blocked.",4832:5106, 1578590 ,16848911,Unavailable
 1578590 ,Complications,C (standard protocol with atropine at 40 mcg/kg/min of dobutamine)," A or B (early protocol when atropine was administered at 10 and 20 mcg/kg/min of dobutamine, respectively)",No significant difference,Complications were similar in both groups.Conclusion,5422:NaN, 1578590 ,16848911,Unavailable
 1578590 ,test time,"A or B (early protocol when atropine was administered at 10 and 20 mcg/kg/min of dobutamine, respectively), C (standard protocol with atropine at 40 mcg/kg/min of dobutamine)",baseline,Significantly increased,"The same findings occurred in the standard protocol (Group C), however the early administration of atropine reduced test time both in the presence and absence of this therapy (p = 0.0001).",5107:5295, 1578590 ,16848911,Unavailable
 1810515 ,Median time to peak plasma concentration (Tmax),Treatment B (OROS® hydromorphone 16 mg; fed conditions,Treatment A (OROS® hydromorphone 16 mg; fasting conditions) ,Significantly decreased,Median Tmax was achieved 4 hours earlier when OROS® hydromorphone was administered under fed conditions compared with fasting conditions (12 vs. 16 hours; P = 0.0062).,20944:21150, 1810515 ,17270055,Unavailable
 1693563 ,forced expiratory spirogram,10 mg intravenous adenosine - Normals,10 mg intravenous adenosine - Asthmatics ,No significant difference,"Similarly, adenosine injection caused no significant changes (p &gt; 0.05) in the forced expiratory spirogram;",4179:4267, 1693563 ,17137511,Unavailable
 1693563 ,development of dyspnea,10 mg intravenous adenosine - Normals,10 mg intravenous adenosine - Asthmatics,Significantly increased,"however, there was a rapid development of dyspnea as signified visually on a modified Borg scale, and a significant (p &lt; 0.05) tachycardia in each subject (Asthmatics +18%, Normals + 34%), and a significant (p &lt; 0.05) increase in Ve (Asthmatics +93%, Normals +130%).",3912:4179, 1693563 ,17137511,Unavailable
 1693563 ,tachycardia,10 mg intravenous adenosine  - Normals,10 mg intravenous adenosine - Asthmatics,Significantly increased,"however, there was a rapid development of dyspnea as signified visually on a modified Borg scale, and a significant (p &lt; 0.05) tachycardia in each subject (Asthmatics +18%, Normals + 34%), and a significant (p &lt; 0.05) increase in Ve (Asthmatics +93%, Normals +130%).",3912:4179, 1693563 ,17137511,Unavailable
 1693563 ,minute ventilation (Ve),10 mg intravenous adenosine - Normals,10 mg intravenous adenosine - Asthmatics,Significantly increased,"however, there was a rapid development of dyspnea as signified visually on a modified Borg scale, and a significant (p &lt; 0.05) tachycardia in each subject (Asthmatics +18%, Normals + 34%), and a significant (p &lt; 0.05) increase in Ve (Asthmatics +93%, Normals +130%).",3912:4179, 1693563 ,17137511,Unavailable
 1693563 ,intensity of dyspnea,10 mg intravenous adenosine - Asthmatics,10 mg intravenous adenosine - Normals,Significantly increased,The intensity of dyspnea was significantly greater (p &lt; 0.05) in the asthmatic subjects.,3912:4179, 1693563 ,17137511,Unavailable
 529470 ,early failures,intraluminal cautery,ligation and excision with fascial interposition,Significantly decreased,We found significantly fewer early failures in the cautery study than in the fascial interposition group from the randomized controlled trial: 1.0% (4/389) versus 4.9% (20/410) (p = 0.0014 by the Fisher exact test).,17244:17459, 529470 ,15509302,Unavailable
 529470 ,severe oligozoospermia,intraluminal cautery,ligation and excision with fascial interposition,Significantly increased,Life-table analyses of time to success showed that the participants in the cautery study reached severe oligozoospermia significantly more rapidly than did those in the fascial interposition study (p = 0.0049) (Figure 2).,18393:18651, 529470 ,15509302,Unavailable
 529470 ,azoospermia,intraluminal cautery,ligation and excision with fascial interposition,Significantly increased,"Using the time to azoospermia outcome, the difference between the two groups was also significant (p &lt; 0.0001) (data not shown).",18911:19039, 529470 ,15509302,Unavailable
 1569640 ,mean body weight,nateglinide,gliclazide,No significant difference,"A small increase in mean body weight of less than 0.5 kg was observed in both groups, but the changes from baseline were not significant in either case and there was no significant difference (P = 0.879) between treatments (data not shown).",22712:22969, 1569640 ,16842480,Unavailable
 1569640 ,maximum postprandial glucose,nateglinide,gliclazide,Significantly decreased,"However, the decrease from baseline in maximum postprandial glucose excursion was significant in the nateglinide group only and the decrease was significantly greater with nateglinide compared with gliclazide (P = 0.037).",23271:23510, 1569640 ,16842480,Unavailable
 1569640 ,The postprandial glucose AUC0−4 h,nateglinide,gliclazide,No significant difference,"The postprandial glucose AUC0−4 h, adjusted for pre-meal values, was significantly decreased after 24 weeks of treatment in the nateglinide group (−2.20 mmolh/l; P &lt; 0.001) but the decrease in the gliclazide group (−0.61 mmolh/l) was not significant; the difference between the changes from baseline did not reach significance (P = 0.054).",23511:23899, 1569640 ,16842480,Unavailable
 1569640 ,The postprandial glucose AUC0−4 h,nateglinide,baseline,Significantly decreased,"The postprandial glucose AUC0−4 h, adjusted for pre-meal values, was significantly decreased after 24 weeks of treatment in the nateglinide group (−2.20 mmolh/l; P &lt; 0.001) but the decrease in the gliclazide group (−0.61 mmolh/l) was not significant; the difference between the changes from baseline did not reach significance (P = 0.054).",23511:23899, 1569640 ,16842480,Unavailable
 1618389 ,The average number of correct answers,Long-menu questions (LMQs),open-ended questions (OEQs),No significant difference,The average number of correct answers for LMQs and OEQs showed no significant difference (p = 0.93).,5411:5511, 1618389 ,17032439,Unavailable
 1618389 ,The response time,Long-menu questions (LMQs),open-ended questions (OEQs),No significant difference,The response time for LMQs did not significantly differ from that of OEQs (p = 0.65).,5608:5693, 1618389 ,17032439,Unavailable
 1968304 ,median survival time,The log-rank test,baseline,Significantly increased,"For 500 simulated patients recruited over a 5 year period and then followed for three additional years, a 50% enhancement of median survival time (to 5.1 years) led to a survival increase detectable at the P = 0.05 level in 780 of 1000 trials, whereas a 50% enhancement of cured fraction (to 40.5%) led to a detectable increase at the same level in only 449 of 1000 trials.",2002:2376, 1968304 ,8318401,Unavailable
 1821028 ,"total cholesterol, LDL-cholesterol","garlic powder tablet (equal to 400 mg garlic, 1 mg allicin) ",baseline,Significantly decreased,"In garlic group: total cholesterol (decreased by 26.82 mg/dl, 12.1% reduction, and P-value: .000), and LDL-cholesterol (decreased by 22.18 mg/dl, 17.3% reduction, and P-value: .000) dropped.",3957:4068, 1821028 ,17328819,Unavailable
 1821028 ,HDL-cholesterol,"garlic powder tablet (equal to 400 mg garlic, 1 mg allicin) ",baseline,Significantly increased,"HDL-cholesterol (increased by 10.02 mg/dl, 15.7% increase, and P-value: .000) increased.",3957:4068, 1821028 ,17328819,Unavailable
 1821028 ,triglyceride,"garlic powder tablet (equal to 400 mg garlic, 1 mg allicin) ",baseline,No significant difference,Although triglyceride dropped by 13.72 mg/dl (6.3%) but this was not significant statistically (P-value: .222).,3957:4068, 1821028 ,17328819,Unavailable
 1821028 , total cholesterol and LDL-cholesterol,anethum tablet (650 mg),baseline,No significant difference,"Anethum could reduce total cholesterol by 0.4 % and LDL-cholesterol by 6.3% but these were not significant statistically (P-value: .828, and .210, respectively).",4147:4308, 1821028 ,17328819,Unavailable
 1949842 ,infants were diagnosed as HIV-infected,Highly active antiretroviral treatment (HAART) group, antiretroviral (scARV) prevention of mother-to-child transmission of HIV (PMTCT),No significant difference,"At 12 mo, 5.7% (95% CI 2.5%–9.0%) of the infants were diagnosed as HIV-infected: 3.3% (95% CI 0.0%–6.9%) in the HAART group and 7.5% (95% CI 2.8%–12.3%) in the scARV for PMTCT group (log-rank test, p = 0.18).",34694:34920, 1949842 ,17713983,Unavailable
 1949842 ,infant feeding practice,Highly active antiretroviral treatment (HAART) group, antiretroviral (scARV) prevention of mother-to-child transmission of HIV (PMTCT),No significant difference,No statistically significant difference was found according to the infant feeding practice (p = 0.48).,34921:35040, 1949842 ,17713983,Unavailable
 1949842 ,the rate of postnatal transmission,Highly active antiretroviral treatment (HAART) group, antiretroviral (scARV) prevention of mother-to-child transmission of HIV (PMTCT),No significant difference,"If we hypothesize that the three cases with unknown timing are possible postnatal cases, the rate of postnatal transmission could be 3.8% (0.4%–12.9%) in the HAART group and 5.7% (1.8%–12.7%) in the PMTCT group.",37814:38026, 1949842 ,17713983,Unavailable
 1949842 ,The overall probability of HIV infection or death among infants aged 12 mo,Highly active antiretroviral treatment (HAART) group, antiretroviral (scARV) prevention of mother-to-child transmission of HIV (PMTCT),No significant difference,"The overall probability of HIV infection or death among infants aged 12 mo of all women enrolled in this study was 11.7% (95% CI 7.5%–15.9%); the probability was 11.2% (95% CI 5.0%–17.4%) among infants born to HAART-treated women, and 12.1% (95% CI 6.4%–17.9%) among infants whose mothers received scARV for PMTCT only (log-rank test, p = 0.90) (Table 4).",38703:39129, 1949842 ,17713983,Unavailable
 1949842 ,rates of premature births,Highly active antiretroviral treatment (HAART) group, antiretroviral (scARV) prevention of mother-to-child transmission of HIV (PMTCT),No significant difference,"No significant difference in the rates of premature births (gestational age &lt;37 wk) was noted between the two groups (7.8% and 7.9% respectively, p = 1.00).",41959:42135, 1949842 ,17713983,Unavailable
 1949842 ,low birth weight,Highly active antiretroviral treatment (HAART) group, antiretroviral (scARV) prevention of mother-to-child transmission of HIV (PMTCT),Significantly increased,"However, a higher proportion of low birth weight (&lt;2,500 g) was observed in neonates whose mothers had received HAART, 26.3% compared with 12.4% among those having received a scARV for PMTCT regimen (p &lt; 0.001).",42136:42367, 1949842 ,17713983,Unavailable
 1977002 ,The incidence of macroscopic haematuria,mesna (2-mercaptoethane sulphonate sodium),baseline,Significantly decreased,"The incidence of macroscopic haematuria was significantly lower in the mesna treated group (chi 2 = 4.03, P less than 0.05).",2230:2547, 1977002 ,6437430,Unavailable
 1334191 ,"C18:1, C20:4 and C22:6 within RBCs","unsaturated (high-USFA, 24 en%) fatty acids",baseline,Significantly increased,"Of the USFAs, higher levels of C18:1 MUFA, C20:4 and C22:6 long chain PUFA on high-USFA diet lead to higher C18:1, C20:4 and C22:6 within RBCs (ANOVA, time*diet, P &lt; 0.05).",5126:5299, 1334191 ,16329761,Unavailable
 1334191 ,RBC C16:0,saturated fatty acids (SFA),baseline,Significantly decreased,"Of the SFAs only RBC C16:0 decreased in response to decreased dietary content on high-USFA treatment (ANOVA, diet, P &lt; 0.05).",4999:5125, 1334191 ,16329761,Unavailable
 1590049 ,HTLV-I proviral load,zidovudine 300 mg plus lamivudine 150 mg twice daily (the active arm),matching zidovudine and lamivudine placebo tablets (the placebo arm),No significant difference,"No significant change in proviral load was seen during the first 24 weeks of the study in the active arm compared with the placebo arm (mean difference (SE): 0.02 (0.17), p = 0.92) (Table 3)",24495:24725, 1590049 ,16984654,Unavailable
 1590049 ,Total Lymphocytes (106/L),zidovudine 300 mg plus lamivudine 150 mg twice daily (the active arm),matching zidovudine and lamivudine placebo tablets (the placebo arm),No significant difference,"6/L in the placebo arm but decreased by 159 × 106/L in the active arm, a mean difference of 307 × 106/L (SE = 158, p = 0.07) (Table 3).",31309:31663, 1590049 ,16984654,Unavailable
 1590049 ,non CD3 lymphocytes,zidovudine 300 mg plus lamivudine 150 mg twice daily (the active arm),matching zidovudine and lamivudine placebo tablets (the placebo arm),Significantly decreased,"However the major impact on the absolute lymphocyte count appears mainly among non-T-lymphocytes with a mean rise of 50 × 106/L non CD3 lymphocytes during the first 24 weeks in the placebo arm compared with a mean decrease of 127 × 106/L from baseline in the active arm, a difference of 177 × 106/L (SE = 31, p &lt; 0.001).",31309:31663, 1590049 ,16984654,Unavailable
 1676011 ,delayed-type hypersensitivity (DTH) responses,"(2) micronutrient mix of 288 mg vitamin E, 375 mg vitamin C, 12 mg β-carotene and 15 mg zinc/day",baseline,Significantly increased,"Overall, consumption of the micronutrient mix significantly enhanced delayed-type hypersensitivity (DTH) responses (p &lt; 0.05).",4760:4886, 1676011 ,17118191,Unavailable
 1676011 ,Plasma concentrations of vitamin C &amp; E and β-carotene.,"(2) micronutrient mix of 288 mg vitamin E, 375 mg vitamin C, 12 mg β-carotene and 15 mg zinc/day, (3) combination of colostrum and micronutrient mix","(1) bovine colostrum concentrate 1.2 g/d (equivalent to ~500 mg/d immunoglobulins), (4) placebo.",Significantly increased,Levels in the micronutrient groups (micronutrient group ▲ and micronutrient + colostrum group △) are significantly different from levels in non-vitamin group (control ■ and colostrum group □) with ** p &lt; 0.0001.,35369:35580, 1676011 ,17118191,Unavailable
 1676011 ,percentage of B cells,"(2) micronutrient mix of 288 mg vitamin E, 375 mg vitamin C, 12 mg β-carotene and 15 mg zinc/day, (3) combination of colostrum and micronutrient mix","(1) bovine colostrum concentrate 1.2 g/d (equivalent to ~500 mg/d immunoglobulins), (4) placebo.",Significantly decreased,"A small but significant (p &lt; 0.05) decrease in the percentage of B cells was observed at 10 weeks in the micronutrient-groups compared to the non-micronutrient groups (LSM (CI) for control, colostrum, micronutrient, micronutrient + colostrum were 14.6 (12.9–16.4), 13.2 (11.5–15.0), 11.8 (10.0–13.6), 12.1(10.4–13.8), respectively).",43276:43608, 1676011 ,17118191,Unavailable
 1977696 ,median survival,45 Gy (in 20 fractions over 4 weeks) with 60 Gy (in 30 fractions over 6 weeks),baseline,Significantly increased,"They suggest a statistically significant prolongation of median survival from 9 months in the 45 Gy group to 12 months in the 60 Gy group (hazard ratio = 0.75, chi 2 = 7.36, d.f. = 1, P = 0.007).",1764:1960, 1977696 ,1654987,Unavailable
 1574360 ,The amount of saturated fat in the foods purchased,fully automated advice that recommended specific switches from selected products higher in saturated fat to alternate similar products lower in saturated fat,control received general non-specific advice about how to eat a diet lower in saturated fat,Significantly decreased,"The amount of saturated fat in the foods purchased by the intervention group was 0.66% lower (95% confidence interval 0.48–0.84, p &lt; 0.001) than in the control group.",5624:5808, 1574360 ,17013429,Unavailable
 1574360 ,the average cost of the food,fully automated advice that recommended specific switches from selected products higher in saturated fat to alternate similar products lower in saturated fat,control received general non-specific advice about how to eat a diet lower in saturated fat,No significant difference,"The effects of the intervention were sustained over consecutive shopping episodes, and there was no difference in the average cost of the food bought by each group.",5809:5973, 1574360 ,17013429,Unavailable
 1847683 , LDL cholesterol ,6 grams/day concentrated oat β-glucan,6 grams/day dextrose (control),Significantly decreased,Treatment of oat β-glucan significantly lowered LDL cholesterol compared to control (p &lt; 0.026).,26520:26616, 1847683 ,17386092,Unavailable
 1847683 ,total cholesterol,6 grams/day concentrated oat β-glucan,6 grams/day dextrose (control),No significant difference,Total Cholesterol (mmol/L)	6.2 ± 0.1	6.2 ± 0.1	0.976,21539:21660, 1847683 ,17386092,Unavailable
 1847683 ,HDL cholesterol,6 grams/day concentrated oat β-glucan,6 grams/day dextrose (control),No significant difference,HDL cholesterol did not change significantly in either the treatment or placebo group.,26617:26703, 1847683 ,17386092,Unavailable
 1847683 ,Triglycerides,6 grams/day concentrated oat β-glucan,6 grams/day dextrose (control),Significantly increased,The triglyceride change between the treatment and control group was significantly different (p = 0.030).,26922:27026, 1847683 ,17386092,Unavailable
 1764200 ,pain (painscores on VAS in millimetres ),meloxicam,placebo,No significant difference,Groups compared using the Wilcoxon two-sample test yielded p = 0.064 when comparing decrease of painscores on VAS in millimetres (Fig. 4).,13083:13258, 1764200 ,12831177,Unavailable
 1764200 ,pain (painscore on VAS was compared as a percentage),meloxicam,placebo,Significantly decreased,"When the groups' decrease of painscore on VAS was compared as a percentage, the Wilcoxon two-sample test yielded p = 0026 (Fig. 5).",13265:13433, 1764200 ,12831177,Unavailable
 1277845 ,triacylglycerol (TAG),"activity trials (30, 60, or 90 min of treadmill walking at 50% of their individual VO2max)",no physical activity,No significant difference,"Compared to the control trial the increase in AUC (dAUC) of TAG was +2% (P = 1.00), -14% (P = 0.24), and -15% (P = 0.23) for the 30, 60, and 90 min walking trials, respectively (Fig. 2).",15133:15357, 1277845 ,16209707,Unavailable
 1277845 ,Insulin concentration,"activity trials (30, 60, or 90 min of treadmill walking at 50% of their individual VO2max)",no physical activity,No significant difference,"Values are means (standard error of the mean). Overall mixed analysis with repeated measurements, effect of trial: P = 0.16.",17541:17666, 1277845 ,16209707,Unavailable
 1277845 ,postprandial insulin,"activity trials (30, 60, or 90 min of treadmill walking at 50% of their individual VO2max)",no physical activity,No significant difference,"Overall mixed model analysis, effect of trial: P = 0.25.",17982:18038, 1277845 ,16209707,Unavailable
 1277845 ,"Concentrations of glucose (A), glucagon (B), fatty acids (C), and glycerol (D)","activity trials (30, 60, or 90 min of treadmill walking at 50% of their individual VO2max)",no physical activity,Significantly decreased,Significant differences between means not sharing a common letter (P &lt; 0.05).,18487:18564, 1277845 ,16209707,Unavailable
 1914252 ,low density lipoprotein  cholesterol (LDL-C),atorvastatin 40&nbsp;mg for 8&nbsp;weeks and thereafter atorvastatin 80&nbsp;mg for the final 8&nbsp;weeks (aggressive treatment),baseline,Significantly decreased,"Lipid levels decreased significantly in the aggressive treatment group (LDL-C reduction 20.8%; P &lt; 0.001),",4928:5052, 1914252 ,17342417,Unavailable
 1914252 ,low density lipoprotein cholesterol (LDL-C),simvastatin 40mg,baseline,Significantly increased,whereas a slight increase was observed in the conventional group (LDL-C increase 3.7%; P = 0.037).,5052:5170, 1914252 ,17342417,Unavailable
 1914252 ,antibodies against oxidized LDL,simvastatin 40mg,baseline,Significantly decreased,and the conventional (26.8%; P &lt; 0.001) group,5171:5434, 1914252 ,17342417,Unavailable
 1914252 ,antibodies against oxidized LDL,atorvastatin 40mg for 8 weeks and thereafter atorvastatin 80 mg for the final 8 weeks (aggressive treatment),baseline,Significantly decreased,A significant reduction in antibodies against oxidized LDL was seen in the aggressive (13.4%; P &lt; 0.001),5171:5292, 1914252 ,17342417,Unavailable
 1914252 ,antibodies against oxidized LDL,atorvastatin 40 mg for 8 weeks and thereafter atorvastatin 80mg for the final 8weeks (aggressive treatment),simvastatin 40mg,No significant difference,"A significant reduction in antibodies against oxidized LDL was seen in the aggressive (13.4%; P &lt; 0.001) and the conventional (26.8%; P &lt; 0.001) group, but there was no difference between groups (P = 0.25).",5171:5434, 1914252 ,17342417,Unavailable
 1550825 ,days alive and free of  acute lung injury (ALI),inhaled salbutamol 'high dose' ≥ 2.2 mg/day ,inhaled salbutamol 'low dose' &lt;2.2 mg/day,Significantly increased,"The high dose salbutamol group had significantly more days alive and free of ALI than the low dose group (12.2 ± 4.4 days versus 7.6 ± 1.9 days, p = 0.02).",5293:5465, 1550825 ,16420663,Unavailable
 1891198 ,2-year event-free survival,100 mg thalidomide daily in addition to standard doses of melphalan and prednisone,baseline,Significantly increased,"It demonstrated that, in older patients with myeloma (median age: 72 years), the 2-year event-free survival was superior in patients who received 100 mg thalidomide daily in addition to standard doses of melphalan and prednisone [54% vs. 27%; hazard ratio (hr): 0.51; 95% confidence interval (ci): 0.35 to 0.75; p = 0.0006].",6531:6891, 1891198 ,17576467,Unavailable
 1891198 ,the 2-year event-free survival,thalidomide also received that drug as maintenance therapy,baseline,No significant difference,"Patients allocated to receive thalidomide also received that drug as maintenance therapy. The trial failed to detect a difference in overall survival (hr: 0.68; 95% ci: 0.38 to 1.22; p = 0.19), but the trial design did not have statistical power sufficient to address that outcome measure.",6891:7216, 1891198 ,17576467,Unavailable
 1891198 , progression-free survival and overall survival,100 mg thalidomide daily in addition to standard doses of melphalan and prednisone,melphalan and prednisone,Significantly increased,"Compared with melphalan and prednisone, the same agents with thalidomide added improved both median progression-free survival (29.5 months vs. 17.5 months, p &lt; 0.001) and overall survival (not reached vs. 30.3 months, p = 0.0008).",7545:7812, 1891198 ,17576467,Unavailable
 1291385 ,relief of pain,dexamethasone (prophylactic 8 mg and postoperative 4 mg IV) and diclofenac K (50 mg Oral before and after surgery),diclofenac K alone (as with first group),Significantly increased,Co-administration of dexamethasone and diclofenac K was significantly superior to diclofenac alone for the relief of pain (P &lt; 0.05),5029:5161, 1291385 ,16274480,Unavailable
 1291385 ,facial swelling up to post-operative 48 hour,dexamethasone (prophylactic 8 mg and postoperative 4 mg IV) and diclofenac K (50 mg Oral before and after surgery),diclofenac K alone (as with first group),Significantly decreased,"Co-administration of dexamethasone and diclofenac K was significantly superior to diclofenac alone for the relief of pain (P &lt; 0.05), and facial swelling up to post-operative 48 hour (P &lt; 0.05).",5029:5223, 1291385 ,16274480,Unavailable
 1291385 ,trismus relief,dexamethasone (prophylactic 8 mg and postoperative 4 mg IV) and diclofenac K (50 mg Oral before and after surgery),diclofenac K alone (as with first group),No significant difference,"However, there was no significant difference for trismus relief between the two medication protocols (P &gt; 0.05).",5224:5336, 1291385 ,16274480,Unavailable
 1978057 ,"Initial micronuclei counts (per 3,000 cells)",beta-carotene supplementation (20 mg d-1),placebo,Significantly increased,"Initial micronuclei counts (per 3,000 cells) were higher in the treatment group than in the placebo group (5.0 vs 4.0, P &lt; 0.05).",1888:2017, 1978057 ,1457358,Unavailable
 1488900 ,Overall asthma symptoms,Azithromycin,"placebo, plus usual community care",Significantly decreased,"Overall asthma symptoms improved in the azithromycin group (+0.55) and worsened in the placebo group (−0.13). The effect size (+0.68; 0.05, 1.29) in favor of azithromycin was statistically significant (p = 0.04) and remained significant (p = 0.004) after controlling for antibody level, age, sex, smoking, skin test status, infectious onset, age of asthma onset, asthma severity, and change in controller medication use (mostly inhaled corticosteroids).",26781:27268, 1488900 ,16871333,Unavailable
 1488900 ,Maximum overall symptom improvement,Azithromycin,"placebo, plus usual community care",Significantly increased,"Maximum overall symptom improvement in the azithromycin group appeared by 3 mo, remained stable through 6 mo, and was significantly (p = 0.04) different from placebo by linear regression analysis.",27421:27634, 1488900 ,16871333,Unavailable
 529310 ,The response rate,"rmhTNF 4 × 106u/m2 was given to the trial group, from the 1st to 7th days, the 11th to 17th days combined with chemotherapy course",control group was given only the same chemotherapy as the trial group.,Significantly increased,The response rate of the trial group was significantly higher than that of the control group (P = 0.022).,5278:5400, 529310 ,15485573,Unavailable
 529310 ,the KPS score,"rmhTNF 4 × 106u/m2 was given to the trial group, from the 1st to 7th days, the 11th to 17th days combined with chemotherapy course",control group was given only the same chemotherapy as the trial group.,Significantly increased,"After the treatment the KPS is 89.00 ± 9.92 in the trial group, and 84.17 ± 8.84 in the control group, with a significant difference between the two groups (P = 0.028).",5637:5822, 529310 ,15485573,Unavailable
 1713262 ,Vomiting,Cotrifazid, mefloquine,Significantly decreased,Vomiting was reported significantly less often in the Cotrifazid group than in the mefloquine group (p &lt; 0.001);,32615:32984, 1713262 ,17192794,Unavailable
 1713262 ,"stomach ache , vomiting, dizziness, and tinnitus",Cotrifazid,standard treatment of quinine with sulfadoxine–pyrimethamine (SP),Significantly decreased,"Vomiting was reported significantly less often in the Cotrifazid group than in the mefloquine group (p &lt; 0.001); stomach ache (p &lt; 0.05), vomiting (p &lt; 0.01), dizziness (p &lt; 0.05), and tinnitus (p &lt; 0.01) were less common in the Cotrifazid than in the quinine + SP group.",32615:32984, 1713262 ,17192794,Unavailable
 1713262 ,shortness of breath,Cotrifazid,mefloquine,Significantly increased,"In contrast, participants in the Cotrifazid group were reported shortness of breath significantly more often than did those in the mefloquine group (p &lt; 0.01) (see Table 2 for details).",32984:33246, 1713262 ,17192794,Unavailable
 1713262 ,the clinical cure rate,Cotrifazid,"mefloquine,	standard treatment of quinine with sulfadoxine–pyrimethamine (SP)",No significant difference,"The three treatment groups were therefore equivalent with regard to the clinical cure rate (100% in Cotrifazid and mefloquine groups and 99% in quinine + SP group, p = 0.32, Fisher's exact test).",37806:38101, 1713262 ,17192794,Unavailable
 1713262 ,Plasmodium-positive patients,Cotrifazid,mefloquine,Significantly increased,"Plasmodium-positive patients was significantly higher in the Cotrifazid group at 15% (11/72) than in the mefloquine group, 0% (0/71), and the quinine + SP group at 4% (3/75) (Fisher's exact test, p = 0.001).",35681:35915, 1713262 ,17192794,Unavailable
 1713262 ,the prevalence of asexual blood stage–positive patients,Cotrifazid,"mefloquine, standard treatment of quinine with sulfadoxine–pyrimethamine (SP)",Significantly increased,"In fact, the prevalence of asexual blood stage–positive patients (counting the missing ones as positive) at day 14 was still significantly higher in the Cotrifazid group (28%) than in the mefloquine group (15%) or the quinine + SP group (12%) (p &lt; 0.001, Fisher's exact test).",37806:38101, 1713262 ,17192794,Unavailable
 1440784 ,systolic blood pressure and diastolic blood pressure,succimer chelation,placebo,No significant difference,"Mixed models with adjustment of covariates showed that, for the interval from initiation of treatment to 9-month follow-up, the overall difference between the succimer and placebo groups is 0.24 mmHg (95% CI, −0.79 to 1.28 mmHg) for systolic blood pressure and 0.46 mmHg (95% CI, −0.44 to 1.36 mmHg) for diastolic blood pressure (both p &gt; 0.05).",18171:18533, 1440784 ,16581549,Unavailable
 1440784 ,systolic blood pressure and diastolic blood pressure,succimer chelation,baseline,Significantly increased,"Adjusted mixed models for the interval from 12-month to 60-month follow-up indicated a higher systolic blood pressure for the succimer group, with an estimated difference of 1.09 mmHg (95% CI, 0.27–1.90 mmHg; p &lt; 0.05); the estimated difference in diastolic blood pressure is 0.15 mmHg (95% CI, −0.45 to 0.75 mmHg; p &gt; 0.05).",18534:18899, 1440784 ,16581549,Unavailable
 1074719 ,Median overall survival,Cisplatin at 100 mg/m2,no further treatment (nihil group),No significant difference,"Median overall survival was 87 months for the cisplatin arm (82.0% at 3 years) and 89 months for the nihil arm (80.3% at 3 years) (p=0.66, log rank test).",15719:15873, 1074719 ,15912203,Unavailable
 1074719 ,Median disease free survival,Cisplatin at 100 mg/m2,no further treatment (nihil group),No significant difference,"Median disease free survival was 68 months (range 1.4-170.0) for the Cisplatin arm (62.1% at three years for the cisplatin arm) and 73 months (range 1.6-169.5) for the nihil arm (62.3% at three years for the nihil arm). There was no statistical difference between the two groups (p=0.41, log rank test).",15873:16177, 1074719 ,15912203,Unavailable
 1253473 ,fruit and vegetable intake," the Little by Little CD-ROM plus two reminder telephone calls,",a stress management CD-ROM (control condition),Significantly increased,"The Little by Little group with phone calls increased fruit and vegetable intake by 1.32 occurrences per day, compared with 0.71 occurrences per day in the stress-reduction group (P = .016).",27545:27770, 1253473 ,15670429,Unavailable
 1253473 ,fruit and vegetable intake, a one-time experience with the Little by Little CD-ROM,a stress management CD-ROM (control condition),No significant difference,"The Little by Little group with no telephone follow-up increased fruit and vegetable intake by 1.20 occurrences per day, also significantly greater than the stress-reduction group (P = .052).",29368:29684, 1253473 ,15670429,Unavailable
 1253473 ,Stage of Readiness for Change," the Little by Little CD-ROM plus two reminder telephone calls,",a stress management CD-ROM (control condition),Significantly increased,"Both Little by Little groups increased in Stage of Readiness for Change, but only the Little by Little group with telephone follow-up was statistically significant (P = .01) compared with the stress-reduction group (Table 4).",29368:29684, 1253473 ,15670429,Unavailable
 1940068 ,"OGG1 activity  or mRNA expression levels of repair enzymes  including HO-1, OGG1, and NUDT1",particles (NC 6169-15362/cm3),filtered air (NC 91-542/cm3),No significant difference,"There were no significant associations between exposure and either the OGG1 activity (p = 0.26) or mRNA expression levels of repair enzymes (p &gt; 0.13) including HO-1, OGG1, and NUDT1.",31139:31356, 1940068 ,17687444,Unavailable
 1173136 ,Systolic blood pressure,one clove of garlic (1 gr) by chewing or swallowing for two months,pre garlic period,Significantly decreased,Systolic blood pressure decreased from138.2 to 132.8 mmHg (p=0.001),4518:4587, 1173136 ,15943877,Unavailable
 1173136 ,Malondialdehyde (MDA),one clove of garlic (1 gr) by chewing or swallowing for two months,pre garlic period,Significantly decreased,Malondialdehyde (MDA) decreased from 2.4 to1.7 nmol/ml (p=0.009) by swallowing route,4591:4681, 1173136 ,15943877,Unavailable
 1173136 ,"Cholesterol , triglyceride",one clove of garlic (1 gr) by chewing or swallowing for two months,pre garlic period,Significantly decreased,"Cholesterol decreased from 205.1 to 195.3 mg/dl (p=0.03), triglyceride decreased from 195.7 to 174.8 mg/dl (p=0.008)",4684:4814, 1173136 ,15943877,Unavailable
 1173136 ,"HDL, LDL and cyclosporine serum levels",one clove of garlic (1 gr) by chewing or swallowing for two months,pre garlic period,No significant difference,"However HDL, LDL and cyclosporine serum levels had no significant differences by both of swallowing and chewing routes.",5095:5231, 1173136 ,15943877,Unavailable
 56204 ,"ST-segment depression (STD) duration (min), Ischaemic burden, Maximum STD (mV)","ramipril 5 mg/day (n = 133), ramipril 1.25 mg/day",placebo,No significant difference,"There were no significant differences in the changes from baseline to study end between the ramipril groups and placebo. STD is defined as ST-segment depression of ≥ 0.1 mV. STD duration and ischaemic burden are given per 24 h. SD, standard deviation.",17953:18204, 56204 ,11806779,Unavailable
 1904193 ,precision score,PICO templates (Protocol A or Protocol B),"Protocol C, the standard PubMed Web interface",No significant difference,"(Question 1: A = 35%, B = 28%, C = 20%; Question 2: A = 5%, B = 6%, C = 4%; Question 3: A = 1%, B = 0%, C = 0%) 95% confidence intervals were calculated for the precision for each question using a lower boundary of zero. However, the 95% confidence limits were overlapping, suggesting no statistical difference between the groups.",5513:5844, 1904193 ,17573961,Unavailable
 1783667 ,Positive Summary Score,comprehensive lifestyle intervention study,baseline,Significantly increased,UC	2.95 (.60)	2.99 (.71)	3.00 (.77)	2.99 (.71)	30.11***	2.96a,47615:47807, 1783667 ,17229325,Unavailable
 1783667 ,Negative Summary Score,comprehensive lifestyle intervention study,baseline,Significantly increased,UC	3.95 (.46)	3.99 (.53)	4.03 (.47)	3.99 (.53)	3.98*,47151:47308, 1783667 ,17229325,Unavailable
 1783667 ,Chronic Illness Resources Survey,comprehensive lifestyle intervention study,baseline,Significantly increased,UC	2.77 (.55)	2.77 (.59)	2.77 (.60)	2.78 (.58)	5.76*,48099:48256, 1783667 ,17229325,Unavailable
 1783667 ,Confidence to Overcome Challenges,comprehensive lifestyle intervention study,baseline,Significantly increased,UC	3.1 (.73)	3.0 (.79)	3.0 (.78)	2.9 (.76)	11.43***,48648:48804, 1783667 ,17229325,Unavailable
 1783667 ,Sallis Self-Efficacy for Diet and Exercise,comprehensive lifestyle intervention study,baseline,Significantly increased,UC	4.1 (.58)	3.8 (.71)	3.9 (.71)	3.8 (.66)	14.51***,49121:49277, 1783667 ,17229325,Unavailable
 1783667 ,Quality of Problem-Solving Strategies,comprehensive lifestyle intervention study,baseline,Significantly increased,UC	3.6 (.68)	3.6 (.78)	3.9 (.70)	3.8 (.68)	11.73***,49613:49769, 1783667 ,17229325,Unavailable
 1783667 ,Quality of Problem-Solving Strategies,comprehensive lifestyle intervention study,baseline,Significantly increased,UC 3.6 (.68) 3.6 (.78) 3.9 (.70) 3.8 (.68) 11.73***,49613:49769, 1783667 ,17229325,Unavailable
 1913555 ,median cardiac mass,agalsidase alfaf 0.2 mg/kg,agalsidase beta of 0.2 mg/kg ,No significant difference,"he median change in the combined groups after 12 months of treatment was −11% (−35 g, range −226 to 136 g; p = 0.10), and this was also non-significant.",80014:80155, 1913555 ,17622343,Unavailable
 1913555 ,Glomerular filtration rate (GFR),agalsidase alfa of 0.2 mg/kg biweekly, agalsidase beta of 0.2 mg/kg ,No significant difference,"A slight increase of 5 ml/min in both groups was noted (ranges: agalsidase alfa −28 to 35 p = 0.37, and agalsidase beta −15 to 25, p = 0.23).",80014:80155, 1913555 ,17622343,Unavailable
 1913555 ,Urinary protein,agalsidase alfa  0.2 mg/kg biweekly,agalsidase beta of 0.2 mg/kg ,No significant difference,"These changes in proteinuria were not different between the two treatment groups (p = 0.16 and p = 0.33, for 12 and 24 months respectively).",80014:80155, 1913555 ,17622343,Unavailable
 1913555 ,Pain Score,agalsidase alfa  0.2 mg/kg,agalsidase beta of 0.2 mg/kg,No significant difference,"No significant reduction of pain score (BPI-3) after 12 months of treatment was noted in any of the groups: alfa 0 (range −5 to 1), beta −1.5 (range −4 to 3). Evaluation after 24 months of treatment (n = 20) did not change this result.",80865:81100, 1913555 ,17622343,Unavailable
 1913555 ,GL-3 in urine and plasma,agalsidase alfa  0.2 mg/kg,agalsidase beta of 0.2 mg/kg,No significant difference,This reduction in GL-3 was not significantly different between the two groups (p = 0.65).,82336:82425, 1913555 ,17622343,Unavailable
 1705528 ,	Median time (days) to lesion healing ,famciclovir,placebo,Significantly decreased,"Famciclovir [2, 15] 1,000&nbsp;mg bid × 1&nbsp;day versus placebo125&nbsp;mg bid × 5&nbsp;days versus placebo 4.3 versus 6.1 (P&nbsp;&lt;&nbsp;.001)3.8 versus 4.8 (P&nbsp;&lt;&nbsp;.001)",13173:13501, 1705528 ,16957911,Unavailable
 1705528 ,Percent of aborted episodes,famciclovir,placebo,Significantly decreased,"Famciclovir [2, 15]	1,000&nbsp;mg bid × 1&nbsp;day versus placebo125&nbsp;mg bid × 5&nbsp;days versus placebo	4.3 versus 6.1 (P&nbsp;&lt;&nbsp;.001)3.8 versus 4.8 (P&nbsp;&lt;&nbsp;.001)	23.3 versus 12.7% (P&nbsp;=&nbsp;.003)",13173:13571, 1705528 ,16957911,Unavailable
 1705528 ,	Median time (days) to lesion healing ,Acyclovir,placebo,Significantly decreased,4.0 versus 6.0 (P&nbsp;=&nbsp;.001) 5.7 versus 7.2a (P&nbsp;≤&nbsp;.001),12351:12463, 1705528 ,16957911,Unavailable
 1705528 ,Percent of aborted episodes,Acyclovir,placebo,Significantly decreased,27.0 versus 10.6% (P&nbsp;=&nbsp;.029) Was not performed,12485:12566, 1705528 ,16957911,Unavailable
 1705528 ,	Median time (days) to lesion healing ,Valacyclovir ,placebo,Significantly decreased,4.4 versus 4.7 (P&nbsp;=&nbsp;NS)4.8 versus 4.8 versus 6.0 (P&nbsp;&lt;&nbsp;.001)b,12884:13001, 1705528 ,16957911,Unavailable
 1705528 ,Percent of aborted episodes,Valacyclovir,placebo,No significant difference,25.4 versus 26.6% (P&nbsp;=&nbsp;NS)25.9 versus 24.8 versus 19.8% (P&nbsp;=&nbsp;NS),13029:13142, 1705528 ,16957911,Unavailable
 1584256 ,The hazard ratio for myocardial infarction/coronary death,conjugated estrogens 0.625 mg with medroxyprogesterone acetate 2.5 mg daily,placebo,No significant difference,"The hazard ratio for myocardial infarction/coronary death with estrogen plus progestin was 1.13 (95% confidence interval 0.68–1.89) among non-users of COX inhibitors, and 1.35 (95% confidence interval 0.86–2.10) among continuous users.",7764:7999, 1584256 ,17016543,Unavailable
 1584256 ,The hazard ratio for myocardial infarction/coronary death,conjugated estrogens 0.625 mg ,placebo,No significant difference,"The hazard ratio with estrogen alone was 0.92 (95% confidence interval 0.57–1.48) among non-users of COX inhibitors, and 1.08 (95% confidence interval 0.69–1.70) among continuous users.",8000:8185, 1584256 ,17016543,Unavailable
 59647 ,Rates of restenosis  at the target site,intracoronary beta radiotherapy with 32P,control,Significantly decreased,"Rates of restenosis (50% diameter stenosis or more) were significantly lower in radiotherapy patients at the target site (8% compared with 39%, P = 0.012)",3027:3299, 59647 ,11806768,Unavailable
 59647 ,Rates of restenosis at the target site plus adjacent segments,intracoronary beta radiotherapy with 32P,control,Significantly decreased,"Rates of restenosis (50% diameter stenosis or more) were significantly lower in radiotherapy patients at the target site (8% compared with 39%, P = 0.012) and at the target site plus adjacent segments (22% compared with 50%, P = 0.018).",3027:3299, 59647 ,11806768,Unavailable
 539050 ,"the time to viral rebound (&gt;5,000 copies/ml)","three successive fixed TIs of 2, 4, and 6 wk, with intervening resumption of therapy with resuppression for 4 wk before subsequent interruption","40 wk of continuous therapy, with a final open-ended TI in both treatment groups",No significant difference,"There was no difference between the groups in time to viral rebound during the open-ended TI (continuous therapy/single TI, median [interquartile range] = 4 [1–8] wk, n = 21; repeated TI, median [interquartile range] = 5 [4–8] wk, n = 21; p = 0.36).",9365:9874, 539050 ,15630469,Unavailable
 547916 ,matrix metalloproteinase-9 (MMP-9),doxycycline (100 mg),placebo,No significant difference,"There was a trend for both MMP-9 levels to be lower in the doxycycline group than in the placebo group (total: 2.18 ± 1.94 vs 3.26 ± 3.58, P = .50; active: 0.48 ± 0.48 vs 0.95 ± 1.01 ng/100 μg protein, P = .25).",5085:5296, 547916 ,15667660,Unavailable
 65527 ,The improvement in Hamilton Rating Scale for Depression (HDRS),electroconvulsive therapy (ECT)  treatment forpatients with major depression according to DSM-IV criteria with severity of the major depressive episode &gt; 16 scores on 17-item Hamilton Rating Scale for Depression (HDRS) (Group 1),"electroconvulsive therapy (ECT)  treatment patients with less severe major depressive episodes or with a variety of comorbid conditions (Group 2, n = 24)",Significantly increased,"The improvement in HDRS score was higher in Group 1 than in Group 2 both in the ITT analysis and among study completers (64.3% vs. 33.1%, t =4.56, df = 38, P = 0.0001; 64.6% vs. 35.9%, t = 3.71, df = 29, P = 0.0009, respectively).",27908:28206, 65527 ,11846888,Unavailable
 65527 ,The number of responders vs. nonresponders,electroconvulsive therapy (ECT)  treatment forpatients with major depression according to DSM-IV criteria with severity of the major depressive episode &amp;gt; 16 scores on 17-item Hamilton Rating Scale for Depression (HDRS) (Group 1),"electroconvulsive therapy (ECT)  treatment patients with less severe major depressive episodes or with a variety of comorbid conditions (Group 2, n = 24)",Significantly increased,"The number of responders vs. nonresponders was higher in Group 1 than in Group 2 both in the ITT analysis (10/6 vs. 2/22, P = 0.0004, Table 3) and among study completers (10/5 vs. 2/14, P = 0.0032).",25362:25633, 65527 ,11846888,Unavailable
 65527 ,The mean  Mini-Mental State Examination (MMSE) scores,electroconvulsive therapy (ECT)  treatment forpatients with major depression according to DSM-IV criteria with severity of the major depressive episode &amp;amp;gt; 16 scores on 17-item Hamilton Rating Scale for Depression (HDRS) (Group 1),"electroconvulsive therapy (ECT)  treatment patients with less severe major depressive episodes or with a variety of comorbid conditions (Group 2, n = 24)",No significant difference,"The difference was non-significant also with pre-ECT MMSE scores and age as covariates in the ITT sample (P = 0.1803, Table 3), and among study completers (P = 0.0961).",29781:30022, 65527 ,11846888,Unavailable
 1619408 ,persistence on treatment, ibandronate plus a patient support programme (PSP),alendronate,Significantly increased,"The distributions of the Kaplan–Meier curves for the two treatment groups were significantly different, with the probability of persistence significantly higher in the ibandronate/PSP group (p &lt; 0.0001, log-rank and Wilcoxon–Gehan tests).",38662:38866, 1619408 ,16800837,Unavailable
 1619408 ,patients discontinued from the study, ibandronate plus a patient support programme (PSP),alendronate,Significantly decreased,"Significantly more patients discontinued from the study in the alendronate group (134/529, 25.3%) compared with the ibandronate/PSP group (107/547, 19.6%; p = 0.023).",32203:32370, 1619408 ,16800837,Unavailable
 1619408 ,patients discontinuing the study because of adverse events, ibandronate plus a patient support programme (PSP),alendronate,No significant difference,There was no significant difference between treatment groups in the proportion of patients discontinuing the study because of adverse events (p = 0.934; Table 2).,38662:38866, 1619408 ,16800837,Unavailable
 1550632 ,quit rates,interactive smoking cessation program,modified program,Significantly increased,"In an ITT analysis, abstinence rates in baseline current smokers were respectively 10.9% and 8.9% (odds ratio [OR]=1.24, 95% confidence interval [CI]1.08-1.43, P=.003) in the original and modified programs, and 25.2% and 15.7% (OR=1.81, CI 1.51-2.16, P&lt;.001) in baseline former smokers.",5294:5614, 1550632 ,15829474,Unavailable
 1550632 ,quit rates  in the contemplation stage,interactive smoking cessation program,modified program,Significantly increased,"While we found statistically significant differences in quit rates in smokers in the contemplation stage favoring the original program (OR=1.54, CI 1.18-2.02, P=.002)",5615:5801, 1550632 ,15829474,Unavailable
 1550632 ,quit rates  in the precontemplation stage,interactive smoking cessation program,modified program,No significant difference,"no between-group differences in quit rates were observed in smokers in the precontemplation (OR=1.07, CI 0.36-3.14, P=.91) and preparation (OR=1.15, CI 0.97-1.37, P=.10) stages of change.",5803:6024, 1550632 ,15829474,Unavailable
 1550632 ,quit rates  in the preparation stage,interactive smoking cessation program,modified program,No significant difference,"no between-group differences in quit rates were observed in smokers in the precontemplation (OR=1.07, CI 0.36-3.14, P=.91) and preparation (OR=1.15, CI 0.97-1.37, P=.10) stages of change.",5803:6024, 1550632 ,15829474,Unavailable
 29022 ,temperature measured inside the tube after 2 days, without an additional humidification system (group B),"electronic jet-ventilator either with (group A)  group C received high-frequency percussive ventilation (HFPV) by a pneumatic high-frequency respirator, using a hot water humidifier for warming and moistening the inspiration gas. Group D received conventional mechanical ventilation using a standard intensive care unit respirator with a standard humidification system.",Significantly decreased,"A significantly low inspiration gas temperature was noted in patients in group B, initially (27.2 ± 2.5°C) and after 2 days (28.0 ± 1.6°C) (P &lt; 0.05).",3944:4120, 29022 ,11056732,Unavailable
 29022 ,humidity of the inspiration gas, without an additional humidification system (group B),"electronic jet-ventilator either with (group A)  group C received high-frequency percussive ventilation (HFPV) by a pneumatic high-frequency respirator, using a hot water humidifier for warming and moistening the inspiration gas. Group D received conventional mechanical ventilation using a standard intensive care unit respirator with a standard humidification system.",No significant difference,The percentage of relative humidity of the inspiration gas in patients in group B was also initially significantly low (69.8 ± 4.1%; P &lt; 0.05) but rose to an average of 98 ± 2.8% after 2 h.,4120:4341, 29022 ,11056732,Unavailable
 1553435 ,Mean weight loss ,clinical weight loss program,extended care group,No significant difference,There were no significant main effects or interactions for weight loss group and extended care group assignment (p &gt; 0.05).,26018:26141, 1553435 ,16846509,Unavailable
 2010236 ,remission and survival,patients on immunotherapy,patients on no maintenance,Significantly increased,Patients receiving immunotherapy had significantly longer remission (P = 0.039) and survival from remission (P = 0.044) as assessed by the log-rank test.,2004:2157, 2010236 ,6992827,Unavailable
 34516 ,Homocysteine (tHcy) concentration,methionine (100 mg/Kg) plus placebo tablets,placebo drink plus placebo tablets,Significantly increased,"Following oral methionine the tHcy concentration at 4 hours increased significantly (7.5 [6.0-9.0] μmol/L vs. 22.8 [19.8-25.8] μmol/L, p &lt; 0.0001 vs. baseline and Placebo, Table 1).",13750:13973, 34516 ,11444999,Unavailable
 34516 ,tHcy,methionine plus vitamin C (2 g orally),placebo drink plus placebo tablets,No significant difference,"Co-administration of vitamin C did not significantly alter the rise in tHcy (7.6 [6.2-9.0] μmol/L vs. 21.6 [18.3-24.9] μmol/L, p &lt; 0.0001 vs. Baseline and Placebo, Table 1).",13973:14189, 34516 ,11444999,Unavailable
 34516 ,endothelial-dependent forearm blood flow (FBF),methionine (100 mg/Kg) plus placebo tablets,placebo drink plus placebo tablets,Significantly decreased,"Following oral methionine the AUC of change in endothelial-dependent FBF from baseline was significantly reduced compared to placebo, (31.2 arbitrary units [22.1-40.3] vs.46.4 arbitrary units [42.0-50.8] vs. p &lt; 0.05 vs. Placebo, Figures 1 &amp;2, Table 1).",17299:17672, 34516 ,11444999,Unavailable
 34516 ,endothelial-dependent forearm blood flow (FBF),methionine plus vitamin C (2 g orally),methionine (100 mg/Kg) plus placebo tablets,No significant difference,"The mean difference in AUC between the methionine and vitamin C groups emphasises the lack of difference these groups (0.2 [-15.9-16.3]) arbitrary units, Table 1).",17990:18193, 34516 ,11444999,Unavailable
 1386666 ,"Vital signs, ECG parameters and oxygen saturation","budesonide/formoterol (320/9 μg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 1280/36 μg]","formoterol (9 μg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 36 μg]",No significant difference,"Vital signs, ECG parameters and oxygen saturation also showed only small changes over time during the course of the study. There were no statistically significant differences between the treatments for the average or maximum/minimum values for any of these variables",30506:30772, 1386666 ,16433920,Unavailable
 1386666 ,heart rate,"budesonide/formoterol (320/9 μg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 1280/36 μg]","formoterol (9 μg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 36 μg]",Significantly decreased,"with the exception of heart rate, for which budesonide/formoterol had a lower maximum value (mean of 91.6 beats per minute) than formoterol (mean of 94.3 beats per minute; p = 0.026).",30774:30957, 1386666 ,16433920,Unavailable
 1131903 ,The number of questionnaires scored,electronic stethoscope,conventional acoustic stethoscope,No significant difference,"Mean scores in the control group and intervention group were 17.2 (SD = 8.7, range 1–30.5) and 17.8 (SD = 8.8, range 0–35) points respectively. The difference is 0.6 points with a 95% CI of (-0.33 – 1.53) points (p = 0.65). (Figure 1)",16211:16482, 1131903 ,15882458,Unavailable
 1131903 ,grading the murmurs,electronic stethoscope,conventional acoustic stethoscope,No significant difference,"When grading the murmurs, the students using conventional stethoscopes had 27 correct and 27 incorrect responses, whereas the students using the electronic stethoscope had 29 correct and 22 incorrect responses (p = 0.47).",16681:16902, 1131903 ,15882458,Unavailable
 1131903 ,characterising murmurs,electronic stethoscope,conventional acoustic stethoscope,No significant difference,"On characterising murmurs the group using conventional stethoscopes had 45 correct and 66 incorrect responses, while the students using the electronic stethoscope had 42 correct and 66 incorrect responses (p = 0.76).",16903:17119, 1131903 ,15882458,Unavailable
 1131903 ,report of false murmurs,electronic stethoscope,conventional acoustic stethoscope,No significant difference,"When tested for report of false murmurs, the group using conventional stethoscopes had 12 correct and 8 incorrect responses. The group using the electronic stethoscope had 11 correct and 9 incorrect responses (p = 0.75). (Table 3)",17119:17389, 1131903 ,15882458,Unavailable
 1913915 ,forced expiratory volume in 1 second (FEV1),tiotropium 18 μg via the HandiHaler®,placebo,Significantly increased,"At Week 12, median improvement in trough FEV1 response with tiotropium versus placebo was 0.06 L (p = 0.0102).",4169:4291, 1913915 ,17605774,Unavailable
 1913915 ,forced vital capacity (FVC),tiotropium 18 μg via the HandiHaler®,placebo,Significantly increased,Trough FVC responses were significantly better with tiotropium compared with placebo on all test days (p &lt; 0.001) (Table 2).,26252:26418, 1913915 ,17605774,Unavailable
 1913915 ,The percentage of patients with ≥1 exacerbation,tiotropium 18 μg via the HandiHaler®,placebo,Significantly decreased,"The percentage of patients with ≥1 exacerbation was reduced (tiotropium 9.5%; placebo 17.9%; p = 0.0147), independent of disease severity.",4437:4576, 1913915 ,17605774,Unavailable
 37407 ,The median volume of administered enteral feeds,feeding in supine position,feeding in  prone position,No significant difference,The median volume of administered enteral feeds was 95 ml after 6 hours in supine position and 110 ml after 6 hours in prone position (P = 0.85).,3207:3369, 37407 ,11511335,Unavailable
 37407 ,The mean gastric residual volume after feeding for 3 hours,feeding in supine position,feeding in  prone position,No significant difference,"The mean gastric residual volume after feeding for 3 hours in the prone position was 59.7 ml (range, 0-200 ml), compared with 59.5 ml (range, 0-180 ml) after 3 hours in the supine position (P = 0.69).",10028:10245, 37407 ,11511335,Unavailable
 37407 ,The mean cumulative dose of morphine/midazolam,feeding in supine position,feeding in  prone position,Significantly decreased,The mean cumulative dose of morphine/midazolam during 6 hours in the prone position was 15.8/11.8 mg compared with 9.7/7.3 mg during 6 hours in the supine position (P = 0.005).,13391:13584, 37407 ,11511335,Unavailable
 29047 ,"respiratory rates, oxygen saturations, arterial pH and arterial partial carbon dioxide tension (PaCO2)",dexmedetomidine,placebo,No significant difference,"There were no statistically significant differences between the placebo and dexmedetomidine groups for oxygen saturations measured by pulse oximetry (P= 0.26) and respiratory rate (P= 0.16) for the 6 h following extubation (Figs 1 and 5). There were no differences in arterial pH (P= 0.77) and PaCO2 (P= 0.75) measurements between the groups, and within the dexmedetomidine group, over the same 6-h period (Figs 2 and 6).",20775:21423, 29047 ,11056756,Unavailable
 29047 ,fractional inspired oxygen (FIO2),dexmedetomidine,placebo,Significantly increased,There were significant differences in the PaO2 : FIO2 ratios for the 6-h extubation period (P= 0.037) and for the 6-h period while intubated before extubation between the two groups (P= 0.036). The dexmedetomidine group showed significantly higher PaO2 : FIO2 ratios throughout these periods (Fig. 3).,20775:21423, 29047 ,11056756,Unavailable
 29047 ,Requirements for morphine,dexmedetomidine,placebo,Significantly decreased,"Requirements for morphine were reduced by half in patients receiving dexmedetomidine while intubated when compared with placebo (0.011 ± 0.02 versus 0.022 ± 0.02 mg/kg per h; P = 0.024), and this morphine-sparing effect of dexmedetomidine was even more pronounced during the extubation period (0.003 ± 0.004 versus 0.008 ± 0.006 mg/kg per h; P= 0.040; Fig. 4).",20174:20605, 29047 ,11056756,Unavailable
 1913938 ,response rate,mail,telephone,No significant difference,"Of the 290 cases in the telephone sample, 170 responded, for a 58.6% response rate; for those in mail sample, 210 out of 382 responded, for a 55.0% response rate. These rates did not differ significantly (χ 2 1= 0.9, P = .34).",26098:26428, 1913938 ,17567564,Unavailable
 1913938 ,weight loss,telephone,mail ,Significantly decreased,"we find significant effects, with the telephone respondents reporting greater weight loss than the mail respondents, whether reported in kilograms (an average weight loss of 3.30 kg for telephone respondents and 1.19 kg for mail respondents; t 320 = 3.1, P = .002) or BMI (an average BMI reduction of 1.20 for telephone respondents and 0.45 for mail respondents; t 315= 2.96, P = .003).",46093:46618, 1913938 ,17567564,Unavailable
 1804280 ,cholesterol level in patients," area-wide, computerised diabetes register incorporating a full structured recall and individualised patient management system",standard structured and recall management system,Significantly decreased,"but the mean cholesterol level in patients from intervention practices was significantly lower (-0.15 mmol/l, 95% CI -0.25, -0.06).",6225:6356, 1804280 ,17306017,Unavailable
 1804280 ,mean HbA1c and blood pressure in patients," area-wide, computerised diabetes register incorporating a full structured recall and individualised patient management system",standard structured and recall management system,No significant difference,"There was no difference in mean HbA1c or BP levels,",6225:6356, 1804280 ,17306017,Unavailable
 1804280 ,the SF36 health status profile," area-wide, computerised diabetes register incorporating a full structured recall and individualised patient management system",standard structured and recall management system,No significant difference,"The ICC for the diabetes symptom score was 0.03, and the ICCs for the SF 36 physical and mental health component scores were 0.03 and 0.02, respectively. There were no statistically significant differences in scores on any of the measures in Table 4, or on any of the items of the DCSQ.",38558:38883, 1804280 ,17306017,Unavailable
 1804280 ,"patient-reported outcomes or in patient-reported use of drugs, or uptake of health services"," area-wide, computerised diabetes register incorporating a full structured recall and individualised patient management system",standard structured and recall management system,No significant difference,"There were no differences in patient-reported outcomes or in patient-reported use of drugs, or uptake of health services.",6357:6479, 1804280 ,17306017,Unavailable
 1804280 ,The average cost per patient," area-wide, computerised diabetes register incorporating a full structured recall and individualised patient management system",standard structured and recall management system,No significant difference,"The economic data relating to service use and patient expenditure are summarised in Table 5, and were not significantly different between intervention and control groups.",46708:46917, 1804280 ,17306017,Unavailable
 1804280 ,"Frequency of at least one diabetes appointment, a foot check, receiving dietary advice, recording of blood pressure"," area-wide, computerised diabetes register incorporating a full structured recall and individualised patient management system",standard structured and recall management system,Significantly increased,"Patients in intervention practices were more likely to have at least one diabetes appointment recorded (OR 2.00, 95% CI 1.02, 3.91), to have a recording of a foot check (OR 1.87, 95% CI 1.09, 3.21), have a recording of receiving dietary advice (OR 2.77, 95% CI 1.22, 6.29), and have a recording of blood pressure (BP) (OR 2.14, 95% CI 1.06, 4.36).",5825:6173, 1804280 ,17306017,Unavailable
 1852556 ,LDL-cholesterol (LDL)-cholesterol,plant sterol esters (PSE) in capsule form (1.3 grams of PSE/day),placebo,Significantly decreased,"In comparison to placebo, LDL-cholesterol was significantly reduced by 7% and 4% (P &lt; 0.05) at both week 3 and week 4;",17614:17755, 1852556 ,17419879,Unavailable
 1852556 ,HDL-cholesterol (HDL)  at week 4,plant sterol esters (PSE) in capsule form (1.3 grams of PSE/day),placebo,No significant difference,"HDL at week 3 of the treatment was significantly increased by 9% (P &lt; 0.01), but not at week 4 (4%);",17614:17755, 1852556 ,17419879,Unavailable
 1852556 ,total cholesterol,plant sterol esters (PSE) in capsule form (1.3 grams of PSE/day),placebo,No significant difference,"Total cholesterol was reduced throughout the treatment phase, but this reduction was not significant.",17755:17856, 1852556 ,17419879,Unavailable
 1852556 ,C-reactive protein (CRP) and triglycerides,plant sterol esters (PSE) in capsule form (1.3 grams of PSE/day),placebo,No significant difference,CRP and triglycerides did not change during the treatment phase.,17614:17755, 1852556 ,17419879,Unavailable
 1852556 ,TC total cholesterol (TC)/HDL and LDL/HDL,plant sterol esters (PSE) in capsule form (1.3 grams of PSE/day),placebo,Significantly decreased,TC/HDL and LDL/HDL ratios were significantly reduced at both day 21 and 28 (P &lt; 0.001) (Table 1).,17614:17755, 1852556 ,17419879,Unavailable
 1950208 ,the risk of severe malaria,Deltaprim (3.125 mg of pyrimethamine plus 25 mg of dapsone),placebo,No significant difference,"Thereafter, there is a tendency for the risk of severe malaria to be lower in the chemosuppressed group, but the difference is not significant.",31171:31316, 1950208 ,17676985,Unavailable
 1950208 ,severe malaria episodes,Deltaprim (3.125 mg of pyrimethamine plus 25 mg of dapsone),placebo,Significantly decreased,"By the end of the follow-up period at the age of 4 y, the CR of severe malaria episodes was slightly lower in the intervention cohort of children who had received chemoprophylaxis during the first year (0.59 versus 0.47), with a rate difference of −0.12 (95% CI: −0.27 to 0.03) (Figure 4B).",31315:31658, 1950208 ,17676985,Unavailable
 1950208 ,risk of anaemia,Deltaprim (3.125 mg of pyrimethamine plus 25 mg of dapsone),placebo,No significant difference,"By the age of 4 y, chemosuppressed children had experienced a marked reduction in the risk of anaemia, and had a reduced CR (0.93 episodes [95% CI: 0.79 to 0.97] versus 1.12 [95% CI: 0.97 to 1.28]), corresponding to an overall difference of −0.19 (95% CI: −0.40 to 0.01).",32687:32930, 1950208 ,17676985,Unavailable
 1950208 ,hospital admissions during the first 4 y of life,Deltaprim (3.125 mg of pyrimethamine plus 25 mg of dapsone),placebo,No significant difference,"Children in the placebo group had, on average, 3.3 hospital admissions during the first 4 y of life (95% CI: 3.03 to 3.60), compared to 3.1 admissions (95% CI: 2.83 to 3.37) for children who had received chemoprophylaxis during the first year.",32687:32930, 1950208 ,17676985,Unavailable
 64502 ,The response rate,questionnaire printed on standard quality paper,questionnaire printed on  or high quality paper.,No significant difference,"The response rate for the recipients of high quality paper was 43/195 (22%) and 57/194 (29%) for standard quality paper (relative rate of response 0.75, 95% CI 0.33–1.05, p = 0.1",3380:3558, 64502 ,11782286,Unavailable
 1550249 ," Mature oocytes; Percent 2pn; Percent oocyte degeneration; Cell number, day 2;	percent fragmentation, day 2; Cell number, day 3; Percent fragmentation, day 3;	16Embryos/ET, day 3; 	Percent compaction(b); percent blastocyst(b);	percent compaction, blast ET; Percent blastocyst, blast ET;",laser-assisted ICSI,conventional ICSI,No significant difference,No significant differences between treatment and control groups were observed for any of the measured outcome variables.,5212:5332, 1550249 ,16822317,Unavailable
 1550249 ,cycles including oocytes with fragile zonae,laser-assisted ICSI,conventional ICSI,Significantly decreased,"These cycles including oocytes with fragile zonae also exhibited significantly lower rates of compaction (23.8% versus 51.5%, P = 0.036)",26663:26799, 1550249 ,16822317,Unavailable
 1550249 ,blastocyst formation rate,laser-assisted ICSI,conventional ICSI,No significant difference,"with a reduced blastocyst formation rate that also approached statistical significance (15.3% versus 31.8%, P = 0.084).",26801:26921, 1550249 ,16822317,Unavailable
 1891439 ,Median (95% confidence interval) fever clearance times,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Median (95% confidence interval) fever clearance times were 92 hours (84–114 hours) for gatifloxacin recipients and 138 hours (105–164 hours) for cefixime-treated patients (Hazard Ratio[95%CI] = 2.171 [1.545–3.051], p&lt;0.0001).",7958:8184, 1891439 ,17593957,Unavailable
 1891439 ,acute clinical failure,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"19 out of 70 (27%) patients who completed the 7 day trial had acute clinical failure in the cefixime group as compared to 1 out of 88 patients (1%) in gatifloxacin group(Odds Ratio [95%CI] = 0.031 [0.004 – 0.237], p&lt;0.001).",8184:8408, 1891439 ,17593957,Unavailable
 1891439 ,Overall treatment failure,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Overall treatment failure patients (relapsed patients plus acute treatment failure patients plus death) numbered 29. They were determined to be (95% confidence interval) 37.6 % (27.14%–50.2%) in the cefixime group and 3.5% (2.2%–11.5%) in the gatifloxacin group (HR[95%CI] = 0.084 [0.025–0.280], p&lt;0.0001).",8408:8715, 1891439 ,17593957,Unavailable
 1891439 ,Relapse rates,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Relapse rates were 12.4% (6/51) in the cefixime group and 3.4% (2/87) in gatifloxacin group (HR[95%CI] = 0.185 [0.037–0.915], p =  0.0199). The Kaplan-Meier plots for the time of relapse are shown in Figure 4.",41968:42229, 1891439 ,17593957,Unavailable
 1891439 ,Median (95% confidence interval) fever clearance times,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Median (95% confidence interval) fever clearance times were 92 hours (84–114 hours) for gatifloxacin recipients and 138 hours (105–164 hours) for cefixime-treated patients (Hazard Ratio[95%CI] = 2.171 [1.545–3.051], p&lt;0.0001).",7958:8184, 1891439 ,17593957,Unavailable
 1891439 ,acute clinical failure,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"19 out of 70 (27%) patients who completed the 7 day trial had acute clinical failure in the cefixime group as compared to 1 out of 88 patients (1%) in gatifloxacin group(Odds Ratio [95%CI] = 0.031 [0.004 – 0.237], p&lt;0.001).",8184:8408, 1891439 ,17593957,Unavailable
 1891439 ,Overall treatment failure,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Overall treatment failure patients (relapsed patients plus acute treatment failure patients plus death) numbered 29. They were determined to be (95% confidence interval) 37.6 % (27.14%–50.2%) in the cefixime group and 3.5% (2.2%–11.5%) in the gatifloxacin group (HR[95%CI] = 0.084 [0.025–0.280], p&lt;0.0001).",8408:8715, 1891439 ,17593957,Unavailable
 1891439 ,Relapse rates,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Relapse rates were 12.4% (6/51) in the cefixime group and 3.4% (2/87) in gatifloxacin group (HR[95%CI] = 0.185 [0.037–0.915], p =  0.0199). The Kaplan-Meier plots for the time of relapse are shown in Figure 4.",41968:42229, 1891439 ,17593957,Unavailable
 1891439 ,Median (95% confidence interval) fever clearance times,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Median (95% confidence interval) fever clearance times were 92 hours (84–114 hours) for gatifloxacin recipients and 138 hours (105–164 hours) for cefixime-treated patients (Hazard Ratio[95%CI] = 2.171 [1.545–3.051], p&lt;0.0001).",7958:8184, 1891439 ,17593957,Unavailable
 1891439 ,acute clinical failure,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"19 out of 70 (27%) patients who completed the 7 day trial had acute clinical failure in the cefixime group as compared to 1 out of 88 patients (1%) in gatifloxacin group(Odds Ratio [95%CI] = 0.031 [0.004 – 0.237], p&lt;0.001).",8184:8408, 1891439 ,17593957,Unavailable
 1891439 ,Overall treatment failure,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Overall treatment failure patients (relapsed patients plus acute treatment failure patients plus death) numbered 29. They were determined to be (95% confidence interval) 37.6 % (27.14%–50.2%) in the cefixime group and 3.5% (2.2%–11.5%) in the gatifloxacin group (HR[95%CI] = 0.084 [0.025–0.280], p&lt;0.0001).",8408:8715, 1891439 ,17593957,Unavailable
 1891439 ,Relapse rates,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Relapse rates were 12.4% (6/51) in the cefixime group and 3.4% (2/87) in gatifloxacin group (HR[95%CI] = 0.185 [0.037–0.915], p =  0.0199). The Kaplan-Meier plots for the time of relapse are shown in Figure 4.",41968:42229, 1891439 ,17593957,Unavailable
 1891439 ,Median (95% confidence interval) fever clearance times,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Median (95% confidence interval) fever clearance times were 92 hours (84–114 hours) for gatifloxacin recipients and 138 hours (105–164 hours) for cefixime-treated patients (Hazard Ratio[95%CI] = 2.171 [1.545–3.051], p&lt;0.0001).",7958:8184, 1891439 ,17593957,Unavailable
 1891439 ,acute clinical failure,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"19 out of 70 (27%) patients who completed the 7 day trial had acute clinical failure in the cefixime group as compared to 1 out of 88 patients (1%) in gatifloxacin group(Odds Ratio [95%CI] = 0.031 [0.004 – 0.237], p&lt;0.001).",8184:8408, 1891439 ,17593957,Unavailable
 1891439 ,Overall treatment failure,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Overall treatment failure patients (relapsed patients plus acute treatment failure patients plus death) numbered 29. They were determined to be (95% confidence interval) 37.6 % (27.14%–50.2%) in the cefixime group and 3.5% (2.2%–11.5%) in the gatifloxacin group (HR[95%CI] = 0.084 [0.025–0.280], p&lt;0.0001).",8408:8715, 1891439 ,17593957,Unavailable
 1891439 ,Relapse rates,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Relapse rates were 12.4% (6/51) in the cefixime group and 3.4% (2/87) in gatifloxacin group (HR[95%CI] = 0.185 [0.037–0.915], p =  0.0199). The Kaplan-Meier plots for the time of relapse are shown in Figure 4.",41968:42229, 1891439 ,17593957,Unavailable
 1891439 ,Median (95% confidence interval) fever clearance times,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Median (95% confidence interval) fever clearance times were 92 hours (84–114 hours) for gatifloxacin recipients and 138 hours (105–164 hours) for cefixime-treated patients (Hazard Ratio[95%CI] = 2.171 [1.545–3.051], p&lt;0.0001).",7958:8184, 1891439 ,17593957,Unavailable
 1891439 ,acute clinical failure,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"19 out of 70 (27%) patients who completed the 7 day trial had acute clinical failure in the cefixime group as compared to 1 out of 88 patients (1%) in gatifloxacin group(Odds Ratio [95%CI] = 0.031 [0.004 – 0.237], p&lt;0.001).",8184:8408, 1891439 ,17593957,Unavailable
 1891439 ,Overall treatment failure,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Overall treatment failure patients (relapsed patients plus acute treatment failure patients plus death) numbered 29. They were determined to be (95% confidence interval) 37.6 % (27.14%–50.2%) in the cefixime group and 3.5% (2.2%–11.5%) in the gatifloxacin group (HR[95%CI] = 0.084 [0.025–0.280], p&lt;0.0001).",8408:8715, 1891439 ,17593957,Unavailable
 1891439 ,Relapse rates,"Gatifloxacin 10 mg/kg, given once daily for 7 days",Cefixime 20 mg/kg/day given in two divided doses for 7 days,Significantly decreased,"Relapse rates were 12.4% (6/51) in the cefixime group and 3.4% (2/87) in gatifloxacin group (HR[95%CI] = 0.185 [0.037–0.915], p =  0.0199). The Kaplan-Meier plots for the time of relapse are shown in Figure 4.",41968:42229, 1891439 ,17593957,Unavailable
 115849 ,patients discontinued due to lack of efficacy,"etoricoxib 90 mg once daily, naproxen 500 mg twice daily",placebo,Significantly increased,"The most common reason for discontinuation was lack of efficacy, and significantly more patients discontinued due to lack of efficacy in the placebo group than in the etoricoxib and naproxen group (25.2%, 12.5%, 10.5%, respectively, p&lt;0.001 vs placebo).",6535:6629, 115849 ,12033987,Unavailable
 115849 ,", or naproxen 500 mg twice daily",etoricoxib 90 mg once daily,placebo,Significantly increased,"Clinical adverse events determined by the investigator as possibly, probably, or definitely drug-related occurred in 15.4%, 23.2%, and 19.3% of patients in the placebo, etoricoxib 90 mg, and naproxen 500 mg twice daily groups (p&lt;0.05 for etoricoxib versus placebo).",29249:29514, 115849 ,12033987,Unavailable
 115849 ,Patient global assessment of disease activity; investigator global assessment of disease activity; Tender joint count; Swollen joint count; Patient global assessment of pain;Health Assessment Questionnaire disability ; Serum C-reactive protein; ACR20 responder criteria; Discontinuation due to lack of efficacy ," etoricoxib 90 mg once daily,  naproxen 500 mg twice daily",placebo,Significantly increased,"Compared with patients receiving placebo, patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints (p&lt;0.05).",6535:6629, 115849 ,12033987,Unavailable
 115849 ,Patient global assessment of disease activity; investigator global assessment of disease activity; Tender joint count; Swollen joint count; Patient global assessment of pain;Health Assessment Questionnaire disability ; Serum C-reactive protein; ACR20 responder criteria; Discontinuation due to lack of efficacy , etoricoxib 90 mg once daily, naproxen 500 mg twice daily,No significant difference,Treatment responses were similar between the etoricoxib and naproxen groups for all endpoints.,6535:6629, 115849 ,12033987,Unavailable
 2002515 ,minimally important improvement in self-reported sleep quality,mailed valerian,placebo,No significant difference,"For the primary outcome of a minimally important improvement in self-reported sleep quality (≥0.5 units on a 7 point scale), the difference between the valerian group (29%) and the placebo group (21%) was not statistically significant (difference 7.5%; 95% CI-0.9 to 15.9; p = 0.08).",6185:6469, 2002515 ,17940604,Unavailable
 2002515 ,perceived their sleep as better or much better,mailed valerian,placebo,Significantly increased,5.5% (95% CI 0.2 to 10.8) more participants in the valerian group compared to the placebo group perceived their sleep as better or much better on the global self-assessment question at the end of the treatment period (p = 0.04) (table 3).,50055:50348, 2002515 ,17940604,Unavailable
 2002515 ,sleep onset latency,mailed valerian,placebo,No significant difference,There were no statistically significant effects of treatment for any of the five outcome measures in the repeated measures analysis of variance (p = 0.06 for night awakenings to 0.89 for sleep onset latency; p = 0.31 for sleep quality).,50796:51032, 2002515 ,17940604,Unavailable
 1847837 ,Forced Expiratory Volume in 1 second; Peak Expiratory Flow;,encapsulated botanical mixture AKL1,placebo,No significant difference,"No significant differences in lung function (active-placebo) were found (Forced Expiratory Volume in 1 second: mean difference [95% CI] = 0.01 [-0.12 to 0.14] L, p = 0.9. Peak Expiratory Flow: -4.08 [-35.03 to 26.89]. L/min, p = 0.8).",4794:5028, 1847837 ,17374147,Unavailable
 1847837 ,Asthma Control Questionnaire,encapsulated botanical mixture AKL1,placebo,No significant difference,"Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.",5035:5430, 1847837 ,17374147,Unavailable
 1847837 ,Asthma Quality of Life Questionnaire,encapsulated botanical mixture AKL1,placebo,No significant difference,"Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.",5035:5430, 1847837 ,17374147,Unavailable
 1847837 ,Leicester Cough Questionnaire,encapsulated botanical mixture AKL1,placebo,No significant difference,"Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.",5035:5430, 1847837 ,17374147,Unavailable
 1420296 ,total scores,case-based discussions,standardized patient case,No significant difference,"There was no difference in total scores between intervention and control group students (13.4, 14.4, p = 0.12).",13957:14122, 1420296 ,16509977,Unavailable
 1420296 ,total scores in the third rotation scored,case-based discussions,standardized patient case,Significantly increased,"However, students in both the intervention and control groups on the third rotation scored significantly higher than first rotation students. (13.6, 15, p = 0.038).",13957:14122, 1420296 ,16509977,Unavailable
 1420296 ,examined the 13 technology items,case-based discussions,standardized patient case,No significant difference,"However, when we examined the 13 technology items, there were no differences between intervention and control group scores (7.5, 7.9, p = 0.25) or between first and third rotation group scores (7.3, 8.3, p = 0.08).",14123:14337, 1420296 ,16509977,Unavailable
 1174877 ,systolic blood pressure  and diastolic blood pressure,telmisartan (80 mg),losartan (50 mg),Significantly decreased,Telmisartan also significantly reduced 24-hour mean systolic blood pressure (p &lt; 0.05) and diastolic blood pressure (p &lt; 0.05) compared with losartan.,5513:5663, 1174877 ,15892894,Unavailable
 1174877 ,free plasma glucose (FPG),telmisartan (80 mg),losartan (50 mg),Significantly decreased,"Compared with losartan, telmisartan reduced FPG by 8% (p &lt; 0.05), FPI by 10% (p &lt; 0.06), HOMA-IR by 26% (p &lt; 0.05) and HbA1c by 9% (p &lt; 0.05) as shown in figure 1.",17765:17988, 1174877 ,15892894,Unavailable
 1174877 ,free plasma insulin (FPI),telmisartan (80 mg),losartan (50 mg),Significantly decreased,"Compared with losartan, telmisartan reduced FPG by 8% (p &lt; 0.05), FPI by 10% (p &lt; 0.06), HOMA-IR by 26% (p &lt; 0.05) and HbA1c by 9% (p &lt; 0.05) as shown in figure 1.",17765:17988, 1174877 ,15892894,Unavailable
 1174877 ,HbA1c (glycosylated haemoglobin),telmisartan (80 mg),losartan (50 mg),Significantly decreased,"Compared with losartan, telmisartan reduced FPG by 8% (p &lt; 0.05), FPI by 10% (p &lt; 0.06), HOMA-IR by 26% (p &lt; 0.05) and HbA1c by 9% (p &lt; 0.05) as shown in figure 1.",17764:17989, 1174877 ,15892894,Unavailable
 1866019 ,relief of upper GI symptoms,esomeprazole 20 mg or 40 mg treatment,placebo,Significantly increased,Esomeprazole was significantly more effective than placebo in maintaining relief of upper GI symptoms throughout 6 months of treatment.,6050:6185, 1866019 ,17391505,Unavailable
 1866019 ,relapse of upper GI symptoms,esomeprazole 20 mg or 40 mg treatment,placebo,Significantly decreased,"Life-table estimates (95% confidence intervals) of the proportion of patients with relapse at 6 months (pooled population) were placebo, 39.1% (32.2% to 46.0%); esomeprazole 20 mg, 29.3% (22.3% to 36.2%) (p = 0.006 versus placebo); and esomeprazole 40 mg, 26.1% (19.4% to 32.9%) (p = 0.001 versus placebo).",6186:6526, 1866019 ,17391505,Unavailable
 1866019 ,The frequency of adverse events,esomeprazole 20 mg or 40 mg treatment,placebo,No significant difference,"Serious AEs occurred in 5.2% of placebo recipients, 5.0% of patients taking esomeprazole 20 mg, and 7.1% of patients taking esomeprazole 40 mg.",24939:25082, 1866019 ,17391505,Unavailable
 1863515 ,"haemoglobin level, leucocyte count, and absolute neutrophil count between 26 and 35 wk",Zidovudine prophylaxis initiation,placebo,Significantly decreased,"Between 26 and 35 wk, haemoglobin, leucocytes, and absolute neutrophil counts decreased in zidovudine-exposed compared to unexposed women (mean difference [95% CI] −0.4 [−0.5 to −0.3], −423 [−703 to −142], −485 [−757 to −213], respectively).",6967:7209, 1863515 ,17476315,Unavailable
 1863515 ,"haemoglobin level, leucocyte count, and absolute neutrophil count at  35 wk gestation",Zidovudine prophylaxis initiation ,placebo,Significantly increased,"During the second period, between the 35-wk visit and delivery, after adjustment, the haemoglobin level, leucocyte count, and absolute neutrophil count increased significantly faster in women randomized to the long regimen than women in the short regimen, as shown by the mean (95% CI) increase associated with exposure to zidovudine of 0.1 (0.0 to 0.1) g/dl/wk, p &lt; 0.001, 105 (18 to 191) cells/mm3/wk, p = 0.02, 147 (59 to 234) cells/mm3/wk, p = 0.001, respectively.",6967:7209, 1863515 ,17476315,Unavailable
 1526611 ,time of analgesia,lumiracoxib 400 mg/day ,placebo,Significantly increased,Lumiracoxib provided better analgesia than placebo 3–5 hours after the first dose (P = 0.004) through to study end.,6565:6697, 1526611 ,16469112,Unavailable
 1526611 ,time of analgesia,lumiracoxib 400 mg/day ,celecoxib 200 mg twice daily,No significant difference,The estimated difference between lumiracoxib and celecoxib 3–5 hours after the first dose was not significant (P = 0.185).,6698:6837, 1526611 ,16469112,Unavailable
 1526611 ,time of analgesia,celecoxib 200 mg twice daily,placebo,No significant difference,Celecoxib was not significantly different from placebo in this analysis (P = 0.069).,6838:6940, 1526611 ,16469112,Unavailable
 1526611 ,complete pain relief,celecoxib 200 mg twice daily,placebo,No significant difference,"WOMAC™ total and subscales improved for both active treatments versus placebo except for difficulty in performing daily activities, for which celecoxib just failed to achieve significance (P = 0.056).",7092:7310, 1526611 ,16469112,Unavailable
 1526611 ,The overall incidence of adverse events,"celecoxib 200 mg twice daily, lumiracoxib 400 mg/day",placebo,No significant difference,"Adverse events assessed by the investigator as being possibly study drug related occurred in 6.3%, 6.2% and 8.0% of patients in the lumiracoxib, celecoxib and placebo groups, respectively.",27856:28045, 1526611 ,16469112,Unavailable
 101395 ,The total amount excreted of codeine and its metabolites,100 mg codeine phosphate plus 50 mg diclofenac sodium,codeine phosphate plus placebo,No significant difference,The total amount excreted of codeine and its metabolites excreted was 81.3% of dose (76.3–86.3 95% CI) vs. 84.9% of dose (81.8–88.0 95% CI) and did not differ between the two treatment groups.,30670:30862, 101395 ,11943073,Unavailable
 101395 ,"The area under the pain threshold-time, the area under the pain tolerance-time",100 mg codeine phosphate plus 50 mg diclofenac sodium,codeine phosphate plus placebo,No significant difference,"The area under the pain threshold-time as well as the area under the pain tolerance-time curves did not differ significantly after administration of codeine + placebo vs. codeine + diclofenac (8.68 ± 12.7 vs. 4.87 ± 9.82 s*h and 23.3 ± 57.5 vs. 13.9 ± 35.6 s*h, respectively). The time courses of pain threshold and pain tolerance are displayed in Figure 4.",36788:37182, 101395 ,11943073,Unavailable
 101395 ,"apparent oral clearance of codeine (CLo) , metabolic clearance of codeine to C-6-G, norcodeine and morphine, of morphine to M-3-G, M-6-G and normorphine or renal clearance of codeine and its metabolites ",100 mg codeine phosphate plus 50 mg diclofenac sodium,codeine phosphate plus placebo,No significant difference,"No significant differences were observed in either the apparent oral clearance of codeine (CLo) (1805 ml min-1; 1498–2112 95% CI vs. 1700 ml min-1; 1470–1929 95% CI), metabolic clearance of codeine to C-6-G, norcodeine and morphine, of morphine to M-3-G, M-6-G and normorphine or renal clearance of codeine and its metabolites between the two treatments (Tables 3 and 4).",30198:30670, 101395 ,11943073,Unavailable
 101395 ,The total amount excreted of codeine and its metabolites excreted,100 mg codeine phosphate plus 50 mg diclofenac sodium,codeine phosphate plus placebo,No significant difference,The urinary recoveries of codeine and its metabolites are listed in Table 5.,30862:30978, 101395 ,11943073,Unavailable
 1783656 ,LDL/HDL ratio and fasting blood glucose,"partially hydrogenated soybean oil (PHSO) , interesterified fat (IE)",palm olein (POL),Significantly increased,"After 4 wk, both PHSO and IE fats significantly elevated both the LDL/HDL ratio and fasting blood glucose, the latter almost 20% in the IE group relative to POL.",4613:4722, 1783656 ,17224066,Unavailable
 1783656 ,insulin,"partially hydrogenated soybean oil (PHSO) , interesterified fat (IE)",palm olein (POL),Significantly decreased,Fasting 4 wk insulin was 10% lower after PHSO (p &gt; 0.05) and 22% lower after IE (p &lt; 0.001) compared to POL.,4613:4722, 1783656 ,17224066,Unavailable
 1783656 ,postprandial study the glucose incremental area, interesterified fat (IE),"palm olein (POL), partially hydrogenated soybean oil (PHSO) ,",Significantly increased,"For the postprandial study the glucose incremental area under the curve (IAUC) following the IE meal was 40% greater than after either other meal (p &lt; 0.001),",4723:4881, 1783656 ,17224066,Unavailable
 1783656 ,insulin and C-peptide, interesterified fat (IE),"palm olein (POL), partially hydrogenated soybean oil (PHSO) ,",Significantly decreased,"For the postprandial study the glucose incremental area under the curve (IAUC) following the IE meal was 40% greater than after either other meal (p &lt; 0.001), and was linked to relatively depressed insulin and C-peptide (p &lt; 0.05).",4722:4954, 1783656 ,17224066,Unavailable
 1500954 ,blood pressure medication,therapeutic lifestyle-modification intervention,control,No significant difference,"There was not a significant difference in the use of blood pressure medication from baseline to 6 months between the intervention and control groups (χ2 1 = 1.14, P = .56).",25132:25343, 1500954 ,16356358,Unavailable
 1969447 ,overall survival,levamisole 2.5 mg kg-1 day-1,placebo therapy in the same schedule,Significantly decreased,"Consequently, overall survival was somewhat greater in the placebo group than in the levamisole group, 68% vs 38% (P &lt; 0.08).",1978:2103, 1969447 ,8198976,Unavailable
 1969447 ,patients surviving 5 years from randomisation,levamisole 2.5 mg kg-1 day-1,placebo therapy in the same schedule,Significantly decreased,"For patients surviving 5 years from randomisation, subsequent survival favoured placebo over levamisole (100% vs 57%; P &lt; 0.03).",2104:2233, 1969447 ,8198976,Unavailable
 1794491 ,Fasting PYY concentration,60-minute duodenal infusion of Ensure® 1 and 2 kcal/minute,healthy subjects,Significantly increased,"Plasma PYY concentrations were higher in patients during nutrient infusion (area under the curve [AUC] at 1 kcal/minute: 2,265 ± 718 versus 1,125 ± 138 pmol/l.min, P &lt; 0.05; at 2 kcal/minute: 2,276 ± 303 versus 1,378 ± 210 pmol/l.min, P = 0.01) compared to healthy subjects.",5750:6064, 1794491 ,17173662,Unavailable
 1794491 ,The magnitude of PYY elevation,60-minute duodenal infusion of Ensure® 1 kcal/minute,60-minute duodenal infusion of Ensure®  2 kcal/minute,Significantly increased,"The magnitude of PYY elevation was greater in patients during the 1 kcal/minute infusion (AUC: 441 ± 153 versus 186 ± 58 pmol/l.min, P &lt; 0.05), but not the 2 kcal/minute infusion.",6065:6262, 1794491 ,17173662,Unavailable
 1794491 ,cholecystokinin (CCK),60-minute duodenal infusion of Ensure® 2 kcal/minute,"60-minute duodenal infusion of Ensure®  1 kcal/minute, healthy subjects",Significantly increased,"The magnitude of elevation in CCK concentration was greater in patients during the 2 kcal/minute infusion (AUC (0–180 min): 255 ± 34 versus 176 ± 22 pmol/l.min, P = 0.045), but not the 1 kcal/minute infusion (AUC (0–180 min): 110 ± 42 versus 140 ± 26 pmol/l.min, P = 0. 42), compared with healthy subjects.",26458:26821, 1794491 ,17173662,Unavailable
 1550594 ,The number of messages sent per patient during the first 6 months,SPPARO (System Providing Access to Records Online),Control Group,Significantly increased,"The difference was more pronounced during the first 6 months of the intervention (150 messages in the intervention group vs. 88 in the control group, p=0.05) than the second 6 months (109 messages vs. 103, p=0.66).",31132:31348, 1550594 ,15249261,Unavailable
 1550594 ,The number of messages sent per patient during the second 6 months,SPPARO (System Providing Access to Records Online),Control Group,Significantly increased,"The difference was more pronounced during the first 6 months of the intervention (150 messages in the intervention group vs. 88 in the control group, p=0.05) than the second 6 months (109 messages vs. 103, p=0.66).",31132:31348, 1550594 ,15249261,Unavailable
 1550594 ,Adherence to medications,SPPARO (System Providing Access to Records Online),Control Group,No significant difference,Adherence to medications showed a similar trend but did not reach statistical significance.,32772:32863, 1550594 ,15249261,Unavailable
 1550594 ,General Adherence,SPPARO (System Providing Access to Records Online),Control Group,Significantly increased,"General Adherence (scored from 0 to 100)	82	81 - 78	+2.3 (-3.7, 8.3)	85 - 78	+6.4 (1.8, 10.9)	0.01*",38444:38777, 1550594 ,15249261,Unavailable
 1550594 ,Number of visits,SPPARO (System Providing Access to Records Online),Control Group,Significantly increased,"The intervention group had more emergency department visits (20 vs. 8, p=0.03)",6023:6102, 1550594 ,15249261,Unavailable
 1224861 ,left ventricular function,off-pump surgery,on-pump surgery,Significantly decreased,"Those patients undergoing off-pump surgery had significantly poorer left ventricular function than those undergoing on-pump surgery (28.6 ± 5.8% vs. 40.5 ± 7.4%, respectively, p &lt; 0.05)",3643:3845, 1224861 ,16124878,Unavailable
 1224861 ,Euroscore values,off-pump surgery,on-pump surgery,Significantly increased,Off-pump patients experienced significantly poorer left ventricular (LV) function (ejection fraction (EF) ≤ 30%) (p &lt; 0.05) and significantly higher Euroscores 12.1 ± 1.8 (p ≤ 0.05).,15786:15956, 1224861 ,16124878,Unavailable
 1224861 ,number of grafts,off-pump surgery,on-pump surgery,No significant difference,"There was no significant difference in the number of grafts between the off-pump and on-pump patients (2.03 ± 0.7 vs.1.99 ± 0.6 grafts per patient respectively, p = 0.15).",13091:13279, 1224861 ,16124878,Unavailable
 1224861 ,duration surgery or aortic cross-clamp time,off-pump surgery,on-pump surgery,No significant difference,"Nor were there any significant differences between on-and off pump patients with regard to duration surgery (105 ± 22 vs. 80 ± 25, respectively, p = 0.26) or aortic cross-clamp time (21.5 ± 7.6 vs. 20.6 ± 7.5 min, respectively, p = 0.861).",13279:13536, 1224861 ,16124878,Unavailable
 1224861 ,low cardiac output syndrome (LCOS),off-pump surgery,on-pump surgery,No significant difference,Three (7.5%) off-pump patients developed low cardiac output syndrome (LCOS) in the postoperative period compared to 1 (2.1%) on-pump patients (p = 0.24).,15786:15956, 1224861 ,16124878,Unavailable
 1224861 ,Postoperative mortality,off-pump surgery,on-pump surgery,No significant difference,There were three (7.5%) deaths in the off-pump patients compared to no death in the on-pump patients (p = 0.06) within 30 days postoperatively.,18648:18808, 1224861 ,16124878,Unavailable
 1940326 ,Survival,"ME-TRAP (the Multiple Epitope string and Thrombospondin Related Adhesion Protein, ME- TRAP [2])",control,No significant difference,The difference in HRs between the two time periods was not statistically significant (the likelihood ratio test for the interaction between time period and vaccination group gave p = 0.11 and p = 0.15 for ITT and ATP analyses respectively).,22374:22614, 1940326 ,17710125,Unavailable
 1940326 ,serious adverse events,"ME-TRAP (the Multiple Epitope string and Thrombospondin Related Adhesion Protein, ME- TRAP [2])",control,No significant difference,"23 events occurred among the 189 children in the FFM ME-TRAP group, and 26 among the 194 children in the control group. In the full 18 months of monitoring, there were 63 events in the FFM ME-TRAP group and 60 in the control group (HR = 1.2, CI 0.84-1.73, p = 0.35).",7157:7424, 1940326 ,17710125,Unavailable
 1664572 ,Spielberger State Trait Anxiety Inventory (STAI)  focusing on the first trimester of pregnancy (STAI-3),Preconception counselling (PCC),control group,No significant difference,Mean scores of the STAI-3 were 38.5 (95% CI 37.7 – 39.3) in the control group (n = 1090) and 38.7 (95% CI 37.9 – 39.5) in the intervention group (n = 1186).,4738:4894, 1664572 ,17083722,Unavailable
 1664572 ,Spielberger State Trait Anxiety Inventory (STAI) before PCC (STAI-1) ,Preconception counselling (PCC),control group,Significantly decreased,"The mean STAI-1-score (n = 466) was 36.4 (95% CI 35.4 – 37.3). Following PCC there was an average decrease of 3.6 points in anxiety-levels (95% CI, 2.4 – 4.8).",4578:4737, 1664572 ,17083722,Unavailable
 1977297 ,"Ability to detect 'early stages', and noninvasive forms of cancer",Edinburgh Randomised Breast Screening Project (EBSP),control,Significantly increased,"The size and negative lymph node status characteristics of invasive cancers from the two populations were significantly different (P less than 0.05). The cancers detected by screening were predominantly 'early stage', with 16% noninvasive (PTIS) and 42% invasive stage I (pT1 node negative), whereas cancers were frequently 'late stage' (more than pT2) and inoperable in nonattenders (44%) and controls (36%).",2247:2657, 1977297 ,1854609,Unavailable
 1977297 ,Ability to detect poor survival probability group ,Edinburgh Randomised Breast Screening Project (EBSP),control,Significantly increased,"When these same histological characteristics were used to compare survival, the capacity to separate invasive cancers into two groups having good and poor survival probabilities was evident, with a significant improvement for the screen detected poor survival group compared with controls (P less than 0.05).",3191:3499, 1977297 ,1854609,Unavailable
 1977297 ,Ability to detect patients with positive lymph node biopsy,Edinburgh Randomised Breast Screening Project (EBSP),control,No significant difference,"Grouped according to customary size ranges of invasive cancers, the proportion of cases lymph node positive differed in those screen detected compared with controls, but the benefit in favour of screen detection was not constant.",3191:3499, 1977297 ,1854609,Unavailable
 1388215 ,microfilarial (mf) loads in patients treated for either 4 or 6 weeks,200 mg doxycycline per day,Untreated patients,Significantly decreased,Controls vs. 4 weeks &gt; 0.9999 0.0058†Controls vs. 6 weeks &gt; 0.9999 0.0221†,27607:27810, 1388215 ,16457735,Unavailable
 1388215 ,microfilarial (mf) loads -  2 weeks regimen,200 mg doxycycline per day ,Untreated patients,Significantly decreased,"Although no significant difference was demonstrated between the 4 and 6 weeks regimens, there was a trend observed, in that, microfilarial reduction appeared to have been greater following the 6 weeks regimen.",27607:27810, 1388215 ,16457735,Unavailable
 1388215 ,microfilarial (mf) loads - after  the 6 weeks regimen,200 mg doxycycline per day,Untreated patients,No significant difference,"Although no significant difference was demonstrated between the 4 and 6 weeks regimens, there was a trend observed, in that, microfilarial reduction appeared to have been greater following the 6 weeks regimen.",27607:27810, 1388215 ,16457735,Unavailable
 65683 ,Mean of daily steps,24-month period of moderate exercise,baseline,Significantly increased,"Mean of daily steps was significantly higher in the exercise group from about 6,800 to over 8,500 steps (P &lt; 0.01).",4393:4525, 65683 ,11846892,Unavailable
 65683 ,Mean of daily steps,control,baseline,No significant difference,"In the control group, the number of daily steps ranged from 5,700 to 6,800 steps throughout the follow-up period.",4526:4639, 65683 ,11846892,Unavailable
 65683 ,high-density lipoprotein cholesterol (HDLC),	24-month period of moderate exercise,control ,Significantly increased,HDLC at 24 months in the exercise group was significantly higher (P &lt; 0.05) than that in the control group.,19559:19687, 65683 ,11846892,Unavailable
 65683 , total cholesterol (TC) : HDLC ratio, 24-month period of moderate exercise,control,Significantly decreased,"In the exercise group, TC : HDLC ratio at 24 months in the exercise group was significantly lower (P &lt; 0.05) than those in the control group.",19688:19849, 65683 ,11846892,Unavailable
 1904445 ,"metabolic control indicator,  macrovascular complications assessment tests, microvascular complications assessment tests",active strategy (training module with administration of the guideline),usual care (control),No significant difference,"Analyses of data measuring the effect of passive dissemination of the guideline shows similar results for all the three primary outcomes, respectively OR 0,93 [0,67–1,30] for the metabolic assessment, OR 0,93 [0,70–1,24] for the macrovascular complications assessment test and OR 1,11 [0,73–1,69] for the microvascular complications assessment test.",38296:38645, 1904445 ,17547760,Unavailable
 1904445 ,"metabolic control indicator,  macrovascular complications assessment tests, microvascular complications assessment tests",passive dissemination (administration of the guideline only),usual care (control),No significant difference,"Analyses of data measuring the effect of passive dissemination of the guideline shows similar results for all the three primary outcomes, respectively OR 0,93 [0,67–1,30] for the metabolic assessment, OR 0,93 [0,70–1,24] for the macrovascular complications assessment test and OR 1,11 [0,73–1,69] for the microvascular complications assessment test.",38296:38645, 1904445 ,17547760,Unavailable
 1851720 ,cognitive function scores,malaria chemoprophylaxis (dapsone/pyrimethamine),placebo,No significant difference,"There were no significant differences in the cognitive function scores between the two arms, with or without adjustment for covariates (adjusted estimates in Table 2; p &gt; 0.10 for all;",34131:34386, 1851720 ,17013430,Unavailable
 1851720 ,educational attainment,malaria chemoprophylaxis (dapsone/pyrimethamine),placebo,No significant difference,The intervention group had higher educational attainment by 0.52 grades (95% CI = −0.041 to 1.089; p = 0.069). School enrolment was similar in the two groups.,7448:7624, 1851720 ,17013430,Unavailable
 1570354 ,forced expiratory volume in one second (FEV1)," formoterol/budesonide (FBC, Symbicort™, AstraZeneca, UK)",placebo,Significantly increased,"In study A, a single inhalation of SFC and FBC produced a sustained bronchodilation at 16 hours with an adjusted mean increase in FEV1 from pre-dose of 0.22 L (95% CI 0.19, 0.35 L) for SFC and 0.25 L (95% CI 0.21, 0.37 L) for FBC, which was significantly greater than placebo for both treatments (-0.05 L; p &lt; 0.001).",4655:4983, 1570354 ,16919161,Unavailable
 1570354 ,the median number of days with no use of relief medication," formoterol/budesonide (FBC, Symbicort™, AstraZeneca, UK)","salmeterol/fluticasone propionate (SFC, Seretide™ GSK, UK) ",No significant difference,"In addition, the median number of days with no use of relief medication was 63% in the SFC group and 61% in the FBC group and the median number of nights with no use of relief medication was also similar with 93% in the SFC group compared to 89% in the FBC group.",25352:25615, 1570354 ,16919161,Unavailable
 1570354 , the median number of nights with no use of relief medication ," formoterol/budesonide (FBC, Symbicort™, AstraZeneca, UK)","salmeterol/fluticasone propionate (SFC, Seretide™ GSK, UK) ",No significant difference,"In addition, the median number of days with no use of relief medication was 63% in the SFC group and 61% in the FBC group and the median number of nights with no use of relief medication was also similar with 93% in the SFC group compared to 89% in the FBC group.",25352:25615, 1570354 ,16919161,Unavailable
 1874716 ,used CPAP( hours per night),telemonitored clinical care (TCC),usual clinical care,No significant difference,"The primary outcome measure of the study was level of CPAP treatment compliance: the TCC group used CPAP 4.1 ± 1.8 hours per night, while the UCC control group used CPAP 2.8 ± 2.2 hours per night (P = .07).",53046:53249, 1874716 ,17513285,Unavailable
 1874716 ,percentage of nights with any amount of CPAP use,telemonitored clinical care (TCC),usual clinical care,No significant difference,There was also a trend for the groups to differ on the percentage of nights with any amount of CPAP use (TCC: 78% ± 22%; UCC: 60% ± 32%; P = .07).,53046:53249, 1874716 ,17513285,Unavailable
 1874716 ,Apnea-Hypopnea Index,telemonitored clinical care (TCC),usual clinical care,No significant difference,Table 5 shows the results of the t test for change in AHI; there was no statistically significant difference between the groups (TCC: 38.1 ± 18.4; UCC: 32.2 ± 14.8; P = .32).,53618:53870, 1874716 ,17513285,Unavailable
 1874716 ,Patients rated their likelihood to continue using CPAP,telemonitored clinical care (TCC),usual clinical care,Significantly increased,Patients in the TCC group rated their likelihood to continue using CPAP significantly higher than the UCC group (4.8 vs 4.3; P = .05).,58827:58978, 1874716 ,17513285,Unavailable
 1994017 ,death or recurrent myocardial infarction  in patients who received no reperfusion therapy or a thrombolytic agent,fondaparinux 2.5 mg once daily,unfractionated heparin,Significantly decreased,"At day 30, fondaparinux significantly reduced the occurrence of the primary efficacy outcome (death or recurrent myocardial infarction) by 14% (p=0.008).",13120:13599, 1994017 ,17323591,Unavailable
 1994017 ,death or recurrent myocardial infarction in patients undergoing primary percutaneous coronary interventions,fondaparinux 2.5 mg once daily, unfractionated heparin ,No significant difference,"At day 30, fondaparinux significantly reduced the occurrence of the primary efficacy outcome (death or recurrent myocardial infarction) by 14% (p=0.008). Consistent reductions in both death and recurrent MI were observed at 6-month follow-up. The benefits were significant in patients who received no reperfusion therapy or a thrombolytic agent, but not in patients undergoing primary percutaneous coronary interventions.",13120:13599, 1994017 ,17323591,Unavailable
 1994017 ,severe bleeds,fondaparinux 2.5 mg once daily,placebo ,No significant difference,There was a trend (p=0.13) towards fewer severe bleeds in the fondaparinux group (1.0% vs 1.3% in the control group).,2845:2962, 1994017 ,17323591,Unavailable
 1994017 ,the incidence of venous thromboembolism in patients undergoing major orthopedic surgery ,fondaparinux 2.5 mg once daily,"low-molecular-weight heparin, enoxaparin",Significantly decreased,"In patients undergoing major orthopedic surgery, fondaparinux reduced the incidence of venous thromboembolism by more than 50% (p&lt;0.001) compared with the low-molecular-weight heparin, enoxaparin (Bauer et al 2001; Eriksson et al 2001; Lassen et al 2002; Turpie et al 2002a, 2002b).",13120:13599, 1994017 ,17323591,Unavailable
 1208877 ,attendance,invitation by telephone, invitation by mail,Significantly increased,"Patients invited by telephone were more likely to attend than those invited by mail (72.3% vs. 44.0%, OR 3.3; 95%CI 1.9–5.7; p &lt; 0.001).",6349:6503, 1208877 ,16111487,Unavailable
 1852321 ,defecation frequency,Nutrilon Omneo (new formula; NF),standard formula,No significant difference,"A significant increase in defecation frequency (NF: 3.5 pre versus 5.6/week post treatment; SF 3.6 pre versus 4.9/week post treatment) was found in both groups, but was not significantly different between the two formulas (p = 0.36)",4530:4763, 1852321 ,17428343,Unavailable
 1852321 ,Improvement of hard stool consistency to soft stool consistency,Nutrilon Omneo (new formula; NF),standard formula,No significant difference,"Improvement of hard stool consistency to soft stool consistency was found more often with NF than SF, but did not reach statistical significance (90% versus 50%; RR, 1.8; 95% CI, 0.9–3.5; p = 0.14).",4764:4963, 1852321 ,17428343,Unavailable
 1852321 ,painful defecation,Nutrilon Omneo (new formula; NF),standard formula,No significant difference,Painful defecation	89%	75%	0.27,21068:21168, 1852321 ,17428343,Unavailable
 1852321 ,The frequency of soft stools ,Nutrilon Omneo (new formula; NF),standard formula,Significantly increased,"The frequency of soft stools was significantly higher in the NF period, with 17% (n = 4) of infants having soft stools when receiving NF but hard stools with SF, compared to no infant with soft stools when receiving SF and hard stools with NF (McNemar test, p = 0.046).",24698:24969, 1852321 ,17428343,Unavailable
 34114 ,number of tender joints,recombinant human IL-11 (rhIL-11),placebo,Significantly decreased,The data suggest a statistically significant reduction in the number of tender joints (P &lt; 0.008) at the 15 μg/kg once-weekly dose schedule but showed no overall significant benefit at the ACR criterion of a 20% response.,6811:7049, 34114 ,11438043,Unavailable
 34114 ,incidence of infection,recombinant human IL-11 (rhIL-11),placebo,No significant difference,A higher incidence of infection in the rhIL-11 treated group (7.8%) than in the placebo group (0%) was not statistically significant (P = 0.34).,19146:19307, 34114 ,11438043,Unavailable
 34114 ,"fibrinogen levels, platelet counts",recombinant human IL-11 (rhIL-11),placebo,No significant difference,There were no statistically significant changes in fibrinogen levels or platelet counts in rhIL-11 treated patients compared with placebo during the study at all doses and schedules.,19749:19931, 34114 ,11438043,Unavailable
 1550259 ,steepening,"Sim K , using both the Goldmann and the Sussman",baseline,Significantly decreased,The results show a significant steepening in Sim K up to the first 15 minutes using both the Goldmann (p = 0.002) and the Sussman (p = 0.004) gonioscopes.,16878:17063, 1550259 ,16780595,Unavailable
 1550259 ,effects produced between the gonioscopes,Auto-Keratometry,Sim K,No significant difference,There were no significant differences in the effects produced between the gonioscopes at any time interval after gonioscopy (Sim K at 0–5 min p = 0.638 and Auto K at 0–5 min p = 0.879).,16878:17063, 1550259 ,16780595,Unavailable
 5980306 ,"concentrations of dust, endotoxin, or fungi."," HD, high dust unit with straw bedding and dry hay feeding; +Ionization","LD low dust, units with shavings bedding and haylage feeding +Ionization",No significant difference,The dust and endotoxin concentrations are shown in Figure 3. Ionization did not significantly affect the amount of dust and endotoxin in the different units.,33900:34111, 5980306 ,29485234,Unavailable
 5980306 ,"concentration of dust, endotoxin, and fungi"," HD, high dust unit with straw bedding and dry hay feeding;","LD low dust, units with shavings bedding and haylage feeding",Significantly increased,"In the units with straw and hay, the concentration of dust, endotoxin, and fungi (difference in logarithmic mean 1.92 (95%CI 1.71‐2.12); 2.86 (95%CI 2.59‐3.14); 1.75 (95%CI 1.13‐2.36)) were significantly higher compared to wood shavings and haylage.",6818:7068, 5980306 ,29485234,Unavailable
 5809703 ,hemodynamic instability and inadequate sedation, Group P2 -  the propofol dose 2 mg/kg; ,"Group P2,5 - 2.5 mg/kg; Group  P1.5- the propofol dose 1.5 mg/kg; ",Significantly decreased,"Group P2 showed a lower incidence of complications (17%) such as hemodynamic instability and inadequate sedation than Group P1.5 (55.3%, P &lt; 0.001) or Group P2.5 (40.4%, P = 0.012).",5255:5436, 5809703 ,29441171,Unavailable
 5809703 ,The incidence and dose of additional propofol,Group    P1.5- the propofol dose 1.5 mg/kg; ,"Group P2,5 - 2.5 mg/kg;   Group P2 -  the propofol dose 2 mg/kg;",Significantly increased,"The incidence and dose of additional propofol increased in Group P1.5 (51%, median [range]; 20 [0–50]) compared with those in the other groups (0%, 0 [0–0] in Group P2 and 8.5%, 0 [0–50] in Group P2.5, all P &lt; 0.001),",5437:5654, 5809703 ,29441171,Unavailable
 5809703 ,the incidence and dose of additional ephedrine,"  Group P2,5 - 2.5 mg/kg; ",  Group P2 -  the propofol dose 2 mg/kg; Group    P1.5- the propofol dose 1.5 mg/kg;,Significantly increased,"and the incidence and dose of additional ephedrine were significantly higher in Group P2.5 (31.9%; 0 [0–20]) than in Group P1.5 (10.6%, P = 0.012; 0 [0–5], P = 0.007, respectively).",5655:5836, 5809703 ,29441171,Unavailable
 4751201 ,canal transportation at the straight part,"ProTaper Universal (PTU, Dentsply Maillefer)","ProTaper Gold (PTG, Dentsply Maillefer)",No significant difference,PTU and PTG systems produced similar canal transportation at the straight part,5484:5562, 4751201 ,26877984,Unavailable
 4751201 ,canal transportation  at the curved part,"ProTaper Universal (PTU, Dentsply Maillefer)","ProTaper Gold (PTG, Dentsply Maillefer)",Significantly increased,while PTG system resulted in lower canal transportation than PTU system at the curved part. Canal transportation was higher at the curved canal portion (p &lt; 0.0001).,5564:5749, 4751201 ,26877984,Unavailable
 5809707 ,The amount of propofol consumed,normal saline in group 1,"50 µg fentanyl in group 2, and 0.5 mg/kg ketamine in group 3 ",Significantly increased,Intergroup comparison with nonparametric tests showed that propofol consumption was significantly higher in group 1 than in group 2 (P = 0.024) or group 3 (P &lt; 0.001).,14968:15136, 5809707 ,29441174,Unavailable
 5809707 ,The amount of propofol consumed,"50 µg fentanyl in group 2, ", 0.5 mg/kg ketamine in group 3,No significant difference,"However, there was no significant difference in propofol consumption between group 2 and group 3 (P = 0.391).",15136:15245, 5809707 ,29441174,Unavailable
 5809707 ,the time to achieve a maximum PADS of 10, 0.5 mg/kg ketamine in group 3,"50 µg fentanyl in group 2,  normal saline in group 1",Significantly increased,"On further intergroup analysis, it was observed that this was longest in group 3, the ketamine group (46.3 ± 15.4 min), and was also statistically significantly higher than in group 2 (37.1 ± 14.6 min, P = 0.001) or group 1 (32.9 ± 13.9 min, P &lt; 0.001) (Table 2).",15399:15707, 5809707 ,29441174,Unavailable
 5809707 ,the time to achieve a maximum PADS of 10, normal saline in group 1,"50 µg fentanyl in group 2, ",No significant difference,There was no difference in the time taken to achieve a PADS of 10 between group 1 and group 2 (P = 0.280).,15708:15814, 5809707 ,29441174,Unavailable
 5809707 ,"the mean blood pressure, heart rate, or SpO2",normal saline in group 1,"50 µg fentanyl in group 2, and 0.5 mg/kg ketamine in group 3 ",No significant difference,"There were no significant differences in the mean blood pressure, heart rate, or SpO2 at any time point among the three groups (Fig. 1).",15979:16163, 5809707 ,29441174,Unavailable
 5809707 ,"incidence of desaturation, hypotension, coughing, or hiccups",normal saline in group 1,"50 µg fentanyl in group 2, and 0.5 mg/kg ketamine in group 3 ",No significant difference,"There were also no differences in the incidence of desaturation (P = 0.922), hypotension (P = 0.880), coughing (P = 0.269), or hiccups (P = 0.727) among the three groups (Table 3).",16164:16384, 5809707 ,29441174,Unavailable
 5809707 ,difference in operator feasibility,normal saline in group 1,"50 µg fentanyl in group 2, and 0.5 mg/kg ketamine in group 3 ",No significant difference,There was no difference in operator feasibility in the groups as rated by the endoscopist (P = 0.595) (Table 4).,16724:16875, 5809707 ,29441174,Unavailable
 3733607 ,WATER DAY the number of falls,"FG (fatigue group) did a fatigue circuit, warm up exercises and then the experimental protocol",CG (control group) warmed up before the experimental protocol  ,Significantly increased,On WATER DAY the number of falls was statistically higher to FG than CG (5.4 ± 1.14 FG and 3.33 ± 1.37 CG p = 0.02) demonstrating the effect of the fatigue protocol on the concentration status of the athletes.,25048:25259, 3733607 ,23875791,Unavailable
 5511975 ,the mean difference of  total lymphocyte count (TLC),HAART regimen plus Immune-Modulator Drug (IMOD) every day for 3 months,control group - only the HAART regimen every day for 3 months.,No significant difference,"Based on Wilcoxon test, there was no significant difference in the mean differences of TLC before and after drug therapy in the two groups (intervention group‘s mean difference=293.6 and p=0.06, and control group’s mean difference=70.5 and p=0.436).",21533:21782, 5511975 ,28748170,Unavailable
 5511975 ,CD4 cell count,HAART regimen plus Immune-Modulator Drug (IMOD) every day for 3 months,control group - only the HAART regimen every day for 3 months.,Significantly increased,"In the intervention group, the mean differences of CD4 before and after drug therapy showed a significant difference (mean difference=172.3, p=0.001). However, in the control group, the mean differences of CD4 before and after drug therapy were not significantly different (mean difference=4.3, p=0.87) (Table 1).",17221:17574, 5511975 ,28748170,Unavailable
 5771057 ,visual accuracy,simple DT  and moderate DT,complex DT,Significantly increased,"Using pairwise comparisons with Bonferroni corrections, it was found that the pairwise comparisons for visual accuracy were statistically significant (P &lt; 0.05). Results suggest that in the simple DT (M = 1.45) and moderate DT (M = 1.26) levels, participants were more accurate than in the complex DT (M = 1.16) levels. Refer Figure 2 for details.",43248:43703, 5771057 ,29319009,Unavailable
 5771057 ,visual processing speed,simple DT  ,"complex DT, moderate DT",Significantly increased,These differences suggest that for the simple DT participants were faster (M = 600) than at the moderate DT (M = 765.94) and the complex DT (M = 758.50) levels. Refer Figure 3 for details.,44903:45179, 5771057 ,29319009,Unavailable
 3651308 ,IBS SSS or IBS-QOL,"over-encapsulated mebeverine, methylcellulose",placebo,No significant difference,At 6&nbsp;weeks there was no significant difference in IBS SSS or IBS-QOL between the medicine groups or for IBS-QOL for the website groups (see Tables&nbsp;4 and 5).,51853:52087, 3651308 ,23602047,Unavailable
 3651308 ,Irritable Bowel Syndrome Quality of Life (IBS-QOL) ," nurse telephone session and email support, minimal email support ", no website,No significant difference,At 6&nbsp;weeks there was no significant difference in IBS SSS or IBS-QOL between the medicine groups or for IBS-QOL for the website groups (see Tables&nbsp;4 and 5).,52088:52401, 3651308 ,23602047,Unavailable
 3651308 ,Irritable Bowel Syndrome (IBS) Severity Scoring System (IBS-SSS)," nurse telephone session and email support, minimal email support ", no website,No significant difference,"However, there was a statistically significant difference seen in the IBS SSS for the website, with the no website group having a lower IBS SSS score than the website groups (IBS SSS no website =162.8 (95% CI 137.4-188.3), website 197.0 (172.4 - 221.7), Website + telephone support 208.0 (183.1-233.0) p = 0.037).",52088:52401, 3651308 ,23602047,Unavailable
 5737852 ,Systolic arterial blood pressure (RR),ketamine group,placebo group,Significantly increased,"Figure 1.Systolic blood pressure during ketamine and placebo infusion, separately to show boxplot. Systolic blood pressure was higher in the ketamine group beginning at timepoint 15 minutes (***P&lt;.001).",28980:29222, 5737852 ,29099972,Unavailable
 5737852 ,Diastolic blood pressure,ketamine group,placebo group,Significantly increased,"Diastolic blood pressure was higher in the ketamine group beginning at timepoint 10 minutes (*P&lt;.05, **P&lt;.01, ***P&lt;.001).",29481:29662, 5737852 ,29099972,Unavailable
 5737852 ,The maximal change in the curve during the observation period (ΔMAX) ,ketamine group women,ketamine group men,Significantly increased,"ΔMAXDia showed higher values in women (18.54 mmHg; 95%CI [15.41, 21.67], maximum 33 mmHg) than in men (10.06 mmHg; 95%CI [7.40, 12.72], maximum 19 mmHg) in the ketamine group (Bonferroni-corrected F1,40=17.403, P&lt;.001, partial η2=0.303).",36201:36492, 5737852 ,29099972,Unavailable
 5737852 ,The maximal change in the curve during the observation period (ΔMAX) ,placebo group women,placebo group men,No significant difference,There was no difference in the placebo group.,36491:36537, 5737852 ,29099972,Unavailable
 5976807 ,left ventricular mass index (LVMI),lisinopril plus telmisartan,lisinopril plus placebo,No significant difference,Treatment outcomes for LVMI with lisinopril/telmisartan versus lisinopril/placebo were not significantly different (Supplementary Figure&nbsp;S1b),19435:19619, 5976807 ,29854969,Unavailable
 3717762 ,all adverse ffects,bimatoprost 0.03% preservative-free (PF),bimatoprost 0.03% (Lumigan),No significant difference,"AEs were reported for 40.5% (122/301) of bimatoprost PF and 44.1% (130/295) of bimatoprost patients (p=0.382), with ocular AEs reported for 31.9% and 34.9%, respectively (p=0.434).",33793:33973, 3717762 ,23743437,Unavailable
 3717762 ,"cup/disc ratio, best-corrected visual acuity at week 12, visual field and  vital signs",bimatoprost 0.03% preservative-free (PF),bimatoprost 0.03% (Lumigan),No significant difference,"There were no statistically or clinically significant between-group differences for change from baseline in cup/disc ratio, best-corrected visual acuity at week 12 or visual field. There were no clinically significant between-group differences in vital signs.",38184:38443, 3717762 ,23743437,Unavailable
 3717762 ,Intraocular pressure ,bimatoprost 0.03% preservative-free (PF),bimatoprost 0.03% (Lumigan),No significant difference,The between-group difference in mean worse eye IOP was &lt;0.4 mm Hg at all time points and was not statistically or clinically significant (see online supplementary figure S2).,24786:24960, 3717762 ,23743437,Unavailable
 5984011 ,arousal score after four and eight weeks of intervention,food product or food product with education,education,No significant difference,No significant differences were observed among the three groups with respect to arousal score before treatment (p=0.07) and four (p=0.75) and eight (p=0.21) weeks after the intervention.,29192:29390, 5984011 ,None,Unavailable
 5984011 ,Orgasm after four weeks of intervention,food product or food product with education,education,No significant difference,The three groups were not significantly different in terms of orgasm before treatment (p=0.08) and four weeks after the intervention (p=0.902).,28401:28561, 5984011 ,None,Unavailable
 5984011 ,Lubrication after four weeks of intervention,food product or food product with education,education,No significant difference,No significant differences were found among the three groups in terms of lubrication before the treatment (p=0.79) and four weeks after the treatment (p=0.17).,28401:28561, 5984011 ,None,Unavailable
 5984011 ,Sexual satisfaction after four and eight weeks of intervention,food product or food product with education,education,No significant difference,"No significant difference was observed among the three groups regarding sexual satisfaction at the pre-treatment stage (p=0.204), and four (p=0.61) and eight (p=0.202) weeks after the intervention.",29192:29390, 5984011 ,None,Unavailable
 5984011 ,total sexual function score after 4 weeks of intervention,food product or food product with education,education,No significant difference,There was no significant difference among the three groups before the treatment (p=0.15) and four weeks after the treatment (p=0.77) in terms of total sexual function score.,30907:31081, 5984011 ,None,Unavailable
 5984011 ,percentage of patients reporting successful treatment,education plus food product,education  or food product,Significantly increased,"Finally, successful treatment was observed in 28%, 52%, and 74% of the patients in the education, food product, and food product plus education groups, respectively, indicating a significant difference among the three groups (p&lt;0.001).",31756:31991, 5984011 ,None,Unavailable
 4722945 ,glucagon concentration up to 20 minutes after administering,intranasal glucagon,intramuscular glucagon,Significantly decreased,"Initially, glucagon concentrations after intranasal administration were lower than concentrations after intramuscular with the mean ± SD peak 3,155 ± 1,956 and 3,672 ± 1,726 pg/mL (P = 0.003) and median (minimum, maximum) time to peak 20 min (10, 90) and 15 min (5, 60) (P &lt; 0.001),",34177:34494, 4722945 ,26681725,Unavailable
 4722945 ,glucagon concentration after 20 minutes upon administering,intranasal glucagon,intramuscular glucagon,No significant difference,but were not different after 20 min (Fig. 1B).,34509:34612, 4722945 ,26681725,Unavailable
 4722945 ,mean time to reach 70 mg/dL or 20 mg/dL increase,intranasal glucagon,intramuscular glucagon,Significantly increased,"mean times to reach 70 mg/dL or 20 mg/dL increase were 16 min and 13 min with intranasal glucagon and intramuscular glucagon, respectively; P &lt; 0.001).",34862:35030, 4722945 ,26681725,Unavailable
 4722945 ,Head/facial discomfort,intranasal glucagon,intramuscular glucagon,Significantly increased,Head/facial discomfort was reported during 25% of intranasal and 9% of intramuscular dosing visits; n,7783:7884, 4722945 ,26681725,Unavailable
 4722945 ,nausea (with or without vomiting),intranasal glucagon,intramuscular glucagon,No significant difference,"nausea (with or without vomiting) occurred with 35% and 38% of visits,",7883:7953, 4722945 ,26681725,Unavailable
 3767897 ,Radiographic evidence of bone union,received an autogenous tricortical bone graft,received an allogenous cancellous bone chip graft,No significant difference,Radiographic evidence of bone union was observed in all cases (52 knees of 51 patients).,15886:15975, 3767897 ,24032100,Unavailable
 3767897 ,The mean bone union period,received an autogenous tricortical bone graft,received an allogenous cancellous bone chip graft,No significant difference,"The mean bone union period was 11.7 weeks in group I and 12.1 weeks in group II, showing no significant difference (p=0.636) (Table 2).",15975:16149, 3767897 ,24032100,Unavailable
 3767897 ,"mean anatomical and mechanical femorotibial angles preoperatively, postoperatively and at the last follow-up",received an autogenous tricortical bone graft,received an allogenous cancellous bone chip graft,No significant difference,"There was no significant intergroup difference in the mean anatomical and mechanical femorotibial angles preoperatively, postoperatively and at the last follow-up (p&gt;0.05).",16156:16329, 3767897 ,24032100,Unavailable
 3767897 ,the mean the visual analog scale (VAS) score  immediately (first postoperative day) after surgery,received an autogenous tricortical bone graft,received an allogenous cancellous bone chip graft,Significantly increased,"On the clinical assessment, the mean VAS score was significantly different immediately after surgery between group I and group II (5.7 vs. 4.5; p=0.006),",17389:17592, 3767897 ,24032100,Unavailable
 3767897 ,mean Knee Society score (KSS),received an autogenous tricortical bone graft,received an allogenous cancellous bone chip graft,No significant difference,There was no significant difference in the mean KSS between group I and group II (92.1 vs. 94.3; p=0.419).,17592:17698, 3767897 ,24032100,Unavailable
 3767897 ,the mean the visual analog scale (VAS) score  after 1 day of  surgery,received an autogenous tricortical bone graft,received an allogenous cancellous bone chip graft,No significant difference,"On the clinical assessment, the mean VAS score was significantly different immediately after surgery between group I and group II (5.7 vs. 4.5; p=0.006), but showed no significant difference thereafter.",17389:17592, 3767897 ,24032100,Unavailable
 3622020 ,No. of neonates who received glucose infusion therapy after delivery,"0 % or 1 %, glucose acetated Ringer’s solution infusion during cesarean delivery ",5 %  glucose acetated Ringer’s solution infusion during cesarean delivery ,No significant difference,"In this study, 6 neonates in Group I, 3 in Group II, and 9 in Group III received a glucose infusion before the first milk feeding; neonates in Group II showed a trend towards a less frequent glucose infusion (P = 0.082) (Table 6).Table 6",19702:20027, 3622020 ,23143044,Unavailable
 3622020 ,maternal blood glucose levels,5 %  glucose acetated Ringer’s solution infusion during cesarean delivery  ,"0 % or 1 %, glucose acetated Ringer’s solution infusion during cesarean delivery ",Significantly increased,"Before and after the start of the intravenous infusion, the maternal blood glucose levels (mg/dL) were 79.2 ± 12.2 and 74.6 ± 4.6 in Group I, 81.2 ± 12.9 and 103.3 ± 11.2 in Group II, and 82.3 ± 8.7 and 252.5 ± 41.8 in Group III (Table 4). Group II and Group III showed significant differences in blood glucose levels before and after the start of the intravenous infusion (Group II, P &lt; 0.001; Group III, P &lt; 0.001), and between-group differences were noted;",13345:13883, 3622020 ,23143044,Unavailable
 3622020 ,umbilical blood glucose level,5 %  glucose acetated Ringer’s solution infusion during cesarean delivery  ,"0 % or 1 %, glucose acetated Ringer’s solution infusion during cesarean delivery ",Significantly increased,"Of the 3 groups, Group III had the highest blood glucose levels, and there were significant differences between the 3 groups (Group I vs. Group II, P &lt; 0.01; Group II vs. Group III, P &lt; 0.01; Group I vs. Group III, P &lt; 0.001; one-way ANOVA, P &lt; 0.05).",14358:14688, 3622020 ,23143044,Unavailable
 3622020 ,The minimum neonatal blood glucose level,"1 %, glucose acetated Ringer’s solution infusion during cesarean delivery  ",0 % or 5 %  glucose acetated Ringer’s solution infusion during cesarean delivery  ,Significantly increased,"The minimum neonatal blood glucose levels within 8 h after birth (mg/dL) were 35.7 ± 9.6 in Group I, 49.8 ± 10.8 in Group II, and 29.2 ± 7.5 in Group III (Table 5). Group I and Group III showed significantly lower minimum blood glucose levels within 8 h after birth than in Group II (Group I vs. Group II, P &lt; 0.05; Group II vs. Group III, P &lt; 0.01).Table 2",14688:15158, 3622020 ,23143044,Unavailable
 5834094 ,operator perception accuracy of the orientation of the axis of maximal gradient of a scalar field,dot mapping,colour mapping,No significant difference,"Perception accuracy of dot mapping was equivalent to colour mapping for both propagation direction (1.5 ± 1.8 vs. 4.8 ± 5.3°, P = 0.24) and focal source localization (1.1 ± 0.7 vs. 1.4 ± 0.5 mm, P = 0.88).",4754:4993, 5834094 ,27702855,Unavailable
 5834094 ,‘dataset co-registration’ domain,dot mapping,colour mapping,Significantly increased,"Dot mapping outperformed colour mapping in the ‘dataset co-registration’ domain (median score 24.5 vs. 10, P &lt; 0.05).",41349:41484, 5834094 ,27702855,Unavailable
 5834094 ,‘Diagnostic accuracy’ and ‘display fidelity’,dot mapping,colour mapping,No significant difference,"‘Diagnostic accuracy’ (17 vs. 21) and ‘display fidelity’ (18 vs. 20) scored similarly, indicating that dot mapping faithfully represents the input datasets and is non-inferior to the separate display of the individual datasets.",41484:41711, 5834094 ,27702855,Unavailable
 5799988 ,bacterial reduction,Chemomechanical debridement (CMD) or CMD and passive ultrasonic irrigation (CMD + PUI) or  CMD and antimicrobial photodynamic therapy (aPDT),CMD and aPDT with activation by ultrasonics.,No significant difference,"The differences in bacterial reduction between the groups were not statistically significant, and all the protocols were almost equally effective in elimination of bacteria",18891:19063, 5799988 ,29430094,Unavailable
 5834094 ,"Perception accuracy, focal source localization",Dot mapping,colour mapping,No significant difference,"Perception accuracy of dot mapping was equivalent to colour mapping for both propagation direction (1.5 ± 1.8 vs. 4.8 ± 5.3°, P = 0.24) and focal source localization (1.1 ± 0.7 vs. 1.4 ± 0.5 mm, P = 0.88).",4754:4994, 5834094 ,27702855,Unavailable
 4644613 ,Hamilton rating scale for depression (HRSD) scores,Ketamine and Propofol,Propofol,No significant difference,"A comparison of the HRSD scores showed similar changes between the groups. There were no significant differences between the groups in terms of the rate and speed of the recovery process (P = 0.82, df = 3, F = 0.31) (Figure 3, Table 2).",32489:32815, 4644613 ,26576166,Unavailable
 4644613 ,The mean cognitive performance recovery time,Ketamine and Propofol,Propofol,Significantly decreased,"The mean cognitive performance recovery time in the intervention group was lower than control group (P = 0.042, df = 5, F = 2.36) (Figure 2 and Table 2).",31917:32160, 4644613 ,26576166,Unavailable
 3562202 ,the Wolf Motor Function Test-Functional Abilities Scale (WMFT-FAS),combined FTP and power training ,functional task practice (FTP ),Significantly increased,"These differences were significantly greater following HYBRID (mean 0.34 ± 0.06(S.E.)) as compared to FTP (mean 0.17 ± 0.06(S.E.)) (p = .03). Figure 5, Panel A).",42072:42273, 3562202 ,23336711,Unavailable
 3562202 ,maximal  isometric joint torque,combined FTP and power training ,functional task practice (FTP ),Significantly increased,A significant effect of treatment revealed greater increases in isometric joint torque following HYBRID (28.17% (±3.9)) than FTP (12.5% (±4.2)) (p &lt; .0001).,6182:6240, 3562202 ,23336711,Unavailable
 3562202 ,joint peak power,combined FTP and power training ,functional task practice (FTP ),Significantly increased,A significant effect of treatment revealed markedly greater increases in joint power following HYBRID (36.66% (±11.6)) as compared to FTP (-7.86% (±3.5)) (p &lt; .0001).,6182:6240, 3562202 ,23336711,Unavailable
 3562202 ,Burst duration at fast speeds ≥120º/s ,combined FTP and power training ,functional task practice (FTP ),Significantly decreased,"Responses at criterion speeds ≥120º/s revealed a greater reduction in burst duration in response to HYBRID which reached statistical significance (F(1,14) = 4.74, p &lt; .05) following the retention period.",6182:6240, 3562202 ,23336711,Unavailable
 3562202 ,proportion of participants achieved minimally important differences (MID),combined FTP and power training ,functional task practice (FTP ),Significantly increased,A greater proportion of participants achieved minimally important differences (MID) following HYBRID vs. FTP (p = .03).,5998:6135, 3562202 ,23336711,Unavailable
 3562202 ,Ashworth scores,combined FTP and power training ,functional task practice (FTP ),No significant difference,Ashworth scores were unchanged (p &gt; .05).,6182:6240, 3562202 ,23336711,Unavailable
 3549293 ,the proportion of participants who returned all questionnaires,"(i) daytrip tickets for the whole family to a popular amusement park if they returned all postal questionnaires, (ii) €12.50-worth gift vouchers for sending back the questionnaire on time after each questionnaire round and (iii) a combination of (i) and (ii)",contol,No significant difference,The effect of the voucher intervention on ‘percentage of all questionnaires received’ was not significant (Wilcoxon P value 0.37).,37487:37617, 3549293 ,23249323,Unavailable
 5982050 ,time spent engaged in  sedentary time (ST) during the school day,Active Schools: Skelmersdale (AS:Sk) pilot intervention,control group,Significantly decreased,"In the adjusted models, time spent engaged in ST during the school day was significantly less for the intervention children compared to the control group (−9.0 min; p = 0.01).",26446:26638, 5982050 ,29772839,Unavailable
 5982050 ,moderate to vigorous physical activity (MVPA),Active Schools: Skelmersdale (AS:Sk) pilot intervention,control group,No significant difference,"The odds of achieving 30 min of MVPA per school day was 2.79 times higher in the intervention group compared to the control group, however this did not reach significance (p = 0.07).",26794:26993, 5982050 ,29772839,Unavailable
 3531427 ,lower walking distance,10 µg iloprost (low dose),placebo,No significant difference,"There was a modest trend to a lower walking distance after low dose iloprost inhalation (estimated difference of the means as compared to placebo (EDOM): −12.4 m, 95% confidence interval (95% CI): −32.7–7.9 m, p = 0.22).",30262:30484, 3531427 ,23300624,Unavailable
 3531427 ,lower walking distance, 20 µg iloprost (high dose),placebo,No significant difference,High dose iloprost inhalation was similar to placebo in regard to walking distance (p = 0.98).,30484:30579, 3531427 ,23300624,Unavailable
 3531427 ,Peak oxygen consumption (VO2 peak),10 µg iloprost (low dose),placebo,Significantly decreased,"VO2 peak was clearly reduced after low dose iloprost inhalation as compared to placebo (EDOM: −76 ml/min, 95% CI: −122–−31 ml/min, p = 0.002).",30704:30858, 3531427 ,23300624,Unavailable
 3531427 ,Peak oxygen consumption (VO2 peak),20 µg iloprost (high dose),placebo,No significant difference,"Noteworthy, inhalation of high dose iloprost seemed not to influence VO2 peak (p = 0.92).",31386:31574, 3531427 ,23300624,Unavailable
 3531427 ,carbon dioxide production during exercise (VCO2 exercise),10 µg iloprost (low dose),placebo,Significantly decreased,"Low dose iloprost impaired VCO2 exercise (EDOM: −70 ml/min, 95% CI: −115–−26 ml/min, p = 0.004) whereas high dose iloprost did not alter VCO2 exercise (p = 0.90).",31063:31247, 3531427 ,23300624,Unavailable
 3531427 ,carbon dioxide production during exercise (VCO2 exercise),20 µg iloprost (high dose),placebo,No significant difference,"Low dose iloprost impaired VCO2 exercise (EDOM: −70 ml/min, 95% CI: −115–−26 ml/min, p = 0.004) whereas high dose iloprost did not alter VCO2 exercise (p = 0.90).",31063:31247, 3531427 ,23300624,Unavailable
 3531427 ,Oxygen saturation  (SpO2 rest),"10 µg iloprost (low dose), 20 µg iloprost (high dose)",placebo,Significantly decreased,"Low dose iloprost (EDOM: −1.0%, 95% CI: −1.9–−0.1%, p = 0.035) as well as high dose iloprost (EDOM: −2.2%, 95% CI: −3.1 −1.2%, p&lt;0.001) significantly diminished SpO2 rest.",31386:31574, 3531427 ,23300624,Unavailable
 3086034 ,Multi-dimensional Assessment of Fatigue (MAF),cognitive behavioural therapy (CBT),control,Significantly decreased,"At 18 weeks CBT participants reported better scores than control participants for fatigue impact: MAF 28.99 versus 23.99 (adjusted difference −5.48, 95% CI −9.50 to −1.46, p=0.008);",6624:6805, 3086034 ,21540202,Unavailable
 3680633 ,the mean anagen rate,"Crescina® HFSC (human follicle stem cell; Labo Cosprophar AG, Basel, Switzerland)",placebo,Significantly increased,Analysis of the mean anagen rate between the active group compared to the placebo group was also statistically significant (P&nbsp;&lt;&nbsp;0.001).,19212:19364, 3680633 ,23888255,Unavailable
 5844373 ,overall survival (OS),"concurrent regimen group- gefitinib (250 mg daily) and carboplatin (6 × area under the curve, day 1)/pemetrexed (500 mg/m2, day 1)",sequential  regimen group - 8 weeks of gefitinib and then two cycles of carboplatin/pemetrexed,Significantly increased,"Median OS was 41.9 months (95% CI, 31.8 to 58.0) in the concurrent regimen group and 30.7 months (95% CI, 22.7 to 38.3 months) in the sequential alternating regimen group (HR 0.58 (95% CI, 0.34 to 0.97); P=0.036; figure 2).",29251:29511, 5844373 ,29531840,Unavailable
 5844373 ,Updated response rates,"concurrent regimen group- gefitinib (250 mg daily) and carboplatin (6 × area under the curve, day 1)/pemetrexed (500 mg/m2, day 1)",sequential  regimen group - 8 weeks of gefitinib and then two cycles of carboplatin/pemetrexed,No significant difference,"Updated response rates were similar in both groups (90.2% and 82.1%, respectively; P=0.34), whereas the disease control rates were 100% and 92.3% (P=0.11; table 2).",29586:29789, 5844373 ,29531840,Unavailable
 3685777 ,total cholesterol,low-calorie diet based on 1400 kcal energy,control group,Significantly decreased,"Total cholesterol was significantly decreased only in the treatment group, the differences (before minus after) between the two groups were significant [P = 0.030, Table 3].",15981:16211, 3685777 ,23798921,Unavailable
 3046499 ,blood lactate level,haloperidol,olanzapine,Significantly increased,Patients receiving haloperidol had significantly higher blood lactate levels than patients receiving olanzapine (P &lt; 0.001).,4530:4672, 3046499 ,21328719,Unavailable
 3046499 ,parkinsonism,haloperidol,olanzapine,No significant difference,"They also more frequently had parkinsonism, which was significantly correlated with both haloperidol treatment at 1 month (P &lt; 0.001) and 6 months (P = 0.016) and olanzapine treatment at baseline (P = 0.016), 3 months (P = 0.019), and 6 months (P = 0.021).",4672:5020, 3046499 ,21328719,Unavailable
 3046499 ,dystonia,haloperidol,olanzapine,Significantly increased,"Of patients receiving haloperidol, 17% did not report any symptoms and more than one-third (37%) reported symptoms of dystonia after 6 months. None of the patients receiving olanzapine reported any symptoms of dystonia or tardive dyskinesia.",26494:26735, 3046499 ,21328719,Unavailable
 3046499 , tardive dyskinesia or akathisia,haloperidol,olanzapine,Significantly increased,"In patients receiving olanzapine, there was a correlation between blood lactate and parkinsonism at baseline and 3 and 6 months (Table 6). There was no correlation between blood lactate and akathisia, dystonia, or tardive dyskinesia at any time points (Table 5, Table 6).",52404:52792, 3046499 ,21328719,Unavailable
 3872585 ,the mean of pain score,intravenous morphine, intravenous acetaminophen,Significantly decreased,"After taking the pain reliever, the mean of pain score in morphine group was (0.75 ± 1.31) and in acetaminophen group was (2.41 ± 3.29), which revealed a statistically significant difference in compare to the time of before intervention. In other words, morphine (P = 0.001) and acetaminophen (P = 0.014) have been effective, separately.",11733:12104, 3872585 ,24381620,Unavailable
 3872585 ,symptoms of dizziness and arterial hypotension,intravenous morphine, intravenous acetaminophen,Significantly increased,"Considering hypotension as a complication, there was a significant difference between two intervention groups (P = 0.014), as presented in Table 2. Furthermore, both groups developed a significant difference (P = 0.000), as far as dizziness as a side-effect in concerned. Results suggest that morphine is more likely to cause symptoms of dizziness and arterial hypotension.",15332:15778, 3872585 ,24381620,Unavailable
 3872585 ,vomiting,intravenous morphine, intravenous acetaminophen,No significant difference,Chi-square test indicates that no significant relationship between vomiting and the type of medication have been proved (P = 0.50).,15177:15325, 3872585 ,24381620,Unavailable
 5816528 ,The rate of canine retraction,piezocision,laser-assisted flapless corticotomy,No significant difference,"The rate of canine retraction decreased significantly over time in the two experimental sides of both groups (p = 0.006 in the PG, p = 0.003 in the LG; Table 5).Table 5",38572:38844, 5816528 ,29454369,Unavailable
 5816528 ,the overall canine retraction duration,piezocision,laser-assisted flapless corticotomy,No significant difference,The overall duration of canine retraction was shortened significantly in the experimental side compared to the control side by a mean of 1.17 month (p = 0.001) in the PG and 1.05 month (p ≤ 0.001) in the LG whereas the difference between the two experimental sides was not significant (p = 0.523; Fig. 7).Fig. 7,37926:38349, 5816528 ,29454369,Unavailable
 5816528 ,loss of anchorage and upper canine rotation,piezocision,laser-assisted flapless corticotomy,No significant difference,There were no significant differences between the experimental and the control sides regarding loss of anchorage and upper canine rotation in both groups (p &gt; 0.05).,6758:6940, 5816528 ,29454369,Unavailable
 5816528 ,The rate of canine retraction,piezocision or laser-assisted flapless corticotomy,flapless surgical intervention ,Significantly increased,The rate of canine retraction was significantly greater in the experimental side than in the control side in both groups by two-fold in the first month and 1.5-fold in the second month (p &lt; 0.001).,6360:6575, 5816528 ,29454369,Unavailable
 5816528 ,the overall canine retraction duration,piezocision or laser-assisted flapless corticotomy,flapless surgical intervention ,Significantly decreased,Also the overall canine retraction duration was significantly reduced in the experimental side as compared with control side in both groups about 25% (p ≤ 0.001).,6575:6757, 5816528 ,29454369,Unavailable
 5498678 ,the responder rate,Cohesive Polydensified Matrix® 26 mg/mL HA gel (CPM-26),Vycross® 20 mg/ml HA gel (VYC-20),No significant difference,"Statistical analysis confirmed that the responder rate of CPM-26 was significantly non-inferior to VYC-20 (difference of responder rate: 0.09, one-sided 95% CI: [−0.07, 1]).",17198:17371, 5498678 ,28721082,Unavailable
 5498678 ,volume augmentation at M3,Cohesive Polydensified Matrix® 26 mg/mL HA gel (CPM-26),Vycross® 20 mg/ml HA gel (VYC-20),Significantly increased,"CPM-26 showed visibly more volume augmentation at all time points, and the difference was significant at M3 (3.44±1.49 vs 2.52±0.83 cm3; CPM-26 vs VYC-20; n=30; p=0.0003).",19252:19531, 5498678 ,28721082,Unavailable
 5498678 ,"subjects showed best grades in terms of esthetic improvement at M1, M3, M12 and M18 visits",Cohesive Polydensified Matrix® 26 mg/mL HA gel (CPM-26),Vycross® 20 mg/ml HA gel (VYC-20),Significantly increased,"Significantly more subjects showed best grades in terms of esthetic improvement on the CPM-26 side than on the VYC-20 side at M1, M3, M12 and M18 visits (p=0.0032, p=0.0074, p=0.0384 and p=0.0110, respectively).",19252:19531, 5498678 ,28721082,Unavailable
 4236282 ,triglyceride level,nutrition psychoeducation (NPC) ,usual care (UC),Significantly decreased,LSD post-hoc analyses showed that post-treatment triglycerides in the NPC were significantly lower compared to UC (p=0.008) and trended towards significance for MIC (p=0.057).,25245:25455, 4236282 ,25298016,Unavailable
 4236282 ,triglyceride level,nutrition psychoeducation (NPC) ,motivational interviewing (MIC),No significant difference,There were no significant differences between MIC and UC (p=0.423).,25455:25539, 4236282 ,25298016,Unavailable
 4236282 ,BDI scores,nutrition psychoeducation (NPC) ,usual care (UC),Significantly decreased,LSD post-hoc analyses showed that NPC BDI scores at post-treatment assessment were significantly lower when compared to UC (p=0.009) but not MIC (p=0.195).,26178:26369, 4236282 ,25298016,Unavailable
 4236282 ,BDI scores,nutrition psychoeducation (NPC) ,motivational interviewing (MIC),No significant difference,There were no significant differences between MIC and UC (p=0.168).,26369:26454, 4236282 ,25298016,Unavailable
 4236282 ,Satisfaction,nutrition psychoeducation (NPC)  or motivational interviewing (MIC),Usual care (UC),Significantly increased,"LSD post-hoc analyses showed UC (M=66.0; SD=11.1) patients were significantly less satisfied than MIC (M=73.3; SD=6.6, p=.001) and NPC (M=75.2; SD=5.3, p&lt;.0005) patients.",20802:21113, 4236282 ,25298016,Unavailable
 4748323 ,Fall risk assessed by the PPA,the exercise program for 16 weeks,received educational material including advice on a healthy lifestyle and fall prevention,Significantly decreased,"Fall risk assessed by the PPA was significantly reduced in the intervention group compared with the control group (F1,127 = 4.54, p = 0.035).",34290:34460, 4748323 ,26865874,Unavailable
 4748323 ,Hand reaction,the exercise program for 16 weeks,received educational material including advice on a healthy lifestyle and fall prevention,Significantly increased,"Hand reaction time worsened significantly in the control group compared to the intervention group (F1,128 = 9.59, p = 0.002).",34460:34614, 4748323 ,26865874,Unavailable
 4748323 ,time for 10 m walking while counting backwards by three,the exercise program for 16 weeks,received educational material including advice on a healthy lifestyle and fall prevention,Significantly decreased,"The reduction in time for 10 m walking while counting backwards by three was more pronounced in the intervention than the control group (F1,127 = 4.32, p = 0.040).Table 2",34614:34841, 4748323 ,26865874,Unavailable
 4748323 ,quality of life,the exercise program for 16 weeks,received educational material including advice on a healthy lifestyle and fall prevention,No significant difference,"There was also a trend for an improvement in quality of life (F1,73 = 3.91, p = 0.052, borderline) when the high-adherence group was compared to the control group.Table 3",42465:42692, 4748323 ,26865874,Unavailable
 3575558 ,The Total upper airway symptom (TUAS) scores,heated humidifier (HH),no heated humidifier (HH),Significantly increased,The TUAS scores were improved in the HH group (p = 0.043) (Fig. 2).,17645:17769, 3575558 ,22311554,Unavailable
 3575558 ,"leak values, AHI reduction, and optimal CPAP pressure",heated humidifier (HH),no heated humidifier (HH),No significant difference,"Leak values, including median leak, 95th percentile leak, and maximum leak, were similar in the two groups (Table 2). Furthermore, AHI reduction amounts and optimal CPAP pressure were not different between the two groups.",17197:17470, 3575558 ,22311554,Unavailable
 3575558 ,individual naso-pharyngeal symptoms,heated humidifier (HH),no heated humidifier (HH),No significant difference,But individual naso-pharyngeal symptoms were not statistically different between the two groups.Table 2,17769:17901, 3575558 ,22311554,Unavailable
 5557991 ,The frequency of crying,ketamine (0.5mg/kg) ,midazolam (0.2mg/kg),Significantly decreased,The frequency of crying decreased significantly following ketamine administration compared to midazolam (P=0.002);,4521:4636, 5557991 ,28828011,Unavailable
 5557991 ,movement of children,ketamine (0.5mg/kg) ,midazolam (0.2mg/kg),Significantly decreased,movement of children decreased with fewer incidence of treatment interruption (P=0.001),4636:4724, 5557991 ,28828011,Unavailable
 5557991 ,sleepiness,ketamine (0.5mg/kg) ,midazolam (0.2mg/kg),Significantly increased,while their sleepiness increased (P=0.003),4724:4766, 5557991 ,28828011,Unavailable
 5557991 ,patients’ overall behavior,ketamine (0.5mg/kg) ,midazolam (0.2mg/kg),No significant difference,"Despite higher success of sedation with ketamine compared to midazolam, no significant differences were found between the two regarding patients’ overall behavior (P&gt;0.05).",4768:4940, 5557991 ,28828011,Unavailable
 5557991 ,respiratory rate and oxygen saturation,ketamine (0.5mg/kg) ,midazolam (0.2mg/kg),No significant difference,"however, no significant difference was found regarding respiratory rate and oxygen saturation (P&gt;0.05).",5009:5113, 5557991 ,28828011,Unavailable
 5891027 ,mean arterial pressure,"The N-P group initially had one-lung ventilation (OLV) with normal saline infusion for 30 minutes; after a 10 minute interval, OLV was then maintained with phenylephrine infusion for 30 minutes.",P-N group had the drug-infusion in the reverse order,Significantly increased,Although phenylephrine infusion significantly increased mean arterial pressure (P &lt; 0.001),11946:12090, 5891027 ,29630639,Unavailable
 5891027 ,arterial partial pressure of oxygen,"The N-P group initially had one-lung ventilation (OLV) with normal saline infusion for 30 minutes; after a 10 minute interval, OLV was then maintained with phenylephrine infusion for 30 minutes.",P-N group had the drug-infusion in the reverse order,No significant difference,", arterial partial pressure of oxygen did not differ between the two timepoints (P = 0.19)",11946:12090, 5891027 ,29630639,Unavailable
 5891027 ,arterial partial pressure of oxygen,"The N-P group initially had one-lung ventilation (OLV)with normal saline infusion for 30 minutes; after a 10 minute interval, OLV was then maintained with phenylephrine infusion for 30 minutes.",P-N group had the drug-infusion in the reverse order,No significant difference,There was no carryover effect in arterial partial pressure of oxygen (P = 0.14).,11946:12090, 5891027 ,29630639,Unavailable
 5891027 ,heart rate  and pulse pressure variation,"The N-P group initially had one-lung ventilation (OLV) with normal saline infusion for 30 minutes; after a 10 minute interval, OLV was then maintained with phenylephrine infusion for 30 minutes.",P-N group had the drug-infusion in the reverse order,Significantly decreased,Phenylephrine infusion significantly decreased heart rate (P = 0.02) and pulse pressure variation (P &lt; 0.001).,11946:12090, 5891027 ,29630639,Unavailable
 3580751 ,mean ± SD length of invasive mechanical ventilation before ventilator-associated pneumonia (VAP)  onset,Interrupted surveillance unit A,"Continuous surveillance, unit B",No significant difference,"In patients who had VAP, mean ± SD length of invasive mechanical ventilation before VAP onset did not change between periods 1 and 2 in the intervention group (11.6 ± 12.5 days vs. 14.0 ± 15.0 days, respectively, P = 0.4) and in the control group (13.1 ± 11.6 days vs. 10.4 ± 9.9 days, respectively, P = 0.11).",23551:23895, 3580751 ,22909033,Unavailable
 3580751 , mean ± SD length of hospital stay between periods 1 and 2 in patients who did not suffer from VAP,Interrupted surveillance unit A,"Continuous surveillance, unit B",Significantly increased,"In patients who did not suffer from VAP, no difference was found regarding mean ± SD length of hospital stay between periods 1 and 2 in the intervention group (9.3 ± 11.9 days vs. 9.9 ± 14.8 days, respectively, P = 0.5),",23895:24133, 3580751 ,22909033,Unavailable
 5835557 ,Flu-like symptoms,seasonal influenza vaccine,placebo,No significant difference,"Flu-like symptoms occurred in 61.3% in the verum group and in 41.9% in the placebo group, however this difference was not statistically significant.",39253:39402, 5835557 ,29337134,Unavailable
 5835557 ,AChR-ab-titer,seasonal influenza vaccine,placebo,No significant difference,"The difference between the relative change of AChR-ab-titer in the verum group and the placebo group in terms of the Hodges-Lehmann-estimate with 95% CI was −&nbsp;4·0% [−&nbsp;13·3%, 4·5%]. There was no difference in the AChR-ab titer between week 3 and week 12 (Table 2).",32852:33157, 5835557 ,29337134,Unavailable
 1579211 ,The mean incision length,SaphLITE Retractor System (Teleflex Medical),"the Clearglide Endoscopic Vessel Harvesting System (Ethicon CardioVations, Inc.)",Significantly increased,"The mean incision length was 3.6 cm (range, 2–6) in the SaphLITE group versus 2.1 cm (range, 1–4) in the Clearglide group (p &lt; 0.05).",4917:5015, 1579211 ,16953895,Unavailable
 1579211 ,The total incision length,SaphLITE Retractor System (Teleflex Medical),"the Clearglide Endoscopic Vessel Harvesting System (Ethicon CardioVations, Inc.)",Significantly increased,The total incision length was 12.9 cm versus 8.9 (p &lt; 0.05) in the SaphLITE and Clearglide groups.,4917:5015, 1579211 ,16953895,Unavailable
 3544534 ,health satisfaction,Tai Chi,proprioception exercise,Significantly increased,Elderly subjects expressed significantly higher health satisfaction in the TC group than in the PE group after 16 weeks (P = 0.036),22121:22269, 3544534 ,23346195,Unavailable
 3544534 ,strength and endurance of the bilateral ankle dorsiflexors and plantar flexors at a speed of 30°/s,Tai Chi,proprioception exercise,No significant difference,We found no significant differences in the strength and endurance of the bilateral ankle dorsiflexors and plantar flexors at a speed of 30°/s for concentric test conditions among groups (Table 2).,21814:22051, 3544534 ,23346195,Unavailable
 3544534 ,smaller amount of absolute error in the right ankle,Tai Chi,proprioception exercise,No significant difference,"subjects in the TC group and PE group had a smaller amount of absolute error in the right ankle than the control group, but there were no significant differences (P = 0.184 for TC, P = 0.883 for PE),",21319:21553, 3544534 ,23346195,Unavailable
 3544534 ,joint position matching of both ankles,Tai Chi,proprioception exercise,No significant difference,"and (3) there were no significant differences in joint position matching of both ankles for the TC group and PE group (P = 0.979 for left, P = 0.184 for right).",21553:21748, 3544534 ,23346195,Unavailable
 4920563 ,"∆% 1st hour and ∆% 5th hour values  total (tPSA), free (fPSA) prostate-specific antigen (PSA)",ejaculation, without ejaculation,Significantly increased,"When study and control groups were compared, a statistically significant difference was detected between ∆% 1st hour and ∆% 5th hour values of total and free PSA (p&lt;0.05).",16681:16824, 4920563 ,27286109,Unavailable
 4920563 ,"between ∆% 24th hour and ∆% 72th hour values  total (tPSA), free (fPSA)",ejaculation, without ejaculation,No significant difference,"However, there weren’t any significant differences between ∆% 24th hour and ∆% 72th hour values (p&gt;0.05).",16550:16682, 4920563 ,27286109,Unavailable
 4920563 ,"1st, 5th, 24th and 72th hours’ complexed PSA (cPSA)",ejaculation, without ejaculation,No significant difference,∆% cPSA values didn’t differ significantly from each other at any time points (p&gt;0.05) (Table-2).,16681:16824, 4920563 ,27286109,Unavailable
 5884496 ,"past-year physical (OR 0.37, p&lt;0.001) and sexual intimate partner violence (IPV)",Bandebereho gender-transformative couples’ intervention,control,Significantly decreased,"Compared to the control group, women in the intervention group reported: less past-year physical (OR 0.37, p&lt;0.001) and sexual IPV (OR 0.34, p&lt;0.001);",14549:14699, 5884496 ,29617375,Unavailable
 5884496 ,attendance and male accompaniment at antenatal care,Bandebereho gender-transformative couples’ intervention,control,Significantly increased,"and greater attendance (IRR 1.09, p&lt;0.001) and male accompaniment at antenatal care (IRR 1.50, p&lt;0.001);",14699:14805, 5884496 ,29617375,Unavailable
 4712164 ,flow mediated changes (Δ) of creatinine,group I (80 mL/minute);, group II (180 mL/minute) and group III (270 mL/minute),No significant difference,"There was no statistically significant (P&gt;0.05) flow mediated changes (Δ) of creatinine (0.23±0.27 vs. 0.38±0.33 vs. 0.26±0.18 mg/dL), MELD (1.25±5.72 vs. 1.70±2.18 vs. 1.45±2.21) or PRA (450.93±614.10 vs. 394.61±954.64 vs. 629.51±1,116.46 pg/mL).",5258:5526, 4712164 ,26770925,Unavailable
 4712164 ,Model End Stage Liver Disease score,group I (80 mL/minute);, group II (180 mL/minute) and group III (270 mL/minute),No significant difference,"There was no statistically significant (P&gt;0.05) flow mediated changes (Δ) of creatinine (0.23±0.27 vs. 0.38±0.33 vs. 0.26±0.18 mg/dL), MELD (1.25±5.72 vs. 1.70±2.18 vs. 1.45±2.21) or PRA (450.93±614.10 vs. 394.61±954.64 vs. 629.51±1,116.46 pg/mL).",5258:5526, 4712164 ,26770925,Unavailable
 4712164 ,Plasma renin activity (PRA),group I (80 mL/minute);, group II (180 mL/minute) and group III (270 mL/minute),No significant difference,"There was no statistically significant (P&gt;0.05) flow mediated changes (Δ) of creatinine (0.23±0.27 vs. 0.38±0.33 vs. 0.26±0.18 mg/dL), MELD (1.25±5.72 vs. 1.70±2.18 vs. 1.45±2.21) or PRA (450.93±614.10 vs. 394.61±954.64 vs. 629.51±1,116.46 pg/mL).",5258:5526, 4712164 ,26770925,Unavailable
 4712164 ,Paracentesis induced circulatory dysfunction (PICD),group I (80 mL/minute);, group II (180 mL/minute) and group III (270 mL/minute),No significant difference,PICD was detected in a similar frequency in the three groups (P&gt;0.05).,5525:5617, 4712164 ,26770925,Unavailable
 3474775 ,"high-sensitivity C-reactive protein (hs-CRP), IL-6 and TNF-α,  total cholesterol, low-density lipoprotein cholesterol (LDL-C)", L-placebo in combination with pravastatin (P) (20 mg daily),P-placebo among participants receiving ART with undetectable HIV RNA levels,No significant difference,"There was no treatment difference for pravastatin vs P-placebo in total cholesterol, LDL-C, or any of the inflammatory biomarkers.",8484:8652, 3474775 ,23082133,Unavailable
 3474775 ,"diastolic BP, hsCRP and TNF-α", lisinopril (L) (10 mg daily) vs, L-placebo in combination with pravastatin (P) (20 mg daily),Significantly decreased,"Participants randomized to lisinopril vs. L-placebo had significant declines in diastolic BP (−3.3 mmHg, p = 0.05), hsCRP (−0.61 µg/mL, p = 0.02) and TNF-α (−0.17 pg/mL, p = 0.04).",8303:8483, 3474775 ,23082133,Unavailable
 3474775 ,missed doses  and have adherence &lt;90% by pill count, lisinopril (L) (10 mg daily) vs, L-placebo in combination with pravastatin (P) (20 mg daily),Significantly increased,Participants taking lisinopril vs L-placebo were more likely to report missed doses (88 vs 35%; p = 0.001) and have adherence &lt;90% by pill count (42 vs. 0%; p = 0.02).,8484:8652, 3474775 ,23082133,Unavailable
 3606616 ,The mean scores on the Breastfeeding Emotional Scale,skin-to-skin contact during the breastfeeding,no skin-to-skin contact during the breastfeeding,Significantly increased,"The mean scores on the Breastfeeding Emotional Scale assessed during the breastfeeding session after intervention was significantly higher in the experimental group than in the control group (mean 69.2, SE 1.68 vs. mean 62.4, SE 2.44, p-value = 0.022).",56761:57013, 3606616 ,23497501,Unavailable
 3606616 ,Breastfeeding Pain Scale,skin-to-skin contact during the breastfeeding,no skin-to-skin contact during the breastfeeding,Significantly decreased,"During the breastfeeding session after intervention, the mothers in the experimental group scored significantly lower on the Breastfeeding Pain Scale than the control group, median 1.0 (Q1 =1.0 – Q3 = 1.0) vs. median 1.0 (Q1 = 1.0 – Q3 = 2.0) p-value = 0.044.",57070:57373, 3606616 ,23497501,Unavailable
 3606616 ,The proportion of infants starting to latch-on and suckle,skin-to-skin contact during the breastfeeding,no skin-to-skin contact during the breastfeeding,No significant difference,"The proportion of infants starting to latch-on and suckle did not differ significantly between the experimental group 75% (n = 40), and control group 86% (n = 43) (Fisher’s Exact test p-value = 0.217).",57470:57671, 3606616 ,23497501,Unavailable
 3606616 ,registered time when infants began latching on,skin-to-skin contact during the breastfeeding,no skin-to-skin contact during the breastfeeding,Significantly decreased,"The 31 infants in the experimental group with registered time began latching on in a significantly shorter median time than the 33 infants with registered time in the control group, 2.0 weeks (Q1 = 1.0, Q3 = 3.7) vs. 4.7 weeks (Q1 = 2.0, Q3 = 8.0), (p-value = 0.020).",57998:58310, 3606616 ,23497501,Unavailable
 3606616 ,The median age of the infants when starting to latch-on and suckle regularly,skin-to-skin contact during the breastfeeding,no skin-to-skin contact during the breastfeeding,No significant difference,"The median age of the infants when starting to latch-on and suckle regularly was 7.7 weeks, (Q1 = 3.7, Q3 = 10.7) in the experimental group vs. 7.1 weeks, (Q1 = 4.6, Q3 = 11.7) in the control group. This difference was not significant (p-value = 0.919).",62737:63034, 3606616 ,23497501,Unavailable
 5117008 ,mean VO2 peak after adjuvant chemotherapy,moderate to high intensity exercise,usual care,No significant difference,"By using analysis of variance (one-way ANOVA) did the primary outcome measure, mean VO2 peak, decrease significantly within groups from baseline to postintervention (12 weeks) in breast cancer groups (high, low and control). There were minor changes within groups",45051:45326, 5117008 ,27900123,Unavailable
 5561409 ,Total sleep time and sleep efficiency,nicotine patch,placebo patch,Significantly decreased,"On the nights with nicotine patch, as compared to the nights with placebo patch, TST (321.8 minutes vs. 422.7 minutes, p&lt;0.01) and sleep efficiency (72.5% vs. 91.6%, p&lt;0.01) were decreased",18042:18230, 5561409 ,28845178,Unavailable
 5561409 ,"wakefulness after sleep onset (WASO), sleep latency to stage 2, and sleep latency to REM stage",nicotine patch,placebo patch,Significantly increased,"wakefulness after sleep onset (WASO) (97.8 minutes vs. 23.8 minutes, p&lt;0.01), sleep latency to stage 2 (23.7 minutes vs 9.2 minutes, p&lt;0.01), and sleep latency to REM stage (105.1 minutes vs. 74.9 minutes, p=0.05) were increased.",18235:18465, 5561409 ,28845178,Unavailable
 5561409 ,percentage of stage 1,nicotine patch,placebo patch,Significantly increased,"as compared to the nights with placebo patch, percentage of stage 1 was increased (15.5% vs. 10.9%, p&lt;0.01)",18535:18642, 5561409 ,28845178,Unavailable
 5561409 ,percentage of stage REM,nicotine patch,placebo patch,Significantly decreased,"percentage of stage REM was decreased (19.7% vs. 23.4%, p&lt;0.05).",18647:18712, 5561409 ,28845178,Unavailable
 5561409 ,alpha activity on EEG during REM sleep,nicotine patch,placebo patch,Significantly increased,"During REM sleep, alpha activity was significantly higher in nights with transdermal nicotine patch compared to nights with placebo patch also on the first NREM-REM cycle of the nights (t=−2.673, df=14, p&lt;0.05) (Figure 3).",19857:20120, 5561409 ,28845178,Unavailable
 5561409 ,"For spindle frequency activity, theta, beta1, and beta2 activity,",nicotine patch,placebo patch,No significant difference,"For spindle frequency activity, theta, beta1, and beta2 activity, no statistical differences were observed.",20120:20227, 5561409 ,28845178,Unavailable
 1079844 ,vascular mortality,40 mg simvastatin,placebo,Significantly decreased,"Overall, allocation to simvastatin produced a highly significant 17% (SE 4; p &lt; 0.0001) proportional reduction in vascular mortality during the 5 years of the study (table 2).",23089:23307, 1079844 ,15771782,Unavailable
 1079844 ,deaths due to coronary causes,40 mg simvastatin,placebo,Significantly decreased,"This reflected a definite 18% (SE 5; p = 0.0005) reduction in deaths due to coronary causes,",23307:23400, 1079844 ,15771782,Unavailable
 1079844 ,deaths from fatal strokes and deaths from other vascular causes,40 mg simvastatin,placebo,No significant difference,"together with a non-significant 20% (SE 12; p = 0.1) reduction in fatal strokes and 12% (SE 13; p = 0.3) reduction in deaths from other vascular causes, with no significant difference between the effects observed on these different vascular causes (heterogeneity p = 0.9).",23400:23673, 1079844 ,15771782,Unavailable
 1079844 ,all-cause mortality,40 mg simvastatin,placebo,Significantly decreased,which translated into a significant reduction in all-cause mortality (p = 0.0003).,3705:3788, 1079844 ,15771782,Unavailable
 1079844 ,deaths from all cancers,40 mg simvastatin,placebo,No significant difference,there were no significant differences between the treatment groups in the numbers of deaths from all cancers or from cancers at particular sites (or in the numbers of incident cancers: see below).,37664:37861, 1079844 ,15771782,Unavailable
 2474855 ,levels of physical activity in the classroom,Physical Activity Across the Curriculum (PAAC),control,Significantly increased,"Students in the intervention schools performed significantly greater levels of physical activity in the classroom than students in the control schools; higher scores indicate higher activity intensity levels (intervention students 3.40 ± 0.02 vs control students 2.17 ± 0.03, p &lt; 0.0001).",33694:33983, 2474855 ,18606013,Unavailable
 2474855 ,the System for Observing Fitness Instruction Time (SOFIT)  scores,Physical Activity Across the Curriculum (PAAC),control,Significantly increased,"As shown in Figure 1, as modeling of an active lesson increased by PAAC teachers (i.e., none vs somewhat or very active participation), student SOFIT scores also increased significantly (p &lt; 0.0001).",35854:36091, 2474855 ,18606013,Unavailable
 3558645 ,The onset time of muscle relaxation,propofol 2 mg/kg plus normal saline 2 ml,propofol 2 mg/kg plus 2% lidocaine 40 mg,No significant difference,"The onset time of muscle relaxation was 164.7 ± 77.9 seconds for Group L, which was quicker than the 186.6 ± 71.0 seconds for Group C, but did not differ statistically.",11908:12076, 3558645 ,23372883,Unavailable
 3558645 ,endotracheal intubation assessment,propofol 2 mg/kg plus normal saline 2 ml,propofol 2 mg/kg plus 2% lidocaine 40 mg,No significant difference,"In the condition of endotracheal intubation assessment, except for one case of a ""Poor"" in Group C, both groups were either Excellent or Good, and did not differ significantly (Table 3).",12083:12308, 3558645 ,23372883,Unavailable
 3558645 ,"Systolic, diastolic blood pressures and heart rate",propofol 2 mg/kg plus normal saline 2 ml,propofol 2 mg/kg plus 2% lidocaine 40 mg,No significant difference,"Systolic, diastolic blood pressures and heart rate did not show any significant differences before inducing anesthesia, after intravenous injection of propofol, just before intubation, immediately after intubation, 1, 2, 3 and 5 minutes after intubation, between the two groups.",12315:12593, 3558645 ,23372883,Unavailable
 5986437 ,"peak, mean, and total AUC glucose",high-carbohydrate diet [HCD]: 67:15:18% carbohydrate:fat:protein,high-fat diet [HFD]: 67:15:18% fat:carbohydrate:protein ,Significantly increased,"consumption of the HCD elevated peak (+1.6 mmol/L, 95%CI: 1.0–2.2 mmol/L; p &lt; 0.001), mean (+0.5 mmol/L, 95%CI: 0.2–0.7 mmol/L; p = 0.001), and total AUC glucose (+670 mmol/L/min, 95%CI: 300–1040 mmol/L/h; p = 0.001) compared with the HFD (Table 2).",35629:35992, 5986437 ,29710870,Unavailable
 3661336 ,the mean fitness,300 mg Ubiquinol,placebo,Significantly increased,The t-test revealed a significant difference of the mean fitness increases between experimental and control groups (p = 0.03).,31177:31320, 3661336 ,23627788,Unavailable
 2836470 ,terminating FVT episodes,15-pulse anti-tachycardia pacing (ATP),eight-pulse anti-tachycardia pacing (ATP),No significant difference,"The overall ATP efficacy in terminating FVT episodes was 71% when unadjusted and 67% when adjusted (95%CI 60–74%). After adjustment, 64% of episodes were terminated by eight-pulse ATP (95%CI 55–75%) versus 70% (95%CI 60–80%) in the 15-pulse group (p = 0.504).",21275:21551, 2836470 ,20087760,Unavailable
 2836470 ,Syncope and near-syncope episodes,15-pulse anti-tachycardia pacing (ATP),eight-pulse anti-tachycardia pacing (ATP),No significant difference,"Syncope and near-syncope occurred in 0.5% and 2.8% of FVT episodes, respectively in the eight-pulse group and in 3.2% and a 0.7% in the 15-pulse group. We found no significant differences between groups with regard to syncope/near-syncope occurrence (p = 0.690).",27424:27704, 2836470 ,20087760,Unavailable
 2836470 ,number of shocks,15-pulse anti-tachycardia pacing (ATP),eight-pulse anti-tachycardia pacing (ATP),No significant difference,"In the eight-pulse arm, 59 out of 250 FVT episodes (22%) required one or more shocks (total shocks 72). In the 15-pulse arm, 45 out of 209 FVT episodes (21%) required one or more shocks (total shocks 50). No significant differences were observed between groups (p = 0.907).",27802:28092, 2836470 ,20087760,Unavailable
 2836470 ,overall mortality,15-pulse anti-tachycardia pacing (ATP),eight-pulse anti-tachycardia pacing (ATP),No significant difference,No significant difference was found between the two randomization groups in terms of causes of death (all p values &gt; 0.5) or overall mortality (Log-rank = 0.22; p = 0.636).,29359:29568, 2836470 ,20087760,Unavailable
 2836470 ,FVT acceleration episodes,15-pulse anti-tachycardia pacing (ATP),eight-pulse anti-tachycardia pacing (ATP),No significant difference,FVT acceleration was observed only for 18 episodes (3.9%) in 13 patients: 3.9% in the eight-pulse group vs. 4% in the 15-pulse group (p = 0.993) as summarized in Table 2.,24541:24769, 2836470 ,20087760,Unavailable
 3665020 ,creatine kinase,vitamin C (250 mg/day),placebo,Significantly decreased,"On comparison between groups, only creatine kinase had a significant change at the end of the period (P = 0.03). However, in the intergroup comparison it was significantly decreased in group 1 (P = 0.002).",17319:17559, 3665020 ,23717764,Unavailable
 3665020 ,Lactate dehydrogenase,vitamin E (400 IU),placebo,Significantly decreased,Lactate dehydrogenase significantly decreased in group 2 (P = 0.02).,17642:17728, 3665020 ,23717764,Unavailable
 5812877 ,skin temperature,running in the hot (31ºC) environment,running in the cool (18ºC) environment,Significantly increased,Participants' skin temperature was significantly higher (p &lt; 0.001) in the hot trial compared to the cool trial (Fig. 3).,24780:24961, 5812877 ,29541134,Unavailable
 5812877 ,tympanic temperature,running in the hot (31ºC) environment,running in the cool (18ºC) environment,Significantly increased,"Similarly, participants' tympanic temperature was significantly higher (p &lt; 0.001) in the hot trial compared to the cool trial (Fig. 4).Fig. 3",24961:25184, 5812877 ,29541134,Unavailable
 5812877 ,heart rate,running in the hot (31ºC) environment,running in the cool (18ºC) environment,Significantly increased,"Moreover, there was also a significant difference on heart rate between trials (p &lt; 0.001) where, heart rate at min 80 and 90 during the 90 min running trial were significantly higher in the hot trial compared to cool trial.Fig. 5",26002:26277, 5812877 ,29541134,Unavailable
 5812877 ,Saliva flow rate,running in the hot (31ºC) environment,running in the cool (18ºC) environment,No significant difference,Saliva flow rate was not significantly (p = 0.949) different between the hot (0.32 ± 0.08 ml/min) and cool (0.27 ± 0.05 ml/min) trials.,5861:6017, 5812877 ,29541134,Unavailable
 5812877 ,salivary lysozyme concentration and secretion rate,running in the hot (31ºC) environment,running in the cool (18ºC) environment,No significant difference,"In addition, there were no significant differences between and within hot and cool trials in salivary lysozyme concentration (p = 0.925; 4.79 ± 1.37 and 4.44 ± 1.11 μg/ml respectively) and secretion rate (p = 0.843; 1.67 ± 1.1 and 1.17 ± 1.0 μg/min respectively).",6197:6497, 5812877 ,29541134,Unavailable
 5791469 ,terms of the variable of the informed choice regarding screening of fetal anomalies,The face-to-face group and group education course,usual care,Significantly increased,"Similarly, pairwise comparison between groups indicated that there was statistically significant difference among face-to-face and control groups (P = 0.001), and group education and control group (P = 0.001)",22751:22993, 5791469 ,29417066,Unavailable
 5791469 ,terms of the variable of the informed choice regarding screening of fetal anomalies,The face-to-face group , group education course,No significant difference,in terms of variable of informed choice but there was no statistically significant difference among face-to-face group and group education (P = 0.077) in terms of this variable [Table 2].,22994:23237, 5791469 ,29417066,Unavailable
 5791469 ,mean score for the variable of knowledge of pregnant women,The face-to-face group and group education course,usual care,Significantly increased,"The result of Mann–Whitney U-test for pairwise comparison of groups showed that there was statistically significant difference in mean score for the variable of knowledge of pregnant women regarding tests after execution of intervention among face-to-face education and control groups (P = 0.001), and group education and control group (P = 0.001).",24399:24535, 5791469 ,29417066,Unavailable
 5791469 ,mean score for the variable of knowledge of pregnant women,The face-to-face group , group education course,No significant difference,"But, there was no statistically significant difference among face-to-face group and group education class (P = 0.059).",24399:24535, 5791469 ,29417066,Unavailable
 5791469 ,mean score for variable attitude of pregnant women,The face-to-face group and group education course,usual care,Significantly increased,result of Mann–Whitney U-test for pairwise comparison of groups indicated that the mean score of variable attitude in pregnant women at postintervention phase included statistically significant difference among group education and control group (P = 0.001) and face-to-face education group and group education (P = 0.001).,25192:25549, 5791469 ,29417066,Unavailable
 5791469 ,mean score for variable attitude of pregnant women,The face-to-face group , group education course,No significant difference,"However, there was no significant difference among face-to-face education and control group (P = 0.76) [Table 3].",25549:25719, 5791469 ,29417066,Unavailable
 5812864 ,Biceps thickness,bench press at 40%1RM (bench-press group)  ,push-ups with position adjusted (e.g. kneeling) to the same load of bench-press 40%1RM (push-up group),Significantly increased,"Biceps thickness significantly increased only in the bench-press group (28.4&nbsp;±&nbsp;3.3 mm to 31.5&nbsp;±&nbsp;3.7 mm, p&nbsp;&lt;&nbsp;0.01).",4604:4720, 5812864 ,29541130,Unavailable
 3599931 ,weight  after three months,standard care plus intervention (LWP),standard care (SC),No significant difference,"On an intent to treat analysis, after three months the patients in the intervention group presented a decrease of 0.48 kg (CI 95% -0.65 to 1.13) while the standard care group showed an increase of 0.48 kg (CI 95% 0.13 to 0.83; p=0.055).",6153:6389, 3599931 ,23418863,Unavailable
 3599931 ,weight after  six-month follow-up,standard care plus intervention (LWP),standard care (SC),Significantly decreased,"At six-month follow-up, there was a significant weight decrease of −1.15 kg, (CI 95% -2.11 to 0.19) in the intervention group compared to a weight increase in the standard care group (+0.5 kg, CI 95% -0.42–1.42, p=0.017).",6390:6611, 3599931 ,23418863,Unavailable
 3655222 ,The proportion of subjects needing additional uterotonic treatment,carbetocin,oxytocin,Significantly decreased,"The proportion of subjects needing additional uterotonic treatment was 3.1 % (95 % confidence interval (CI) 1.7–5.1 %) in the carbetocin group and 7.2 % (95 % CI 5.8–8.9 %) in all oxytocin groups combined, p = 0.0110 (Table 2).",17278:17563, 3655222 ,23329341,Unavailable
 3655222 ,The need for additional uterotonics,carbetocin,oxytocin,Significantly decreased,"The need for additional uterotonics was significantly lower after carbetocin versus the subgroup oxytocin 5 IU (3.1 vs. 9.3 %, p = 0.0067),",20286:20442, 3655222 ,23329341,Unavailable
 3655222 ,Blood transfusions,carbetocin,oxytocin,No significant difference,Blood transfusions were administrated in 2.2 % of the cases in the carbetocin group and 2.7 % in the oxytocin group (NS).,22351:22473, 3655222 ,23329341,Unavailable
 3655222 ,Mean number of packed cells per patient,carbetocin,oxytocin,No significant difference,"Mean number of packed cells per patient was 0.04 versus 0.09 in the carbetocin and oxytocin groups, respectively (p = 0.129).",22879:23022, 3655222 ,23329341,Unavailable
 3655222 ,The need for additional operative interventions related to PPH,carbetocin,oxytocin,Significantly decreased,"The need for additional operative interventions related to PPH (i.e. uterine tamponade, ligation of vessels or relaparotomy) tended to be lower in the carbetocin group than in the oxytocin group (0.4 % vs. 1.2 %, p = 0.0737).",23733:23975, 3655222 ,23329341,Unavailable
 3628587 ,"Mean arterial blood pressure (MAP) before and after the opening of sternum, and  before the closure of sternum",high thoracic epidural anesthesia (HTEA),control,Significantly decreased,"Before induction, MAP was similar in the study groups, but it was significantly lower in the HTEA group before and after the opening of sternum, before the closure of sternum (p&lt;0.05).",17789:17974, 3628587 ,23531633,Unavailable
 3628587 ,mixed venous oxygen saturation (SvO2) at 10-60 min after CPB,high thoracic epidural anesthesia (HTEA),control,Significantly increased,"There was no significant difference in SvO2 between values before and after induction, but it started to increase in the HTEA group at 10 min and stayed high until 60 min after CPB (p&lt;0.05) (Table 3).",19379:19651, 3628587 ,23531633,Unavailable
 3628587 ,need for transfusion after CPB before the patient is transferred to ICU,high thoracic epidural anesthesia (HTEA),control,Significantly decreased,There was significantly less need in the HTEA group than the control group for transfusion after CPB (56–84%) before the patient is transferred to ICU (p&lt;0.01).,20314:20474, 3628587 ,23531633,Unavailable
 3628587 ,Recovery scores,high thoracic epidural anesthesia (HTEA),control,Significantly decreased,Recovery scores were less in the HTEA group (p&lt;0.001).,21320:21375, 3628587 ,23531633,Unavailable
 3628587 ,"Extubation time, stay in ICU and stay in hospital",high thoracic epidural anesthesia (HTEA),control,Significantly decreased,"Extubation time, stay in ICU and stay in hospital were all shorter in the HTEA group (p&lt;0.001) (Table 5).",21376:21554, 3628587 ,23531633,Unavailable
 3376123 ,number of people developing mild and moderate POCD at one week post-operatively,Depth of anaesthesia and rSO2 were monitored using BIS and SICO ,Depth of anaesthesia and rSO2 were not monitored ,Significantly decreased,At one week post-operatively the treatment group showed significant reduction in the number of people developing mild (58% v 89% Fisher’s exact test p = 0·018) and moderate (χ2 = 4.4 57% v 26% p = 0·037) POCD.,24103:24212, 3376123 ,22719840,Unavailable
 3376123 ,number of people developing severe POCD,Depth of anaesthesia and rSO2 were monitored using BIS and SICO ,Depth of anaesthesia and rSO2 were not monitored ,No significant difference,Incidence of severe POCD was numerically lower in the intervention group (5% v 25% Fisher’s exact test p = 0.12).,24103:24212, 3376123 ,22719840,Unavailable
 3376123 ,number of people developing mild POCD at 12 weeks post-operatively,Depth of anaesthesia and rSO2 were monitored using BIS and SICO ,Depth of anaesthesia and rSO2 were not monitored ,Significantly decreased,At 12 weeks the incidence of mild POCD was significantly reduced in the intervention group (54% v 82% χ2 = 5.1 p = 0·02).,24103:24212, 3376123 ,22719840,Unavailable
 3376123 ,number of people developing moderate and severe POCD at 12 weeks post-operatively,Depth of anaesthesia and rSO2 were monitored using BIS and SICO ,Depth of anaesthesia and rSO2 were not monitored ,No significant difference,The levels of moderate and severe POCD were not statistically different between the intervention and control groups at this juncture.,24103:24212, 3376123 ,22719840,Unavailable
 3376123 ,number of people developing mild and moderate POCD at 52 weeks post-operatively,Depth of anaesthesia and rSO2 were monitored using BIS and SICO ,Depth of anaesthesia and rSO2 were not monitored ,Significantly decreased,At 52 weeks mild and moderate POCD were significantly lower in the intervention group (84% v 56% χ2 = 5.9 p = 0·015 and 37.5% v 11.1% χ2 = 5.4 p = 0·02).,24103:24212, 3376123 ,22719840,Unavailable
 3376123 ,number of people developing severe POCD at 52 weeks post-operatively,Depth of anaesthesia and rSO2 were monitored using BIS and SICO ,Depth of anaesthesia and rSO2 were not monitored ,No significant difference,Severe POCD remained numerically lower in the intervention group (12.5% v 3.7% Fisher’s exact test p = 0.36).,24103:24212, 3376123 ,22719840,Unavailable
 3483284 , improving of low peak torque in set 2,supplemental ATP (400 mg/d divided into 2 daily doses),placebo,Significantly increased,"however, low peak torque in set 2 was significantly improved (p &lt; 0.01",5541:5611, 3483284 ,23046855,Unavailable
 3483284 ,torque fatigue,supplemental ATP (400 mg/d divided into 2 daily doses),placebo,No significant difference,"Additionally, in set 3, a trend was detected for less torque fatigue with ATP supplementation (p &lt; 0.10).",5614:5719, 3483284 ,23046855,Unavailable
 3728073 ,The level of plasma heparin-binding protein (HBP),80 mg simvastatin,placebo,Significantly decreased,We found that the fold change of plasma HBP in patients with ALI treated with simvastatin was significantly lower than in placebo-treated patients (P = 0.04) (Figure&nbsp;3B).,17129:17329, 3728073 ,23870614,Unavailable
 3728073 ,The level of plasma heparin-binding protein (HBP) at day 7,80 mg simvastatin,placebo,Significantly decreased,"In contrast, and similarly to above (Figures&nbsp;3A &amp; B), there was a significant decrease (p = 0.004) in HBP levels in patients treated with simvastatin at day 7 (Figure&nbsp;3C).",17129:17329, 3728073 ,23870614,Unavailable
 3728073 ,The fold change of heparin-binding protein (HBP) at day 7 versus day 0,80 mg simvastatin,placebo,Significantly decreased,The fold change of HBP at day 7 versus day 0 in patients treated with simvastatin was significantly (p = 0.014) lower than in placebo-treated patients (Figure&nbsp;3D).,17129:17329, 3728073 ,23870614,Unavailable
 1134663 ,latency differences between the onset of the abductor pollicis brevis (APB) and deltoid muscle contraction,memantine,placebo,No significant difference,"Memantine did not affect this training effect, as shown by the non-significant influence of the factor ""drug"" (F(1,14) = 1.876, p = 0.192), and by the non-significant interaction between both factors (F(3.14,43.95) = 1.646, p = 0.191).",11331:11566, 1134663 ,15890074,Unavailable
 1134663 ,latency differences between the onset of the APB and deltoid muscle contraction during training,memantine,placebo,No significant difference,"Again, memantine did not affect this training effect, as shown by the non-significant influence of the factor ""drug"" (F(1,12) = 0.422, p = 0.528), and by the non-significant interaction between both factors (F(1.79,21.46) = 0.476, p = 0.607).",13104:13347, 1134663 ,15890074,Unavailable
 1134663 ,mapping parameters,memantine,placebo,No significant difference,"For none of the mapping parameters, including the y-coordinate of the COG (-5.460 ± 0.692 with placebo, -5.359 ± 0.503 with memantine, p = 0.301), a significant difference could be observed between the baseline maps (Table 1), indicating that memantine alone had no effect on the mapping parameters.",14483:14821, 1134663 ,15890074,Unavailable
 5759220 ,"weight,  BMI, waist circumference, and HbA1c",liraglutide,metformin,Significantly decreased,"Treatment with liraglutide resulted in a greater weight loss, reduction in BMI, waist circumference, and HbA1c in comparison to metformin (p&nbsp;&lt;&nbsp;0.05, Table&nbsp;2).",29602:29805, 5759220 ,29310645,Unavailable
 5759220 ,"pulse wave velocity (PWVc), AI, systolic blood pressure and central systolic blood pressure",liraglutide,metformin,Significantly decreased,"Thus, post treatment patients that received liraglutide had lower PWV, AI, systolic blood pressure and central systolic blood pressure than those on metformin (p&nbsp;&lt;&nbsp;0.05).Table&nbsp;2",30206:30419, 5759220 ,29310645,Unavailable
 5759220 ,the percentage difference between peak twisting and untwisting at MVO (%dpTw–UtwMVO),liraglutide,metformin,Significantly decreased,"Thus, post treatment patients that received liraglutide had lower peak twisting and peak untwisting velocity and higher &nbsp;%dpTw–UtwMVO than those on metformin (p&nbsp;&lt;&nbsp;0.05).",21540:21631, 5759220 ,29310645,Unavailable
 5799931 ,number of mature (metaphase II) oocytes,"Group A: single dose of gonadotropin-releasing hormone agonist (GnRHa) 0.2 mg, 35 h prior to oocyte retrieval",Group B: 0.2 mg GnRHa 35 h prior to oocyte retrieval + repeat dose of 0.1 mg 12 h following the 1st dose,Significantly decreased,A higher number of mature (metaphase II) oocytes were obtained in Group B compared to Group A (OR of 0.47; CI: 0.38–0.57; P &lt; 0.01).,5720:5869, 5799931 ,29430154,Unavailable
 5799931 ,number of blastocysts,"Group A: single dose of gonadotropin-releasing hormone agonist (GnRHa) 0.2 mg, 35 h prior to oocyte retrieval",Group B: 0.2 mg GnRHa 35 h prior to oocyte retrieval + repeat dose of 0.1 mg 12 h following the 1st dose,Significantly decreased,Significantly a higher number of blastocysts were obtained in Group B than Group A (4.00 vs. 3.04; P = 0.023).,5870:6001, 5799931 ,29430154,Unavailable
 5799931 ,The odds of clinical pregnancy per patient,"Group A: single dose of gonadotropin-releasing hormone agonist (GnRHa) 0.2 mg, 35 h prior to oocyte retrieval",Group B: 0.2 mg GnRHa 35 h prior to oocyte retrieval + repeat dose of 0.1 mg 12 h following the 1st dose,Significantly decreased,"The odds of clinical pregnancy per patient were higher in Group B (OR = 0.56; CI [0.27–1.24]), with a trend towards better clinical pregnancy in Group B than in Group A.",6000:6170, 5799931 ,29430154,Unavailable
 3464298 ,The State-Trait Anxiety Inventory (STAI) score,slow breathing with or without biofeedback,no-treatment,Significantly decreased,"hose who received intervention showed significantly decreased STAI-S scores following intervention, t(df) = 3.33, p = 0.001 where as those in the control group showed negligible differences, t(df) = 0.5, p = 0.314.",6275:6592, 3464298 ,23056361,Unavailable
 4650105 ,quadriceps strength,6-month exercise programme and a patient education component (OsteoACTIVE) on quadriceps strength,patient education only,No significant difference,Over the 1-year follow-up no difference was found between the OsteoACTIVE group and the control group for the main outcome quadriceps strength (Table 2).,23879:24074, 4650105 ,26578370,Unavailable
 4650105 ,"BMD, dynamic balance, walking capacity, physical activity level and quality of life",6-month exercise programme and a patient education component (OsteoACTIVE) on quadriceps strength,patient education only,No significant difference,"Furthermore, no significant differences were found for any of the secondary outcome measures between the groups (Table 2).Table 2",24074:24273, 4650105 ,26578370,Unavailable
 5698974 ,tibial displacement for 5 mm or less,Endobutton,Rigidfix,No significant difference,"In examination of Ant. drawer test, 8 (53.3%) patients in Group Endobutton and 10 (66.7%) in Rigidfix, experienced tibial displacement for 5 mm or less, 7 (46.7%) patients in Endobutton and 5 (33.3%) patients in Rigidfixed experienced displacement within the range of 6 to 10 mm. The displacement in none of the patients was over 10 mm. (P = 0.46).",15291:15656, 5698974 ,29279834,Unavailable
 5698974 ,knee stability by using the pivot shift test,Endobutton,Rigidfix,No significant difference,"In examination of knee stability using the pivot shift test and comparison of the two groups, showed that 4 patients in Endobutton and 5 patients in Rigidfix obtained test result equal (26.7% vs. 33.3%), 9 patients in Endobutton and 8 patients in Rigidfix obtained glide (60% vs. 53.5) and 2 (13.3%) from each group obtained clunk. The pivot test did not yield any gross (+++). The comparison of the two groups was not statistically significant (P = 0.99).",15663:16136, 5698974 ,29279834,Unavailable
 5698974 , the mean scores of satisfaction with surgery by using a subjective questionnaire IKDC 2000,Endobutton,Rigidfix,Significantly increased,"In order to compare the satisfaction with surgery results, a subjective questionnaire IKDC 2000 was used. In comparison of the scores from both groups, the mean scores for Endobutton and Rigidfix were 89 ± 4.3 and 85 ± 2.9 respectively and patients satisfaction in Endobutton was statistically higher than the Rigidfix group (P = 0.006).",16143:16498, 5698974 ,29279834,Unavailable
 5698974 ,The ability to perform sports activities,Endobutton,Rigidfix,Significantly increased,The ability to perform sports activities was 85.2 ± 4.6 in Endobutton and 80.5 ± 4 in Rigidfix and there is an statistically difference between the two groups (P = 0.006).,16677:16865, 5698974 ,29279834,Unavailable
 5698974 ,The frequency and intensity of pain,Endobutton,Rigidfix,No significant difference,"The frequency and intensity of pain in patients was assessed through the VAS questionnaire. In examination of the two group for the frequency of knee pain over the last month, the two groups Endobutton and Rigidfix experienced pain respectively 2.5 ± 1.4 and 3.4 ± 1.4 (P = 0.08), and the pain scores were 2.9 ± 1.5 and 2.6 ± 1.1 in the two groups and the difference was not statistically significant (P = 0.49).",16872:17318, 5698974 ,29279834,Unavailable
 5698974 ,The knee range of motion,Endobutton,Rigidfix,No significant difference,The knee range of motion in Endobutton and Rigidfix were 135.73 ± 2.63 and 129.87 ± 7.14° resprectively (P = 0.06).,4167:4300, 5698974 ,29279834,Unavailable
 5388694 ,accuracy,receiving a 4-month multi-domain cognitive training,nothing or receiving a 4-month relaxation training,Significantly increased,"The accuracy data yielded a significant main effect of Test Time (F(1,100) = 4.1, p &lt; 0.05, ηp2 = 0.04) and a significant interaction of Test Time × Group (F(2,100) = 3.4, p &lt; 0.05, ηp2 = 0.06). Bonferroni post hoc tests showed reduced error rates at posttest compared to pretest only in the cognitive training group (p &lt; 0.01), but not in the two control groups (both ps &gt; 0.84).",36137:37002, 5388694 ,28446870,Unavailable
 5388694 ,N2 amplitude,receiving a 4-month multi-domain cognitive training,nothing or receiving a 4-month relaxation training,Significantly increased,"Post hoc tests showed an increase in N2 amplitude from pretest to posttest for the cognitive training group (p &lt; 0.01), but not for the two control groups (both ps &gt; 0.34, see Figure 3).",45782:46063, 5388694 ,28446870,Unavailable
 5388694 ,The P2 latency,receiving a 4-month multi-domain cognitive training,nothing or receiving a 4-month relaxation training,Significantly decreased,"Post hoc tests showed reduced P2 latencies at posttest compared to pretest, but only on single trials of the cognitive training group (p &lt; 0.01; all other ps &gt; 0.14, see Figure 3).",44345:44619, 5388694 ,28446870,Unavailable
 5388694 ,P3 amplitudes,receiving a 4-month multi-domain cognitive training,nothing or receiving a 4-month relaxation training,Significantly decreased,"For both control groups, post hoc tests showed no significant amplitude differences between pre- and posttest, irrespective of trial type and electrode position (all ps &gt; 0.21; see Figure 3). For the cognitive training group, on the other hand, P3 amplitudes decreased from pretest to posttest: at Fz, amplitude decreases were significant for single and switch trials (both ps &lt; 0.01).",47384:47861, 5388694 ,28446870,Unavailable
 4233234 ,Aβ5-X and Aβ5-40 levels,90 mg of LY2811376,placebo,Significantly increased,"While the placebo concentrations were low, in the range of approximately 100 pg/mL and approximately 50 pg/mL for Aβ5-X and Aβ5-40, respectively, there were clear increases in the LY2811376 high dose (90 mg) group over time for both Aβ5-X and Aβ5-40 (Figure 3C-D) of which the increase in Aβ5-X was statistically significant (P =0.02).",22072:22464, 4233234 ,25404952,Unavailable
 4233234 ,Aβ1-34 level,90 mg of LY2811376,placebo,Significantly decreased,"The BACE1 inhibitor LY2811376 dose-dependently reduced Aβ1-34 relative to baseline with a nadir of 42% in the 30-mg group (P =0.002) and 57% in the 90-mg group (P &lt;0.001) respectively, 24 hours after drug administration (Figure 3A).",22072:22464, 4233234 ,25404952,Unavailable
 5207788 ,the Expanded Disability Status Scale (EDSS) progression at 2 years,cyclophosphamide (CPM),methylprednisolone (MP),No significant difference,"The proportion of patients with sustained EDSS progression at 2 years was 18·1% (n = 13) in the CPM group and 31·8% (n = 21) in the MP group (p = 0·06), but a high proportion of patients could not be assessed for this outcome, more frequently in the CPM group than in the MP group (Table 2).",37804:38149, 5207788 ,28045953,Unavailable
 5207788 ,chance to change from “on treatment” state to “discontinued treatment” state ,cyclophosphamide (CPM),methylprednisolone (MP),Significantly increased,"According to this analysis, patients in the CPM group were 2.2 times more likely to discontinue their treatment as compared to the MP group (HR = 2.21; 95% CI: 1.14–4.29), but they were 2.7 times more likely not to experience sustained EDSS progression (HR = 0.37; 95% CI: 0.17–0.84) (Fig 2). The two transition HRs were statistically significant (p = 0.019 and p = 0.018) showing that patients had more chance to change from “on treatment” state to “discontinued treatment” state and from “stable EDSS” state to “deteriorated EDSS” state).",43260:43853, 5207788 ,28045953,Unavailable
 5207788 ,chance to change from “stable EDSS” state to “deteriorated EDSS” state),cyclophosphamide (CPM),methylprednisolone (MP),Significantly decreased,but they were 2.7 times more likely not to experience sustained EDSS progression (HR = 0.37; 95% CI: 0.17–0.84) (Fig 2). The two transition HRs were statistically significant (p = 0.019 and p = 0.018) showing that patients had more chance to change from “on treatment” state to “discontinued treatment” state and from “stable EDSS” state to “deteriorated EDSS” state).,43432:43853, 5207788 ,28045953,Unavailable
 5207788 ,adverse events,cyclophosphamide (CPM),methylprednisolone (MP),No significant difference,"A similar proportion of patients in the two treatment groups had adverse events (CPM: 97·2% versus MP: 92·4%), most of which were mild to moderate in severity (Tables 3 and 4).",46004:46289, 5207788 ,28045953,Unavailable
 3493722 ,eradication rate of H. pylori,1-week quadruple rescue therapy,2-week quadruple rescue therapy,No significant difference,"The 1-week PPI+BMT regimen achieved 83.5% (95% CI, 76% to 91%) eradication rate in ITT analysis and 87.7% (95% CI, 80% to 95%) in PP analysis, while the 2-week PPI+BMT regiment obtained 87.7% (95% CI, 78% to 93%) eradication rate in ITT and 88.9% (95% CI, 82% to 96%) in PP analysis. There was no statistically significant difference between the two treatment modalities (Table 2).",19266:19687, 3493722 ,23170146,Unavailable
 3493722 ,side effects,1-week quadruple rescue therapy,2-week quadruple rescue therapy,No significant difference,There was no statistically significant difference in side effects between the two groups (Table 3).,20255:20394, 3493722 ,23170146,Unavailable
 3493722 ,The compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,No significant difference,"The compliance rates of the 1-week PPI+MBT group were 91.4% 'good' compliance, 9.9% 'well' compliance and 2.5% 'poor' compliance. In the 2-week PPI+MBT treatment group, the compliance rates were 91.4%, 4.6%, and 3.7%, respectively (Table 2).",19687:19968, 3493722 ,23170146,Unavailable
 3987889 ,walking speed,twelve 1-hour Lokomat trainings over one month,no interventions,Significantly increased,"In the Lokomat group, subjects in Class 2 increased their walking speed at a rate of 0.033 m/s/week (P = 0.01).",5255:5312, 3987889 ,24661681,Unavailable
 3987889 ,endurance,twelve 1-hour Lokomat trainings over one month,no interventions,No significant difference,however no significant change in endurance was observed.,5255:5312, 3987889 ,24661681,Unavailable
 1488896 ,increase in disability,visited by an occupational therapist who provided training and education about assistive devices,not visited by an occupational therapist,No significant difference,"The increase in disability was not significantly different between study groups (0.08 points; 95% CI, −1.1–1.2; p = 0.75).",5916:6059, 1488896 ,16871324,Unavailable
 1488896 ,self-evaluations of well-being and feelings of loneliness,visited by an occupational therapist who provided training and education about assistive devices,not visited by an occupational therapist,No significant difference,"There was also no difference between study groups for any of the secondary outcome measures. Moreover, all differences between study groups at 24 mo were also not significant (Table 2).",21892:22131, 1488896 ,16871324,Unavailable
 3646683 ,health-related quality of life (SF-36),ProActive Heart intervention,usual care,No significant difference,"Improvements in health status (SF-6D) were observed in both groups, with no significant difference between the groups at six [0.012 (-0.016, 0.041), p = 0.372] or 12&nbsp;months [0.011 (-0.028, 0.051) p = 0.738].",5006:5213, 3646683 ,23634982,Unavailable
 3646683 ,admitted to hospital due to causes unrelated to cardiovascular disease,ProActive Heart intervention,usual care,Significantly increased,Patients in the health coaching group were significantly more likely to be admitted to hospital due to causes unrelated to cardiovascular disease (p = 0.042).,5214:5373, 3646683 ,23634982,Unavailable
 3646683 ,"The overall cost for the health,  hospitalisation costs",ProActive Heart intervention,usual care,Significantly increased,"The overall cost for the health coaching group was higher ($10,574 vs. $8,534, p = 0.021), mainly due to higher hospitalisation (both CHD and non-CHD) costs ($6,841 vs. $4,984, p = 0.036). The incremental cost-effectiveness ratio was $85,423 per QALY.",5373:5624, 3646683 ,23634982,Unavailable
 3698086 ,percentage of elastin-containing crests ,diaphragm through a left thoracotomy (DH),SHAM (sham DH/sham TO),Significantly decreased,"As compared to SHAM lungs, elastin showed abnormal deposition in DH lungs with a reduced percentage of elastin-containing crests (P = 0.025) and an increased percentage of elastic fibers in the alveolar walls (P = 0.043), which looked thickened.",56175:56341, 3698086 ,23840910,Unavailable
 3698086 , percentage of elastic fibers within alveolar walls,diaphragm through a left thoracotomy (DH),SHAM (sham DH/sham TO),Significantly increased,"As compared to SHAM lungs, elastin showed abnormal deposition in DH lungs with a reduced percentage of elastin-containing crests (P = 0.025) and an increased percentage of elastic fibers in the alveolar walls (P = 0.043), which looked thickened.",56175:56341, 3698086 ,23840910,Unavailable
 3698086 ,relative abundance of elastin-containing secondary crests,diaphragm through a left thoracotomy (DH) +  tracheal occlusion (TO) lungs ,diaphragm through a left thoracotomy (DH) ,Significantly increased,"In DH+ TO lungs, the relative abundance of elastin-containing secondary crests was increased as compared to DH lungs (P = 0.01), above the level of SHAM lungs (P = 0.017).",55663:55869, 3698086 ,23840910,Unavailable
 3698086 , the percentage of elastic fibers in the alveolar walls ,diaphragm through a left thoracotomy (DH) + TO ,SHAM (sham DH/sham TO),Significantly decreased,Moreover TO decreased the percentage of elastic fibers in the alveolar walls of DH lungs (P = 0.004) to a comparable level to that of the SHAM lungs.,56175:56341, 3698086 ,23840910,Unavailable
 3698086 , the percentage of elastic fibers in the alveolar walls , tracheal occlusion (TO) lungs,SHAM (sham DH/sham TO),No significant difference,Moreover TO decreased the percentage of elastic fibers in the alveolar walls of DH lungs (P = 0.004) to a comparable level to that of the SHAM lungs.,56175:56341, 3698086 ,23840910,Unavailable
 3494213 ,The levels of serum leptin,aerobic exercise training lasted for 6 months,control,No significant difference,The levels of serum leptin did not change significantly.,14328:14384, 3494213 ,23193504,Unavailable
 3494213 ,C-Reactive Protein (CRP),aerobic exercise training lasted for 6 months,control,No significant difference,"In addition, during the training, there was no significant change in serum CRP levels in both groups.",14384:14486, 3494213 ,23193504,Unavailable
 5383744 ,dermal density after 4 and 8 weeks,soluble micro-spicule containing epidermal growth factor (MS-EGF) cream,epidermal growth factor (EGF) cream,Significantly increased,"The MS-EGF group also demonstrated a significant increase in dermal density after 4 and 8 weeks compared to EGF alone group, respectively (p&lt;.0.05, p&lt;.0.01; Fig. 2B).",15380:15626, 5383744 ,28392646,Unavailable
 5383744 ,dermal depth,soluble micro-spicule containing epidermal growth factor (MS-EGF) cream,epidermal growth factor (EGF) cream,Significantly increased,MS-EGF group showed a significantly increase in dermal depth after 8 weeks compared to the EGF alone group (p&lt;.0.05; Fig. 2C).,15829:16013, 5383744 ,28392646,Unavailable
 5383744 ,Wrinkle severity score,soluble micro-spicule containing epidermal growth factor (MS-EGF) cream,epidermal growth factor (EGF) cream,Significantly increased,"however, the MS-EGF group showed significant improvement in wrinkle score compared to EGF alone group after 8 weeks (p&lt;.0.05) (Fig. 3C).",16732:16925, 5383744 ,28392646,Unavailable
 3611645 ,the mean pain intensity,Foeniculum vulgare,placebo,Significantly increased,There were significant differences (P`0.01) between the two groups during the first three days of the cycles.,11782:11908, 3611645 ,23559811,Unavailable
 5801518 ,emphasis on benefits,"websites presented a video of a personal testimonial, an informational mechanism of action- video  viewed a video without drug risk information", viewed the video with drug risk information ,Significantly increased,"Participants who viewed a video without drug risk information thought that the website placed more emphasis on benefits, compared with participants who viewed the video with drug risk information (P≤.01).",7595:7817, 5801518 ,29362205,Unavailable
 5801518 ,patients thought that the drug was less effective in the high blood pressure sample,"websites presented a video of a personal testimonial, an informational mechanism of action- video  viewed a video without drug risk information", viewed the video with drug risk information ,Significantly increased,"Compared with participants who viewed a video without drug risk information, participants who viewed a video with drug risk information thought that the drug was less effective in the high blood pressure sample (P=.03)",7816:8052, 5801518 ,29362205,Unavailable
 5801518 ,patients thought that the drug was less effective in the acid reflux sample,"websites presented a video of a personal testimonial, an informational mechanism of action- video  viewed a video without drug risk information", viewed the video with drug risk information ,Significantly increased,"Compared with participants who viewed a video without drug risk information, participants who viewed a video with drug risk information thought that the drug was less effective in the high blood pressure sample (P=.03) and thought that risks were more serious in the acid reflux sample (P=.01).",7817:8145, 5801518 ,29362205,Unavailable
 4707401 ,total intubation time,GlideRite Rigid stylet (Group GS),Parker Flex-It stylet (Group PS),No significant difference,No significant differences between both groups regarding the total intubation time (p=0.08) was observed.,4662:4784, 4707401 ,26620987,Unavailable
 4707401 ,ease of execution of intubation,GlideRite Rigid stylet (Group GS),Parker Flex-It stylet (Group PS),Significantly decreased,Intubation was significantly easier in group PS compared with group GS as measured by visual analogue scale (p=0.001),4785:4919, 4707401 ,26620987,Unavailable
 4707401 ,the rate of successful tracheal intubation from first attempt,GlideRite Rigid stylet (Group GS),Parker Flex-It stylet (Group PS),No significant difference,no significant differences between the groups regarding the rate of successful tracheal intubation from first attempt (p=0.524).,4924:5070, 4707401 ,26620987,Unavailable
 4707401 ,the number of attempts at intubation and usage of external laryngeal manipulation,GlideRite Rigid stylet (Group GS),Parker Flex-It stylet (Group PS),No significant difference,"However, the number of attempts at intubation and usage of external laryngeal manipulation were similar in both groups (p&gt;0.05).",5071:5217, 4707401 ,26620987,Unavailable
 4707401 ,"The incidence of sore throat, dysphagia, hoarseness, and trauma",GlideRite Rigid stylet (Group GS),Parker Flex-It stylet (Group PS),Significantly increased,"The incidence of sore throat, dysphagia, hoarseness, and trauma were significantly higher in group GS (p&lt;0.05).",5217:5348, 4707401 ,26620987,Unavailable
 5519050 ,local or systemic reactogenicity,"1/10th the DNA dose as DgDgMMM given at 0, 2, 4, 6 and 8 months","full dose DgDgM_M , given at 0, 2, 4, and 8 months;  DgDgMM_M regimens, given 0, 2, 4, 6, and 10 months",Significantly increased,Participants receiving full dose vaccine regimens did not have significantly more local or systemic reactogenicity than those in the 1/10 dose arm.,55680:55821, 5519050 ,28727817,Unavailable
 5519050 ,Adverse events (AEs), active group,placebo group,No significant difference,"Adverse events (AEs) were reported by 94% of participants, with no significant difference in AE reporting between active and placebo groups.",55680:55821, 5519050 ,28727817,Unavailable
 5519050 ,The median anti-GM-CSF measurement, active group,placebo group,No significant difference,"The median anti-GM-CSF measurement for all participants post-DNA doses was 0.242 mcg/ml, range from 0.156 to 2.762 mcg/ml, with no significant difference between active arm and placebo recipients.",56399:56595, 5519050 ,28727817,Unavailable
 5519050 ,Overall CD4+ T cell response rates, active group,placebo group,No significant difference,"Overall CD4+ T cell response rates were higher than CD8+ T cell responses within each vaccine group, and were not significantly different between groups.",57752:57905, 5519050 ,28727817,Unavailable
 5519050 ,CD4+ and CD8+ T cell magnitudes at peak time points,"1/10th the DNA dose as DgDgMMM given at 0, 2, 4, 6 and 8 months","full dose DgDgM_M , given at 0, 2, 4, and 8 months;  DgDgMM_M regimens, given 0, 2, 4, 6, and 10 months",No significant difference,CD4+ and CD8+ T cell magnitudes at peak time points were also not significantly different between 2- vs. 3-dose MVA or the 2- vs. 4-month pause arms (Fig 7B and 7D).,70644:70861, 5519050 ,28727817,Unavailable
 3580298 ,International Prostatic Symptom Score (IPSS) at week 4, increase their dose to 0.4 mg once daily (escalators),maintain the 0.2 mg/d tamsulosin dosage (nonescalators),Significantly decreased,"Compared with the nonescalators, the escalators had higher IPSS-storage scores at baseline (p=0.027) and week 4 (p=0.027), higher IPSS-total at week 4 (p=0.038), and lower IPSS-QoL scores at week 4 (p=0.016).",12046:12255, 3580298 ,23550146,Unavailable
 3580298 ,International Index of Erectile Function (IIEF-5)  in patients who showed no improvement of lower urinary tract symptoms (LUTS),maintain the 0.2 mg/d tamsulosin dosage (nonescalators),increase their dose to 0.4 mg once daily (escalators) ,No significant difference,"The difference in the IIEF-5 score between the 2 groups was not significant (1.2 for escalators vs. 0.8 for nonescalators, p=0.859) in 15 patients who showed no improvement of LUTS,",13580:13732, 3580298 ,23550146,Unavailable
 3580298 ,International Index of Erectile Function (IIEF-5)  in patients who showed improvement of lower urinary tract symptoms (LUTS), increase their dose to 0.4 mg once daily (escalators) ,maintain the 0.2 mg/d tamsulosin dosage (nonescalators),Significantly increased,"and a statistically significant increase (4.6 for escalators vs. 1.7 for nonescalators, p=0.002) was observed in only 35 patients who had improved LUTS.",13580:13732, 3580298 ,23550146,Unavailable
 4694692 ,mean forced expiratory volume in 1 second (FEV1),"FF/VI 100/25 mcg (BREO™ [RELVAR™, REVINTY™], GlaxoSmithKline plc [GSK], London, UK) delivered via the ELLIPTA™ inhaler (GSK, London, UK)","TIO 18 mcg (Spiriva®, Boehringer Ingelheim, Ingelheim, Germany) delivered from blister capsules by the HandiHaler® (Spiriva, Boehringer Ingelheim)",No significant difference,"Results of the primary efficacy measure, change from baseline trough in 24-hour weighted mean FEV1 after 12 weeks’ treatment, were similar between the treatment groups (Figure 2), with a least squares (LS) mean change from baseline of 117 mL and 95 mL in the FF/VI and TIO groups, respectively, with a difference of 0.022 L (95% confidence interval [CI] −0.012 to 0.055) (P=0.201).",23917:24375, 4694692 ,26730183,Unavailable
 4694692 ,"brain natriuretic peptide (BNP), fibrinogen,  IL-6","FF/VI 100/25 mcg (BREO™ [RELVAR™, REVINTY™], GlaxoSmithKline plc [GSK], London, UK) delivered via the ELLIPTA™ inhaler (GSK, London, UK)","TIO 18 mcg (Spiriva®, Boehringer Ingelheim, Ingelheim, Germany) delivered from blister capsules by the HandiHaler® (Spiriva, Boehringer Ingelheim)",No significant difference,"There were no significant changes from baseline in BNP, fibrinogen, or IL-6 with either FF/VI or TIO.",28319:28420, 4694692 ,26730183,Unavailable
 4694692 ,"high-sensitivity C-reactive protein (hsCRP),  pulmonary and activation-regulated chemokine (more currently referred to as chemokine [C-C motif] ligand 18 [CCL-18]), fibrinogen, interleukin-6 (IL-6), surfactant protein D (SP-D), Clara cell secretory protein-16 (CC-16), and brain natriuretic peptide (BNP)","FF/VI 100/25 mcg (BREO™ [RELVAR™, REVINTY™], GlaxoSmithKline plc [GSK], London, UK) delivered via the ELLIPTA™ inhaler (GSK, London, UK)","TIO 18 mcg (Spiriva®, Boehringer Ingelheim, Ingelheim, Germany) delivered from blister capsules by the HandiHaler® (Spiriva, Boehringer Ingelheim)",No significant difference,"However, for all seven biomarkers, the change from baseline was not significantly different between the two treatment groups (data not shown).",31604:31950, 4694692 ,26730183,Unavailable
 4694692 ,"pulse rate, heart rate, or QTc intervals","FF/VI 100/25 mcg (BREO™ [RELVAR™, REVINTY™], GlaxoSmithKline plc [GSK], London, UK) delivered via the ELLIPTA™ inhaler (GSK, London, UK)","TIO 18 mcg (Spiriva®, Boehringer Ingelheim, Ingelheim, Germany) delivered from blister capsules by the HandiHaler® (Spiriva, Boehringer Ingelheim)",No significant difference,"There were no clinically significant differences between groups in mean changes from baseline for pulse rate, heart rate, or QTc intervals.",30985:31124, 4694692 ,26730183,Unavailable
 4694692 ,"including mean heart rate, cardiac rhythm abnormalities (ventricular ectopic events), or other prespecified abnormalities of potential clinical importance","FF/VI 100/25 mcg (BREO™ [RELVAR™, REVINTY™], GlaxoSmithKline plc [GSK], London, UK) delivered via the ELLIPTA™ inhaler (GSK, London, UK)","TIO 18 mcg (Spiriva®, Boehringer Ingelheim, Ingelheim, Germany) delivered from blister capsules by the HandiHaler® (Spiriva, Boehringer Ingelheim)",No significant difference,"Holter monitoring was conducted in a subset of subjects (158 FF/VI, 153 TIO), with no significant difference between FF/VI and TIO groups in abnormalities of potential clinical significance, including mean heart rate, cardiac rhythm abnormalities (ventricular ectopic events), or other prespecified abnormalities of potential clinical importance.",31604:31950, 4694692 ,26730183,Unavailable
 3932837 ,"additional probing pocket depths (PPD), relative attachment level (RAL), and relative gingival recession (RGR)",enamel matrix derivative (EMD),nanocrystalline hydroxyapatite (NHA),No significant difference,"Between groups, no significant differences of secondary clinical outcomes (PPD, RAL, and RGR) were found for any of the variables at 6 and 12 months (Table 2).",22939:23140, 3932837 ,24689056,Unavailable
 3932837 ,bone level,enamel matrix derivative (EMD),nanocrystalline hydroxyapatite (NHA),No significant difference,"Furthermore, a comparison of mean differences in clinical measurements (bone level, PPD, RAL, and RGR) as calculated after 12 months with the mean differences as calculated after 6 months showed no statistically significant changes in both groups (Table 2, P &gt; 0.05, paired t-test).",23141:23501, 3932837 ,24689056,Unavailable
 4393831 ,"PAP, Pulmonary artery pressure;",anticoagulant [Enoxaparin (1 mg/kg twice a day)] plus a thrombolytic [Alteplase (100 mg) or Streptokinase (1500000 u/2 hours)],an anticoagulant [Enoxaparin (1 mg/kg twice a day)] alone,Significantly decreased,PAP (at the time of discharge) (mmHg)	33.0±9.2	31.5±9.1	34.5±9.2	0.018,20583:20893, 4393831 ,25870626,Unavailable
 4393831 ,"NLRV, Normalized right ventricle",anticoagulant [Enoxaparin (1 mg/kg twice a day)] plus a thrombolytic [Alteplase (100 mg) or Streptokinase (1500000 u/2 hours)],an anticoagulant [Enoxaparin (1 mg/kg twice a day)] alone,No significant difference,NLRV 0.122  No 18/47 (38.3) 7/25 (28.0) 11/22 (50.0)   Yes 29/47 (61.7) 18/25 (72.0) 11/22 (50.0),22335:23567, 4393831 ,25870626,Unavailable
 4393831 ,"NYHA FC, New York Heart Association functional class",anticoagulant [Enoxaparin (1 mg/kg twice a day)] plus a thrombolytic [Alteplase (100 mg) or Streptokinase (1500000 u/2 hours)],an anticoagulant [Enoxaparin (1 mg/kg twice a day)] alone,No significant difference,NYHA FC				0.213  1	24/47 (51.1)	15/25 (60.0)	9/22 (40.9)	  2	16/47 (34.0)	7/25 (28.0)	9/22 (40.9)	  3	7/47 (14.9)	3/25 (12.0)	4/22 (18.2),22335:23567, 4393831 ,25870626,Unavailable
 4393831 ,Hematuria,anticoagulant [Enoxaparin (1 mg/kg twice a day)] plus a thrombolytic [Alteplase (100 mg) or Streptokinase (1500000 u/2 hours)],an anticoagulant [Enoxaparin (1 mg/kg twice a day)] alone,No significant difference,Hematuria occurred in one patient in the anticoagulant-alone group and in 2 patients in the thrombolytic-plus-anticoagulant group.,23961:24092, 4393831 ,25870626,Unavailable
 4393831 ,The mean duration of hospital stay,anticoagulant [Enoxaparin (1 mg/kg twice a day)] plus a thrombolytic [Alteplase (100 mg) or Streptokinase (1500000 u/2 hours)],an anticoagulant [Enoxaparin (1 mg/kg twice a day)] alone,No significant difference,The mean duration of hospital stay was 7.5 ± 1.5days in both groups.,24092:24160, 4393831 ,25870626,Unavailable
 5038098 ,the excellent response at the end of 36 weeks,isotretinoin 20 mg daily,isotretinoin 20 mg alternate days,Significantly increased,"At the end of 24 weeks, the excellent response in treatment groups A and B was seen in 98.3% and 93.96% patients, respectively (P 0.166), which at the end of 36 weeks decreased to 90.6% and 74.1% patients, respectively (P 0.004) (Figures 4–6: clinical photographs).",13684:14021, 5038098 ,27730033,Unavailable
 5038098 ,the excellent response at the end of 24 weeks,isotretinoin 20 mg daily,isotretinoin 20 mg alternate days,No significant difference,"At the end of 24 weeks, the excellent response in treatment groups A and B was seen in 98.3% and 93.96% patients, respectively (P 0.166), which at the end of 36 weeks decreased to 90.6% and 74.1% patients, respectively (P 0.004) (Figures 4–6: clinical photographs).",14982:15355, 5038098 ,27730033,Unavailable
 5038098 ,frequency of adverse effects,isotretinoin 20 mg daily,isotretinoin 20 mg alternate days,No significant difference,"Although the frequency of adverse effects was slightly higher in Group A as compared with Group B, the difference was not statistically significant (P &gt; 0.05).",16778:16954, 5038098 ,27730033,Unavailable
 5038098 ,acne free at the end of  24 and 36 weeks,isotretinoin 20 mg daily,isotretinoin 20 mg alternate days,No significant difference,"At 24 weeks 68.64% (Group A) and 56.03% (Group B) patients were acne free, which at the end of 36 weeks decreased to 50.84% and 39.65%, respectively (P 0.51) [Table 6].",16099:16323, 5038098 ,27730033,Unavailable
 5038098 ,response rate in cases of severe acne,isotretinoin 20 mg daily,isotretinoin 20 mg alternate days,Significantly increased,"When the results were evaluated according to severity of acne, in cases of severe acne a statistically significant difference in response rate was noted between both groups (Group A better than Group B) during the whole study period (P value &lt; 0.005 at each follow up) [Figure 2],",13684:14021, 5038098 ,27730033,Unavailable
 3264513 ,percentages of dominant groups of the human gut microbiome,isoenergetic HCF (cereal-fiber 43 g/day),"cereal-fiber 14 g/day, or high-protein (HP, 28% of energy-intake, cereal-fiber 14 g/day), or moderately high cereal fiber/protein diets (MIX; protein 23% of energy-intake, cereal-fiber 26 g/day)",No significant difference,"In the full model there were no significant diet-induced changes in any of the here investigated dominant groups of the human gut microbiome, p &gt; 0.23 for all measured gut microbiota groups after 6 weeks, and p &gt; 0.58 for all groups after 18 weeks (Table 2).",32252:32555, 3264513 ,22177085,Unavailable
 3264513 ,fecal SCFA profiles,isoenergetic HCF (cereal-fiber 43 g/day),"cereal-fiber 14 g/day, or high-protein (HP, 28% of energy-intake, cereal-fiber 14 g/day), or moderately high cereal fiber/protein diets (MIX; protein 23% of energy-intake, cereal-fiber 26 g/day)",No significant difference,"Re-analysing all the here investigated markers after normalizing for baseline value levels (week 0) again did not show any significant diet induced effects on fecal SCFA. In addition, diet-induced effects on fecal valeric acid concentrations failed to reach significance level in the full model after correction for baseline levels (6 weeks, p = 0.076; 18 weeks, p = 0.90).",44669:45042, 3264513 ,22177085,Unavailable
 3264513 ,insulin sensitivity,isoenergetic HCF (cereal-fiber 43 g/day),"cereal-fiber 14 g/day, or high-protein (HP, 28% of energy-intake, cereal-fiber 14 g/day), or moderately high cereal fiber/protein diets (MIX; protein 23% of energy-intake, cereal-fiber 26 g/day)",No significant difference,Therefore the subgroup described here showed similar changes in insulin sensitivity as the entire study group [12].,47946:48100, 3264513 ,22177085,Unavailable
 3264513 ,body fat distribution and liver fat content,isoenergetic HCF (cereal-fiber 43 g/day),"cereal-fiber 14 g/day, or high-protein (HP, 28% of energy-intake, cereal-fiber 14 g/day), or moderately high cereal fiber/protein diets (MIX; protein 23% of energy-intake, cereal-fiber 26 g/day)",No significant difference,Effects of the here investigated isoenergetic diets on body fat distribution and liver fat content have been published and showed no differences between groups [8].,48149:48351, 3264513 ,22177085,Unavailable
 3757803 ,The incidence and severity of Emergence agitation (EA),propofol 1 mg/kg or dexmedetomidine 0.3 ug/kg-1,10 ml saline 0.9% ,Significantly decreased,"The incidence and severity of EA were significantly lower in group P and group D compared to group C at T0, T5, T15 but not at T30.",15619:15723, 3757803 ,24015133,Unavailable
 3757803 ,The incidence and severity of Emergence agitation (EA),propofol 1 mg/kg or,dexmedetomidine 0.3 ug/kg-1,Significantly increased,"Compared to group D, the incidence and severity of EA in group P were significantly higher at T0, T5, and T15 but not at T30.",15619:15723, 3757803 ,24015133,Unavailable
 3757803 ,The number of patients who developed severe EA (PAED &gt;15),propofol 1 mg/kg or dexmedetomidine 0.3 ug/kg-1,10 ml saline 0.9% ,Significantly decreased,The number of patients who developed severe EA (PAED &gt;15) was significantly lower in group D and group P compared to group C.,15619:15723, 3757803 ,24015133,Unavailable
 3757803 ,The number of patients who developed severe EA (PAED &gt;15),propofol 1 mg/kg or,dexmedetomidine 0.3 ug/kg-1,No significant difference,"Compared to group D, group P showed no statistically significant difference.",15619:15723, 3757803 ,24015133,Unavailable
 3757803 ,Modified Children's Hospital of Eastern Ontario Pain Scale (CHEOPS),dexmedetomidine 0.3 ug/kg-1,10 ml saline 0.9% or propofol 1 mg/kg ,Significantly decreased,Modified CHEOPS was significantly lower in group D compared to group P and group C at T0 and T5,15619:15723, 3757803 ,24015133,Unavailable
 3757803 ,Times to emergence and extubation,propofol 1 mg/kg ,10 ml saline 0.9% or dexmedetomidine 0.3 ug/kg-1,Significantly increased,Times to emergence and extubation in group P were significantly longer compared to group C and group D.,15619:15723, 3757803 ,24015133,Unavailable
 3757803 ,Time to discharge from the PACU,propofol 1 mg/kg or dexmedetomidine 0.3 ug/kg-1,10 ml saline 0.9% ,No significant difference,"The incidence and severity of EA were significantly lower in group P and group D compared to group C at T0, T5, T15 but not at T30.",15619:15723, 3757803 ,24015133,Unavailable
 5852975 ,acceptance of illness,with a social media (SM) experience,without a social media (SM) experience,Significantly increased,Improved acceptance of illness	3.15 ± 0.51	3.65 ± 0.53	0.03,37884:37982, 5852975 ,29540181,Unavailable
 5852975 ,optimism and control over the future,with a social media (SM) experience,without a social media (SM) experience,Significantly increased,Increased optimism and control over the future	3.81 ± 0.55	4.27 ± 0.47	0.03,38124:38238, 5852975 ,29540181,Unavailable
 5852975 ,social well being,with a social media (SM) experience,without a social media (SM) experience,Significantly increased,Improved social well being	2.69 ± 0.90	3.46 ± 0.81	0.04,38365:38459, 5852975 ,29540181,Unavailable
 5852975 ,Empowering Outcome Total Score,with a social media (SM) experience,without a social media (SM) experience,Significantly increased,Empowering Outcome Total Score	24.6 ± 2.54	27.1 ± 3.1	0.04,38494:38591, 5852975 ,29540181,Unavailable
 5852975 ,"CASE Children’s Arthritis Self-Efficacy scale,",with a social media (SM) experience,without a social media (SM) experience,Significantly increased,CASE	37.0 ± 2.9	36.6 ± 2.9	0.47	34.3 ± 3.4	38.5 ± 3.4	0.04,34796:34917, 5852975 ,29540181,Unavailable
 5852975 ,SOA sense of agency and SOC sense of community,with a social media (SM) experience,without a social media (SM) experience,Significantly increased,SOA	16.2 ± 1.5	17.3 ± 1.2	0.2	17.0 ± 1.8	20.8 ± 1.3	0.03SOC	143.1 ± 14.0	152.2 ± 11.3	0.4	138.3 ± 13.4	168.3 ± 10.2	0.03,35077:35358, 5852975 ,29540181,Unavailable
 5852975 ,MASRI medication adherence self-report inventory,with a social media (SM) experience,without a social media (SM) experience,No significant difference,MASRI (mean)	87.8 ± 4.0 (12)	90.4 ± 2.4 (12)	0.76	85.4 ± 6.7 (11)	84.2 ± 7.7 (11)	0.44*,31209:31344, 5852975 ,29540181,Unavailable
 5852975 ,MPR mediation possession ratio,with a social media (SM) experience,without a social media (SM) experience,Significantly increased,MPR (mean)	0.79 ± 0.07 (12)	0.81 ± 0.05 (12)	0.56	0.75 ± 0.06 (12)	0.92 ± 0.03 (12)	&lt; 0.001*,30663:30818, 5852975 ,29540181,Unavailable
 1971800 ,the size of the primary breast cancer, chemotherapy,primary endocrine therapy,Significantly decreased,We conclude that primary chemotherapy in patients with primary breast cancer is more effective in rapidly reducing the size of the primary breast cancer than endocrine therapy (P = 0.001) and alters significantly the future management of these patients.,2287:2540, 1971800 ,1825469,Unavailable
 3611103 ,The mean values of systolic blood pressure (SBP),"the sleeve group, the rolled sleeve group,",the bare arm group,No significant difference,These results indicate that there were no significant differences among the three groups (P = 0.32).,4226:4326, 3611103 ,23560214,Unavailable
 3611103 ,the mean values of diastolic blood pressure (DBP),"the sleeve group, the rolled sleeve group,",the bare arm group,No significant difference,These results indicate that there were no significant differences among the three groups (P = 0.77).,4580:4680, 3611103 ,23560214,Unavailable
 2855831 ,Bronchitis Severity Score (BSS),60 mg or 90 mg EPs-7630,placebo,Significantly decreased,"The subsequent pairwise comparisons of each active treatment group with placebo using the ANCOVA model revealed statistically significant differences in the decrease in the BSS total score for the EPs 7630 60 mg and 90 mg groups (p = 0.0004 and p &lt; 0.0001 respectively, two-sided ANCOVA p-values).",22478:22775, 2855831 ,20070280,Unavailable
 2855831 ,"‘coughing’ , ‘sputum’  and ‘pulmonary rales at auscultation’",60 mg or 90 mg EPs-7630,placebo,Significantly decreased,"Pairwise comparisons with placebo showed statistically significant advantages of EPs 7630 in the 60 mg and 90 mg group for the symptoms ‘coughing’ (p = 0.0433 and p = 0.0002 respectively), ‘sputum’ (p = 0.0499 and p = 0.0048 respectively) and ‘pulmonary rales at auscultation’ (p = 0.0014 and p &lt; 0.0001 respectively, two-sided t-test, each).",25095:25457, 2855831 ,20070280,Unavailable
 2855831 ,The frequency of AEs," 30 mg, 60 mg or 90 mg EPs-7630",placebo,No significant difference,"The frequency of patients with suspected drug-related AEs was 5.9% [6 of 101 patients; EPs 7630 (30 mg) group], 5.1% [5 of 99 patients; EPs 7630 (60 mg) group], 5.1% [5 of 99 patients; EPs 7630 (90 mg) group] and 4.8% (5 of 101 patients; placebo group).",29433:29688, 2855831 ,20070280,Unavailable
 2699720 ,"total cholesterol, triglycerides, or calculated LDL",low-carbohydrate diet,low-fat diet,No significant difference,"Over 12 months, there were no significant differences in total cholesterol, triglycerides, or calculated LDL between dietary groups.",32309:32442, 2699720 ,19366978,Unavailable
 2699720 ,HDL,low-carbohydrate diet,low-fat diet,Significantly increased,"There was a significant increase in HDL in the low-carbohydrate group, which occurred at 6 months and was sustained at 12 months (Table 2).",32441:32620, 2699720 ,19366978,Unavailable
 2699720 ,Systolic blood pressure and diastolic blood pressure,low-carbohydrate diet,low-fat diet,No significant difference,Systolic blood pressure and diastolic blood pressure were similar between dietary groups at baseline and did not change over the 12-month period (Table 2).,32076:32270, 2699720 ,19366978,Unavailable
 2699720 ,A1C,low-carbohydrate diet,low-fat diet,No significant difference,There was no difference in the rate of change in A1C in either the early or late phase of dietary intervention,30864:30974, 2699720 ,19366978,Unavailable
 2699720 ,rates of weight change,low-carbohydrate diet,low-fat diet,Significantly increased,The difference in the early- and late-phase rates of weight change between the dietary groups was significant (P = 0.005).,23086:23229, 2699720 ,19366978,Unavailable
 2699720 ,weight ,low-carbohydrate diet,low-fat diet,No significant difference,"At 1 year, there was a 3.4% weight reduction in both groups.",23025:23086, 2699720 ,19366978,Unavailable
 3766084 ,total days of physical activity (PA) ,printed basic intervention or the printed environmental intervention,waiting list (control),Significantly increased,Both the printed basic intervention (B = 0.64; p = .002; ES = .23) and the printed environmental intervention (B = 0.70; p = .001; ES = .38) were also significantly effective in increasing total days of PA compared to the control group.,49934:50024, 3766084 ,24228862,Unavailable
 3766084 ,total days of physical activity (PA) ,Web-based intervention,waiting list (control),No significant difference,No significant effects on days of PA behaviour were found in the Web-based interventions.,49934:50024, 3766084 ,24228862,Unavailable
 1090588 ,reaction time,anodal and cathodal transcranial direct current (tDCS) stimulation (260 μA) bilaterally at fronto-cortical electrode sites on the scalp over 15 min repeatedly (15 sec-on/15 sec-off),sham-transcortical direct current stimulation (tDCS),Significantly decreased,"However, reaction time was slowed during both anodal and cathodal stimulation as compared to placebo (p &lt; 0.05) indicating that real stimulation hampered neuronal processing related to response selection and preparation.",10759:10912, 1090588 ,15819988,Unavailable
 1090588 ,negative and positive response types zero intercepts,anodal and cathodal transcranial direct current (tDCS) stimulation (260 μA) bilaterally at fronto-cortical electrode sites on the scalp over 15 min repeatedly (15 sec-on/15 sec-off),sham-transcortical direct current stimulation (tDCS),Significantly increased,"For both negative and positive response types zero intercepts for tDCS were higher (slower reaction times) than for sham-tDCS (F[1,11] = 11.77, p &lt; 0.01)",10759:10912, 1090588 ,15819988,Unavailable
 4771973 ,mean carotid IMT,metformin,placebo,No significant difference,"Change in the mean carotid IMT did not differ significantly between the groups (between-group difference 0.012 mm (95% CI −0.003 to 0.026), p=0.11).",12210:12359, 4771973 ,26916684,Unavailable
 4771973 ,HbA1c,metformin,placebo,Significantly decreased,"HbA1c was more reduced in the metformin group (between-group difference −0.42% (95% CI −0.62% to −0.23%), p&lt;0.001)),",12359:12486, 4771973 ,26916684,Unavailable
 4771973 ,insulin dose,metformin,placebo,Significantly decreased,"despite the significantly lower insulin dose at end of trial in the metformin group (1.04 IU/kg (95% CI 0.94 to 1.15)) compared with placebo (1.36 IU/kg (95% CI 1.23 to 1.51), p&lt;0.001).",12486:12672, 4771973 ,26916684,Unavailable
 4771973 ,gain weight,metformin,placebo,Significantly decreased,"The metformin group gained less weight (between-group difference −2.6 kg (95% CI −3.3 to −1.8), p&lt;0.001).",12673:12778, 4771973 ,26916684,Unavailable
 4771973 ,non-severe hypoglycaemic episodes,metformin,placebo,Significantly increased,"the metformin group had more non-severe hypoglycaemic episodes (4347 vs 3161, p&lt;0.001).",12916:13003, 4771973 ,26916684,Unavailable
 5827033 ,Time to first flatus,transcutaneous electroacupuncture (TEA),control group,Significantly decreased,"Time to first flatus in the TEA group was significantly shorter than in the control group (73.19 ± 15.61 vs 82.82 ± 20.25 h, P = 0.038)",7159:7328, 5827033 ,29492186,Unavailable
 5827033 ,Time to first flatus after  open gastrectomy,transcutaneous electroacupuncture (TEA),control group,Significantly decreased,"especially for open gastrectomy (76.53 ± 14.29 vs 87.23 ± 20.75 h, P = 0.048).",7330:7442, 5827033 ,29492186,Unavailable
 5827033 ,Bowel sounds on day 2,transcutaneous electroacupuncture (TEA),control group,Significantly increased,"Bowel sounds on day 2 in the TEA group were significantly greater than in the control group (2.30 ± 2.61/min vs 1.05 ± 1.26/min, P = 0.017).",7443:7618, 5827033 ,29492186,Unavailable
 5827033 ,Time to nasogastric tube removal,transcutaneous electroacupuncture (TEA),control group,Significantly decreased,"Time to nasogastric tube removal in the TEA group was earlier than in the control group (4.22 ± 1.01 vs 4.97 ± 1.67 d, P = 0.049),",7618:7782, 5827033 ,29492186,Unavailable
 5827033 ,the time to liquid diet,transcutaneous electroacupuncture (TEA),control group,Significantly decreased,"Time to nasogastric tube removal in the TEA group was earlier than in the control group (4.22 ± 1.01 vs 4.97 ± 1.67 d, P = 0.049), as well as the time to liquid diet (5.0 ± 1.34 vs 5.83 ± 2.10 d, P = 0.039).",7618:7893, 5827033 ,29492186,Unavailable
 5758851 ,the DHE intensity,Chamaecyparis obtusa (CO) eye mask 0.1%,placebo,Significantly decreased,"However, pretreatment with CO extracts significantly reduced the DHE intensity in a concentration-dependent manner (0.001% CO: P = 0.96 versus positive control; 0.01% CO: P = 0.04 versus positive control; 0.1% CO: P &lt; 0.01 versus positive control; and P = 0.01 versus 0.001% CO)",28843:29192, 5758851 ,29441148,Unavailable
 5758851 ,Tear Volume for murine experimental dry eye (EDE),Chamaecyparis obtusa (CO) eye mask 0.1%,placebo,Significantly increased,Tear volume in the 0.1% CO treatment group was significantly greater than those in the other groups (all P &lt; 0.01; Figure 4(a)).,30428:30615, 5758851 ,29441148,Unavailable
 5758851 ,Tear Volume,Chamaecyparis obtusa (CO) eye mask 0.1%,placebo,Significantly increased,. Tear volume in the 0.1% CO treatment group was significantly greater than those in the other groups (all P &lt; 0.01; Figure 4(a)).,30426:30615, 5758851 ,29441148,Unavailable
 5758851 ,tear film break-up time (TBUT),Chamaecyparis obtusa (CO) eye mask 0.001%,"balanced salt solution (BSS), experimental dry eye (EDE) model",No significant difference,"However, the 0.001% CO extract group did not differ significantly from the EDE and BSS groups in terms of TBUT. (1.68 ± 0.14 s; P = 0.27 and P = 0.98, resp.).",31239:31431, 5758851 ,29441148,Unavailable
 5758851 ,The mean concentration of IFN-γ,Chamaecyparis obtusa (CO) eye mask 0.1%,experimental dry eye (EDE) model,Significantly decreased,"The 0.01% CO group showed significantly lower levels of IFN-γ than the EDE group (9.76 ± 0.86 pg/mL, P = 0.02);",32874:33021, 5758851 ,29441148,Unavailable
 5758851 ,The mean levels of IP-10,Chamaecyparis obtusa (CO) eye mask 0.1%,"balanced salt solution (BSS), experimental dry eye (EDE) model",Significantly decreased,"The 0.1% CO group showed significantly lower levels than the EDE and BSS groups (22.23 ± 1.15 pg/mL and 19.21 ± 0.89 pg/mL, P = 0.02 in both case).",33286:33450, 5758851 ,29441148,Unavailable
 3702133 ,MCV values," group II (120 mg/kg BW of Immuforte in gum acacia), group III (360 mg/kg BW of Immuforte in gum acacia)",group I (vehicle control; gum acacia),Significantly increased,"In females, MCV values in low dose (120 mg/kg BW) and mid dose (360 mg/kg BW) were significantly higher as compared to control (P &lt; 0.05).",18245:18400, 3702133 ,23833443,Unavailable
 3702133 ,percent lymphocyte count," group II (120 mg/kg BW of Immuforte in gum acacia), group III (360 mg/kg BW of Immuforte in gum acacia),  group IV (600 mg/kg BW of Immuforte in gum acacia)",group I (vehicle control; gum acacia),Significantly decreased,There was significant decrease in percent lymphocyte count (P &lt; 0.05) and increase in percent neutrophil count (P &lt; 0.05) of treated group as compared to control. This finding was same in recovery group.,18401:18644, 3702133 ,23833443,Unavailable
 3702133 ,percent neutrophil count," group II (120 mg/kg BW of Immuforte in gum acacia), group III (360 mg/kg BW of Immuforte in gum acacia),  group IV (600 mg/kg BW of Immuforte in gum acacia)",group I (vehicle control; gum acacia),Significantly increased,There was significant decrease in percent lymphocyte count (P &lt; 0.05) and increase in percent neutrophil count (P &lt; 0.05) of treated group as compared to control.,18401:18604, 3702133 ,23833443,Unavailable
 3672758 ,The Ki-67 mean change,pre-operative celecoxib (400 mg) twice daily,placebo,Significantly decreased,"The Ki-67 mean change relative to baseline was -29.1% (P = 0.019) and -8.2% (P = 0.384) in the treatment and control arm, respectively. Between treatment groups, the change in Ki-67 was statistically significant (P = 0.029).",8532:8807, 3672758 ,23566419,Unavailable
 3672758 ,Cleaved caspase-3 and CD34 expression,pre-operative celecoxib (400 mg) twice daily,placebo,No significant difference,Cleaved caspase-3 and CD34 expression were not significantly different between the celecoxib-treated and placebo-treated groups.,8808:8936, 3672758 ,23566419,Unavailable
 4727391 ,first attempt at successful insertiontion time,laryngeal mask (LM) ventilation,endotracheal intubation (ETI),No significant difference,"There was no significant difference in the first attempt at successful insertion between the groups (χ2  = 0.363, p = 0.547).",15066:15236, 4727391 ,26811060,Unavailable
 4727391 ," insertion time, Apgar score at 1 and 5min, response time, ventilation time, successful resuscitation",laryngeal mask (LM) ventilation,endotracheal intubation (ETI),No significant difference,"There were no significant differences in first attempt at successful insertion (LM, 94.4&nbsp;% vs. ETI, 90.6&nbsp;%), insertion time (LM, 7.58 ± 1.16&nbsp;s vs. ETI, 7.89 ± 1.52&nbsp;s), Apgar score at 1 and 5&nbsp;min, response time, ventilation time, successful resuscitation (LM, 86.1&nbsp;% vs. ETI,&nbsp; 96.9&nbsp;%), and adverse events (LM, n =3 vs. ETI, n =4) between groups.",15066:15236, 4727391 ,26811060,Unavailable
 4727391 ,Adverse effects,laryngeal mask (LM) ventilation,endotracheal intubation (ETI),No significant difference,"There was no significant difference in the incidence of adverse effects between the LM and ETI groups (8.33&nbsp;% vs 12.5&nbsp;%, p &gt; 0.05).",20955:21103, 4727391 ,26811060,Unavailable
 3707768 ,serum creatinine,a tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI/r) group,control,Significantly increased,"Compared to control, the TDF+PI/r group exhibited higher levels of serum creatinine (79 vs. 69.7 μmol/L, P&lt;0.001) and a lower rate of eGFR (93.0 vs. 101.6 ml/min/1.73m2, P=0.009) at the end of week 48.",5353:5603, 3707768 ,23815472,Unavailable
 3707768 ,serum creatinine,a tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI/r) group,control,Significantly decreased,"Compared to control, the TDF+PI/r group exhibited higher levels of serum creatinine (79 vs. 69.7 μmol/L, P&lt;0.001) and a lower rate of eGFR (93.0 vs. 101.6 ml/min/1.73m2, P=0.009) at the end of week 48.",5353:5603, 3707768 ,23815472,Unavailable
 4307364 ,monthly migraine frequency,cinnarizine,topiramate,No significant difference,"however, these values demonstrated no differences between the cinnarizine and the topiramate group (p&gt; 0.05).",24269:24379, 4307364 ,25657766,Unavailable
 4307364 ,related adverse effects,cinnarizine,topiramate,No significant difference,The analysis revealed no statistically significant differences between the cinnarizine group and the topiramate group for treatment related adverse effects (p= 0.29).,31091:31257, 4307364 ,25657766,Unavailable
 4588424 ,the occurrence of stroke and transient ischemic attack (TIA),10&nbsp;mg of pravastatin/day,no statins,No significant difference,"As the primary endpoint, total stroke and TIA similarly occurred in pravastatin and control group (2.56 vs. 2.65%/year, p&nbsp;=&nbsp;0.82, adjusted HR 0.97 [95%CI 0.73 to 1.29], Fig.&nbsp;3A), and the finding was virtually unaffected when TIA was excluded from the analysis (2.35 vs. 2.47%/year, p&nbsp;=&nbsp;0.74, adjusted hazard ratio 0.95 [95%CI 0.71 to 1.28]).",23831:24213, 4588424 ,26501105,Unavailable
 4588424 ,"Occurrence of lacunar infarction, cardioembolic infarction, and intracranial hemorrhage, the occurrence of myocardial infarction, vascular accidents, death, and hospitalization",10mg of pravastatin/day,no statins,No significant difference,"Occurrence of lacunar infarction (Fig.&nbsp;3C), cardioembolic infarction (Fig.&nbsp;3D), and intracranial hemorrhage (Fig.&nbsp;3E) was similar between the two groups, so was the occurrence of myocardial infarction, vascular accidents, death, and hospitalization (Table&nbsp;2).",24675:25096, 4588424 ,26501105,Unavailable
 3718763 ,"TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-density lipoprotein cholesterol, VLDL-TG, oxidized LDL, and remnant-like particle cholesterol  in  total (all subjects with diabetes—overall median baseline glycosylated hemoglobin A1c [A1c] = 6.8%), better-controlled diabetes (below median baseline A1c), and less-controlled diabetes (above median baseline A1c)",IPE (4g/day),placebo,Significantly decreased,"Compared with placebo, IPE 4&nbsp;g/day significantly reduced TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-density lipoprotein cholesterol, VLDL-TG, oxidized LDL, and remnant-like particle cholesterol in all 3 diabetes groups, LDL-C in the total diabetes group, and hsCRP in the total and less-controlled diabetes groups.",6100:6262, 3718763 ,23835245,Unavailable
 3718763 ,"LDL-C in the total diabetes group  total (all subjects with diabetes—overall median baseline glycosylated hemoglobin A1c [A1c] = 6.8%), and less-controlled diabetes (above median baseline A1c)",IPE (4g/day),placebo,Significantly decreased,"Compared with placebo, IPE 4&nbsp;g/day significantly reduced TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-density lipoprotein cholesterol, VLDL-TG, oxidized LDL, and remnant-like particle cholesterol in all 3 diabetes groups, LDL-C in the total diabetes group, and hsCRP in the total and less-controlled diabetes groups.",6100:6262, 3718763 ,23835245,Unavailable
 3718763 ,"hsCRP in the total (all subjects with diabetes—overall median baseline glycosylated hemoglobin A1c [A1c] = 6.8%), and less-controlled diabetes (above median baseline A1c)",IPE (4g/day),placebo,Significantly decreased,"Compared with placebo, IPE 4&nbsp;g/day significantly reduced TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-density lipoprotein cholesterol, VLDL-TG, oxidized LDL, and remnant-like particle cholesterol in all 3 diabetes groups, LDL-C in the total diabetes group, and hsCRP in the total and less-controlled diabetes groups.",6100:6262, 3718763 ,23835245,Unavailable
 3718763 ,"fasting plasma glucose, A1c, insulin, or homeostasis model assessment-estimated insulin total (all subjects with diabetes—overall median baseline glycosylated hemoglobin A1c [A1c] = 6.8%), better-controlled diabetes (below median baseline A1c), and less-controlled diabetes (above median baseline A1c).",IPE (4g/day),placebo,No significant difference,"There were no significant increases in fasting plasma glucose, A1c, insulin, or homeostasis model assessment-estimated insulin resistance in any group.",6100:6262, 3718763 ,23835245,Unavailable
 5830079 ,Parenteral nutrition associated cholestasis,"mixed lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil-(intervention)",soybean oil-based lipid emulsion (control),No significant difference,Parenteral nutrition associated cholestasis was 11 of 110 (10.1%) in the intervention and 18 of 113 (15.9%) in the control group (P = .20).,5157:5314, 5830079 ,29269199,Unavailable
 5830079 ,other neonatal morbidity,"mixed lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil-(intervention)",soybean oil-based lipid emulsion (control),No significant difference,There was no statistically significant effect on any other neonatal morbidity.,5555:5633, 5830079 ,29269199,Unavailable
 5830079 ,mortality,"mixed lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil-(intervention)",soybean oil-based lipid emulsion (control),No significant difference,Infants receiving fish oil as a rescue therapy did not differ between groups in mortality (SMOF-LE: 0/3 vs soybean oil-based lipid emulsion: 1/4; P = .35),21573:21744, 5830079 ,29269199,Unavailable
 5830079 ,normalization of parenteral nutrition associated cholestasis (PNAC) until discharge,"mixed lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil-(intervention)",soybean oil-based lipid emulsion (control),No significant difference,or normalization of PNAC until discharge (SMOFLE: 1/3 vs soybean oil-based lipid emulsion: 0/4; P = .21).,21745:21868, 5830079 ,29269199,Unavailable
 3658908 ,"change in lesion score in the esophagus, stomach, and duodenum",irsogladine group (Group I; n = 16) receiving diclofenac sodium 75 mg and irsogladine 4 mg daily for 14 days,omeprazole group (Group O; n = 16) receiving diclofenac sodium 75 mg and omeprazole 10 mg daily for 14 days,No significant difference,"There was no significant difference between Group O (from 0.6 ± 0.9 to 1.5 ± 1.1) and Group I (from 0.5 ± 1.1 to 0.9 ± 1.0) in the gastric Lanza score either before or after treatment (p = 0.20). A similar result was obtained for the duodenal Lanza scores (Group O, 0.0 ± 0.0 to 0.4 ± 0.8; Group I, 0.0 ± 0.0 to 0.4 ± 0.9; p = 0.94) (Table 2).",23616:23998, 3658908 ,23672202,Unavailable
 3658908 ,the number of small intestinal mucosal breaks,irsogladine group (Group I; n = 16) receiving diclofenac sodium 75 mg and irsogladine 4 mg daily for 14 days,omeprazole group (Group O; n = 16) receiving diclofenac sodium 75 mg and omeprazole 10 mg daily for 14 days,Significantly decreased,"NSAID treatment significantly increased the number of small intestinal mucosal breaks per subject by capsule endoscopic evaluation, from a basal level of 0.1 ± 0.3 up to 1.9 ± 2.0 lesions in Group O (p = 0.0002). In contrast, there were no significant changes in the mean number of mucosal breaks before and after co-treatment in Group I (0.3 ± 0.8 to 0.5 ± 0.7, p = 0.62), and the between-group difference was significant (p = 0.0040).",6561:6998, 3658908 ,23672202,Unavailable
 3658908 ,Fecal calprotectin concentration,irsogladine group (Group I; n = 16) receiving diclofenac sodium 75 mg and irsogladine 4 mg daily for 14 days,omeprazole group (Group O; n = 16) receiving diclofenac sodium 75 mg and omeprazole 10 mg daily for 14 days,Significantly decreased,"Fecal calprotectin concentration, when the concentration before treatment was defined as 1, was significantly increased both in Group O (from 1.0 ± 0.0 to 18.1 ± 37.1, p = 0.0002) and Group I (from 1.0 ± 0.0 to 6.0 ± 11.1, p = 0.0280); the degree of increase in Group O was significantly higher compared with that in Group I (p&lt;0.05).",6998:7332, 3658908 ,23672202,Unavailable
 3658908 ,fecal occult blood levels,irsogladine group (Group I; n = 16) receiving diclofenac sodium 75 mg and irsogladine 4 mg daily for 14 days,omeprazole group (Group O; n = 16) receiving diclofenac sodium 75 mg and omeprazole 10 mg daily for 14 days,Significantly decreased,"In addition, fecal occult blood levels increased significantly in Group O (p = 0.0018), but there was no change in Group I (p = 1.0), and the between-group difference was significant (p = 0.0031).",7332:7529, 3658908 ,23672202,Unavailable
 3707735 , free fat mass index (FFMI),"group A with daily dietary supplementation with Creatine 340 mg + 320 mg Coenzyme Q-Ter (Eufortyn®, Scharper Therapeutics Srl) for 2 months",Group B received placebo,Significantly increased,"After 2 months of therapy (T1) the FFMI increased in the daily dietary supplementation group (+ 3.7 %) and decreased in the placebo group (- 0.6 %), resulting in a statistically significant (p &lt; 0.001) treatment difference.",4946:5170, 3707735 ,23800154,Unavailable
 3707735 ,"improvement in the degree of dyspnea, and independence level in activities of daily living; 2) improvement in quality of life in activity section ;","group A with daily dietary supplementation with Creatine 340 mg + 320 mg Coenzyme Q-Ter (Eufortyn®, Scharper Therapeutics Srl) for 2 months",Group B received placebo,Significantly increased,"Group A patients also showed significant: 1) improvement in the degree of dyspnea (VAS: p &lt; 0.05; Borg: p &lt; 0.05; MRC: p &lt; 0.001; BDI1: p &lt; 0.05; BDI3: p &lt; 0.03), and independence level in activities of daily living (p &lt; 0.03); 2) improvement in quality of life in activity section (- 6.63 pt) and in total score (- 5.43 pt); 3) exacerbation number decrease (p &lt; 0.02). No significant differences were found (end of study vs baseline) in group B.",5306:5752, 3707735 ,23800154,Unavailable
 3707735 ,exacerbation number decrease,"group A with daily dietary supplementation with Creatine 340 mg + 320 mg Coenzyme Q-Ter (Eufortyn®, Scharper Therapeutics Srl) for 2 months",Group B received placebo,Significantly decreased,"Group A patients also showed significant: 1) improvement in the degree of dyspnea (VAS: p &lt; 0.05; Borg: p &lt; 0.05; MRC: p &lt; 0.001; BDI1: p &lt; 0.05; BDI3: p &lt; 0.03), and independence level in activities of daily living (p &lt; 0.03); 2) improvement in quality of life in activity section (- 6.63 pt) and in total score (- 5.43 pt); 3) exacerbation number decrease (p &lt; 0.02). No significant differences were found (end of study vs baseline) in group B.",5306:5752, 3707735 ,23800154,Unavailable
 2826100 ,"overall quality of life (QOL), fatigue, mood disturbance,  inflammation (CRP)",Medical Qigong (MQ),usual care,Significantly increased,"Regression analysis indicated that the MQ group significantly improved overall QOL (t144 = −5.761, P &lt; 0.001), fatigue (t153 = −5.621, P &lt; 0.001), mood disturbance (t122 =2.346, P = 0.021) and inflammation (CRP) (t99 = 2.042, P &lt; 0.044) compared with usual care after controlling for baseline variables.",5720:6209, 2826100 ,19880433,Unavailable
 5843211 ,Experiences in Close Relationships Questionnaire (ECR-R),cognitive-behavioral (CBT) ,short term psychodynamic therapy (PDT),No significant difference,With regard to long-term treatment effects we did not find statistically significant differences between the treatment groups.,57672:57798, 5843211 ,29518077,Unavailable
 5843211 ,attachment anxiety scores ,cognitive-behavioral (CBT) ,"short term psychodynamic therapy (PDT), waiting list (WL)",No significant difference,"In contrast, attachment avoidance remained rather stable after treatment with no differential treatment effects (CBT: Mpost = 2.67, SDpre = .99 vs. M12-months = 2.62, SD12-months = 1.03; t(97) = -.23, p = .82; PDT: Mpost = 2.95, SDpre = 1.07 vs. M12-months = 2.87, SD12-months = 1.09; t(88) = .93, p = .36).",58646:59246, 5843211 ,29518077,Unavailable
 5812983 ,"psychological distress , cancer-specific distress, and unmet psychological care needs",Web-based cognitive behavioral therapy (CBT) intervention,patient education website,Significantly decreased,"However, per-protocol analyses found a greater decrease for the CancerCope group in psychological distress (P=.04), cancer-specific distress (P=.02), and unmet psychological care needs (P=.03) from baseline to 8 weeks compared with the patient education group.",11283:11594, 5812983 ,29386173,Unavailable
 2784391 ,Right rectus femoris and right vastus intermedius cross sectional diameter (CSD),EMS sessions of both lower extremities (electrical muscle stimulation (EMS)-group),control group,Significantly decreased,"However, the CSD of the right rectus femoris decreased significantly less in the EMS group (-0.11 ± 0.06 cm, -8 ± 3.9%) as compared to the control group (-0.21 ± 0.10 cm, -13.9 ± 6.4%; P &lt; 0.05)",6439:6654, 2784391 ,19814793,Unavailable
 2784391 ,the CSD of the right vastus intermedius,EMS sessions of both lower extremities (EMS-group),control group,Significantly decreased,"the CSD of the right vastus intermedius decreased significantly less in the EMS group (-0.10 ± 0.05 cm, -12.5 ± 7.4%) as compared to the control group (-0.29 ± 0.28 cm, -21.5 ± 15.3%; P &lt; 0.05).",6439:6654, 2784391 ,19814793,Unavailable
 3738153 ,all-cause mortality,Mediterranean diets supplemented with nuts or olive oil,control diet,No significant difference,"Nut consumption was associated with a significantly reduced risk of all-cause mortality (P for trend &lt;0.05, all).",10043:10174, 3738153 ,23866098,Unavailable
 3738153 ,mortality risk,Mediterranean diets supplemented with nuts or olive oil,control diet,No significant difference,"In fully adjusted models, participants who consumed total nuts, walnuts, or non-walnut nuts &gt;3 servings per week had significant reductions in total mortality risk of 39%, 45%, and 34%, respectively, compared to those who rarely or never consumed nuts. The relationship between nut consumption and total mortality was linear for all the models (P for trend &lt;0.05), except for the crude model of nut consumption excluding walnuts.",37701:38150, 3738153 ,23866098,Unavailable
 3483098 ,The mean difference in HbA1c, continuous glucose monitoring (CGM) Sensor On,continuous glucose monitoring (CGM) Sensor Off arm ,Significantly decreased,"The mean difference in HbA1c was –0.43% (–4.74&nbsp;mmol/mol) in favour of the Sensor On arm (8.04% [64.34&nbsp;mmol/mol] vs 8.47% [69.08&nbsp;mmol/mol]; 95% CI −0.32%, −0.55% [−3.50, −6.01&nbsp;mmol/mol]; p &lt; 0.001).",5221:5447, 3483098 ,22965294,Unavailable
 3483098 ,time was spent with sensor glucose, continuous glucose monitoring (CGM) Sensor On,continuous glucose monitoring (CGM) Sensor Off arm ,Significantly decreased,"Following cessation of glucose sensing, HbA1c reverted to baseline levels. Less time was spent with sensor glucose &lt;3.9&nbsp;mmol/l during the Sensor On arm than in the Sensor Off arm (19 vs 31&nbsp;min/day; p = 0.009).",5447:5690, 3483098 ,22965294,Unavailable
 3483098 ,The mean number of daily boluses, continuous glucose monitoring (CGM) Sensor On,continuous glucose monitoring (CGM) Sensor Off arm ,Significantly increased,"The mean number of daily boluses increased in the Sensor On arm (6.8 ± 2.5 vs 5.8 ± 1.9, p &lt; 0.0001)",5691:5808, 3483098 ,22965294,Unavailable
 3483098 ,the frequency of use of the temporary basal rate  and manual insulin suspend  functions, continuous glucose monitoring (CGM) Sensor On,continuous glucose monitoring (CGM) Sensor Off arm ,Significantly increased,"together with the frequency of use of the temporary basal rate (0.75 ± 1.11 vs 0.26 ± 0.47, p &lt; 0.0001) and manual insulin suspend (0.91 ± 1.25 vs 0.70 ± 0.75, p &lt; 0.018) functions.",5809:6032, 3483098 ,22965294,Unavailable
 3483098 ,events of severe hypoglycaemia, continuous glucose monitoring (CGM) Sensor On,continuous glucose monitoring (CGM) Sensor Off arm ,No significant difference,"Four vs two events of severe hypoglycaemia occurred in the Sensor On and Sensor Off arm, respectively (p = 0.40).",6032:6165, 3483098 ,22965294,Unavailable
 4980729 ,Sneezing,pranlukast,placebo,Significantly decreased,"On the following morning, the score increased in the placebo group, but was inhibited slightly in the pranlukast group (0.897 vs. 0.564, p = 0.094) (Figure 2).",18079:18296, 4980729 ,27536428,Unavailable
 4980729 ,nasal discharge score,pranlukast,placebo,Significantly decreased,"After the subjects left the chamber, the score increased continuously until the following morning in the placebo group, but was significantly inhibited in the pranlukast group (1.179 vs. 0.718, p = 0.037) (Figure 4).",19743:20016, 4980729 ,27536428,Unavailable
 4980729 ,Nasal itching,pranlukast,placebo,Significantly decreased,"After leaving the chamber, the score increased at night in the placebo group, but tended to decrease in the pranlukast group and became significantly lower than that of the placebo group at night on the day of exposure (0.667 vs. 0.333, p = 0.025).",20417:20685, 4980729 ,27536428,Unavailable
 4980729 ,Itchy eyes,pranlukast,placebo,Significantly decreased,"The score was significantly lower on the following afternoon in the pranlukast compared to the placebo group (0.154 vs. 0.436, p = 0.039).",22034:22189, 4980729 ,27536428,Unavailable
 4980729 ,Watery eyes,pranlukast,placebo,No significant difference,"During and after exposure in the pollen challenge chamber, score for water eyes was ≤ 0.2 in both groups, indicating that this symptom was very mild or absent.",22209:22368, 4980729 ,27536428,Unavailable
 3532083 ,Healing rates of ulcers,four-layer bandage (4LB),short-stretch bandage (SSB).,No significant difference,"Healing rates were also not different between treatments: at 12 weeks, the healing rate was 58% for 4LB and 53% for SSB; the corresponding rate was 71% and 78% at 26 weeks and 83% and 92% at 52 weeks (data not shown).",34178:34396, 3532083 ,23031428,Unavailable
 3532083 ,recurrence rates of ulcers,four-layer bandage (4LB),short-stretch bandage (SSB).,No significant difference,"Both groups attained similar improvement in quality-of-life weights at healing and sustained the improvement comparably at 3 months post healing (Figure 1, broken lines), partially reflecting similar recurrence rates (10% for 4LB and 13% for SSB at 52 weeks, data not shown).",36405:36718, 3532083 ,23031428,Unavailable
 5813072 ,the recognition of fearful faces ,"3,4-Methylenedioxymethamphetamine (MDMA)",placebo or methylphenidate or modafinil,Significantly decreased,"The post hoc tests showed that MDMA significantly impaired the recognition of fearful faces compared with placebo (p &lt; 0.001), methylphenidate (p &lt; 0.01), and modafinil (p &lt; 0.05).",41981:42222, 5813072 ,28551715,Unavailable
 5813072 , scores on the “Evaluative” “Physiological” and “Motivational” scales,"3,4-Methylenedioxymethamphetamine (MDMA)",placebo,Significantly increased,"Only MDMA increased scores on the “Evaluative” (p &lt; 0.001), “Physiological” (p &lt; 0.001), and “Motivational” (p &lt; 0.05) scales compared with placebo,",43375:43582, 5813072 ,28551715,Unavailable
 5813072 ,misclassifications of emotions as angry,methylphenidate or modafinil,placebo,Significantly increased,"In contrast, methylphenidate (p &lt; 0.05) and modafinil (p &lt; 0.05) increased misclassifications of emotions as angry (main effect of drug: F 3,63 = 3.38 p &lt; 0.05).",42509:42759, 5813072 ,28551715,Unavailable
 5813072 ,misclassification of emotions as happy,"3,4-Methylenedioxymethamphetamine (MDMA)",placebo,Significantly increased,"There was a significant main effect of drug on misclassification of emotions as happy (F 3,63 = 3.35 p &lt; 0.05). MDMA significantly increased the misclassification of emotions as happy compared with placebo (p &lt; 0.05).",42223:42509, 5813072 ,28551715,Unavailable
 5813072 ,Adverse effects,"3,4-Methylenedioxymethamphetamine (MDMA) or methylphenidate or modafinil ",placebo,Significantly increased,"On the List of Complaints, MDMA, methylphenidate, and modafinil produced significant and comparable acute adverse effects (up to 6 h) compared with placebo (Supplementary Table S1).",45069:45293, 5813072 ,28551715,Unavailable
 3354371 ,incidence of apnoea,ketamine injection 0.5 mg/kg  (group I),fentanyl injection (1.5 μg/kg) (group II),Significantly decreased,incidence of apnoea was more in group II (P&lt;0.05),10394:10537, 3354371 ,22624097,Unavailable
 3354371 ,"Awakening time (spontaneous eye opening) and recovery time (when patient was able to answer simple questions such as name, age, date of birth, time, and place)",ketamine injection 0.5 mg/kg,fentanyl injection (1.5 μg/kg),No significant difference,"Awakening time (spontaneous eye opening) and recovery time (when patient was able to answer simple questions such as name, age, date of birth, time, and place) were statistically insignificant in both groups [Table 4].",10926:11183, 3354371 ,22624097,Unavailable
 3354371 ,"mean systolic, diastolic blood pressure, and pulse rate intraoperatively ",ketamine injection 0.5 mg/kg,fentanyl injection (1.5 μg/kg),No significant difference,There was no statistically significant difference in both the groups [Figures 1–3].,12461:12618, 3354371 ,22624097,Unavailable
 3354371 ,Pain due to propofol injection and presence of abnormal movements ,ketamine injection 0.5 mg/kg,fentanyl injection (1.5 μg/kg),No significant difference,Pain due to propofol injection and presence of abnormal movements were statistically insignificant (P&gt;0.05) in both the groups,10394:10537, 3354371 ,22624097,Unavailable
 4439020 ,mean volume change of pneumocephalus,normobaric hyperoxia at FiO2 100% over an endotracheal tube for 3 hours (treatment arm),room air ,Significantly increased,"Following the administration of normobaric hyperoxia, the first co-primary endpoint mean volume change of pneumocephalus was 87.83 (SE: 3.31) ml in patients treated with 100% O2 and it was 71.29 (SE: 3.31) ml in patients in the control arm (ANCOVA; estimate: 16.54 ml; 95% confidence interval (CI): [-26.00–7.08]; p = 0.001; Table 3).",36485:36738, 4439020 ,25992622,Unavailable
 4439020 ,air resorption rate,normobaric hyperoxia at FiO2 100% over an endotracheal tube for 3 hours (treatment arm),room air ,Significantly increased,"The second co-primary endpoint air resorption rate was higher as well in patients treated with 100% O2 (3.57; SE: 0.13 ml/h) as compared to untreated patients (2.93; SE: 0.13 ml/h; ANCOVA; estimate: -0.63; 95% CI: [-1.01, -0.26]; p = 0.0015).",36485:36738, 4439020 ,25992622,Unavailable
 4439020 ,Stanford Sleepiness Scale (SSS),normobaric hyperoxia at FiO2 100% over an endotracheal tube for 3 hours (treatment arm),room air ,Significantly decreased,"Patients in the treatment were more alert, with a lower score of 3.18 ± 0.3, in comparison to patients in the control arm (mean 4.27 ± 0.3; t-test; 95% CI: [0.22, 1.98]; p = 0.015).",52746:52927, 4439020 ,25992622,Unavailable
 4439020 ,Stroop test,normobaric hyperoxia at FiO2 100% over an endotracheal tube for 3 hours (treatment arm),room air ,No significant difference,"No differences between preoperative and postoperative measurements were found in the remainder. In addition, there were no differences between the treatment arm and the control arm.",48505:48686, 4439020 ,25992622,Unavailable
 3685778 ,"mean Pulsatility Index (PI), resistance index (RI) and Systolic/Diastolic ratio (S/D)",Sildenafil,placebo,Significantly increased,"In middle cerebral arteries, a significant increase (95% CI) was noted in mean Pulsatility Index (PI), resistance index (RI) and Systolic/Diastolic ratio (S/D) after Sildenafil administration [Table 3].",16393:16635, 3685778 ,23798922,Unavailable
 3685778 ,Mean Middle Cerebral Artery Pulsatility Index (MCA PI),Sildenafil,placebo,Significantly increased,"Mean Middle Cerebral Artery Pulsatility Index (MCA PI) significantly increased in the Sildenafil group (0.51 [SD 0.60] [95% Cl 0.16-0.85], P=0.008).",16636:16801, 3685778 ,23798922,Unavailable
 3685778 ,Mean umbilical artery systolic/diastolic ratio (UA S/D),Sildenafil,placebo,Significantly decreased,"Mean umbilical artery systolic/diastolic ratio (UA S/D) significantly decreased in the Sildenafil group as compared to the the placebo group (0.60 [SD 0.40] [95% Cl 0.37-0.84], P=0.000).",15995:16198, 3685778 ,23798922,Unavailable
 3685778 ,Mean umbilical artery pulsatility index (UA PI),Sildenafil,placebo,Significantly decreased,"Mean umbilical artery pulsatility index (UA PI) significantly decreased in the Sildenafil group in comparison with the placebo group (0.12 [SD 0.15] [95% Cl 0.02-0.22], P=0.019.",16199:16394, 3685778 ,23798922,Unavailable
 3685779 ,interleukin 6 and F2-isoprostane,"500 mg quercetin + 250 mg vitamin C as pro-oxidant (Q+C), ","250 mg of vitamin C alone (C), and placebo (Control), 500 mg of quercetin alone (Q)",No significant difference,Within group differences in interleukin 6 and F2-isoprostane only for group 1 was marginally significant (P&lt;0.1).,13262:13397, 3685779 ,23798923,Unavailable
 3685779 ,E-selectin,"500 mg quercetin + 250 mg vitamin C as pro-oxidant (Q+C), ","250 mg of vitamin C alone (C), and placebo (Control), 500 mg of quercetin alone (Q)",No significant difference,"Also, pre- and postchanges in E-selectin was marginally significant for all study groups (P&lt;0.1).",13397:13514, 3685779 ,23798923,Unavailable
 3750658 ,activities of daily living (ADL),Continuum of Care for Frail Older People,control group,No significant difference,"There were no differences between the groups among those who had maintained the same degree of independence compared to baseline either at the three-, six-, or twelve-month follow-ups.",37484:37669, 3750658 ,23875866,Unavailable
 5752804 ,Postoperative analgesic requirement,"1 g intravenous PCM, in 100 ml solution before incision (Group I)",dexmedetomidine 1 μg/kg as bolus over 10 min followed by infusion of 0.5 μg/kg/h (Group II),Significantly decreased,"Postoperative analgesic requirement significantly decreased (P = 0.001), with a lower score on VAS, better patient satisfaction scores, and Ramsay Sedation Score ranges from 3 to 5 (62%) in Group I.",5273:5488, 5752804 ,29308357,Unavailable
 5752804 ,"nausea and vomiting, hypotension, and bradycardia","1 g intravenous PCM, in 100 ml solution before incision (Group I)",dexmedetomidine 1 μg/kg as bolus over 10 min followed by infusion of 0.5 μg/kg/h (Group II),Significantly increased,"The incidence of nausea and vomiting, hypotension, and bradycardia was comparable in both the groups except shivering, which was found significantly less in Group II.",5489:5655, 5752804 ,29308357,Unavailable
 5752787 ,sodium levels,"Group H (n = 20), 3% HTS was infused at 20–30 mL/h aiming for correction of 6 mEq/L/day","Group T received oral tolvaptan 15 mg on the 1st day. If daily correction was &lt;4 mEq/L, the dose was increased by 15 mg/day to a maximum of 45 mg",Significantly decreased,Group T had significantly higher sodium levels as compared to Group H (133.4 ± 1.9 vs. 131.3 ± 2.4 mEq/L).,4302:4409, 5752787 ,29307906,Unavailable
 5752787 ,potassium level,"Group H (n = 20), 3% HTS was infused at 20–30 mL/h aiming for correction of 6 mEq/L/day","Group T received oral tolvaptan 15 mg on the 1st day. If daily correction was &amp;amp;lt;4 mEq/L, the dose was increased by 15 mg/day to a maximum of 45 mg",Significantly decreased,Serum potassium levels also showed a similar trend with comparable values on day 1 and 2 with a significantly lower level on day 3 in Group H as compared to Group T [Table 2].,13113:13327, 5752787 ,29307906,Unavailable
 3666902 ,"improvement in the primary outcome measure, MADRS total score",olanzapine,placebo,Significantly increased,"Compared to placebo, patients in the olanzapine group experienced greater improvement in the primary outcome measure, MADRS total score (−14.9 vs. −10.7; p = .01).",5730:5894, 3666902 ,23672672,Unavailable
 3666902 ,reductions in the following secondary measures: CGI- BP Depression,olanzapine,placebo,Significantly increased,"They also had greater reductions in the following secondary measures: CGI- BP Depression (−1.41 vs. -0.89; p = .008),",5894:6011, 3666902 ,23672672,Unavailable
 3666902 ,"rates of response, recovery, and remission",olanzapine,placebo,No significant difference,"Differences in rates of response, recovery, and remission were not statistically significant.",6125:6220, 3666902 ,23672672,Unavailable
 3666902 ,treatment- emergent adverse events,olanzapine,placebo,Significantly increased,A greater proportion of olanzapine-treated patients reported treatment- emergent adverse events (87.5% vs. 59.6%; p &lt; .001).,6220:6345, 3666902 ,23672672,Unavailable
 3666902 , number of patients shifted from borderline to high cholesterol,olanzapine,placebo,Significantly increased,"Compared with placebo-group patients, more olanzapine-group patients shifted from borderline to high cholesterol (25.0% vs. 0.0%; p = .007)",6651:6790, 3666902 ,23672672,Unavailable
 3666902 ,weight gain,olanzapine,placebo,Significantly increased,"Compared with placebo-group patients, more olanzapine-group patients shifted from borderline to high cholesterol (25.0% vs. 0.0%; p = .007) and had clinically significant weight gain (≥7% body weight) (20.2% vs. 1.9%; p = .001).",6651:6879, 3666902 ,23672672,Unavailable
 4307366 ,mean serum phenylalanine,risperidone,buspirone,No significant difference,"None of the patients had phenylalanine more than 10 mg/ dl during treatment, and the mean serum phenylalanine of the patients was not significantly different during treatment with the two drugs (p = 0.537).",15574:15780, 4307366 ,25657768,Unavailable
 4307366 ,hyperactivity  and disruptive/stereotypic,risperidone,buspirone,Significantly decreased,"In comparison of the effects of risperidone and buspirone, a decrease in the subscales of hyperactivity (p=0.024) and disruptive/stereotypic (p=0.042) in the risperidone group was significantly different from the buspirone group.",16469:16699, 4307366 ,25657768,Unavailable
 4307366 ,self-isolation  and insecure/anxious,risperidone,buspirone,No significant difference,"Also, a decrease in the subscales of self-isolation (p=0.004) and insecure/anxious (p=0.031) in risperidone group was significantly different from the buspirone group; however, the comparison of before and after treatment was not significantly different (Table 2).",16699:17002, 4307366 ,25657768,Unavailable
 4307366 ,overall clinical efficacy,risperidone,buspirone,Significantly increased,"Concerning overall clinical efficacy according to CGI, risperidone (2.61 ± 0.50) was significantly more effective compared to buspirone (4.23 ± 1.48; p=0.006).",17010:17169, 4307366 ,25657768,Unavailable
 5862000 ,systolic blood pressure (SBP),AZL-M/CTD 20/12.5 mg once daily or AZL-M/CTD 40/12.5 mg once daily,olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5 mg FDC once daily,Significantly decreased,"Greater reductions in clinic SBP from a baseline of 165 mmHg were observed (P &lt; 0.001) in both AZL-M/CTD arms (−37.6 and −38.2 mmHg) versus OLM/HCTZ (−31.5 mmHg), despite greater dose titration in the OLM/HCTZ group.",5614:5847, 5862000 ,29334491,Unavailable
 5862000 ,systolic blood pressure (SBP) at week 8,AZL-M/CTD 20/12.5 mg once daily or AZL-M/CTD 40/12.5 mg once daily,olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5 mg FDC once daily,Significantly decreased,"At 8 weeks, both AZL-M/CTD FDCs reduced 24-h SBP more than OLM/HCTZ (−26.4 and −27.9 versus −20.7 mmHg; both P &lt; 0.001),",5848:5988, 5862000 ,29334491,Unavailable
 3606371 ,physical and mental  component summaries,etanercept and methotrexate (ETN + MTX),synthetic disease modifying antirheumatic drugs (DMARDs) and methotrexate (DMARD + MTX),Significantly increased,The improvements were significantly greater among the ETN + MTX patients compared to DMARD + MTX patients for both physical (P = 0.003) and mental (P = 0.047) component summaries.,23435:23649, 3606371 ,23294908,Unavailable
 3606371 ,improvement of the Hospital Anxiety and Depression Scale (HADS),etanercept and methotrexate (ETN + MTX),synthetic disease modifying antirheumatic drugs (DMARDs) and methotrexate (DMARD + MTX),Significantly increased,"Statistically significant greater improvements were observed in the ETN + MTX patient group compared to the DMARD + MTX group in Anxiety subscale scores—29.1% improvement versus 18.5% improvement, respectively (P = 0.026) as well as Depression subscale scores—28.7% improvement versus 16.4% improvement, respectively (P = 0.016).",24711:25074, 3606371 ,23294908,Unavailable
 3606371 ,improvement in the FACIT-Fatigue scale,etanercept and methotrexate (ETN + MTX),synthetic disease modifying antirheumatic drugs (DMARDs) and methotrexate (DMARD + MTX),Significantly increased,"however the mean percentage improvement in the FACIT-Fatigue scale was significantly greater in the ETN + MTX group compared with the DMARD group at week 16 (28.0% versus 10.4%, P = 0.001, Table&nbsp;2).",25174:25428, 3606371 ,23294908,Unavailable
 3606371 ,activity impairment of The Work Productivity and Activity Impairment Questionnaire,etanercept and methotrexate (ETN + MTX),synthetic disease modifying antirheumatic drugs (DMARDs) and methotrexate (DMARD + MTX),Significantly decreased,"At week 16, percent usual activity impairment due to health declined to 41% in the DMARD + MTX group and to 30% in the ETN + MTX group, a significant difference between the two groups based on all patients (P &lt; 0.001).",29388:29623, 3606371 ,23294908,Unavailable
 3735277 ,increase in HDL-C levels,two uncooked Roma tomatoes a day,300 g of cucumber (control group),Significantly increased,"A significant increase in HDL-C levels was observed in the tomato group (from 36.5 ± 7.5 mg/dL to 41.6 ± 6.9 mg/dL, P &lt; 0.0001 versus the control group).",5025:5195, 3735277 ,23935376,Unavailable
 3735277 ,"triglycerides, LDL-C, and total cholesterol",two uncooked Roma tomatoes a day,300 g of cucumber (control group),No significant difference,"Levels of triglycerides, LDL-C, and total cholesterol did not change significantly.",21821:21905, 3735277 ,23935376,Unavailable
 5006415 ,The median (IQR) time to completion of the tasks ,choreography of the focused history in series,in parallel to the clinical assessment of an acutely decompensating patient,No significant difference,"The median (IQR) time to completion of the tasks in series was 125 (112 – 158) seconds and in parallel 122 (108 – 158) seconds, p = 0.92.",6071:6225, 5006415 ,27578062,Unavailable
 5006415 ,The median (IQR) overall NASA TLX task load index,choreography of the focused history in series,in parallel to the clinical assessment of an acutely decompensating patient,No significant difference,"The median (IQR) overall NASA TLX task load index for series was 39 (17 – 58) and for parallel 43 (27 – 52), p = 0.57.",5935:6071, 5006415 ,27578062,Unavailable
 3524789 ,Motor dexterity and eye hand coordination (CMDT),Tai-chi program and standard residential care,standard residential care,No significant difference,"There is a significant difference in how the Tai-chi group and the waitlist group faired on the displacing test (Z = −2.28; P = 0.023; r = 0.42) and marginal significance the one-hand test (Z = −1.95; P = 0.065; r = 0.36). Therefore, the Tai-chi class buffered from deteriorations in movement coordination but effects were not sustained at maintenance (T3).",23084:23543, 3524789 ,23304224,Unavailable
 3524789 ,Negative Symptoms,Tai-chi program and standard residential care,standard residential care,No significant difference,Between group comparison also failed to reach significance.,23724:23783, 3524789 ,23304224,Unavailable
 5569261 ,pain at the injection site,80 mg of intramuscular Depo-Medrone,40 mg of intralesional Depo-Medrone,No significant difference,Statistical significance was not reached at 24 hours (p=0.031) nor at 48 hours (p=0.113) (table 5).,31898:32036, 5569261 ,28879024,Unavailable
 116601 ,global CBF 30-minutes post-acetazolamide,enzyme replacement therapy (ERT),controls,Significantly decreased,A significant reduction (p = 0.036) in the global CBF was found 30-minutes post-acetazolamide in the ERT group compared to the placebo group.,23036:23178, 116601 ,12079501,Unavailable
 116601 ,CBF at the 20-minutes post-acetazolamide time point,enzyme replacement therapy (ERT),controls,No significant difference,"Following the enzyme replacement trial, no significant change in the global CBF was found at the 20-minutes post-acetazolamide time point in the ERT group compared to the placebo group",22761:22945, 116601 ,12079501,Unavailable
 3269572 ,The metastasis-to-liver SI ratio,1.6&nbsp;g CMC-001,0.1&nbsp;mmol/kg gadobenate dimeglumine,Significantly increased,"The metastasis-to-liver SI ratio was significantly higher after CMC-001 than after gadobenate dimeglumine (0.51 and 0.21 respectively, P &lt; 0.0001).",4021:4185, 3269572 ,21953376,Unavailable
 3269572 ,"clinical laboratory changes, vital signs, ECG or at physical examination",1.6g CMC-001,0.1mmol/kg gadobenate dimeglumine,No significant difference,"There were no clinically significant changes in clinical laboratory changes, vital signs, ECG or at physical examination.",29054:29175, 3269572 ,21953376,Unavailable
 3738453 ,blood caffeine,decaffeinated,control,No significant difference,"When comparing between the first and second tests within groups, the control group showed no changes (P = 0.317), as in the decaffeinated group (P = 0.066),",20193:20383, 3738453 ,23946663,Unavailable
 3738453 ,blood caffeine,caffeine,"control, decaffeinated ",Significantly increased,"When comparing between the first and second tests within groups, the control group showed no changes (P = 0.317), as in the decaffeinated group (P = 0.066),",NaN:NaN, 3738453 ,23946663,Unavailable
 5066795 ,minimal disease activity (MDA) response rates,golimumab 50/100 mg,placebo,Significantly increased,"Treatment with golimumab yielded significantly higher MDA response rates versus patients randomized to placebo at week 14 (23.5% versus 1.0%; P &lt; 0.0001), week 24 (28.1% versus 7.7%; P &lt; 0.0001), and week 52 (42.4% versus 30.2%; P = 0.037).",10904:11201, 5066795 ,25779603,Unavailable
 5808926 ,History of a wheeze,amoxicillin and benzyl penicillin,routine care,Significantly increased,"History of a wheeze was more common among trial participants (35.4% vs. 11.2%; P&nbsp;&lt;&nbsp;0.01), while dehydration was more common among nontrial participants (8.6% vs. 5.9%; P&nbsp;=&nbsp;0.05).",4670:4885, 5808926 ,29097339,Unavailable
 5808926 ,dehydration,amoxicillin and benzyl penicillin,routine care,Significantly decreased,"History of a wheeze was more common among trial participants (35.4% vs. 11.2%; P&nbsp;&lt;&nbsp;0.01), while dehydration was more common among nontrial participants (8.6% vs. 5.9%; P&nbsp;=&nbsp;0.05).",4670:4885, 5808926 ,29097339,Unavailable
 5769198 ,Mental health scores,yoga-based lifestyle program (YLSP),control group (CLSP) continued conventional cardiac rehabilitation only,No significant difference,"There was nonsignificant change in YLSP group (3.20%, P = 0.203) and in CLSP group (−2.09%, P = 0.640) after 5 years.",20131:20282, 5769198 ,29343930,Unavailable
 5769198 ,social interaction scores,yoga-based lifestyle program (YLSP),control group (CLSP) continued conventional cardiac rehabilitation only,No significant difference,"There were nonsignificant improvement in YLSP group (−2.12%, P = 0.601) and significant improvement in CLSP group (−7.4%, P = 0.098) after 5 years.",20498:20680, 5769198 ,29343930,Unavailable
 5769198 ,Environmental health scores,yoga-based lifestyle program (YLSP),control group (CLSP) continued conventional cardiac rehabilitation only,No significant difference,Environmental health scores showed the nonsignificant change between groups after 5 years (P = 0.240).,20752:20872, 5769198 ,29343930,Unavailable
 5769198 ,Perceived stress scores,yoga-based lifestyle program (YLSP),control group (CLSP) continued conventional cardiac rehabilitation only,Significantly decreased,Perceived stress scores were significantly reduced in the YLSP group as compared to CLSP group at the end of 5 years (P = 0.011).,21119:21266, 5769198 ,29343930,Unavailable
 5769198 ,Hospital anxiety and depression scale,yoga-based lifestyle program (YLSP),control group (CLSP) continued conventional cardiac rehabilitation only,No significant difference,No significant between-group differences were observed for either HADS-A or HADS-D score at the end of 5 years.,22609:22721, 5769198 ,29343930,Unavailable
 3685774 ," high sensitive CRP (hs-CRP), fibrinogen and IL-6 levels at week 8",250 mg magnesium as magnesium oxide,placebo,No significant difference,"However hs-CRP, fibrinogen and IL-6 levels at week 8 or any changes during the study were not statistically different between the two groups.",5269:5329, 3685774 ,23798918,Unavailable
 3685774 ,Serum magnesium,250 mg magnesium as magnesium oxide,placebo,No significant difference,Serum magnesium showed no significant changes in any groups.,5269:5329, 3685774 ,23798918,Unavailable
 5633094 ,maximal inspiratory pressure (MIP),intermittent nebulization program (INP),electronic inspiratory muscle training (EIMT),Significantly decreased,"In the EIMT group, maximal inspiratory pressure (MIP) after training was significantly higher than that before (P = 0.017),",5936:6045, 5633094 ,29038671,Unavailable
 5633094 ,total weaning time,intermittent nebulization program (INP),electronic inspiratory muscle training (EIMT),Significantly decreased,"there were no hemodynamic changes, and the total weaning time was shorter than in the INP group (P = 0.0192).",5936:6045, 5633094 ,29038671,Unavailable
 5842470 ,body temperature,oral isotonic solution (OIS),plain water,No significant difference,The differences in body temperature between groups were not significant (P = 0.218).,13057:13158, 5842470 ,29531435,Unavailable
 5842470 ,mean arterial pressure (MAP) values,oral isotonic solution (OIS),plain water,No significant difference,There were no significant differences in MAP values between groups (P = 0.711),14809:14963, 5842470 ,29531435,Unavailable
 5842470 ,"sodium , potassium",oral isotonic solution (OIS),plain water,No significant difference,Differences in the blood electrolytes were not significant between groups (sodium P = 0.707; potassium P = 0.581).,15142:15290, 5842470 ,29531435,Unavailable
 5842470 ,hematocrit level,oral isotonic solution (OIS),plain water,No significant difference,There were no significant differences in the hematocrit level between groups (P = 0.60) [Figure 1c].,14809:14963, 5842470 ,29531435,Unavailable
 3558644 ,The overall incidence of withdrawal movements,rocuronium with lidocaine; rocuronium with ketorolac; rocuronium with lidocaine &amp; ketorolac;,placebo,Significantly decreased,"The overall incidence of withdrawal movements after rocuronium was 34.3% with lidocaine (P = 0.001), 40% with ketorolac (P = 0.004), and 8.6% with both (P &lt; 0.001), compared with 74.3% with placebo.",4691:4890, 3558644 ,23372882,Unavailable
 3558644 ,The overall incidence of withdrawal movements, rocuronium with lidocaine ; ketorolac;,rocuronium with lidocaine; rocuronium with ketorolac;,Significantly decreased,"There was a significantly lower incidence of withdrawal movements in patients receiving the lidocaine/ketorolac combination than in those receiving lidocaine or ketorolac alone (P = 0.009 and 0.002, respectively).",4890:5103, 3558644 ,23372882,Unavailable
 3558644 ,The overall incidence of withdrawal movements, rocuronium with ketorolac;,rocuronium with lidocaine;,No significant difference,There was no significant difference in withdrawal movement between the lidocaine group and the ketorolac group.,5295:5406, 3558644 ,23372882,Unavailable
 3935224 ,(Neurobehavioral Cognitive Status Examination) and MMSE (Mini-Mental State Examination),Cognitive stimulation therapy (CST),control,Significantly increased,There were significant improvements in cognition [COGNISTAT (Neurobehavioral Cognitive Status Examination) and MMSE (Mini-Mental State Examination)] for the treatment group compared with the control group (p &lt; 0.01).,5565:5798, 3935224 ,23550665,Unavailable
 3935224 ,the self-administered health index of EQ-5D,Cognitive stimulation therapy (CST),control,Significantly increased,"Regarding QOL, the EQ-5D was significant (p = 0.019)",5798:5872, 3935224 ,23550665,Unavailable
 3935224 ,QoL-AD (Quality of Life – Alzheimer's Disease),Cognitive stimulation therapy (CST),control,No significant difference,the QoL-AD (Quality of Life – Alzheimer's Disease) showed a positive trend (p = 0.06),5875:5979, 3935224 ,23550665,Unavailable
 3935224 ,scale for mood,Cognitive stimulation therapy (CST),control,Significantly increased,"Using a nonparametrical analysis, there were significant improvements in the face scale for mood when rated by both the participants (p &lt; 0.01) and the care workers (p = 0.017).",6063:6277, 3935224 ,23550665,Unavailable
 5457616 ,HDL-C,"symbiotic group (SG) consumed 500&nbsp;mg/d of symbiotic supplementations containing probiotics (Lactobacillus family, Bifidobacterium family, Streptococus thermophilus), Prebiotics (Fructo oligosaccharide) and B group vitamins (1&nbsp;mg), lactose (0.5&nbsp;mg), malt-dextrin, magnesium saturate","placebo group (PG) consumed capsules filled with row starch and also B group vitamins (1&nbsp;mg), lactose (0.5&nbsp;mg), malt-dextrin, magnesium saturate",No significant difference,"HDL-C was increased in the SG compared with the PG (P = 0.586 and P = 0.287), but wasn’t statistically significantly.Table 4",31802:31989, 5457616 ,28589103,Unavailable
 5457616 ,BMI,"symbiotic group (SG) consumed 500mg/d of symbiotic supplementations containing probiotics (Lactobacillus family, Bifidobacterium family, Streptococus thermophilus), Prebiotics (Fructo oligosaccharide) and B group vitamins (1mg), lactose (0.5mg), malt-dextrin, magnesium saturate","placebo group (PG) consumed capsules filled with row starch and also B group vitamins (1mg), lactose (0.5mg), malt-dextrin, magnesium saturate",No significant difference,"BMI had significant differences at the end of study in PG and SG statistically (P = 0.012 and P = 0.054, respectively).",30900:31165, 5457616 ,28589103,Unavailable
 5457616 ,difference in energy and other nutrient intakes,"symbiotic group (SG) consumed 500mg/d of symbiotic supplementations containing probiotics (Lactobacillus family, Bifidobacterium family, Streptococus thermophilus), Prebiotics (Fructo oligosaccharide) and B group vitamins (1mg), lactose (0.5mg), malt-dextrin, magnesium saturate","placebo group (PG) consumed capsules filled with row starch and also B group vitamins (1mg), lactose (0.5mg), malt-dextrin, magnesium saturate",No significant difference,No significant difference in energy and other nutrient intakes was observed between the two groups at the beginning and the end of the study (P &gt; 0.05).Table 3,NaN:NaN, 5457616 ,28589103,Unavailable
 5457616 ,"Urea, Creatinine, Triglyceride, Cholesterol total, HDL-C and LDL-C","symbiotic group (SG) consumed 500mg/d of symbiotic supplementations containing probiotics (Lactobacillus family, Bifidobacterium family, Streptococus thermophilus), Prebiotics (Fructo oligosaccharide) and B group vitamins (1mg), lactose (0.5mg), malt-dextrin, magnesium saturate","placebo group (PG) consumed capsules filled with row starch and also B group vitamins (1mg), lactose (0.5mg), malt-dextrin, magnesium saturate",No significant difference,"According to Table&nbsp;4, there was no statistically significant difference in Urea, Creatinine, Triglyceride, Cholesterol total, HDL-C and LDL-C between or within the groups at the end of the study (P &gt; 0.05).",30900:31165, 5457616 ,28589103,Unavailable
 4788673 ,test D and test E,Group 3 had access to both pre- and post-course e-learning (sandwich e-learning) activities;," group 4 listened classroom presentations only (classroom teaching only).  Group 1 had access to pre-course e-learning, but not to post-course e-learning. Instead of a pre-course e-learning, group 2 listened to presentations at the day of the course (classroom teaching) and had access to the post-course learning activity using Facebook.",No significant difference,"When comparing group 3 (sandwich e-learning) with the other groups (post-course learning alone, pre-course learning only, and classroom-based), no significant differences were found both in test D and test E (p&nbsp;=&nbsp;0.3; p&nbsp;=&nbsp;0.5) (Fig.&nbsp;3).",21209:21518, 4788673 ,26968408,Unavailable
 4788673 ,test A,"Group 3 had access to both pre- and post-course e-learning (sandwich e-learning) activities; Group 1 had access to pre-course e-learning, but not to post-course e-learning. Instead of a pre-course e-learning,", group 4 listened classroom presentations only (classroom teaching only).   group 2 listened to presentations at the day of the course (classroom teaching) and had access to the post-course learning activity using Facebook.,Significantly increased,Groups 1 and 3 performed significantly better in test A compared to groups 2 and 4 (p&nbsp;&lt;&nbsp;0.05).,21519:21631, 4788673 ,26968408,Unavailable
 4788673 ,tests B and C,"Group 3 had access to both pre- and post-course e-learning (sandwich e-learning) activities; Group 1 had access to pre-course e-learning, but not to post-course e-learning. Instead of a pre-course e-learning,", group 4 listened classroom presentations only (classroom teaching only).   group 2 listened to presentations at the day of the course (classroom teaching) and had access to the post-course learning activity using Facebook.,No significant difference,"Results of tests B and C did not show any significant difference. The results and a detailed discussion of tests A, B, and C have previously been published elsewhere [14].Fig.&nbsp;3",21630:21873, 4788673 ,26968408,Unavailable
 3772299 ,high on-treatment platelet reactivity (HOPR),genotype directed treatment, phenotype directed treatment,No significant difference,Five subjects (16.2%) in the genotype-directed group and one (3.3%) in the phenotype-directed group had HOPR at day 30 (p=0.086).,6737:6866, 3772299 ,24044013,Unavailable
 4809387 ,Average time to death,"Sugammadex (S), Sugammadex plus 20% lipid emulsion (SL), 20% lipid emulsion (L)",control (C),Significantly increased,Time to death was significantly longer in other groups than in the control group (p&lt;0.05).,8279:8369, 4809387 ,27012816,Unavailable
 4169371 ,Initial cure,amphotericin B (AmB) liposomal formulation (LAmB), amphotericin B (AmB) lipid emulsion (ABLE),Significantly increased,"Initial cure was achieved by 95.9% of patients in the ABLE group compared to 100% in the LAmB group (p = 0.028; 95% CI: −0.0663, −0.0150).",7917:8056, 4169371 ,25233346,Unavailable
 4169371 ,Clinical improvement,amphotericin B (AmB) liposomal formulation (LAmB), amphotericin B (AmB) lipid emulsion (ABLE),No significant difference,"Overall, clinical improvement was 98.9% in ABLE group compared to 98.4% in LAmB group (p = 0.6414; 95% CI: −0.0248, 0.0359) (Table 2).",34951:35139, 4169371 ,25233346,Unavailable
 4169371 ,Definitive cure,amphotericin B (AmB) liposomal formulation (LAmB), amphotericin B (AmB) lipid emulsion (ABLE),Significantly increased,Definitive cure was achieved in 85.9% with ABLE compared to 98.4% with LAmB.,8142:8218, 4169371 ,25233346,Unavailable
 3598394 ,quality of life after 20 months,usual school health services  with dance twice weekly during eight months,usual school health services alone,Significantly increased,"After 20 months, the participants in the intervention group had increased their QOL by 0.08 units more than those in the control group (P = .04) (Table  4).",26511:26724, 3598394 ,23425608,Unavailable
 5313491 ,The ICU length of stay,intraoperative goal-directed fluid restriction (GDFR) strategy,usual care,Significantly decreased,"The ICU length of stay was significantly shorter in the GDFR group (3 days [1–5] vs. 6 days [3–11], p = 0.001) (Fig. 1).",23479:23655, 5313491 ,28211020,Unavailable
 5313491 ,lactate level,intraoperative goal-directed fluid restriction (GDFR) strategy,usual care,Significantly decreased,"At the end of the surgical procedure, lactates were lower in the GDFR group (1.79 ± 0.85 vs. 2.23 ± 1.36 mmol/l, p = 0.003).",23655:23798, 5313491 ,28211020,Unavailable
 5313491 ,Median hospital length of stay,intraoperative goal-directed fluid restriction (GDFR) strategy,usual care,No significant difference,"Median hospital length of stay was decreased by 2 days, but the difference did not reach statistical significance (Table 3)",24020:24184, 5313491 ,28211020,Unavailable
 5313491 ,"heart rate, mean arterial pressure, PETCO2, natremia, and urine output",intraoperative goal-directed fluid restriction (GDFR) strategy,usual care,No significant difference,"No differences were found in heart rate, mean arterial pressure, PETCO2, natremia, and urine output during the surgery between the two groups (Table 4).Fig. 1",24186:24429, 5313491 ,28211020,Unavailable
 5313491 ,The total number of complications,intraoperative goal-directed fluid restriction (GDFR) strategy,usual care,Significantly decreased,"The total number of complications (46 vs. 99, p = 0.043) and the proportion of patients who developed one or more complications (19.2 vs. 34.7%, p = 0.034) were smaller in the GDFR group.",5395:5617, 5313491 ,28211020,Unavailable
 1821024 ,number of patients that feel much better,receive a weekly 30-minute session of hydrotherapy for 6 weeks,similar exercises on land for 6 weeks,Significantly increased,"Significantly more patients treated with hydrotherapy (40/46, 87%) felt much better or very much better than the patients treated with land exercise (19/40, 47.5%), p &lt; 0.001 Fisher's exact test.",22298:22480, 1821024 ,17331241,Unavailable
 1821024 ,number of patient failed to complete treatment,receive a weekly 30-minute session of hydrotherapy for 6 weeks,similar exercises on land for 6 weeks,No significant difference,Eleven patients allocated land exercise failed to complete treatment compared with 4 patients allocated hydrotherapy (p = 0.09).,22298:22480, 1821024 ,17331241,Unavailable
 1821024 ,Ten-metre walk time,receive a weekly 30-minute session of hydrotherapy for 6 weeks,similar exercises on land for 6 weeks,No significant difference,"Ten-metre walk time improved after treatment and gains were maintained 3 months after treatment in both cases (median pre-treatment time for both groups combined 10.9 seconds(s), post treatment 9.1 s and at 3 months post treatment 9.6 s). There was no difference between treatment groups (p = 0.551).",22298:22480, 1821024 ,17331241,Unavailable
 1821024 ,"HAQ, EQ-5D utility score, EQ VAS and pain VAS",receive a weekly 30-minute session of hydrotherapy for 6 weeks,similar exercises on land for 6 weeks,No significant difference,"Similarly, there were no significant differences between groups in terms of changes to HAQ, EQ-5D utility score, EQ VAS and pain VAS (Table 2).",22298:22480, 1821024 ,17331241,Unavailable
 5490100 ,The Hamilton Anxiety Rating Scale (HAM-A) score after video clippings/images,video clippings/images of other previously operated patients and their hospital journey including surgery and anesthesia,treated in normal way and not shown any type of images/videos.,Significantly decreased,"After showing videos/images, the mean HAM-A score was 18 and 24 in Group I and II with statistically significant difference of P value (P &lt; 0.001) and t value.",17608:17831, 5490100 ,28663639,Unavailable
 5490100 ,mean The Hamilton Anxiety Rating Scale (HAM-A) score 1 hour before surgery ,video clippings/images of other previously operated patients and their hospital journey including surgery and anesthesia,treated in normal way and not shown any type of images/videos.,Significantly decreased,"One hour before surgery, mean HAM-A score in Group I was 20, and it was 28 in Group II again with a statistically significant difference (P &lt; 0.001 h) [Table 1].",17608:17831, 5490100 ,28663639,Unavailable
 3653866 ,adverse events,0.1 µg C-Tb (preserved with 0.5% phenol),standard 2 TU PPD RT 23 SSI dose,No significant difference,"Among 151 participants 48 (32%) experienced an adverse injection site reaction at the C-Tb injection site, versus 31 (21%) at the PPD injection site (p = 0.036).",39215:39377, 3653866 ,23691171,Unavailable
 3653866 ,specificity for 5 or 10 mm induration,0.1 µg C-Tb (preserved with 0.5% phenol),standard 2 TU PPD RT 23 SSI dose,Significantly increased,"Preliminary results indicate the cut-off of C-Tb to be 5 mm. However, any induration will correspond to a specificity of 97.3% (95% CI 93.2–99.3%) and 5 mm to a specificity of 99.3% (95% CI 96.3–100.0%; Figure 6B) for C-Tb. The specificity of PPD was 62.6% [95% CI 54.2–70.4%] using a cut-off of 5 mm, increasing to 76.9% [69.2–83.4%] and 91.8% [86.2–95.7%] using cut-offs of 10 and 15 mm respectively.",34744:35199, 3653866 ,23691171,Unavailable
 5781264 ,delivered a mean of protein ,supplemental  Parenteral nutrition (PN) strategy (intervention group),usual care enteral nutrition (EN) delivery,Significantly increased,"Those in the usual care group were delivered a mean 53 (29) g of protein daily compared to 86 (35) g of protein daily in the intervention group, p &lt; 0.0001.",34180:34357, 5781264 ,29361959,Unavailable
 5781264 ,the mean energy,supplemental  Parenteral nutrition (PN) strategy (intervention group),usual care enteral nutrition (EN) delivery,Significantly increased,"Including all energy sources for the duration of ICU stay increased the mean energy to 1331 (720) kcal and 1718 (468) kcal in the usual and intervention groups, respectively, p &lt; 0.0001.",35389:35596, 5781264 ,29361959,Unavailable
 5781264 ,"the duration of mechanical ventilation, ICU , hospital stay, mortality, witnessed complications of feeding, functional outcomes",supplemental  Parenteral nutrition (PN) strategy (intervention group),usual care enteral nutrition (EN) delivery,No significant difference,"There were no significant differences between the two groups in the duration of mechanical ventilation, ICU or hospital stay, mortality, witnessed complications of feeding or functional outcomes (Table&nbsp;3).Table 3",39601:39883, 5781264 ,29361959,Unavailable
 3691658 ,25-OH-D levels,800&nbsp;IU of vitamin D3 per day (low dose),"4,370&nbsp;IU per day (high dose)",Significantly increased,The high dose supplementation resulted in significantly higher serum 25-OH-D levels compared to low dose throughout the follow up (P &lt; 0.001).,23843:23985, 3691658 ,23767916,Unavailable
 3691658 ,parathyroid hormone (PTH),800 IU of vitamin D3 per day (low dose),"4,370 IU per day (high dose)",No significant difference,"PTH decreased in the high dose group, while it did not significantly change with low dose vitamin D (Table&nbsp;2).",25007:25156, 3691658 ,23767916,Unavailable
 3261693 ,Mean improvement in visual acuity (VA),0.59- or a 2.1-mg fluocinolone acetonide (FA) implant,standard-of-care local treatment,Significantly increased,Mean improvement in VA was significantly greater in implanted than non-implanted eyes at 1 (P = 0.0047) and 3 months (P = 0.0015) postoperatively;,4336:4518, 3261693 ,22275811,Unavailable
 3261693 ,anterior chamber cells,0.59- or a 2.1-mg fluocinolone acetonide (FA) implant,standard-of-care local treatment,Significantly decreased,significantly fewer anterior chamber cells were seen in implanted than non-implanted eyes at 1 (P = 0.0084) and 3 months (P = 0.0002),4518:4685, 3261693 ,22275811,Unavailable
 3261693 ,Severity of vitreous haze,0.59- or a 2.1-mg fluocinolone acetonide (FA) implant,standard-of-care local treatment,Significantly decreased,Severity of vitreous haze was less in implanted than non-implanted eyes at 3 months postoperatively (P = 0.0005).,4687:4817, 3261693 ,22275811,Unavailable
 3261693 ,The postsurgical uveitis recurrence rate,0.59- or a 2.1-mg fluocinolone acetonide (FA) implant,standard-of-care local treatment,Significantly decreased,The postsurgical uveitis recurrence rate was lower in implanted than non-implanted eyes (26.5% vs 44.4%; P = 0.0433).,4818:4953, 3261693 ,22275811,Unavailable
 3261693 ,Glaucoma,0.59- or a 2.1-mg fluocinolone acetonide (FA) implant,standard-of-care local treatment,Significantly increased,Glaucoma was reported in 19.7% of implanted eyes and no non-implanted eyes (P = 0.0008) postoperatively.,4953:5074, 3261693 ,22275811,Unavailable
 3257955 ,spirometry values (Forced expiratory volume during the first second (FEV1) or Forced Vital Capacity  (FVC)),HFCWO (SmartVest®) device,4 weeks in a conventional phase with a 2-week washout,No significant difference,"There was no significant change in spirometry values (FEV1 or FVC) with HFCWO baseline FEV1 1.05 (SD 0.37) versus postintervention FEV1 1.07 (SD 0.38) L or in the conventional phase (baseline FEV1 0.97 [SD 0.37]) versus postintervention (FEV1 1.01 [SD 0.36] L, P = not significant), as shown in Figure 2.",13285:13709, 3257955 ,22259246,Unavailable
 3257955 ,Sputum expectoration,HFCWO (SmartVest®) device,4 weeks in a conventional phase with a 2-week washout,No significant difference,"Sputum expectoration remained individually variable but showed a trend toward a reduction after HFCWO. In the HFCWO phase, the mean change in sputum volume was −2.6 mL (range −53 to +27 mL), and in the conventional phase the mean change was +6 mL (range −70 to +40 mL), P = 0.06.",13716:14012, 3257955 ,22259246,Unavailable
 5732479 ,Viral load,"Escherichia coli-derived lipopolysaccharide (LPS), 2 ng/kg",placebo,No significant difference,"Viral load gradually returned to baseline levels in the following weeks, with no differences between the LPS and placebo pretreatment groups.",39605:39746, 5732479 ,29312282,Unavailable
 5732479 ,seroconversion,"Escherichia coli-derived lipopolysaccharide (LPS), 2 ng/kg",placebo,No significant difference,"Likewise, the proportion of subjects that displayed seroconversion was similar between groups [10 out of 13 (77%) in the LPS–Fluenz group and all 13 subjects in the placebo–Fluenz group, p = 0.22].",39948:40163, 5732479 ,29312282,Unavailable
 5732479 ,"total leukocyte counts, numbers of mononuclear cells , neutrophils in nasal wash","Escherichia coli-derived lipopolysaccharide (LPS), 2 ng/kg",placebo,No significant difference,"Neither total leukocyte counts nor numbers of mononuclear cells and neutrophils in nasal wash were affected by Fluenz vaccination, and no differences between groups were observed (Figure 11).",47721:47950, 5732479 ,29312282,Unavailable
 5722253 ,dL and db values in Porcelain samples,Oral Essentials® Whitening Strips,Crest® 3D White Whitestrips™,No significant difference,"Moreover, no significant differences in dL and db values after use of either strip were determined (two way ANOVA P&gt;0.05.)",18714:18956, 5722253 ,29226023,Unavailable
 5722253 ,post-whitening roughness in the composite samples,Oral Essentials® Whitening Strips,Crest® 3D White Whitestrips™,No significant difference,"Significantly increased post-whitening roughness was documented in the composite samples exposed to the control bleaching strips (ANOVA, P&gt;0.05).",18714:18956, 5722253 ,29226023,Unavailable
 5722253 ,bleaching effects in Composite Samples,Oral Essentials® Whitening Strips,Crest® 3D White Whitestrips™,No significant difference,"There was no difference in bleaching effects between the control and the test treatment at any time point [two way ANOVA followed by Bonferroni post-test P&gt;0.05], thus the 2 treatments showed equivalency between each other at all-time points.",18714:18956, 5722253 ,29226023,Unavailable
 5781293 ,"In the intention-to-treat analysis, mean ΔCMS score",intraoperative BES applied to the spinal accessory nerve (SAN) ,no stimulation (NS),Significantly increased,Mann-Whitney U-test demonstrated a significantly higher CMS score in the BES group at 12 months indicating significantly better preservation of shoulder function compared to the NS group (p = 0.007) (Fig. 3).,30468:30872, 5781293 ,29361981,Unavailable
 5781293 ,number of patients with clinically relevant shoulder dysfunction after treatment,intraoperative BES applied to the spinal accessory nerve (SAN) ,no stimulation (NS),Significantly decreased,Six (BES) and 17 (NS) patients demonstrated a decline in CMS score greater than the MICD. This difference indicates clinically relevant shoulder dysfunction in significantly fewer patients in the BES group (p = 0.023) (Fig. 4).,30013:30297, 5781293 ,29361981,Unavailable
 5781293 ,NDII scores and CMAP amplitudes,intraoperative BES applied to the spinal accessory nerve (SAN) ,no stimulation (NS),No significant difference,"However, NDII scores (p = 0.089) and CMAP amplitudes (p = 0.067) between the groups did not reach statistical significance at 12 months.",9098:9269, 5781293 ,29361981,Unavailable
 5781293 , ΔCMS and ΔCMAP scores in patients with Level IIb + V neck dissections ,intraoperative BES applied to the spinal accessory nerve (SAN) ,no stimulation (NS),Significantly increased,"A subgroup analysis of ΔCMS, ΔNDII, and ΔCMAP results was undertaken in patients with Level IIb + V neck dissection (Table 3). The mean ΔCMS and ΔCMAP results were significantly higher in the BES group at 12 months (p = 0.048 and p = 0.025, respectively).",33307:33638, 5781293 ,29361981,Unavailable
 3751553 ,bedtime and wake-up time,during the second week of Ramadan while fasting (Ramadan)  ,4 weeks before Ramadan while performing the Islamic fasting for 1 week (baseline fasting) (BLF) or 1 week before Ramadan (non-fasting baseline) (BL),Significantly increased,"However, bedtime and wake-up time were significantly delayed during Ramadan (p &lt; 0.05), reflecting the delay in the start of work.",31363:31431, 3751553 ,23937904,Unavailable
 3751553 ,Serum glucose,4 weeks before Ramadan while performing the Islamic fasting for 1 week (baseline fasting) (BLF) or 1 week before Ramadan (non-fasting baseline) (BL),during the second week of Ramadan while fasting (Ramadan),No significant difference,"Serum glucose measurements at 15:30 h revealed no differences between BL, BLF and Ramadan: 6.2 ± 0.4, 5.6 ± 0.5 and 5.7 ± 0.5 mmol/L, respectively.",24490:24637, 3751553 ,23937904,Unavailable
 3751553 ,REM sleep percentages,4 weeks before Ramadan while performing the Islamic fasting for 1 week (baseline fasting) (BLF) or during the second week of Ramadan while fasting (Ramadan),1 week before Ramadan (non-fasting baseline) (BL) ,Significantly decreased,"However, REM sleep percentages were significantly lower at BLF (17.7 ± 8.1%) and Ramadan (18.6 ± 10.7%) (compared with BL (25.6 ± 4.8%) (p &lt; 0.05).",27806:27971, 3751553 ,23937904,Unavailable
 3751553 ,Johns drowsiness sale scores and blink total durations,4 weeks before Ramadan while performing the Islamic fasting for 1 week (baseline fasting) (BLF) or 1 week before Ramadan (non-fasting baseline) (BL),during the second week of Ramadan while fasting (Ramadan),No significant difference,"There were no significant differences between JDS scores and blink total durations during the two tests periods in BL, BLF and Ramadan.",31227:31363, 3751553 ,23937904,Unavailable
 3751553 ,MRT: mean reaction time,4 weeks before Ramadan while performing the Islamic fasting for 1 week (baseline fasting) (BLF) or 1 week before Ramadan (non-fasting baseline) (BL),during the second week of Ramadan while fasting (Ramadan),No significant difference,"There was no significant increase in MRT during BL, BLF and Ramadan.",31363:31431, 3751553 ,23937904,Unavailable
 4601439 ,global aesthetic improvement scale for nasolabial folds,injection of growth factor concentrate (GFC),injection of platelet-rich plasma (PRP),Significantly increased,"Between both the groups, GFC showed highly significant improvement which was prominently visible within 1 month of injection than PRP (P &lt; 0.001).",22182:22349, 4601439 ,26538718,Unavailable
 3714019 ,number of patients received at least one RBC transfusion during chemotherapy,epoetin alfa,non–erythropoiesis-stimulating agent (ESA),Significantly decreased,"For the intent-to-treat population, more than twice as many subjects in the control group received at least one RBC transfusion during chemotherapy as compared with subjects in the epoetin alfa group (86 [28.1%] vs 41 [12.8%] subjects, respectively). The difference between groups was statistically significant (P &lt; .0001).",29628:29968, 3714019 ,23860204,Unavailable
 3714019 ,The 5-year relapse free survival rates,epoetin alfa,non–erythropoiesis-stimulating agent (ESA),No significant difference,"The 5-year relapse free survival rates were 71% (95% CI = 66% to 76%) and 72% (95% CI = 67% to 77%) for subjects in the control and epoetin alfa groups, respectively. The hazard ratio was 1.03 (95% CI = 0.77 to 1.37), and the difference between groups was not statistically significant (P = .86).",30804:31117, 3714019 ,23860204,Unavailable
 3714019 ,Overall Survival,epoetin alfa,non–erythropoiesis-stimulating agent (ESA),No significant difference,"The Kaplan–Meier estimates of overall survival for the intent-to-treat population are shown in Figure 5. The hazard ratio was 0.97 (95% CI = 0.67 to 1.41), and the difference between groups was not statistically significant (P = .89).",31600:31888, 3714019 ,23860204,Unavailable
 3714019 ,The median Hb level  from baseline to cycle 9 of chemotherapy,epoetin alfa,non–erythropoiesis-stimulating agent (ESA),Significantly increased,"The median baseline Hb level was somewhat lower in the epoetin alfa group (12.40g/dL; interquartile range [IQR] = 11.7–13.3g/dL) than the control group (12.80g/dL; IQR = 12.2–13.6g/dL) and decreased for both groups over the first three cycles of chemotherapy. However, there was no decline from baseline to cycle 9 in the epoetin alfa group (12.4g/dL at both cycle 1 and cycle 9). In contrast, the decline from baseline to cycle 9 for patients in the control group was 2.20g/dL (P &lt; .001).",28028:28534, 3714019 ,23860204,Unavailable
 3714284 ,"protection against HPV31, 51, 52, 56, 39, or 6/11",the HPV16/18 vaccine,hepatitis A vaccine,No significant difference,"There was no evidence of statistically significant protection against HPV31, 51, 52, 56, 39, or 6/11(Table 4).",58087:58252, 3714284 ,23873171,Unavailable
 3714284 ,protection against HPV 16/18,the HPV16/18 vaccine,hepatitis A vaccine,Significantly increased,The corresponding VE against prevalent cervical HPV16/18 infection for the same cohort of women at the same visit was 72·0% (95%CI = 63·0% to 79·1%) (p versus oral HPV VE = 0·04). The VE estimate against cervical HPV16 was similar to that against HPV18.,50603:50873, 3714284 ,23873171,Unavailable
 5858078 ,reduction in area of white spot lesions,a 12-week regimen of a cream containing casein phosphopeptide-amorphous calcium phosphate and fluoride (MI Paste Plus) or a 12-week regimen of a cream containing hydroxyapatite and fluoride (Remin Pro),control,Significantly increased,"All groups showed reduction in area of WSLs throughout the experiment, but the degree of reduction was significantly greater in Remin Pro and MI Paste Plus groups, as compared to the control group [P &lt; 0.05; Table 2].",25923:26264, 5858078 ,29576772,Unavailable
 5858078 ,mineral content of WSLs,a 12-week regimen of a cream containing casein phosphopeptide-amorphous calcium phosphate and fluoride (MI Paste Plus) or a 12-week regimen of a cream containing hydroxyapatite and fluoride (Remin Pro),control,Significantly increased,Pairwise comparison by Tukey test also revealed that both experimental groups exhibited significantly greater increase in mineral content of WSLs as compared to the control group [P &lt; 0.05; Table 3].,25664:25923, 5858078 ,29576772,Unavailable
 5858078 ,reduction in the color difference between sound and demineralized enamel,a 12-week regimen of a cream containing casein phosphopeptide-amorphous calcium phosphate and fluoride (MI Paste Plus) or a 12-week regimen of a cream containing hydroxyapatite and fluoride (Remin Pro),control,Significantly increased,"Comparison of the alteration in values between baseline and end of the experiment revealed that both experimental groups experienced significantly greater reduction in the color difference between sound and demineralized enamel, as compared to the control group [P &lt; 0.05; Table 4].",25923:26264, 5858078 ,29576772,Unavailable
 5858078 ,side effects,a 12-week regimen of a cream containing casein phosphopeptide-amorphous calcium phosphate and fluoride (MI Paste Plus) or a 12-week regimen of a cream containing hydroxyapatite and fluoride (Remin Pro),control,No significant difference,No side effect was observed throughout the experiment.,4845:4899, 5858078 ,29576772,Unavailable
 5986466 ,Insulin levels,behavioral therapy and mangosteen,behavioral therapy alone,Significantly decreased,"Insulin levels at 26 weeks decreased significantly in the treatment group compared to control (−53.2% vs. −15.2%, p = 0.004) (Figure 1A).",20218:20431, 5986466 ,29747432,Unavailable
 5986466 ,weight loss,behavioral therapy and mangosteen,behavioral therapy alone,No significant difference,"The mangosteen arm experienced a weight loss (−4.5 ± 6.2%, −4.07 ± 6.01 kg; p = 0.048) that the control failed to show (−1.42 ± 4.9%, −0.88 ± 4.51 kg; p = 0.420) (Figure 2A), but groupwise comparison was not significant.",21025:21337, 5986466 ,29747432,Unavailable
 5986466 ,HsCRP level,behavioral therapy and mangosteen,behavioral therapy alone,No significant difference,"HsCRP was significantly reduced in the mangosteen group, with a mean decrease of 0.41 ± 0.34 mg/L (p = 0.004, −35.7 ± 22.51%). However, comparison with the control group failed to show any significant group-wise difference (Figure 3A).",21839:22150, 5986466 ,29747432,Unavailable
 5986466 ,HDL cholesterol levels,behavioral therapy and mangosteen,behavioral therapy alone,No significant difference,"HDL cholesterol levels increased significantly in the mangosteen group, suggesting an antiatherogenic effect (p = 0.024). However, comparison with control was not statistically significant.",22503:22709, 5986466 ,29747432,Unavailable
 5986466 ,fibrinogen levels,behavioral therapy and mangosteen,behavioral therapy alone,No significant difference,"Similarly, fibrinogen levels had a trend decrease in the mangosteen group (−57 ± 93 mg/L, −9.9 ± 19.0%, p = 0.100) but failed to be significantly different when compared to control (Figure 3B).",22150:22418, 5986466 ,29747432,Unavailable
 3672778 ,mean estrogen-receptor (ER) expression,fulvestrant 500 mg on Day 1 plus anastrozole 1 mg/day for 14 to 21 days (F + A); fulvestrant plus anastrozole placebo (F),fulvestrant placebo plus anastrozole (A),Significantly increased,F and F + A led to greater reductions in ER versus A (both P = 0.0001),6553:6751, 3672778 ,23497452,Unavailable
 3672778 ,mean estrogen-receptor (ER) expression,fulvestrant 500 mg on Day 1 plus anastrozole 1 mg/day for 14 to 21 days (F + A); ,fulvestrant plus anastrozole placebo (F),No significant difference,F + A did not lead to additional reductions versus F.,6498:6552, 3672778 ,23497452,Unavailable
 3672778 ,progesterone-receptor (PgR) and Ki67 expression,fulvestrant 500 mg on Day 1 plus anastrozole 1 mg/day for 14 to 21 days (F + A);  fulvestrant placebo plus anastrozole (A),fulvestrant plus anastrozole placebo (F),No significant difference,"PgR and Ki67 expression were significantly reduced with all treatments (means were -34% to -45%, and -75% to -85%, respectively; all P = 0.0001), with no differences between groups.",6553:6751, 3672778 ,23497452,Unavailable
 3488187 ,median progression-free survival,erlotinib (150 mg per day), placebo,No significant difference,median progression-free survival was 2·8 months (95% CI 2·6–3·0) with erlotinib versus 2·6 months (2·4–2·9) with placebo (figure 2B).,21619:21792, 3488187 ,23078958,Unavailable
 3488187 ,rash,erlotinib (150 mg per day), placebo,Significantly increased,More patients assigned erlotinib had rash at any time and of any grade than did those assigned placebo (56% [188 of 334] vs 15% [46 of 313] p&lt;0·0001). 24% (79 of 334) of patients assigned erlotinib had a high-grade (C or D) rash versus 2% (five of 313) of those assigned to placebo (p&lt;0·0001).,22265:22575, 3488187 ,23078958,Unavailable
 3488187 ,diarrhoea of grade 3–4,erlotinib (150 mg per day), placebo,Significantly increased,. Significantly more patients assigned erlotinib had diarrhoea of grade 3–4 than did those assigned placebo (table 2). 21% (69 of 334) of patients assigned erlotinib had diarrhoea of grade 1–2 versus 8% (24 of 313) for placebo (p&lt;0·0001),22574:22858, 3488187 ,23078958,Unavailable
 3488187 ,"overall survival , progression-free survival (Among patients assigned erlotinib who developed rash)",erlotinib (150 mg per day), placebo,Significantly increased,"Among patients assigned erlotinib who developed rash (compared with all those assigned placebo), overall survival was significantly longer (HR 0·76, 95% CI 0·63–0·92, p=0·0058), as was progression-free survival (0·66, 0·54–0·80, p&lt;0·0001).",24850:25089, 3488187 ,23078958,Unavailable
 3093782 ,triglyceride (TG),"(b) intense intermittent exercise - INT-EX  , (c) moderate continuous exercise -CON-EX", no exercise (control),Significantly decreased,"Post-hoc analyses indicated that the mean TG concentrations at 2, 3 and 4 h after INT-EX and CON-EX were lower than in the control trial (p&lt;0.05).",19755:19902, 3093782 ,21655743,Unavailable
 3093782 ,very low-density lipoprotein (VLDL),"(b) intense intermittent exercise - INT-EX  , (c) moderate continuous exercise -CON-EX", no exercise (control),Significantly decreased,The VLDL AUC was significantly increased by 12.5% in the control trial when compared with INT-EX (p&lt;0.05) and tended to be increased by 11.4% in the control trial when compared with CON-EX (p = 0.06).,20506:20707, 3093782 ,21655743,Unavailable
 3691744 ,mean peak and trough forced expiratory volume in one second (FEV1) values,"AZD3199 (200, 400 or 800 μg o.d.)",placebo via Turbuhaler®,Significantly increased,"After 4 weeks of treatment, all doses of AZD3199 had increased mean peak and trough FEV1 values compared with placebo, but no clear dose–response was observed (Figure 2);",28619:28837, 3691744 ,23731768,Unavailable
 3691744 ,mean peak and trough forced expiratory volume in one second (FEV1) values,"AZD3199 (200, 400 μg o.d.)",AZD3199 ( 800 μg o.d.),No significant difference,"After 4 weeks of treatment, all doses of AZD3199 had increased mean peak and trough FEV1 values compared with placebo, but no clear dose–response was observed (Figure 2);",28619:28837, 3691744 ,23731768,Unavailable
 3691744 ,FEV1,"AZD3199 (200, 400 or 800 μg o.d.)",formoterol (9 μg b.i.d.),No significant difference,"On trough FEV1 there was a tendency towards increased bronchodilation for all doses of AZD3199 versus formoterol 9 μg twice-daily (79–93 ml increase), but no statistically significant differences were observed (p &gt; 0.05) (Table 2).",29796:30081, 3691744 ,23731768,Unavailable
 3691744 ,Forced vital capacity (FVC),"AZD3199 (200, 400 or 800 μg o.d.)",formoterol (9 μg b.i.d.),No significant difference,There was no statistically significant difference in peak FVC between AZD3199 once-daily and formoterol 9 μg twice-daily (Table 2).,41690:41860, 3691744 ,23731768,Unavailable
 3691744 ,Overall mean Clinical COPD Questionnaire [CCQ] scores,"AZD3199 (200, 400 or 800 μg o.d.), formoterol (9 μg b.i.d.)",placebo,Significantly decreased,"Overall mean CCQ scores (Table 3) were statistically significantly reduced in the AZD3199 800 μg and formoterol 9 μg twice-daily treatment groups, in comparison with placebo (p = 0.016 and 0.018 respectively).",41918:42166, 3691744 ,23731768,Unavailable
 5985578 ,TKR rates,three intra-articular injections of LMWF-5A,saline,No significant difference,"Overall, there were no differences in TKR rates by treatment arm (39% LMWF-5A vs. 38% saline, p = 0.92).",5249:5371, 5985578 ,None,Unavailable
 5985578 ,TKR rates in the severe osteoarthritis subset,three intra-articular injections of LMWF-5A,saline,No significant difference,"In the severe osteoarthritis subset (n = 16), treatment with LMWF-5A resulted in a lower incidence of TKR compared to saline vehicle arm (40% vs. 83%, p = 0.15).",5371:5566, 5985578 ,None,Unavailable
 5985578 ,TKR rates  in patients who responded to treatment,three intra-articular injections of LMWF-5A,saline,Significantly decreased,"TKR rates were significantly lower with LMWF-5A in patients who responded to treatment (14% with LMWF-5A, vs. 100% with saline, p = 0.03).",5567:5722, 5985578 ,None,Unavailable
 3782125 ,The self-reported quit rate at 6 months,behavioural counselling with free nicotine replacement therapy (NRT) for 2 weeks ,behavioural counselling with free nicotine replacement therapy (NRT) for 1 week,No significant difference,"Table 3 shows that, at 6-month followup, the self-reported 7-day point prevalence quit rate was similar in the A1 group (27.5%; 78/284) and the A2 group (27.3%; 76/278) (OR = 1.0, 95% CI: 0.7–1.4, P = 0.97).",22683:22855, 3782125 ,24089693,Unavailable
 3782125 ,The self-reported quit rate at 12 months,behavioural counselling with free nicotine replacement therapy (NRT) for 2 weeks, behavioural counselling with free nicotine replacement therapy (NRT) for 1 week,No significant difference,"The self-reported quit rate at 12 months was also almost similar in groups A1 (21.1%; 60/284) and A2 (21.2%; 59/278) (OR = 1.0, 95% CI: 0.7–1.5; P = 0.98).",22683:22855, 3782125 ,24089693,Unavailable
 3663731 ,mean non-core food (NCF) scores at 2-month,four telephone contacts and print materials,generic print materials only,Significantly decreased,"Main analysis revealed that mean NCF scores were significantly lower in the intervention compared to the control group at 2-month follow-up (z=-2.89, p&lt;0.01).",37716:37875, 3663731 ,23566360,Unavailable
 3663731 ,mean non-core food (NCF) scores at 6 months ,four telephone contacts and print materials,generic print materials only,No significant difference,6 month (n=343)	2.47±0.10	2.29±0.09	0.20,39781:40014, 3663731 ,23566360,Unavailable
 5801240 ,The incidences of genital mycotic infection (GMI),ertugliflozin 15 mg or 5 mg,glimepiride,Significantly increased,The incidences of AEs related to GMIs were significantly greater in patients of both genders receiving ertugliflozin 15 mg or 5 mg (2.1–10.0%) than those receiving glimepiride (0–1.4%; Table 3).,43439:43675, 5801240 ,29282633,Unavailable
 5801240 ,The incidence of  symptomatic hypoglycemia,ertugliflozin 15 mg or 5 mg,glimepiride,Significantly decreased,"The incidence of symptomatic hypoglycemia was lower in the ertugliflozin groups compared with the glimepiride group (Table 3). Severe hypoglycemia was reported in 1 (0.2%), 1 (0.2%), and 10 (2.3%) patients in the ertugliflozin 15 mg, ertugliflozin 5 mg, and glimepiride groups, respectively.",42479:42811, 5801240 ,29282633,Unavailable
 5801240 ,HbA1c decrease &gt; 5.5 mmol/mol (0.5%) at week 52,ertugliflozin 15 mg or 5 mg,glimepiride,No significant difference,"At week 52, 38.0%, 34.4%, and 43.5% of patients in the ertugliflozin 15 mg, ertugliflozin 5 mg, and glimepiride groups, respectively, had an HbA1c &lt; 53 mmol/mol (7.0%) (Table 2).Table 2",29038:29296, 5801240 ,29282633,Unavailable
 5801240 ,body weight,ertugliflozin 15 mg or 5 mg,glimepiride,Significantly decreased,"Greater reductions from baseline in body weight were observed at week 52 in the ertugliflozin groups compared with glimepiride (Fig. 2b). The LS mean changes (95% CI) in body weight from baseline at week 52 were − 3.4 kg (− 3.7, − 3.0), − 3.0 kg (− 3.3, − 2.6), and 0.9 kg (0.6, 1.3) in the ertugliflozin 15 mg, ertugliflozin 5 mg, and glimepiride groups, respectively (Fig. 2b)",34269:34725, 5801240 ,29282633,Unavailable
 5801240 ,Blood pressure (systolic and diastolic),ertugliflozin 15 mg or 5 mg,glimepiride,Significantly decreased,"Relative to glimepiride, greater reductions from baseline in SBP were observed in the ertugliflozin groups at week 52 (Fig. 2c). LS mean changes from baseline at week 52 were − 3.8 mmHg (− 4.9, − 2.7), − 2.2 mmHg (− 3.4, − 1.1) and 1.0 mmHg (− 0.1, 2.1) in the ertugliflozin 15 mg, ertugliflozin 5 mg, and glimepiride groups, respectively. The LS mean differences (95% CI) versus glimepiride at week 52 were − 4.8 mmHg (− 6.3, − 3.2) and − 3.2 mmHg (− 4.7, − 1.7) for ertugliflozin 15 mg and 5 mg, respectively (p &lt; 0.001 vs. glimepiride). Reductions from baseline in DBP were also observed in the ertugliflozin groups compared with the glimepiride group (p &lt; 0.05; Table 2; Fig. 2e).",34960:35803, 5801240 ,29282633,Unavailable
 3661822 ,GI symptoms,metformin plus rosiglitazone (M + R) ,metformin (M) or metformin plus lifestyle program (M + L),Significantly decreased,"Before PO, fewer participants reported GI symptoms in the M + R group (33 vs. 41% in the M group and 45% in the M + L group; P = 0.0054).",15015:15170, 3661822 ,23704676,Unavailable
 3661822 ,number of patients experienced anemia,metformin plus rosiglitazone (M + R)  ,metformin (M)  ,Significantly decreased,"after PO more participants in the M group experienced anemia than in the M + R group (19 and 10%, respectively; P = 0.014).",22927:23116, 3661822 ,23704676,Unavailable
 3661822 ,weight gain,metformin plus rosiglitazone (M + R) ,metformin (M) or metformin plus lifestyle program (M + L),No significant difference,Excessive weight gain occurred in 6.9% before PO and 8.8% after PO. There was no statistically significant difference among treatment groups for our defined AE of excessive weight gain.,16091:16276, 3661822 ,23704676,Unavailable
 3661822 ,transaminase level, metformin plus rosiglitazone (M + R) , metformin (M) or metformin plus lifestyle program (M + L),Significantly decreased,"djustment because of transaminase elevation was significantly different among treatment groups (28 in the M group, 8 in the M + R group, 19 in the M + L group; P = 0.005).",22927:23116, 3661822 ,23704676,Unavailable
 3510731 ,Clicked on Results link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,Significantly decreased,Clicked on Results link 		247 (4.1%)a 	515 (8.7%)a,19446:19632, 3510731 ,23160103,Unavailable
 3510731 ,Clicked on Protocol link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,Significantly decreased,licked on Protocol link 		202 (3.3%)a 	362 (6.1%)a,19965:20151, 3510731 ,23160103,Unavailable
 3510731 ,Median time in seconds (interquartile range) - Results link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,No significant difference,Median time in seconds (interquartile range) 25.0 (37.2)b 25.3 (35.8)b,NaN:19895, 3510731 ,23160103,Unavailable
 3510731 ,Median time in seconds (interquartile range) - Protocol link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,No significant difference,Median time in seconds (interquartile range)	3.5 (5.4)c 	3.6 (3.9)c,NaN:20410, 3510731 ,23160103,Unavailable
 5818021 ,The mean percentage brain volume change (PBVC),cladribine tablets ,placebo,Significantly decreased,"The mean PBVC was assessed from months 6 to 24 to avoid confounding influence of pseudoatrophy in the first 6 months (see section “Materials and methods” and Figure 1(a)). This was significantly reduced in patients treated with cladribine tablets 3.5 mg/kg (−0.77% ± 0.94%, p = 0.02, n = 336) and 5.25 mg/kg (−0.77% ± 0.95%, p = 0.02, n = 351) compared with those treated with placebo (−0.95% ± 1.06%, n = 338; Figure 1(b)).",15893:16514, 5818021 ,28140753,Unavailable
 5818021 ,The risk of disability progression,cladribine tablets ,placebo,Significantly decreased,"The risk of disability progression was significantly lower in patients treated with cladribine tablets 3.5 mg/kg (hazard ratio (HR) = 0.63, 95% confidence interval (CI) = 0.438, 0.894; p = 0.010) and 5.25 mg/kg (HR = 0.58, 95% CI = 0.406, 0.833; p = 0.003) than in those treated with placebo.",17686:18012, 5818021 ,28140753,Unavailable
 4947120 ,MGHHS Massachusetts General Hospital Hair pulling Scale,six sessions of cognitive therapy (CT),six sessions of behaviour therapy (BT),No significant difference,MGHHS	CT (sd)BT (sd)	15.23 (4.36)15.36 (4.38)	9.69 (6.75)9.86 (6.56)	12.42 (6.25)14.52 (6.19)	1.220.99	0.550.16,32139:32500, 4947120 ,27471331,Unavailable
 4947120 ,SURF-urge,six sessions of cognitive therapy (CT),six sessions of behaviour therapy (BT),No significant difference,SURF-urge	CT (sd)BT (sd)	64.3 (29.2)61.6 (22.2)	48.4 (30.4)46.5 (30.6)	61.2 (32.1)68.3 (27.1)	0.570.56	0.11−0.26b,32531:32899, 4947120 ,27471331,Unavailable
 4947120 ,SURF-resistance,six sessions of cognitive therapy (CT),six sessions of behaviour therapy (BT),No significant difference,SURF-resistance	CT (sd)BT (sd)	59.8 (29.1)57.6 (28.2)	41.6 (30.6)39.1 (32.5)	48.0 (30.8)60.9 (30.1)	0.610.61	0.39−0.11b,32937:33311, 4947120 ,27471331,Unavailable
 4947120 ,SCCQ-rewarding,six sessions of cognitive therapy (CT),six sessions of behaviour therapy (BT),No significant difference,SCCQ-rewarding	CT (sd)BT (sd)	8.35 (5.12)7.95 (6.73)	4.23 (4.95)4.18 (6.12)	5.41 (6.08)5.33 (5.92)	1.120.91	0.660.74,33349:33715, 4947120 ,27471331,Unavailable
 4947120 ,SCCQ-impossible,six sessions of cognitive therapy (CT),six sessions of behaviour therapy (BT),No significant difference,SCCQ-impossible	CT (sd)BT (sd)	13.35 (4.97)12.95 (3.86)	8.88 (5.94)6.73 (5.55)	9.87 (5.61)10.33 (5.17)	1.011.50	0.930.78,33746:34116, 4947120 ,27471331,Unavailable
 3782125 ,patterns of NRT use between subjects,A1-  behavioural counselling with free free nicotine replacement therapy (NRT) for 1 week;,A2 - similar counselling with free NRT for 2 weeks,No significant difference,There was no significant difference in the patterns of NRT use between subjects in the A1 and A2 groups,22451:22683, 3782125 ,24089693,Unavailable
 3782125 ,7-day point prevalence quit rate,A1- behavioural counselling with free free nicotine replacement therapy (NRT) for 1 week;,A2 - similar counselling with free NRT for 2 weeks,No significant difference,"Table 3 shows that, at 6-month followup, the self-reported 7-day point prevalence quit rate was similar in the A1 group (27.5%; 78/284) and the A2 group (27.3%; 76/278) (OR = 1.0, 95% CI: 0.7–1.4, P = 0.97).",22451:22683, 3782125 ,24089693,Unavailable
 3782125 ,The biochemically validated quit rate at 6 months,A1- behavioural counselling with free free nicotine replacement therapy (NRT) for 1 week;,A2 - similar counselling with free NRT for 2 weeks,No significant difference,"The biochemically validated quit rate at 6 months was higher in group A2 (12.6%; 35/278) than in group A1 (7.7%; 22/284), but the difference was not statistically significant (OR = 1.7, 95% CI: 0.9–3.0).",22855:23059, 3782125 ,24089693,Unavailable
 5805511 ,Median plasma YKL-40 levels,bevacizumab,placebo plus radiotherapy/temozolomide,No significant difference,"Median plasma YKL-40 levels did not change greatly during treatment or follow up (Supplementary Figure 2, available online only) and no apparent difference was noted in temporal YKL-40 levels between the placebo and bevacizumab cohorts.",54471:54765, 5805511 ,29467925,Unavailable
 3483184 ,peak plantar pressure,DH Pressure Relief Shoe™,standard shoe,Significantly decreased,"A statistically significant difference in peak plantar pressure was found between shoes (F2-12 = 11.813, p = 0.001).",24083:24228, 3483184 ,23021860,Unavailable
 3711370 ,mean change (SD) from baseline in synovitis,abatacept (∼10 mg/kg),placebo,No significant difference,The primary endpoint was not achieved; mean change (SD) from baseline in synovitis was −0.44 (1.47) for abatacept versus 0.52 (1.38) for placebo (p=0.103) at Month 4.,7219:7386, 3711370 ,22915624,Unavailable
 3647148 ,"Haemoglobin, weight, and height","6-monthly vitamin A (retinol capsule of 200 000 IU retinyl acetate in oil, to be cut and dripped into the child's mouth every 6 months)","albendazole (400 mg tablet every 6 months), both, or neither (open control)",No significant difference,"Haemoglobin, weight, and height were not significantly affected.",21395:21459, 3647148 ,23498849,Unavailable
 3647148 ,Deaths per child-care centre at ages 1·0–6·0 years during the 5-year study (the primary trial endpoint),"6-monthly vitamin A (retinol capsule of 200 000 IU retinyl acetate in oil, to be cut and dripped into the child's mouth every 6 months)", neither (open control),No significant difference,"Deaths per child-care centre at ages 1·0–6·0 years during the 5-year study (the primary trial endpoint) were 3·01 retinol versus 3·15 control (absolute reduction 0·14 [SE 0·11], mortality rate ratio [RR] 0·96, 95% CI 0·89–1·03, p=0·22),",23907:24143, 3647148 ,23498849,Unavailable
 4497726 ,Verbal Memory and Reasoning,"Aerobic Exercise 75 min/wk, 150 min/wk, 225 min/wk  ",No physical exercise,No significant difference,"The Verbal Memory (ΔX2 = 29.8) and Reasoning (ΔX2 = 34.1) domains also improved from baseline; however, all groups including controls improved equivalently, indicating a practice effect.",46148:46356, 4497726 ,26158265,Unavailable
 4497726 ,VO2 peak (% change),Aerobic Exercise 150 min/wk or  225 min/wk  ,no physical exercise,Significantly increased,"VO2 peak (% change) -4.4 (7.1) 6.4 (6.7) 8.7 (7.4) 11.0 (8.9) F(3,76) = 15.8, p&lt;0.001",48998:49266, 4497726 ,26158265,Unavailable
 4497726 ,Adverse effects,Aerobic Exercise 150 min/wk or  225 min/wk  ,Aerobic Exercise 75 min/wk,Significantly increased,"Within the 3 exercising groups, AE were more common (X2[2] = 11.3, p = 0.003) in individuals exercising at 150min/wk (n = 40, 35 mild) and 225 min/wk (n = 36, 34 mild) than 75 min/wk (n = 15, 15 mild).",48998:49266, 4497726 ,26158265,Unavailable
 4497726 ,Visuospatial Processing,"Aerobic Exercise 75 min/wk, 150 min/wk, 225 min/wk  ",No physical exercise,Significantly increased,"Visuospatial Processing improved in a dose-response like function across the four doses of exercise, although the 75min/wk and 150min/wk groups were similar (ΔX2 = 18.0).",45966:46148, 4497726 ,26158265,Unavailable
 4497726 ,Simple Attention,"Aerobic Exercise 75 min/wk, 150 min/wk, 225 min/wk  ",No physical exercise,Significantly increased,Simple Attention improved in all exercise groups equivalently indicating an intervention effect (ΔX2 = 22.0).,45845:45966, 4497726 ,26158265,Unavailable
 5045682 ,efficacy on pain relieve,Amlexanox four times daily for 7 days.,Adcortyl four times daily for 7 days.,No significant difference,There were no significant differences between Adcortyl and Amlexanox in terms of their efficacy on pain relieve observed in the present study (Fig. 1).,11226:11417, 5045682 ,27703603,Unavailable
 5045682 ,efficacy on tingling relieve,Amlexanox four times daily for 7 days.,Adcortyl four times daily for 7 days.,No significant difference,"However, there were no significant differences between Adcortyl and Amlexanox in terms of their efficacy on tingling relieve observed in the present study (Fig. 2).",12385:12586, 5045682 ,27703603,Unavailable
 5045682 ,lesion size,Amlexanox four times daily for 7 days.,Adcortyl four times daily for 7 days.,No significant difference,". However, there were no significant differences between the two groups in terms of lesion size at 1st, 3d, 5th and 7th day follow-ups (Fig. 3 right).",13404:13594, 5045682 ,27703603,Unavailable
 5045682 ,reduction of ulcer size,Amlexanox four times daily for 7 days.,Adcortyl four times daily for 7 days.,No significant difference,There was no significant difference between the Amlexanox and Adcortyl groups for reduction of ulcer size (right).,14157:14271, 5045682 ,27703603,Unavailable
 5782437 ,Goodman and Baron’s qualitative scores,fractional CO2 laser (FCL) with platelet-rich plasma (PRP) ,fractional CO2 laser (FCL) ,No significant difference,"The final scores indicated no significant difference in the quality of scars between the right and the left sides of the face (P = 0.2891). Though there was a significant improvement on both sides of the face, the addition of PRP to FCL on the left side of the face did not result in superior scar improvement as compared to the right side of the face that was treated with FCL only [Table 2, Figures 9–11].",16988:17526, 5782437 ,29403184,Unavailable
 5782437 ,"The redness, swelling, and pain",fractional CO2 laser (FCL) with platelet-rich plasma (PRP) ,fractional CO2 laser (FCL) ,Significantly decreased,"The redness, swelling, and pain experienced by each patient were significantly lesser on the side treated with FCL + PRP (left side) than that on the FCL-only treated side (P &lt; 0.05) [Table 4].",19540:19792, 5782437 ,29403184,Unavailable
 5843437 ,"weight gain, weight for length Z score (WLZ) and weight for age Z score (WAZ) ","new supplementary blended flour (containing chickpea, rice, wheat and barley, named Shadameen) ",multivitamin / mineral supplement and nutritional counseling alone,Significantly increased,"The mean weight, WLZ and WAZ increments between baseline and end of intervention were significantly greater in the Shadameen group (0.81±0.29 gr) (p=0.002), (0.36±0.36) (p=0.003), (0.40±0.33) (p=0.001) compared with 0.55±0.33 gr, 0.02±0.52 and 0.09±0.37 in group 2.",22150:22309, 5843437 ,29560163,Unavailable
 5843437 ,the mean length and  length for weight Z score (LAZ) increments,"new supplementary blended flour (containing chickpea, rice, wheat and barley, named Shadameen)  ",multivitamin / mineral supplement and nutritional counseling alone,No significant difference,"Although the mean length and LAZ increments between baseline and end of intervention was greater in the Shadameen group (3.36±1.04 cm) (0.17±0.390) in comparison to group 2, this rate did not differ significantly (3.10±1.02 cm) (p=0.31), (0.10±0.39) (p=0.53).",22150:22309, 5843437 ,29560163,Unavailable
 5843437 ,The proportion of children who recovered,"new supplementary blended flour (containing chickpea, rice, wheat and barley, named Shadameen)  ",multivitamin / mineral supplement and nutritional counseling alone,Significantly increased,The proportion of children who recovered was significantly higher in the Shadameen group [26 n (68.4%)] compared with [12 n (31.6%)] the other group (p=0.001).,22150:22309, 5843437 ,29560163,Unavailable
 3661741 ,total peptide YY (PYY) concentrations,"continuous exercise condition ((EX) 1-h exercise) or intermittent exercise condition ((INT) 12 hourly, 5-minute bouts)","control condition (sedentary behavior-SED),",No significant difference,"Integrated area under the curve analysis for total PYY over the course of the day were comparable among the SED, EX, and INT conditions, and examination of the 2 h total PYY responses to each meal revealed no significant differences between conditions during any of these meal blocks (P&gt;0.05).",18613:18906, 3661741 ,23418154,Unavailable
 3661741 ,the VAS scores for hunger,"continuous exercise condition ((EX) 1-h exercise) or intermittent exercise condition ((INT) 12 hourly, 5-minute bouts)","control condition (sedentary behavior-SED),",No significant difference,"When the 12 h tAUC and iAUC for the VAS scores for hunger were compared, no significant differences were noted across conditions (tAUC: SED: 1705.4±315.8, EX: 1744.9±584.2, INT: 1490.617.8 mm*min for 12 h; iAUC SED: 1622.5±298.8, EX: 1669.2±573.2, INT: 1402.4±623.2 mm*min for 12 h).",19162:19445, 3661741 ,23418154,Unavailable
 3661741 ,hunger,"intermittent exercise condition ((INT) 12 hourly, 5-minute bouts)",control condition (sedentary behavior-SED) or continuous exercise condition ((EX) 1-h exercise),Significantly decreased,"Between 1500–1700 h, the hunger tAUC was lower in response to the INT compared to the SED and EX conditions (Figure 2b; SED: 286.1±24.2, EX: 294.3±33.9, INT: 221.7±39.2 mm*min for 2 h; P&lt;0.05).",19815:20049, 3661741 ,23418154,Unavailable
 3661741 ,satiety,"control condition (sedentary behavior-SED)  or intermittent exercise condition ((INT) 12 hourly, 5-minute bouts)",continuous exercise condition ((EX) 1-h exercise)  ,Significantly increased,"Between 1300–1500 h and 1500–1700 h, the 2 h tAUC for satiety was higher (P&lt;0.05) in the SED and INT conditions than the EX condition (Figure 3b; 1300: SED: 167.9±30.3, EX: 123.3±27.6, INT: 154.2±31; 1500: SED: 173.1±32.7, EX: 117.9±26.1, INT: 150.2±31.3 mm*min for 2 h; P&lt;0.05).",20745:21064, 3661741 ,23418154,Unavailable
 3661741 ,total peptide YY (PYY) concentrations,"continuous exercise condition ((EX) 1-h exercise) or intermittent exercise condition ((INT) 12 hourly, 5-minute bouts)","control condition (sedentary behavior-SED),",No significant difference,"Integrated area under the curve analysis for total PYY over the course of the day were comparable among the SED, EX, and INT conditions, and examination of the 2 h total PYY responses to each meal revealed no significant differences between conditions during any of these meal blocks (P&gt;0.05).",18613:18906, 3661741 ,23418154,Unavailable
 3661741 ,the VAS scores for hunger,"continuous exercise condition ((EX) 1-h exercise) or intermittent exercise condition ((INT) 12 hourly, 5-minute bouts)","control condition (sedentary behavior-SED),",No significant difference,"When the 12 h tAUC and iAUC for the VAS scores for hunger were compared, no significant differences were noted across conditions (tAUC: SED: 1705.4±315.8, EX: 1744.9±584.2, INT: 1490.617.8 mm*min for 12 h; iAUC SED: 1622.5±298.8, EX: 1669.2±573.2, INT: 1402.4±623.2 mm*min for 12 h).",19162:19445, 3661741 ,23418154,Unavailable
 3661741 ,hunger,"intermittent exercise condition ((INT) 12 hourly, 5-minute bouts)",control condition (sedentary behavior-SED) or continuous exercise condition ((EX) 1-h exercise),Significantly decreased,"Between 1500–1700 h, the hunger tAUC was lower in response to the INT compared to the SED and EX conditions (Figure 2b; SED: 286.1±24.2, EX: 294.3±33.9, INT: 221.7±39.2 mm*min for 2 h; P&lt;0.05).",19815:20049, 3661741 ,23418154,Unavailable
 3661741 ,satiety,"control condition (sedentary behavior-SED)  or intermittent exercise condition ((INT) 12 hourly, 5-minute bouts)",continuous exercise condition ((EX) 1-h exercise)  ,Significantly increased,"Between 1300–1500 h and 1500–1700 h, the 2 h tAUC for satiety was higher (P&lt;0.05) in the SED and INT conditions than the EX condition (Figure 3b; 1300: SED: 167.9±30.3, EX: 123.3±27.6, INT: 154.2±31; 1500: SED: 173.1±32.7, EX: 117.9±26.1, INT: 150.2±31.3 mm*min for 2 h; P&lt;0.05).",20745:21064, 3661741 ,23418154,Unavailable
 5838794 ,% Weight loss in treated participants at 3 months,6 months of free access to in‐person meetings and online tools,weight loss handout,Significantly decreased,"In contrast, treated participants in the WW condition lost more weight at 3 months than those in SG (−3.35 kg vs. −1.97 kg; F(1,125) = 4.96; P = 0.03),",33353:33538, 5838794 ,29388385,Unavailable
 5838794 ,% Weight loss in Untreated spouses,6 months of free access to in‐person meetings and online tools,weight loss handout,No significant difference,"Untreated spouses lost weight at 3 months (M = −1.30 kg; F(1,126)= 22.61; P &lt; 0.001) and 6 months (M = −2.02 kg; F(1,126) = 33.52; P &lt; 0.001), but there was no effect of treatment condition on untreated spouses' weight loss at either time point (Ps &gt; 0.59).",26891:27290, 5838794 ,29388385,Unavailable
 5838794 ,% Weight loss in treated participants at 6 months,6 months of free access to in‐person meetings and online tools,weight loss handout,No significant difference,"In contrast, treated participants in the WW condition lost more weight at 3 months than those in SG (−3.35 kg vs. −1.97 kg; F(1,125) = 4.96; P = 0.03), but there was no difference by condition at 6 months (P = 0.18).",33353:33620, 5838794 ,29388385,Unavailable
 5057363 ,Hypersensitivity reactions ,atacicept,placebo,Significantly increased,"Hypersensitivity reactions were more frequent in atacicept‐treated patients (9 [50.0%]) than in placebo‐treated patients (2 [22.2%]), and led to withdrawal in 2 atacicept‐treated patients.",38277:38466, 5057363 ,26137975,Unavailable
 5057363 ,"levels of IgG, IgM, and IgA",atacicept,placebo,Significantly decreased,"Treatment with atacicept was associated with greater median reductions from baseline to week 32 in the levels of IgG, IgM, and IgA (median change from baseline −31.2% [IQR −49.6, −24.1], −60.9% [IQR −71.88, −54.43]), and −56.4% [IQR −66.84, −45.49], respectively) compared to placebo (median change from baseline −4.4% [IQR −10.17, −1.32], −15.9% [IQR −22.92, −7.82], and −8.2% [IQR −19.69, −2.02], respectively) (Figure 3).",43954:44431, 5057363 ,26137975,Unavailable
 5057363 ,"the ACR20, ACR50, and ACR70 improvement response criteria",atacicept,placebo,No significant difference,"There were no noteworthy between‐group differences in clinical response to treatment over time, as defined by the ACR20, ACR50, and ACR70 improvement response criteria based on the CRP level (Figure 4).",45634:45889, 5057363 ,26137975,Unavailable
 3936115 ,The number of diverticulitis clinical symptom occurrences during 12months,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,Significantly decreased,"The number of diverticulitis clinical symptom occurrences during 12&nbsp;months of observation was 2 (6.67&nbsp;%) in the MSB group and was significantly lower (p = 0.0425) than the clinical symptoms of diverticulitis reported in the control group (7 occurrences, 31.8&nbsp;%).",17627:17907, 3936115 ,24343275,Unavailable
 3936115 ,the number of abdominal ultrasound examinations performed for suspected diverticulitis and subsequent number of diverticulitis diagnosed based on abdominal US,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,Significantly decreased,"In comparison to the placebo group, the number of abdominal ultrasound examinations performed for suspected diverticulitis and subsequent number of diverticulitis diagnosed based on abdominal US was significantly lower (1 vs 5, p = 0.0229).",17906:18165, 3936115 ,24343275,Unavailable
 3936115 ,Subjective improvement in observed symptoms based on a single closed-end question (yes or no answer): “Did you observe adequate relief of diverticulosis related to abdominal pain or discomfort within the past 12&nbsp;months?”,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,Significantly increased,"Subjective improvement in observed symptoms based on a single closed-end question (yes or no answer): “Did you observe adequate relief of diverticulosis related to abdominal pain or discomfort within the past 12&nbsp;months?” was reported to be higher in the treatment group (55.67 vs 22.73&nbsp;%, p = 0.0143).",18502:18820, 3936115 ,24343275,Unavailable
 4282697 ,The 2-year overall survival rate,chemo-immunotherapy (group A),chemotherapy (group B),Significantly increased,The differences were statistically significantly better in group A. The hazard ratio (HR) was 0.229 (p&nbsp;=&nbsp;0.0013).,4379:4509, 4282697 ,25262164,Unavailable
 4282697 ,The 2- and 5-year recurrence-free survival rate,chemo-immunotherapy (group A),chemotherapy (group B),Significantly increased,Those differences were also statistically significant (log-rank test p&nbsp;=&nbsp;0.0020). The HR was 0.423 (p&nbsp;=&nbsp;0.0027) in favor of group A.,4625:4792, 4282697 ,25262164,Unavailable
 4161888 ,Mortality rates,citrate,heparin,No significant difference,"Mortality rates at 28 and 90&nbsp;days did not differ between groups: 22/66 (33%) of citrate-treated patients died versus 25/72 (35%) of heparin-treated patients at 28&nbsp;days, and 27/65 (42%) of citrate-treated patients died versus 29/69 (42%) of heparin-treated patients at 90&nbsp;days (P = 1.00 for both).",6605:6903, 4161888 ,25128022,Unavailable
 4161888 ,independency of renal replacement therapy,citrate,heparin,No significant difference,"Renal outcome, i.e. independency of renal replacement therapy 28&nbsp;days after initiation of CVVH in surviving patients, did not differ between groups: 29/43 (67%) in the citrate-treated patients versus 33/47 (70%) in heparin-treated patients (P = 0.82).",6903:7154, 4161888 ,25128022,Unavailable
 4161888 ,discontinuation,citrate,heparin,Significantly decreased,Heparin was discontinued in 24/73 (33%) of patients whereas citrate was discontinued in 5/66 (8%) of patients (P &lt; 0.001).,7154:7277, 4161888 ,25128022,Unavailable
 4161888 ,survival times,citrate,heparin,Significantly increased,"Filter survival times were superior for citrate (median 46 versus 32&nbsp;hours, P = 0.02), as were the number of filters used (P = 0.002) and the off time within 72&nbsp;hours (P = 0.002).",7277:7511, 4161888 ,25128022,Unavailable
 4236431 ,hearing improvement,gelatin hydrogels impregnated with IGF-1 in the middle ear,four intratympanic injections with dexamethasone,No significant difference,"In the IGF-1 group, 66.7% (95% confidence interval [CI], 52.9–78.6%) of the patients showed hearing improvement compared to 53.6% (95% CI, 39.7–67.0%) of the patients in the Dex group (P = 0.109).",10084:10297, 4236431 ,25406953,Unavailable
 4236431 ,Tympanic membrane perforation,gelatin hydrogels impregnated with IGF-1 in the middle ear,four intratympanic injections with dexamethasone,Significantly decreased,"Tympanic membrane perforation did not persist in any patient in the IGF-1 group, but did persist in 15.5% (95% CI, 7.3–27.4%) of the patients in the Dex group (P = 0.001).",10527:10716, 4236431 ,25406953,Unavailable
 5723032 ,cerebrospinal fluid (CSF) levels,gantenerumab 105&nbsp;mg or 225,placebo,No significant difference,"No significant change in the levels of CSF Aβ42 over 2&nbsp;years of gantenerumab treatment compared with placebo were observed, even though a numerical increase was seen with gantenerumab 225&nbsp;mg at week 104 only.Table 3",41212:41467, 5723032 ,29221491,Unavailable
 65514 ,LDL-cholesterol,"The generic product tested was Eucor©, locally manufactured by Greater Pharma Ltd., Part, Thailand","reference product was Zocor© (Merck Sharp &amp; Dohme, USA)",No significant difference,no significant difference in blood LDL-cholesterol between the first (Eucor©-treated) and the second (Zocor©-treated) groups was observed.,4897:5057, 65514 ,11835697,Unavailable
 65514 ,all tested blood parameters,"The generic product tested was Eucor©, locally manufactured by Greater Pharma Ltd., Part, Thailand","reference product was Zocor© (Merck Sharp &amp;amp; Dohme, USA)",No significant difference,"there was also no statisticaly significant difference in the changes of all tested blood parameters between the two products (randomized block ANOVA, N = 37).",5096:5255, 65514 ,11835697,Unavailable
 5777645 ,HbA1c levels,to peer-led structured patient education,conventional care alone,Significantly decreased,"From baseline to 12 months, the decrease in HbA1c levels was 1.05% (SD = 2.0; CI95%: 1.54;-0.56) in the intervention group compared with 0.15% (SD = 1.7; CI95%: -0.56; 0.26) in the control group, p = 0.006.",13075:13282, 5777645 ,29357380,Unavailable
 5777645 ,Mean BMI change,to peer-led structured patient education,conventional care alone,Significantly decreased,"Mean BMI change was -1.65 kg/m2 (SD = 2.5; CI95%: -2.25; -1.06) in the intervention group and +0.05 kg/m2 (SD = 3.2; CI95%: -0.71; 0.81) in the control group, p = 0.0005.",13283:13454, 5777645 ,29357380,Unavailable
 5777645 ,Mean waist circumference,to peer-led structured patient education,conventional care alone,Significantly decreased,"Mean waist circumference decreased by 3.34 cm (SD = 9.3; CI95%: -5.56;-1.13) in the intervention group and increased by 2.65 cm (SD = 10.3; CI95%: 0.20; 5.09) in the control group, p = 0.0003.",13454:13646, 5777645 ,29357380,Unavailable
 3707772 ,"1,25-diOH-D3 - Vitamin D",protease inhibitor (PI),non-nucleosidic reverse transcriptase inhibitor (NNRTI),No significant difference,"In parallel, the active 1,25-diOH-D3 increased by 25% at 21&nbsp;months, significantly in the NNRTI group. However, the difference between groups of 1,25-diOH D3 increase at 21&nbsp;months was not significant (p = 0.54).",51021:51231, 3707772 ,23809140,Unavailable
 3636954 ,The mean change in alveolar crest level,hydroxyapatite granules Periobone-G,hydroxyapatite granules (control group),Significantly increased,The mean change in alveolar crest level between control and experimental groups was significant (P=0.02).,24418:24657, 3636954 ,23633782,Unavailable
 3636954 ,The mean percentage of original defect resolved,hydroxyapatite granules Periobone-G,hydroxyapatite granules (control group),No significant difference,The mean percentage of original defect resolved when compared between control and experimental groups 9 months postsurgery was not significant (P=0.19) [Figure 13].,24418:24657, 3636954 ,23633782,Unavailable
 4173586 ,patients desaturated,nasal prongs (NP),nasopharyngeal catheter (NC),Significantly increased,"In the Group NP, 32% of patients desaturated [Table 2] against none in Group NC (P = 0.001).",14098:14246, 4173586 ,25886106,Unavailable
 4173586 ,The grades of laryngoscopy,nasal prongs (NP),nasopharyngeal catheter (NC),No significant difference,The grades of laryngoscopy [Table 3] between the two groups are also comparable (P = 0.104).,14430:14579, 4173586 ,25886106,Unavailable
 5438446 ,St George’s Respiratory Questionnaire for COPD (SGRQ-C),EDGE‚ sElf-management anD support proGrammE),usual care,No significant difference,The estimated difference in SGRQ-C at 12 months (EDGE−usual care) was −1.7 with a 95% CI of −6.6 to 3.2 (P=.49).,9451:9581, 5438446 ,28468749,Unavailable
 5438446 ,The relative risk of hospital admission,EDGE‚ sElf-management anD support proGrammE),usual care,No significant difference,"The relative risk of hospital admission for EDGE was 0.83 (0.56-1.24, P=.37) compared with usual care.",9581:9701, 5438446 ,28468749,Unavailable
 5438446 ,Generic health status,EDGE‚ sElf-management anD support proGrammE),usual care,Significantly increased,"Generic health status (EQ-5D, EuroQol 5-Dimension Questionnaire) between the groups differed significantly with better health status for the EDGE group (0.076, 95% CI 0.008-0.14, P=.03).",9701:9904, 5438446 ,28468749,Unavailable
 5438446 ,The median number of visits to general practitioners,EDGE‚ sElf-management anD support proGrammE),usual care,No significant difference,The median number of visits to general practitioners for EDGE versus usual care were 4 versus 5.5 (P=.06),9904:10028, 5438446 ,28468749,Unavailable
 5438446 ,The median number of visits to practice nurses,EDGE‚ sElf-management anD support proGrammE),usual care,No significant difference,"The median number of visits to general practitioners for EDGE versus usual care were 4 versus 5.5 (P=.06) and to practice nurses were 1.5 versus 2.5 (P=.03), respectively.",9905:10110, 5438446 ,28468749,Unavailable
 3647147 ,"vomiting, diarrhoea, or fever","vitamin A +  albendazole,  albendazole alone",vitamin A alone,No significant difference,"No significant differences in vomiting, diarrhoea, or fever were seen between retinol plus albendazole, retinol alone, and albendazole alone.",24319:24462, 3647147 ,23498850,Unavailable
 3647147 ,The proportion with tapeworm eggs (Hymenolepis spp),"vitamin A +  albendazole,  albendazole alone",vitamin A alone,No significant difference,"The proportion with tapeworm eggs (Hymenolepis spp) was, as expected, not significantly reduced.",23799:23912, 3647147 ,23498850,Unavailable
 3647147 ,"weight, height, or haemoglobin","vitamin A +  albendazole,  albendazole alone",vitamin A alone,No significant difference,"When, however, children in the same control village were compared with each other, the presence of faecal eggs was not associated with any significant differences in weight, height, or haemoglobin (table 2);",25593:25842, 3647147 ,23498850,Unavailable
 3636841 ,"Microbial growth,mean total bacterial count (TBC), and total lactobacilli count (TLC)",conventional method,Papacárie® method,No significant difference,"Microbial growth was observed in 36.7% of group A samples and 56.7% of group B samples [Figure 1]. The mean TBC were 0.9 × 102, 1.15 × 102 and LBC were 0.35 × 102, 0.41 × 102, respectively, for group A and B [Figure 2]. Although the mean TBC and LBC in the Conventional method was less than the Papacárie® method the results were not statistically significant (P = 0.36).",9628:10145, 3636841 ,23633794,Unavailable
 3636841 ,The mean cavity entrance size,Papacárie® method (group B),conventional method (group A),Significantly decreased,"The mean cavity entrance size [Figure 3] with group A was 0.98133 mm, and group B was 0.26083 mm (P &lt; 0.001).",10615:10779, 3636841 ,23633794,Unavailable
 3636841 ,The mean preparation time,Papacárie® method (group B),conventional method (group A),Significantly increased,The mean preparation time [Figure 4] for group A was 280.89 s and group B was 1077.60 s (P &lt; 0.001).,10779:10936, 3636841 ,23633794,Unavailable
 3636841 ,behavioral score,Papacárie® method (group B),conventional method (group A),No significant difference,Majority of kids of both group A and B scored 3 [Figure 5] before and after the treatment showing no statistical difference in their behavioral score (P = 1).,11876:12171, 3636841 ,23633794,Unavailable
 3636841 ,preference of treatment,Papacárie® method (group B),conventional method (group A),No significant difference,"Considering the preference 36.7% of children preferred conventional method, 60% preferred Papacárie® , and 3.3% preferred both the methods [Figure 7]. There was no statistical difference in the preference of treatment (P = 0.12).",11876:12171, 3636841 ,23633794,Unavailable
 5741924 ,incidence of GDM and preeclampsia,exercise,no exercise,No significant difference,There were no significant differences in the incidence of GDM and preeclampsia (p &gt; 0.05) between groups in the ITT and per protocol analyses (Table 3).,37657:37870, 5741924 ,29273044,Unavailable
 5741924 ,weight gain,exercise,no exercise,No significant difference,"Women in the intervention group gained less weight compared with those in the control group after 16 weeks of intervention for all three analyses (ITT, per protocol &gt; = 70%, per protocol 100%), but this difference was not statistically significant (Table 4).",41298:41600, 5741924 ,29273044,Unavailable
 5741924 ,proportion of newborns small-for-gestational age and large-for-gestational age,exercise,no exercise,No significant difference,There were no differences in the proportion of newborns small-for-gestational age and large-for-gestational age between intervention and control groups.,46741:46893, 5741924 ,29273044,Unavailable
 5741924 ,"mean birth weight, length, and head circumference ",exercise,no exercise,No significant difference,"We also did not find statistically significant differences between the two groups in mean birth weight (p = 0.63), length (p = 0.33), and head circumference (p = 0.34) according to ITT analyses (Table 5). Similar results were found when these outcomes were evaluated by per protocol analysis.Table 5",47190:47610, 5741924 ,29273044,Unavailable
 3549213 ,agitation,"Professional ‘ElderClowns’ provided 9–12 weekly humour therapy sessions, augmented by resident engagement by trained staff ‘LaughterBosse 5980378 ,Median and IQR of peak increment of plasma Pi concentrations (ΔPi‐C Max),NaH2PO4 or Na2HPO4 or MgHPO4,control,Significantly increased,ΔPi‐C Max 	mg/dL	0.06a [0.03–0.25]	3.19b [2.11–4.04]	5.33b [5.26–5.35]	4.3b [3.59–4.68],28720:29169, 5980378 ,29572937,Unavailable
 5980378 ,area under the concentration‐time curve of plasma Pi concentration increment (ΔPi‐AUC),NaH2PO4 or Na2HPO4 or MgHPO4,control,Significantly increased,"Pi‐AUC	mg*h/L	0.68a [–0.68‐3.5]	54.17b [37.54–66.96]	93.48c [82.07–101.04]	78.94a,b [74.73–85.97]",29696:30127, 5980378 ,29572937,Unavailable
 5980378 ,area under the concentration‐time curve of plasma Pi concentration increment (ΔPi‐AUC),NaH2PO4 or Na2HPO4,MgHPO4,Significantly increased,"Pi‐AUC mg*h/L 0.68a [–0.68‐3.5] 54.17b [37.54–66.96] 93.48c [82.07–101.04] 78.94a,b [74.73–85.97]",29696:30127, 5980378 ,29572937,Unavailable
 3590691 ,percentage of arterial blood oxygen saturation,"open suctioning was carried out and after three hours of cleaning, closed suctioning was done","closed suctioning was firstly done and following three hours of cleaning, open suctioning was implemented",Significantly decreased,"Moreover, percentage of arterial blood oxygen saturation in open suctioning had a significant reduction compared to closed method during and immediately after suctioning",13900:14070, 3590691 ,23493041,Unavailable
 3590691 ,Respiratory rate (RR),"open suctioning was carried out and after three hours of cleaning, closed suctioning was done","closed suctioning was firstly done and following three hours of cleaning, open suctioning was implemented",Significantly decreased,as well as RR three minutes after open suctioning in both steps (p &lt; 0.05) Table 1.,14070:14195, 3590691 ,23493041,Unavailable
 5852777 ,Bifidobacterium (BIF),prolonged oligofructose-enriched inulin (Synergy 1) 10 g/day for 3 months,placebo (maltodextrin; 7 g/day) for 3 months,Significantly increased,A comparison of bacteria counts between the experimental groups after the three-month intervention revealed a significant increase (p &lt; 0.05) in BIF count in the Synergy 1 group.,21324:21519, 5852777 ,29439526,Unavailable
 5852777 ,faecal acetate and propionate levels,prolonged oligofructose-enriched inulin (Synergy 1) 10 g/day for 3 months,placebo (maltodextrin; 7 g/day) for 3 months,Significantly increased,A comparison of both groups after the intervention revealed significantly (p &lt; 0.05) higher levels of acetate and propionate in the Synergy 1 group.,22766:22935, 5852777 ,29439526,Unavailable
 5852777 ,faecal concentration of total SCFAs,prolonged oligofructose-enriched inulin (Synergy 1) 10 g/day for 3 months,placebo (maltodextrin; 7 g/day) for 3 months,Significantly increased,"At the end of experiment, the faecal concentration of total SCFAs in the Synergy 1 group was significantly (p &lt; 0.05) higher than in the placebo group.",22935:23106, 5852777 ,29439526,Unavailable
 4518420 ,pain,Ksharasutra (cotton Seton coated with Ayurvedic medicines),fistulotomy,Significantly decreased,Patients in Ksharasutra group experienced significantly (P = 0.001) less pain than fistulotomy patients.,14506:14628, 4518420 ,26283840,Unavailable
 4518420 ,Amount of postoperative wound discharge,Ksharasutra (cotton Seton coated with Ayurvedic medicines),fistulotomy,No significant difference,Amount of postoperative wound discharge was mild for both group and not statistically different (P = 0.814).,14628:14754, 4518420 ,26283840,Unavailable
 4518420 ,duration of stay in the hospital,Ksharasutra (cotton Seton coated with Ayurvedic medicines),fistulotomy,Significantly decreased,"Whereas those patients who underwent fistulotomy maximum and minimum duration of hospital stay were 72 h and 24 h, respectively. Ksharasutra group had significant (P &lt; 0.001) lesser duration of stay in the hospital.",15071:15303, 4518420 ,26283840,Unavailable
 4518420 ,number of days for healing,Ksharasutra (cotton Seton coated with Ayurvedic medicines),fistulotomy,Significantly increased,"The mean duration of healing was 53.00 ± 26.75 days in medicated Ksharasutra group. Whereas in fistulotomy group, mean duration of healing was 35.67 ± 9.17 days. Ksharasutra group required significantly (P = 0.002) more number of days for healing.",15313:15577, 4518420 ,26283840,Unavailable
 4518420 ,number of days “off-work”,Ksharasutra (cotton Seton coated with Ayurvedic medicines),fistulotomy,Significantly decreased,"However, in Ksharasutra group 19 out of 26 patients resumed their work the following day after the procedure. The maximum and minimum duration “off-work” was 8 and 26 days, respectively. Ksharasutra group had significantly (P &lt; 0.001) few days “off-work” compared to fistulotomy group.",15578:15881, 4518420 ,26283840,Unavailable
 4917592 ,complete resolution of sleep disturbance due to heartburn or other reflux symptoms,esomeprazole 20 mg,placebo,Significantly increased,"In the best-fit logistic regression model of complete resolution of sleep disturbance due to heartburn or other reflux symptoms, treatment with esomeprazole 20 mg [adjusted odds ratio (OR) 2.39; 95 % confidence interval (CI) 1.70–3.36; p &lt; 0.0001],",21358:21624, 4917592 ,27074935,Unavailable
 4917592 ,absence of daytime heartburn during treatment,esomeprazole 20 mg,placebo,Significantly increased,"absence of daytime heartburn during treatment (adjusted OR 3.50; 95 % CI 1.59–7.69; p = 0.0018),",21624:21740, 4917592 ,27074935,Unavailable
 4917592 ,absence of nighttime heartburn during treatment,esomeprazole 20 mg,placebo,Significantly increased,absence of nighttime heartburn during treatment (adjusted OR 12.07; 95 % CI 3.53–41.22; p &lt; 0.0001),21745:21862, 4917592 ,27074935,Unavailable
 3713949 ,The percentages of participants who succeeded in weight maintenance or in further loss,virtual reality protocol aimed at unlocking the negative memory of the body (ECT),inpatient multimodal treatment (IP),Significantly increased,"The percentages of participants who succeeded in weight maintenance or in further loss was 44.4% in ECT versus 10.5% in IP (OR 6.8, 95% CI 1.3-35.4, P=.014).",54984:55159, 3713949 ,23759286,Unavailable
 3713949 ,percentages of weight and BMI reductions at 1-year follow-up from baseline,virtual reality protocol aimed at unlocking the negative memory of the body (ECT),inpatient multimodal treatment (IP),Significantly increased,"With respect to percentages of weight and BMI reductions at 1-year follow-up from baseline, almost significant differences emerged between the three groups (P=.052 for both) in favor of ECT and CBT (Figure 4). Post hoc comparisons showed a significant difference between ECT and IP (P=.027).",54480:54848, 3713949 ,23759286,Unavailable
 3713949 ,percentages of patients with improving or maintaining weight loss,virtual reality protocol aimed at unlocking the negative memory of the body (ECT),inpatient multimodal treatment (IP),Significantly increased,"Also CBT was significantly better after 1-year follow-up in improving or maintaining weight loss than IP alone, with 40% of participants being successful (OR 5.7, 95% CI 1.09-31.5, P=.035).",55159:55366, 3713949 ,23759286,Unavailable
 5836873 ,total costs,community‐based intervention,usual care,No significant difference,"The mean group difference in total cost change excluding hospital costs was $236.92 (favoring the intervention, although not statistically significant).",55952:56104, 5836873 ,29178317,Unavailable
 5836873 ,Physical Component Summary (PCS),community‐based intervention,usual care,No significant difference,"For the primary outcome (PCS), the group difference in mean 6‐month scores adjusted for baseline values was not statistically significant.",39766:39905, 5836873 ,29178317,Unavailable
 5836873 ,"12‐item Short‐Form Health Survey (SF‐12), Mental Component Summary (MCS), Summary of Diabetes Self‐Care Activities (SDSCA)",community‐based intervention,usual care,Significantly increased,"For the secondary outcomes, there was a significant difference between the intervention and control groups on the SF‐12 general health subdomain (mean difference = 3.11, 95% CI = 0.05–5.71, P = .02) and MCS (mean difference = 2.74, 95% CI = 0.28–5.19, P = .03) and for the SDSCA (mean difference = 3.74, 95% CI = 0.9–6.57, P = .01). These differences favored the intervention group.",39906:40339, 5836873 ,29178317,Unavailable
 5836873 ,"CES‐D, GAD‐7 or for self‐efficacy",community‐based intervention,usual care,No significant difference,There was no significant group difference between the intervention and control groups on the CES‐D or GAD‐7 or for self‐efficacy.,40340:40469, 5836873 ,29178317,Unavailable
 4713062 ,carotid blood flow (CaBF),single sustained inflation (SI),"conventional ventilation, consecutive sustained inflation (SI)",Significantly increased,"CaBF increased more rapidly and to a greater extent during a single SI (p = 0.01), which then decreased below both other groups by 10 min",7805:7942, 4713062 ,26765258,Unavailable
 4713062 ,cerebral oxygen delivery,single sustained inflation (SI),"conventional ventilation, consecutive sustained inflation (SI)",Significantly increased,"CaBF increased more rapidly and to a greater extent during a single SI (p = 0.01), which then decreased below both other groups by 10 min, due to a higher cerebral oxygen delivery (p = 0.01).",7805:7996, 4713062 ,26765258,Unavailable
 4713062 ,numbers of blood vessel profiles with plasma protein extravasation,single sustained inflation (SI),"conventional ventilation, consecutive sustained inflation (SI)",Significantly increased,Blood brain barrier disruption was increased in single SI lambs as indicated by increased numbers of blood vessel profiles with plasma protein extravasation (p = 0.001) in the cerebral cortex.,7996:8189, 4713062 ,26765258,Unavailable
 4713062 ,carotid blood flow (CaBF), consecutive sustained inflation (SI),"conventional ventilation,",No significant difference,There were no differences in CaBF or cerebral oxygen delivery between the multiple SI and no SI lambs.,8190:8292, 4713062 ,26765258,Unavailable
 3714436 , unified Parkinson's disease rating scale (UPDRS) total  score,pramipexole (1·5 mg a day),placebo,Significantly decreased,"For period 1, recipients of early pramipexole showed relative stability in total UPDRS scores: in the period 2 full-analysis set, the adjusted mean change over the first 6–9 months of the study was −0·5 (SE 0·6) points, as assessed by study investigators, compared with 4·3 (0·6) for placebo recipients, a difference of −4·8 points (95% CI −6·3 to −3·2, p&lt;0·0001; table 2).",21515:21932, 3714436 ,23726851,Unavailable
 3714436 ,BDI score,pramipexole (1·5 mg a day),placebo,No significant difference,"At 15 months, two of the three quality of life measures and the mean BDI score did not differ significantly between treatment groups.",23312:23446, 3714436 ,23726851,Unavailable
 3714436 ,EuroQoL visual analogue scale (EQVAS),pramipexole (1·5 mg a day),placebo,No significant difference,"The third quality of life scale, the EQVAS, continued to show a small difference that favoured early pramipexole but was of doubtful clinical significance (table 3). At 15 months, the odds ratio for CGI-I category improvement was 0·81 (95% CI 0·44–1·48, p=0·50), with 176 (88%) of 200 patients in the early pramipexole group and 158 (86%) of 184 patients in the delayed pramipexole group rated as essentially unchanged from baseline.",23445:23921, 3714436 ,23726851,Unavailable
 3718630 ,dietary glycaemic load,complex intervention,routine antenatal care,Significantly decreased,"Compared to women in the control arm, women in the intervention arm had a significant reduction in dietary glycaemic load (33 points, 95% CI −47 to −20), (p &lt; 0.001) and saturated fat intake (−1.6% energy, 95% CI −2.8 to −0. 3) at 28 weeks’ gestation.",8625:8877, 3718630 ,23855708,Unavailable
 3718630 ,self-reported walking for leisure for 14;min/day,complex intervention,routine antenatal care,Significantly increased,"Women in the intervention group self-reported walking for leisure for 14&nbsp;min/day more than those in the control group at 28&nbsp;weeks’ gestation (95% CI 5 to 23&nbsp;min, p = 0.003).",54878:55051, 3718630 ,23855708,Unavailable
 3698174 ,"chronic cough, chronic expectoration and chronic bronchitis",Lung Support Formula capsule,placebo capsule,Significantly decreased,". The percentage of patients reported to have chronic cough, chronic expectoration and chronic bronchitis were significantly decreased in the treatment group when compared with baseline after a 3-month intervention (P &lt; 0.05).",6292:6535, 3698174 ,23641817,Unavailable
 4644316 ,the degree of satisfaction,conversational hypnosis intervention,control,No significant difference,"Also, the degree of satisfaction in the experiment group was higher than that of the control group. However, the difference was insignificant (P = 0.368).",24659:24814, 4644316 ,26587402,Unavailable
 4644316 ,"The adverse side effects such as vomiting, nausea, and hiccups",conversational hypnosis intervention,control,No significant difference,"The adverse side effects such as vomiting, nausea, and hiccups in the experiment group was less than the control group, though this difference was not significant (P = 0.54).",24308:24482, 4644316 ,26587402,Unavailable
 4644316 ,the pain score,conversational hypnosis intervention,control,No significant difference,"In the experiment group, the pain score with a mean of 0.28 (± 0.89) was lower than that of the control group (0.49 ± 1.17), but this difference was not significant (P = 0.25).",24483:24660, 4644316 ,26587402,Unavailable
 4644316 ,the mean anxiety,conversational hypnosis intervention,control,Significantly decreased,"The results suggested that the mean anxiety of the experimental group declined by about 5.72 in the period between pretest and posttest, while this reduction in the control group was only 4.93. Furthermore, the covariance analysis of the anxiety proved the significant effect of pretest. In other words, the pretest could influence the score of posttest (P = 0.004).",24821:25187, 4644316 ,26587402,Unavailable
 2866241 ,number of patients who prefer the HC formulation compared for the MC formulation,high-concentration formulation (HC) (0.4 ml of 50 mg/ml in prefilled syringe; pre-attached needle).,medium-concentration formulation (MC) (2.0 ml of 10 mg/ml solution in prefilled syringe; separate needle),Significantly increased,"At the end of the study, 93.0% of all patients stated that they would prefer the HC formulation compared to 2.3% of the patients expressing a preference for the MC formulation (95% confidence interval: [87.1%; 96.7%]). The result was highly statistically significant (P&lt;0.0001).",19733:20028, 2866241 ,20461222,Unavailable
 2866241 ,global assessment of syringe usability,high-concentration formulation (HC) (0.4 ml of 50 mg/ml in prefilled syringe; pre-attached needle).,medium-concentration formulation (MC) (2.0 ml of 10 mg/ml solution in prefilled syringe; separate needle),Significantly increased,"Using a visual analogue scale, physician-reported global assessment of syringe usability was 82.0 mm (Q1-Q3: 59-100) at the time of administration of the MC formulation. A significant increase in to 96.0 mm (Q1-Q3: 86-100) was observed at time of HC administration (P &lt; 0.0001).",19733:20028, 2866241 ,20461222,Unavailable
 3280326 ,number of participants seen at least once with a helmet,receive “helmet only” or“helmet and information” ,"control or “information only”,",Significantly increased,"Participants seen at least once with a helmet amounted to 6.6% of all observed participants (Table 2), with higher rates in the two groups who received a helmet at baseline (helmet only: 11.4%; helmet and information: 9.2%) as compared with the others (control: 3.7%; information only: 3.2%; p = 0.008).",32680:33037, 3280326 ,22355384,Unavailable
 3280326 ,Helmet use,receive “helmet only” or“helmet and information” ,"control or “information only”,",Significantly increased,"Helmet use was observed in 3.8% (99 out of 2621) of observed movements, with higher rates in movements of participants who received a helmet at baseline (helmet only: 10.0%; helmet and information: 5.1%) as compared with the others (control: 1.1%; information only: 0.8%; p&lt;0.001).",33038:33320, 3280326 ,22355384,Unavailable
 3680656 ,SIB Severe Impairment Battery,extended-release memantine,placebo,Significantly increased,"SIB Memantine ER 332 76.8 ± 17.5 2.7 ± 11.2 2.6 [1.0, 4.2] 0.001 Placebo 327 75.2 ± 19.3 0.3 ± 11.5",30973:31321, 3680656 ,23733403,Unavailable
 3680656 ,CIBIC-Plus Clinician’s Interview-Based Impression of Change Plus Caregiver Input,extended-release memantine,placebo,Significantly decreased,CIBIC-Plusb Memantine ER 333 4.5 ± 0.87 3.8 ± 1.2b N/A 0.008 Placebo 328 4.5 ± 0.82 4.1 ± 1.2b,30973:31321, 3680656 ,23733403,Unavailable
 3680656 ,ADCS–ADL 19 19-item Alzheimer’s Disease Cooperative Study–Activities of Daily Living,extended-release memantine,placebo,No significant difference,"ADCS–ADL19 Memantine ER	331	33.1 ± 11.1	−0.7 ± 6.9	0.7 [−0.3, 1.8]	0.177 Placebo	328	32.8 ± 11.0	−1.3 ± 7.7",30156:30529, 3680656 ,23733403,Unavailable
 3680656 ,NPI Neuropsychiatric Inventory,extended-release memantine,placebo,Significantly decreased,"NPI Memantine ER 318 17.2 ± 15.6 −4.3 ± 14.6 −2.7 [−4.5, −0.8] 0.005 Placebo 321 16.5 ± 15.4 −1.6 ± 12.7",30973:31321, 3680656 ,23733403,Unavailable
 3680656 ,VFT verbal fluency test,extended-release memantine,placebo,Significantly increased,"VFT Memantine ER	330	5.8 ± 3.8	0.3 ± 2.8	0.5 [0.2, 0.9]	0.004 Placebo	326	5.7 ± 3.7	−0.3 ± 2.5",30973:31321, 3680656 ,23733403,Unavailable
 3525560 ,Clinical efficacy,artesunate monotherapy with 2 or 4 mg/kg/day once daily,quinine plus doxycycline TID for 7 days,No significant difference,"All patients successfully cleared their asexual parasitemia within the first week of treatment. The 28 and 42-day cure rate for Arm 1 by Kaplan-Meier analysis was 97.8% (95% confidence interval, CI: 87.8–99.8%), 100% (95% CI: 91.1–100%) for Arm 2, and 100% (95% CI: 83.4–100%) for Arm 3 (Table 2).",27782:28134, 3525560 ,23272227,Unavailable
 3525560 ,The median parasite clearance times (PCTs),artesunate monotherapy with 2 or 4 mg/kg/day once daily,quinine plus doxycycline TID for 7 days,Significantly decreased,"The median parasite clearance times (PCTs) were similar in the artesunate lower and higher dose arms with 29.8 (interquartile range, IQR: 24.3–32.8) h and 29.5 (IQR: 19.8–32.4) h, respectively. With 43.1 (IQR: 33.6–54.8) h the PCT in the control group was significantly (P&lt;0.001) slower.",39669:39957, 3525560 ,23272227,Unavailable
 3525560 ,"The median parasite reduction ratios at 12, 24 h",artesunate monotherapy with 2 or 4 mg/kg/day once daily,quinine plus doxycycline TID for 7 days,Significantly decreased,The ratios in the artesunate groups were lower than in the quinine group after 12 and 24 hours (P&lt;0.001).,41049:41155, 3525560 ,23272227,Unavailable
 3525560 ,adverse events,artesunate monotherapy with 2 or 4 mg/kg/day once daily,quinine plus doxycycline TID for 7 days,No significant difference,"Out of 78 recorded adverse events, 48 (61.5%; 95% CI: 49.8–72.1%) were classified as drug-related. No difference in the proportion of patients with/without adverse events was observed between the three groups (P = 0.91).",43415:43636, 3525560 ,23272227,Unavailable
 3525560 ,median FCT,artesunate monotherapy with 2 or 4 mg/kg/day once daily,quinine plus doxycycline TID for 7 days,Significantly decreased,"With a median FCT of 17.9 (IQR: 4.6–20.7), 19.1 (IQR: 6.6–23.6), and 29.3 (IQR: 16.0–43.1) h, for Arms 1–3, respectively, the artesunate arms showed a significantly (P = 0.001) faster clinical response than the control group.",41254:41479, 3525560 ,23272227,Unavailable
 387830 ,pain during the first month of treatment,celecoxib (Celebrex 200 mg) ,S-Adenosylmethionine (SAMe),Significantly decreased,Celecoxib showed significantly more reduction in pain than SAMe during the first month of treatment (p = 0.024).,27926:28040, 387830 ,15102339,Unavailable
 387830 ,pain during the second month of treatment,celecoxib (Celebrex 200 mg) ,S-Adenosylmethionine (SAMe),No significant difference,"By the second month of Phase 1, both groups were significantly improved from baseline (ps &lt; 0.01) and there was no significant difference between them.",28040:28191, 387830 ,15102339,Unavailable
 387830 ,SF-36 Scores,celecoxib (Celebrex 200 mg) ,S-Adenosylmethionine (SAMe),No significant difference,SF-36 scores are shown in Table 4. ANOVA showed no significant difference between SAMe and celecoxib on any measure.,31007:31163, 387830 ,15102339,Unavailable
 387830 ,The vitality measure,celecoxib (Celebrex 200 mg) ,S-Adenosylmethionine (SAMe),Significantly increased,The vitality measure showed a significant improvement for the celecoxib group (p = 0.012) but the magnitude of this effect was quite small.,31642:31781, 387830 ,15102339,Unavailable
 3688183 ,Hand hygiene (HH) compliance,performance feedback (PF) with patient participation (PP),performance feedback (PF),Significantly increased,"Only PP+FB showed a significant effect on HH compliance in our trial (OR 1.33, P=0.04), with PF alone not sufficient (OR 1.17, P=0.25).",6510:6646, 3688183 ,None,Unavailable
 3478157 ,IIEF-Erectile Function (EF) score,VigRX Plus (VXP),placebo,Significantly increased,"After 12 weeks of treatment, the mean (sd) IIEF-EF score at baseline increased from 16.08 (2.87) to 25.08 (4.56) in the VXP group versus 15.86 (3.24) to 16.47 (4.25) in the placebo group (P &lt; 0.0001).",5378:5578, 3478157 ,22978405,Unavailable
 3478157 ,mean (sd) Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) score,VigRX Plus (VXP),placebo,Significantly increased,There was a significant difference for VXP versus placebo comparison of mean (sd) EDITS scores of patients: 82.31(20.23) vs 36.78(22.53) and partners :(82.75(9.8) vs 18.50(9.44);P &lt; 0.001.,5746:5955, 3478157 ,22978405,Unavailable
 3478157 ,"sperm count, semen volume and sperm motility",VigRX Plus (VXP),placebo,No significant difference,"There was no significant difference in the changes in sperm count, semen volume and sperm motility between the two treatment groups.",35575:35708, 3478157 ,22978405,Unavailable
 5809706 ,Insertion success rate,i-gel,Laryngeal Mask Airway Supreme™ (LMA Supreme),No significant difference,Insertion success rate was similar in both groups.,4841:4893, 5809706 ,29441173,Unavailable
 5809706 ,oropharyngeal leak pressure (OLP),i-gel,Laryngeal Mask Airway Supreme™ (LMA Supreme),Significantly increased,OLP for the i-gel (26.0 ± 3.8 cmH2O) was higher than for the LMA Supreme (23.7 ± 3.2 cmH2O) (P = 0.016).,4893:5019, 5809706 ,29441173,Unavailable
 5809706 ,Insertion time,i-gel,Laryngeal Mask Airway Supreme™ (LMA Supreme),Significantly decreased,Insertion time for the i-gel (16.4 ± 2.8 s) was shorter than for the LMA Supreme (18.5 ± 2.7 s) (P = 0.002).,5020:5128, 5809706 ,29441173,Unavailable
 5809706 ,"fiberoptic view of the larynx, airway quality, airway manipulations, and complications",i-gel,Laryngeal Mask Airway Supreme™ (LMA Supreme),No significant difference,"There were no differences in fiberoptic view of the larynx, airway quality, airway manipulations, and complications between the two groups.",5129:5268, 5809706 ,29441173,Unavailable
 4504059 ,HbA1c,MF (500 mg BD) + VG (50 mg BD) metformin-vidagliptin ,MF (500 mg BD) + GP (2 mg BD) metfromin-glimepiride (MF-GP),No significant difference,HbA1c was also reduced significantly in both groups at 12 weeks (P &lt; 0.01).,4449:4544, 4504059 ,26229753,Unavailable
 4504059 ,weight and body mass index,MF (500 mg BD) + VG (50 mg BD) metformin-vidagliptin ,MF (500 mg BD) + GP (2 mg BD) metfromin-glimepiride (MF-GP),No significant difference,Both weight and body mass index did not alter statistically from baseline in either of the groups as well as demonstrated no difference statistically on comparison (P &gt; 0.05).,4902:5097, 4504059 ,26229753,Unavailable
 4173592 ,"SBP, DBP and MAP",Group B it was continued ACEI or angiotensin II receptor antagonist,  Group A - ACEI or angiotensin II receptor antagonist was stopped the day before surgery,Significantly decreased,"There was a significant reduction in SBP, DBP and MAP in Group B at 3, 5, 10, 15, 30, 45 and 60 min (P &lt; 0.01, P &lt; 0.05, P &lt; 0.01 respectively) [Tables 1-3 and Figures 1-3].",9734:10120, 4173592 ,25886100,Unavailable
 4763470 ,Total cholesterol (TC), 2 - probiotic yogurt (150 g); 3 - C. ficifolia plus probiotic yogurt (100 g C. ficifolia plus 150 g yogurt);, 1 - green C. ficifolia (100 g); and 4 -control (dietary advice),Significantly decreased,"Total cholesterol (TC) decreased significantly in yogurt and yogurt plus C. ficifolia groups (within groups P = 0.010, and P &lt; 0.001, respectively).",5847:6046, 4763470 ,26955460,Unavailable
 4763470 ,triglyceride (TG), 3 - C. ficifolia plus probiotic yogurt (100 g C. ficifolia plus 150 g yogurt);, 1 - green C. ficifolia (100 g); and 4 -control (dietary advice);  2 - probiotic yogurt (150 g);,Significantly decreased,"C. ficifolia plus yogurt consumption resulted in a decrease in triglyceride (TG) and an increase in high-density lipoprotein cholesterol (HDL-C) (within groups P &lt; 0.001 and P = 0.001, respectively).",6046:6304, 4763470 ,26955460,Unavailable
 4763470 ,high-density lipoprotein cholesterol (HDL-C), 3 - C. ficifolia plus probiotic yogurt (100 g C. ficifolia plus 150 g yogurt);, 1 - green C. ficifolia (100 g); and 4 -control (dietary advice);  2 - probiotic yogurt (150 g);,Significantly increased,"C. ficifolia plus yogurt consumption resulted in a decrease in triglyceride (TG) and an increase in high-density lipoprotein cholesterol (HDL-C) (within groups P &lt; 0.001 and P = 0.001, respectively).",6058:6303, 4763470 ,26955460,Unavailable
 3671244 ,community occupational therapy in dementia program (COTiD program) referrals at 6 months,"access to a website, received newsletters, and were approached by telephone",no interventions and occupational therapists received a postgraduate course,No significant difference,"At 6 months there was no significant difference between the number of COTiD referrals between groups (difference in change from baseline to 6 months: 1.2, 95%-CI from −1,42 to 3,90).",35313:35708, 3671244 ,23718565,Unavailable
 3671244 ,community occupational therapy in dementia program (COTiD program) referrals at 12 months,"access to a website, received newsletters, and were approached by telephone",no interventions and occupational therapists received a postgraduate course,Significantly increased,"However, at 12 months the mean number of COTiD referrals per cluster was significantly higher in the experimental group: difference in change from baseline to 12 months: 3.2, 95%-CI from 0.50 to 5.8 with an average of 2,07 referrals (SD 5,14) in the control group and 5,24 referrals (SD 5,75) in the experimental group. The effect size at 12 months was 0.58 which is considered a medium effect.",35313:35708, 3671244 ,23718565,Unavailable
 4354617 ,frontal hip flexion (FHF),resistance training (RT) three times per week,resistance training (RT) two times per week,Significantly increased,"Significant group-by-time interaction (P&lt;0.01) was observed only for FHF, in which G3x showed a higher increase than G2x (+12.8%, and +3.0%, respectively).",23812:23987, 4354617 ,25767380,Unavailable
 4354617 ,skeletal muscle mass,resistance training (RT) three times per week,resistance training (RT) two times per week,No significant difference,"No statistically significant differences were noted for the increase in skeletal muscle mass between training three versus two times a week (+7.4% vs +4.4%, respectively).",5945:6116, 4354617 ,25767380,Unavailable
 4354617 ,"flexibility in cervical extension, right hip flexion, and left hip flexion",resistance training (RT) three times per week,resistance training (RT) two times per week,No significant difference,"Both groups increased flexibility in cervical extension (G2x=+19.1%, G3x=+20.0%), right hip flexion (G2x=+14.6%, G3x=+15.9%), and left hip flexion (G2x=+25.7%, G3x=+19.2%), with no statistical difference between groups.",5725:5944, 4354617 ,25767380,Unavailable
 5850145 ,capillary density in the inferior segment of the peri‐infarct zone and the remote zone,Transplantation of adventitial pericytes (APCs),placebo,Significantly increased,"The injection of sAPCs increased the capillary density in the inferior segment of the peri‐infarct zone (51%, P=0.003 versus vehicle) and the remote zone (34%, P=0.04 versus vehicle) (Figure 10A and 10B).",134223:134565, 5850145 ,29358198,Unavailable
 5850145 ,interstitial fibrosis in the infarct border zone,Transplantation of adventitial pericytes (APCs),placebo,Significantly decreased,"Importantly, hAPC therapy reduced interstitial fibrosis in the infarct border zone (−19% compared with the vehicle, P&lt;0.01, Figure 3D and 3E), whereas the infarct scar was unaffected.",93305:93612, 5850145 ,29358198,Unavailable
 5850145 ,ejection fraction,Transplantation of adventitial pericytes (APCs),placebo,No significant difference,Transplantation of hAPCs reduced fibrosis but failed to improve the other efficacy end points.,12666:12813, 5850145 ,29358198,Unavailable
 5850145 ,cardiac magnetic resonance imaging indices of contractility,Transplantation of adventitial pericytes (APCs),placebo,No significant difference,Transplantation of allogeneic sAPCs benefited capillary density and fibrosis but did not improve cardiac magnetic resonance imaging indices of contractility.,13454:13664, 5850145 ,29358198,Unavailable
 3661377 ,mean  the Dermatology Life Quality Index (DLQI) scores at week 16,apremilast 20 mg or 30 mg,placebo,Significantly decreased,"At week 16, mean DLQI scores were significantly lower (vs. placebo) with apremilast 20 mg BID (P&lt;0.001) and 30 mg BID (P=0.005), but not with 10 mg BID (P=0.132).",25223:25473, 3661377 ,23663752,Unavailable
 3661377 ,pruritus VAS scores,apremilast 20 mg or 30 mg,placebo,Significantly decreased,"Significantly greater reductions from baseline in mean pruritus scores at week 16 were reported with apremilast 20 mg BID (P=0.005) and 30 mg BID (P&lt;0.001), but not with 10 mg BID (P=0.366) versus placebo.",28944:29203, 3661377 ,23663752,Unavailable
 3661377 ,≥minimum clinically important differences (MCID),apremilast 20 mg or 30 mg,placebo,Significantly increased,"Twenty-two (25.0%) placebo, 30 (33.7%) apremilast 10 mg BID (P=0.249), 43 (49.4%) 20 mg BID (P=0.001 vs. placebo), and 39 (44.3%) 30 mg BID (P=0.011 vs. placebo) patients reported improvements ≥MCID.",25223:25473, 3661377 ,23663752,Unavailable
 3661377 ,mental component summary (MCS) scores,apremilast 10 or 20 mg or 30 mg,placebo,Significantly increased,"fter 16 weeks of treatment, mean changes from baseline in MCS scores were significantly greater with apremilast 10, 20, or 30 mg BID than placebo (Figure 1), exceeding MCID, and approaching US normative values (range: 49.0–49.9).",29957:30153, 3661377 ,23663752,Unavailable
 3661377 ,physical component summary (PCS) scores,apremilast 10 or 20 mg or 30 mg,placebo,No significant difference,"Week 16 mean changes from baseline in PCS scores were numerically greater with apremilast 10, 20, and 30 mg BID than placebo but were neither statistically significantly nor clinically meaningful.",29957:30153, 3661377 ,23663752,Unavailable
 4469426 ,value of plasma α-tocopherol,CON diet with almonds (85 g/day) (ALM),CON diet,Significantly increased,"Compared to the CON diet, the ALM diet increased the post-intervention value of plasma α-tocopherol by 10.2 % (P = 0.0065)",26016:26155, 4469426 ,26080804,Unavailable
 4469426 ,value of plasma γ-tocopherol,CON diet with almonds (85 g/day) (ALM),CON diet,Significantly decreased,"Compared to the CON diet, the ALM diet increased the post-intervention value of plasma α-tocopherol by 10.2 % (P = 0.0065) and decreased γ-tocopherol by 16.5 % (P = 0.047).Table 2",26015:26258, 4469426 ,26080804,Unavailable
 4469426 ,"Plasma Lipid Profile (Total cholesterol, HDL-C, LDL-C,Total triglycerides, Small dense LDL-C, Apo-B100, Apo-AI)",CON diet with almonds (85 g/day) (ALM),CON diet,No significant difference,"Plasma Lipid Profile				 Total cholesterol, mg/dL	146.2 ± 37.8	146.9 ± 32.4	149.8 ± 43.2	148.6 ± 38.3 HDL-C, mg/dL	41.0 ± 11.2	41.7 ± 11.2	41.7 ± 10.8	43.3 ± 15.6 LDL-C, mg/dL	78.7 ± 28.6	80.3 ± 26.2	82.67 ± 36.3	77.9 ± 26.3 Total triglycerides, mg/dL	123.6 ± 90.9	124.3 ± 60.7	129.2 ± 75.5	131.4 ± 60.2 Small dense LDL-C, mg/dL	30.9 ± 14.1	32.8 ± 14.1	33.7 ± 19.9	29.6 ± 12.1 Apo-B100, mg/dL	69.0 ± 20.8	71.9 ± 19.0	72.3 ± 25.0	67.1 ± 19.8 Apo-AI, mg/dL	118.0 ± 22.0	118.4 ± 22.1	118.8 ± 21.0	121.0 ± 28.1",39495:40383, 4469426 ,26080804,Unavailable
 4469426 ,"Plasma Inflammatory cytokines (C-reactive Protein, TNFα, IL-6)",CON diet with almonds (85 g/day) (ALM),CON diet,No significant difference,"Plasma Inflammatory cytokines				 C-reactive Protein, mg/L	4.0 ± 6.4	3.3 ± 4.2	4.5 ± 5.7	3.9 ± 5.1 TNFα, pg/mL	1.8 ± 1.8	1.8 ± 1.6	1.6 ± 1.4	1.7 ± 1.5 IL-6, pg/mL	3.5 ± 2.2	3.6 ± 2.5	3.8 ± 2.9	4.1 ± 2.9",40401:40785, 4469426 ,26080804,Unavailable
 4469426 ,"Endothelial function (Plasma E-selectin, Plasma VCAM-1, Plasma nitric oxide, Urinary nitric oxide)",CON diet with almonds (85 g/day) (ALM),CON diet,No significant difference,"Plasma Inflammatory cytokines  C-reactive Protein, mg/L 4.0 ± 6.4 3.3 ± 4.2 4.5 ± 5.7 3.9 ± 5.1 TNFα, pg/mL 1.8 ± 1.8 1.8 ± 1.6 1.6 ± 1.4 1.7 ± 1.5 IL-6, pg/mL 3.5 ± 2.2 3.6 ± 2.5 3.8 ± 2.9 4.1 ± 2.9",40401:40785, 4469426 ,26080804,Unavailable
 3751456 ,caloric consumption,normoglucidic low-calorie diet (NGLCD),low-fat diet (LFD),No significant difference,"After 6 and 12 months of intervention, both groups had a significant decrease in caloric consumption (Table 2), without differences between groups (p = 0.839 at 6 months, and p = 0.96 at 12 months);",38979:39217, 3751456 ,23941362,Unavailable
 3751456 ,weight loss At 6 months,normoglucidic low-calorie diet (NGLCD),low-fat diet (LFD),Significantly decreased,"At 6 months, weight loss was greater in the NGLCD group (−5.02 [95% CI −5.9, -4.1]kg vs. −4.1 [95% CI −4.8, -3.3]kg; p = 0.002) compared to the LFD group.",39389:39561, 3751456 ,23941362,Unavailable
 3751456 ,weight loss at 1 year,normoglucidic low-calorie diet (NGLCD),low-fat diet (LFD),No significant difference,"At 1-year, however, weight loss was similar in both groups (−3.9 [95% CI −4.8, -3.1]kg vs. −3.1 [95% CI −3.8, -2.3]kg; p = 0.139).",39561:39708, 3751456 ,23941362,Unavailable
 3751456 ,severity of steatosis,normoglucidic low-calorie diet (NGLCD),low-fat diet (LFD),No significant difference,"The two diets were associated with reduction of both prevalence and severity of steatosis (all p &lt; 0.001) without significant differences between groups; in NGLCD group - mild: 68.6% vs. 77.4%, moderate: 25.7% vs. 22.6%, severe: 5.7% vs. 0%; in LFD group - mild: 58.3% vs. 76.2%, moderate: 29.2% vs. 23.8%, severe: 12.5% vs. 0%.",87336:87769, 3751456 ,23941362,Unavailable
 3751456 ,"renal function (eGFR, creatinin, urea)",normoglucidic low-calorie diet (NGLCD),low-fat diet (LFD),No significant difference,"There were no differences between the two diets regarding the changes in renal function (eGFR, creatinin, urea). In both groups, there were no associations between the changes in protein intake (g/day) and the change in eGFR (r = 0.04, p = 0.29) or creatinin (r = 0.07, p = 0.34).",88745:89093, 3751456 ,23941362,Unavailable
 5812981 ,adherence to pharmacological treatment,Remote collaborative depression care (RCDC),enhanced usual care or EUC,No significant difference,No significant differences were observed across groups at 12-week follow-up in terms of adherence to pharmacological treatment (Fisher exact test P value=.98).,30294:30470, 5812981 ,29386172,Unavailable
 5812981 ,Satisfaction with psychological care,Remote collaborative depression care (RCDC),enhanced usual care or EUC,Significantly increased,"Satisfaction with psychological care was the only aspect of treatment satisfaction that displayed a significant difference between the groups (Wilcoxon rank-sum test P value=.04), with the RCDC intervention scoring higher (Table 2).",30567:30859, 5812981 ,29386172,Unavailable
 3580299 ,the number of extracorporeal shock wave lithotripsy (ESWL),Alfuzosin 10 mg (once daily) and loxoprofen sodium 68.1 mg (as needed) were prescribed to group 1,loxoprofen sodium 68.1 mg (as needed) only was prescribed to group 2,No significant difference,"The number of ESWL sessions was 1.34±0.65 and 1.41±0.85 in groups 1 and 2, respectively (p=0.33).",4699:4797, 3580299 ,23550174,Unavailable
 3580299 ,ultimately passed stones,Alfuzosin 10 mg (once daily) and loxoprofen sodium 68.1 mg (as needed) were prescribed to group 1,loxoprofen sodium 68.1 mg (as needed) only was prescribed to group 2,No significant difference,Thirty-nine of 41 (95.1%) patients in group 1 and 40 of 43 (93.0%) patients in group 2 ultimately passed stones (p=0.96).,4577:4698, 3580299 ,23550174,Unavailable
 3580299 ,The patients who required analgesics after ESWL,Alfuzosin 10 mg (once daily) and loxoprofen sodium 68.1 mg (as needed) were prescribed to group 1,loxoprofen sodium 68.1 mg (as needed) only was prescribed to group 2,No significant difference,The patients who required analgesics after ESWL were 8 (19.5%) in group 1 and 13 (30.2%) in group 2 (p=0.31).,4797:4906, 3580299 ,23550174,Unavailable
 3580299 ,severity scores,Alfuzosin 10 mg (once daily) and loxoprofen sodium 68.1 mg (as needed) were prescribed to group 1,loxoprofen sodium 68.1 mg (as needed) only was prescribed to group 2,No significant difference,"Visual analogue scale pain severity scores were 5.33±1.22 and 6.43±1.36 in groups 1 and 2, respectively (p=0.056).",4906:5021, 3580299 ,23550174,Unavailable
 3580299 ,The time to stone expulsion,Alfuzosin 10 mg (once daily) and loxoprofen sodium 68.1 mg (as needed) were prescribed to group 1,loxoprofen sodium 68.1 mg (as needed) only was prescribed to group 2,Significantly decreased,"The time to stone expulsion in groups 1 and 2 was 9.5±4.8 days and 14.7±9.8 days, respectively (p=0.005).",5021:5128, 3580299 ,23550174,Unavailable
 4696193 ,frequency and duration of side effects,ITNs from birth (group A),from age 6&nbsp;months (group B),No significant difference,There were no significant differences in the frequency and duration of side effects between the two study groups,6413:6525, 4696193 ,26714758,Unavailable
 4696193 ,the frequency of headache,ITNs from birth (group A),from age 6&amp;nbsp;months (group B),Significantly increased,except that the frequency of headache was significantly higher in group A compared to group B mothers (p&nbsp;=&nbsp;0.01).,6527:6640, 4696193 ,26714758,Unavailable
 5856890 ,progression-free survival (PFS),osimertinib,platinum-based doublet chemotherapy,Significantly increased,"After adjustment for baseline differences between the two groups, osimertinib demonstrated a statistically significant improvement in progression-free survival (PFS) versus platinum-based doublet chemotherapy (hazard ratio [HR]&nbsp;=&nbsp;0.278, 95% confidence interval [CI] 0.188–0.409, p&nbsp;&lt;&nbsp;0.0001; median PFS 10.9 vs. 5.3&nbsp;months).",6596:6937, 5856890 ,29247383,Unavailable
 5856890 ,objective response rate (ORR) and disease control rate,osimertinib,platinum-based doublet chemotherapy,Significantly increased,"Improvements were also observed for objective response rate (ORR) and disease control rate (DCR) (ORR: 64.3 vs. 33.3%; odds ratio [OR]&nbsp;=&nbsp;5.31, 95% CI 2.47–11.40, p&nbsp;&lt;&nbsp;0.001; DCR: 92.1 vs. 75.0%; OR&nbsp;=&nbsp;4.72, 95% CI 1.92–11.58, p&nbsp;&lt;&nbsp;0.001).",6937:7213, 5856890 ,29247383,Unavailable
 5856890 ,overall survival (OS),osimertinib,platinum-based doublet chemotherapy,Significantly increased,"A statistically significant improvement in OS was observed for the osimertinib group (HR&nbsp;=&nbsp;0.412, 95% CI 0.273–0.622, p&nbsp;&lt;&nbsp;0.0001).",7312:7462, 5856890 ,29247383,Unavailable
 3580671 ,Microbiological success rate,Infusion group,Bolus group,Significantly increased,Microbiological success rate was higher in the Infusion group as opposed to the Bolus group (90.6% vs. 78.4%; P = 0.020).,5795:5933, 3580671 ,22742765,Unavailable
 3580671 ,Meropenem-related ICU stay,Infusion group,Bolus group,Significantly decreased,Meropenem-related ICU stay was shorter in the Infusion group compared to the Bolus group (10 (7 to 14) days vs. 12 (7 to 19) days; P = 0.044),6139:6298, 3580671 ,22742765,Unavailable
 3580671 ,duration of meropenem therapy,Infusion group,Bolus group,Significantly decreased,shorter duration of meropenem therapy (7 (6 to 8) days vs. 8 (7 to 10) days; P = 0.035),6309:6413, 3580671 ,22742765,Unavailable
 3580671 ,total dose of meropenem,Infusion group,Bolus group,Significantly decreased,Meropenem-related ICU stay was shorter in the Infusion group compared to the Bolus group (10 (7 to 14) days vs. 12 (7 to 19) days; P = 0.044) as well as shorter duration of meropenem therapy (7 (6 to 8) days vs. 8 (7 to 10) days; P = 0.035) and lower total dose of meropenem (24 (21 to 32) grams vs. 48 (42 to 60) grams; P &lt; 0.0001).,6138:6524, 3580671 ,22742765,Unavailable
 3580671 ,adverse events,Infusion group,Bolus group,No significant difference,No severe adverse events related to meropenem administration in either group were observed.,6523:6615, 3580671 ,22742765,Unavailable
 5782456 ,reading rates of males and females,"compact fluorescent light (CFL), tungsten light (TUNG)","fluorescent tube light (FLUO), and light emitting diode (LED)",No significant difference,There was no statistically significant difference between the reading rates of males and females under the different illuminations (P = 0.99);,3775:3935, 5782456 ,29403589,Unavailable
 3656551 ,"improvement in immune responses, reactogenicity and safety",thimerosal-free trivalent inactivated influenza vaccine at 2 different doses 0.50&nbsp;mL,thimerosal-free trivalent inactivated influenza vaccine at 2 different doses   0.25&nbsp;mL,No significant difference,"A modest but not statistically significant improvement in immune responses was observed with the higher dose and reactogenicity, and safety of the 2 doses was not significantly different.",5892:6080, 3656551 ,23687572,Unavailable
 5614421 ,The incidence of respiratory distress syndrome,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,No significant difference,"The incidence of respiratory distress syndrome was similar in both study groups—10.5% (42/402) in the progesterone group and 10.6% (41/388) in the placebo group (adjusted relative risk [RR] 0.98, 95% confidence interval [CI] 0.64–1.49, p = 0.912)",15947:16210, 5614421 ,28949973,Unavailable
 5614421 ,severity of any neonatal respiratory disease,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,No significant difference,"The incidence of respiratory distress syndrome was similar in both study groups—10.5% (42/402) in the progesterone group and 10.6% (41/388) in the placebo group (adjusted relative risk [RR] 0.98, 95% confidence interval [CI] 0.64–1.49, p = 0.912)—as was the severity of any neonatal respiratory disease (adjusted treatment effect 1.02, 95% CI 0.69–1.53, p = 0.905).",15947:16346, 5614421 ,28949973,Unavailable
 5614421 ,"other respiratory morbidities and adverse infant outcomes, including serious infant composite outcome",vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,No significant difference,"No differences were seen between study groups for other respiratory morbidities and adverse infant outcomes, including serious infant composite outcome (155/406 [38.2%] in the progesterone group and 152/393 [38.7%] in the placebo group, adjusted RR 0.98, 95% CI 0.82–1.17, p = 0.798).",16347:16648, 5614421 ,28949973,Unavailable
 5614421 ,side effects,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,No significant difference,"In 9.9% (39/394) of the women in the progesterone group and 7.3% (28/382) of the women in the placebo group, treatment was stopped because of side effects (adjusted RR 1.35, 95% CI 0.85–2.15, p = 0.204).",17052:17272, 5614421 ,28949973,Unavailable
 5834147 ,"composite of stroke or systemic embolism), any stroke, cardiovascular mortality, and all-cause mortality",dabigatran,warfarin,No significant difference,"In patients without LVH, the rates of primary outcome were 1.59%/year with warfarin, 1.60% with dabigatran 110 mg (HR vs. warfarin 1.01, 95% confidence interval (CI) 0.75–1.36) and 1.08% with dabigatran 150 mg (HR vs. warfarin 0.68, 95% CI 0.49–0.95).",7007:7259, 5834147 ,28520924,Unavailable
 2869037 ,Average score of preference,frovatriptan (F),zolmitriptan (Z),No significant difference,Average score of preference was 2.9&nbsp;±&nbsp;1.3 (F) versus 3.0&nbsp;±&nbsp;1.3 (Z; p&nbsp;=&nbsp;NS).,4441:4533, 2869037 ,20464583,Unavailable
 2869037 ,Rate of pain-free (PF) episodes at 2&nbsp;h,frovatriptan (F),zolmitriptan (Z),No significant difference,Rate of PF episodes at 2&nbsp;h was 26% with F and 31% with Z (p&nbsp;=&nbsp;NS).,4534:4618, 2869037 ,20464583,Unavailable
 2869037 ,Rate of recurrence,frovatriptan (F),zolmitriptan (Z),No significant difference,Rate of recurrence was 21 (F) and 24% (Z; p&nbsp;=&nbsp;NS).,4693:4760, 2869037 ,20464583,Unavailable
 2869037 ,Time to recurrence within 48&nbsp;h,frovatriptan (F),zolmitriptan (Z),Significantly increased,Time to recurrence within 48&nbsp;h was better for F especially between 4 and 16&nbsp;h (p&nbsp;&lt;&nbsp;0.05).,4761:4868, 2869037 ,20464583,Unavailable
 2869037 ,Drug-related adverse events,frovatriptan (F),zolmitriptan (Z),Significantly decreased,Drug-related adverse events were significantly (p&nbsp;&lt;&nbsp;0.05) less under F (3 vs. 10).,4937:5037, 2869037 ,20464583,Unavailable
 3744251 ,annual average total costs per-test,international organization for standardization (ISO 15189) courses,control group,Significantly decreased,"whereas the post-intervention results showed that the annual average total costs per-test for study and control groups was 1.57 ± 0.23 and 2.08 ± 0.38 SDG, respectively with significant effect (P= 0.019) Table 4.",17948:18119, 3744251 ,23967422,Unavailable
 3744251 ,cost effectiveness,international organization for standardization (ISO 15189) courses,control group,Significantly decreased,while in post-intervention results the cost effectiveness of the study group (1.98) was substantially lower than that of control group (3.84) with efficiency ratio (0.75) and cost effectiveness ratio (0.52) Table 6.,17948:18119, 3744251 ,23967422,Unavailable
 3744251 ,The compliance to ISO 15189,international organization for standardization (ISO 15189) courses,control group,Significantly increased,79 % for study group vs. 54% for control group with P value 0.00 in post intervention phase (Table 2).,17948:18119, 3744251 ,23967422,Unavailable
 5985893 ,"The prevalence of anaemia at term, 37 weeks gestation and above",oral mebendazole (500 mg),placebo,Significantly decreased,"The prevalence of anaemia at term, 37 weeks gestation and above, among the treatment arm was 12.6% compared with 29.9% in the placebo arm (p &lt; 0.001).",4775:4926, 5985893 ,None,Unavailable
 5985893 ,"incidences of postpartum haemorrhage, puerperal pyrexia,  low birth weight, asphyxia and perinatal death",oral mebendazole (500 mg),placebo,No significant difference,"There were no statistically significant differences in incidences of postpartum haemorrhage (p = 0.119), Puerperal, pyrexia (p = 0.943), low birth weight (p = 0.556) asphyxia (p = 0.706) and perinatal death (p = 0.621).",5011:5230, 5985893 ,None,Unavailable
 2596788 ,GERD-knowledge,education,control,Significantly increased,The GERD -education group scored at both times higher than the control group (p &lt; 0.001).,19202:19291, 2596788 ,19014552,Unavailable
 5629746 ,the PaO2 and SpO2 at 24h after extubation,high-flow nasal cannula,air entrainment mask,Significantly increased,"In addition, the HFNC significantly improved the PaO2 and SpO2 at 24h after extubation compared to the air entrainment mask (83.2±10.5 mmHg vs. 74.5±13.1 mmHg, p=0.016; 98.0±1.3% vs. 96.9±1.4%, p=0.011, respectively).",17039:17348, 5629746 ,29069260,Unavailable
 5629746 ,The PaCO2 values,high-flow nasal cannula,air entrainment mask,No significant difference,"The PaCO2 values were similar between the two groups (p=0.591, Table 2).",17348:17499, 5629746 ,29069260,Unavailable
 5629746 ,The respiratory rate,high-flow nasal cannula,air entrainment mask,Significantly decreased,"The respiratory rate was significantly lower for the HFNC group than for the air entrainment mask group (22±3.6 breaths/min vs. 26±4.3 breaths/min, p=0.003).",17499:17690, 5629746 ,29069260,Unavailable
 5629746 ,heart rate and mean arterial pressure,high-flow nasal cannula,air entrainment mask,No significant difference,No significant differences in heart rate and mean arterial pressure were observed between the two groups (Table 2).,17691:17856, 5629746 ,29069260,Unavailable
 5629746 ,Discomforts related to the interface and symptoms of airway dryness,high-flow nasal cannula,air entrainment mask,Significantly decreased,"Discomforts related to the interface and symptoms of airway dryness were significantly lower in the HFNC group than those in the air entrainment mask group [3(3-4.5) vs. 7(6-8); 3(2-3.5) vs. 5(4.7-6), both p&lt;0.001] (Figure 2).",17863:18191, 5629746 ,29069260,Unavailable
 5865491 ,“off” time,Extended-release (ER) carbidopa-levodopa (CD-LD),immediate-release (IR) CD-LD or IR CD-LD plus entacapone (CLE),Significantly decreased,The decrease from baseline to end of double-blind treatment in “off” time was significantly greater in patients given ER CD-LD versus IR CD-LD (Fig. 1A) or ER CD-LD versus CLE (Fig. 1D) with or without concomitant dopaminergic agonist administration.,17500:17825, 5865491 ,29432286,Unavailable
 5865491 ,“on” time without troublesome dyskinesia,Extended-release (ER) carbidopa-levodopa (CD-LD),immediate-release (IR) CD-LD or IR CD-LD plus entacapone (CLE),Significantly increased,The improvement in “on” time without troublesome dyskinesia was significantly greater with ER CD-LD versus IR CD-LD (Fig. 1B; ADVANCE-PD) and with ER CD-LD versus CLE (Fig. 1E; ASCEND-PD) in patients receiving a concomitant dopaminergic agonist.,17825:18144, 5865491 ,29432286,Unavailable
 5865491 ,The overall percentage of adverse events,Extended-release (ER) carbidopa-levodopa (CD-LD),immediate-release (IR) CD-LD or IR CD-LD plus entacapone (CLE),No significant difference,The overall percentage of AEs for those patients taking concomitant medications was similar for ER LD-CD and IR CD-LD groups in ADVANCE-PD and for ER LD-CD and CLE in ASCEND-PD.,23642:23819, 5865491 ,29432286,Unavailable
 5865491 ,“on” time with troublesome dyskinesia,Extended-release (ER) carbidopa-levodopa (CD-LD),immediate-release (IR) CD-LD or IR CD-LD plus entacapone (CLE),No significant difference,"There was no significant change in “on” time with troublesome dyskinesia with ER CD-LD, IR CD-LD, or CLE with or without concomitant amantadine (Figs. 3C, F).",20675:20870, 5865491 ,29432286,Unavailable
 3634960 ,claudication distances (ICDs) in the second treadmill test,no RIPC prior to the first treadmill test and RIPC prior to the second treadmill test,'both treadmill tests were performed without RIPC' or 'RIPC prior to the first treadmill test and no RIPC prior to the second treadmill test',Significantly increased,"urthermore, the ICD was greater in Group A patients when compared with the other groups.",13469:13838, 3634960 ,23778346,Unavailable
 3634960 ,the total walking distance (TWD),no  RIPC prior to the first treadmill test and RIPC prior to the second treadmill test,'both treadmill tests were performed without RIPC' or 'RIPC prior to the first treadmill test and no RIPC prior to the second treadmill test',No significant difference,"Table 2 also shows that the total walking distance (TWD) was lower in the first test than in the second test for Group A and Group B. However, there were no significant differences between the groups (see Figures 1 and 2).",13469:13838, 3634960 ,23778346,Unavailable
 4526972 ,key-feature test results at t1 ,paper handouts with two Web-based VPs with embedded video clips,paper handouts,Significantly increased,"The intervention group showed a significantly superior increase in procedural knowledge at t1 compared with the control group (92.2%, SD 4.7 vs 68.8%, SD 16.3; P&lt;.001).",35273:35470, 4526972 ,26139388,Unavailable
 4526972 ,adherence to the algorithm,paper handouts with two Web-based VPs with embedded video clips,paper handouts,Significantly increased,"Regarding adherence to the algorithm, the intervention group was already better than the control group at t1 (93.4%, SD 7.1 vs 72.0%, SD 17.7; P&lt;.001), which continued at t2 (99.8%, SD 1.1 vs 95.7%, SD 7.2; P=.008).",35666:35941, 4526972 ,26139388,Unavailable
 4526972 ,adherence to temporal specifications,paper handouts with two Web-based VPs with embedded video clips,paper handouts,Significantly increased,"The intervention group already showed significantly better adherence to temporal specifications than the control group at t1 (67.6%, SD 21.4 vs 43.3%, SD 23.4; P&lt;.001), which continued at t2 (82.4%, SD 17.8 vs 55.8%, SD 27.8; P&lt;.001).",36139:36433, 4526972 ,26139388,Unavailable
 4526972 ,The performance quality score,paper handouts with two Web-based VPs with embedded video clips,paper handouts,Significantly increased,"The performance quality score of the intervention group was significantly superior to that of the control group at t1 (68.2%, SD 15.0 vs 48.8%, SD 20.2; P&lt;.001).",36936:37126, 4526972 ,26139388,Unavailable
 4526972 ,The global ratings of competence,paper handouts with two Web-based VPs with embedded video clips,paper handouts,Significantly increased,"The global ratings of competence showed significant differences in favor of the intervention group, again already at t1 and continuing at t2 (0/30 CG vs 5/27 IG rated “competent”, P=.02; 17/30 CG vs 23/27 IG, P=.02, respectively).",37405:37691, 4526972 ,26139388,Unavailable
 5788508 ,systolic blood pressure immediately after anesthesia induction,fentanyl 5μg/kg,1 mg of midazolam along with 2 μg/kg fentanyl,Significantly increased,"However, this increase was transient and after 3 minutes returned to its normal value. post hoc analysis and Scheffe tests showed a difference among groups in terms of systolic blood pressure immediately after anesthesia induction. This difference was especially significant between the fentanyl and the control groups (P&lt;0.001).",16230:16560, 5788508 ,29416204,Unavailable
 5788508 ,diastolic blood pressure after anesthesia induction,three lidocaine spray along with intravenous lidocaine 0.75 mg/kg,1 mg of midazolam along with 2 μg/kg fentanyl,Significantly increased,Statistical tests showed differences in diastolic blood pressure after anesthesia induction among different groups and this difference between group 3 (spray along with intravenous injection) and the control group was statistically significant (P&lt;0.001).,16230:16560, 5788508 ,29416204,Unavailable
 3701780 ,brachial  Flow mediated vasodilation (FMD) after 6 months,atorvastatin 10 mg,atorvastatin 40 mg,No significant difference,"After 6 months of statin therapy, FMD was significantly improved in both groups (from 7.7 ± 2.5% to 8.9 ± 2.2% in group I, p = 0.001, from 7.9 ± 2.7% to 9.5 ± 2.8% in group II, p &lt; 0.001) (Fig. 2), but the FMD at 6 month and the degree of FMD change were not different between the groups.",16524:16886, 3701780 ,23837115,Unavailable
 3701780 ,Nitroglycerin-mediated dilation (NMD) of the brachial artery after 6 months,atorvastatin 10 mg,atorvastatin 40 mg,No significant difference,"After 6 months of statin therapy, NMD was not changed in both groups (from 19.4 ± 5.2% to 19.5 ± 4.9% in group I, from 20.5 ± 5.5% to 21.0 ± 5.4% in group II, p = ns).",17081:17265, 3701780 ,23837115,Unavailable
 3701780 ,carotid IMT and plaque after 6 months,atorvastatin 10 mg,atorvastatin 40 mg,No significant difference,"he carotid IMT was not changed in both groups despite of 6 months of statin therapy (from 0.61 ± 0.06 mm to 0.61 ± 0.06 mm in group I, from 0.60 ± 0.06 mm to 0.60 ± 0.06 mm in group II, p = ns).Carotid plaque was identified 16 patients in group I and 18 patients in group II. The presence of carotid plaque was not different between the groups and was not changed after 6 months of statin therapy.",17493:17914, 3701780 ,23837115,Unavailable
 3701780 ,The decrease of total cholesterol ,atorvastatin 40 mg ,atorvastatin 10 mg,Significantly increased,"The decrease of total cholesterol was significantly greater in group II than in group I,",16086:16175, 3701780 ,23837115,Unavailable
 3701780 ,decrease of LDL-cholesterol,atorvastatin 40 mg ,atorvastatin 10 mg,No significant difference,but the decrease of LDL-cholesterol was not significantly different between the groups (Fig. 1).,16175:16308, 3701780 ,23837115,Unavailable
 3626633 ,"Body weight at week 4, 8, 12",Calcium plus vitamin D3,Control,No significant difference,Body weight (kg)	−2.2 ± 1.4 b	−1.7 ± 1.2	0.16	−3.3 ± 1.6	−3.3 ± 1.4	0.94	−4.1 ± 1.8	−3.5 ± 1.9	0.25,6333:NaN, 3626633 ,None,Unavailable
 3626633 ,Fat mass at week 4,Calcium plus vitamin D3,Control,No significant difference,Fat mass (kg)	−1.7 ± 1.7	−1.0 ± 1.1	0.13,6931:7164, 3626633 ,None,Unavailable
 3626633 ,Fat mass at week 8 and 12,Calcium plus vitamin D3,Control,Significantly decreased,Fat mass (kg)	−1.7 ± 1.7	−1.0 ± 1.1	0.13	−2.4 ± 1.2	−1.7 ± 0.8	0.03	−2.8 ± 1.3	−1.8 ± 1.3	0.02,6931:NaN, 3626633 ,None,Unavailable
 3626633 ,"Lean mass (kg) at week 4, 8 , 12",Calcium plus vitamin D3,Control,No significant difference,Lean mass (kg)	−0.4 ± 1.0	−0.5 ± 1.2	0.77	−0.8 ± 0.9	−1.2 ± 1.7	0.24	−1.1 ± 1.1	−1.4 ± 1.2	0.31,8104:NaN, 3626633 ,None,Unavailable
 3626633 ,"visceral fat area VFA (cm2) at week 8 , 12",Calcium plus vitamin D3,Control,Significantly decreased,VFA (cm2) c	−6.6 ± 7.6	−2.9 ± 6.6	0.12	−10.9 ± 7.2	−4.6 ± 4.9	&lt;0.01	−12.0 ± 6.4	−6.5 ± 7.2	0.02,9279:9606, 3626633 ,None,Unavailable
 5883519 , BMI standard deviation scores (SDS) at the 6-month ,recombinant human growth hormone (rhGH),control ,Significantly decreased,"At the 6-month visit, the BMI SDS of subjects in the rhGH treatment group were significantly reduced compared with controls (2.32 ± 0.85 vs. 2.80 ± 0.61; P = 0.041) (Table 3, Fig. 2a).",32023:32327, 5883519 ,29615058,Unavailable
 5883519 ,Insulin-like growth factor 1(IGF-1) at the 3-month and 6-month,recombinant human growth hormone (rhGH),control ,Significantly increased,"At the 3-month visit, there was a significant increase in IGF-1 in the rhGH treatment group compared with the control group (587.35 ± 271.74 vs. 345.60 ± 131.75 ng/mL, P = 0.001) (Table 2). At the 6-month visit, IGF-1 level increased during rhGH treatment, in comparison with the control group (702.91 ± 246.03 vs. 348.3 ± 131.93 ng/mL, P &lt; 0.001) (Table 3, Fig. 2b).",32023:32327, 5883519 ,29615058,Unavailable
 5883519 ,LDL-C at the 6-month,recombinant human growth hormone (rhGH),control ,Significantly decreased,"At the 6-month visit, LDL-C values decreased (2.20 ± 0.45 vs. 2.63 ± 0.76 mmol/L, P = 0.027) (Fig. 2c)",30976:31135, 5883519 ,29615058,Unavailable
 5883519 ,HDL-C level,recombinant human growth hormone (rhGH),control ,Significantly increased,"and HDL-C level increased (1.45 ± 0.40 vs. 1.19 ± 0.23 mmol/L, P = 0.016) (Fig. 2d) in the rhGH treatment group compared with the control group.",31135:31336, 5883519 ,29615058,Unavailable
 5883519 ,AST and ALT at the 6-month,recombinant human growth hormone (rhGH),control ,Significantly decreased,"At the 6-month visit, the 6-month rhGH treatment reduced serum levels of AST (21.26 ± 5.72 vs. 32.30 ± 17.68 mmol/L, P = 0.006) and ALT (16.70 ± 6.72 vs. 45.20 ± 46.62 mmol/L, P = 0.002) compared with the control group (Table 3).",32023:32327, 5883519 ,29615058,Unavailable
 5827475 ,PIP during maximum flexion ,I-Gel™ ,ProSeal™ laryngeal mask airway (PLMA),Significantly increased,"Significantly higher PIP was recorded with I-Gel™ than PLMA during maximum flexion (17.7[4] vs. 14.6 [2.4] cm H2O, P = 0.001), [Table 2].",16216:16370, 5827475 ,29491514,Unavailable
 5827475 ,The percentage increase in PIP from neutral to flexion,I-Gel™ ,ProSeal™ laryngeal mask airway (PLMA),Significantly increased,"The percentage increase in PIP from neutral to flexion was significantly more with I-Gel™ compared to PLMA (51.2% vs. 25.9%, P &lt; 0.001).",16216:16370, 5827475 ,29491514,Unavailable
 5827475 ,expired tidal volume inflexion,ProSeal™ laryngeal mask airway (PLMA) ,I-Gel™ ,Significantly increased,PLMA had significantly higher expired tidal volume inflexion compared to I-Gel™ (P = 0.0017) [Table 2].,16536:16696, 5827475 ,29491514,Unavailable
 5827475 ,percentage decrease in expired tidal volume during flexion ,I-Gel™ ,ProSeal™ laryngeal mask airway (PLMA),Significantly increased,Significantly greater percentage decrease in expired tidal volume was seen with I-Gel™ compared to PLMA (38.6% vs. 23.6%) during flexion (P = 0.001).,16695:16862, 5827475 ,29491514,Unavailable
 5827475 ,ventilation scores in all the three positions.,I-Gel™ ,ProSeal™ laryngeal mask airway (PLMA),No significant difference,"There was worsening of ventilation score median (range) with both PLMA 1 (0–3) and I-Gel™ 1 (0–3) inflexion of the head-and-neck. However, the ventilation scores were comparable between the two devices in all the three positions.",16869:17098, 5827475 ,29491514,Unavailable
 4355142 ,"absolute monocytes, MCH, creatinine, eGFR , and total cholesterol","Pre-workout supplements (PWS) (caffeine, beta-alanine, and nitrate in undisclosed dosages)",remain unsupplemented (CRL),No significant difference,"Although there were statistically significant (p &lt; 0.05) group by time interactions for absolute monocytes, MCH, creatinine, eGFR, and total cholesterol, all of the results remained well within accepted physiological ranges and were not clinically significant.",6232:6492, 4355142 ,25762869,Unavailable
 5777641 ,SCL90,"cognitive therapy, relaxation therapy and emotional support",control,Significantly decreased,SCL90	132.73±20.60	172.57±38.067	0.00,51539:51724, 5777641 ,29357358,Unavailable
 5777641 ,MCMQ,"cognitive therapy, relaxation therapy and emotional support",control,Significantly increased,MCMQ	51.03±3.39	49.13±3.15	0.03,54291:54470, 5777641 ,29357358,Unavailable
 5777641 ,IL-2 (ng/ml),"cognitive therapy, relaxation therapy and emotional support",control,Significantly increased,IL-2 (ng/ml)	35.22±10.52	30.02±8.34	0.04,55284:55472, 5777641 ,29357358,Unavailable
 5777641 ,Cortisol,"cognitive therapy, relaxation therapy and emotional support",control,Significantly decreased,Cortisol (ng/ml)	302.23±79.49	442.41±67.60	0.00,55533:55728, 5777641 ,29357358,Unavailable
 5789504 ,The mean time taken to intubate,C-MAC D-Blade videolaryngoscope™,standard Macintosh laryngoscope,Significantly decreased,The mean time taken to intubate with Macintosh laryngoscope was 50.34 ± 26.76 s whereas with C-MAC D-Blade time taken was 39.56 ± 15.65 s in Group C (P &lt; 0.05) and is statistically significant [Figure 3].,16470:16731, 5789504 ,29416454,Unavailable
 5789504 ,The percentage of Cormack–Lehane Grade 1,C-MAC D-Blade videolaryngoscope™,standard Macintosh laryngoscope,Significantly increased,"The percentage of Cormack–Lehane Grade 1 was much higher in the C-Mac D-Blade group as compared to Macintosh group [Table 3]. Eighty-six percent (43/50) patients had CL Grade 1 versus 30% (15/50, P &lt; 0.001), 6% (3/50) patients had CL Grade IIa versus 16% (11/50, P = 0.041), 4% (2/50) had CL Grade IIb versus 16% (12/50, P = 0.008), 4% (2/50) had Grade III versus 22% (11/50, P = 0.015), and none versus 1 patient had CL Grade IV in C-Mac D-Blade and Macintosh group, respectively [Table 3].",17400:18040, 5789504 ,29416454,Unavailable
 5789504 ,"number of patients, which were successfully intubated in first attempt",C-MAC D-Blade videolaryngoscope™,standard Macintosh laryngoscope,Significantly increased,"In Group C, 98% (49/50) patients were intubated in first attempt and one patient required second attempt due to inadequate exposure, and in Group M, 86%(42/50, P = 0.031) were intubated in first attempt,",18863:19283, 5789504 ,29416454,Unavailable
 5789504 ,"number of patients, which were intubated directly without difficulty",C-MAC D-Blade videolaryngoscope™,standard Macintosh laryngoscope,Significantly increased,"The use of accessory maneuvers was less in D-Blade group compared to Macintosh group. Nearly 52% (26/50) of patients were intubated directly without difficulty and 34% (17/50) required external laryngeal manipulation. In Macintosh group, 30% (15/50, P &lt; 0.05) of patients were intubated directly without difficulty and 68% (34/50, P = 0.001) required external laryngeal manipulation.",18863:19283, 5789504 ,29416454,Unavailable
 5789504 ,"number of anesthetists, which considered intubations as easy",C-MAC D-Blade videolaryngoscope™,standard Macintosh laryngoscope,Significantly increased,The intubating anesthetists considered 47/50 (94%) intubations as easy in D-Blade group versus 29/50 (58%) in the Macintosh group (P &lt; 0.001).,19503:19662, 5789504 ,29416454,Unavailable
 3643134 ,number of students which were more likely to define the steps of cesarean section,simulator-based training,no simulator-based training,Significantly increased,"Compared with their peers in the study, students in the simulator group were significantly more likely to define the steps of cesarean section (91% vs 61.5%),",11345:11504, 3643134 ,23745067,Unavailable
 3643134 ,number of students which were comfortable in assisting cesarean section,simulator-based training,no simulator-based training,Significantly increased,and were comfortable in assisting cesarean section (100% vs 46.15%) as they were able to identify the layers of abdomen opened during cesarean section.,11503:11655, 3643134 ,23745067,Unavailable
 3643134 ,number of students which were able to identify the basic instruments for the procedure,simulator-based training,no simulator-based training,Significantly increased,Twelve students (100%) in the simulator group were able to identify the basic instruments for the procedure compared with only 3 of 13 in the control group of students (23%).,11656:11831, 3643134 ,23745067,Unavailable
 3643134 ,number of students which were ready to close the rectus sheath and skin under supervision,simulator-based training,no simulator-based training,Significantly increased,"hen asked whether they felt ready to close the rectus sheath and skin under supervision, 12 students (100%) in the simulator group indicated that they felt confident that they could perform the procedure with minimal supervision or independently, compared with only 2 of 13 in the control group of students (15.3%) (Table 1).",11832:12208, 3643134 ,23745067,Unavailable
 5801514 ,Competence,high amounts of medical technical jargon (MTJ),low amounts of medical technical jargon (MTJ),Significantly increased,"Both main effects showed significance: MTJ affected all the 3 subscales of the METI; Expertise F1,96=37.54, P&lt;.001, ηp2=.28, Integrity, F1,96=10.77, P=.001, ηp2=.101, and Benevolence, F1,96=9.75, P=.002, ηp2=.092. High amounts of MTJ led to higher expertise ratings (mean 2.82, SD 0.80) than did low amounts of MTJ (mean 3.19, SD 0.79).",38645:38859, 5801514 ,29362212,Unavailable
 5801514 ,Integrity and Benevolence ratings ,high amounts of medical technical jargon (MTJ),low amounts of medical technical jargon (MTJ),Significantly decreased,"However, low amounts of MTJ led to higher Integrity (mean 3.42, SD 0.62) and Benevolence ratings (mean 3.47, SD 0.67) compared with conditions of high amounts of MTJ (Integrity: mean 3.57, SD 0.55; Benevolence: mean 3.66, SD 0.57).",40194:40425, 5801514 ,29362212,Unavailable
 5801514 ,accommodation to the audience ,high amounts of medical technical jargon (MTJ),low amounts of medical technical jargon (MTJ),Significantly decreased,"MTJ affected the overall score of the ROS and all subscales, all F1,96≥72.17, P&lt;.001, ηp2≥.43, where more expert accommodation was found in the low MTJ condition.",38645:38859, 5801514 ,29362212,Unavailable
 5801514 ,Credibility of Information,high amounts of medical technical jargon (MTJ),low amounts of medical technical jargon (MTJ),No significant difference,"There were no main effects of MTJ (F1,96=0.07, P=.40) and of designated audience (F1,96=0.52, P=.24) regarding credibility.",38645:38859, 5801514 ,29362212,Unavailable
 5805693 ,percentage of time below 4.0 mmol/L,adequately categorized breakfast  with a dual-hormone (insulin and glucagon) closed-loop system (DH-CLS) ,overestimated breakfast with a dual-hormone (insulin and glucagon) closed-loop system (DH-CLS) ,No significant difference,"For both meals, percentage of time &lt;4.0 mmol/L did not differ between the adequate estimation and overestimation (0 [0–0] vs. 0 [0–0]% for both meals, p = 0.47 and p = 0.31 for the 75 g and 45 g meals, respectively).",23095:23307, 5805693 ,29422651,Unavailable
 5805693 ,"time in target range (4.0 to 10.0 mmol/L), peak glucose, and time to peak glucose",adequately categorized breakfast  with a dual-hormone (insulin and glucagon) closed-loop system (DH-CLS) ,overestimated breakfast with a dual-hormone (insulin and glucagon) closed-loop system (DH-CLS) ,No significant difference,"No significant difference was observed in any of the other secondary outcomes including time in target range (4.0 to 10.0 mmol/L), peak glucose, and time to peak glucose between overestimation or adequate estimation (p &gt; 0.05).Figure 2",23095:23307, 5805693 ,29422651,Unavailable
 5805693 ,meal insulin boluses,adequately categorized breakfast  with a dual-hormone (insulin and glucagon) closed-loop system (DH-CLS) ,overestimated breakfast with a dual-hormone (insulin and glucagon) closed-loop system (DH-CLS) ,Significantly increased,"For the 75 g of carbohydrate meal, despite different meal insulin boluses (8.1 [7.3–9.1] vs. 9.2 [8.2–9.6] U; p = 0.03), the subsequent basal insulin infusion over 4-h was not different in adequate estimation compared to overestimation (4.2 [3.9–5.3] vs. 4.3 [3.1–5.4] U; p = 0.60) (Table 3).",23095:23307, 5805693 ,29422651,Unavailable
 5805693 ,the subsequent basal insulin infusion over 4-h ,adequately categorized breakfast  with a dual-hormone (insulin and glucagon) closed-loop system (DH-CLS) ,overestimated breakfast with a dual-hormone (insulin and glucagon) closed-loop system (DH-CLS) ,No significant difference,the subsequent basal insulin infusion over 4-h was not different in adequate estimation compared to overestimation (4.2 [3.9–5.3] vs. 4.3 [3.1–5.4] U; p = 0.60) (Table 3).,23095:23307, 5805693 ,29422651,Unavailable
 4756949 ,"decrease of FEV1, FVC, FEF25 and FEF25–75 after the operation",laparoscopic nephrectomy  (LN),open nephrectomy (ON),Significantly decreased,"In both groups, a decrease in all spirometric variables was detected on the postoperative day 1. A decrease of 39.7%, 37.4%, 27.7%, 51.8% in Group ON and 29.9%, 32.5%, 23.2%, 44.5% in Group LN was detected for FEV1, FVC, FEF25 and FEF25–75, respectively, when compared to preoperative values. The difference was significantly lower in Group LN (p&lt;0.05).",28671:28823, 4756949 ,26742981,Unavailable
 4756949 ,PEF and FIV1,laparoscopic nephrectomy  (LN),open nephrectomy (ON),No significant difference,PEF and FIV1 showed the same tendency in both groups without a significant difference between the two groups.,16535:16658, 4756949 ,26742981,Unavailable
 4756949 ,"Blood gas data (PaCO2, PaO2, SaO2, pH)",laparoscopic nephrectomy  (LN),open nephrectomy (ON),No significant difference,Blood gas data are presented in Table-3. There were no statistically significant differences between the two groups for all parameters of blood gas analysis.,23509:23705, 4756949 ,26742981,Unavailable
 4756949 ,VAS = Visual analogue scale,laparoscopic nephrectomy  (LN),open nephrectomy (ON),No significant difference,"The VAS pain scores were similar in both groups half an hour, an hour and 24 hours after the operation (Table-4).",28671:28823, 4756949 ,26742981,Unavailable
 4431716 ,The average hospitalization,osteopathic manipulative treatment,usual prenatal care,Significantly decreased,The average hospitalization for the study group and control group was 13.8 (8.1) and 17.5 (14.5) respectively (p value &lt;0.001).,36491:36619, 4431716 ,25974071,Unavailable
 4431716 ,The mean cost per newborn,osteopathic manipulative treatment,usual prenatal care,Significantly decreased,"The mean cost per newborn in the study group was 6,277.28 € and 7,863.29€ for the controls. This led to a difference between the two groups of 1,586.01€ (95% CI 1,087.18 to 6,277.28; p&lt;0.001) per newborn.",40417:40621, 4431716 ,25974071,Unavailable
 4431716 ,A drop-out from the study,osteopathic manipulative treatment,usual prenatal care,No significant difference,"A drop-out analysis showed that the rate in the study group was 2.2% (8/360) compared to 4.7% (17/360) in the controls (X2 = 3.36; RR = 0.47; 95% CI 0.21–1.08; z = 1.76, p = 0.07).",45407:45600, 4431716 ,25974071,Unavailable
 4431716 ,Adverse events,osteopathic manipulative treatment,usual prenatal care,No significant difference,"Moreover, no morbidities and/or complications were observed after the application of OMT.",45599:45689, 4431716 ,25974071,Unavailable
 3532036 ,"survival with disease, and overall survival",sorafenib 400 mg bid,capecitabine 1500 mg bid,Significantly increased,"On the other hand, survival with disease (χ2 = 6.901, P = 0.009) and overall survival (χ2 = 7.154, P = 0.007) were significantly longer in the sorafenib group than in the capecitabine group.",13640:13886, 3532036 ,23277740,Unavailable
 3532036 ,disease-free survival,sorafenib 400 mg bid,capecitabine 1500 mg bid,No significant difference,"Although disease-free survival was longer in the sorafenib group, this was not significantly different compared with the capecitabine group (χ2 = 2.444, P = 0.118).",13447:13640, 3532036 ,23277740,Unavailable
 3532036 ,The one-year recurrence rates of the disease,sorafenib 400 mg bid,capecitabine 1500 mg bid,Significantly decreased,"The one-year recurrence rates were 53.3% and 86.6% in patients treated with sorafenib and capecitabine, respectively (χ2 = 3.968, P &lt; 0.05),",3908:4077, 3532036 ,23277740,Unavailable
 3532036 ,the one-year survival rates,sorafenib 400 mg bid,capecitabine 1500 mg bid,Significantly increased,"and the one-year survival rates were 93.3% and 46.6%, respectively (χ2 = 7.777, P &lt; 0.05).",4076:4198, 3532036 ,23277740,Unavailable
 3532036 ,The incidence of diarrhea and hand-foot syndrome,sorafenib 400 mg bid,capecitabine 1500 mg bid,Significantly increased,"The incidence of diarrhea and hand-foot syndrome was significantly higher and that of rash and hypertension was slightly higher, although not significantly, in the sorafenib group than in the capecitabine group.",14477:14689, 3532036 ,23277740,Unavailable
 3626227 ,pain at one week and at four weeks,2 ml autologous blood drawn from contralateral upper limb vein + 1 ml 0.5% bupivacaine,2 ml local corticosteroid + 1 ml 0.5% bupivacaine,Significantly increased,"The corticosteroid injection group showed a statistically significant decrease in pain compared with autologous blood injection group in both visual analogue scale (VAS) and Nirschl stage at one week (both p &lt; 0.001) and at four weeks (p = 0.002 and p = 0.018, respectively).",-1:-1, 3626227 ,23610690,Unavailable
 3626227 ,pain at the 12-week and six-month follow-up,2 ml autologous blood drawn from contralateral upper limb vein + 1 ml 0.5% bupivacaine,2 ml local corticosteroid + 1 ml 0.5% bupivacaine,Significantly decreased,"At the 12-week and six-month follow-up, autologous blood injection group showed statistically significant decrease in pain compared with corticosteroid injection group (12 weeks: VAS p = 0.013 and Nirschl stage p = 0.018; six months: VAS p = 0.006 and Nirschl p = 0.006).",4416:4687, 3626227 ,23610690,Unavailable
 3744465 ,heart rate (HR),"40 g/d PSPC (N = 17) (2,136 mg/d gallic acid equivalents)",placebo,No significant difference,"For PSPC and placebo groups, 3-d averages during 7.5 h running for heart rate (HR) were 152±15.3 (82.1±3.6% HRmax) and 151±9.7 bpm (84.2±3.6% HRmax),",48131:48302, 3744465 ,23967286,Unavailable
 3744465 ,oxygen consumption (VO2),"40 g/d PSPC (N = 17) (2,136 mg/d gallic acid equivalents)",placebo,No significant difference,"oxygen consumption (VO2) were 37.8±3.9 (66.5±7.2% VO2max) and 36.5±3.2 ml.kg−1.min−1 (67.8±7.9% VO2max), respectively (P = 0.326),",48330:48526, 3744465 ,23967286,Unavailable
 3744465 ,Other gut-derived metabolites,"40 g/d PSPC (N = 17) (2,136 mg/d gallic acid equivalents)",placebo,Significantly increased,"Other gut-derived metabolites from PSPC polyphenolics that were elevated post-exercise compared to placebo included 2-hydroxyhippurate (interaction effect, P = 0.0221), 3-hydroxyhippurate (P = 0.0352), catechol sulfate (P = 0.0687), and O-methylcatecholsulfate (P = 0.085).",55700:55973, 3744465 ,23967286,Unavailable
 3744465 ,"5, 3-hydroxybutyrate (3-HBA) and acetoacetate (AcAc)","40 g/d PSPC (N = 17) (2,136 mg/d gallic acid equivalents)",placebo,Significantly increased,"As summarized in Figures 4 and 5, 3-hydroxybutyrate (3-HBA) and acetoacetate (AcAc) were elevated in PSPC versus placebo at the recovery time point (fold differences, 1.75 and 1.60, respectively, both contrasts, P&lt;0.01, with Q-values of 0.265 and 0.246, respectively), indicative of increased fatty acid oxidation and ketone synthesis.",53664:54155, 3744465 ,23967286,Unavailable
 5027814 ,Time to clinically definite multiple sclerosis (CDMS),early treatment ,late treatment,Significantly increased,Time to CDMS was shorter in the delayed-treatment arm (log rank p = 0.0034),72772:72814, 5027814 ,27511182,Unavailable
 5027814 ,time to first relapse,early treatment ,late treatment,Significantly increased,"Time to CDMS was shorter in the delayed-treatment arm (log rank p = 0.0034) as well as time to first relapse (hazard ratio 0.655 [95% CI 0.517–0.830], p = 0.0005).",72772:72814, 5027814 ,27511182,Unavailable
 5027814 ,risk of relapses,early treatment ,late treatment,Significantly decreased,"The overall ARR over the 11-year study period was lower in the early-treatment group than in the delayed-treatment group, resulting in a 19.1% reduction in risk of relapses (risk ratio [RR] 0.8094 [95% CI 0.7090–0.9242], p = 0.0018; figure 2B).",87192:87491, 5027814 ,27511182,Unavailable
 5027814 , Paced Auditory Serial Addition Task–3 (PASAT-3) total score,early treatment ,late treatment,Significantly increased,"Over the entire study period, the mean PASAT-3 total score was higher in the early- than the delayed-treatment group (p = 0.0070). PASAT-3 = Paced Auditory Serial Addition Task–3.",90788:90984, 5027814 ,27511182,Unavailable
 5027814 ,MRI metrics,early treatment ,late treatment,No significant difference,MRI metrics did not differ between groups.,72772:72814, 5027814 ,27511182,Unavailable
 3640933 ,Health knowledge,eight classroom sessions on smoking prevention education over two months,control,Significantly increased,Health knowledge (mean ± SD)	6.7 ± 2.4***	7.7 ± 2.6	6.8 ± 2.8***	8.6 ± 2.6	&lt; 0.001,37908:NaN, 3640933 ,23596980,Unavailable
 3640933 ,Smoking attitude (mean ± SD),eight classroom sessions on smoking prevention education over two months,control,Significantly increased,Smoking attitude (mean ± SD)	51.1 ± 14.4***	41.5 ± 10.7	46.1 ± 10.1*	42 ± 9.5	&lt; 0.001,38673:38998, 3640933 ,23596980,Unavailable
 3640933 ,Intention to smoke next year,eight classroom sessions on smoking prevention education over two months,control,No significant difference,"Following the intervention, there were no significant main effects on intention to smoke in next year for either the health-based program (OR = 1.1, 95% CI = 0.3–3.4, p = 0.91) or the Islamic-based program (OR = 1.0, 95% CI = 0.3–3.1, p = 0.95) (Table 3).",52457:52768, 3640933 ,23596980,Unavailable
 3640933 ,Intention to smoke when older,eight classroom sessions on smoking prevention education over two months,control,No significant difference,"Following the interventions, there were no significant main effects on intention to smoke when older for either the health-based program (OR = 1.2, 95% CI = 0.6–2.4, p = 0.52) or the Islamic-based program (OR = 1.4, 95% CI = 0.7–2.7, p = 0.31)",66373:66617, 3640933 ,23596980,Unavailable
 3640933 ,intention to smoke during senior high school,eight classroom sessions on smoking prevention education over two months,control,No significant difference,"Following the intervention, there were no significant main effects on intention to smoke during senior high school for either the Islamic-based program (OR = 1.1, 95% CI = 0.4–3.1, p = 0.80) or the health-based program (OR = 1.2, 95% CI = 0.4–3.2, p = 0.73) (Table 4).",65542:65849, 3640933 ,23596980,Unavailable
 3573541 ,Uric acid,yoga,controls,No significant difference,"There was an increase in the mean uric acid level as the pregnancy advanced, in both groups, with no significant difference between groups (P &gt; 0.05).",21277:21445, 3573541 ,23440456,Unavailable
 3573541 ,Pregnancy-induced hypertension / pre-eclampsia,yoga,controls,Significantly decreased,"There were 12 (37.7%) cases of PIH / PE in the control group, while only 3 (10.3%) in the yoga group, resulting in a highly significant difference between the means (P = 0.018, chi2) [Table 5].",22830:23090, 3573541 ,23440456,Unavailable
 3573541 ,number of women with reduced platelet count (within normal range) at 20th to 28th week,yoga,controls,Significantly increased,"A subgroup analysis on the number of subjects who had increased platelet or decreased platelet counts in the two groups showed that the number of women with reduced platelet count (within normal range) was significantly higher in the yoga group than in the control group, at the twentieth (P = 0.016, Chi2 = 8.32) and also in twenty-eighth week (P=0.004, chi2 = 8.09).",20681:21105, 3573541 ,23440456,Unavailable
 4967511 ,Coordination with Precision,Programmes based on the World Health Organization’s Health Promoting Schools framework (HPS),control,Significantly increased,"Children in the intervention arm compared with those in the control group had better results for Coordination with Precision (additional 2.58 steps balancing backwards on a beam, p =0.01),)",42298:42506, 4967511 ,27475339,Unavailable
 4967511 ,Spatial Orientation Skills,Programmes based on the World Health Organization’s Health Promoting Schools framework (HPS),control,Significantly increased,"Spatial Orientation Skills” (additional 0.46 points in correctly touched balls, p &lt; 0.01. Higher scores indicate better spatial orientation skills)",42506:42671, 4967511 ,27475339,Unavailable
 4967511 ,Complex Reaction Ability,Programmes based on the World Health Organization’s Health Promoting Schools framework (HPS),control,Significantly increased,"a faster Complex Reaction Ability (12.38 cm less distance till a ball could be stopped, p &lt; 0.01. Shorter distance indicates better complex reaction ability).",42675:42854, 4967511 ,27475339,Unavailable
 4967511 ,"Emotional and Social Experience in school, Physical Activity, Well-being, and Attention Performance",Programmes based on the World Health Organization’s Health Promoting Schools framework (HPS),control,No significant difference,"We could not detect any statistically significant differences between groups for the outcomecategories Emotional and Social Experience in school (p = 0.22 to 0.78), Physical Activity, Well-being, and Attention Performance.",6000:6291, 4967511 ,27475339,Unavailable
 3474842 ,influenza attack rate among residents,oseltamivir (75 mg twice a day for 5 days) (T&amp;P) ,oseltamivir  75 mg once a day for 10 days (T),Significantly decreased,The policy of T&amp;P resulted in a significant reduction in the influenza attack rate amongst residents: 93/255 (36%) in residents in T facilities versus 91/397 (23%) in T&amp;P facilities (p = 0.002).,9876:10071, 3474842 ,23082123,Unavailable
 3474842 ,influenza attack rate among staff,oseltamivir (75 mg twice a day for 5 days) (T&amp;amp;P) ,oseltamivir  75 mg once a day for 10 days (T),No significant difference,We observed a non-significant reduction in staff: 46/216 (21%) in T facilities versus 47/350 (13%) in T&amp;P facilities (p = 0.5).,10071:10198, 3474842 ,23082123,Unavailable
 3474842 ,mean duration of outbreaks,oseltamivir (75 mg twice a day for 5 days) (T&amp;amp;P) ,oseltamivir  75 mg once a day for 10 days (T),Significantly decreased,"There was a significant reduction in mean duration of outbreaks (T = 24 days, T&amp;P = 11 days, p = 0.04).",10199:10303, 3474842 ,23082123,Unavailable
 3474842 ,"Deaths, hospitalisations and pneumonia",oseltamivir (75 mg twice a day for 5 days) (T&amp;amp;amp;P) ,oseltamivir  75 mg once a day for 10 days (T),No significant difference,"Deaths, hospitalisations and pneumonia were non-significantly reduced in the T&amp;P allocated facilities.",10303:10406, 3474842 ,23082123,Unavailable
 5155184 ,"heart rate, oxygen saturation level, or ECG changes",inhalation of nitrous oxide,inhalation of pure oxygen,No significant difference,"There was no significant difference in heart rate, oxygen saturation level, or ECG changes between the two groups.",16613:16727, 5155184 ,28028373,Unavailable
 5155184 ,Physician and patient satisfaction,inhalation of nitrous oxide,inhalation of pure oxygen,Significantly increased,"Physician and patient satisfaction with the examination process was significantly higher in the nitrous oxide group compared with the pure oxygen group (patient scores 87 vs 72, t = 4.702, P &lt; 0.05; physician scores 91 vs 70, t = 10.163, P &lt; 0.05).",18742:19095, 5155184 ,28028373,Unavailable
 5769181 ,Mean glycosylated hemoglobin,12 weeks of telephone follow-up training by the center,no follow-up,Significantly decreased,Independent t-test showed a statistically significant difference between experimental and control groups in terms of mean glycosylated hemoglobin after the intervention (p = 0.030) [Table 3].,15345:15610, 5769181 ,29344042,Unavailable
 5769181 ,the mean score of self-care,12 weeks of telephone follow-up training by the center,no follow-up,Significantly increased,Paired t-test showed a statistically significant difference between the mean self-care score before and after the intervention in the experimental group (p &lt; 0.001).,15903:16103, 5769181 ,29344042,Unavailable
 3493721 ,long-term survival,Weekly granulocyte/monocyte adsorption (GMA),no additional intervention,Significantly increased,"Accordingly, we believe that the monthly GMA should increase the long-term survival (without relapse) as indicated by the Kaplan-Meier survival analysis (p=0.0219, vs Sham; p=0.0439, vs Control).",19481:19677, 3493721 ,23170145,Unavailable
 3493721 ,non-relapsing ratio (% avoiding relapse [AR]) over week 48,Weekly granulocyte/monocyte adsorption (GMA),no additional intervention,No significant difference,"AR rates in True, Sham, and Control were 40.0%, 9.1%, 18.2%, respectively, yet statistically no significant difference was seen between the three arms (Fig. 3).",18375:18573, 3493721 ,23170145,Unavailable
 2825665 , decline Disability Assessment for Dementia scale,synthetic amyloid-β peptide (Aβ42) (AN1792),placebo,Significantly increased,Significantly less decline was observed on the Disability Assessment for Dementia scale among antibody responders than placebo-treated patients (p=0.015) after 4.6 years.,5652:5841, 2825665 ,19355849,Unavailable
 2825665 ,Dependence Scale,synthetic amyloid-β peptide (Aβ42) (AN1792),placebo,Significantly decreased,Significant differences in favor of responders were also observed on the Dependence Scale (p=0.033).,5841:5958, 2825665 ,19355849,Unavailable
 2825665 ,Clinical Dementia Rating–Sum of Boxes (CDR-SOB),synthetic amyloid-β peptide (Aβ42) (AN1792),placebo,No significant difference,"although this difference was not statistically significant (mean change ± SD of 7.63 ± 4.48 for placebo vs 6.09 ± 4.75 for antibody responders, p=0.185).",26869:27039, 2825665 ,19355849,Unavailable
 3872586 ,The specimen retrieval time,10-mm transumbilical group,5-mm transabdominal group,Significantly decreased,"The specimen retrieval time was significantly shorter in the transumbilical group than in the transabdominal group (43.5 ± 14.5 s vs. 69.4 ± 20.5 s, P &lt; 0.001).",14544:14722, 3872586 ,24381621,Unavailable
 3872586 ,intact tubes,10-mm transumbilical group,5-mm transabdominal group,Significantly increased,"On the other hand, specimen evaluation after complete removal of the retrieval bag showed that intact tubes were detected in 3 cases in the transabdominal group and 18 cases in the transumbilical group (P &lt; 0.001, OR: 51.0, CI 95%: 7.56-343.73).",15082:15345, 3872586 ,24381621,Unavailable
 3872586 ,"overall satisfaction with surgery, cosmetic results",10-mm transumbilical group,5-mm transabdominal group,No significant difference,"Similar rating were obtained in the transumbilical group and the transabdominal group with regard to overall satisfaction with surgery (9.2 ± 0.6 vs. 9.5 ± 0.6, respectively, P = 0.69) and cosmetic results (9.6 ± 0.5 vs. 9.8 ± 0.4, respectively, P = 0.74).",15578:15871, 3872586 ,24381621,Unavailable
 3525027 ,Pao2 and PH,"NTG 50 μg/min (Group N1), 100 μg/min (Group N2)",150 μg/min (Group N3),No significant difference,No significant difference was noted in mean values of Pao2 and PH during surgery between three groups (P &gt; 0.05).,5423:5554, 3525027 ,23264783,Unavailable
 3525027 ,HCO3,"NTG 50 μg/min (Group N1), 100 μg/min (Group N2)",150 μg/min (Group N3),No significant difference,There was no significant difference in HCO3 values in different time intervals among three groups (P &gt; 0.05).,5554:5683, 3525027 ,23264783,Unavailable
 3659039 ,Plasma PC Eicosapentaenoic acid (EPA),72 hour infusion of total parenteral nutrition with (treatment group),without (control group) omega-3 PUFAs,Significantly increased,"Plasma PC EPA was higher in the treatment group than in the control group at 20, 44, 68 and 72 hr (all P &lt; 0.001).",17250:17365, 3659039 ,23648075,Unavailable
 3659039 ,Plasma PC docosahexaenoic acid (DHA),72 hour infusion of total parenteral nutrition with (treatment group),without (control group) omega-3 PUFAs,Significantly increased,Plasma PC DHA was higher in the treatment group than in the control group at 68 (P = 0.007) and 72 (P = 0.067) hr.,18818:18932, 3659039 ,23648075,Unavailable
 3659039 ,Plasma PC arachidonic acid (ARA),72 hour infusion of total parenteral nutrition with (treatment group),without (control group) omega-3 PUFAs,Significantly increased,"However, there were no significant differences from baseline in either group and there were no differences between groups at any timepoint.",19365:19504, 3659039 ,23648075,Unavailable
 3659039 ,Plasma PC linoleic,72 hour infusion of total parenteral nutrition with (treatment group),without (control group) omega-3 PUFAs,Significantly decreased,Plasma PC linoleic acid differed between the control and treatment groups at 68 (P = 0.038) and 72 (P = 0.009) hr.,19972:20086, 3659039 ,23648075,Unavailable
 3659039 ,Erythrocyte EPA,72 hour infusion of total parenteral nutrition with (treatment group),without (control group) omega-3 PUFAs,No significant difference,"However, further analysis did not show any significant differences compared to baseline erythrocyte EPA or compared with the control group.",20968:21107, 3659039 ,23648075,Unavailable
 3556286 ,average number of bacterial colonies,rinse their mouth with 0.05% sodium fluoride mouth rinse,0.5% green tea mouth rinse,No significant difference,Independent t-test showed no significant differences in the average number of bacterial colonies before and after intervention in both groups (P&gt;0.05).,4556:4741, 3556286 ,23372597,Unavailable
 2649924 ,magnesium values,"3 g of magnesium sulphate (MgSO4) [20 ml = 24.32 mEq/L Mg+2] in 100 cc of isotonic 0.9% solution over 2 hours intravenously at the following times: 12 hours prior to the operation, immediately following the operation, and on postoperative days 1, 2, and 3 (Group 1)",preoperative infusion of amiodarone (1200 mg) on first post-operative day (Group 2),Significantly increased,"In the postoperative period, the magnesium values were significantly higher in Group 1 than in Group 2 for all measurements.",5049:5173, 2649924 ,19232084,Unavailable
 2649924 ,total arrhythmia,"3 g of magnesium sulphate (MgSO4) [20 ml = 24.32 mEq/L Mg+2] in 100 cc of isotonic 0.9% solution over 2 hours intravenously at the following times: 12 hours prior to the operation, immediately following the operation, and on postoperative days 1, 2, and 3 (Group 1)",preoperative infusion of amiodarone (1200 mg) on first post-operative day (Group 2),Significantly increased,The use of amiodarone for total arrhythmia was significantly more effective than prophylactic treatment with magnesium sulphate (p = 0.015).,5173:5315, 2649924 ,19232084,Unavailable
 2649924 ,preventing supraventricular arrhythmia,"3 g of magnesium sulphate (MgSO4) [20 ml = 24.32 mEq/L Mg+2] in 100 cc of isotonic 0.9% solution over 2 hours intravenously at the following times: 12 hours prior to the operation, immediately following the operation, and on postoperative days 1, 2, and 3 (Group 1)",preoperative infusion of amiodarone (1200 mg) on first post-operative day (Group 2),No significant difference,There was no difference between the two drugs in preventing supraventricular arrhythmia,5315:5402, 2649924 ,19232084,Unavailable
 2649924 ,revealing time of atrial fibrillation,"3 g of magnesium sulphate (MgSO4) [20 ml = 24.32 mEq/L Mg+2] in 100 cc of isotonic 0.9% solution over 2 hours intravenously at the following times: 12 hours prior to the operation, immediately following the operation, and on postoperative days 1, 2, and 3 (Group 1)",preoperative infusion of amiodarone (1200 mg) on first post-operative day (Group 2),Significantly increased,although amiodarone significantly delayed the revealing time of atrial fibrillation (p = 0.026).,5404:5501, 2649924 ,19232084,Unavailable
 2649924 ,side effects,"3 g of magnesium sulphate (MgSO4) [20 ml = 24.32 mEq/L Mg+2] in 100 cc of isotonic 0.9% solution over 2 hours intravenously at the following times: 12 hours prior to the operation, immediately following the operation, and on postoperative days 1, 2, and 3 (Group 1)",preoperative infusion of amiodarone (1200 mg) on first post-operative day (Group 2),No significant difference,No side effects of the drugs were observed.,5717:5761, 2649924 ,19232084,Unavailable
 2529259 ,Total blood loss,600 mcg sublingual misoprostol,placebo in addition to standard PPH treatment with injectable oxytocics,Significantly decreased,"Among those women receiving additional interventions (twelve in the misoprostol group; nineteen in the placebo group), total measured blood loss was significantly higher (940 ± 341 ml, p = .028) compared with women (n = 29) who did not receive any additional intervention beyond standard treatment (780 ± 176 ml).",24228:24542, 2529259 ,18718007,Unavailable
 2529259 ,hemoglobin,600 mcg sublingual misoprostol,placebo in addition to standard PPH treatment with injectable oxytocics,Significantly increased,"Similarly, drop in postpartum hemoglobin was significantly higher among women requiring additional interventions (2.5 g/dL (± 1.5) vs. 1.7 g/dL (± 0.9); p = .022).",24542:24705, 2529259 ,18718007,Unavailable
 5791441 ,mean self-efficacy score,e-learning package based on religious-spiritual content,control group,No significant difference,"Paired t-test in two groups was significant (P = 0.042, P = 0.045) but independent t-test showed no significant difference in scores of childbirth self-efficacy before and after intervention in two groups (P = 0.061).",5354:5657, 5791441 ,29417074,Unavailable
 3714433 ,The total dose of GnRH antagonist,conventional group (group A),cessation group (group B),Significantly increased,"The total dose of GnRH antagonist was significantly lower in group B than group A (2.5±0.9 vs. 3.2±0.8 ampoules, p&lt;0.05).",5321:5460, 3714433 ,23875164,Unavailable
 3714433 ,The proportion of mature oocytes and fertilization rate,conventional group (group A),cessation group (group B),No significant difference,"The proportion of mature oocytes and fertilization rate were not significantly different in group B than group A (70.7% vs. 66.7%; 71.1% vs. 66.4%, respectively).",5521:5683, 3714433 ,23875164,Unavailable
 3714433 ,implantation or clinical pregnancy rates,conventional group (group A),cessation group (group B),No significant difference,There were no significant differences in the implantation or clinical pregnancy rates.,5684:5770, 3714433 ,23875164,Unavailable
 5861369 ,Waist circumference,"20 mg escitalopram/day,",placebo,Significantly increased,"The median change in waist during escitalopram vs placebo was 1 (0; 3) cm vs −1 (−2; 0) cm, respectively, P = 0.005.",21237:21370, 5861369 ,29472241,Unavailable
 5861369 ,"Lipid status (cholesterol, triglycerides, LDL and HDL), insulin resistance (HOMA-ir, Matsuda index, AUC insulin and AUC C-peptide), insulin secretion (HOMA-%B, insulinogenic index and disposition index) ","20 mg escitalopram/day,",placebo,No significant difference,"Lipid status (cholesterol, triglycerides, LDL and HDL) and measures of insulin resistance (HOMA-ir, Matsuda index, AUC insulin and AUC C-peptide) and insulin secretion (HOMA-%B, insulinogenic index and disposition index) were unchanged during study intervention (Table 1). Table 1",21836:22203, 5861369 ,29472241,Unavailable
 5861369 ,"cortisol levels (cortisol 0, cortisol 60, peak cortisol and area under the curve for cortisol during ACTH test)","20 mg escitalopram/day,",placebo,Significantly increased,"ncreased cortisol levels (cortisol 0, cortisol 60, peak cortisol and area under the curve for cortisol during ACTH test), all P &lt; 0.05 vs changes during placebo.",5187:5386, 5861369 ,29472241,Unavailable
 5861369 ,mental health or HRQoL,"20 mg escitalopram/day,",placebo,No significant difference,"Escitalopram had no significant effect on measures of insulin sensitivity, insulin secretion, fasting lipids, mental health or HRQoL.",5386:5519, 5861369 ,29472241,Unavailable
 4706730 ,the success rate in the treatment of ectopic pregnancy,double dose of methotrexate (MTX),single  dose of methotrexate (MTX),No significant difference,"As demonstrated in Table 2, the success rate of single dose was 69% and in double dose group, it was 79%. However these differences were not statistically significant (P = 0.29).",29961:30096, 4706730 ,26756008,Unavailable
 4706730 ,The necessity of extra dose of MTX,double dose of methotrexate (MTX),single  dose of methotrexate (MTX),No significant difference,"The necessity of extra dose of MTX in the single dose grope was 14% and in the double dose group, it was 6% (P = 0.23).",15388:15507, 4706730 ,26756008,Unavailable
 4706730 ,the rate of operation at the β-HCG level of 2000 - 4000 mIU/mL,double dose of methotrexate (MTX),single  dose of methotrexate (MTX),Significantly decreased,Results showed that only the rate of operation at the β-HCG level of 2000 - 4000 mIU/mL was lower in the double dose compared to the single dose group (P = 0.05).,29653:29815, 4706730 ,26756008,Unavailable
 4706730 ,Duration of hospitalization,double dose of methotrexate (MTX),single  dose of methotrexate (MTX),Significantly decreased,"Duration of hospitalization in double dose group was significantly lower than that of the single dose group (11.55 vs. 14.76 d, P &lt; 0.001).",29822:29961, 4706730 ,26756008,Unavailable
 4706730 ,The rate of complications,double dose of methotrexate (MTX),single  dose of methotrexate (MTX),No significant difference,"The rate of complications in double dose group was more than single dose group, but no significant difference was observed (P = 0.32).",29961:30096, 4706730 ,26756008,Unavailable
 5762805 ,Recurrent goiter,total thyroidectomy (TT),Dunhill operation (DO) or bilateral subtotal thyroidectomy (BST),Significantly decreased,"Recurrent goiter was found at 10 years in 1 (0.6%) TT versus 15 (8.6%) DO versus 39 (22.4%) BST patients (p &lt; 0.001 for TT vs. DO or BST and for DO vs. BST),",22220:22394, 5762805 ,28942461,Unavailable
 5762805 ,Recurrent goiter,Dunhill operation (DO) ,bilateral subtotal thyroidectomy (BST),Significantly decreased,"Recurrent goiter was found at 10 years in 1 (0.6%) TT versus 15 (8.6%) DO versus 39 (22.4%) BST patients (p &lt; 0.001 for TT vs. DO or BST and for DO vs. BST),",22220:22394, 5762805 ,28942461,Unavailable
 5762805 ,revision thyroidectomy,total thyroidectomy (TT),Dunhill operation (DO) or bilateral subtotal thyroidectomy (BST),Significantly decreased,revision thyroidectomy was necessary in 1 (0.6%) TT versus 5 (2.8%) DO versus 14 (8.0%) BST subjects (p &lt; 0.001 for TT vs. BST and p = 0.019 for DO vs. BST).,22399:22596, 5762805 ,28942461,Unavailable
 5762805 ,revision thyroidectomy,Dunhill operation (DO),bilateral subtotal thyroidectomy (BST),Significantly decreased,revision thyroidectomy was necessary in 1 (0.6%) TT versus 5 (2.8%) DO versus 14 (8.0%) BST subjects (p &lt; 0.001 for TT vs. BST and p = 0.019 for DO vs. BST).,22399:22596, 5762805 ,28942461,Unavailable
 5762805 ,Any permanent morbidity at 10 years,total thyroidectomy (TT),Dunhill operation (DO) or bilateral subtotal thyroidectomy (BST),No significant difference,Any permanent morbidity at 10 years was present in 5 (2.8%) TT patients following initial surgery versus 7 (4.0%) DO and 10 (5.7%) BST patients following initial and revision thyroidectomy (nonsignificant differences).,5503:5722, 5762805 ,28942461,Unavailable
 3713945 ,exercise duration,worked in online teams,worked individually,Significantly increased,"Those who exercised in online teams (n=80) exercised significantly longer (time=78.8s, P&lt;.001) than those who worked individually (n=35).",7463:7617, 3713945 ,23732514,Unavailable
 3713945 ,exercise duration,capable partner gave verbal encouragement,capable partner did not give verbal encouragement,Significantly decreased,"However, exercise duration was shorter when one’s more capable partner gave verbal encouragement (n=55) than when s/he did not (n=25) (a mean difference of 31.14s).",7618:7783, 3713945 ,23732514,Unavailable
 4796457 ,symptoms according International Consultation on Incontinence Questionnaire (ICIQ),pelvic muscle exercises,control group,Significantly decreased,"The results is shown that after the intervention, ICIQ score has a significant difference between the two groups (P=0.001).",4439:4562, 4796457 ,25716389,Unavailable
 4796457 ,improved the score of self-esteem,pelvic muscle exercises,control group,Significantly increased,"In other words, the training sessions improved the score of self-esteem in the experimental group (P&lt;0.001) versus control group (P=0.08).",4702:4841, 4796457 ,25716389,Unavailable
 4796457 ,The number of frequencies of leakage urine,pelvic muscle exercises,control group,Significantly decreased,"In comparison, before the treatment, there was no difference between two groups (p = 0.2) but after the treatment was observed a significant statistical difference (p = 0.04).",18520:18696, 4796457 ,25716389,Unavailable
 4796457 ,The measurement of amount of leakage urine,pelvic muscle exercises,control group,Significantly decreased,But after the treatment a significant statistical difference (p = 0.001) was observed.,19176:19262, 4796457 ,25716389,Unavailable
 4796457 ,Time of leakage urine,pelvic muscle exercises,control group,No significant difference,And also between the two groups wasn’t observed any differences; before the treatment (p = 0.1) and after it (p = 0.6).,20051:20170, 4796457 ,25716389,Unavailable
 2699734 ,Total per-person costs,home telemedicine,usual care,Significantly increased,"Total per-person costs were between $9,500 and $9,800 higher for treatment group than for control group members for cohort 1 and $6,200 to $8,700 for cohort 2 (P &lt; 0.001).",19851:20039, 2699734 ,19366971,Unavailable
 3580327 ,"cognition,  function,  global status",memantine 20 mg/day,placebo,Significantly increased,"After 24 weeks of treatment, patients in the MOD-SEV subgroup receiving memantine added to donepezil showed significantly better efficacy across all examined domains of cognition, function, and global status than patients treated with placebo added to donepezil. The overall standardised effect sizes for memantine versus placebo were: 0.36 (P &lt; 0.0001) for cognition, 0.21 (P = 0.02) for function, and 0.23 (P = 0.010) for global status (all LOCF; see Figure 2a).",28394:28949, 3580327 ,23336974,Unavailable
 3580327 ,"cognition,  function,  global status",memantine 20 mg/day + donepezil 10 mg/day,placebo,Significantly increased,"The overall standardised effect sizes for memantine versus placebo were: 0.28 (P = 0.008) for cognition, 0.21 (P = 0.04) for function, and 0.28 (P = 0.008) for global status (all LOCF; see Figure 2b).",30057:30345, 3580327 ,23336974,Unavailable
 1824772 ,incidence of fracture,one-on-one educational visits with primary care physicians,control group,No significant difference,No differences between groups were observed in the incidence of fracture.,5305:5378, 1824772 ,17356969,Unavailable
 3669105 ,Improvement in LVEF,"50–60&nbsp;mg/kg 12–24&nbsp;hr/day sc or iv 7 times weekly, combined with either DFP 75 at mg/kg/day (combination arm)",placebo (DFO monotherapy arm),No significant difference,The LVEF trend did not reach statistical difference between study arms (p = 0.89).,7297:7379, 3669105 ,23688265,Unavailable
 3669105 ,Myocardial T2,"50–60&amp;nbsp;mg/kg 12–24&amp;nbsp;hr/day sc or iv 7 times weekly, combined with either DFP 75 at mg/kg/day (combination arm)",placebo (DFO monotherapy arm),No significant difference,"Myocardial T2* improved in both arms (combination +1.9 ± 1.6&nbsp;ms p = 0.04; and DFO monotherapy +1.9 ± 1.4&nbsp;ms p = 0.04), but with no significant difference between treatments (p = 0.65).",7837:8021, 3669105 ,23688265,Unavailable
 5809875 ,At least one effective method is acceptable,access to an app plus intervention messages,access to the app plus control messages,No significant difference,"In the intervention arm, 66% (151/228) reported that at least one method of contraception was acceptable compared to 64% (156/244) in the control arm (Table 2). There was no evidence of a difference in acceptability between the groups (crude OR 1.11, 95% CI .76–1.62, p = 0.60; adjusted OR 1.21, 95% CI .80–1.83, p = 0.36).Table 2",38998:39432, 5809875 ,29433506,Unavailable
 5809875 ,"use of effective contraception at 4 months and during the study, acceptability of individual methods, service uptake, unintended pregnancy and induced abortion",access to an app plus intervention messages,access to the app plus control messages,No significant difference,There were no differences in the secondary or process outcomes between groups.,8324:8402, 5809875 ,29433506,Unavailable
 5843959 ,The length of the need for nCPAP,budesonide,control,No significant difference,The length of the need for nCPAP was not statistically different in both groups (P = 0.54).,22973:23082, 5843959 ,29541430,Unavailable
 5843959 ,The number of newborns who needed invasive mechanical ventilation,budesonide,control,No significant difference,The number of newborns who needed invasive mechanical ventilation also showed no significant difference (P = 0.14).,23082:23214, 5843959 ,29541430,Unavailable
 5843959 ,The number of newborns who were diagnosed with CLD,budesonide,control,No significant difference,The number of newborns who were diagnosed with CLD also had no statistically meaningful difference (P = 0.053).,23215:23344, 5843959 ,29541430,Unavailable
 5843959 ,Pneumothorax prevalence,budesonide,control,No significant difference,Pneumothorax prevalence had no significant difference in the groups (P = 0.57).,23344:23441, 5843959 ,29541430,Unavailable
 5843959 ,the number of newborns receiving two administrations of surfactant,budesonide,control,Significantly decreased,the number of newborns receiving two administrations of surfactant showed a statistically significant decrease in the interventional group (P = 0.041).,23598:23766, 5843959 ,29541430,Unavailable
 2699722 ,A1C test rates at 12 months postintervention,providing customized clinical information to 1) patient only or 2) physician only or 3) both the patient and physician,control (neither patient nor physician),No significant difference,There were no significant differences in A1C test rates among groups at 12 months postintervention.,32253:32352, 2699722 ,19366977,Unavailable
 2699722 ,LDL cholesterol test rates in the 12-month postintervention period,providing customized clinical information to 1) patient only or 2) physician only or 3) both the patient and physician,control (neither patient nor physician),Significantly decreased,"Among 2,547 subjects with a preintervention LDL cholesterol test, LDL cholesterol test rates in the 12-month postintervention period were significantly lower for all three intervention groups than for the control group.",46192:46411, 2699722 ,19366977,Unavailable
 2699722 ,A1C test rates among patients not using insulin 6 months postintervention,providing customized clinical information to 1) patient only or 2) physician only or 3) both the patient and physician,control (neither patient nor physician),Significantly decreased,"Among the n = 3,702 patients with a preintervention A1C test, A1C test rates were significantly lower in the three intervention groups (Mpt = 67.0, Mphys = 70.7, and Mpt × phys = 66.0) compared with that for the control group (Mc = 76.9) among patients not using insulin 6 months postintervention, whereas the A1C test rate only dropped in the physician intervention among insulin users (Mc = 76.2, Mpt = 74.8, Mphys = 70.0, and Mpt × phys = 74.8).",31563:32253, 2699722 ,19366977,Unavailable
 2699722 ,LDL cholesterol values,providing customized clinical information to 1) patient only or 2) physician only or 3) both the patient and physician,control (neither patient nor physician),No significant difference,"Interventions had no effect on LDL cholesterol values (P = 0.64), which improved in all groups over time.",4816:4942, 2699722 ,19366977,Unavailable
 2699722 ,risky prescribing events or treatment intensification,providing customized clinical information to 1) patient only or 2) physician only or 3) both the patient and physician,control (neither patient nor physician),No significant difference,Interventions did not reduce risky prescribing events or increase treatment intensification.,5171:5265, 2699722 ,19366977,Unavailable
 3630066 ,TIME (pain ratings for insufflation 1 to 4),continuous nasal insufflation of CO2,placebo,No significant difference,"Likewise, a repeated-measures ANOVA for the factors TIME (pain ratings for insufflation 1 to 4) and GROUP (CO2 or air) yielded no significant main effect for TIME (F1.3,63.3 = 2.039; p = 0.153), but significant results for both the main factor GROUP (F1,47 = 4.438; p = 0.041) and the interaction term TIME*GROUP (F2.6,121.2 = 3.3; p = 0.029).",22481:22868, 3630066 ,23574808,Unavailable
 3558408 ,minute volume (Mv) in ml per kg,"The C:V ratios 3:1, ",The C:V ratios 9:3,Significantly increased,"The C:V ratio of 3:1 gave both higher TI and VT than the ratio of 9:3, giving a significantly higher minute volume (Mv) in ml per kg with 3:1 compressions to ventilations: 191(183–199) (median (IQR)) than in the 9:3 group: 140 (134–144) (p&lt;0.001).",22101:22371, 3558408 ,23075128,Unavailable
 3558408 ,The ventilation rate,"The C:V ratios 3:1, ",The C:V ratios 15:2,Significantly increased,The ventilation rate (median (IQR)) at a C:V ratio of 15:2 (14 (13–15) per minute) was significantly lower than at a ratio of 3:1 (30 (29–30) per minute) giving a significantly lower Mv in ml per kg with 15:2 compressions to ventilations (77 (74–83)) (p&lt;0.001) (Table 1).,22371:22687, 3558408 ,23075128,Unavailable
 3558408 ,VT = tidal volume,"The C:V ratios 3:1, ",Continuous chest compressions with asynchronous ventilation,Significantly increased,Continuous chest compressions with asynchronous ventilation gave lower VT than coordinated compressions and ventilations at a ratio of 3:1 (p=0.002).,23162:23322, 3558408 ,23075128,Unavailable
 5850777 ,mean number of oocytes retrieved,recombinant human FSH plus recombinant human LH (follitropin alfa plus lutropin alfa; r-hFSH/r-hLH),r-hFSH monotherapy,Significantly decreased,"lower mean number of oocytes retrieved was observed with r-hFSH/r-hLH (3.3) compared with r-hFSH (3.6). Furthermore, country was shown to have a significant effect on the number of oocytes retrieved (P &lt; 0.001).",50565:50795, 5850777 ,28137754,Unavailable
 5850777 ,biochemical pregnancy rate,recombinant human FSH plus recombinant human LH (follitropin alfa plus lutropin alfa; r-hFSH/r-hLH),r-hFSH monotherapy,Significantly decreased,the biochemical pregnancy rate being lower with r-hFSH/r-hLH compared with r-hFSH (17.3% versus 23.9%; P = 0.020).,51359:51491, 5850777 ,28137754,Unavailable
 5850777 ,pregnancy rates and live birth rate,recombinant human FSH plus recombinant human LH (follitropin alfa plus lutropin alfa; r-hFSH/r-hLH),r-hFSH monotherapy,No significant difference,"Clinical (14.1% versus 16.8%) and ongoing (11.0% versus 12.4%) pregnancy rates and live birth rate (10.6% versus 11.7%) were similar in both groups (r-hFSH/r-hLH and r-hFSH, respectively)",51163:51350, 5850777 ,28137754,Unavailable
 3682809 ,"total fruit, total vegetable, dark green and orange vegetables and legumes (DGOV&amp;L)",church-based diet and physical activity intervention,control,No significant difference,"Significant increases in the mean HEI-2005 total fruit, total vegetable, dark green and orange vegetables and legumes (DGOV&amp;L), and total scores occurred in both the intervention and control groups (range, 0.2 to 3.4 points; Table 3); there were no significant differences between groups (ie, no intervention effects).",38016:38377, 3682809 ,23742940,Unavailable
 3682809 ,"Weight, Body mass index, Systolic blood pressure, Diastolic blood pressure, High density lipoprotein cholesterol,  Low density lipoprotein cholesterol, Total cholesterol, Triglycerides, Glucose, ",church-based diet and physical activity intervention,control,No significant difference,No changes were significant in anthropometric and clinical outcomes for either group.,38378:38463, 3682809 ,23742940,Unavailable
 5773984 ,occlusal discrepancies,Group A: two 2.5 mm stainless steel lag screws were placed,Group B: two 2.5 mm miniplates were placed for the fixation of fractures,No significant difference,"There were no occlusal discrepancies throughout the period of 1st postoperative day to 3rd postoperative month in Group A, whereas in Group B, very mild occlusal discrepancies was noted in 4 cases (40%) 1st postoperatively day with P = 0.171 and in 3 cases (30%) 1st postoperatively month with P = 0.317.",13257:13639, 5773984 ,29386813,Unavailable
 5773984 ,mean time taken for implant placement,Group A: two 2.5 mm stainless steel lag screws were placed,Group B: two 2.5 mm miniplates were placed for the fixation of fractures,Significantly decreased,"It was found that the mean time taken for implant placement in Group A (13.34 ± 1.95) was less than the mean time taken for implant placement in the Group B (17.50 ± 2.24), which was highly significant (P = 0.048) [Graph 7].",14429:14707, 5773984 ,29386813,Unavailable
 3636944 ,gingival inflammation,probing pocket depth (PPD) of 3-4 mm - II and III trimester,"control, probing pocket depth (PPD) of 3-4 mm - I trimester",Significantly increased,Increase in gingival inflammation was observed in II and III trimester as compared with I trimester and control,4531:4642, 3636944 ,23633772,Unavailable
 3636944 ,Plaque scores,probing pocket depth (PPD) of 3-4 mm - II and III trimester,"control, probing pocket depth (PPD) of 3-4 mm - I trimester",No significant difference,Plaque scores did not show any significant difference between pregnant and nonpregnant women.,4644:4737, 3636944 ,23633772,Unavailable
 3636944 ,Aggregatibacter actinomycetumcomitans,probing pocket depth (PPD) of 3-4 mm - II and III trimester,"control, probing pocket depth (PPD) of 3-4 mm - I trimester",No significant difference,Remaining of the 7 samples in each group did not show the presence of organism in the culture.,17042:17136, 3636944 ,23633772,Unavailable
 3636944 ,Fusobacterium nucleatum,probing pocket depth (PPD) of 3-4 mm - II and III trimester,"control, probing pocket depth (PPD) of 3-4 mm - I trimester",No significant difference,Remaining of the 9 samples did not show the presence of the organism in the culture.,18501:18585, 3636944 ,23633772,Unavailable
 5866486 ,progress in Dizziness Handicap Inventory (DHI) score,medical therapy (Betaserc),rehabilitation and medical therapy,Significantly decreased,"After 1 month of rehabilitation, patients receiving vestibular rehabilitation and medication showed greater progress than patients receiving medication only (P=0.000).",5118:5285, 5866486 ,29594074,Unavailable
 5807625 ,degrees of freedom,"4% TiF4 varnish (2.45 % F-, pH 1, FGM)","5% NaF varnish (2.26% F-, pH 5, Duraphat, Colgate)",No significant difference,"cDf: degrees of freedom. Df = baseline – final value, where positive values indicate regression and negative values indicate lesions progression. Kruskal-Wallis Test (p=.39).",30539:30736, 5807625 ,29374001,Unavailable
 5807625 ,variation of the mean fluorescence loss,"4% TiF4 varnish (2.45 % F-, pH 1, FGM)","5% NaF varnish (2.26% F-, pH 5, Duraphat, Colgate)",No significant difference,"Type of varnish	ΔWS area (mm2)a,b	ΔΔF (%)b,cTiF4	0.01 (–9.15 to 1.19)	–1.29 (–16.30 to 4.74)NaF	0.17 (–2.38 to 1.47)	–0.55 (–5.80 to 6.10)Placebo	0.19 (–1.14 to 4.36)	–0.23 (–5.17 to 5.10)aΔbKruskal-Wallis Test (p=.59 and p=.45, respectively).",31252:32127, 5807625 ,29374001,Unavailable
 5721487 ,the mean of severity of symptoms of Allergic rhinitis (AR),N. bracteata syrup (NBS) for 4 weeks as three times a day,placebo,Significantly decreased,"Furthermore, the mean of severity of symptoms was 7.10 ± 1.92 and 2.37 ± 1.76 before and after treatment by NBS, respectively (P &lt; 0.001), but the mean of severity of symptoms was 6.38 ± 2.18 and 6.00 ± 1.95 before and after treatment by placebo, respectively (P = 0.096), showed in Table 2.",23396:23763, 5721487 ,29259639,Unavailable
 5721487 ,improvement in symptoms of Allergic rhinitis (AR),N. bracteata syrup (NBS) for 4 weeks as three times a day,placebo,Significantly decreased,"Thus, overall improvement in symptoms in treatment group (mean ± SD = 1.84 ± 4.73) was significantly more than control group (mean ± SD = 2.06 ± 0.38) (P &lt; 0.0001) [Table 2]. On the other hand, NBS improved all symptoms of AR, significantly in the treatment group (P &lt; 0.001).",22904:23260, 5721487 ,29259639,Unavailable
 3702143 ,"scores of knowledge, attitude (Health Belief Model dimensions), and practice after 2 months",seven sessions of education based on Health Belief Model,did not receive the education,Significantly increased,"As presented in Table 2, mean scores of knowledge, attitude (Health Belief Model dimensions), and practice before education showed no significant difference in both groups, but a significant difference 2 months after that (p &lt; 0.001).",19641:19917, 3702143 ,23833623,Unavailable
 2667135 ,number of days with received courses of antibiotics,some portion of therapy outside of the hospital (CoPAT) ,full course of therapy in the hospital setting,Significantly increased,"CoPAT patients received longer courses of study antibiotics with a mean of 25.4 days (range 9–74 days) compared with 13.5 days (range 1–43) in the IPAT group (P &lt; 0.001),",35079:35271, 2667135 ,19264792,Unavailable
 2667135 ,proportion of patients completed therapy,some portion of therapy outside of the hospital (CoPAT)  ,full course of therapy in the hospital setting,Significantly increased,"a higher proportion of CoPAT patients completed therapy as part of the study (90.3% versus 45.4%, P &lt; 0.001).",35079:35271, 2667135 ,19264792,Unavailable
 2667135 ,early discontinuations,some portion of therapy outside of the hospital (CoPAT) ,full course of therapy in the hospital setting,Significantly decreased,The shorter duration of study treatment for IPAT patients was influenced by early discontinuations: there were 53 (54.6%) versus 10 (9.7%) in the CoPAT group.,35079:35271, 2667135 ,19264792,Unavailable
 2667135 ,rate of clinical success at the test-of-cure visit,some portion of therapy outside of the hospital (CoPAT) ,full course of therapy in the hospital setting,Significantly increased,"A higher rate of clinical success at the test-of-cure visit was observed among CoPAT patients (89/103, 86.4%) compared with that among IPAT patients (54/97, 55.7%) (P &lt; 0.001).",35079:35271, 2667135 ,19264792,Unavailable
 2667135 ,deaths,some portion of therapy outside of the hospital (CoPAT) ,full course of therapy in the hospital setting,Significantly decreased,"Fewer deaths occurred in the CoPAT group (4/103, 3.9%) compared with those in the IPAT group (18/97, 18.6%; P = 0.001) (Table 4).",35079:35271, 2667135 ,19264792,Unavailable
 3698474 ,"Heart rate, systolic blood pressure, and rate pressure product (RPP)",dietary supplement (OxyELITE Pro™),placebo,Significantly increased,"Heart rate (P = 0.02), systolic blood pressure (P &lt; 0.0001), and RPP (P = 0.002) were higher for supplement compared to placebo.",4141:4323, 3698474 ,23882145,Unavailable
 3698474 ,"Area under the curve (AUC) for glycerol, free fatty acids (FFA), and kilocalorie expenditure",dietary supplement (OxyELITE Pro™),placebo,Significantly increased,"AUC was greater for supplement compared to placebo for glycerol (22.74 ± 1.98 μg · mL−1 · 2 hr−1 vs. 15.76 ± 1.36 μg · mL−1 · 2 hr−1; P = 0.001), FFA (1.62 ± 0.07 mmol · L−1· 2 hr−1 vs. 0.78 ± 0.12 mmol · L−1 · 2 hr−1; P &lt; 0.0001), and kilocalorie expenditure (149 ± 7 kcal · 2 hr−1 vs. 122 ± 8 kcal · 2 hr−1; P = 0.005).",3644:4141, 3698474 ,23882145,Unavailable
 3702089 ,"duration of the treatment, the number of retrieved oocytes, number of transferred embryo and serum E2 level on the day of HCG administration",Buserelin (GnRH agonist),Cetrorelix (GnRH antagonist),No significant difference,"No significant difference was found between 2 groups regarding the duration of the treatment, the number of retrieved oocytes, number of transferred embryo and serum E2 level on the day of HCG administration;",12464:12673, 3702089 ,23833582,Unavailable
 3702089 ,total number of gonadotropin ampoules,Buserelin (GnRH agonist),Cetrorelix (GnRH antagonist),Significantly increased,"however, in the antagonist group, the total number of gonadotropin ampoules was significantly lower than the agonist group [Table 2].",12673:12845, 3702089 ,23833582,Unavailable
 3702089 ,relative frequency of chemical pregnancy and ongoing pregnancy and rate of OHSS (moderate and severe),Buserelin (GnRH agonist),Cetrorelix (GnRH antagonist),No significant difference,"Despite higher relative frequency of chemical pregnancy and ongoing pregnancy and lower rate of OHSS (moderate and severe) in the antagonist group, no significant difference was observed between 2 groups [Table 3].",13065:13318, 3702089 ,23833582,Unavailable
 4173573 ,duration of postoperative analgesia ,magnesium 50 mg in normal saline 1 mL or dexamethasone 0.1 mg/kg in normal saline 1 mL,corresponding volume of normal saline ,Significantly increased,"postoperative analgesia persisted for a longer duration in groups RM and RD, 8 (5-11) h and 12 (8-16) h, respectively compared with 4 (3-5) h in group R, with a (P &lt; 0.001) [Table 2].",14757:15001, 4173573 ,25886097,Unavailable
 4173573 ,The emergence time,magnesium 50 mg in normal saline 1 mL or dexamethasone 0.1 mg/kg in normal saline 1 mL,corresponding volume of normal saline ,No significant difference,"The emergence time of group R was 3.8 ± 1.3 min and that of groups RM and RD was 4.2 ± 1.6 and 4.0 ± 1.5 min, respectively (P = 0.35).",15001:15153, 4173573 ,25886097,Unavailable
 4173573 ,The emergence behaviour score,magnesium 50 mg in normal saline 1 mL or dexamethasone 0.1 mg/kg in normal saline 1 mL,corresponding volume of normal saline ,Significantly decreased,"The emergence behaviour score of group R was 3.5 ± 0.4 min and that of groups RM and RD was 1.6 ± 0.3 and 1.5 ± 0.3 min, respectively (P &lt; 0.001) [Table 2].",15153:15369, 4173573 ,25886097,Unavailable
 4173573 ,The incidence of rescue pethidine in the PACU and rescue oral paracetamol in ward,magnesium 50 mg in normal saline 1 mL or dexamethasone 0.1 mg/kg in normal saline 1 mL,corresponding volume of normal saline ,Significantly decreased,The incidence of rescue pethidine in the PACU and rescue oral paracetamol in ward was significantly higher in group R children compared with groups RM and RD children (P &lt; 0.01) [Table 3].,16177:16424, 4173573 ,25886097,Unavailable
 4173573 ,The time to first oral paracetamol administration,magnesium 50 mg in normal saline 1 mL or dexamethasone 0.1 mg/kg in normal saline 1 mL,corresponding volume of normal saline ,Significantly increased,"The time to first oral paracetamol administration was significantly longer in groups RM and RD children (500 ± 190 and 730 ± 260 min), respectively compared with group R (260 ± 65 min) (P &lt; 0.001) [Table 3].",16612:16881, 4173573 ,25886097,Unavailable
 5986513 ,weight gain,higher protein HMF providing 1.8 g protein per 100 mL,standard HMF providing 1 g protein per 100 mL,No significant difference,"There was no difference in the rate of weight gain between groups (Table 2) (mean (95% CI) high protein 245 (230, 260) g/week and standard protein 258 (244, 272) g/week, adjusted mean difference −14 (−32, 4) p = 0.12).",22633:22928, 5986513 ,29772833,Unavailable
 5986513 ,rate of length or head circumference gain,higher protein HMF providing 1.8 g protein per 100 mL,standard HMF providing 1 g protein per 100 mL,No significant difference,There were no differences in rate of length or head circumference gain (Table 2).,23206:23348, 5986513 ,29772833,Unavailable
 5862433 ,protection against S. aureus infection,preoperative vaccination against S. aureus,placebo,Significantly increased,"Vaccination was univariately associated with the primary outcome. V710 was protective against S. aureus infection (OR 0.67, 95% CI 0.48–0.91, p = 0.011), and remained so after correction for other predictors (OR 0.67, 95% CI 0.48–0.91, p = 0.012).",45293:45575, 5862433 ,29561866,Unavailable
 5769187 ,the prevalence and severity of keratopathy,standard care with normal saline,standard care,Significantly increased,"); however, the increased in prevalence and severity of keratopathy in the intervention group was significant (p = 0.03). In other words, administration of NS increased the prevalence and severity of keratopathy.",15758:15987, 5769187 ,29344048,Unavailable
 4733222 ,attrition rates,ePaper ,Mobile,Significantly increased,"Participants in ePaper conditions had higher attrition rates compared to participants in Mobile conditions, χ3 2=9.96, P=.02 (N=124).",6974:7146, 4733222 ,26772910,Unavailable
 4733222 ,mean average weekly compliance,ePaper ,Mobile,Significantly increased,"The main effect of media type yielded an F 1,88 = 60.82, P&lt;.001, indicating that the mean average weekly compliance was significantly greater for participants in ePaper conditions (mean [SD] 0.91 [0.2]) than for those in Mobile conditions (mean [SD] 0.39 [0.38]).",43156:43465, 4733222 ,26772910,Unavailable
 4733222 ,frequency of guessing,ePaper ,Mobile,Significantly increased,"Participants in the ePaper condition had a much higher frequency of guessing while reporting as compared to those in the Mobile condition (chi-square test was highly significant, χ1 2 = 25.25 (N=63), P&lt;.001.",47343:47589, 4733222 ,26772910,Unavailable
 4733222 ,positive attitudes,ePaper ,Mobile,Significantly increased,"Table 2). Specifically, this analysis showed that participants in the ePaper Solo condition reported significantly more positive attitudes (mean [SD] 6.37 [0.87]) than did people in the Mobile Solo condition (mean [SD] 5.05 [1.27], P=.01) or marginally significantly more positive than did people in the Mobile Team condition (mean [SD] 5.33 [1.64], P=.06).",39506:39904, 4733222 ,26772910,Unavailable
 4733222 ,frequency of guessing,ePaper ,Mobile,Significantly increased,"Participants in the ePaper condition had a much higher frequency of guessing while reporting as compared to those in the Mobile condition (chi-square test was highly significant, χ1 2 = 25.25 (N=63), P&lt;.001.",48143:48521, 4733222 ,26772910,Unavailable
 4021157 ,total number of antenatal visits received after 20 weeks gestation,"received calls from a midwife at 28, 33 and 36 weeks and additional UADS at 20 weeks’ gestation","received calls from a midwife at 28, 33 and 36 weeks",No significant difference,The differences between the groups in the total number of antenatal visits received after 20 weeks gestation were small and not statistically significant (p = 0.74);,33392:33558, 4021157 ,24685072,Unavailable
 4021157 ,the numbers of routine and unscheduled visits,"received calls from a midwife at 28, 33 and 36 weeks and additional UADS at 20 weeks’ gestation","received calls from a midwife at 28, 33 and 36 weeks",No significant difference,the numbers of routine and unscheduled visits were also similar in the three groups (Table 3).,33558:33691, 4021157 ,24685072,Unavailable
 4021157 ,the level of state anxiety,"received calls from a midwife at 28, 33 and 36 weeks and additional UADS at 20 weeks’ gestation","received calls from a midwife at 28, 33 and 36 weeks",No significant difference,Differences between the three groups in the level of state anxiety as measured by the STAI at each of the time points were very small and not statistically significant (Table 4).,36241:36459, 4021157 ,24685072,Unavailable
 4021157 ,levels of satisfaction,"received calls from a midwife at 28, 33 and 36 weeks and additional UADS at 20 weeks’ gestation","received calls from a midwife at 28, 33 and 36 weeks",No significant difference,There were no statistically significant differences in levels of satisfaction between the three trial groups.,41784:41893, 4021157 ,24685072,Unavailable
 4021157 ,the proportion of women who had a SGA baby (BW ≤ 10th centile),"received calls from a midwife at 28, 33 and 36 weeks and additional UADS at 20 weeks’ gestation","received calls from a midwife at 28, 33 and 36 weeks",No significant difference,There were no clinically significant differences between groups in the proportion of women who had a SGA baby (BW ≤ 10th centile) in the group of women who had negative UADS at 20 weeks compared to those who had a positive result at 20 weeks and then a negative result at 24 weeks (p = 0.14).,42649:42941, 4021157 ,24685072,Unavailable
 4177075 ,intention to use a cholesterol test,interactive online DA with general information on self-testing and test-specific information on cholesterol or diabetes self-testing,received a limited information sheet with general information on self-testing,No significant difference,Analyses revealed no significant effect of group on the intention to use a cholesterol test (Table 3).,33924:34096, 4177075 ,25194420,Unavailable
 4177075 ,Time spent on the website,interactive online DA with general information on self-testing and test-specific information on cholesterol or diabetes self-testing,received a limited information sheet with general information on self-testing,Significantly increased,"In the diabetes intervention group, the mean time spent on the website was 169 seconds (range 7 – 2989 seconds, SD 284). In the diabetes control group, the mean time spent on the PDF was 74 seconds (range 13 – 771, SD 81). The mean time spent on the website in the cholesterol intervention group was 194 seconds (range 12–2352 seconds, SD 315). In the cholesterol control group, the mean time spent on the PDF was 89 seconds (range 9 – 791, SD 98). Differences between the intervention and control groups were statistically significant (p &lt; .000).",51787:52334, 4177075 ,25194420,Unavailable
 4595873 ,WOMAC score and visual pain scale at 3 months and 6 months ,three intraarticular injection of autologous platelet rich plasma (PRP),3 intra-articular injections of high molecular weight hyaluronic acid (HA),Significantly decreased,Statistically significant better results in the WOMAC score and visual pain scale was determined in PRP group than HA group at 3 months and 6 months follow up.,4018:4178, 4595873 ,None,Unavailable
 4595873 ,WOMAC score and visual pain scale at 12 months ,three intraarticular injection of autologous platelet rich plasma (PRP),3 intra-articular injections of high molecular weight hyaluronic acid (HA),No significant difference,"At 12 months' of follow-up, PRP and HA treatments offered similar results.",4260:4334, 4595873 ,None,Unavailable
 5729492 ,changes in visceral fat area (VFA) (%),informed about results of visceral fat area (VFA),not informed about results of visceral fat area (VFA),No significant difference,"There was no significant difference in the changes in VFA (%) from baseline to the end of the study between the control and feedback groups ( −4.4 [12.6] vs. −3.0 [16.8]; 95% CI, −3.8 to 5.5).",35794:35987, 5729492 ,29259799,Unavailable
 5729492 ,BMI changes (%),informed about results of visceral fat area (VFA),not informed about results of visceral fat area (VFA),No significant difference,"There was no significant difference in BMI changes (%) from baseline to the end of the study between the control and feedback groups (−0.3 [4.6] vs. 0.04 [4.8]; 95% CI, −1.7 to 1.2).",36200:36383, 5729492 ,29259799,Unavailable
 5729492 ,WC changes (%),informed about results of visceral fat area (VFA),not informed about results of visceral fat area (VFA),No significant difference,"There was no significant difference in WC changes (%) from baseline to the end of the study between the control and feedback groups (−0.9 [4.0] vs. −2.2 [4.1]; 95% CI, −1.8 to 0.7).",36606:36787, 5729492 ,29259799,Unavailable
 5729492 ,total scores for eating style on the eating behaviour questionnaire,informed about results of visceral fat area (VFA),not informed about results of visceral fat area (VFA),Significantly decreased,"At the end of the study, the total scores for eating style on the eating behaviour questionnaire in the VFA decrease group had significantly improved more than those in the VFA increase group (−4.6 [11.4] vs. 3.6 [12.8]; p = 0.049) (Table 5).",72922:73239, 5729492 ,29259799,Unavailable
 5729492 ,The feeling of hunger/satiation,informed about results of visceral fat area (VFA),not informed about results of visceral fat area (VFA),Significantly decreased,"The feeling of hunger/satiation was significantly improved in the control group compared with the feedback group (−5.2 vs. 2.9; 95% CI, 0.9 to 7.6) (Table 3).",48558:48774, 5729492 ,29259799,Unavailable
 3580725 ,Mortality at 90 days,single-pass batch dialysis system (SLED-BD),continuous veno-venous hemofiltration (CVVH),No significant difference,Mortality at 90 days was similar in ICU patients with acute kidney disease (AKI) treated with SLED-BD or with CVVH.,33353:33468, 3580725 ,22839577,Unavailable
 3580725 ,effective blood flow,single-pass batch dialysis system (SLED-BD),continuous veno-venous hemofiltration (CVVH),Significantly increased,"SLED was accomplished with a significantly higher effective blood flow (P &lt; 0.001), whereas ultrafiltration (UF) volume (P = 0.08),",33533:33702, 3580725 ,22839577,Unavailable
 3580725 ,The nursing time spent,single-pass batch dialysis system (SLED-BD),continuous veno-venous hemofiltration (CVVH),Significantly decreased,The nursing time spent for RRT was significantly higher in the CVVH group than in the SLED group (Table 4).,37241:37387, 3580725 ,22839577,Unavailable
 3580725 ,"Duration of mechanical ventilation and of ICU-stay , and time to renal recovery ",single-pass batch dialysis system (SLED-BD),continuous veno-venous hemofiltration (CVVH),Significantly decreased,"Duration of mechanical ventilation (P = 0.047) and of ICU-stay (P = 0.038), and time to renal recovery (P = 0.049) were significantly shorter in the SLED group (Table 3)",34206:34465, 3580725 ,22839577,Unavailable
 3580725 ,The quantity of blood transfusions,single-pass batch dialysis system (SLED-BD),continuous veno-venous hemofiltration (CVVH),Significantly decreased,"he quantity of blood transfusions given was significantly higher in the CVVH than in the SLED patient cohort, although the mean daily heparin dose did not differ (Table 2).",35580:35792, 3580725 ,22839577,Unavailable
 5735483 ,time to S1 sensory regression,buprenorphine (60 μg) or dexmedetomidine (5 μg),Sterile water (0.2 mL),No significant difference,"Time to S1 regression was 130 ± 46 min (Group C), 144 ± 51.3 min (Group B) and 164 ± 55.99 min (Group D), P = 0.117.",4769:4920, 5735483 ,29284844,Unavailable
 5735483 ,Time to complete motor recovery,buprenorphine (60 μg) or dexmedetomidine (5 μg),Sterile water (0.2 mL),Significantly increased,"Time to complete motor recovery was 177 ± 56.9 min (Group C), 236 ± 60 min (Group B) and 234 ± 61.71 min (Group D), P &lt; 0.001.",5065:5208, 5735483 ,29284844,Unavailable
 5735483 ,The time to first analgesic request,buprenorphine (60 μg) or dexmedetomidine (5 μg),Sterile water (0.2 mL),No significant difference,"The time to first analgesic request in the remaining patients was 509 ± 199.8 min, 589 ± 158.3 min, and 429 ± 134 min in control, buprenorphine and dexmedetomidine groups, respectively.",15296:15482, 5735483 ,29284844,Unavailable
 5749033 ,absolute and relative peak power,low-volume Wingate-based High Intensity Interval Training (HIIT,control,Significantly increased,"he post-hoc analysis revealed that the ABS_Ppeak and REL_Ppeak changes in the HIIT group were much higher than those observed in the control group (ABS_Ppeak: 14.7% vs. 2.4%, P=0.023, d=1.39, see Figure 2A; REL_Ppeak: 15.0% vs. 2.3%; P=0.021, d=1.41).",21529:21861, 5749033 ,29199186,Unavailable
 5749033 ,size of the H-reflex,low-volume Wingate-based High Intensity Interval Training (HIIT,control,Significantly increased,"The results revealed a significant increase in the size of the H-reflex after HIIT (P=0.004, d=0.77), while this remained unchanged in the control group (P=0.134, d=0.31). The post-hoc analysis also revealed that pre- to post-test trial changes in the HITT group were statistically different from those observed in the control group (24% vs. -10%, respectively; P=0.003, d=1.73).",26018:26398, 5749033 ,29199186,Unavailable
 5749033 ,maximum voluntary contraction (MVC),low-volume Wingate-based High Intensity Interval Training (HIIT,control,No significant difference,"However, no significant changes were found in the MVC (P&gt;0.05 for both groups).",4097:4176, 5749033 ,29199186,Unavailable
 5749033 ,V-wave or in the Vwave/Mwave ratio,low-volume Wingate-based High Intensity Interval Training (HIIT,control,No significant difference,No significant changes were observed either in the V-wave or in the Vwave/Mwave ratio (P&gt;0.05 for both groups).,4317:4453, 5749033 ,29199186,Unavailable
 3544690 ,the walked distance in the six-minute walking test,"60 minutes of electrostimulation (wave frequency was 20 Hz, pulse duration of 20 us) two times a day",conventional rehabilitation,Significantly increased,"Our primary end-point, the walked distance in the six-minute walking test, showed a 75% of improvement in the electrostimulation group (p&lt;0.001) (Figure 2). On the other hand, the walked distance in the control group did not change (Table 2).",18987:19308, 3544690 ,23153062,Unavailable
 3544690 ,blood lactate and venous saturation of oxygen ,"60 minutes of electrostimulation (wave frequency was 20 Hz, pulse duration of 20 us) two times a day",conventional rehabilitation,Significantly decreased,Patients in the electrostimulation group decreased the blood lactate in 34% and venous saturation of oxygen in 12% (p&lt;0.001) (Table 2). The control group did not show differences in the blood lactate and in venous saturation of oxygen.,21917:22194, 3544690 ,23153062,Unavailable
 3505775 ,mean SCORAD index,anion textile,pure cotton,Significantly decreased,"In patients from group A who wore the anion textile garment, the mean SCORAD index decreased significantly from 47.2±14.0 to 36.1±16.5 (p&lt;0.0001), compared to the baseline. In contrast, the mean SCORAD index of the subjects in group B, who wore the pure cotton textile garment, decreased only slightly from 41.8±16.3 to 37.7±17.2 (p=0.0839). Overall, the SCORAD index values between groups A and B were significantly different (p=0.0308) (Fig. 2).",13138:13677, 3505775 ,23197910,Unavailable
 3505775 ,the mean TEWL from eczematous lesions,anion textile,pure cotton,Significantly decreased,"The mean TEWL from eczematous lesions on the flexor surface of the forearm for group A decreased significantly, compared to the baseline from 37.1±17.1 to 20.7±15.5 g/h/m2 (p&lt;0.0001). Although the value for group B also decreased from 30.4±19.8 to 23.5±15.2 g/h/m2, the reduction was not significant (p=0.0607). A significant difference was detected in the mean TEWL from eczematous lesions between groups A and B (p=0.0359) (Fig. 3).",14593:15141, 3505775 ,23197910,Unavailable
 3505775 ,the mean TEWL from perilesional normal skin,anion textile,pure cotton,No significant difference,And no significant difference was observed in the mean TEWL from perilesional normal skin between groups A and B (p=0.0822).,15141:15282, 3505775 ,23197910,Unavailable
 3505775 ,mean SCH for eczematous lesions,anion textile,pure cotton,No significant difference,"n addition, no significant difference was seen in the mean SCH for eczematous lesions between groups A and B (p=0.6788) (Fig. 4).",15825:16008, 3505775 ,23197910,Unavailable
 3505775 ,The mean skin erythema in eczematous lesions on the flexor surface of the forearm,anion textile,pure cotton,Significantly decreased,"The mean skin erythema in eczematous lesions on the flexor surface of the forearm in group A decreased significantly from 425.6±75.8 to 379.6±91.4 AUs, compared to the baseline (p=0.0025). In contrast, the mean values for group B increased only slightly from 356.8±51.3 to 362.7±62.3 AUs (p=0.0692); a statistically significant difference, however, was detected in the mean values between groups A and B (p=0.0106) (Fig. 5).",16245:16758, 3505775 ,23197910,Unavailable
 4861263 ,systemic and mucosal antibodies,HIV-1 Clade C CN54gp140 envelope glycoprotein vaccine administered by intramuscular (IM) route,HIV-1 Clade C CN54gp140 envelope glycoprotein vaccine administered by intranasal (IN) or intravaginal (IVAG) route,Significantly increased,Three IM immunizations of CN54 gp140 at either 20 or 100 μg elicited significantly greater systemic and mucosal antibodies than either IN or IVAG immunizations.,17377:17538, 4861263 ,27159166,Unavailable
 5985865 ,percentage of change of sign scores,combination of topical steroids and ozone ,topical corticosteroids alone or ozone alone,Significantly increased,"Regarding the sign scores, the greatest percentage of change was noted in the combined group, whereas the least percent of change was recorded in the steroid group. ANOVA test revealed that the difference was statistically significant (p&lt;0.0001).",33812:34059, 5985865 ,None,Unavailable
 5985865 ,percentage of change of pain scores,combination of topical steroids and ozone ,ozone alone,Significantly increased,"Regarding the sign scores, the greatest percentage of change was noted in the combined group, whereas the least percent of change was recorded in the steroid group. ANOVA test revealed that the difference was statistically significant (p&lt;0.0001).",33812:34059, 5985865 ,None,Unavailable
 5788993 ,Skin dryness score,"Day and night creams containing Mel, carried in lipospheres (Melatosphere™) on one half of the face",Not treated another half of the face,Significantly decreased,Skin dryness score was significantly lower in the active-treated side in comparison with the non-treated side (p=0.01; Mann–Whitney U test; 1.5±0.4 vs 3.5±0.6; Figure 1A).,13478:13732, 5788993 ,29416368,Unavailable
 5788993 ,"Skin tonicity (resistance to traction, resistance to pinching and recovery after pinching)","Day and night creams containing Mel, carried in lipospheres (Melatosphere™) on one half of the face",Not treated another half of the face,Significantly increased,"Skin tonicity (resistance to traction, resistance to pinching and recovery after pinching) significantly improved by 33% in comparison with the baseline value on the side treated with Mel creams only (from 3.0±0.5 to 2.1±0.4; Figure 1B and C).",13733:14026, 5788993 ,29416368,Unavailable
 5788993 ,Crow’s feet photographic severity score,"Day and night creams containing Mel, carried in lipospheres (Melatosphere™) on one half of the face",Not treated another half of the face,Significantly decreased,Crow’s feet photographic severity score was reduced significantly (p=0.05) by −15% with the creams in comparison with both baseline value (2.3±0.2 vs. 2.7±0.3) and value of the non-treated side after 3 months.,14026:14253, 5788993 ,29416368,Unavailable
 5788993 ,Surface microrelief photographic score,"Day and night creams containing Mel, carried in lipospheres (Melatosphere™) on one half of the face",Not treated another half of the face,Significantly decreased,Surface microrelief photographic score was significantly reduced by −26.5% at the end of treatment in comparison with both baseline value (2.4±0.5 vs. 3.4±0.6; p=0.001; Wilcoxon test) and value of the control side at month 3 (2.4±0.5 vs. 3.3±0.6; p=0.001; Mann–Whitney U test).,14253:14582, 5788993 ,29416368,Unavailable
 5788993 ,"roughness profile, wrinkles’ maximum depth, total wrinkles’ ","Day and night creams containing Mel, carried in lipospheres (Melatosphere™) on one half of the face",Not treated another half of the face,Significantly decreased,"Skin profilometry evaluation showed a −13% reduction in roughness profile, −13% reduction in wrinkles’ maximum depth and −7.2% reduction in total wrinkles’ height in comparison with baseline and control sides.",15104:15313, 5788993 ,29416368,Unavailable
 5850960 ,Th1-biased PAP-specific T-cell responses,sipuleucel-T alone followed by intradermal immunization with pTVG-HP DNA vaccine ,sipuleucel-T alone,No significant difference,"Th1-biased PAP-specific T-cell responses were detected in 11/18 individuals, and were not statistically different between study arms.",5424:5558, 5850960 ,29534736,Unavailable
 5850960 ,overall survival,sipuleucel-T alone followed by intradermal immunization with pTVG-HP DNA vaccine ,sipuleucel-T alone,No significant difference,". Similarly, while the trial was not powered to detect differences in overall survival, no significant differences in overall survival between study arms were noted (Fig. 6b). Median overall survival was 715 days (24 months) in Arm 1 versus 901 (30 months) in Arm 2 (with DNA vaccine).",36728:37052, 5850960 ,29534736,Unavailable
 5850960 ,PSA doubling time,sipuleucel-T alone followed by intradermal immunization with pTVG-HP DNA vaccine ,sipuleucel-T alone,No significant difference,"There were no significant changes in PSA doubling time observed post-treatment (2.6 months overall, 2.5 months Arm 1, 2.6 months Arm 2).Fig. 6",37437:37601, 5850960 ,29534736,Unavailable
 5850960 ,median time to radiographic progression,sipuleucel-T alone followed by intradermal immunization with pTVG-HP DNA vaccine ,sipuleucel-T alone,No significant difference,Median time to progression was less than 6 months and not statistically different between study arms.,5669:5770, 5850960 ,29534736,Unavailable
 3691625 ,the mean and median survival time,radiotherapy plus nimotuzumab,placebo,No significant difference,"For AA patients, the mean and median survival time was 41.29 and 44.56 months, if they received nimotuzumab vs. 29.67 and 17.56 months for the control patients (Weibull statistics, p = 0.311).",32306:32498, 3691625 ,23782513,Unavailable
 3691625 ,mean and median overall survival in glioblastoma multiforme (GBM) patients,radiotherapy plus nimotuzumab,placebo,Significantly increased,"For the GBM patients, mean and median overall survival corresponded to 17.24 and 8.40 (nimotuzumab arm) vs. 9.84 and 8.36 months (placebo arm), respectively (Weibull statistics, p = 0.026).",32499:32688, 3691625 ,23782513,Unavailable
 3524756 ,Average population CVD risk, NHS Health Check service plus additional lifestyle support in Stoke,NHS Health Check service only,No significant difference,There was no significant difference between the two groups at either measurement point.,5889:5976, 3524756 ,23116213,Unavailable
 3524756 ,Prevalence of central obesity, NHS Health Check service plus additional lifestyle support in Stoke,NHS Health Check service only,Significantly increased,Prevalence of central obesity was reduced significantly (p &lt;0.01) in the group receiving additional lifestyle support but not in the NHS Health Check only group.,6094:6255, 3524756 ,23116213,Unavailable
 4809147 ,level of device mastery,Spiromax, Easyhaler and Turbuhaler,Significantly increased,Spiromax was associated with a greater level of device mastery compared with Easyhaler or Turbuhaler; 37.5% of participants were able to use Spiromax with no errors in step 1 (intuitive use) compared with 0% with Easyhaler (p&lt;0.001) and 9.2% with Turbuhaler (p&lt;0.001; table 1).,21449:21789, 4809147 ,27026804,Unavailable
 4809147 ,The mean proportion of observed errors,Spiromax, Easyhaler and Turbuhaler,Significantly decreased,The mean proportion of observed errors during steps 1 and 2 was also lower with Spiromax (12.4% and 0.8%) compared with Easyhaler (18.7% and 5.0%; both p&lt;0.001) or Turbuhaler (17.6% (p&lt;0.002) and 2.8% (p&lt;0.001));,22001:22213, 4809147 ,27026804,Unavailable
 4809147 ,"‘overall ease of use’, ‘quality of PIL instructions’, ‘preparing the dose’,  ‘clarity of dose counter’",Spiromax, Easyhaler and Turbuhaler,Significantly increased,"Participants were also asked to rate their satisfaction with five features for the three devices: ‘overall ease of use’, ‘quality of PIL instructions’, ‘preparing the dose’, ‘inhaling procedure’ and ‘clarity of dose counter’. With the exception of ‘inhaling procedure’, participants rated Spiromax significantly higher compared with both Easyhaler and Turbuhaler (p&lt;0.001 for all comparisons).",28175:28569, 4809147 ,27026804,Unavailable
 4809147 ,‘inhaling procedure’,Spiromax, Easyhaler and Turbuhaler,No significant difference,The difference was not significant for satisfaction with the ‘inhaling procedure’ between the three devices.,28569:28677, 4809147 ,27026804,Unavailable
 4809147 ,‘quality of PIL instructions’,Turbuhaler, Easyhaler ,Significantly increased,Turbuhaler was rated significantly higher than Easyhaler for the ‘quality of PIL instructions’ (p&lt;0.003),28678:28783, 4809147 ,27026804,Unavailable
 4836696 ,vehicle-subtracted weight loss,GSK457 (10% w/w) combined with the exendin-4 AlbudAb,placebo,Significantly decreased,"Pre-dosing GSK457 for a week followed by a combination of GSK457 and the exendin-4 AlbudAb for 28 days resulted in a vehicle-subtracted weight loss of 30.8%, far exceeding the sum of the exendin-4 AlbudAb and GSK457 effects, p &lt; 0.001 (Fig 4).",42653:42955, 4836696 ,27093610,Unavailable
 4836696 ,The final body weight,GSK457 (10% w/w) combined with the exendin-4 AlbudAb,placebo,No significant difference,"The final body weight (32 ± 0.8 g) of the GSK457 + exendin-4 AlbudAb combination group was not different from the final body weight of the lean control group (31.7 ± 0.6 g) (p = 0.68), reflecting a complete reversal of the diet induced obesity.",42955:43200, 4836696 ,27093610,Unavailable
 3698202 ,"psychometric scores of perceived recovery, soreness, or readiness to train",48&nbsp;g of rice protein isolate,48&nbsp;g of  whey protein isolate,No significant difference,"No detectable differences were present in psychometric scores of perceived recovery, soreness, or readiness to train (p &gt; 0.05).",6465:6593, 3698202 ,23782948,Unavailable
 3698202 , lean body mass,48g of rice protein isolate,48g of  whey protein isolate,No significant difference,"There was a significant time effect (p &lt;0.01) for lean body mass, which increased in both the rice (58.5 ± 5.5 (baseline) to 59.5 ± 4.5 (week 4) to 61.0 ± 5.6&nbsp;kg (week 8) and whey protein (59.6 ± 5.2 to 61.9 ± 4.5 to 62.8 ± 5.2&nbsp;kg) conditions, with no differences between conditions (no condition X time effect).",27137:27479, 3698202 ,23782948,Unavailable
 3698202 ,body fat,48g of rice protein isolate,48g of  whey protein isolate,No significant difference,"There was a significant time effect for body fat (p &lt; 0.05), which decreased in both conditions, 17.8 ± 6.0 to 16.6 ± 4.8 to 15.6 ± 4.9&nbsp;kg in the rice protein condition and 16.3 ± 5.1 to 15.7 ± 4.8 to 15.6 ± 4.9&nbsp;kg in the whey protein condition, from pre to post training, with no differences between conditions (no condition X time effect).",27137:27479, 3698202 ,23782948,Unavailable
 3698202 ,quadriceps and biceps thickness,48g of rice protein isolate,48g of  whey protein isolate,No significant difference,"There was a significant time effect for quadriceps and biceps thickness (p &lt; 0.05), which increased from pre to post training in the rice protein (5.0 ± 0.4 to 5.1 ± 0.4 to 5.2 ± 0.5&nbsp;cm and 3.6 ± 0.3 to 3.9 ± 0.3 to 4.1 ± 0.4&nbsp;cm, respectively) and whey protein (4.8 ± 0.7 to 5.0 ± 0.5 to 5.1 ± 0.5&nbsp;cm and 3.6 ± 0.2 to 4.0 ± 0.3 to 4.1 ± 0.3&nbsp;cm, respectively) conditions, with no differences between conditions (no condition X time effect). Body composition data is displayed in Figure&nbsp;1.",27479:28012, 3698202 ,23782948,Unavailable
 3698202 ,1-RM bench press strength,48g of rice protein isolate,48g of  whey protein isolate,No significant difference,"There was a significant time effect (p &lt; 0.01) for 1-RM bench press strength, which increased from baseline to week 8 in both the rice protein (85.9 ± 20.5 to 95.5 ± 21.4&nbsp;kg) and whey protein (89.5 ± 18.5 to 98.5 ± 16.4&nbsp;kg ) conditions, with no differences between groups (no condition X time effect).",28376:28677, 3698202 ,23782948,Unavailable
 3666914 ,Clinical Interview Schedule – revised (CIS-R) score,individual cognitive behavioural therapy (CBT) with usual care ,usual care only,Significantly decreased,The continuous CIS-R mean score was also lower for the intervention group compared with the usual care group at 33&nbsp;weeks post-randomisation.,52895:53035, 3666914 ,23339584,Unavailable
 5838771 ,serum IL-6 levels,"bipolar and ultrasonic energy (Thunderbeat), ultrasonic (Harmonic)",electrothermal bipolar vessel sealing system (Ligasure),Significantly decreased,There was a significantly higher increase in serum IL-6 levels in the Ligasure group as compared with Thunderbeat and Harmonic groups at 24 hours (p=0.010).,15645:15801, 5838771 ,29503255,Unavailable
 5838771 ,"TNF-α, RANTES, MIP-1 α, and MIP-1 β levels","bipolar and ultrasonic energy (Thunderbeat), ultrasonic (Harmonic)",electrothermal bipolar vessel sealing system (Ligasure),No significant difference,"However, there was no significant difference between the three groups in terms of inflammatory response as seen in levels of TNF-α, RANTES, MIP-1 α, and MIP-1 β levels.",15877:16045, 5838771 ,29503255,Unavailable
 5838771 ,GI activity,"bipolar and ultrasonic energy (Thunderbeat), ultrasonic (Harmonic)",electrothermal bipolar vessel sealing system (Ligasure),No significant difference,"No significant difference was observed between the three groups in terms of return of GI activity at 6 hours [group 1: 17 (85%) vs. group 2: 18 (90%) vs. group 3: 16 (80%); p=0.676], fever [group 1: 0% vs. group 2: 1 (5%) vs. group 3: 3 (13%); p=0.153] and mean VAS score (group 1: 3.60±0.94 vs. group 2: 3.35±0.87 vs. group 3: 3.60±0.94; p=0.613).",16437:16785, 5838771 ,29503255,Unavailable
 4132222 ,decrease in average lesion,application of a canola phenolic acid-based cream (CPA),placebo,No significant difference,"Furthermore, the proportion of participants with a $10% decrease in average lesion area was significantly higher in the CPA group than the placebo group at weeks 3 (P=0.05) and 6 (P=0.02), and showed a trend at week 12 (P=0.06).",4926:5205, 4132222 ,25143750,Unavailable
 4132222 ,"higher prevalence of lesion scabbing, a sign of healing",application of a canola phenolic acid-based cream (CPA),placebo,No significant difference,"The CPA group showed a trend toward higher prevalence of lesion scabbing, a sign of healing, after 12 weeks of treatment (6.8%) than those treated with placebo (1.3%, P=0.09).",25295:25487, 4132222 ,25143750,Unavailable
 5791430 ,"mean total age, working experience, and working hours of the nurses",electronic group,workshop group,No significant difference,"Independent t-test showed that there was no significant difference in mean total age (P = 0.23), working experience (P = 0.12), and working hours of the nurses (P = 0.41), before the study between the two groups that meant the two groups were homogeneous.",15827:16150, 5791430 ,29417070,Unavailable
 5791430 ,knowledge’ scores,electronic group,workshop group,Significantly increased,"In addition to these changes, knowledge’ scores in both groups showed the highest increase in electronic (78%) compared to workshop group (41%).",16708:16853, 5791430 ,29417070,Unavailable
 1241419 ,occlusion-induced peak ST-segment elevation,breathe CAPs on the second exposure day,filtered air at other times,Significantly increased,"Exposure to CAPs (median, 285.7; range, 161.3-957.3 microg/m3) significantly (p = 0.007) enhanced occlusion-induced peak ST-segment elevation in precordial leads V4 (9.4 +/- 1.7 vs. 6.2 +/- 0.9 mm, CAPs vs. filtered air, respectively)",3077:3311, 1241419 ,12676590,Unavailable
 5217661 ,reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures,"co-administration of fimasartan 120&nbsp;mg/rosuvastatin 20&nbsp;mg (FMS/RSV),  ","rosuvastatin 20&nbsp;mg (RSV) alone, ",Significantly decreased,"After 8&nbsp;weeks of treatment, the FMS/RSV treatment group showed greater reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures than those in the group receiving RSV alone (both p &lt; 0.001).",13026:13252, 5217661 ,28057081,Unavailable
 5217661 ,reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures,"co-administration of fimasartan 120mg/rosuvastatin 20mg (FMS/RSV),  ",fimasartan 120 mg (FMS) alone,No significant difference,"Reductions in siSBP and siDBP were not significantly different between the FMS/RSV and FMS alone groups (p = 0.500 and p = 0.734, respectively).",13252:13434, 5217661 ,28057081,Unavailable
 5217661 , low-density lipoprotein cholesterol (LDL-C) level,"co-administration of fimasartan 120mg/rosuvastatin 20mg (FMS/RSV),  ",fimasartan 120 mg (FMS) alone,Significantly decreased,"After 8&nbsp;weeks of treatment, FMS/RSV treatment showed greater efficacy in percentage reduction of low-density lipoprotein cholesterol (LDL-C) level from baseline than that shown by FMS alone treatment (p &lt; 0.001).",13434:13664, 5217661 ,28057081,Unavailable
 3622234 ,weight loss,"conventional fractionation (2.0 Gy per day, total 68 Gy during 7 weeks)","accelerated fractionation (1.1 + 2.0 Gy per day, total 68 Gy during 4.5 weeks)",No significant difference,No difference in weight loss was seen between the two RT fractionation schedules (p = 0.839).,5033:5128, 3622234 ,23106176,Unavailable
 3622234 ,"swallowing problems , mucositis  and used opioid analgesics","conventional fractionation (2.0 Gy per day, total 68 Gy during 7 weeks)","accelerated fractionation (1.1 + 2.0 Gy per day, total 68 Gy during 4.5 weeks)",Significantly decreased,"However, significantly more patients treated with AF were reported to have swallowing problems (AF 56.9%, CF 43.1%, missing n = 38), mucositis (AF 54.2%, CF 45.8%, missing n = 51) and used opioid analgesics (AF 58.6%, CF 41.4%, missing n = 39) more frequently at the end of RT (p &lt; 0.001, 0.001 and 0.001, respectively).",15737:16058, 3622234 ,23106176,Unavailable
 3622234 ,tube feeding (TF),"conventional fractionation (2.0 Gy per day, total 68 Gy during 7 weeks)","accelerated fractionation (1.1 + 2.0 Gy per day, total 68 Gy during 4.5 weeks)",Significantly decreased,At the end of RT patients treated with AF received TF more frequently than patients treated with CF (p &lt; 0.001).,16768:16880, 3622234 ,23106176,Unavailable
 5707237 ,connectivity between the left dorsal posterior cingulate cortex Brodmann Area (BA31) and the left piriform cortex (BA27),REHACOP group (cognitive rehabilitation),control group (occupational therapy),Significantly decreased,"Baseline differences in brain activation in resting-state fMRI were found between groups, showing the CG more connectivity between the left dorsal posterior cingulate cortex Brodmann Area (BA31) and the left piriform cortex (BA27) compared to the REHACOP group (t&nbsp;=&nbsp;3.96; p&nbsp;=&nbsp;0.04 FDR-corrected).",36029:36360, 5707237 ,27757820,Unavailable
 4717436 ,The maintenance of clinical remission at 1 year,"budesonide (mean dose 4.5 mg/day; Budenofalk 3 mg capsules, two or one capsule on alternate days)",placebo,Significantly increased,"The maintenance of clinical remission at 1 year was achieved by 61.4% (27/44 patients) in the budesonide group versus 16.7% (8/48 patients) receiving placebo (treatment difference 44.5% in favour of budesonide; 95% CI (26.9% to 62.7%), p&lt;0.001).",11636:11881, 4717436 ,25425655,Unavailable
 5807541 ,fatigue sevety,open-label placebo (OLP),treatment as usual (TAU),Significantly increased,"Compared to those randomized to TAU, OLP participants reported a 29% improvement in fatigue severity (average difference in the mean change scores (MD) 12.47, 95% CI 3.32, 21.61; P = 0.008), medium effect (d = 0.63),",5560:5776, 5807541 ,29426869,Unavailable
 5807541 ,fatigue-disrupted quality of life,open-label placebo (OLP),treatment as usual (TAU),Significantly increased,"and a 39% improvement in fatigue-disrupted quality of life (MD = 11.76, 95% CI 4.65, 18.86; P = 0.002), a large effect (d = 0.76).",5776:5908, 5807541 ,29426869,Unavailable
 5704406 ,Time to achieve remission,intravenous cyclophosphamide (IVCP) -  Group 1,oral cyclophosphamide (OCP) -  Group 2,Significantly increased,Time to achieve remission was significantly longer in the Group 1 (86.07 + 29.10 days) as compared to Group 2 (47.45 + 26.06 days) (P = 0.002).,13160:13320, 5704406 ,29217878,Unavailable
 5704406 ,Major side effects,intravenous cyclophosphamide (IVCP) -  Group 1,oral cyclophosphamide (OCP) -  Group 2,No significant difference,"The difference was not significant, P = 0.417. Minor side effects were seen in seven patients; four in Group 1, three in Group 2; which were comparable (P = 1.00).",13420:13618, 5704406 ,29217878,Unavailable
 5704406 ,"hemoglobin, creatinine",intravenous cyclophosphamide (IVCP) -  Group 1,oral cyclophosphamide (OCP) -  Group 2,No significant difference,"There was no significant change in hemoglobin or creatinine after CP therapy in either of the two groups (P = 0.587 and 0.936, respectively) [Table 3].",13868:14075, 5704406 ,29217878,Unavailable
 5704406 ,Mean duration of remission,intravenous cyclophosphamide (IVCP) -  Group 1,oral cyclophosphamide (OCP) -  Group 2,No significant difference,Mean duration of remission was similar in both groups 8.13 + 8.85 months versus 9.15 + 8.28 months (P = 0.963).,14710:14838, 5704406 ,29217878,Unavailable
 5934946 ,"chief complaints like perennial pain, P/V discharge, Perineal muscle laxity and Feeling of something coming out P/V",Mulabandha yoga therapy + conventional treatment,only on conventional treatment,Significantly decreased,"Results At the end of 12 weeks, Post-study comparison between the two groups showed a significant improvement in chief complaints like perennial pain, P/V discharge, Perineal muscle laxity and Feeling of something coming out P/V (P &lt; 0.001).",4893:5159, 5934946 ,29755220,Unavailable
 5725301 ,body weight,combination  diuretic group (received 7.5 mg of tolvaptan),conventional diuretic group (received 40 mg of furosemide),Significantly decreased,"Following 1 wk of treatment, a significantly greater reduction in body weight was observed in the combination diuretic group compared to that in the conventional diuretic group (P = 0.0412).",7094:7301, 5725301 ,29259382,Unavailable
 3701833 ,8-OHdG levels,"sham group, only scaling and root planing (SRP) was done; placebo group, local delivery of placebo gel after SRP;","lycopene group, local delivery of lycopene gel after SRP",Significantly decreased,There was a significant reduction in the 8-OHdG levels at the end of the first week when compared to week 12 in the sham and the placebo groups only (Fig. 2).,20258:20456, 3701833 ,23837126,Unavailable
 3701833 ,modified gingival index (MGI) scores,"sham group, only scaling and root planing (SRP) was done; placebo group, local delivery of placebo gel after SRP;","lycopene group, local delivery of lycopene gel after SRP",No significant difference,"In addition, in all of the groups, there was no significant reduction when the MGI score at the end of the second week was compared to the baseline score (Table 1).",21510:21717, 3701833 ,23837126,Unavailable
 3701833 ,the mean plaque scores,"sham group, only scaling and root planing (SRP) was done; placebo group, local delivery of placebo gel after SRP;","lycopene group, local delivery of lycopene gel after SRP",Significantly increased,"Likewise, the lycopene group showed a highly significant reduction in the mean plaque scores at the end of two weeks (P&lt;0.001) and a significant reduction (P&lt;0.01) in the MPI at the end of four weeks and twelve weeks when compared to the other two groups.",22520:22816, 3701833 ,23837126,Unavailable
 3681386 ,colonisation index,single drug (nystatin),control,Significantly decreased,"The corrected colonisation index was similar in the two groups at T0 (P = 0.36), while a significant statistical difference was observed between the treatment and control groups at T6 (median 0.14 and 0.33, respectively; P = 0.0016), at T9 (median 0.00 and 0.28, respectively; P = 0.0001), at T12 (median 0.00 and 0.41, respectively; P = 0.0008), and at T15 (median 0.00 and 0.42, respectively; P &lt;0.0003).",5807:6302, 3681386 ,22490643,Unavailable
 3681386 ,proportion of positive stomach samples,single drug (nystatin),control,Significantly decreased,"During hospitalisation in the ICU the proportion of positive stomach samples significantly decreased in the treatment group (from 59 to 49%) as opposed to the control group (from 58 to 74%; P &lt;0.00009) at T6, and this difference persisted over time.",22810:23080, 3681386 ,22490643,Unavailable
 4925999 ,adherence to dietary and medication regimen,nurse-led telephone follow-up,control group,Significantly increased,"However, a statistically significant difference was found between the two groups in this regard after the intervention (P&lt;0.05).",5433:5561, 4925999 ,27382586,Unavailable
 4925999 ,dietary and medication adherence scores,nurse-led telephone follow-up,control group,Significantly increased,The mean differences of dietary and medication adherence scores between pre- and post-tests were significantly different between the two groups. Independent t-test showed these differences (P=0.001).,5562:5761, 4925999 ,27382586,Unavailable
 4364400 ,image quality,gadopentetate dimeglumine,gadoxetic acid,No significant difference,"No significant difference was observed in image quality between both GBCAs for either observer (overall IQ score (max 16): 14 ± 2.4 vs. 13.9 ± 2.5, P = 0.7 for observer 1 and 15.0 ± 2.1 vs. 14.0 ± 2.3 for observer 2 for gadopentetate dimeglumine and gadoxetic acid, respectively).",27694:27992, 4364400 ,25793110,Unavailable
 4364400 ,qualitative vascular enhancement,gadopentetate dimeglumine,gadoxetic acid,No significant difference,"There was no significant difference in qualitative vascular enhancement between gadopentetate dimeglumine and gadoxetic acid,",27992:28118, 4364400 ,25793110,Unavailable
 4364400 ,qualitative vascular enhancement for hepatic veins ,gadopentetate dimeglumine,gadoxetic acid,Significantly increased,"with the exception of higher scores for hepatic veins on gadopentetate dimeglumine-set (9.7 ± 1.6) vs. gadoxetic acid-set (7.3 ± 1.9, P &lt; 0.005) for observer 2.",28117:28295, 4364400 ,25793110,Unavailable
 4364400 ,lesion conspicuity CE T1W imaging dynamic phases,gadopentetate dimeglumine,gadoxetic acid,No significant difference,"No significant differences in lesion conspicuity were observed between gadopentetate dimeglumine and gadoxetic acid CE T1W imaging dynamic phases,",29233:29380, 4364400 ,25793110,Unavailable
 4364400 ,lesion conspicuity score on AP1,gadopentetate dimeglumine,gadoxetic acid,Significantly increased,"with the exception of higher lesion conspicuity score on AP1 with gadopentetate dimeglumine (3.9 ± 1.5) compared to gadoxetic acid-set (2.5 ± 1.7, P &lt; 0.007) for observer 2.",29379:29570, 4364400 ,25793110,Unavailable
 3131514 ,Peripheral glucose uptake,prednisolone 7.5&nbsp;mg once daily, placebo,No significant difference,"Peripheral glucose uptake was not reduced by prednisolone 7.5&nbsp;mg, but was decreased by prednisolone 30&nbsp;mg by 34 ± 6% (p &lt; 0.0001).",5103:5251, 3131514 ,21562755,Unavailable
 3131514 ,Peripheral glucose uptake,prednisolone 30 mg once daily, placebo,Significantly decreased,"Peripheral glucose uptake was not reduced by prednisolone 7.5&nbsp;mg, but was decreased by prednisolone 30&nbsp;mg by 34 ± 6% (p &lt; 0.0001).",5103:5251, 3131514 ,21562755,Unavailable
 3131514 ,lipolysis in the fasted state,"prednisolone 30 mg once daily and  prednisolone 7,5 mg once daily", placebo,No significant difference,"Compared with placebo, prednisolone treatment tended to decrease lipolysis in the fasted state (p = 0.062)",5250:5377, 3131514 ,21562755,Unavailable
 3131514 ,insulin-mediated suppression of lipolysis,"prednisolone 30 mg once daily and  prednisolone 7,5 mg once daily", placebo,Significantly decreased,"but both prednisolone 7.5&nbsp;mg and prednisolone 30&nbsp;mg decreased insulin-mediated suppression of lipolysis by 11 ± 5% and 34 ± 6%, respectively.",5378:5521, 3131514 ,21562755,Unavailable
 3131514 ,whole-body proteolysis during hyperinsulinaemia,"prednisolone 30 mg once daily and  prednisolone 7,5 mg once daily", placebo,No significant difference,"Finally, prednisolone treatment increased whole-body proteolysis during hyperinsulinaemia, which tended to be driven by prednisolone 30&nbsp;mg (5 ± 2%; p = 0.06).",5521:5697, 3131514 ,21562755,Unavailable
 5057414 ,quality‐of‐care score,Achievable Benchmark of Care (ABC) method,control group (CG),Significantly increased,We observed statistically significant changes in the score during follow‐ups between the two groups and the mean effect of intervention was 19.0%‐point (95% CI 16.7%‐ to 21.3%‐point; P &lt; 0.001).,38061:38273, 5057414 ,26331280,Unavailable
 3556314 ,fracture union success rate,Pulsed electromagnetic field (PEMF),sham treatment,No significant difference,"Meanwhile, the fracture union success rate was 22.2% (6 out of 27, 95% CI, 0.08 to 0.42) for Group 2, which was slightly lower than that for Group 1 (P = 0.256), but not statistically significant.",20809:21023, 3556314 ,23331333,Unavailable
 3556314 ,the average lengths of treatment,Pulsed electromagnetic field (PEMF),sham treatment,Significantly increased,"At the end of the study, the average lengths of treatment were 4.8 months and 4.4 months in the two groups (P = 0.489), with a union rate of 77.4% (24 out of 31, 95% CI, 0.58 to 0.90) in Group 1 (Figure 4) compared with a union rate of 48.1% (13 out of 27, 95% CI, 0.28 to 0.68) in Group 2 (P = 0.029, Table 1).",21233:21654, 3556314 ,23331333,Unavailable
 3556314 ,The total times from operation,Pulsed electromagnetic field (PEMF),sham treatment,No significant difference,The total times from operation to the end of the study were averaged at 9.6 months and 9.5 months in Group 1 and Group 2 respectively (P = 0.849).,21724:21887, 3556314 ,23331333,Unavailable
 5771578 , The Pregnancy Unique Quantification of Emesis (PUQE) total: LOCF imputation (doxylamine-pyridoxine vs placebo)*,doxylamine 10 mg and pyridoxine 10 mg taken between 2 and 4 times per day,placebo,Significantly decreased,Primary outcome PUQE total: LOCF imputation (doxylamine-pyridoxine vs placebo)* -4.8 ± 2.7 vs -3.9 ± 2.6 (p = 0.006) -4.8 ± 2.7 vs -3.9 ± 2.6 (p = 0.006) (p = 0.006),44129:44689, 5771578 ,29342163,Unavailable
 5041384 ,reduction in aggression,Yoga group,control group,Significantly decreased,Postintervention results revealed that Yoga group showed statistically significant (P &lt; 0.001) reduction in aggression and significant (P &lt; 0.001) enhancement in PA in comparison to the control group.,4486:4740, 5041384 ,27833364,Unavailable
 5041384 ,positive affectivity (PA),Yoga group,control group,Significantly increased,Postintervention results revealed that Yoga group showed statistically significant (P &lt; 0.001) reduction in aggression and significant (P &lt; 0.001) enhancement in PA in comparison to the control group.,4486:4740, 5041384 ,27833364,Unavailable
 4407951 ,"Quality of Life, Utility Weights, and QALYs",programs for stress urinary incontinence (SUI) without face-to-face contact:  Internet-based one sent by post,programs for stress urinary incontinence (SUI) without face-to-face contact: sent by post,No significant difference,"The differences between the groups were not significant (P = 0.52 at 4 months, P = 0.79 at 1 year).",32999:33136, 4407951 ,24347521,Unavailable
 3576014 , heart rate,advanced care group (ACG),usual care group (UCG),No significant difference,"Further, during the course of the study, no significant difference in heart rate was detected between the two groups and, after 6 months, there was no decrease in heart rate in the ACG (P = 0.23) or the UCG (P = 0.72).",17323:17575, 3576014 ,23426275,Unavailable
 3576014 ,body weight,advanced care group (ACG),usual care group (UCG),No significant difference,After 6 months: the average weight of participants in both groups showed a slight nonsignificant decrease – minus 700 g in the ACG (P = 0.90) and minus 400 g in the UCG (P = 0.93);,15517:15732, 3576014 ,23426275,Unavailable
 3769981 ,serum phosphorus concentration,paricalcitol (1 or 2 μg/day),placebo-,Significantly decreased,"Following treatment withdrawal, the serum phosphorus concentration decreased to below baseline in the paricalcitol groups (paricalcitol 1 μg/day, P = 0.001 versus placebo; paricalcitol 2 μg/day, P = 0.034 versus placebo). FIGURE&nbsp;1:",23119:23393, 3769981 ,23787544,Unavailable
 3769981 ,calcium,paricalcitol (1 or 2 μg/day),placebo-,Significantly increased,Increases from baseline in serum calcium were observed for the paricalcitol 1-μg/day (0.16 mg/dL; P = 0.039 versus placebo) and 2-μg/day groups (0.48 mg/dL; P &lt; 0.001 versus placebo).,24427:24611, 3769981 ,23787544,Unavailable
 3769981 ,24-h urinary calcium excretion,paricalcitol (1 or 2 μg/day),placebo-,Significantly increased,"Increases in 24-h urinary calcium excretion from baseline to last on-treatment assessment paralleled changes in serum calcium, with 19.73-mg (P = 0.003 versus placebo) and 26.12-mg increases (P &lt; 0.001 versus placebo) for the paricalcitol 1- and 2-μg/day groups, respectively.",24835:25112, 3769981 ,23787544,Unavailable
 3769981 ,intact PTH (iPTH) (parathyroid hormone),paricalcitol (1 or 2 μg/day),placebo-,Significantly decreased,"In the active treatment groups, there was a dose-dependent reduction in iPTH, with a 26.9-pg/mL decrease in the 1-μg/day group (20.9% reduction; P &lt; 0.001 versus placebo) and a 52.7-pg/mL reduction in the 2-μg/day group (48.9% reduction; P &lt; 0.001 versus placebo).",25914:26179, 3769981 ,23787544,Unavailable
 4511433 ,LDL cholesterol,2.5&nbsp;mg or 5&nbsp;mg elobixibat,placebo,Significantly decreased,"When analyzing the mean and median change values from baseline to Days 14 and 28, there was a more prominent reduction in the drug-treated groups as compared to placebo whereas on day 42 (14&nbsp;days after cessation of treatment) there was no clear difference.Fig. 2",22426:22711, 4511433 ,26197999,Unavailable
 4689586 ,cortisol concentration,"3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxymethamphetamine (MDMA)+methylphenidate (MPH)","placebo, MPH alone",Significantly increased,The most striking difference between the drug conditions was an increase in cortisol concentration upon exposure to MDMA (p &lt; 0.001) or MDMA/MPH (p &lt; 0.0001) compared to placebo or MPH alone (Fig 1C).,21323:21594, 4689586 ,26700184,Unavailable
 4689586 ,epinephrine concentrations," 3,4-methylenedioxymethamphetamine (MDMA)+methylphenidate (MPH)",MPH alone,Significantly increased,The increase in epinephrine concentrations was higher in individuals exposed to MDMA/MPH (p &lt; 0.0001) than in those exposed to MDMA alone (p &lt; 0.01),21822:21971, 4689586 ,26700184,Unavailable
 4312979 ,pain scores,kinetic oscillation stimulation (KOS) in the nasal cavity,placebo treatment,Significantly decreased,"The changes in pain scores differed between the 2 treatments by 3.3 points (95% CI: 2.3, 4.4), P &lt; .001. Individual VAS scores for all 35 analyzed patients are presented in Figures 4 and 5.",29932:30221, 4312979 ,25546476,Unavailable
 4312979 ,the proportion of headache days,kinetic oscillation stimulation (KOS) in the nasal cavity,placebo treatment,No significant difference,"Correspondingly, the proportion of headache days increased in the placebo group, with a similar pattern during both months, but the difference was not significant (P = .39 run-in to first month of follow-up, P = .53 to the second).",48993:49259, 4312979 ,25546476,Unavailable
 4312979 ,The pain intensity and attack duration,kinetic oscillation stimulation (KOS) in the nasal cavity,placebo treatment,No significant difference,"The pain intensity and attack duration tended to decrease in the active group compared with the placebo group during the first month of follow-up (P = .42 and P = .37, respectively).",49266:49482, 4312979 ,25546476,Unavailable
 5545112 ,vitamin D levels,"2,000 IU  of oral vitamin D3","4,000 IU of oral vitamin D3",Significantly increased,"However, the increase in vitamin D levels after 90 days of oral vitamin D3, in the 4,000 IU group was significantly higher 16.80&nbsp;±&nbsp;9.15 (p&nbsp;&lt;&nbsp;0.001) compared to the 2,000 IU group of vitamin D 5.00&nbsp;±&nbsp;3.12 (p&nbsp;=&nbsp;0.008).",5740:6004, 5545112 ,28791200,Unavailable
 5545112 ,Partial Mayo UC Score,"2,000 IU  of oral vitamin D3","4,000 IU of oral vitamin D3",No significant difference,"In the 2,000 IU of vitamin D3 group the mean decrease in the Partial Mayo UC Score was −0.5&nbsp;±&nbsp;1.5 (p&nbsp;=&nbsp;0.38) compared to −1.3&nbsp;±&nbsp;2.9 (p&nbsp;=&nbsp;0.19) in the 4,000 IU vitamin D3 group but this was not statistically significant.",6441:6716, 5545112 ,28791200,Unavailable
 3510891 ,"reaction time, kinetic time, α-angle, maximum amplitude and coagulation index",Hydroxyethyl starches (HES) 130/0.4 (Voluven®),130/0.42 (Venofundin®),No significant difference,"Measurements of reaction time, kinetic time, α-angle, maximum amplitude and coagulation index before and after colloid infusion did not differ between the groups.",3954:4116, 3510891 ,23041738,Unavailable
 3598549 ,"overall survival (OS) , progression-free survival",(A) fotemustine and dacarbazine repeated on 3-week cycle; (B) same treatment as (A) plus IFN-α2b three times per week;,(C) dacarbazine alone repeated on 3-week cycle; (D) same treatment as (C) plus IFN-α2b three times per week,No significant difference,"Addition of fotemustine did not significantly improve overall survival (OS) (p=0.28) or progression-free survival (PFS) (p=0.55); Hazard ratio (HR) for OS was 0.93 (95% CI 0.71-1.21). Similarly, addition of IFN-α2b did not improve OS (p=0.68) or PFS (p=0.65); HR for OS was 0.92 (95% CI 0.70-1.20).",8032:8330, 3598549 ,23402397,Unavailable
 5866829 ,frequency of spontaneous bowel movements,"elobixibat (5, 10, or 15&nbsp;mg)",placebo,Significantly increased,"In the 10- and 15-mg groups, frequency of spontaneous bowel movements (±standard deviation) were significantly higher than baseline (5.7&nbsp;±&nbsp;4.2 and 5.6&nbsp;±&nbsp;3.5&nbsp;times per week, respectively, compared with 2.6&nbsp;±&nbsp;2.9&nbsp;times per week in the placebo group [P&nbsp;=&nbsp;0.0005, P&nbsp;=&nbsp;0.0001, respectively]).",4644:4966, 5866829 ,28840422,Unavailable
 5866829 ,LDL cholesterol ,"elobixibat (5, 10, or 15&amp;nbsp;mg)",placebo,Significantly decreased,"Compared with the placebo group, the 5-, 10-, and 15-mg elobixibat groups showed significant decreases in LDL cholesterol from baseline levels after 14&nbsp;days of treatment (t test; P&nbsp;=&nbsp;0.0118, P&nbsp;&lt;&nbsp;0.001, P&nbsp;=&nbsp;0.0067, respectively).",33437:33736, 5866829 ,28840422,Unavailable
 5866829 ,HDL cholesterol,"elobixibat (5, 10, or 15&amp;amp;nbsp;mg)",placebo,No significant difference,There were no significant changes in HDL cholesterol in all groups.,34235:34302, 5866829 ,28840422,Unavailable
 3718707 ,daily energy intake,"counseling sessions focusing on diet, physical activity, and weight monitoring",control,Significantly decreased,"Women in the control group increased their daily energy intake from on average 2,110 (± 409) kcal at baseline to 2,328 (± 410) kcal at the end of pregnancy (p = 0.027), while women from the intervention group maintained a stable energy intake throughout their pregnancy (Table&nbsp;4).",50493:50813, 3718707 ,23865624,Unavailable
 5732440 ,HbA1c,Educational Program,usual care,Significantly decreased,EG had a decrease in 11% more (effect-size r2 = .11) than CG for HbA1c (p &lt; .001),6007:6105, 5732440 ,29246139,Unavailable
 5732440 ,BMI,Educational Program,usual care,Significantly decreased,and 4% more (effect-size r2 = .04) in BMI (p &lt; .05).,6105:6178, 5732440 ,29246139,Unavailable
 3733748 ,Brachial-ankle pulse wave velocity (baPWV),"cilostazol group (50 mg for 2 weeks, 100 mg for 6 weeks)",placebo,No significant difference,"Compared with the placebo group, the mean baPWV did not improve in the cilostazol group (mean difference 31.42 cm/sec, 95% CI −55.67 to 118.5).",5404:5547, 3733748 ,23886346,Unavailable
 3733748 ,soluble vascular cellular adhesion molecule-1 (sVCAM-1) level,"cilostazol group (50 mg for 2 weeks, 100 mg for 6 weeks)",placebo,No significant difference,"Cilostazol treatment significantly reduced soluble vascular cellular adhesion molecule-1 (sVCAM-1) level (from 1288.7 ± 285.6 to 1168.2 ± 252.3 ng/dL, P = 0.0003), and there was also significant mean difference between groups (mean difference 105.18 ng/dL, 95% CI 10.65 to 199.71).",5548:5846, 3733748 ,23886346,Unavailable
 3733748 ,"lipid profiles, high sensitivity C-reactive protein, adiponectin, interleukin-6, tumor necrosis factor-alpha, monocyte chemotactic protein-1, and soluble intercellular adhesion molecule-1","cilostazol group (50 mg for 2 weeks, 100 mg for 6 weeks)",placebo,No significant difference,"However, other biochemical markers including lipid profiles, high sensitivity C-reactive protein, adiponectin, interleukin-6, tumor necrosis factor-alpha, monocyte chemotactic protein-1, and soluble intercellular adhesion molecule-1 did not improve with cilostazol treatment.",5847:6122, 3733748 ,23886346,Unavailable
 4315810 ,Attention towards all categories of warnings,standardized packs,branded packs,Significantly increased,"Attention towards all categories of warnings increased when they were presented on standardized packs compared to branded packs (F(1,29)&nbsp;=&nbsp;26.9, p&nbsp;&lt;&nbsp;0.001, partial η2&nbsp;=&nbsp;0.481).",23591:23833, 4315810 ,25542740,Unavailable
 4315810 ,Attention towards all categories of warnings,colour text,colour image &amp; text,Significantly increased,"There were also clear differences in accumulated gaze time between the three types of health warnings, with greater gaze times for colour text compared to colour image &amp; text, and for colour image &amp; text compared to black &amp; white text (F(2,58)&nbsp;=&nbsp;52.6, p&nbsp;&lt;&nbsp;0.001, partial η2&nbsp;=&nbsp;0.645).",23833:24193, 4315810 ,25542740,Unavailable
 4315810 ,Attention towards all categories of warnings,for colour image &amp; text,black &amp; white text,Significantly increased,"There were also clear differences in accumulated gaze time between the three types of health warnings, with greater gaze times for colour text compared to colour image &amp; text, and for colour image &amp; text compared to black &amp; white text (F(2,58)&nbsp;=&nbsp;52.6, p&nbsp;&lt;&nbsp;0.001, partial η2&nbsp;=&nbsp;0.645).",23833:24193, 4315810 ,25542740,Unavailable
 4315810 ,Attention towards all categories of warnings,for colour image &amp;amp; text,black &amp;amp; white text,Significantly increased,"There were also clear differences in accumulated gaze time between the three types of health warnings, with greater gaze times for colour text compared to colour image &amp; text, and for colour image &amp; text compared to black &amp; white text (F(2,58)&nbsp;=&nbsp;52.6, p&nbsp;&lt;&nbsp;0.001, partial η2&nbsp;=&nbsp;0.645).",23833:24193, 4315810 ,25542740,Unavailable
 3612059 ,The mean adherence to medicines,"antimalarials and antibiotics, and antimalarials and amoxicillin  (intervention areas)",antimalarials only (control areas),Significantly increased,The mean adherence to medicines was more than 95% in all three treatment groups but was significantly lower in the control arm (mean 96%) compared to the group in the intervention arm using AL only (mean 99%) and that using both AL and amoxicillin (mean 99%) (p&lt;0.001) (Table 2).,35811:36148, 3612059 ,23555980,Unavailable
 3612059 ,The mean adherence to medicines,antimalarials and antibiotics, antimalarials and amoxicillin,No significant difference,There was no difference in adherence between children taking AL alone and children taking AL plus amoxicillin in the intervention arm (p = 0.19).,36148:36293, 3612059 ,23555980,Unavailable
 5729494 ,L‐VLDL and the content of triglycerides in S‐VLDL,weight maintenance with meal replacements with  liraglutide (1.2&nbsp;mg&nbsp;daily),weight maintenance with meal replacements without liraglutide (1.2&nbsp;mg&nbsp;daily),Significantly decreased,"All VLDL and LDL particles increased after 1&nbsp;year of weight maintenance in the control group whereas, and in contrast to, in the liraglutide‐treated group, only L‐VLDL and the content of triglycerides in S‐VLDL increased (Table S2).",34399:34705, 5729494 ,29259801,Unavailable
 4301658 ,Birmingham IBS Symptom Scale and IBS QOL Scale scores,moxibustion,sham moxibustion group (control group),Significantly decreased,"After treatment, the decrease in Birmingham IBS Symptom Scale and IBS QOL Scale scores in moxibustion group was significantly greater than that of control group (P &lt; 0.01).",7101:7273, 4301658 ,25516481,Unavailable
 4301658 ,The defecation urge threshold and the pain perception threshold,moxibustion,sham moxibustion group (control group),Significantly increased,The defecation urge threshold and the pain perception threshold of moxibustion group was also significantly higher after treatment than that of control group (P &lt; 0.01).,7274:7443, 4301658 ,25516481,Unavailable
 4301658 ,pain score during the 100&nbsp;ml rectal balloon distention,moxibustion,sham moxibustion group (control group),Significantly decreased,The decrease in pain score during the 100&nbsp;ml rectal balloon distention in moxibustion group was significantly greater than that of control group (P &lt; 0.05).,7444:7600, 4301658 ,25516481,Unavailable
 5728271 ,improvements in both their parenting efficacy and satisfaction,culturally tailored societal information combined with the Connect parenting programme,waiting-list (control group),Significantly increased,Parents in the intervention group reported greater improvements in both their parenting efficacy (95% CI −8.15 to −5.29; d=1.79) and satisfaction (95% CI −4.48 to −2.69; d=0.89) compared with parents in the control group.,38263:38484, 5728271 ,29222136,Unavailable
 5728271 ,mental health,culturally tailored societal information combined with the Connect parenting programme,waiting-list (control group),Significantly increased,"Finally, the total effect of change on parents’ mental health (c path) was significant (β=−3.90, p&lt;0.001), indicating that parents who received the intervention had improved mental health.",48277:48483, 5728271 ,29222136,Unavailable
 5817800 ,The closure rate of molecular hole,"group A: conventional internal limiting membrane peeling, group B: inverted-flap technique",group C: free-flap technique,No significant difference,The closure rate was in group A and B: 91.6%; 95% CI 61.52–99.79%. In group C: 85.71%; 95% CI 57.19–98.22%. There were no differences in the macular hole closure rate between groups (p&nbsp;=&nbsp;0.85).,6180:6392, 5817800 ,29479478,Unavailable
 3669033 ,"Depression, Vigor, or Fatigue",hot-water extract of TA root (TA),Placebo (PL),No significant difference,"Mood state parameters showed mixed results (Figure 1), with no effect observed between supplementation groups for indices of Depression, Vigor, or Fatigue",19885:20076, 3669033 ,23705671,Unavailable
 3669033 ,"Tension , Anger, and Confusion",hot-water extract of TA root (TA),Placebo (PL),Significantly decreased,"whereas significant improvements were found in the TA group for Tension (−11%), Anger (−12%), and Confusion (−15%) compared to placebo.",20078:20213, 3669033 ,23705671,Unavailable
 3669033 ,Global Mood State,hot-water extract of TA root (TA),Placebo (PL),No significant difference,A non-significant trend (p = .083) was found for an improvement in overall well-being in the TA group (+3% in Global Mood State).,20213:20343, 3669033 ,23705671,Unavailable
 3669033 ,Salivary cortisol level,hot-water extract of TA root (TA),Placebo (PL),Significantly decreased,"Salivary cortisol. Salivary cortisol levels were significantly lower (−16% compared to placebo, PL) following tongkat ali (TA) supplementation (200 mg/day for 4 weeks). * = p &lt; 0.05 by ANOVA.Figure 3",21231:21547, 3669033 ,23705671,Unavailable
 3669033 ,Salivary testosterone level,hot-water extract of TA root (TA),Placebo (PL),Significantly increased,"Salivary testosterone. Salivary testosterone levels were significantly higher (+37% compared to placebo, PL) following tongkat ali (TA) supplementation (200 mg/day for 4 weeks). * = p &lt; 0.05 by ANOVA.",21573:21780, 3669033 ,23705671,Unavailable
 4681166 ,total and abdominal area fat,"30&nbsp;g of whey proteins,", isocaloric carbohydrates (maltodextrin),Significantly decreased,"However, the whey protein group reduced more total and abdominal area fat when compared to the carbohydrate group independent of the type of RT (P &lt; 0.05).",5486:5661, 4681166 ,26677350,Unavailable
 4681166 ,fat-free mass,"30g of whey proteins,", isocaloric carbohydrates (maltodextrin),Significantly increased,"Thus, a larger relative increase (per kg bodyweight) in fat-free mass was observed in the protein vs. carbohydrate group (P &lt; 0.05) without significant differences to the combined group.",5662:5868, 4681166 ,26677350,Unavailable
 4681166 ,fat-free mass,protein + carbohydrates; 30 g of whey proteins;, isocaloric carbohydrates (maltodextrin);,No significant difference,"Thus, a larger relative increase (per kg bodyweight) in fat-free mass was observed in the protein vs. carbohydrate group (P &lt; 0.05) without significant differences to the combined group.",5869:5940, 4681166 ,26677350,Unavailable
 4681166 ,serum lipids,protein + carbohydrates, isocaloric carbohydrates (maltodextrin),No significant difference,No systematic effects of the interventions were found for serum lipids.,5869:5940, 4681166 ,26677350,Unavailable
 3621795 ,Mean Se level,Se (as sodium selenite) per os on the days of RT (SeG group),receive no supplement during RT (CG - control group),Significantly increased,"Mean Se levels did not differ between SeG and CG upon study initiation, but were significantly higher in the SeG compared to the CG at the end of RT.",8921:9109, 3621795 ,23531280,Unavailable
 3621795 ,radiation induced diarrhoea,Se (as sodium selenite) per os on the days of RT,receive no supplement during RT,Significantly decreased,The actuarial incidence of at least CTC 2 radiation induced diarrhoea in the SeG was 20.5% compared to 44.5% in the CG (p=0.04).,8557:8685, 3621795 ,23531280,Unavailable
 3621795 ,actuarial incidence of at least CTC 2 diarrhoea,Se (as sodium selenite) per os on the days of RT,receive no supplement during RT,No significant difference,With a PTV of &lt;= 1302 ml (n=41) the actuarial incidence of at least CTC 2 diarrhoea in the SeG was 22.3% (4 of 18 patients) compared to 34.8% (8 of 23 patients) in the CG (p=0.50).,8740:8920, 3621795 ,23531280,Unavailable
 3621795 ,actuarial incidence of at least CTC 2 diarrhoea ( in patients with a PTV of &gt; 1302 ml),Se (as sodium selenite) per os on the days of RT,receive no supplement during RT,Significantly decreased,In patients with a PTV of &gt; 1302 ml (n=40) the actuarial incidence of at least CTC 2 diarrhoea in the SeG was 19.1% (4 of 21 patients) versus 52.6% (10 of 19 patients) in the CG (p=0.046).,8921:9109, 3621795 ,23531280,Unavailable
 5526285 ,body weight,motivational interviewing (MI) , behavioral weight-loss programs (BWLPs),No significant difference,"For both groups, body weight decreased from baseline to the end of the BWLP, B = −2.55, SE = .39; t(262.50) = −6.54, p &lt; .001 (CI = −3.31, −1.78), but body weight did not change from baseline to the 6-month follow-up, B = −.66, SE = .39; t(261.53) = −1.70, p = .09 (CI = −1.42, .10) (see Table&nbsp;2).Table 2",33942:34459, 5526285 ,28743313,Unavailable
 5526285 ,missed  sessions,motivational interviewing (MI) , behavioral weight-loss programs (BWLPs),No significant difference,"These means did not differ between groups, t(102) = −.46, p = .65.",36658:36758, 5526285 ,28743313,Unavailable
 3578670 ,preferrence,brinzolamide/timolol,dorzolamide/timolol,Significantly increased,A significantly greater percentage preferred brinzolamide/timolol to dorzolamide/timolol (67.0% versus 30.4%; P &lt; 0.001).,4616:4756, 3578670 ,23440904,Unavailable
 3578670 ,The ocular discomfort,brinzolamide/timolol,dorzolamide/timolol,Significantly decreased,"The ocular discomfort (expressed as mean [standard deviation]) with brinzolamide/timolol was significantly lower than with dorzolamide/timolol (day 2:1.9 [2.3] versus 3.7 [2.8], respectively [P = 0.0003];",4755:4980, 3578670 ,23440904,Unavailable
 3563445 ,Composition of the microbiota at age of 6 months,Lactobacillus rhamnosus GG,placebo,No significant difference,"Composition of the microbiota did not differ between study groups at age of 6 months,",5814:5899, 3563445 ,23339708,Unavailable
 3563445 ,Composition of the microbiota at age of 18 months,Lactobacillus rhamnosus GG,placebo,Significantly increased,"Composition of the microbiota did not differ between study groups at age of 6 months, but was significantly different at age of 18 months as assessed by MCPP (p=0.01).",5814:5982, 3563445 ,23339708,Unavailable
 3563445 ,Clostridium difficile et rel at 18 months of age,Lactobacillus rhamnosus GG,placebo,Significantly decreased,"Moreover, the placebo group children had higher levels of Clostridium difficile et rel at 18 months of age as compared to the LGG group children (1.19 ± 0.85% and 0.78 ± 0.60%, respectively, p=0.047).",37322:37540, 3563445 ,23339708,Unavailable
 4166055 ,"The mean systolic  blood pressure (SBP) at min 2 and min 5, mean of diastolic blood pressure ( DBP) at min 2, 5, and 15, mean of heart rate (HR) at all time points and mean of  mean arterial pressure (MAP) at min 2 and 15 ",hypertonic saline 5% (2.3 ml/kg),normal saline (13 ml/kg),No significant difference,"The mean SBP at min 2 and min 5, mean of DBP at min 2, 5, and 15, mean of HR at all time points and mean of MAP at min 2 and 15 between groups were no significantly different (P &gt; 0.05)",4022:4225, 4166055 ,25250297,Unavailable
 4166055 ,"mean of SBP at min 10 and 15, mean of DBP at min 10, and mean of MAP at min 5 and 10",hypertonic saline 5% (2.3 ml/kg),normal saline (13 ml/kg),Significantly increased,"but mean of SBP at min 10 and 15, mean of DBP at min 10, and mean of MAP at min 5 and 10 in hypertonic saline group was significantly more than the normal group (P &lt; 0.05).",4227:4419, 4166055 ,25250297,Unavailable
 5826979 ,numbers at the intention to act stage,generic list (LIST),CONTROL (no information),No significant difference,"At baseline, between the 3 groups there was no significant difference in numbers at the intention to act stage (FAQ, 53/104; LIST, 48/74; CONTROL, 37/60; χ24=8.2, P=.09).",35073:35299, 5826979 ,29434013,Unavailable
 5826979 ,movement directly to action from any “lower” decision stage,generic list (LIST),CONTROL (no information),No significant difference,"there was no statistically significant difference in movement directly to action from any “lower” decision stage by intervention group, age band, or gender, although there was a suggestion of a stronger association of willingness with exposure to FAQs, compared with LIST or CONTROL (P=.06). Results are shown in Table 2.",35419:35801, 5826979 ,29434013,Unavailable
 5826979 ,perceived usability and acceptability for the 2 websites,generic list (LIST),CONTROL (no information),No significant difference,"There was no significant difference in perceived usability and acceptability for the 2 websites (FAQs, n=104: mean 64.01 [SD 7.62]; LIST, n=73: mean 64.26 [SD 6.85]; t175=−0.224, P=.82).",44647:44878, 5826979 ,29434013,Unavailable
 5809626 ,perceived pain score,injection (filler or neurotoxin) plus vapocoolant,injection (filler or neurotoxin) alone,Significantly decreased,"Vapocoolant spray at the time of cosmetic facial injections leads to a 59% decrease in perceived pain score with neurotoxin injections (range, 0%-100% change) and 64% decrease in perceived pain score with filler injections (range, 0%-100% change). These results were statistically significant with P &lt; .05.",5192:5515, 5809626 ,29484087,Unavailable
 4601415 ,difference in evaluation after 1 month after treatment,fractional CO2 laser treatment,"one session of punch elevation combined with two sessions of laser fractional CO2 laser treatment, separated by an interval of 1 month",No significant difference,No significant difference in evaluation was observed 1 month after treatment (P = 0.56).,5785:5890, 4601415 ,26538695,Unavailable
 4601415 ,efficacy,fractional CO2 laser treatment,"one session of punch elevation combined with two sessions of laser fractional CO2 laser treatment, separated by an interval of 1 month",Significantly decreased,"Their evaluation found that fractional CO2 laser treatment combined with punch elevation had greater efficacy than that with fractional CO2 laser treatment alone, assessed 4 months after treatment (P = 0.02).",5891:6138, 4601415 ,26538695,Unavailable
 4601415 ,coagulated crust formation and pruritus at day,fractional CO2 laser treatment,"one session of punch elevation combined with two sessions of laser fractional CO2 laser treatment, separated by an interval of 1 month",No significant difference,"Among all side effects, coagulated crust formation and pruritus at day 3 after fractional CO2 laser treatment was significant on both treatment sides (P &lt; 0.05).",6139:6328, 4601415 ,26538695,Unavailable
 1087200 ,carring gametocytes within the 4 weeks following treatment,chloroquine (CQ) and sulphadoxine-pyrimethamine (SP),artemether in fixed combination with lumefantrine,Significantly increased,Children treated with co-artemether were significantly less likely to carry gametocytes within the 4 weeks following treatment than those receiving CQ/SP (30 of 378 [7.94%] versus 42 of 86 [48.8%]; p &lt; 0.0001).,7287:7514, 1087200 ,15839740,Unavailable
 1087200 ,Carriers  harboured gametocytes at densities and time periods,chloroquine (CQ) and sulphadoxine-pyrimethamine (SP),artemether in fixed combination with lumefantrine,Significantly increased,"Carriers in the co-artemether group harboured gametocytes at significantly lower densities, for shorter periods (0.3 d versus 4.2 d; p &lt; 0.0001) and were less infectious to mosquitoes at day 7 (p &lt; 0.001) than carriers who had received CQ/SP.",7515:7797, 1087200 ,15839740,Unavailable
 1087200 ,infectious to mosquitoes at day 7,chloroquine (CQ) and sulphadoxine-pyrimethamine (SP),artemether in fixed combination with lumefantrine,Significantly increased,"Carriers in the co-artemether group harboured gametocytes at significantly lower densities, for shorter periods (0.3 d versus 4.2 d; p &lt; 0.0001) and were less infectious to mosquitoes at day 7 (p &lt; 0.001) than carriers who had received CQ/SP.",7515:7797, 1087200 ,15839740,Unavailable
 5805426 ,β-HCG levels,uterine artery embolization (UAE) combined with local infusion of methotrexate (MTX),uterine artery embolization (UAE) combined with local infusion of  MTX and 5-fluorouracil (5-FU),No significant difference,"No significant difference was seen in the effects of the 2 medications on the inhibition of β-HCG levels during the observation periods using repeated ANOVA (F = 0.284, P = .597) (Fig. 2).",18693:18953, 5805426 ,29384854,Unavailable
 5805426 ,The time to successful resolution,uterine artery embolization (UAE) combined with local infusion of methotrexate (MTX),uterine artery embolization (UAE) combined with local infusion of  MTX and 5-fluorouracil (5-FU),No significant difference,"The time to successful resolution was 26.74 ± 5.57 days for patients receiving MTX treatment combined with UAE, and 27.57 ± 5.08 days for those treated with the combination of MTX and 5-FU along with UAE (P &gt; .05).",19171:19402, 5805426 ,29384854,Unavailable
 5827422 ,Teacher positive behaviours,Incredible Years (IY) teacher-training programme,control,Significantly increased,"Teacher positive behavioursb,c	8.26 (6.67–9.85)	0.13	3.35 (2.70–3.98)	&lt;0.0001",69079:69409, 5827422 ,29507743,Unavailable
 5827422 ,Teacher negative behaviours,Incredible Years (IY) teacher-training programme,control,Significantly decreased,"Teacher negative behavioursb,c −2.57 (−3.41 to −1.73) 0.03 −1.29 (−0.87 to −1.71) &lt;0.0001",71024:71375, 5827422 ,29507743,Unavailable
 5827422 ,child interest and enthusiasm,Incredible Years (IY) teacher-training programme,control,Significantly increased,Level of children's interest nd enthusiasmb 0.49 (0.24–0.75) 0.30 0.98 (0.48–1.50) 0.001,71024:71375, 5827422 ,29507743,Unavailable
 5827422 ,Level of children's appropriate classroom behaviour,Incredible Years (IY) teacher-training programme,control,Significantly increased,"Level of children's appropriate classroom behaviourb,f	3.34 (0.76–5.91)	0.49	0.73 (0.17–1.30)	0.01",71024:71375, 5827422 ,29507743,Unavailable
 5827422 ,Opportunities to share &amp; help each other,Incredible Years (IY) teacher-training programme,control,Significantly increased,Opportunities to share &amp; help each otherb	0.69 (0.47–0.91)	0.18	5.72 (3.88–7.58)	&lt;0.0001,71943:72220, 5827422 ,29507743,Unavailable
 5845829 ,PD-1 expression on CD8 T cells,two doses of M72/AS01E,placebo,No significant difference,No difference was seen in PD-1 expression on CD8 T cells among the groups (Fig S5D).,25087:25228, 5845829 ,26072017,Unavailable
 3606470 ,The completion rate for the 78-week,"dapagliflozin 2.5 to 5, or 10 mg) plus open-label metformin (≥1,500 mg)",placebo,Significantly increased,The completion rate for the 78-week double-blind extension period was lower for the placebo group (63.5%) than for the dapagliflozin groups (68.3% to 79.8%).,5385:5543, 3606470 ,23425012,Unavailable
 3606470 ,HbA1c,"dapagliflozin 2.5 to 5, or 10 mg) plus open-label metformin (≥1,500 mg)",placebo,Significantly decreased,"At week 102, mean changes from baseline HbA1c (8.06%) were +0.02% for placebo compared with -0.48% (P = 0.0008), -0.58% (P &lt;0.0001), and -0.78% (P &lt;0.0001) for dapagliflozin 2.5 to 5, and 10 mg, respectively.",5544:5806, 3606470 ,23425012,Unavailable
 2855860 ,progression-free survival (PFS),sunitinib 37.5&nbsp;mg/day,"capecitabine 1,250&nbsp;mg/m2",No significant difference,No statistical evidence supported the hypothesis that sunitinib improved PFS compared with capecitabine (one-sided P&nbsp;=&nbsp;0.999).,6276:6422, 2855860 ,20339913,Unavailable
 2855860 ,progression-free survival (PFS),sunitinib 37.5mg/day,"capecitabine 1,250mg/m2",Significantly decreased,"The data indicated that PFS was shorter with sunitinib than capecitabine (median 2.8 vs. 4.2&nbsp;months, respectively; HR, 1.47; 95% CI, 1.16–1.87; two-sided P&nbsp;=&nbsp;0.002).",6423:6606, 2855860 ,20339913,Unavailable
 2855860 ,Median overall survival; objective response rates;,sunitinib 37.5mg/day,"capecitabine 1,250mg/m2",Significantly decreased,"Median overall survival (15.3 vs. 24.6&nbsp;months; HR, 1.17; two-sided P&nbsp;=&nbsp;0.350) and objective response rates (11 vs. 16%; odds ratio, 0.65; P&nbsp;=&nbsp;0.109) were numerically inferior with sunitinib versus capecitabine.",6606:6851, 2855860 ,20339913,Unavailable
 4589005 ,pain-on-movement (POM),DSG 1%,placebo,Significantly decreased,DSG 1% treatment resulted in a significant decrease of POM mean scores when compared with placebo (57 mm vs. 21 mm respectively; p&lt;0.0001).,4926:5082, 4589005 ,None,Unavailable
 4589005 ,ankle swelling,DSG 1%,placebo,Significantly decreased,"The difference in circumference between the injured and non-affected ankles for subjects treated with DSG 1% vs. placebo was 1.9 cm vs. 2.4 cm at 12 hours, 1.4 cm vs. 2.0 cm at 24 hours, 0.8 cm vs. 1.5 cm at 72 hours, and 0.2 cm vs. 0.8 cm at 7 days (p&lt;0.0001 at all time points).",5182:5482, 4589005 ,None,Unavailable
 4589005 ,the mean total ankle joint function score,DSG 1%,placebo,Significantly increased,"In subjects treated with DSG 1%, the mean total ankle joint function score was 24.5 at baseline vs. 25.3 for the placebo group. At 72 hours and Day 7, mean ankle joint function scores were 56.3 and 79.7, respectively, for the DSG 1% group vs. 35.6 and 47.0, respectively, for the placebo group. The differences between treatment groups were significant at all time points (p&lt;0.0001).",5956:6360, 4589005 ,None,Unavailable
 5773922 ,Fasting serum TAG,"fish, krill oil",control oil,No significant difference,Fasting serum TAG did not change between the groups.,5879:5931, 5773922 ,29372051,Unavailable
 5773922 ,plasma levels of marine n-3 fatty acids," krill oil, fish oil",control oil,Significantly increased,"Furthermore, plasma levels of marine n-3 fatty acids increased significantly in the fish and krill groups compared with the control (all P&nbsp;≤&nbsp;0·0003).",6450:6633, 5773922 ,29372051,Unavailable
 5773922 ,"total lipids , phospholipids, cholesterol, cholesteryl esters and non-esterified cholesterol", krill oil,"control oil, fish oil",Significantly increased,"The concentration of total lipids (P&nbsp;=&nbsp;0·007), phospholipids (P&nbsp;=&nbsp;0·015), cholesterol (P&nbsp;=&nbsp;0·009), cholesteryl esters (P&nbsp;=&nbsp;0·022) and non-esterified cholesterol (P&nbsp;=&nbsp;0·002), but not TAG, in the smallest VLDL subclass (XS-VLDL) significantly increased in the krill group compared with the fish group and the control group (Fig. 4).",53178:53634, 5773922 ,29372051,Unavailable
 5773922 ,the particle concentration of XS-VLDL, krill oil,"control oil, fish oil",Significantly increased,"Furthermore, the particle concentration of XS-VLDL increased significantly in the krill group compared with the fish group and the control group (P&nbsp;=&nbsp;0·007, not shown).",53635:53821, 5773922 ,29372051,Unavailable
 5773922 ,The level of vitamin D, fish oil, krill oil,Significantly increased,"The overall difference between the three groups was significant, and pairwise comparisons showed that the increase in the fish group was significantly different from the decrease in the krill group (P&nbsp;=&nbsp;0·004).",56496:56724, 5773922 ,29372051,Unavailable
 3629990 ,body condition,mat group (M),antibiotic group (A),No significant difference,"Although body condition was not significant (P=0.10), the two variables body condition and treatment were subsequently combined into a new variable with four levels.",33926:34109, 3629990 ,23414554,Unavailable
 3629990 ,The least square,mat group (M),antibiotic group (A),Significantly increased,The least square means showed that the effect of treatment was statistically significant for lean sows (with mat: size of ulcer on day 14 was 3.8 cm2 versus antibiotic spray 9.5 cm2 – P-value for difference &lt;0.0001 – Table  4).,34611:34920, 3629990 ,23414554,Unavailable
 3629990 ,lean of the ulcer on day 21,mat group (M),antibiotic group (A),Significantly increased,"For lean sows with mats, the ulcer on day 21 was 3.4 cm2 versus 6.6 cm2 for lean sows which received antibiotic spray (P-value for difference =0.0001).",46287:46478, 3629990 ,23414554,Unavailable
 5498708 ,Mean reduction in the severity of symptoms,methylphenidate plus PUFA,PUFA and methylphenidate plus placebo,No significant difference,Mean reduction in the severity of symptoms in the group under methylphenidate therapy was 19.7±5.9 and in PUFA and placebo group it was 15.1±9.3 (p&lt;0.067).,5041:5196, 5498708 ,28713515,Unavailable
 5498708 ,Response to treatment,methylphenidate plus PUFA,PUFA and methylphenidate plus placebo,Significantly increased,"Response to treatment (a reduction of at least 25% in the signs) in the group taking methylphenidate plus PUFA was 90% (18 patients) and in methylphenidate plus placebo group, it was 60% (12 patients) (p=0.028).",5197:5408, 5498708 ,28713515,Unavailable
 4354798 ,OHQ composite score,droxidopa group,placebo,Significantly decreased,"In a post hoc analysis, the mean±SD change in OHQ composite score from randomization to end of study was +0.11±2.18 in the droxidopa group versus +1.22±2.39 in the placebo group (P=0.013).",20004:20210, 4354798 ,25350981,Unavailable
 4354798 ,CGI improvement scores,droxidopa group,placebo,No significant difference,"For CGI improvement scores, neither patients’ self-ratings (P=0.384) nor clinicians’ ratings (P=0.448) showed a significant difference between treatment groups.",21078:21273, 4354798 ,25350981,Unavailable
 4354798 ,the mean change in mm Hg,droxidopa group,placebo,No significant difference,"From randomization to end of study, the mean change was –7.6±19.7 mm Hg among continuing droxidopa recipients versus –5.2±26.8 mm Hg among patients withdrawn to placebo (P=0.680).",21751:21947, 4354798 ,25350981,Unavailable
 4005035 ,Maternal general health hospital,Netmums Helping With Depression (NetmumsHWD),treatment-as-usual (TAU),No significant difference,Maternal general health hospital&nbsp;Baseline	0.05 (0.22)	2/41 (4.9)	0.17 (0.66)	4/42 (9.5)	0.28&nbsp;17-week follow-up	0	0/30	0	0/27	n.a.,64179:64729, 4005035 ,24148703,Unavailable
 4005035 ,Infant hospital,Netmums Helping With Depression (NetmumsHWD),treatment-as-usual (TAU),No significant difference,Infant hospital&nbsp;Baseline	1.17 (3.26)	12/41 (29.3)	0.88 (2.01)	11/42 (26.2)	0.63&nbsp;17-week follow-up	0.24 (0.99)	4/30 (13.3)	0.38 (1.35)	6/27 (22.2)	0.60,64776:65330, 4005035 ,24148703,Unavailable
 4005035 ,Mental health hospital,Netmums Helping With Depression (NetmumsHWD),treatment-as-usual (TAU),No significant difference,Mental health hospital&nbsp;Baseline	0	0/41	0.05 (0.31)	1/42 (2.4)	0.11&nbsp;17-week follow-up	0	0/30	0.05 (0.31)	1/27 (2.4)	0.33,65372:65895, 4005035 ,24148703,Unavailable
 4005035 ,Antidepressant medication,Netmums Helping With Depression (NetmumsHWD),treatment-as-usual (TAU),No significant difference,Antidepressant medication&nbsp;Baseline	2.95 (0.77)	27/41 (65.9)	3.07 (0.75)	23/42 (59.5)	0.47&nbsp;17-week follow-up	2.96 (0.76)	19/27 (70.4)	3.07 (0.75)	19/30 (63.3)	0.38,67210:NaN, 4005035 ,24148703,Unavailable
 4689556 ,"prescribed a wheezing medication, prescribed an eczema medication","single oral bolus of 200,000 IU cholecalciferol","no Vitamin D, 800 IU ergocalciferol daily until delivery",No significant difference,"Here we found no difference in the number of prescriptions issued for medicated skin creams (median 1.0 IQR 0.0, 2.0 combined vitamin D versus 0.0 (0.0, 2.0) controls; p = 0.27) or wheezing medications (median 0.0 IQR 0.0, 1.0 combined vitamin D versus 0.0 (0.0, 0.0) controls; p = 0.42).",87422:87712, 4689556 ,26698303,Unavailable
 4666408 ,cardiovascular risk,Selenium and coenzyme Q10,placebo,Significantly decreased,"Evaluating risk, the active treatment group displayed significantly reduced cardiovascular risk compared to the placebo group in the univariate Cox regression analysis (HR: 0.52; 95%CI 0.36–0.74; P = 0.0004).",33517:33743, 4666408 ,26624886,Unavailable
 4666408 ,all-cause mortality,Selenium and coenzyme Q10,placebo,Significantly decreased,A reduced all-cause mortality in the active group compared to the placebo group (98/221 vs. 120/222; χ 2:4.18; P = 0.041) could also be seen.,45827:46014, 4666408 ,26624886,Unavailable
 4666408 ,mortality in malignancies,Selenium and coenzyme Q10,placebo,No significant difference,"Evaluating mortality in malignancies was performed, with no differences between the two groups (active treatment: 20/221 vs. placebo 19/222; χ 2:0.03; P = 0.86).",46014:46220, 4666408 ,26624886,Unavailable
 3714386 ,Duration of block procedure values,Group E : ultrasound guided axillary block using echogenic needle,Group NS: ultrasound guided axillary block using non-echogenic needle with nerve stimulator assistance,No significant difference,Duration of block procedure values were found similar in group E and group NS and significantly lower than in group N (p&lt;0.05).,13239:13366, 3714386 ,23869186,Unavailable
 3714386 ,Duration of block procedure values, Group N : ultrasound guided axillary block using non-echogenic needle,Group E : ultrasound guided axillary block using echogenic needle  Group NS: ultrasound guided axillary block using non-echogenic needle with nerve stimulator assistance,Significantly decreased,Duration of block procedure values were found similar in group E and group NS and significantly lower than in group N (p&lt;0.05).,13239:13366, 3714386 ,23869186,Unavailable
 3714386 ,Sensory and motor block onset time, Group N : ultrasound guided axillary block using non-echogenic needle ,Group E : ultrasound guided axillary block using echogenic needle ,Significantly increased,"Sensory and motor block onset time values were found higher in group E and group N, besides significantly higher in group N than in group E (p&lt;0.05).",13367:13516, 3714386 ,23869186,Unavailable
 3714386 ,Patient and surgeon satisfaction scores, Group E : ultrasound guided axillary block using echogenic needle; Group NS : ultrasound guided axillary block using non-echogenic needle with nerve stimulator assistance., Group N : ultrasound guided axillary block using non-echogenic needle  ,Significantly increased,Patient and surgeon satisfaction scores were higher in group E and group NS (p&lt;0.05) (Table 3).,13997:14134, 3714386 ,23869186,Unavailable
 535936 ,average rank of the exam score,attend a lecture series at our main campus,view digital versions of the same lectures at community-based teaching sites,No significant difference,The differences between the groups for both sets of items were not statistically significant for means (t-test) or medians (Mann-Whitney) at the p &lt; 0.05 level.,16265:16425, 535936 ,15569389,Unavailable
 535936 ,the variance of the items from the other four lectures,attend a lecture series at our main campus,view digital versions of the same lectures at community-based teaching sites,No significant difference,There was no statistically significant difference among the groups for the variance of the items from the other four lectures.,19207:19333, 535936 ,15569389,Unavailable
 5830087 ,objective response rate (ORR),"BTH1677 arm ( intravenous [IV] BTH1677, 4&nbsp;mg/kg, weekly; IV bevacizumab, 15&nbsp;mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6&nbsp;mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200&nbsp;mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),No significant difference,ORR was higher in the BTH1677 vs Control arm but the difference between groups was not statistically significant (60.4% vs 43.5%; P = .2096).,7871:8029, 5830087 ,29486797,Unavailable
 5830087 ,"disease control rate, duration of objective response, and progression-free survival","BTH1677 arm ( intravenous [IV] BTH1677, 4&amp;nbsp;mg/kg, weekly; IV bevacizumab, 15&amp;nbsp;mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6&amp;nbsp;mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200&amp;nbsp;mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),No significant difference,All other clinical endpoints also favored the BTH1677 arm but none statistically differed between arms. PK was consistent with previous studies.,8030:8174, 5830087 ,29486797,Unavailable
 2852703 ,The proportion of successful preparations at follow-up endoscopy,a water-intake group,a prolonged fasting group,Significantly increased,"The proportion of successful preparations at follow-up endoscopy was higher for the water-intake group (70%) than for the prolonged fasting group (40%, p=0.025).",5118:5279, 2852703 ,20431744,Unavailable
 4541705 ,The time required for wound surface treatment completion,a snare cauterization,clip closure group,Significantly decreased,"The time required for wound surface treatment completion was 3.26&nbsp;±&nbsp;1.57&nbsp;min in the snare cauterization group and 12.7&nbsp;±&nbsp;2.92&nbsp;min in the clip closure group, thus demonstrating a significant difference (P&nbsp;=&nbsp;0.0001).",4820:5051, 4541705 ,25480613,Unavailable
 4541705 ,bleeding,a snare cauterization,clip closure group,No significant difference,"Delayed bleeding was observed in two patients in the clip group, but was not observed in the snare cauterization group (P&nbsp;=&nbsp;0.098).",5052:5200, 4541705 ,25480613,Unavailable
 5976949 ,ANGPTL4 expression,"GDM1 (tight glycaemic targets, fasting blood glucose &lt; 5.1 mmol/L and &lt;7.0 mmol/L postprandial,) and GDM2 (less tight glycaemic targets, &lt;5.3 mmol/L and &lt; 7.8 mmol/L",control group- normal glucose tolerance,Significantly decreased,"ANGPTL4 expression was decreased in the HUVECs from GDM patients versus the control group (23.11 ± 5.71, 21.47 ± 5.64, and 98.33 ± 20.92, for GDM1, GDM2, and controls; p &lt; 0.001) with no difference between GDM1 and GDM2.",5931:6169, 5976949 ,29861725,Unavailable
 5976949 ,ANGPTL4 expression,"GDM1 (tight glycaemic targets, fasting blood glucose 5.1 mmol/L and 7.0 mmol/L postprandial,) ","GDM2 (less tight glycaemic targets, 5.3 mmol/L and  7.8 mmol/L)",No significant difference,"ANGPTL4 expression was decreased in the HUVECs from GDM patients versus the control group (23.11 ± 5.71, 21.47 ± 5.64, and 98.33 ± 20.92, for GDM1, GDM2, and controls; p &lt; 0.001) with no difference between GDM1 and GDM2.",5931:6169, 5976949 ,29861725,Unavailable
 5976949 ,leptin/adiponectin ratio (LAR)," GDM2 (less tight glycaemic targets,5.3 mmol/L and 7.8 mmol/L","GDM1 (tight glycaemic targets, fasting blood glucose 5.1 mmol/L and 7.0 mmol/L postprandial,), control group- normal glucose tolerance",Significantly increased,"In cord blood, leptin/adiponectin ratio (LAR) was increased in GDM2 compared to controls and GDM1 (p = 0.038) and did not differ between GDM1 and controls.",6306:6483, 5976949 ,29861725,Unavailable
 5976949 ,leptin/adiponectin ratio (LAR),"GDM1 (tight glycaemic targets, fasting blood glucose 5.1 mmol/L and 7.0 mmol/L postprandial,), ",control group- normal glucose tolerance,No significant difference,"In cord blood, leptin/adiponectin ratio (LAR) was increased in GDM2 compared to controls and GDM1 (p = 0.038) and did not differ between GDM1 and controls.",6306:6483, 5976949 ,29861725,Unavailable
 3658334 ,QTc prolongation,8 mg of ondansetron,1 mg of granisetron,Significantly increased,The incidence of significant QTc prolongation was significantly higher in the ondansetron group (22 of 37 (59.4%) vs. 11 of 33 patients (33.33%) (P&lt;0.05)).,3977:4149, 3658334 ,23716765,Unavailable
 3494172 ,"BV, candidiasis and trichomoniasis","BufferGel, 0.5% PRO2000 Gel",placebo gel and no gel,No significant difference,"No statistically significant differences were observed in BV, candidiasis and trichomoniasis between the four study arms throughout the three-month study period.",19509:19671, 3494172 ,22944480,Unavailable
 5807505 ,"performance [checklist vs. model—time (s), safety metrics",Group A practiced mental rehearsal with the use of a pre-prepared checklist,Group B mental rehearsal with the checklist combined with virtual models matching the anatomical variations of the SLCs,No significant difference,There was no statistical difference in performance [checklist vs. model—time (s): 445.5 vs. 496 p&nbsp;=&nbsp;0.64—NOM: 437 vs. 413 p&nbsp;=&nbsp;0.88 – PL [75]: 1317 vs. 1059 p&nbsp;=&nbsp;0.32] or safety metrics [checklist vs. model—per: 0.5 vs. 0 p&nbsp;=&nbsp;0.22—NCB: 0 vs. 0 p&nbsp;=&nbsp;0.71—DVS: 0 vs. 0 p&nbsp;=&nbsp;0.2] between the two groups (Fig.&nbsp;5).Fig.&nbsp;5,27414:27928, 5807505 ,28840324,Unavailable
 5807505 ,number of damage to vital structures,Group A practiced mental rehearsal with the use of a pre-prepared checklist,Group B mental rehearsal with the checklist combined with virtual models matching the anatomical variations of the SLCs,Significantly increased,There was no statistical difference in all metrics but the number of damage to vital structures that was significantly greater in the Group A [checklist vs. model—time (s): 464.3 vs. 555 p&nbsp;=&nbsp;0.2—NOM: 506 vs. 481 p&nbsp;=&nbsp;0.86—PL [75]: 1363 vs. 1118 p&nbsp;=&nbsp;0.17—per: 0.5 vs. 0 p&nbsp;=&nbsp;0.13—NCB: 0 vs. 0 p&nbsp;=&nbsp;0.2—DVS: 4 vs. 0 p&nbsp;=&nbsp;0.03 η 2&nbsp;= 0.34] (Fig.&nbsp;5).,28233:28783, 5807505 ,28840324,Unavailable
 5807505 ,Normal Anatomy (NA) simulated laparoscopic cholecystectomy (LC),Group A practiced mental rehearsal with the use of a pre-prepared checklist,Group B mental rehearsal with the checklist combined with virtual models matching the anatomical variations of the SLCs,No significant difference,no statistically significant difference in the performance of the NA LC [checklist vs. model total CAT score—NA: 23.63 vs. 26.69 p&nbsp;=&nbsp;0.2—SCD: 20.5 vs. 26.31 p&nbsp;=&nbsp;0.02 η 2&nbsp;=&nbsp;0.32—DA: 24.75 vs. 30.5 p&nbsp;=&nbsp;0.03 η 2&nbsp;=&nbsp;0.28] (Fig.&nbsp;6).Fig.&nbsp;6,29680:30080, 5807505 ,28840324,Unavailable
 5755346 ,mean diastolic blood pressure,"assessment of resting energy expenditure (REE), heart rate, and blood pressure following the ingestion of a MIPS",placebo,Significantly increased,"There was an overall main effect for condition regarding mean diastolic blood pressure following ingestion of the MIPS compared to the PLA (MIPS: 84 ± 1.1; PLA: 64.8 ± 1.3&nbsp;mmHg, p = 0.011);",28796:29003, 5755346 ,29311763,Unavailable
 5755346 ,number of BP repetitions,"assessment of resting energy expenditure (REE), heart rate, and blood pressure following the ingestion of a MIPS",placebo,Significantly increased,Subjects completed a significantly higher number of BP repetitions to failure following ingestion of the MIPS condition compared to PLA (p = 0.037) as seen in Fig.&nbsp;2.Fig. 2,29172:29422, 5755346 ,29311763,Unavailable
 5755346 ,back squat (BS) performance,"assessment of resting energy expenditure (REE), heart rate, and blood pressure following the ingestion of a MIPS",placebo,No significant difference,"There was no significant difference in BS performance between the MIPS and PLA (MIPS: 13.5 ± 3.7; PLA: 12.8 ± 3.1 reps, p = 0.28).",29661:29808, 5755346 ,29311763,Unavailable
 5755346 ,amount of total work (m) during the 25-s treadmill sprint,"assessment of resting energy expenditure (REE), heart rate, and blood pressure following the ingestion of a MIPS",placebo,Significantly increased,"Subjects completed a significantly greater amount of total work (m) during the 25-s treadmill sprint following ingestion of the MIPS compared to the PLA (MIPS: 93.97 ± 6.63; PLA: 93.01 ± 7.49&nbsp;m, p = 0.039).",29809:30032, 5755346 ,29311763,Unavailable
 5483485 ,Clinical Global Impressions of Improvement (CGI-I) score,cognitive behavioural therapy (CBT),solution-focused brief therapy,No significant difference,"Inter-rater reliability was high for the primary outcome of CGI-I (mean κ=0·92, 95% CI 0·86–1·0). 40 (59%) children in the brief guided parent-delivered CBT group versus 47 (69%) children in the solution-focused brief therapy group had an improvement of much or very much in CGI-I score at the assessment after treatment, and 45 (66%) versus 49 (72%) children had an improvement at the 6 month follow-up assessment (table 2), with no significant differences between groups across both timepoints (relative risk 1·01, 95% CI 0·86–1·19; p=0·95; table 3).Table 2",39512:40199, 5483485 ,28527657,Unavailable
 5483485 ,societal costs,cognitive behavioural therapy (CBT),solution-focused brief therapy,Significantly decreased,"When brief guided parent-delivered CBT was compared with solution-focused brief therapy in terms of the societal costs per extra child with a CGI-I outcome of much or very much improved (mean difference: effect −0·008, 95% CI −0·160 to 0·144; p=0·92; cost: −£448, −934 to 37; p=0·070),",62160:62445, 5483485 ,28527657,Unavailable
 3698199 ,PTSD symptom severity,combined treatment (TAU + Structured Writing Therapy for PTSD (SWT)),Treatment As Usual (TAU),No significant difference,"For the TAU group no significant decreases in PTSD symptom severity were found between the measurement points F’s (1, 15) ≤ 0.924, p’s ≥ .353, partial η2’s ≤ 0.62.",73175:73383, 3698199 ,23782590,Unavailable
 3698199 ,PTSD diagnostic status,combined treatment (TAU + Structured Writing Therapy for PTSD (SWT)),Treatment As Usual (TAU),No significant difference,Post-treatment results indicated a trend for between-group differences in PTSD diagnostic status (p = .06).,74310:74435, 3698199 ,23782590,Unavailable
 3698199 ,the number of Primary  Substance Use Disorder (SUD) diagnoses,combined treatment (TAU + Structured Writing Therapy for PTSD (SWT)),Treatment As Usual (TAU),No significant difference,"For TAU, the number of Primary SUD diagnoses decreased significantly from pre- to post-treatment, McNemars χ2 (1, N = 15) = 4.7, p = .03, and a trend was noticed for the decrease of total number of SUD diagnoses, McNemars χ2 (1, N = 15) = 3.4, p = .06.",76518:76871, 3698199 ,23782590,Unavailable
 5986449 ,Changes in the left eye’s AA after rest in non-presbyopic subjects younger than 45 years, another group received “Sunrouge” extract containing 11.2 mg anthocyanin and 323.6 mg epigallocatechin-3-O-gallate (EGCG),“Yabukita” extract containing 322.2 mg EGCG,Significantly increased,Changes in the left eye’s AA after rest in non-presbyopic subjects younger than 45 years of age at week 8 (p = 0.031) significantly improved in the “Sunrouge” group compared to the “Yabukita” group (Figure 3A).,21307:21592, 5986449 ,29734777,Unavailable
 5986449 ,ache behind the eyes at week 12, the placebo group received barley extract without catechin,“Yabukita” extract containing 322.2 mg EGCG,No significant difference,"Subjects younger than 45 years in the “Yabukita” group experienced less ache behind the eyes at week 12 compared to those in the placebo group, though the difference was not statistically significant (p = 0.052) (Figure 5D).",27373:27672, 5986449 ,29734777,Unavailable
 5986449 ,HDL cholesterol levels, “Yabukita” extract containing 322.2 mg EGCG, the placebo group received barley extract without catechin,No significant difference,"Subjects younger than 45 years in the “Yabukita” group experienced less ache behind the eyes at week 12 compared to those in the placebo group, though the difference was not statistically significant (p = 0.052) (Figure 5D).",27373:27672, 5986449 ,29734777,Unavailable
 5561674 ,mothers’ education and occupation and the number of children in the families,happiness training program,control group,No significant difference,"Furthermore, there was no significant difference in the mothers’ education and occupation and the number of children in the families between the two groups (P &gt; 0.05).",19165:19352, 5561674 ,28852658,Unavailable
 5561674 ,the mean self-esteem score,happiness training program,control group,No significant difference,"Furthermore, paired t-test exhibited a significant difference in mean self-esteem score between before and after the training in the intervention group (P &lt; 0.05), but the difference was not statistically significant for the control group (P &gt; 0.05) [Table 1].",19624:19983, 5561674 ,28852658,Unavailable
 5827032 ,Pathologic CR in the breast and the axilla (TpCR),  docetaxel (T) and epirubicin (E) +  lobaplatin (L), docetaxel (T) and epirubicin (E),Significantly increased,"After neoadjuvant chemotherapy, the patients treated with the TEL chemotherapy regimen showed a TpCR rate of 38.7% (24/62), whereas the patients who were treated with the TE regimen showed a TpCR rate of 12.7% (8/63) (odds ratio (OR), 4.342, 95% CI 1.764–10.687; P = 0.001; Fig.&nbsp;2).",15694:16032, 5827032 ,29483583,Unavailable
 5827032 ,overall response rate (ORR),  docetaxel (T) and epirubicin (E) +  lobaplatin (L), docetaxel (T) and epirubicin (E),Significantly increased,"TE docetaxel and epirubicin, TEL docetaxel, epirubicin, and lobaplatin. *indicates statistically significant differences between the two groups (P &lt; 0.05)",16876:17048, 5827032 ,29483583,Unavailable
 5827032 ,grade 3–4 thrombocytopenia and anemia,  docetaxel (T) and epirubicin (E) +  lobaplatin (L), docetaxel (T) and epirubicin (E),Significantly increased,"Compared with the patients assigned to the non-lobaplatin-containing regimens, those assigned to the TEL regimen were more likely to develop grade 3–4 thrombocytopenia (34.4% vs. 1.7%, P &lt; 0.001) and anemia (52.5% vs. 10%, P &lt; 0.001).",18520:18791, 5827032 ,29483583,Unavailable
 5976852 ,whole-body protein degradation,low-protein diet (LPD) (0.55 g protein/kg,usual diet (1.1 g protein/kg,Significantly decreased,"0 In accordance with previous observations,9, 10 an LPD induced a slight decrease in whole-body protein degradation (0.64 ± 2 vs. 0.69 ± 2 μmol/kg per minute per 1.73 m2 LPD vs. usual protein diet, P&nbsp;&lt; 0.06).",37260:37590, 5976852 ,29854979,Unavailable
 5710015 ,Tracheal intubation time,McGrath MAC (M group),Macintosh laryngoscope (N group) Airway scope (A group),Significantly decreased,"Tracheal intubation time was 26.8 ± 5.7&nbsp;s (mean ± standard deviation) for M group, 36.4 ± 11.0&nbsp;s for A group, and 36.5 ± 8.9&nbsp;s for N group, indicating significantly shorter tracheal intubation time in M group than in A group (p &lt; 0.01) and N group (p &lt; 0.01).",20042:20215, 5710015 ,29191160,Unavailable
 5710015 ,The Cormack Lehane grade,McGrath MAC (M group),Macintosh laryngoscope (N group) ,Significantly increased,The Cormack Lehane grade was significantly improved in M group compared to N group (p &lt; 0.05).,19716:19830, 5710015 ,29191160,Unavailable
 5710015 ,head was tilted back,Macintosh laryngoscope (N group) ,McGrath MAC (M group);  Airway scope - (A group),Significantly increased,"In terms of whether the head position was adjusted, the head was tilted back more often during intubation for N group than for M and A groups (p &lt; 0.01).",20042:20215, 5710015 ,29191160,Unavailable
 5710015 ,"desaturation, lip bleeding, and dental injury",Macintosh laryngoscope (N group) ,McGrath MAC (M group);  Airway scope - (A group),No significant difference,"With regard to desaturation, lip bleeding, and dental injury, there were no statistically significant difference among the three groups.",20216:20353, 5710015 ,29191160,Unavailable
 5710015 ,"mucosal bleeding, oesophageal intubation, postoperative pharyngeal pain",Macintosh laryngoscope (N group) ,McGrath MAC (M group);  Airway scope - (A group),No significant difference,"Although there were no statistically significant difference, mucosal bleeding and oesophageal intubation were observed in A group (p =&nbsp;0.12). Also postoperative pharyngeal pain was observed less frequently in M group than in A and N groups (p =&nbsp;0.19).Table 2",20352:20677, 5710015 ,29191160,Unavailable
 5851005 ,complete response (CR)  in the overall phase (OP),the aprepitant regimen (aprepitant plus tropisetron and dexamethasone),the standard regimen (tropisetron and dexamethasone),Significantly increased,A CR during the OP (primary endpoint) was exhibited by 80.0% (40/50) of patients receiving the aprepitant triple regimen and 56.0% (28/50) of those receiving the standard regimen (P =0.018; Figure 1).,22903:23178, 5851005 ,29577093,Unavailable
 5851005 ,complete response (CR) in the delay phase (DP),the aprepitant regimen (aprepitant plus tropisetron and dexamethasone),the standard regimen (tropisetron and dexamethasone),Significantly increased,"Similarly, CR during the DP was significantly higher in the aprepitant regimen group than in the standard therapy group (80.0% vs. 56.0%, P = 0.018).",23178:23345, 5851005 ,29577093,Unavailable
 5851005 ,complete response (CR)  in the acute phase (AP),the aprepitant regimen (aprepitant plus tropisetron and dexamethasone),the standard regimen (tropisetron and dexamethasone),No significant difference,"Secondary endpoints were the CR in the acute phase (AP, 0–24 h) and delay phase (DP, 25–120 h) between the two groups.",5813:5931, 5851005 ,29577093,Unavailable
 1065073 ,resuscitated lambs,arteriovenous (AV) extracorporeal membrane oxygenation (ECMO),conventional mechanical ventilation (CMV),Significantly increased,"Analysis of the use of resuscitative measures as indicators of hemodynamic stability between the CMV and AV-ECMO groups revealed that significantly more lambs in the AV-ECMO group (including survivors and nonsurvivors) were resuscitated than in the CMV group (Table 4; P &lt; 0.001, Fisher's exact test).",24938:25295, 1065073 ,15566597,Unavailable
 1065073 ,mortality,arteriovenous (AV) extracorporeal membrane oxygenation (ECMO),conventional mechanical ventilation (CMV),No significant difference,"However, there was no significant difference in 'mortality' between AV-ECMO and CMV groups within the 6-hour period of study (P &gt; 0.05, Fisher's exact test).",25296:25473, 1065073 ,15566597,Unavailable
 1403758 ,Forced vital capacity during first second (FVC 1),terbutaline,placebo,No significant difference,"Figure 2 shows means and SE's for FEV1 measured one hour after fenoterol inhaled directly after the previous PD20 1 between terbutaline pre-treatment and placebo pre-treatment varied over the fenoterol dose (interaction: pre-treatment * fenoterol dose, P = 0.46), nor that the difference in FEV1 between the two treatments, averaged over fenoterol dose, is related to allelic genotype (interaction: pre-treatment * genotype, P = 0.29, see table 5).",30246:30814, 1403758 ,16448568,Unavailable
 1403758 ,FEV1,terbutaline,placebo,Significantly decreased,There was some evidence that averaged over fenoterol dose and genotype terbutaline decreases FEV1 compared to placebo (P = 0.027) by an estimated 1.58 (SE 0.68) percent points.,31003:31190, 1403758 ,16448568,Unavailable
 5856421 ,The duration of surgery,conventional laparoscopic cholecystectomy (CLC),harmonic scalpel assisted laparoscopic cholecystectomy (HLC),No significant difference,The duration of surgery did not significantly differ between the groups (67.3 vs. 64.3 mins; p = 0.30).,6735:6839, 5856421 ,29560297,Unavailable
 5856421 ,The rate of GB perforation,conventional laparoscopic cholecystectomy (CLC),harmonic scalpel assisted laparoscopic cholecystectomy (HLC),No significant difference,The rate of GB perforation between the two groups was not statistically&nbsp;significant (p = 0.714).,21167:21263, 5856421 ,29560297,Unavailable
 5856421 ,intraperitoneal drain,conventional laparoscopic cholecystectomy (CLC),harmonic scalpel assisted laparoscopic cholecystectomy (HLC),No significant difference,Six patients (30%) in the CLC group and four patients (20%) in the HLC group required an&nbsp;intraperitoneal drain. The difference was not significant (p = 0.716).,21345:21504, 5856421 ,29560297,Unavailable
 3668608 ,dropout rates,interpersonal psychotherapy (IPT),active control treatment (MoodGYM),Significantly decreased,"Furthermore, dropout rates were significantly higher for participants assigned to MoodGYM (451/613, 74%) compared with IPT (414/620, 67%) or CBT (429/610, 70%; χ2 2= 6.8, P=.03).",32477:32694, 3668608 ,23669884,Unavailable
 3668608 ,Mean depression scores,interpersonal psychotherapy (IPT),active control treatment (MoodGYM),No significant difference,"Mean depression scores were not significantly different across the 3 programs at posttest (IPT vs MoodGYM: 2.01, 95% CI –0.32 to 4.34, P=.09, higher for IPT; CBT vs MoodGYM: 0.22, 95% CI: –2.17 to 2.61, P=.86, higher for CBT).",36930:37193, 3668608 ,23669884,Unavailable
 3668608 , Center for Epidemiological Studies Depression scale (CES-D) ,interpersonal psychotherapy (IPT),active control treatment (MoodGYM),No significant difference,"No differences between the treatments over time were found on the CES-D (F 4,451.2=0.976, P=.42).",60275:60421, 3668608 ,23669884,Unavailable
 4748327 ,"fall risk score , proprioception, reaction time, sit-to-stand performance and executive functioning",step-mat-training (SMT),control,Significantly increased,"Compared to the control group, SMT participants improved their fall risk score (p = 0.036), proprioception (p = 0.015), reaction time (p = 0.003), sit-to-stand performance (p = 0.011) and executive functioning (p = 0.001),",6343:6550, 4748327 ,26865875,Unavailable
 4748327 ,muscle strength and vision,Microsoft-Kinect® (KIN) exergames,control,Significantly increased,"while KIN participants improved their muscle strength (p = 0.032) and vision (p = 0.010), and showed a trend towards improved fall risk scores (p = 0.057).",6343:6550, 4748327 ,26865875,Unavailable
 4748327 ,fall risk scores,Microsoft-Kinect® (KIN) exergames,control,No significant difference,"while KIN participants improved their muscle strength (p = 0.032) and vision (p = 0.010), and showed a trend towards improved fall risk scores (p = 0.057).",6343:6550, 4748327 ,26865875,Unavailable
 5819580 ,adverse events (AEs),30 mg meloxicam IV; 60 mg meloxicam IV,placebo,No significant difference,"No serious AEs were reported; there were no withdrawals due to AEs, including injection-related AEs.",5141:5241, 5819580 ,29497329,Unavailable
 5819580 ,summed pain intensity differences over the first 48 hours (SPID48),30 mg meloxicam IV; 60 mg meloxicam IV,placebo,Significantly decreased,"The estimated effect size for SPID48 versus placebo was 1.15 and 1.01 for meloxicam IV doses 30 mg and 60 mg, respectively (P≤0.01).",5242:5402, 5819580 ,29497329,Unavailable
 5819580 ,pain reductions,30 mg meloxicam IV; ,placebo,Significantly increased,The proportions of subjects with ≥30% and ≥50% overall reduction in pain from baseline after 6 and 24 hours were significantly higher with meloxicam IV 30 mg doses versus placebo,5563:5741, 5819580 ,29497329,Unavailable
 5819580 ,pain reductions,60 mg meloxicam IV,placebo,No significant difference,"The proportions of subjects with ≥30% and ≥50% overall reduction in pain from baseline after 6 and 24 hours were significantly higher with meloxicam IV 30 mg doses versus placebo, but not with meloxicam IV 60 mg doses.",5563:5781, 5819580 ,29497329,Unavailable
 5819580 ,The time to first use of rescue medication,60 mg meloxicam IV,placebo,Significantly increased,"The time to first use of rescue medication was significantly longer versus placebo with meloxicam IV 60 mg (P&lt;0.05), but not with meloxicam IV 30 mg doses.",5782:5954, 5819580 ,29497329,Unavailable
 5819580 ,The time to first use of rescue medication,30 mg meloxicam IV,placebo,No significant difference,"The time to first use of rescue medication was significantly longer versus placebo with meloxicam IV 60 mg (P&lt;0.05), but not with meloxicam IV 30 mg doses.",5782:5954, 5819580 ,29497329,Unavailable
 4138365 ,"parental health, primary carer",Trial annual visit,Community survey,No significant difference,There was no significant difference in parental health or primary carer between the two groups (data not shown).,31068:31181, 4138365 ,25100338,Unavailable
 4138365 ,fuel source,Trial annual visit,Community survey,No significant difference,"In crude analysis, there was a significant difference in fuel source between the two groups, but this was no longer significant after adjustment for other household characteristics (P = 0.33).",35055:35265, 4138365 ,25100338,Unavailable
 4138365 ,Reported diarrhoea,Trial annual visit,Community survey,No significant difference,"Reported diarrhoea was more common among trial children, although this difference was not significant after adjusting for other parental and household factors (P = 0.26).",36042:36229, 4138365 ,25100338,Unavailable
 3499458 ,Mean (sd) percentage of adherent days,oral glucose lowering medication (OGLM),usual care,Significantly increased,"Mean (sd) percentage of adherent days was 77.4% (26.3) in the intervention group and 69.0% (30.8) in standard care (mean difference between groups 8.4%, 95% confidence interval 0.2% to 16.7%, p = 0.044).",7028:7248, 3499458 ,22480341,Unavailable
 3743070 ,serum potassium concentration, BAY 94-8862 5 mg once daily; BAY 94-8862 10 mg once daily;,placebo,Significantly increased,"Patients receiving BAY 94-8862 at doses of 10 mg q.d. and 5 mg b.i.d. showed significantly greater mean increases in serum potassium concentration from baseline at the study endpoint [i.e. the mean of changes at visits 6 (day 22 ± 2) and 7 (day 29 ± 2)] than the placebo group (P = 0.0243 and P = 0.0003, respectively).",37421:37776, 3743070 ,23713082,Unavailable
 3743070 ,serum potassium concentration," BAY 94-8862  5 mg once daily; BAY 94-8862 2,5 mg once daily;",placebo,No significant difference,"However, in the 5 and 2.5 mg q.d. groups, the mean increases in serum potassium concentration were not significantly different from those in the placebo group at visit 4 (day 15 ± 1) or at the study endpoint (P = 0.1623 and P = 0.5745, respectively) (Figure&nbsp;2).",37775:38132, 3743070 ,23713082,Unavailable
 3743070 ,"hyperkalaemia/increased blood potassium levels, renal failure; renal impairment;","BAY 94-8862 (2.5, 5, or 10 mg q.d., or 5 mg twice daily",placebo,No significant difference,"Compared with the placebo group, the pooled BAY 94-8862 groups had higher incidences of investigator-reported hyperkalaemia/increased blood potassium levels (5.3 vs. 1.5%, P = 0.3195) and renal failure (1.5 vs. 0%, P = 1.0000) and a lower incidence of renal impairment (3.8 vs. 9.2%, P = 0.0996).",48346:48758, 3743070 ,23713082,Unavailable
 3743070 ,"hyperkalaemia/increased blood potassium levels, renal failure; renal impairment;","BAY 94-8862 (2.5, 5, or 10 mg q.d., or 5 mg twice daily",spironolactone (25 or 50 mg/day),Significantly decreased,"The incidence of each of these adverse events was significantly lower in the BAY 94-8862 groups than in the spironolactone group (hyperkalaemia/increased blood potassium levels: 5.3 vs. 12.7%, P = 0.048; renal failure: 1.5 vs. 7.9%, P = 0.0153; renal impairment: 3.8 vs. 28.6%, P &lt; 0.0001).",48005:48347, 3743070 ,23713082,Unavailable
 3544352 ,the mean incision size,WhiteStar Signature® system with the Ellips™ FX transversal continuous ultrasound (US) mode for group I,the Infiniti® system with the OZil® Intelligent Phaco (IP) torsional US mode for group II,No significant difference,"Before intraocular lens implantation, the mean incision size was 2.24 ± 0.06 mm in both groups (P = 0.75).",3599:3724, 3544352 ,23326184,Unavailable
 3544352 ,corneal endothelial cell density,WhiteStar Signature® system with the Ellips™ FX transversal continuous ultrasound (US) mode for group I,the Infiniti® system with the OZil® Intelligent Phaco (IP) torsional US mode for group II,No significant difference,"In terms of corneal endothelial cell density, neither preoperative (I vs II: 2304.1 ± 122.5 cell/mm2 vs 2315.6 ± 83.1 cell/mm2, P = 0.80) nor postoperative (I vs II: 2264.1 ± 124.3 cell/mm2 vs 2270.3 ± 89.9 cell/mm2, P = 0.98) differences between the groups were statistically significant.",3723:4091, 3544352 ,23326184,Unavailable
 3544352 ,central pachymetry,WhiteStar Signature® system with the Ellips™ FX transversal continuous ultrasound (US) mode for group I,the Infiniti® system with the OZil® Intelligent Phaco (IP) torsional US mode for group II,No significant difference,"Furthermore, no significant differences between groups I and II were found preoperatively (P = 0.40) and postoperatively (P = 0.68) in central pachymetry.",4197:4385, 3544352 ,23326184,Unavailable
 4748139 ,Ease of learning,daily physical activity (DPA),healthy controls,Significantly decreased,Ease of learning was significantly lower in patients with COPD compared with healthy participants in pilot study C1 (P&lt;.004 for C2; P=.017 for C3).,26077:26265, 4748139 ,26813682,Unavailable
 5883528 ,The total cholesterol,high-intensity training (HIT),moderate continuous training (MCT),No significant difference,"The total cholesterol response expressed as area under curve (AUC)(0–240) was lower following HIT than following MCT, but no significant differences were observed (8%, P &gt; 0.05).",7992:8200, 5883528 ,29615070,Unavailable
 5883528 ,triglycerides,high-intensity training (HIT),moderate continuous training (MCT),No significant difference,"Similarly, triglycerides AUC(0–240) was also lower after HIT compared with MCT, which trended towards significance (24%, P = 0.076).",8200:8363, 5883528 ,29615070,Unavailable
 5883528 ,glucose response,high-intensity training (HIT),moderate continuous training (MCT),Significantly decreased,"The AUC(0–240) for the glucose response was significantly lower following HIT than MCT (10%, P = 0.008).",8364:8496, 5883528 ,29615070,Unavailable
 5883528 ,"flow-mediated vasodilation (FMD), normalized brachial artery FMD (nFMD)",high-intensity training (HIT),moderate continuous training (MCT),Significantly increased,"FMD and nFMD AUC(0–240) were significantly higher following HIT than following MCT (46.9%, P = 0.021 and 67.3%, P = 0.009, respectively).",8497:8680, 5883528 ,29615070,Unavailable
 5883528 ,aortic pulse wave velocity (PWV),high-intensity training (HIT),moderate continuous training (MCT),No significant difference,"PWV AUC(0–240) did not differ following between the two exercise groups (2.3%, P &gt; 0.05).",8680:8780, 5883528 ,29615070,Unavailable
 5498774 ,hospital stay,broad-spectrum treatment,standard,Significantly decreased,"Compared to standard group, we observed a statistically significant reduction in hospital stay from 17.8 to 11.8 days (p&lt;0.002) for patients treated with broad-spectrum antibiotics.",5527:5726, 5498774 ,28721080,Unavailable
 5369684 ,Alzheimer’s Disease Assessment Scale–cognitive [ADAS-Cog]) and self-reported QoL (Quality of Life Alzheimer’s Disease [QoL-AD]),Cognitive stimulation therapy (CST),treatment as usual (TAU),No significant difference,"At the post-test (26 wk), there were no differences between the iCST and TAU groups in the outcomes of cognition (mean difference [MD] = −0.55, 95% CI −2.00–0.90; p = 0.45) and self-reported QoL (MD = −0.02, 95% CI −1.22–0.82; p = 0.97) for people with dementia, or caregivers’ general health status (MD = 0.13, 95% CI −1.65–1.91; p = 0.89).",17276:17668, 5369684 ,28350796,Unavailable
 5369684 ,relationship with their caregiver,Cognitive stimulation therapy (CST),treatment as usual (TAU),Significantly increased,"However, people with dementia receiving iCST rated the relationship with their caregiver more positively (MD = 1.77, 95% CI 0.26–3.28; p = 0.02), and iCST improved QoL for caregivers (EQ-5D, MD = 0.06, 95% CI 0.02–0.10; p = 0.01).",17668:17933, 5369684 ,28350796,Unavailable
 5762815 ,proportions of facility births and deliveries facilitated by skilled birth attendants,neonatal bag and mask resuscitation and oral antibiotic therapy,routine care through the existing national programme,No significant difference,We noted no significant differences between the intervention and control clusters in the proportions of facility births (53% vs 54%; p=0·73) and deliveries facilitated by skilled birth attendants (54% vs 56%; p=0·53; table 4).,44610:44913, 5762815 ,28716351,Unavailable
 5762815 ,home deliveries were attended by lady health workers (LHWs),neonatal bag and mask resuscitation and oral antibiotic therapy,routine care through the existing national programme,Significantly increased,A significantly higher proportion of home deliveries were attended by LHWs in the intervention clusters than in the control clusters (14% vs 1%; p&lt;0·0001; table 4).,44913:45139, 5762815 ,28716351,Unavailable
 5762815 ,Clean delivery kits were used,neonatal bag and mask resuscitation and oral antibiotic therapy,routine care through the existing national programme,Significantly increased,Clean delivery kits were used significantly more often for home deliveries in the intervention clusters than in the control clusters (p&lt;0·0001; table 4).Table 4,45139:45389, 5762815 ,28716351,Unavailable
 5762815 ,rates of early fetal loss,neonatal bag and mask resuscitation and oral antibiotic therapy,routine care through the existing national programme,Significantly increased,"During the study period, rates of early fetal loss, although much lower than reported baseline values, were broadly similar in both groups (61 per 1000 pregnancies in intervention clusters vs 63 per 1000 pregnancies in control clusters; risk ratio [RR] 0·97, 95% CI 0·88–1·08; p=0·60; table 5).Table 5",49483:49888, 5762815 ,28716351,Unavailable
 5762815 ,Stillbirth rates,neonatal bag and mask resuscitation and oral antibiotic therapy,routine care through the existing national programme,No significant difference,"Stillbirth rates were somewhat higher than those reported in the baseline survey, but again did not differ significantly between groups after baseline rates and randomisation were controlled for (RR 0·89, 95% CI 0·76–1·04; p=0·13; table 5; appendix).",52885:53215, 5762815 ,28716351,Unavailable
 3488177 ,hemoglobin dilution,total knee replacement (TKA) with tourniquet, without tourniquet,Significantly increased,Pain VAS measurements were lower in the non-tourniquet group (p = 0.01).,4618:4691, 3488177 ,22974220,Unavailable
 3488177 ,morphine consumption,total knee replacement (TKA) with tourniquet, without tourniquet,Significantly increased,There was no significant difference in morphine consumption.,4692:4752, 3488177 ,22974220,Unavailable
 3488177 ,Range of motion,total knee replacement (TKA) with tourniquet, without tourniquet,Significantly decreased,Range of motion was 11° more in the non-tourniquet group (p = 0.001 at 2 years).,4753:4833, 3488177 ,22974220,Unavailable
 5302797 ,delayed retention test,(quiet eye training; QET),technical training (TT),Significantly increased,"The significant difference between groups was maintained at delayed retention test where the QET group exhibited significantly earlier (p = .003) QE2 onsets (M = 102.36, SD = 44.59ms) compared to the TT group (M = 207.75, SD = 79.23ms; see Fig 2 middle).",48218:48609, 5302797 ,28187138,Unavailable
 5302797 ,aiming durations,(quiet eye training; QET),technical training (TT),Significantly increased,"However, the QET group had significantly longer (p &lt; .001) QE1 aiming durations (M = 594.15, SD = 150.09ms) at retention compared to the TT group (M = 297.80, SD = 176.67ms).",46177:46440, 5302797 ,28187138,Unavailable
 5302797 ,to track the ball prior to the catch (QE2) durations at retention,(quiet eye training; QET),technical training (TT),No significant difference,"The difference between QET (M = 253.73, SD = 55.18ms) and TT (M = 162.14, SD = 92.67ms) groups at delayed retention tests failed to reach adjusted levels of significance (p = .022, see Fig 2 bottom).",49351:49687, 5302797 ,28187138,Unavailable
 5777928 ,high-contrast-visual-acuity (HCVA) averaged across distances,extended-depth-of-focus prototypes (EDOF)," AIROPTIX Aqua multifocal (AOMF), ACUVUE OASYS for presbyopia (AOP)",Significantly increased,EDOF was significantly better than AOMF and AOP for HCVA averaged across distances (p&nbsp;≤&nbsp;0.038);,5658:5770, 5777928 ,28619486,Unavailable
 5777928 ,low-contrast-visual-acuity (LCVA), AIROPTIX Aqua multifocal (AOMF),extended-depth-of-focus prototypes (EDOF) ,Significantly decreased,significantly worse than AOMF for LCVA (p&nbsp;=&nbsp;0.021),5771:5838, 5777928 ,28619486,Unavailable
 5777928 ,contrast-sensitivity (CS) in medium and high add-groups, AIROPTIX Aqua multifocal (AOMF),extended-depth-of-focus prototypes (EDOF) ,Significantly decreased,significantly worse than AOMF for LCVA (p&nbsp;=&nbsp;0.021) and significantly worse than AOMF for CS in medium and high add-groups (p&nbsp;=&nbsp;0.006).,5771:5939, 5777928 ,28619486,Unavailable
 5777928 ,mean stereoacuity (36 and 13 seconds-of-ar,extended-depth-of-focus prototypes (EDOF) ," AIROPTIX Aqua multifocal (AOMF), ACUVUE OASYS for presbyopia (AOP)",Significantly increased,significantly worse than AOMF for LCVA (p&nbsp;=&nbsp;0.021) and significantly worse than AOMF for CS in medium and high add-groups (p&nbsp;=&nbsp;0.006).,5771:5939, 5777928 ,28619486,Unavailable
 5777928 ,lack-of-ghosting averaged across distances,extended-depth-of-focus prototypes (EDOF) , ACUVUE OASYS for presbyopia (AOP),Significantly increased,"For lack-of-ghosting averaged across distances, EDOF was significantly better than AOP (p&nbsp;&lt;&nbsp;0.001) but not AOMF (p&nbsp;=&nbsp;0.186).",6290:6451, 5777928 ,28619486,Unavailable
 5707229 ,the median effective dose (ED50) of 0.5% hypobaric bupivacaine,intrathecal 0.5% hypobaric bupivacaine USpA (group B),0.5% hypobaric ropivacaine USpA (group R),Significantly increased,"We find the ED50 were lower, and the ED50 of 0.5% hypobaric bupivacaine and ropivacaine was 4.66 mg (95% CI 4.69–4.63 mg) and 6.43 mg (95% CI 6.47–6.39 mg),",6215:6382, 5707229 ,29071370,Unavailable
 5668343 ,Disease-free survival,adjuvant tamoxifen,adjuvant letrozole; sequence of the two drugs,No significant difference,Disease-free survival	All	0.95	(0.75–1.21)	0.68	AIB1 Low	0.85	(0.61–1.18)		0.32AIB1 High	1.08	(0.76–1.54),47334:NaN, 5668343 ,28766132,Unavailable
 5668343 ,Overall survival,adjuvant tamoxifen,adjuvant letrozole; sequence of the two drugs,No significant difference,Overall survival	All	0.91	(0.68–1.23)	0.54	AIB1 Low	0.91	(0.60–1.37)		0.99AIB1 High	0.91	(0.59–1.41),47923:NaN, 5668343 ,28766132,Unavailable
 4331444 ,"mitral annular plane systolic excursion (MAPSE) of the ventricular septum, early diastolic filling velocity (E-velocity), and the ratio of early to late ventricular filling velocities (E/A ratio)",receive cisplatin and 5-fluorouracil with or without the addition of 40&nbsp;Gy radiotherapy prior to surgery,receive cisplatin and 5-fluorouracil without the addition of 40&nbsp;Gy radiotherapy prior to surgery,Significantly decreased,"In the chemoradiotherapy group there was no change in left ventricular global strain but mitral annular plane systolic excursion (MAPSE) of the ventricular septum, early diastolic filling velocity (E-velocity), and the ratio of early to late ventricular filling velocities (E/A ratio) decreased significantly (p = 0.02, p = 0.01, and p = 0.03, respectively).",6285:6644, 4331444 ,25582305,Unavailable
 4331444 ,plasma N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP),receive cisplatin and 5-fluorouracil with or without the addition of 40 Gy radiotherapy prior to surgery,receive cisplatin and 5-fluorouracil without the addition of 40 Gy radiotherapy prior to surgery,No significant difference,"After neoadjuvant treatment we observed a significant increase of NT-proBNP in the chemoradiotherapy group (mean 140%, CI 27–357%, p = 0.05), but no significant change after chemotherapy (mean 14%, CI 1–82%, p &gt; 0.99) and a trend towards an interaction effect (p = 0.07) (Table&nbsp;2).",30055:30380, 4331444 ,25582305,Unavailable
 3654568 ,HbA1c,canagliflozin 100 or 300 mg,placebo,Significantly decreased,"Both canagliflozin 100 and 300 mg reduced HbA1c from baseline compared with placebo at week 26 (–0.33, –0.44 and –0.03%; p &lt; 0.05).",6002:6134, 3654568 ,23464594,Unavailable
 3654568 ,fasting plasma glucose (FPG),canagliflozin 100 or 300 mg,placebo,No significant difference,"The comparison of canagliflozin 300 mg versus placebo in change in FPG was not statistically significant and, therefore, the statistical comparison of canagliflozin 100 mg versus placebo did not proceed based on the closed testing procedure.",35275:35516, 3654568 ,23464594,Unavailable
 3654568 ,adverse event (AE),canagliflozin 100 or 300 mg,placebo,No significant difference,"Overall AE rates were similar for canagliflozin 100 and 300 mg and placebo (78.9, 74.2 and 74.4%).",6305:6404, 3654568 ,23464594,Unavailable
 5132127 ,occiput anterior position,take a hands and knees position for at least for 10 minutes,control group received the usual care,No significant difference,"One hour after the randomisation, 35 of 203 (17%) fetuses were diagnosed as being in the occiput anterior position in the intervention group compared with 24 of 209 (12%) in the control group. This difference was not statistically significant (relative risk 1.50; 95% CI 0.93–2.43; P = 0.13).",6231:6593, 5132127 ,26806596,Unavailable
 3961245 ,muscles and pain control after 4 and 16 weeks,strengthening exercises (STRE),flexibility (FLEX) exercises,Significantly increased,The STRE group was more effective to strength gain for all muscles and pain control after 4 and 16 weeks (p&lt;0.05).,7169:7284, 3961245 ,24651512,Unavailable
 3961245 ,improvements in anxiety,flexibility (FLEX) exercises,strengthening exercises (STRE) ,Significantly increased,The STRE group was more effective to strength gain for all muscles and pain control after 4 and 16 weeks (p&lt;0.05).,7169:7284, 3961245 ,24651512,Unavailable
 3961245 ,quality of life (QOL),flexibility (FLEX) exercises,strengthening exercises (STRE) ,No significant difference,"Both groups showed improvements in the QOL, and there was no significant difference observed between the groups.",7347:7459, 3961245 ,24651512,Unavailable
 3961245 ,Heart Rate Variability (HRV),flexibility (FLEX) exercises,strengthening exercises (STRE) ,No significant difference,There was no change in the HRV of the STRE and FLEX groups.,7460:7519, 3961245 ,24651512,Unavailable
 4569055 ,progress,computerized provider order entry (CPOE),chief resident (CR),No significant difference,"Thirty-six students show no better progress (beginning and final test means = 69.87 and 80.98 points out of 176 for the control group, 64.60 and 78.11 for the CPOE group, p = 0.556) during their rotation in either group",8419:8638, 4569055 ,26367388,Unavailable
 4569055 ,satisfaction with patient care and involvement in the medical team,computerized provider order entry (CPOE),chief resident (CR),Significantly increased,"even after adjusting for each student and CR, but show a better satisfaction with patient care and greater involvement in the medical team in the CPOE group (p = 0.035*).",8639:8810, 4569055 ,26367388,Unavailable
 5651290 ,Patients who achieved HbA1c&nbsp;&lt;&nbsp;7.0% (53&nbsp;mmol/mol),DSME&nbsp;+&nbsp;DSMS; intervention group,DSME-only; control group,No significant difference,"After 2&nbsp;years, an HbA1c&nbsp;&lt;&nbsp;7.0% (53&nbsp;mmol/mol), which was considered ‘controlled diabetes’, was achieved by 33.9% of subjects in the intervention group and 31.1% in the control group (Table 1, aggregate analysis). This difference was not statistically significant (p&nbsp;=&nbsp;0.39).",33534:33852, 5651290 ,29067248,Unavailable
 5651290 ,the percent increase in subjects with controlled diabetes,DSME+DSMS; intervention group,DSME-only; control group,Significantly increased,"In Kin-réseau, the percent increase in subjects with controlled diabetes was significantly larger in the intervention than in the control group (4.4% vs. 0.6%, p&nbsp;=&nbsp;0.04).",35297:35467, 5651290 ,29067248,Unavailable
 5651290 ,OR,DSME+DSMS; intervention group,DSME-only; control group,No significant difference,"In the logistic regression model, the OR for improving by at least one category after the intervention was 1.4 (0.9–2.0, p&nbsp;=&nbsp;0.10).",38027:38158, 5651290 ,29067248,Unavailable
 4391304 ,wet weight of feces,100&nbsp;g of fermented milk (FM) + Lactobacillus gasseri SBT2055 (LG2055),100&nbsp;g of fermented milk (FM),No significant difference,There were no statistically significant differences in wet weight of feces between groups (270.1 ± 159.0&nbsp;g in control FM group vs. 336.8 ± 116.9&nbsp;g in active FM group before FM intake; 264.9 ± 151.0&nbsp;g in control FM group vs. 304.4 ± 128.7&nbsp;g in active FM group after FM intake).,37967:38243, 4391304 ,25884980,Unavailable
 4391304 ,fecal fat levels,100&amp;nbsp;g of fermented milk (FM) + Lactobacillus gasseri SBT2055 (LG2055),100&amp;nbsp;g of fermented milk (FM),No significant difference,"The amount of change between pre- and post-FM intake periods increased in the active FM group compared with the control FM group, although the difference was not statistically significant (P = 0.086).Figure 5",38485:38733, 4391304 ,25884980,Unavailable
 4391304 ,fecal fat levels,100&amp;amp;nbsp;g of fermented milk (FM) + Lactobacillus gasseri SBT2055 (LG2055),100&amp;amp;nbsp;g of fermented milk (FM),No significant difference,"The amount of change between pre- and post-FM intake periods increased in the active FM group compared with the control FM group, although the difference was not statistically significant (P = 0.086).Figure 5",38485:38733, 4391304 ,25884980,Unavailable
 3590687 ,pain intensity,listened to their preferred music by headphones for 30 minutes,did not listen to music,Significantly decreased,Repeated measures ANOVA showed music to significantly reduce pain intensity (p = 0.0001),5298:5386, 3590687 ,23493927,Unavailable
 5498709 ,"systolic, diastolic and mean arterial pressures (SAP, DBP and MAP) and heart rate (HR)",treatment mechanical pump (Group M),control group (Group C),Significantly increased,"Heart rate, MPA, DAP and SAP changes were significantly higher in off-pump group in the baseline and 1st-minute (p&lt;0.05), and in the other times, this change was significantly different with control groups.",4718:4924, 5498709 ,28713516,Unavailable
 5498709 ,difference in hypotension,treatment mechanical pump (Group M),control group (Group C),No significant difference,There is no difference in hypotension between the two groups (p=0.17).,14687:14759, 5498709 ,28713516,Unavailable
 5498709 ,The occurrence of nausea,treatment mechanical pump (Group M),control group (Group C),Significantly decreased,"The occurrence of nausea (24 patients in the M group versus 48 in the C group, p=0.005) and vomiting (4 patients in the M group versus 68 in the C group, p=0.001) was significantly lower in the M group.",16273:16476, 5498709 ,28713516,Unavailable
 5498709 ,The total administered dosage of ephedrine,treatment mechanical pump (Group M),control group (Group C),Significantly decreased,"The total administered dosage of ephedrine was significantly lower in the M group (median 4.1mg vs. 17.1mg, p=0.001).",16477:16595, 5498709 ,28713516,Unavailable
 3652643 ,Satisfaction with Care ratings,behavioural therapy group,usual care,No significant difference,"Satisfaction with Care ratings for both patients and carers were higher for the behavioural therapy group compared with usual care, but these differences were not significant (P = 0.06–0.61).",44091:44299, 3652643 ,23059701,Unavailable
 3652643 ,receiving medication for mood problems,behavioural therapy group,usual care,No significant difference,"At six months, 15 (28%) of the control group and 14 (27%) of the intervention group were receiving medication for mood problems, and this was not significant (chi-square = 0.00, P = 1.0).",43880:44084, 3652643 ,23059701,Unavailable
 1513406 ,The prevalence of parasitological failure,"chloroquine (CQ) alone, ","CQ/SP group, sulphadoxine-pyrimethamine (SP) alone",Significantly increased,"The prevalence of parasitological failure by day 28 for the CQ group was 60.3%, compared to 17.6% for SP (odds ratio [OR], 0.106; 95% confidence interval [CI], 0.057–0.194; p &lt; 0.001) and 13.9% for CQ/SP (OR versus CQ, 0.140; 95% CI, 0.078–0.250; p &lt; 0.001).",6954:7250, 1513406 ,16871319,Unavailable
 1513406 ,The prevalence of parasitological failure,sulphadoxine-pyrimethamine (SP) alone,"CQ/SP group, ",No significant difference,"There was no difference between the SP and CQ/SP groups (OR, 1.324; 95% CI, 0.705–2.50).",7250:7338, 1513406 ,16871319,Unavailable
 4218710 ,the duration of surgery,endoscopy procedure group (group A),traditional surgery group (group B),No significant difference,No significant difference between the groups was noted with respect to the duration of surgery (P=0.06).,12267:12371, 4218710 ,25371723,Unavailable
 4218710 ,skin defects,endoscopy procedure group (group A),traditional surgery group (group B),No significant difference,"Three patients in group A (Fig. 1) and six in group B required a skin transplant for skin defects, but the rate of skin transplantation was not statistically different between the two groups (P=0.21; Table II).",12371:12690, 4218710 ,25371723,Unavailable
 4218710 ,intra-operative blood loss,endoscopy procedure group (group A),traditional surgery group (group B),Significantly decreased,"Patients in group A had a mean intra-operative blood loss of 327±89 ml, which was significantly reduced [mean difference (MD), −78.00; 95% CI, −132.68 to −23.32; P=0.005] when compared with that of group B (405±177 ml).",12690:12909, 4218710 ,25371723,Unavailable
 4218710 ,The intra-operative volume of irrigation saline,endoscopy procedure group (group A),traditional surgery group (group B),Significantly decreased,"The intra-operative volume of irrigation saline was lower in group A compared with that in group B, and the difference was statistically significant (MD, −770.00; 95% CI, −1082.82 to −457.18; P&lt;0.00001).",12910:13113, 4218710 ,25371723,Unavailable
 4218710 ,The mean wound healing time,endoscopy procedure group (group A),traditional surgery group (group B),Significantly decreased,"The mean wound healing time was also significantly shorter (MD, −9.40; 95% CI, −10.99 to −7.81; P&lt;0.00001) in group A (10.0±2.5 days) than in group B (19.4±5.2 days).",13123:13289, 4218710 ,25371723,Unavailable
 3707921 ,reducing the frequency of rule violation in the TOLDX,Nei Yang Gong (experimental group),PMR (control group),Significantly decreased,"Although both groups showed improvement in reducing the frequency of rule violation in the TOLDX, the mean reduction of the experimental group (−8.53) after the intervention was about four times that of the control group (−2.82), and the group difference was statistically significant with a large effect size (0.84), t(34) = 2.45, p = 0.019.",48911:49299, 3707921 ,23874533,Unavailable
 3707921 ,The reduction in impulsivity,Nei Yang Gong (experimental group),PMR (control group),Significantly decreased,"The reduction in impulsivity of the treatment group was greater than that of the control group, with a medium effect size (0.77), t(33) = −2.27, p = 0.03.",49700:49890, 3707921 ,23874533,Unavailable
 3707921 ,the mean reduction of completion time,Nei Yang Gong (experimental group),PMR (control group),No significant difference,"Although the between-group difference in the mean reduction of completion time did not reach statistical significance, t(33) = 1.61, p = 0.12, the effect size (0.55) is at the medium level.",50308:50531, 3707921 ,23874533,Unavailable
 3664372 ,developed stroke,Single Lead Atrial Pacing (AAIR),Dual Chamber Pacing in Sick Sinus Syndrome(DDDR),No significant difference,Mean follow-up was 4.3±2.5 years. In the AAIR group 6.9% patients developed stroke versus 6.1% in the DDDR group (NS).,6803:6922, 3664372 ,23539553,Unavailable
 3664372 ,Mortality,Single Lead Atrial Pacing (AAIR),Dual Chamber Pacing in Sick Sinus Syndrome(DDDR),No significant difference,"In the AAIR group 209 patients (29.6%) died versus 193 (27.3%) patients in the DDDR group (unadjusted HR 1.06; 95% CI 0.88 to 1.29, p=0.53).",27919:28059, 3664372 ,23539553,Unavailable
 3640960 ,Heparin Binding Protein (HBP),filgrastim 300 micrograms/day,placebo,No significant difference,"At day 7, there was no difference in HBP levels 15.9 ng/ml [12.6-20.7 ng/ml] vs. 17.8 ng/ml [13.6-20.9 ng/ml] in filgrastim and placebo groups (p = 0.774), respectively.",15977:16147, 3640960 ,23363492,Unavailable
 3640960 ,The absolute neutrophil count and white blood cell counts,filgrastim 300 micrograms/day,placebo,Significantly increased,The absolute neutrophil count and white blood cell counts were similar in filgrastim and placebo groups at baseline but at days 4 and 7 there were significant increase in filgrastim group (p &lt; 0.01 for both; Table 2).,19866:20125, 3640960 ,23363492,Unavailable
 3669518 ,median overall survival,open-label EOC (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2 on day 1 and capecitabine 1250 mg/m2 per day on days 1–21),"modified-dose EOC plus panitumumab (mEOC+P; epirubicin 50 mg/m2 and oxaliplatin 100 mg/m2 on day 1, capecitabine 1000 mg/m2 per day on days 1–21, and panitumumab 9 mg/kg on day 1)",Significantly increased,"Based on 251 events (EOC 110, mEOC+P 141) at the time of reporting, median overall survival was lower in the mEOC+P group than in the EOC group (HR 1·37, 95% CI 1·07–1·76, p=0·013; figure 2).",21141:21372, 3669518 ,23594787,Unavailable
 3669518 ,terms of grade 3–5 toxicity,open-label EOC (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2 on day 1 and capecitabine 1250 mg/m2 per day on days 1–21),"modified-dose EOC plus panitumumab (mEOC+P; epirubicin 50 mg/m2 and oxaliplatin 100 mg/m2 on day 1, capecitabine 1000 mg/m2 per day on days 1–21, and panitumumab 9 mg/kg on day 1)",No significant difference,"Overall, we noted no significant difference between the two groups in terms of grade 3–5 toxicity when all toxicities were combined (p=0·21).",23622:23763, 3669518 ,23594787,Unavailable
 5739614 ,serum CK-MB and cardiac troponin I (cTnI) level,"trimetazidine (60 mg/d, administered 3 days before PCI)",control (no trimetazidine),Significantly decreased,"Compared with the control group, the TMZ group had a significantly lower proportion of patients with post-PCI cTnI (38.2% vs. 70.4%, P&lt;0.05)",22572:22806, 5739614 ,29285227,Unavailable
 5739614 ,creatine kinase-MB (CK-MB),"trimetazidine (60 mg/d, administered 3 days before PCI)",control (no trimetazidine),Significantly increased,"CK-MB (18.7% vs. 44.2%, P&lt;0.05) levels higher than the reference values at 16-24 h.",22572:22806, 5739614 ,29285227,Unavailable
 5739614 ,high-sensitivity C-reactive protein (hs-CRP) level,"trimetazidine (60 mg/d, administered 3 days before PCI)",control (no trimetazidine),Significantly decreased,"Both groups had significantly elevated hs-CRP levels post-PCI compared with baseline values, with significantly higher levels found in the control group (5.85±1.32 mg/l vs. 9.63±0.67 mg/l, P&lt;0.05).",22572:22806, 5739614 ,29285227,Unavailable
 5926629 ,pain level,diclofenac suppository group (Group 1),Lidocaine group (Group 2),Significantly decreased,VAS 1 score was stated in 9 (17%) patients in group 2 and 19 (38%) patients in Group 1 (p = 0.030).,5231:5330, 5926629 ,29732205,Unavailable
 5980265 ,mortality rate,"fenoldopam, constant rate infusion [CRI] of 0.1 µg/kg/min",saline,No significant difference,"Overall, 14/40 dogs (35%) died, with no significant (P = .507) mortality rate difference between the fenoldopam (6/20 dogs; 30%) and placebo (8/20; 40%) groups.",6119:6298, 5980265 ,29575360,Unavailable
 5980265 ,The proportion of dogs with Acute kidney injury (AKI),"fenoldopam, constant rate infusion [CRI] of 0.1 µg/kg/min",saline,No significant difference,"The proportion of dogs with AKI did not differ between the fenoldopam and the placebo groups (9/20; 45% versus 13/20; 65%, respectively; P = .204).",6463:6556, 5980265 ,29575360,Unavailable
 5980265 ,"Urine production (UP), glomerular filtration rate (GFR) and sodium fractional excretion (NaFE)","fenoldopam, constant rate infusion [CRI] of 0.1 µg/kg/min",saline,No significant difference,"There were no differences in UP, GFR, and NaFE between the fenoldopam and the placebo groups.",6463:6556, 5980265 ,29575360,Unavailable
 4675066 ,"The mean cognitive, language and motor scores on the Bayley-III",iodine (150&nbsp;μg/d),placebo,No significant difference,"The mean cognitive, language and motor scores on the Bayley-III (iodine versus placebo, respectively) were 99.4 ± 12.2 versus 101.7 ± 8.2 (mean difference (MD) −2.3, 95&nbsp;% confidence interval (CI) −7.8, 3.2; P = 0.42), 97.2 ± 12.2 versus 97.9 ± 11.5 (MD −0.7, 95&nbsp;% CI −7.0, 5.6; P = 0.83) and 93.9 ± 10.8 versus 92.4 ± 9.7 (MD 1.4, 95&nbsp;% CI −4.0, 6.9; P = 0.61), respectively.",7427:7852, 4675066 ,26654905,Unavailable
 4675066 ,The median (interquartile range) breast milk iodine concentration,iodine (150μg/d),placebo,No significant difference,"The median (interquartile range) breast milk iodine concentration at 6&nbsp;weeks after birth was 107 (79–147) μg/l overall, and there was no difference in breast milk concentration between the iodine and the placebo group (Table&nbsp;3)",26391:26659, 4675066 ,26654905,Unavailable
 5066848 ,forced expiratory volume in 1 second (FEV1),indacaterol (IND)/glycopyrronium (GLY) 110/50 μg once daily,"GLY 50 μg od, IND 150 μg od, open-label tiotropium (TIO) 18 μg od, and placebo",Significantly increased,IND/GLY showed an improvement in FEV1 AUC5 min–4 h versus all comparators (all P&lt;0.05).,5380:5508, 5066848 ,27785010,Unavailable
 3516972 ,pain,mesh fixation with the use of sutures , adhesive in Lichtenstein's inguinal hernia repair,No significant difference,"Later on, VAS measures did not differ; pain intensity was similar.",25729:25795, 3516972 ,23256009,Unavailable
 3516972 ,time necessary for return to daily activities,mesh fixation with the use of sutures , adhesive in Lichtenstein's inguinal hernia repair,No significant difference,"Return to daily activities, sport and driving was similar in both groups.",30354:30428, 3516972 ,23256009,Unavailable
 3540956 ,volume of distribution (Vd) and clearance (CL),37 mg/m2 of ursolic acid nanoliposomes (UANL),"74, and 98 mg/m2 of ursolic acid nanoliposomes (UANL)",No significant difference,"However, the mean t1/2, volume of distribution (Vd) and clearance (CL) were not significantly different among the three doses (P &gt; 0.05), suggesting that clearance was constant over that specific dose interval.",21655:21955, 3540956 ,23319864,Unavailable
 5840469 ,The occurrence rate of esophageal stricture,polyglycolic acid (PGA) plus stent group (PGA sheet-coated stent placement was performed),Stent group (only stent placement was performed),Significantly decreased,"The occurrence rate of esophageal stricture in the PGA plus stent group was 20.5% (n = 7), which was lower than that in the stent group (46.9%, n = 15) (P = 0.024).",5467:5683, 5840469 ,29531468,Unavailable
 5840469 ,The mean value of esophageal stricture time,polyglycolic acid (PGA) plus stent group (PGA sheet-coated stent placement was performed),Stent group (only stent placement was performed),No significant difference,"The mean value of esophageal stricture time was 59.6 ± 16.1 d and 70.7 ± 28.6 d in the PGA plus stent group and stent group (P = 0.174), respectively.",5682:5851, 5840469 ,29531468,Unavailable
 5840469 ,Times of balloon dilatation,polyglycolic acid (PGA) plus stent group (PGA sheet-coated stent placement was performed),Stent group (only stent placement was performed),Significantly decreased,"Times of balloon dilatation in the PGA plus stent group were less than those in the stent group [4 (2-5) vs 6 (1-14), P = 0.007].",5850:6015, 5840469 ,29531468,Unavailable
 5840469 ,The length and diameter of esophageal strictures,polyglycolic acid (PGA) plus stent group (PGA sheet-coated stent placement was performed),Stent group (only stent placement was performed),No significant difference,"The length (P = 0.080) and diameter (P = 0.061) of esophageal strictures were numerically decreased in the PGA plus stent group, whereas no difference in location (P = 0.232) between the two groups was found.",6015:6274, 5840469 ,29531468,Unavailable
 3646538 ,congestion on study 1,mometasone furoate nasal spray (MFNS) 100 μg,placebo,Significantly decreased,MFNS (n=134) reduced congestion significantly more than placebo (n=135) on day 2 (P=.004) and on 23/29 days (P≤.037).,4472:4624, 3646538 ,23663488,Unavailable
 3646538 ,congestion on study 2,mometasone furoate nasal spray (MFNS) 100 μg,placebo,Significantly decreased,Study 2: MFNS (n=185) reduced congestion significantly more than placebo (n=189) on day 3 (P=.015) and on 22/29 days (P≤.047).,4814:4978, 3646538 ,23663488,Unavailable
 4511434 ,amount of calories,"Lunch 2 (L2), experiment meal","Lunch 1 (L1), control meal",No significant difference,"Unrestrained eaters in the calories and exercise equivalents group ordered an average of 275 fewer calories at Lunch 2 compared with Lunch 1, with a proportionate decrease of 14.0%, although this was not statistically significant (p = 0.24).",27435:27693, 4511434 ,26217508,Unavailable
 4752985 ,Oral Hygiene Index (OHI) and Gingival Index (GI),oral health education message through short messaging service (SMS) in mobile phones,no such reinforcement - control group,Significantly decreased,"Mean OHI and GI scores in intervention group were significantly (p &lt; 0.01) less than those of control group after the 2nd, 3rd, and 6th month.",5237:5396, 4752985 ,26941793,Unavailable
 5587887 ,Internal consistency of the global satisfaction score,self-complete a set of questionnaires using a dedicated website,provide answers to the same questionnaires administered during a telephone interview,Significantly increased,Internal consistency of the global satisfaction score was higher (P=.03) in the Internet group (Cronbach alpha estimate=.89; 95% CI 0.86-0.91) than in the telephone group (Cronbach alpha estimate=.84; 95% CI 0.79-0.87).,13033:13248, 5587887 ,28835354,Unavailable
 5587887 ,The mean global satisfaction score,self-complete a set of questionnaires using a dedicated website,provide answers to the same questionnaires administered during a telephone interview,Significantly decreased,"The mean global satisfaction score was lower (P=.03) in the Internet group (68.9; 95% CI 66.4-71.4) than in the telephone group (72.1; 95% CI 70.4-74.6), with a corresponding effect size of the difference at −0.253.",13033:13248, 5587887 ,28835354,Unavailable
 4232915 ,[Investigator's Global Assessment (IGA) score,oral liarozole (75 or 150&nbsp;mg),placebo,Significantly decreased,Mean IGA and scaling scores decreased from baseline in both liarozole groups at weeks 8 and 12 vs. placebo;,5761:5869, 4232915 ,24102348,Unavailable
 4232915 ,Dermatology Life Quality Index (DLQI),oral liarozole (75 mg),placebo,Significantly increased,"Mean DLQI score improved significantly from baseline at week 12 in patients receiving liarozole 75&nbsp;mg vs. patients receiving placebo [mean (SD) change, −4·3 (6·0); P&nbsp;=&nbsp;0·014].",31656:31867, 4232915 ,24102348,Unavailable
 4232915 ,Dermatology Life Quality Index (DLQI),oral liarozole (150 mg),placebo,No significant difference,"No significant difference was observed between the 150-mg liarozole and the placebo groups in change from baseline of mean DLQI score at week 12 [mean (SD) change, −2·8 (3·4); P&nbsp;=&nbsp;0·06];",32086:32306, 4232915 ,24102348,Unavailable
 4232915 ,"‘daily activities’, ‘leisure’, and ‘symptoms and feelings’",oral liarozole (150 mg),placebo,Significantly increased,"however, the 150-mg liarozole group showed a significant improvement from baseline vs. the placebo group in the ‘daily activities’ (P&nbsp;=&nbsp;0·008), ‘leisure’ (P&nbsp;=&nbsp;0·026), and ‘symptoms and feelings’ (P&nbsp;=&nbsp;0·023) domains.",32306:32624, 4232915 ,24102348,Unavailable
 4232915 ,Adverse events,"oral liarozole (150, 75 mg)",placebo,No significant difference,"Both liarozole groups presented a higher number of AEs than the placebo group; however, the difference between groups was not significant (liarozole 75 or 150&nbsp;mg vs. placebo, P&nbsp;≥&nbsp;0·062), and AE incidence did not appear to be related to liarozole dose.",33009:33296, 4232915 ,24102348,Unavailable
 3590541 ,intracuff pressure,nitrous oxide (group N),oxygen and air (group A),Significantly increased,"In group N, [Table 2] there was a consistent and significant increase in intracuff pressure over time (P &lt; 0.001) while in group A, it remained stable throughout the procedure (maximum intracuff pressure of 45 mmHg).",14662:14934, 3590541 ,23493234,Unavailable
 3590541 ,The rise in peak airway pressure after carboperitoneum,nitrous oxide (group N),oxygen and air (group A),No significant difference,The rise in peak airway pressure after carboperitoneum was comparable between the two groups.,15272:15365, 3590541 ,23493234,Unavailable
 3590541 ,displacement of device ,nitrous oxide (group N),oxygen and air (group A),No significant difference,There was no evidence of displacement of device in either group.,15366:15430, 3590541 ,23493234,Unavailable
 1868017 ,depression and distress among men,multifactorial fall prevention programme intervention group (IG) ,control group (CG),Significantly decreased,Differences in the changes between IG and CG were found in depression (p = 0.017) and distress (p = 0.029),21566:21848, 1868017 ,17462083,Unavailable
 1868017 ,marginal differences in usual activities and sexual activity among men,multifactorial fall prevention programme intervention group (IG) ,control group (CG),No significant difference,Differences in the changes between IG and CG were found in depression (p = 0.017) and distress (p = 0.029) and marginal differences in usual activities (p = 0.058) and sexual activity (p = 0.051) among men (additional file 2).,21566:21848, 1868017 ,17462083,Unavailable
 1868017 ,discomfort/symptoms among women,multifactorial fall prevention programme intervention group (IG) ,control group (CG),Significantly decreased,"In women, the analyses showed differences in the changes between the groups in usual activities (p = 0.005) and discomfort/symptoms (p = 0.047) (additional file 3.). These differences in changes were in favour of IG.",21848:22121, 1868017 ,17462083,Unavailable
 1868017 , usual activities among women,multifactorial fall prevention programme intervention group (IG) ,control group (CG),Significantly increased,"In women, the analyses showed differences in the changes between the groups in usual activities (p = 0.005) and discomfort/symptoms (p = 0.047) (additional file 3.). These differences in changes were in favour of IG.",21848:22121, 1868017 ,17462083,Unavailable
 5569270 ,second peak knee flexor moment  ,neuromuscular exercise therapy (ET),no attention control group (CG),Significantly increased,"Second peak flexor moment (late stance), Nm/kg 0.05 (−0.02 to 0.11) −0.5 (−0.11 to 0.01) 0.10 (0.01 to 0.19) 0.04",52302:52603, 5569270 ,28879038,Unavailable
 5569270 ,second peak vertical ground reaction force,neuromuscular exercise therapy (ET),no attention control group (CG),Significantly increased,"Second peak vertical ground reaction force, N	−2.7 (−5.9 to 0.6)	2.3 (−0.9 to 5.4)	−4.9 (−9.5:−0.4)	0.03",62143:62487, 5569270 ,28879038,Unavailable
 3872578 ,The mean arterial blood pressure,lidocaine or air was used to fill the tracheal tube cuff,air group,No significant difference,The mean arterial blood pressure was not statistically significant different between two groups (P = 0.72).,15296:15420, 3872578 ,24381613,Unavailable
 3872578 ,oxygen saturation,lidocaine or air was used to fill the tracheal tube cuff,air group,No significant difference,"Consequently, oxygen saturation was not statistically significant different between lidocaine and air groups during the 48 h (P = 0.134).",15557:15711, 3872578 ,24381613,Unavailable
 3872578 ,erosion and hemorrhage on the anterior wall of trachea,lidocaine or air was used to fill the tracheal tube cuff,air group,No significant difference,"Bronchoscopy findings after 48 h indicated erythema and edema of tracheal mucosa in the same patients (2 patients (7.7%) in lidocaine group and 6 patients (24%) of air group). In one of the patients of air group, erosion and hemorrhage on the anterior wall of trachea was present (P = 0.147).",16053:16363, 3872578 ,24381613,Unavailable
 4752820 ,Blood glucose level,4) PP: placebo before and after the surgery; ,3) SS: supplement before and after the surgery; SP (supplement/placebo): supplement seven days before and placebo 30 days after the surgery; 2) PS: placebo before and supplement after the surgery;,Significantly increased,"Blood glucose levels were increased postoperatively in the four groups (&lt; 0.001), but a significantly higher increase occurred in the PP group compared to the SP (0.027), PS (0.026), and SS (0.004) groups.",5929:6135, 4752820 ,26889394,Unavailable
 4752820 ,superficial wound infection rate,4) PP: placebo before and after the surgery; ,3) SS: supplement before and after the surgery; SP (supplement/placebo): supplement seven days before and placebo 30 days after the surgery; 2) PS: placebo before and supplement after the surgery;,Significantly increased,"The superficial wound infection rate was significantly different between the four groups (0.021): 26.08% in PP, 9.09% in SP, 4.54% in PS, and 0% in SS.",6135:6286, 4752820 ,26889394,Unavailable
 4359699 ,low disease activity (LDA),etanercept 50&nbsp;mg,placebo,No significant difference,"At week 12, 33% on etanercept and 21% on placebo achieved LDA (P = 0.055); remission was achieved in 19% and 12%, respectively (P = 0.14).",5142:5319, 4359699 ,25793152,Unavailable
 4882812 ,"non-smoking intentions, for cigarette refusal self-efficacy",sport-for-health smoking prevention programme (SmokeFree Sports),usual smoking education only,No significant difference,"There were no significant differences between the two study groups for non-smoking intentions (T1: β = 0.02, 95&nbsp;% CI = -0.08–0.12; T2: β = 0.08, 95&nbsp;% CI = -0.02–0.17) or for cigarette refusal self-efficacy (T1: β = 0.28, 95&nbsp;% CI = -0.11–0.67; T2: β = 0.23, 95&nbsp;% CI = -0.07–0.52).",5820:6100, 4882812 ,27229464,Unavailable
 4882812 ,"‘definitely’ believing that: ‘it is not safe to smoke for a year or two as long as you quit after that’ , ‘it is difficult to quit smoking once started’ , ‘smoke from other peoples’ cigarettes is harmful to you’ , and ‘smoking affects sports performance’",sport-for-health smoking prevention programme (SmokeFree Sports),usual smoking education only,Significantly increased,"At T1, compared with children in the comparison group, children that participated in the SFS intervention were more likely to ‘definitely’ believe that: ‘it is not safe to smoke for a year or two as long as you quit after that’ (RR = 1.19, 95&nbsp;% CI 1.07 to 1.33, p &lt; 0.001), ‘it is difficult to quit smoking once started’ (RR = 1.56, 95&nbsp;% 1.38 to 1.76, p &lt; 0.001), ‘smoke from other peoples’ cigarettes is harmful to you’ (RR = 1.19, 95&nbsp;% CI 1.20 to 2.08, p &lt; 0.001), and ‘smoking affects sports performance’ (RR = 1.73, 95&nbsp;% CI 1.59 to 1.88, p &lt; 0.001).",48198:48828, 4882812 ,27229464,Unavailable
 4757005 ,The mean time off from work,Group A patients - conventional surgical hydrocelectomy (Jaboulay's procedure),group B - the new minimal access hydrocelectomy,Significantly increased,The mean time off from work in group B was 9±2.35 days and in group A was 13.5±4. (P=0.0001).,17594:17687, 4757005 ,26401869,Unavailable
 4757005 ,The operative time,Group A patients - conventional surgical hydrocelectomy (Jaboulay's procedure),group B - the new minimal access hydrocelectomy,Significantly increased,The operative time in group B ranged between 12-18 minutes and the mean was 15.1±4.24 minutes and in group A ranged between 25-40 minutes with mean value 32.5±4.76 minutes with significant distribution (P≤0.02).,16826:17037, 4757005 ,26401869,Unavailable
 4757005 ,The mean time of hospital stay,Group A patients - conventional surgical hydrocelectomy (Jaboulay's procedure),group B - the new minimal access hydrocelectomy,Significantly increased,"The mean time of hospital stay for group B was 13.48±6.38 hours with 10 hours as a minimum and 30 hours as a maximum value, while in group A was 21.19±11.65 hours with 12 hours as a minimum and 48 hours as a maximum value but this distribution was not significant (P≥0.05).",17038:17311, 4757005 ,26401869,Unavailable
 3375426 ,The median times until improvement,polyethylene glycol-treated human IgG (drug code GB-0998),placebo,No significant difference,"The median times until improvement were 16.5&nbsp;days in the GB-0998 group, and 29.0&nbsp;days in the placebo group, but the difference between the two groups was not statistically significant (log-rank test, p&nbsp;=&nbsp;0.1154).Fig.&nbsp;3",33227:33484, 3375426 ,21971943,Unavailable
 3375426 ,The median time until normalization of the serum CK level,polyethylene glycol-treated human IgG (drug code GB-0998),placebo,Significantly decreased,"The median time until normalization of the serum CK level was significantly less in the GB-0998 group, at 22.0&nbsp;days, than in the placebo group, in which it was 57.5&nbsp;days (generalized Wilcoxon test, p&nbsp;=&nbsp;0.0301).Fig.&nbsp;4",34378:34634, 3375426 ,21971943,Unavailable
 3375426 ,MMT score,polyethylene glycol-treated human IgG (drug code GB-0998),placebo,No significant difference,"Even after week&nbsp;8 of the first period, no statistically significant intergroup difference in the percentage of subjects showing improvement was found (Fisher direct probability test, p&nbsp;=&nbsp;0.0809).",36319:36531, 3375426 ,21971943,Unavailable
 3375426 ,swallowing action,polyethylene glycol-treated human IgG (drug code GB-0998),placebo,Significantly increased,"Among these actions, the difference (value 1.17) with respect to swallowing action at week&nbsp;8 of the first period between an increase of 1.00 in the GB-0998 group and a decrease of −0.17 in the placebo group (the normal score is 3) was statistically significant (t test, p&nbsp;=&nbsp;0.0222).Fig.&nbsp;8",40882:41226, 3375426 ,21971943,Unavailable
 3375426 ,Dysphagia,polyethylene glycol-treated human IgG (drug code GB-0998),placebo,No significant difference,"The number of subjects showing symptoms of dysphagia in the GB-0998 group before initiation of study drug administration in the first period was 7 of 12, whereas the number in the placebo group was 2 of 14. At week&nbsp;8 of the first period, the symptoms had ceased in 5 of the 7 subjects in the GB-0998 group, whereas they had not ceased with either of the two subjects in the placebo group (Fisher direct probability test, p&nbsp;=&nbsp;0.1667).",41698:42148, 3375426 ,21971943,Unavailable
 3641298 ,average pain intensity,pain education plus telemonitoring (experimental arm),pain education alone (control arm),No significant difference,"The portion of the patients with an average pain intensity ≥4 was significantly reduced in the standardized education plus telemonitoring groups compared to the standardized education only group (35&nbsp;% to 19&nbsp;%, P = 0.02). The average (−1.2 vs. −1.9) and worst (−0.7 vs. −1.2) pain scales decreased more in the telemonitoring group, but this was not statistically significant.",29882:30273, 3641298 ,23338230,Unavailable
 3641298 ,"Symptomatic scales involving fatigue , pain , and insomnia",pain education plus telemonitoring (experimental arm),pain education alone (control arm),Significantly decreased,"Interventions not only improved pain but also resolved other clinical outcomes, including anxiety (HADS score ≥ 11, 75&nbsp;% to 56&nbsp;%, P &lt; 0.01), depression (HADS score ≥ 11, 73&nbsp;% to 51&nbsp;%, P &lt; 0.01), and Karnofsky performance (32 to 66, P &lt; 0.01).",25984:26285, 3641298 ,23338230,Unavailable
 3641298 ,"fatigue, pain , and insomnia",pain education plus telemonitoring (experimental arm),pain education alone (control arm),Significantly decreased,"Symptomatic scales involving fatigue (68 to 63, P &lt; 0.01), pain (90 to 76, P &lt; 0.01), and insomnia (83 to 74, P &lt; 0.01) were also improved, but constipation was increased (53 to 72, P &lt; 0.01).",26409:26682, 3641298 ,23338230,Unavailable
 3641298 ,constipation,pain education plus telemonitoring (experimental arm),pain education alone (control arm),Significantly increased,"Symptomatic scales involving fatigue (68 to 63, P &lt; 0.01), pain (90 to 76, P &lt; 0.01), and insomnia (83 to 74, P &lt; 0.01) were also improved, but constipation was increased (53 to 72, P &lt; 0.01).",26409:26682, 3641298 ,23338230,Unavailable
 3641298 ,distress scale,pain education plus telemonitoring (experimental arm),pain education alone (control arm),No significant difference,"The level of distress scale was not significantly decreased (distress scale ≥ 4, 92&nbsp;% to 87&nbsp;%, P = 0.27) and the average number of problems did not change (21 of total 40 problems, P = 0.49).",26682:26910, 3641298 ,23338230,Unavailable
 3493727 ,The average specimen size,the propofol group,the combination group (propofol plus midazolam),Significantly decreased,The average specimen size was 34.74±13.65 mm in the propofol group and 42.74±16.86 mm in the combination group (p=0.003).,16461:16582, 3493727 ,23170151,Unavailable
 3493727 ,the mean procedure time,the propofol group,the combination group (propofol plus midazolam),No significant difference,"Table 3 shows that the mean procedure time was not significantly different between the two groups (57 minutes vs 53 minutes, p=0.528).",16621:16762, 3493727 ,23170151,Unavailable
 3493727 ,The mean propofol infusion rate,the propofol group,the combination group (propofol plus midazolam),Significantly increased,"The mean total dose of propofol administered was lower in the combination group than in the propofol group (378±220 mg vs 466±200 mg, p=0.012).",16763:16906, 3493727 ,23170151,Unavailable
 3493727 ,mean recovery time,the propofol group,the combination group (propofol plus midazolam),Significantly decreased,"but the combination group had a longer mean recovery time (7.9±3.78 minutes vs 10.5±8.74 minutes, p=0.027) (Fig. 1).",17031:17187, 3493727 ,23170151,Unavailable
 3493727 ,mild hypoxemia,the propofol group,the combination group (propofol plus midazolam),No significant difference,There were three cases of mild hypoxemia in the propofol group and one in the combination group (p=0.362),17393:17498, 3493727 ,23170151,Unavailable
 3781990 ,tumor size ,500 ml of pomegranate juice,500 ml of placebo,Significantly increased,"Statistically significant differences in tumor size (T3; 31% in the control vs. 51% in the intervention group, p=.036)",19043:19162, 3781990 ,24069070,Unavailable
 3781990 ,distant tumor spread,500 ml of pomegranate juice,500 ml of placebo,Significantly decreased,"Statistically significant differences in tumor size (T3; 31% in the control vs. 51% in the intervention group, p=.036) and distant tumor spread (M1; 18% in controls vs. 44%, p=.032) at the time of initial diagnosis were observed (Table 1).",19044:19323, 3781990 ,24069070,Unavailable
 3781990 ,PSA progression,500 ml of pomegranate juice,500 ml of placebo,No significant difference,PSA progression within the first four weeks was observed in 41% in the control group compared to 38% in the pomegranate group (p=0.83).,20736:20872, 3781990 ,24069070,Unavailable
 3781990 ,pain,500 ml of pomegranate juice,500 ml of placebo,No significant difference,The patients reported pain values in the range from 0-5 at study entry without significant group differences (mean pain score A=0.97 and B=0.98; p=0.49).,22455:22608, 3781990 ,24069070,Unavailable
 5706840 ,The median progression-free survival,chemotherapy alone (CT),chemotherapy plus cetuximab (CTX),Significantly decreased,"The median progression-free survival for the combined populations with mid or high miR-31-3p expression was shorter in the CTX versus the CT arm (26.7 months versus 12.3 months, HR=2.28 95%CI 1.27; 4.09 p=0.006).",6107:6319, 5706840 ,29212194,Unavailable
 5706840 ,miR-31-3p expressers,chemotherapy alone (CT),chemotherapy plus cetuximab (CTX),No significant difference,Low miR-31-3p expressers had similar outcomes irrespective of treatment (HR=1.06 95%CI 0.43; 2.61 p=0.9).,6320:6425, 5706840 ,29212194,Unavailable
 5446277 ,"comprehension score , subjective understanding , overall satisfaction with consent",cover sheet added to the permission form (intervention),standard form (control),No significant difference,"There were no differences in comprehension score (16.8 ± 5.7 v. 16.3 ± 3.5), subjective understanding (median 6.0 v. 6.5), or overall satisfaction with consent (median 7.0 v. 6.5) between control and intervention groups (all p&gt;0.50).",4699:4932, 5446277 ,28358380,Unavailable
 3525038 ,reduce bispectral index (BIS),isobaric bupivacaine,hyperbaric bupivacaine,Significantly decreased,"Difference of BIS from baseline was not significant between two groups at most time points except for the 45th minute after injection that it was 5.9 ± 9 vs. 2.7 ± 4.6 for hyperbaric and isobaric bupivacaine, respectively (p = 0.047).",4748:5010, 3525038 ,23264794,Unavailable
 4173564 ,heart rate (HR),nalbuphine 0.2 mg/kg,pentazocine 0.5 mg/kg,Significantly increased,"On intergroup comparison these changes were statistically insignificant (P &gt; 0.05) until IAETI, but became statistically highly significant (P &lt; 0.01) towards the end of the study period [Table 3].",11778:12054, 4173564 ,25885977,Unavailable
 4173564 ,blood pressure (BP),nalbuphine 0.2 mg/kg,pentazocine 0.5 mg/kg,Significantly decreased,"On intergroup comparison, these changes were statistically insignificant (P &gt; 0.05) until 5 min after study drugs, but became highly statistically significant a (P &lt; 0.01) at IAETI and statistically significant (P &lt; 0.05) toward the end of the study period [Table 3].",13763:13974, 4173564 ,25885977,Unavailable
 4173564 ,Rate pressure product (RPP),nalbuphine 0.2 mg/kg,pentazocine 0.5 mg/kg,Significantly decreased,"On intergroup comparison, except for the initial 1 min after the study drugs all the changes were statistically highly significant (P &lt; 0.01) [Table 3].",13763:13974, 4173564 ,25885977,Unavailable
 2526991 ,the mean WOMAC pain,C = Garcinia kola,A = Placebo,Significantly decreased,The change in the mean WOMAC pain VAS after six weeks of G. kola was significantly reduced compared to the placebo (p &lt; 0.001).,5765:5912, 2526991 ,18667082,Unavailable
 2526991 ,the mean WOMAC pain,C = Garcinia kola,"B = Naproxen,  D = Celebrex",No significant difference,Multiple comparisons of the mean VAS pain change of G. kola group was not lowered significantly against the naproxen and celebrex groups (p &gt; 0.05).,5913:6081, 2526991 ,18667082,Unavailable
 2526991 ,The duration of therapeutic effect,C = Garcinia kola,placebo,Significantly increased,The duration of therapeutic effect of Garcinia kola was longer than the placebo (p &gt; 0.001).,6250:6366, 2526991 ,18667082,Unavailable
 2526991 ,The duration of therapeutic effect,C = Garcinia kola,"B = Naproxen, D = Celebrex",No significant difference,The mean change in mobility of the G. kola group when compared to the active comparators was not significantly better (p &lt; 0.05).,6598:6748, 2526991 ,18667082,Unavailable
 2526991 ,The mean change of knee joint stiffness,C = Garcinia kola,placebo,Significantly decreased,The mean change of knee joint stiffness (p &lt; 0.001) and the change of mean WOMAC score (p &lt; 0.001) were improved on Garcinia kola as compared to the placebo.,6747:6931, 2526991 ,18667082,Unavailable
 5976307 ,"induction time, total procedure time  and awake time",etomidate,propofol based on midazolam,No significant difference,"Sedation-related outcomes such as induction time (P = .833), total procedure time (P = .111) and awake time (P = .070) were not different (Table 2).",20277:20515, 5976307 ,29768328,Unavailable
 5976307 ,The incidence rate of all cardiopulmonary adverse events,etomidate,propofol based on midazolam,Significantly decreased,The incidence rate of all cardiopulmonary adverse events was significantly higher in the propofol group (72.6%) than in the etomidate group (54.8%) (P = .040) (Fig. 2).,21169:21392, 5976307 ,29768328,Unavailable
 5976307 ,The incidence rate of vital sign fluctuation (VSF),etomidate,propofol based on midazolam,Significantly decreased,The incidence rate of VSF was significantly higher in the propofol group (50.0%) than in the etomidate group (27.4%) (P = .010).,22041:22240, 5976307 ,29768328,Unavailable
 5976307 ,the incidence rate of adverse events disturbing the procedure,etomidate,propofol based on midazolam,Significantly increased,"In contrast, the incidence rate of adverse events disturbing the procedure was significantly higher in the etomidate group (25.8%) than in the propofol group (8.1%) (P = .008).",21846:22040, 5976307 ,29768328,Unavailable
 5976307 ,The incidence rate of myoclonus,etomidate,propofol based on midazolam,Significantly increased,The incidence rate of myoclonus was significantly higher in the etomidate group (16.1%) than in the propofol group (1.6%) (P = .004) (Table 3).,22041:22240, 5976307 ,29768328,Unavailable
 5707413 ,Serum testosterone (ST),"PORT, prostate-only radiation therapy","WPRT, whole-pelvis radiation therapy",No significant difference,The difference in the median change in ST between the WRPT and PORT groups was not statistically significant at either the end of RT (P = .216) or 3 months after RT (P = .277).,27963:28173, 5707413 ,29204528,Unavailable
 5777682 ,Mean pain,Lozenge group,Control group,Significantly decreased,"Mean pain was 35 mm in patients in the Lozenge group and 51 mm in patients in the Control group (difference between groups −16 mm, 95% CI: −26 to −6, P = 0.0032) (Table 2 and Fig. 3).",26158:26434, 5777682 ,29392234,Unavailable
 5777682 ,intensity of oral cavity pain,Lozenge group,Control group,Significantly decreased,"When pain for the Lozenge group was measured as the mean pain score 60 minutes after lozenge administration, the intensity of oral cavity pain was significantly lower in the Lozenge group than in the Control group (mean difference: −18 mm, 95% CI: −27 to −10, P = 0.0002).",27375:27664, 5777682 ,29392234,Unavailable
 5777682 ,Pharyngeal mucositis pain,Lozenge group,Control group,No significant difference,"Pharyngeal mucositis pain did not show a significant difference between groups (P = 0.0630) (Table 2, Fig. 4).",27665:27868, 5777682 ,29392234,Unavailable
 5777682 ,the mean pain score immediately before the next lozenge,Lozenge group,Control group,Significantly decreased,"When pain for the Lozenge group was measured as the mean pain score immediately before the next lozenge, pain was significantly lower in the Lozenge group than in the Control group for both the oral cavity (mean difference: −15 mm, 95% CI: −23 to −7, P = 0.0004) and the pharynx (mean difference: −11 mm, 95% CI: −22 to 0, P = 0.0452) (Table 2, Fig. 5).",28684:29147, 5777682 ,29392234,Unavailable
 3917487 ,Average changes in the records,400 ml probiotic yogurt (intervention group),ordinary yogurt (control group),No significant difference,"Average changes in the records of the intervention and control groups were 3.9 and 0.5 seconds, respectively(p= 0.22).",5116:5235, 3917487 ,24791124,Unavailable
 3917487 ,complained of dyspnea,400 ml probiotic yogurt (intervention group),ordinary yogurt (control group),Significantly decreased,The intervention group complained of dyspnea for 2.4 days and the value for the controlwas 4.4 days (p=0.024). Values for ear pain were 0.5 and 1.6 days (p=0.008) respectively.,5235:5411, 3917487 ,24791124,Unavailable
 3917487 ,Values for ear pain,400 ml probiotic yogurt (intervention group),ordinary yogurt (control group),Significantly decreased,Values for ear pain were 0.5 and 1.6 days (p=0.008) respectively.,5346:5412, 3917487 ,24791124,Unavailable
 3917487 ,The average numberof episodes of respiratory infection,400 ml probiotic yogurt (intervention group),ordinary yogurt (control group),Significantly decreased,"The average numberof episodes of respiratory infection in the intervention group was 0.9 day, which was statistically fewer than thatin the control group (1.4 days), P=0.009.",5412:5586, 3917487 ,24791124,Unavailable
 5976950 ,stratification and minimisation criteria,1 g intravenous tranexamic acid bolus followed by an 8 h infusion of 1 g tranexamic acid,placebo,No significant difference,"There was no difference in the distribution (shift) in the mRS at day 90 after adjustment for stratification and minimisation criteria, with an adjusted odds ratio (aOR) of 0·88 (95% CI 0·76–1·03, p=0·11; table 2 and figure 2).",40858:41167, 5976950 ,29778325,Unavailable
 5976950 ,proportional odds assumption,1 g intravenous tranexamic acid bolus followed by an 8 h infusion of 1 g tranexamic acid,placebo,No significant difference,A formal goodness-of-fit test showed no evidence that the proportional odds assumption was violated (p=0·97).,41166:41276, 5976950 ,29778325,Unavailable
 5976950 ,proportion of participants who were dead or dependent at day 90,1 g intravenous tranexamic acid bolus followed by an 8 h infusion of 1 g tranexamic acid,placebo,No significant difference,"In a sensitivity analysis, we detected no difference between the groups in the proportion of participants who were dead or dependent at day 90 (mRS &gt;3) and the aOR was 0·82 (95% CI 0·65–1·03, p=0·08; table 2).Figure 1",41276:41560, 5976950 ,29778325,Unavailable
 5976950 ,haematoma expansion at day 2,1 g intravenous tranexamic acid bolus followed by an 8 h infusion of 1 g tranexamic acid,placebo,Significantly decreased,"Fewer participants had haematoma expansion at day 2 in the tranexamic acid group (265 [25%] of 1054 participants) than in the placebo group (304 [29%] of 1058 participants; aOR 0·80, 95% CI 0·66 to 0·98, p=0·0300).",49913:50128, 5976950 ,29778325,Unavailable
 5976950 ,The mean increase in haematoma volume,1 g intravenous tranexamic acid bolus followed by an 8 h infusion of 1 g tranexamic acid,placebo,Significantly decreased,"The mean increase in haematoma volume from baseline to 24 h was also less in the tranexamic acid group (3·72 mL, SD 15·9) than in the placebo group (4·90 mL, 16·0; adjusted mean difference −1·37, 95% CI −2·71 to −0·04, p=0·0432).",50128:50357, 5976950 ,29778325,Unavailable
 5604064 ,"cardiorespiratory fitness, social participation, and BMI","closed-skill (bike riding or brisk walking/jogging),","control group,  open-skill (table tennis)",No significant difference,"Even when the post-exercise cardiorespiratory fitness, social participation, and BMI were controlled for, the results of ANCOVA on the ARs in the 2-back condition still indicated a significant difference in the three groups [F(2, 58) = 9.90, p &lt; 0.001], with post-hoc analysis indicating that closed-skill group performed significantly better than the open-skill (closed-skill vs. open-skill: p &lt; 0.001) and control (closed-skill vs. control: p &lt; 0.001) groups after the exercise intervention",61973:62567, 5604064 ,28959200,Unavailable
 5604064 ,P3 amplitudes,"closed-skill (bike riding or brisk walking/jogging), open-skill (table tennis)","control group,  ",Significantly increased,"with post-hoc analysis showing that both open- (4.02 μV) and closed-skill (4.52 μV) groups showed significantly larger P3 amplitudes as compared to the control group (2.17 μV) after the intervention (open-skill vs. control: p = 0.032; closed-skill vs. control: p = 0.005); and (3) both the open- and closed-skill groups exhibited significantly larger P3 amplitudes [open-skill: F(1, 21) = 7.59, p = 0.012; closed-skill: F(1, 20) = 16.83, p = 0.001] across all three conditions and electrodes after the intervention relative to baseline.",72945:73622, 5604064 ,28959200,Unavailable
 5496216 ,perfect queries, English version of the query builder,French  version of the query builder,Significantly decreased,There were significantly more perfect queries in the French group vs. the English group (respectively 37.9% vs. 17.9%; p &lt; 0.01).,7125:7271, 5496216 ,28673304,Unavailable
 5496216 ,time to build each query, English version of the query builder,French  version of the query builder,Significantly increased,"It took significantly more time for the members of the English group than the members of the French group to build each query, respectively 194&nbsp;sec vs. 128&nbsp;sec; p &lt; 0.01.",7272:7462, 5496216 ,28673304,Unavailable
 3687883 ,"The postoperative nausea and vomiting (PONV) rate after 1-2 h in the recovery room, after 2-12 and 12-24 h in the ward","cetirizine, ondansetron",placebo,Significantly decreased,"The postoperative nausea and vomiting (PONV) rate after 1-2 h in the recovery room, after 2-12 and 12-24 h in the ward in placebo, and both groups of cetirizine and ondansetron were 50%, 21%, and 11%, respectively while the difference was significant (P value &lt; 0.05).",4508:4793, 3687883 ,23798943,Unavailable
 5805208 ,clinical duration of rocuronium,Group A (based on  fat-free mass (FFM)),Group B (based on  real body weight (RBW)),No significant difference,Patients in Group B had a longer clinical duration of rocuronium than those in Group A;,15326:15413, 5805208 ,28627976,Unavailable
 5805208 ,"intubation condition as assessed by the Cooper score, in the first-pass intubation success rate",Group A (based on  fat-free mass (FFM)),Group B (based on  real body weight (RBW)),No significant difference,No significant difference was observed between the two groups in the intubation condition as assessed by the Cooper score or in the first-pass intubation success rate (Table 2). Table 2.,15616:15953, 5805208 ,28627976,Unavailable
 4272222 ,Summed pain intensity difference over 48 hours,sufentanil sublingual tablet system (SSTS) group,placebo group,Significantly increased,"Summed pain intensity difference over 48 hours was significantly higher in the SSTS group than in the placebo group (least squares mean [SEM], 105.60 [10.14] vs 55.58 [13.11]; P = 0.001).",5068:5273, 4272222 ,25318408,Unavailable
 4272222 ,Mean  summed pain intensity difference (SPID) and total pain relief (TOTPAR) scores at all time points from 1 hour (SPID) or 2 hours (TOTPAR) until 72 hours,sufentanil sublingual tablet system (SSTS) group,placebo group,Significantly increased,Mean SPID and TOTPAR scores were significantly higher in the SSTS group at all time points from 1 hour (SPID) or 2 hours (TOTPAR) until 72 hours (P &lt; 0.05).,5273:5446, 4272222 ,25318408,Unavailable
 4272222 ,global assessment ratings of good or excellent,sufentanil sublingual tablet system (SSTS) group,placebo group,Significantly increased,"In the SSTS group, patient global assessment and health care provider global assessment ratings of good or excellent were greater than placebo at all time points (P &lt; 0.01).",5446:5640, 4272222 ,25318408,Unavailable
 4272222 ,"Safety parameters, including adverse events and vital signs",sufentanil sublingual tablet system (SSTS) group,placebo group,No significant difference,"Safety parameters, including adverse events and vital signs, were similar for SSTS and placebo.",5641:5736, 4272222 ,25318408,Unavailable
 3700147 ,The mean scores of tenderness,diclofenac sodium pre operatively,placebo pre operatively,No significant difference,"The mean scores of tenderness in our study at 1-hour post-operatively in the experimental group and control group are 1.86 and 2.16, respectively, with P-value of 0.099 which is less significant;",14238:14450, 3700147 ,23833488,Unavailable
 3700147 ,the mean scores for 3 days post-operatively,diclofenac sodium pre operatively,placebo pre operatively,Significantly decreased,"however, the mean scores for 3 days post-operatively for the experimental group and control group are 3.5 and 5.1, respectively, with P-value of 0.001 which is highly significant.",14451:14647, 3700147 ,23833488,Unavailable
 3700147 ,Score mean of tenderness on the 6th post-operative day,diclofenac sodium pre operatively,placebo pre operatively,Significantly decreased,Score mean of tenderness on the 6th post-operative day for experimental group is 1.6 and for control group is 3.6 with P value of 0.001 which shows a highly significant difference.,14648:14856, 3700147 ,23833488,Unavailable
 3700147 ,trismus mean score at 1-hour post-operatively,diclofenac sodium pre operatively,placebo pre operatively,Significantly decreased,"And for trismus mean score at 1-hour post-operatively for experimental group is 0.36 and control group 0.66 with P value of 0.02, which shows a significant difference.",14857:15041, 3700147 ,23833488,Unavailable
 3636834 ,post-operative pain,combination of hand files,rotary protaper system,No significant difference,"There was no statistically significant difference (P = 0.338) in post-operative pain, between both the groups at all the three time intervals [Table 5].",13591:13799, 3636834 ,23633809,Unavailable
 4301654 ,patients were independent,Early supported discharge (ESD) 1 and ESD 2,treatment as usual,Significantly increased,More patients in the pooled ESD groups were independent at 3 (p = 0.086) and 6&nbsp;months (p = 0.122) compared to controls and there also was a significant difference in 3&nbsp;month change score between them (p = 0.049).,6379:6592, 4301654 ,25528166,Unavailable
 4301654 ,patients were independent,Early supported discharge (ESD) 1 ,ESD 2,No significant difference,There were no differences between the two ESD groups. Length of stay in the stroke unit was 11&nbsp;days in all groups.,6592:6706, 4301654 ,25528166,Unavailable
 4301654 ,Patient satisfaction,"Early supported discharge (ESD) 1 , ESD 2",control,No significant difference,"Patient satisfaction was rated better in ESD groups 1 and 2 at 3&nbsp;months (1.32 and 1.49) compared to the control group (1.71), though not significantly (p = 0.115).",31686:31849, 4301654 ,25528166,Unavailable
 4590707 ,quality of sleep index (PSQI),1 or 3&nbsp;mg melatonin,placebo,No significant difference,"According to quality of sleep index (PSQI), both groups had a good quality of sleep at baseline (5 in placebo group vs. 4.5 in melatonin group). No significant changes between groups were found in response to treatment.",29555:29774, 4590707 ,26424587,Unavailable
 4590707 ,poor quality sleep/insomnia,1 or 3 mg melatonin,placebo,Significantly decreased,"Restricting analyses to study subjects with a score above normal range, i.e. associated with a poor quality sleep/insomnia, this was reported more frequently by women in the placebo group compared with women in the melatonin group (49 vs. 23&nbsp;%, respectively, p = 0.02) (Table&nbsp;1).",29775:30112, 4590707 ,26424587,Unavailable
 4590707 ,insomnia,1 or 3 mg melatonin,placebo,Significantly decreased,"In response to treatment, the women in the melatonin group rated with insomnia reduced their score by −37.5&nbsp;% (IQR: −64.5;−15.5) compared with −13.3&nbsp;% (IQR: −32.1;9.4) in the placebo group (p = 0.08 for between group changes).Table 4",30113:30392, 4590707 ,26424587,Unavailable
 4590707 ,Heart rate and blood pressure,1 or 3 mg melatonin,placebo,No significant difference,"Compared with placebo, melatonin caused a non-significantly decrease in systolic (5&nbsp;mmHg, p = 0.12) and diastolic (2&nbsp;mmHg, p = 0.40) blood pressure (Fig.&nbsp;1). Heart rate did not change in response to treatment (data not shown).Fig. 1",33925:34252, 4590707 ,26424587,Unavailable
 3525331 ,the mean reduction of migraine days,Chinese herbal ChuanXiong Ding Tong herbal formula granule (CXDT-HFG),placebo,Significantly decreased,"In other words, the mean reduction of migraine days in the CXDT-HFG group were 3.04 days, compared with 2.20 days in the placebo group at 12 weeks (95% CI, −4.13 to −1.93 versus 95% CI, −3.74 to −0.66; P = 0.033)",25481:25710, 3525331 ,23304233,Unavailable
 3525331 ,proportion of patients with a reduction of migraine days by at least 50%,Chinese herbal ChuanXiong Ding Tong herbal formula granule (CXDT-HFG),placebo,Significantly decreased,"And there was significant difference in the proportion of patients with a reduction of migraine days by at least 50% between the CXDT-HFG group and the placebo group at follow-up period (83.7% versus 64.3%, P = 0.014) (Table 1; Figure 2).",25923:26258, 3525331 ,23304233,Unavailable
 3525331 ,frequency of migraine attacks,Chinese herbal ChuanXiong Ding Tong herbal formula granule (CXDT-HFG),placebo,Significantly decreased,"After 12 weeks' treatment, the frequency of migraine attacks of the CXDT-HFG group reduced 2.84 times, while the placebo group reduced 2.67 times (95% CI, −3.35 to −2.33 versus 95% CI, −4.11 to −1.24; P = 0.043).",26467:26697, 3525331 ,23304233,Unavailable
 3525331 ,attack frequency,Chinese herbal ChuanXiong Ding Tong herbal formula granule (CXDT-HFG),placebo,Significantly decreased,"At follow-up period the attack frequency of the CXDT-HFG group reduced 3.08 times from baseline and the placebo group reduced 2.72 times (95% CI, −3.57 to −2.58 versus 95% CI, −4.17 to −1.28; P = 0.033).",26697:26917, 3525331 ,23304233,Unavailable
 3525331 ,"The number of patients using acute pain drugs, such as aspirin, phenacetin, or ibuprofen, etc.",Chinese herbal ChuanXiong Ding Tong herbal formula granule (CXDT-HFG),placebo,No significant difference,"The number of patients using acute pain drugs, such as aspirin, phenacetin, or ibuprofen, etc., has no significant difference between the 2 groups from baseline to follow-up period (P &gt; 0.05) (Table 1; Figure 4).",28029:28341, 3525331 ,23304233,Unavailable
 3672764 ,change in pain in the index joint,subcutaneous (SC) rilonacept 320 mg at baseline plus oral indomethacin 50 mg TID for 3 days followed by 25 mg TID for up to 9 days; ,SC placebo at baseline plus oral indomethacin as above,No significant difference,"Although primary endpoint pain reduction was greater with rilonacept plus indomethacin (-1.55 ± 0.92) relative to indomethacin alone (-1.40 ± 0.96), the difference was not statistically significant (P = 0.33), so formal comparison between monotherapy groups was not performed.",6851:7147, 3672764 ,23375025,Unavailable
 3672764 ,Pain reduction,subcutaneous (SC) rilonacept 320 mg at baseline plus oral indomethacin 50 mg TID for 3 days followed by 25 mg TID for up to 9 days; ,SC placebo at baseline plus oral indomethacin as above,No significant difference,"Pain reduction over the 72-hour period with rilonacept alone (-0.69 ± 0.97) was less than that in the other groups, but pain reduction was similar among groups at 72 hours.",7148:7320, 3672764 ,23375025,Unavailable
 3672764 ,Pain reduction according to the numerical rating scale (NRS),SC rilonacept 320 mg at baseline plus oral placebo,SC placebo at baseline plus oral indomethacin as above,Significantly increased,"While the NRS change with rilonacept plus indomethacin was similar to that of indomethacin alone (P = 0.2533), the ad hoc analysis significantly favored indomethacin monotherapy relative to rilonacept monotherapy (P &lt; 0.0001).",27022:27282, 3672764 ,23375025,Unavailable
 3672764 ,high sensitivity C-reactive protein (hs-CRP),subcutaneous (SC) rilonacept 320 mg at baseline plus oral indomethacin 50 mg TID for 3 days followed by 25 mg TID for up to 9 days,SC rilonacept 320 mg at baseline plus oral placebo,Significantly increased,". At day 4, these reductions were significantly greater with rilonacept plus indomethacin (P &lt; 0.0001) and rilonacept monotherapy (P = 0.0142) relative to indomethacin monotherapy.",29079:29296, 3672764 ,23375025,Unavailable
 4372550 ,the intubation time,lightwand only; lightwand under direct laryngoscopy;,lightwand with WEI JET under direct laryngoscopy,Significantly decreased,"Although the intubation time was significantly longer in the WEI group (110.8±18.3 s) than the LW group (63.3±27.5 s, p = 0.000) or DL group (66.7±29.4 s, p = 0.000)",29616:29764, 4372550 ,25803435,Unavailable
 4372550 ,successful tracheal intubation attempts,lightwand only; ,lightwand with WEI JET under direct laryngoscopy,Significantly increased,"The WEI JET significantly reduced successful tracheal intubation attempts compared to the LW group (1.0±0 VS. 1.21±0.4, p = 0.043).",29616:29764, 4372550 ,25803435,Unavailable
 4372550 ,successful tracheal intubation attempts,lightwand only; ,lightwand under direct laryngoscopy;,No significant difference,There was no difference in time taken for intubation and number of intubation attempts between LW group and DL group (Table 2).,29765:29959, 4372550 ,25803435,Unavailable
 4188038 ,ADHD symptoms and a computerized continuous performance functions test. ,"alpha-linolenic acid (ALA), a medium-chained, plant-based omega-3 fatty acid (18:3)",placebo,No significant difference,No between-group difference was found in the changes of the various measures of ADHD symptoms throughout the study period.,6425:6548, 4188038 ,25339885,Unavailable
 3686162 ,Delirium,mobilisation and orientation in addition to usual care,usual care alone,No significant difference,Delirium occurred in 4.9% (95% CI 2.3% to 7.3%) of the intervention group (15/305) and in 5.9% (20/339; 95% CI 3.8% to 9.2%) of the group receiving usual care. No difference was observed between groups (χ2; p=0.5).,7879:8104, 3686162 ,23794558,Unavailable
 3686162 ,survival,mobilisation and orientation in addition to usual care,usual care alone,No significant difference,"Similarly, survival analyses found no difference between the groups (χ20.49; p=0.5 by the log rank test, see figure 2).",31871:32055, 3686162 ,23794558,Unavailable
 3686162 ,"duration of delirium,  length of stay",mobilisation and orientation in addition to usual care,usual care alone,No significant difference,Cox regression methods did not reveal any effect of the intervention on duration of delirium (HR 1.2; 95% CI 0.6 to 2.5; p=0.5) or on length of stay (HR 1.08; 95% CI 0.9 to 1.3; p=0.3).,32161:32347, 3686162 ,23794558,Unavailable
 3686162 ,Rates of delirium,mobilisation and orientation in addition to usual care,usual care alone,No significant difference,"Rates of delirium were not different between the groups (intervention, 15/249 vs control 21/280; p=0.6).",32590:32694, 3686162 ,23794558,Unavailable
 4301466 ,clinical responses,Diosmectite group (diosmectite and mesalazine),Placebo group (placebo and mesalazine),No significant difference,There was no significant difference in clinical responses between the Diosmectite group and the Placebo group (P&gt;0.05).,19665:19784, 4301466 ,25582578,Unavailable
 4301466 ,The defecation frequency,Diosmectite group (diosmectite and mesalazine),Placebo group (placebo and mesalazine),No significant difference,"The defecation frequency of the Diosmectite group was lower than in the Placebo group, but the difference was not significant (P=0.80).",21031:21166, 4301466 ,25582578,Unavailable
 5951872 ,"experienced symptoms, concerns about the illness",survivorship care plans (SCPs),‘usual care.’,Significantly increased,"Significantly more endometrial patients in the SCP care arm compared to the usual care arm reported high experienced symptoms (18% vs 9%, p = 0.02) and high concerns about the illness (16% vs 7%, p = 0.02).",37413:37653, 5951872 ,29511906,Unavailable
 5951872 ,emotional impact of the disease,survivorship care plans (SCPs),‘usual care.’,No significant difference,"No significant differences between the trial arms were found in emotional impact of the disease (19% vs 14%, p = 0.27) in endometrial cancer",37654:37811, 5951872 ,29511906,Unavailable
 5951872 ,trust that the treatment would help to cure the illness,survivorship care plans (SCPs),‘usual care.’,No significant difference,"or low trust that the treatment would help to cure the illness (16% vs 14%, p = 0.60) in ovarian cancer.",37813:37935, 5951872 ,29511906,Unavailable
 5799990 ,periapical healing evaluated by Kruskal–Wallis test,"Group I was medicated with ApexCal paste and obturated using the standardized protocol in second visit 7–10 days later. subgroup IA and subgroup IIA, obturation was done using Apexit Plus sealer","Group II was obturated at the first visit. subgroup IB and subgroup IIB, AH Plus sealer was used",No significant difference,"When scores obtained by radiographic evaluation were submitted to Kruskal–Wallis test, there was no statistically significant difference in periapical healing between teeth in subgroups IA, IB, IIA, and IIB at the baseline, 1-, 3-, or 6-month evaluation with P = 0.342, 0.839, 0.218, and 0.780, respectively.",NaN:NaN, 5799990 ,29430096,Unavailable
 5799990 ,periapical healing evaluated by one-way ANOVA test,"Group I was medicated with ApexCal paste and obturated using the standardized protocol in second visit 7–10 days later. subgroup IA and subgroup IIA, obturation was done using Apexit Plus sealer","Group II was obturated at the first visit. subgroup IB and subgroup IIB, AH Plus sealer was used",No significant difference,"Results when evaluated by one-way ANOVA test revealed no significant difference between periapical healing of different subgroups from preoperative periapical status to immediate postoperative, 1-, 3-, and 6-month follow-up with P = 0.104, 0.368, 0.672, and 0.317, respectively [Table 1 and Graph 1].",NaN:NaN, 5799990 ,29430096,Unavailable
 5411411 ,The mean cecal intubation time,Group I included patients who were examined using endoscopes equipped with responsive insertion technology (RIT),group II included patients who were examined using conventional variable stiffness colonoscopies,Significantly decreased,The mean cecal intubation time was 209&nbsp;s in group I and 224&nbsp;s in group II (p&nbsp;&lt;&nbsp;0.05).,6826:6928, 5411411 ,27631316,Unavailable
 5411411 ,loop formation,Group I included patients who were examined using endoscopes equipped with responsive insertion technology (RIT),group II included patients who were examined using conventional variable stiffness colonoscopies,Significantly decreased,Increased loop formation was observed upon endoscope insertion in group II (1.7 vs. 1.35) (p&nbsp;&lt;&nbsp;0.05),6929:7050, 5411411 ,27631316,Unavailable
 5411411 ,manual pressure to the abdomen,Group I included patients who were examined using endoscopes equipped with responsive insertion technology (RIT),group II included patients who were examined using conventional variable stiffness colonoscopies,Significantly decreased,required more manual pressure to the abdomen (2.2 vs. 1.7) (p&nbsp;=&nbsp;0.001).,7054:7145, 5411411 ,27631316,Unavailable
 5411411 ,discomfort and pain,Group I included patients who were examined using endoscopes equipped with responsive insertion technology (RIT),group II included patients who were examined using conventional variable stiffness colonoscopies,Significantly decreased,"In group I, less discomfort and pain, as graded on a VAS (2.3 vs. 2.6), were noted.",7146:7229, 5411411 ,27631316,Unavailable
 5980435 ,incidence of transfusion reactions,received cross‐match and blood type compatible pRBCs,noncross‐matched blood type compatible pRBCs,No significant difference,"No significant difference in incidence of transfusion reactions between cross‐matched and noncross‐matched groups (CM+ 4/24; 17%, CM– 7/24; 29%, P = .16).",6153:6324, 5980435 ,29573055,Unavailable
 5980435 ,packed cell volume,received cross‐match and blood type compatible pRBCs,noncross‐matched blood type compatible pRBCs,No significant difference,"No significant difference between groups in mean change in PCV after transfusion scaled to dose of pRBCs administered at any time point after transfusion (immediate: CM+ 0.62 ± 0.59, CM– 0.75 ± 0.48, P = .41; 1 hour: CM+ 0.60 ± 0.66, CM– 0.74 ± 0.53, P = .43; 12 hours: CM+ 0.70 ± 0.55, CM– 0.66 ± 0.60, P = .81; 24 hours: CM+ 0.64 ± 0.71, CM– 0.55 ± 0.48, P = .70).",6325:6759, 5980435 ,29573055,Unavailable
 5827295 ,visual acuity’s improvement,continuous occlusion, split part-time occlusion,No significant difference,Best corrected visual acuity’s improvement was comparable between continuous and split part-time occlusion (0.20±0.27 vs 0.21±0.25; p = 0.79).,4087:4246, 5827295 ,29515681,Unavailable
 5827295 ,visual acuity of moderate and severe amblyopia,continuous occlusion, split part-time occlusion,No significant difference,There was no significant difference between the visual acuity of moderate and severe amblyopia in both groups (p = 0.64; p = 0.52).,9164:9314, 5827295 ,29515681,Unavailable
 5986584 ,weight loss,WL program consisting of standard structured energy-restricted meal plans (1200–1500 Kcal/day) and physical activity,control group,Significantly increased,Subjects in the intervention group had significantly more weight loss (WL:−3.7 ± 0.5 kg; Control:−1.6 ± 0.5 kg; p=0.007) than the control group,6579:6722, 5986584 ,29203893,Unavailable
 5986584 ,total fat mass,WL program consisting of standard structured energy-restricted meal plans (1200–1500 Kcal/day) and physical activity,control group,Significantly decreased,total fat mass was significantly reduced (WL:−2.1 ± 0.4; Control: 0.1 ± 0.3; p=0.015).,6727:6813, 5986584 ,29203893,Unavailable
 5986584 ,apoptotic or proliferation index,WL program consisting of standard structured energy-restricted meal plans (1200–1500 Kcal/day) and physical activity,control group,No significant difference,There was no significant difference in apoptotic or proliferation index between the groups.,6814:6905, 5986584 ,29203893,Unavailable
 5986584 ,triglyceride and insulin level,WL program consisting of standard structured energy-restricted meal plans (1200–1500 Kcal/day) and physical activity,control group,Significantly decreased,"Among the other biomarkers, triglyceride and insulin levels were significantly decreased in the WL compared to the control group.",6906:7035, 5986584 ,29203893,Unavailable
 5773985 ,mean volume of both the solutions used,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 μg buprenorphine (3 μg/kg)in group II,No significant difference,The difference in the mean volume of both the solutions used was found to be statistically nonsignificant (P = 0.84).,15272:15406, 5773985 ,29386814,Unavailable
 5773985 ,subjective and objective onset of action,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 μg buprenorphine (3 μg/kg)in group II,No significant difference,"Statistically, no significant difference was observed between both groups regarding subjective (P = 0.79) and objective onset of action (P = 0.81).",15770:15951, 5773985 ,29386814,Unavailable
 5773985 ,duration of surgical procedure,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 μg buprenorphine (3 μg/kg)in group II,No significant difference,"Similarly, there was no significant difference in the duration of surgical procedure (P = 0.76)",16133:16245, 5773985 ,29386814,Unavailable
 5773985 ,the mean duration of postoperative analgesia,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 μg buprenorphine (3 μg/kg)in group II,Significantly decreased,"However, the mean duration of postoperative analgesia in bupivacaine group (508.92 ± 63.30 min) was observed to be quite less than buprenorphine combination group (1840.84 ± 819.51 min), and value was found to be highly significant statistically (P &lt; 0.001) [Table 2].",16442:16769, 5773985 ,29386814,Unavailable
 5773985 ,number of analgesic tablets,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 μg buprenorphine (3 μg/kg)in group II,Significantly increased,The difference between both the anesthetic solutions regarding number of analgesic tablets was found to be statistically significant (P = 0.006) [Table 3].,17271:17482, 5773985 ,29386814,Unavailable
 1190172 ,time to response,covering letter with either a computer printed signature,covering letter a hand written signature,No significant difference,"Kaplan-Meier survival analysis was performed on time to response and no difference between the groups was detected (Log rank = 0.72, p = 0.39; Figure 2).",9797:9987, 1190172 ,16091137,Unavailable
 5771543 ,CGI-I response rate,fluoxetine,placebo,Significantly increased,"At week 8, the CGI-I response rate for fluoxetine (78.2%) was significantly greater compared with placebo (62.6%; p = 0.017).",34350:34492, 5771543 ,29189044,Unavailable
 5771543 ,CGI-I response rate,desvenlafaxine,placebo,No significant difference,"Week 8 CGI-I response rate for desvenlafaxine (68.7%) was also greater than placebo, although this comparison did not reach statistical significance (p = 0.343).",34493:34671, 5771543 ,29189044,Unavailable
 5771543 ,Treatment-emergent adverse events (TEAEs),"desvenlafaxine, fluoxetine",placebo,No significant difference,There were no statistically significant differences between desvenlafaxine or fluoxetine and placebo in the incidence of any prespecified TEAEs of clinical interest for desvenlafaxine (tier-1 TEAEs) (Supplementary Table S2).,41827:42108, 5771543 ,29189044,Unavailable
 3269419 ,gametocytaemia, CQ+(3 d)AS;,SP+(3 d)AS,Significantly decreased,"By contrast, artesunate seemed as effective when combined with chloroquine as it was when combined with SP (MH-OR = 1.04, P = 0.83).",67431:67563, 3269419 ,22303437,Unavailable
 5722980 ,symptom severity over time,mobile app designed to target agoraphobia (called Agoraphobia Free),mobile app designed to help with symptoms of anxiety in general (called Stress Free).,No significant difference,"Both groups had statistically significant improvements in symptom severity over time (difference –5.97, 95% CI –8.49 to –3.44, P&lt;.001 for Agoraphobia Free and –6.35, 95% CI –8.82 to –3.87, P&lt;.001 for Stress Free), but there were no significant between-group differences on the primary outcome (difference 0.38, 95% CI –1.96 to 3.20, P=.64).",6545:6942, 5722980 ,29175809,Unavailable
 5722980 ,PAS: Panic and Agoraphobia Scale,mobile app designed to target agoraphobia (called Agoraphobia Free),mobile app designed to help with symptoms of anxiety in general (called Stress Free).,No significant difference,We carried out the same linear mixed model analysis (n=142) using each PAS subscale as the dependent variable to examine whether there was a difference between the 2 groups in terms of symptom dimensions. We found no significant interactions between group and time for any of those outcomes (all P&gt;.05).,40329:40649, 5722980 ,29175809,Unavailable
 3544627 ,"hunger at 5, 10, 15, 20 min",slow eating, fast eating ,Significantly increased,"Post hoc testing revealed that in the slow condition, hunger was significantly higher at 5, 10, 15, and 20min (p &lt; 0.001) and was significantly lower at 60min (p = 0.003) compared with the fast condition, as shown in Figure 2A.",28896:29173, 3544627 ,23171246,Unavailable
 3544627 ,hunger at 60 min, slow eating, fast eating,Significantly decreased,"Post hoc testing revealed that in the slow condition, hunger was significantly higher at 5, 10, 15, and 20min (p &lt; 0.001) and was significantly lower at 60min (p = 0.003) compared with the fast condition, as shown in Figure 2A.",28896:29173, 3544627 ,23171246,Unavailable
 3544627 ,"desire-to-eat at 5, 10, 15, 20 min", slow eating, fast eating,Significantly increased,"Post hoc testing revealed that in the slow condition, desire-to-eat was significantly higher at 5, 10, 15, and 20min (p &lt; 0.001) and tended to be lower at 60min (p = 0.008) compared with the fast condition, as shown in Figure 2B.",29761:30039, 3544627 ,23171246,Unavailable
 3544627 ,desire-to-eat at 60 min, slow eating, fast eating,Significantly decreased,"Post hoc testing revealed that in the slow condition, desire-to-eat was significantly higher at 5, 10, 15, and 20min (p &lt; 0.001) and tended to be lower at 60min (p = 0.008) compared with the fast condition, as shown in Figure 2B.",29761:30039, 3544627 ,23171246,Unavailable
 3544627 ,"satiety at 5, 10, 15, 20 min",  fast eating, slow eating,Significantly increased,"Post hoc testing revealed that in the slow condition, desire-to-eat was significantly higher at 5, 10, 15, and 20min (p &lt; 0.001) and tended to be lower at 60min (p = 0.008) compared with the fast condition, as shown in Figure 2B.",29761:30039, 3544627 ,23171246,Unavailable
 3544627 ,satiety at 60 min,  fast eating, slow eating,Significantly decreased,"Post hoc testing revealed that in the fast condition, satiety was significantly higher at 5, 10, and 15min (p &lt; 0.001) and tended to be lower at 60min (p = 0.017) compared with the slow condition, as shown in Figure 2C.",30675:30943, 3544627 ,23171246,Unavailable
 3646783 ,percentage stained area of versican  and collagen III,30-months inhaled steroids treatment,placebo,Significantly increased,30-Months inhaled steroids increased the percentage stained area of versican (9.6% [CI 0.9 to 18.3%]; p = 0.03) and collagen III (20.6% [CI 3.8 to 37.4%]; p = 0.02) compared to placebo.,10583:10769, 3646783 ,23667615,Unavailable
 4702321 ,Respiratory Symptoms scale,ivacaftor (150&nbsp;mg),placebo,Significantly increased,"Respiratory Symptoms scale with a mean improvement of 5.9 points observed among patients receiving ivacaftor, exceeding the MCID value of 4 points, vs. a mean decline of 2.7 points among those receiving placebo (treatment effect of 8.6 points, P &lt; 0.001) [12].Table 1",22193:22549, 4702321 ,26135562,Unavailable
 4702321 ,"Physical Functioning , Health Perceptions, and Vitality",ivacaftor (150 mg),placebo,Significantly increased,"Differences between treatment groups (favoring ivacaftor) were greatest for Respiratory Symptoms (p &lt; 0.001), Physical Functioning (p = 0.002), Health Perceptions (p = 0.019), and Vitality (p = 0.030).",25789:26061, 4702321 ,26135562,Unavailable
 5747107 ,Hamilton Depression Rating Scale,ESM-I consisting of six weeks of ESM combined with weekly feedback regarding the individual’s positive affective experiences,(iii) treatment as usual only,No significant difference,"At 32&nbsp;weeks, mean HDRS score was three units lower in the ESM-I group than in the control group (after adjustment for baseline HDRS scores), which was statistically imprecise by conventional alpha (Table&nbsp;3; B = −3.1, p = 0.051, intention-to-treat analysis).",42109:42424, 5747107 ,29284448,Unavailable
 5747107 ,symptomatic remission,ESM-I consisting of six weeks of ESM combined with weekly feedback regarding the individual’s positive affective experiences,(iii) treatment as usual only,No significant difference,"There was no evidence that ESM-I participants were more often in symptomatic remission compared with control group participants (OR = 2.65, p = 0.12);",42524:42692, 5747107 ,29284448,Unavailable
 5747107 ,rate of symptomatic remission,ESM-I consisting of six weeks of ESM combined with weekly feedback regarding the individual’s positive affective experiences,"(ii) six weeks of ESM without feedback,",No significant difference,"There was no evidence that ESM-I participants were more often in symptomatic remission compared with control group participants (OR = 2.65, p = 0.12);",42524:42692, 5747107 ,29284448,Unavailable
 3616744 ,relapse (defined as symptom return ≥ 90% of baseline in ADHD Rating Scale (ADHD-RS) total scores and ≥ 2 points on the CGI-Severity [CGI-S] scale),atomoxetine,placebo,Significantly decreased,"At the 9-month study endpoint, 22.3% of subjects who continued with atomoxetine exhibited relapse (defined as symptom return ≥ 90% of baseline in ADHD Rating Scale (ADHD-RS) total scores and ≥ 2 points on the CGI-Severity [CGI-S] scale) compared to 37.9% of those given a placebo (P = 0.002).",19482:19793, 3616744 ,23576871,Unavailable
 3616744 ,symptom relapse,lisdexamfetamine dimesylate (LDX),placebo,Significantly decreased,"During the randomized withdrawal phase, symptom relapse (defined as ≥ 50% increase in ADHD-RS-IV score and an increase in CGI-S rating ≥ 2, indicating deterioration of symptom control) was seen in 8.9% of subjects who continued on LDX, compared with 75% of subjects assigned a placebo (P &lt; 0.0001) (Figure 4).",23170:23547, 3616744 ,23576871,Unavailable
 5986495 ,Plasma glucose and insulin concentrations, a sucrose-sweetened (SUC) drink,"water (WAT), NNS-sweetened (NNS)",Significantly increased,"Plasma glucose and insulin concentrations were significantly higher in SUC at T = 30 min (glucose: t17 = −3.77 and t17= −2.46; insulin: t17 = −3.94 and t17 = −5.11; all p &lt; 0.05) as compared to WAT and NNS, respectively.",38988:39289, 5986495 ,29762471,Unavailable
 5986495 ,Plasma ghrelin concentration, a sucrose-sweetened (SUC) drink,"water (WAT), ",Significantly decreased,"Plasma ghrelin concentration, on the other hand, was significantly lower in SUC, as compared to WAT; this difference being significant at T = 30 min (t15 = −2.77; p &lt; 0.05) and T = 60 min (t15 = −2.48; p &lt; 0.05).",39289:39598, 5986495 ,29762471,Unavailable
 5986495 ,Plasma ghrelin concentration,NNS-sweetened (NNS),"water (WAT), ",No significant difference,No differences were observed between WAT and NNS for any of the parameter kinetics.,39599:39682, 5986495 ,29762471,Unavailable
 5986495 ,Hunger ratings, a sucrose-sweetened (SUC) drink,"water (WAT), NNS-sweetened (NNS)",Significantly decreased,Hunger ratings were lower in SUC as compared with WAT (t17 = −2.71; p &lt; 0.05) and NNS (t17 = −2.66; p &lt; 0.05).,41166:41339, 5986495 ,29762471,Unavailable
 5986495 ,Hunger ratings,NNS-sweetened (NNS),water (WAT),No significant difference,No difference in hunger ratings was found between WAT and NNS (t17 = 0.28; p = ns).,41338:41453, 5986495 ,29762471,Unavailable
 4745960 ,The mean of visual capacity,EX-PRESS P-50 implant,standard trabeculectomy (TBC),Significantly increased,"The mean of visual capacity measured in logarithm of the minimum angle of resolution (logMAR), per group of treatment during the study period (1 day, 1 week, 1 month, 3, 6, and 12 months), showed on the first day a significant difference in visual acuity between the EX-PRESS P-50 and TBC groups, with P=0.049.",14313:14640, 4745960 ,26893540,Unavailable
 4745960 ,Intraocular pressure,EX-PRESS P-50 implant,standard trabeculectomy (TBC),No significant difference,"Finally, pressures were 7–19 mmHg in the control group and 9–18 mmHg in the EX-PRESS P-50 group, with no significant differences (P=0.627; Table 3 and Figure 2).",15785:16063, 4745960 ,26893540,Unavailable
 4745960 ,Surgical success,EX-PRESS P-50 implant,standard trabeculectomy (TBC),No significant difference,"Finally, 80% were still successful with EX-PRESS P-50, while 72.7% with TBC were successful (P=0.867; Table 4 and Figure 3).",16587:16829, 4745960 ,26893540,Unavailable
 4745960 ,Surgical complications,EX-PRESS P-50 implant,standard trabeculectomy (TBC),No significant difference,Neither was there any significant difference found (P=0.405) in the sixth month.,18319:18416, 4745960 ,26893540,Unavailable
 4681154 ,Numeric Rating Scale (NRS) score,group L -  100-ml injections of 0.2&nbsp;% ropivacaine and 0.5&nbsp;mg epinephrine to the surgical region,group S -  SNB with 20&nbsp;ml of 0.375&nbsp;% ropivacaine,Significantly increased,"NRS score changes were greater in group L than in group S (P &lt; 0.01, ANOVA) and greater in group L than in group S at three postoperative time points: 3&nbsp;h (P &lt; 0.01), 6&nbsp;h (P &lt; 0.01), and 12&nbsp;h (P = 0.013; Mann–Whitney U test).",6827:7146, 4681154 ,26669859,Unavailable
 4681154 ,side effects,group L -  100-ml injections of 0.2 ropivacaine and 0.5mg epinephrine to the surgical region,group S -  SNB with 20ml of 0.375% ropivacaine,No significant difference,No other side effects or unanticipated postoperative complications were recognized in either group.,28150:28249, 4681154 ,26669859,Unavailable
 4511442 ,"maximal inspiratory pressure, maximal expiratory pressure, forced vital capacity or rapid shallow breathing index",progressive discontinuation of pressure support ventilation (PSV) with SmartCare™,respiratory physiotherapy–driven weaning,No significant difference,"There was no difference in maximal inspiratory pressure, maximal expiratory pressure, forced vital capacity or rapid shallow breathing index at the beginning of the weaning trial.",7008:7187, 4511442 ,26580673,Unavailable
 4511442 ,pressure support ventilation (PSV)  and positive end-expiratory pressure (PEEP),progressive discontinuation of pressure support ventilation (PSV) with SmartCare™,respiratory physiotherapy–driven weaning,Significantly decreased,"PEEP, VT, FiO2, SpO2, respiratory rate, EtCO2 and P0.1 were similar between the two groups, but PSV was not (median: 8 vs. 10 cmH2O; p =0.007).",7188:7412, 4511442 ,26580673,Unavailable
 4511442 ,Total duration of mechanical ventilation and extubation failure,progressive discontinuation of pressure support ventilation (PSV) with SmartCare™,respiratory physiotherapy–driven weaning,No significant difference,Total duration of mechanical ventilation (3.5 [2.0–7.3] days vs. 4.1 [2.7-7.1] days; p =0.467) and extubation failure (2 vs. 2; p =1.00) were similar between the two groups.,7660:7870, 4511442 ,26580673,Unavailable
 4511442 ,Weaning duration,progressive discontinuation of pressure support ventilation (PSV) with SmartCare™,respiratory physiotherapy–driven weaning,Significantly increased,Weaning duration was shorter in the respiratory physiotherapy–driven weaning group (60 [50–80] minutes vs. 110 [80–130] minutes; p &lt;0.001).,7871:8027, 4511442 ,26580673,Unavailable
 4458006 ,amplitude of whisking,facial nerve transection and subsequent repair either at the main trunk of the nerve (group 1),"2&nbsp;cm distally, at the main bifurcation (group 2)",No significant difference,"There was no statistically significant difference between the two groups at 2, 4, and 6&nbsp;weeks after facial nerve surgery (p &gt; 0.05).",5602:5751, 4458006 ,26003541,Unavailable
 5816600 ,urinary albumin/creatinine ratio (UACR),angiotensin II receptor blocker (ARB)-based antihypertensive therapy,non-ARB therapy,Significantly decreased,"UACR was significantly less in ARB group than in non-ARB group during follow-up period in patients with G3b and/or A3 (P = 0.0003),",7774:7905, 5816600 ,29453374,Unavailable
 5816600 ,"eGFR, plasma BNP levels, and blood pressure",angiotensin II receptor blocker (ARB)-based antihypertensive therapy,non-ARB therapy,No significant difference,"while eGFR, plasma BNP levels, and blood pressure were comparable between ARB and non-ARB groups.",7906:8004, 5816600 ,29453374,Unavailable
 5816600 ,incidence of cardiovascular events,angiotensin II receptor blocker (ARB)-based antihypertensive therapy,non-ARB therapy,Significantly decreased,"In patients with G3b and/or A3, the incidence of cardiovascular events was significantly less in ARB group than in non-ARB group (11 vs 22, respectively) (HR = 0.465: 95%CI = 0.224–0.965; P = 0.040).",7573:7773, 5816600 ,29453374,Unavailable
 4210946 ,identified breast cancer,"targeted gender- and Aboriginal status-sensitive, breast cancer-specific (intervention) messages",compare standard (control) messages,Significantly increased,"Among girls who requested more information (n=119), a significantly greater proportion of girls in the intervention group (27/48, 56%) compared with the control group (14/71, 20%) identified breast cancer as an illness caused by exposure to cigarette smoke (P=.003).",47859:48143, 4210946 ,25271096,Unavailable
 4210946 ,agreed with the statement that being exposed to secondhand smoke (SHS) increases their risk of breast cancer,"targeted gender- and Aboriginal status-sensitive, breast cancer-specific (intervention) messages",compare standard (control) messages,Significantly increased,"a significantly greater proportion of girls in the intervention group (170/194, 87.6%) compared with the control group (244/305, 80.0%) agreed with the statement that being exposed to SHS increases their risk of breast cancer (P=.03).",48202:48454, 4210946 ,25271096,Unavailable
 4752899 ,the percent change in S. japonicum (epg) from screening to 22 weeks gestation,praziquantel (60 mg/kg in split dose),placebo,No significant difference,"There was also a difference between groups in the percent change in S. japonicum (epg) from screening to 22 weeks gestation, though this did not reach statistical significance (−53.11 versus 128.7; P = 0.054).",30752:30998, 4752899 ,26511959,Unavailable
 4752899 ,creatinine,praziquantel (60 mg/kg in split dose),placebo,Significantly increased,"Women in the praziquantel group experienced a significantly higher change in creatinine from pre to post-dosing compared to the placebo group (0.07 versus 0.01 mg/dL, respectively; P = 0.004), however, these were all mild (grade I) elevations.",31976:32236, 4752899 ,26511959,Unavailable
 5983010 ,Macular sensitivity,DHA supplementation group,control group,No significant difference,Macular sensitivity increased from a mean (SD) of 25.9 (2.4) dB at baseline to 27.3 (2.3) dB at 90 days (P=0.030) in the DHA group only (between-group differences P&lt;0.19).,5287:5492, 5983010 ,None,Unavailable
 5983010 ,The macular integrity index,DHA supplementation group,control group,Significantly decreased,The macular integrity index decreased from 71.2 (33.2) at baseline to 63.5 (36.4) at 45 days and to 51.6 (35.9) at 90 days (P=0.002) in the DHA group only (between-group differences P&lt;0.05).,5493:5720, 5983010 ,None,Unavailable
 5735450 ,Cuff pressure and volume achieved in the end of surgery,lignocaine group,air group,Significantly decreased,Cuff pressure and volume achieved in the end of surgery were much higher in air group as compared to lignocaine group (P &lt; 0.05).,4665:4814, 5735450 ,29284875,Unavailable
 5735450 ,incidence of coughing,lignocaine group,air group,Significantly decreased,Significant difference determined by Pearson Chi-square test and Fisher's exact test showed P &lt; 0.05 thereby substantiating the reduced incidence of coughing and POST in L group.,14818:15013, 5735450 ,29284875,Unavailable
 5791588 ,pertussis toxin (PT)-specific PB,"investigational aP (groups: aP1, aP2, and aP4), ","investigational TdaP (groups: T5d2aP1, T5d2aP2, T5d2aP4, T5d4aP1, T5d4aP2, T5d4aP4)",Significantly increased,"Although there were no major differences across the 3 vaccine groups in percentage of participants with measurable frequencies of IgG-secreting PB, there was a significantly higher frequency of PT-specific PB in the high aP dose Tdap group than in the low-dose group (p &lt; 0.0015).",58493:58642, 5791588 ,29172945,Unavailable
 5791588 ,IgG-secreting PB against filamentous hemagglutinin [FHA] antige,licensed TdaP comparator,T5d2aP1 group and T5d2aP4,Significantly increased,the IgG-secreting PB against FHA antigen were higher in the comparator group than in the T5d2aP1 group (p &lt; 0.0004) and T5d2aP4 group (p &lt; 0.0004).,58493:58642, 5791588 ,29172945,Unavailable
 3701988 ,absolute cardiovascular disease (CVD) event reduction,“structured care” with atorvastatin,usual care,Significantly decreased,"the absolute CVD event reduction between “structured” and “usual care” was 16.5% (p &lt; 0.0001), while in the younger patients (mean age 51 ±3 years and 52 ±3 years in the “structured” and “usual care”, respectively) this was 8.5% (p = 0.016);",7013:7131, 3701988 ,23847661,Unavailable
 3701988 ,relative risk reduction (RRR),“structured care” with atorvastatin,usual care,Significantly decreased,relative risk reduction (RRR) 60% (p &lt; 0.0001) vs. 42% respectively (p = 0.001).,7013:7131, 3701988 ,23847661,Unavailable
 1693922 ,quality of life,"docetaxel, cisplatin, 5 FU (TCF)","epirubicin, cisplatin, 5-FU (ECF)",Significantly increased,"However, only the TCF group showed statistically and clinically meaningful improvement in global QOL (P = 0.001).",4171:4284, 1693922 ,17147808,Unavailable
 1693922 ,survival rate,"docetaxel, cisplatin, 5 FU (TCF)","epirubicin, cisplatin, 5-FU (ECF)",Significantly increased,Surgical and pathologic response was better with TCF but there was no difference in survival rate between two groups.,4285:4402, 1693922 ,17147808,Unavailable
 1693922 ,"global QOL , social and emotional functioning, pain  and sleep difficulties","docetaxel, cisplatin, 5 FU (TCF)","epirubicin, cisplatin, 5-FU (ECF)",Significantly increased,"Although in both groups physical functioning improved and pain decreased but only in the TCF group statistically and clinically significant improvement was observed for global QOL (P = 0.001), social (P = 0.03) and emotional functioning (P = 0.004), pain (P = 0.03) and sleep difficulties (P = 0.02).",11210:11510, 1693922 ,17147808,Unavailable
 1693922 ,social functioning  and nausea and vomiting,"docetaxel, cisplatin, 5 FU (TCF)","epirubicin, cisplatin, 5-FU (ECF)",No significant difference,As indicated there were no significant differences between two groups after treatment except for social functioning (P = 0.03) and nausea and vomiting (P = 0.01) in the TCF group.,11678:11857, 1693922 ,17147808,Unavailable
 3540345 ,able to apply the technique,written information as a refresher,watched the video,Significantly increased,The difference observed between those who had seen the video and those who had read up on the technique turned out to be an average of 6.19 points in favour of the first (P&nbsp;&lt;&nbsp;0.05).,6320:6520, 3540345 ,23316461,Unavailable
 3611107 ,BMI,Lactobacillus gasseri BNR17,placebo,Significantly decreased,BMI in the BNR17 group decreased after the 12th week compared with week 0 (-0.5 ± 0.9 kg; P &lt; 0.05).,19042:19142, 3611107 ,23560206,Unavailable
 3611107 ,"total cholesterol, high density lipoprotein, low density lipoprotein (LDL), and triglyceride",Lactobacillus gasseri BNR17,placebo,No significant difference,"All serum lipids including total cholesterol, high density lipoprotein, low density lipoprotein (LDL), and triglyceride showed no significant clinical differences between the two groups.",20057:20243, 3611107 ,23560206,Unavailable
 3611107 ,"systolic or diastolic blood pressure, pulse rate",Lactobacillus gasseri BNR17,placebo,No significant difference,There were no significant changes in systolic or diastolic blood pressure or pulse rate between groups during the study period (Table 4).,20363:20539, 3611107 ,23560206,Unavailable
 5644405 ,The end-pressure difference (intraocular pressure at 60 minutes),filtration surgerie ( trabeculectomy),filtration surgerie (tube),Significantly decreased,The end-pressure difference (intraocular pressure at 60 minutes vs. baseline) was significantly greater in the tube group (5.6 ± 3.6 mmHg; 41% change) than in the trabeculectomy group (3.2 ± 4.7; 23% change; P = 0.03).,4813:5052, 5644405 ,29090048,Unavailable
 3686216 ,moderate/vigorous physical activity (MVPA),"no home access to electronic games, ",home access to traditional electronic games,No significant difference,"Table&nbsp;1 shows that in comparison to traditional games, removal of all electronic games resulted in no significant change in daily MVPA over the whole week.",28924:29086, 3686216 ,23818650,Unavailable
 3686216 ,sedentary time in the after-school period,active input games,home access to traditional electronic games,Significantly decreased,"Furthermore, replacement of traditional games with active input games resulted in a significant decrease in sedentary time in the after-school period of 6.2 min/day (1.4 to 11.1, p=0.012).",30380:30568, 3686216 ,23818650,Unavailable
 4784348 ,perceived benefits,invited to access the e-therapeutic platform (Next.Step) during 12&nbsp;weeks in addition to the standard intervention,standard intervention,No significant difference,"Multiple comparisons showed that, in general, the mean score of perceived benefits at 3&nbsp;months was lower (M = 4.52; SD = .07) than the mean score at 0&nbsp;months (M = 4.48; SD = .06), but there was no significant differences.",21766:22055, 4784348 ,26966545,Unavailable
 3751573 ,improvement in nursing,phase I externship program,phase II corporate-academic cooperation program,Significantly increased,"Students who participated in the corporate-academic cooperation program achieved a statistically significant improvement in nursing competence and retention rates relative to those who participated in the externship program (p &lt; 0.01 and p &lt; 0.05, respectively).",4664:4966, 3751573 ,23945287,Unavailable
 4359698 ,"The root mean square of successive R-R differences calculated for consecutive 30-s windows (rMSSD30s), heart rate recovery (HRR)",cycling maximal cardiopulmonary exercise testing (CPET),the walking and running CPETs,Significantly increased,Both HRR and rMSSD30s were significantly greater during recovery from the cycling CPET compared to the walking and running CPETs (P &lt; 0.001).,5026:5198, 4359698 ,25793148,Unavailable
 4359698 ,"VO2peak, HRpeak, peak oxygen pulse, and energy expenditure",cycling maximal cardiopulmonary exercise testing (CPET),the walking and running CPETs,Significantly decreased,"The VO2peak, HRpeak, peak oxygen pulse, and energy expenditure were significantly higher in the walking and running CPET compared to the cycling CPET. Mean RERmax was significantly higher only during treadmill walking vs. running (P &lt; 0.001),",24936:25231, 4359698 ,25793148,Unavailable
 5758845 ,FAACT ACS,3 g of Sipjeondaebo-tang,placebo,No significant difference,but the changes of FAACT ACS score were not significantly different between the two groups (p = 0.245).,18689:18810, 5758845 ,29441116,Unavailable
 5758845 ,anorexia VAS,3 g of Sipjeondaebo-tang,placebo,No significant difference,but the changes of anorexia VAS were not significantly different between the two groups (p = 0.346). I,19908:20028, 5758845 ,29441116,Unavailable
 5758845 ,"ACTH, cortisol, ghrelin, IL-6, ESR, and CRP",3 g of Sipjeondaebo-tang,placebo,No significant difference,"between-group analysis, the change of ACTH, cortisol, ghrelin, IL-6, ESR, and CRP between baseline and the end of study did not show statistically significant difference (Table 3). In within-group analysis, all clinical laboratory tests did not show significant difference.",20379:20694, 5758845 ,29441116,Unavailable
 5758845 ,qi deficiency scale and blood deficiency scale,3 g of Sipjeondaebo-tang,placebo,No significant difference,"In between-group analysis, the changes of qi deficiency scale and blood deficiency scale between baseline and end of the study did not show statistically significant difference (Table 4).",20788:21016, 5758845 ,29441116,Unavailable
 5758845 ,"systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse, AST, ALT, blood urea nitrogen (BUN), and creatinine",3 g of Sipjeondaebo-tang,placebo,No significant difference,"systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse, AST, ALT, blood urea nitrogen (BUN), and creatinine did not show significant difference between SJDBT group and placebo group (Table 5).",21287:21534, 5758845 ,29441116,Unavailable
 29053 ,Total respiratory heat loss,ventilated with a heated humidifier (HH),ventilated with a hydrophobic heat-moisture exchanger (HME) or a hygroscopic HME,Significantly decreased,Total respiratory heat loss was significantly less with the HH than with either HME (P &lt; 0.01).,15817:15956, 29053 ,11178222,Unavailable
 29053 ,inspired RH and AH over the 24-h ,ventilated with a heated humidifier (HH),ventilated with a hydrophobic heat-moisture exchanger (HME) or a hygroscopic HME,Significantly increased,"With regard to both RH and AH, the HH achieved the best performance when compared with the other two devices (P &lt; 0.001).",15817:15956, 29053 ,11178222,Unavailable
 3598524 ,The median of overall hands-off time,"Combitube, EasyTube, I-Gel, Laryngeal Mask Airway and Laryngeal tube",endotracheal intubation,Significantly decreased,"The median of overall hands-off time was significantly higher for endotracheal intubation (39.4s; 95% CI 34.0-44.9s) compared to Laryngeal tube (6.1s; 5.2-6.9s), Combitube (7.9s; 6.9-9.0s), LMA (10.2s; 8.6-11.7s), EasyTube (8.8s; 7.3-10.3s), and I-Gel (11.9s; 10.2-13.7s) (Table 1).",16695:17017, 3598524 ,23433462,Unavailable
 3598524 ,Mean number of attempts,"Combitube, EasyTube, I-Gel, Laryngeal Mask Airway and Laryngeal tube",endotracheal intubation,Significantly decreased,"Mean number of attempts for conventional endotracheal intubation was 1.9 (95% CI 1.8-2.1), which was significantly higher compared to Combitube (1.1; 1.1-1.2), EasyTube (1.2; 1.1-1.3), Laryngeal tube (1.2; 1.1-1.3), LMA (1.4; 1.3-1.5), and I-Gel (1.6; 1.5-1.8).",29555:29816, 3598524 ,23433462,Unavailable
 4527103 ,reduction of cough severity,"received homeopathic syrup for 10 days plus oral antibiotic treatment (amoxicillin/clavulanate, clarithromycin, and erythromycin) for 7 days",received homeopathic syrup alone for 10 days,No significant difference,with a non-significant difference in progressive reduction of cough severity between the two groups (Table 2).,17290:17444, 4527103 ,26251722,Unavailable
 4527103 ,adverse events,"received homeopathic syrup for 10 days plus oral antibiotic treatment (amoxicillin/clavulanate, clarithromycin, and erythromycin) for 7 days",received homeopathic syrup alone for 10 days,Significantly increased,We observed a total of 11 adverse events with a significantly (P = 0.020) higher frequency in patients who received syrup plus antibiotic treatment than in those who took syrup alone.,21964:22164, 4527103 ,26251722,Unavailable
 4527103 ,cough resolution,"received homeopathic syrup for 10 days plus oral antibiotic treatment (amoxicillin/clavulanate, clarithromycin, and erythromycin) for 7 days",received homeopathic syrup alone for 10 days,No significant difference,No significant differences in cough severity or resolution were found between the two groups of children in any of the 28 days of the study.,5938:6078, 4527103 ,26251722,Unavailable
 3733617 ,The final response rate,receive an attractive pen,receive no pen,No significant difference,"The final response rate for the intervention and control group were 61.9% and 46.8% respectively and was not statistically significant (Chi-square = 2.89, P = 0.089).",12936:13102, 3733617 ,23899116,Unavailable
 4579488 ,total reaction time (TRT),Received single dose of N. sativa oil (500 ml capsule),Received single dose of garlic (500 mg capsule) or Received single dose of CoQ10 (120 mg capsule) or received single dose of matching oral placebo (300 mg starch capsule),No significant difference,Table 1 shows that the neither placebo nor nutraceuticals exerted a significant effect on TRT.,11281:11383, 4579488 ,26401411,Unavailable
 4579488 ,The recognition reaction time (RRT),Received single dose of N. sativa oil (500 ml capsule),Received single dose of garlic (500 mg capsule) or Received single dose of CoQ10 (120 mg capsule) or received single dose of matching oral placebo (300 mg starch capsule),No significant difference,"The RRT is insignificantly reduced by 2.77% (placebo), 5.83% (N. Sativa), 7.21% (Garlic) and 12.64% (CoQ10) from the pretreatment values [Table 1].",11383:11587, 4579488 ,26401411,Unavailable
 4579488 ,The motor reaction time (MRT),Received single dose of N. sativa oil (500 ml capsule),Received single dose of garlic (500 mg capsule) or Received single dose of CoQ10 (120 mg capsule) or received single dose of matching oral placebo (300 mg starch capsule),Significantly decreased,"Placebo treatment reduced the MRT by 1.4% while the nutraceutical preparations prolonged the MRT by 12.22% (N Sativa), 30% (Garlic) and 8.82% (CoQ10).",11742:11910, 4579488 ,26401411,Unavailable
 5853038 ,plaque index,Meswak-based toothpaste,TTO-based toothpaste.,Significantly decreased,"Analysis of plaque scores showed a reduction in plaque index after using either of the two herbal-based toothpastes; however, when compared with TTO, Meswak-based toothpaste resulted in significantly less plaque.",5090:5302, 5853038 ,29629325,Unavailable
 3759413 ,Circulating irisin,simvastatin 40 mg,ezetimibe 10 mg,Significantly increased,Circulating irisin increased significantly in simvastatin-treated but not in ezetimibe-treated subjects.,6888:6992, 3759413 ,24023786,Unavailable
 3806786 ,mortality and extreme adverse outcome (EAO),standard obstetric hemorrhage/shock protocols plus application of the Non-pneumatic Anti-Shock Garment (NASG),standard obstetric hemorrhage/shock protocols,No significant difference,"The intervention was associated with a 46% reduction in the odds of mortality (OR 0.54, 95% CI 0.14–2.05, p = 0.37) and 54% reduction in the odds of the composite EAO (OR 0.46, 95% CI 0.13–1.62, p = 0.22); these differences were not statistically significant.",60258:60518, 3806786 ,24194839,Unavailable
 3806786 ,The median time in minutes to return to SI,standard obstetric hemorrhage/shock protocols plus application of the Non-pneumatic Anti-Shock Garment (NASG),standard obstetric hemorrhage/shock protocols,Significantly decreased,"The median time in minutes to return to SI &lt;0.98 (HR 99/SBP101) was 170 minutes (IQR 96–299) for the intervention group vs. 209 minutes (IQR 114–386) for the control group (HR 1.25 (95% CI 1.02–1.52, p = 0.03), indicating a 25% faster rate of recovery for women in the intervention group.",68403:68597, 3806786 ,24194839,Unavailable
 3806786 ,abdominal pain,standard obstetric hemorrhage/shock protocols plus application of the Non-pneumatic Anti-Shock Garment (NASG),standard obstetric hemorrhage/shock protocols,Significantly increased,"At the RH, women in the intervention group were more likely to have reported abdominal pain (OR 1.96, 95% CI 1.12–3.45, p = 0.02) (Table 5).",68403:68597, 3806786 ,24194839,Unavailable
 5840243 ,The total number of patients who reported at least one DAS at follow-up,PROMISE instrument at the start of the CMR,PROMISE without a subsequent CMR,No significant difference,"The total number of patients who reported at least one DAS at follow-up was 56 (72%) in the IG and 51 (76%) in the CG. The IG was 15% less likely to report at least one DAS at follow-up; however, this difference was not statistically significant [odds ratio (OR) 0.85; 95% CI 0.38–1.88] (Table 2).",38495:38833, 5840243 ,29209863,Unavailable
 5840243 ,patients reported ‘good’ self-efficacy,PROMISE instrument at the start of the CMR,PROMISE without a subsequent CMR,Significantly increased,"More patients in the IG reported ‘good’ self-efficacy at follow-up compared with the CG (OR 2.91, 95% CI 1.20–7.06).",38998:39114, 5840243 ,29209863,Unavailable
 5827478 ,the incidence of etomidate-induced myoclonus (EM),IV lignocaine 1 mg/kg (Group III) or 1.5 mg/kg (Group IV) ,saline placebo (Group I),Significantly decreased,"However, the individual group-to-group analysis demonstrated a statistically significant reduction in the incidence of EM2 (primary outcome) between Groups I and III (76% vs. 42%, relative risk [RR] = 0.503, 95% confidence interval [CI] = 0.339–0.747, P = 0.001) and Groups I and IV (76% vs. 54%, RR = 0.632, 95% CI = 0.435–0.919, P = 0.035) only.",12496:12878, 5827478 ,29491517,Unavailable
 5827478 ,the incidence of severe myoclonus at 2 min,IV lignocaine 1 mg/kg (Group III) or 1.5 mg/kg (Group IV) ,saline placebo (Group I),Significantly decreased,"Lignocaine 1 mg/kg and 1.5 mg/kg significantly reduced the incidence of severe myoclonus at 2 min (14% each) compared to Groups I (42%, P = 0.003) and II (32%, P = 0.032).",4222:4427, 5827478 ,29491517,Unavailable
 3714488 ,plasma glucose,Intermittent hypoxia (IH),placebo,Significantly decreased,"A significant decrease in plasma glucose (P &lt; 0.01) occurred after the hypoxic exposure, whereas no significant change was apparent on the placebo day (Fig. 2A).",24045:24281, 3714488 ,23536585,Unavailable
 3714488 , hypercapnic ventilatory responses (HCVR),Intermittent hypoxia (IH),placebo,Significantly increased,"HCVR significantly increased after IH (Fig. 1) and tended to remain elevated (3 h after IH: P = 0.096; 6 h after IH: P = 0.105) thereafter. In contrast, an opposite trend could be observed immediately after the placebo exposure, which, however, was no more apparent at 3 h or 6 h after exposure.",21509:21876, 3714488 ,23536585,Unavailable
 3714488 ,Systolic and diastolic blood pressures,Intermittent hypoxia (IH),placebo,Significantly increased,"Systolic and diastolic blood pressures significantly increased subsequent to the hypoxia exposure,",23556:23654, 3714488 ,23536585,Unavailable
 4173566 ,heart rate,oral metoprolol 50 mg,oral clonidine 300 mcg,Significantly decreased,"While comparing HRs among groups, there was a significant difference between groups at pre-induction, 15, 30, 45, 60, 75 and 90 min (P &lt; 0.05) with Group B patients showing a statistically lower HR.",12516:12731, 4173566 ,25885986,Unavailable
 4173566 ,systolytic blood pressure,oral metoprolol 50 mg,oral clonidine 300 mcg,No significant difference,"There was no significant difference between groups at 15, 30, 45, 60, 75, 90 and 105 min (P &gt; 0.05) [Table 5, Figure 2].",13483:13699, 4173566 ,25885986,Unavailable
 4173566 ,diastolic blood pressure,oral metoprolol 50 mg,oral clonidine 300 mcg,No significant difference,"When DBP was compared between groups, there was a significant difference between groups at 30 and at 60 min (P value 0.00 and 0.01 respectively) with Group B patients showing a statistically lower DBP. There was no significant difference between groups at pre-induction, 15, 45, 75, 90, 105 and 120 min (P values more than 0.05) [Table 6, Figure 3].",14053:14512, 4173566 ,25885986,Unavailable
 4173566 ,mean arterial pressure,oral metoprolol 50 mg,oral clonidine 300 mcg,No significant difference,"When MAP was compared between the groups, there was a significant difference between groups at 30 min (P = 0.01) and at 75 min (P = 0.04) with Group B patients showing a statistically lower MAP [Table 7, Figure 4].",14513:14837, 4173566 ,25885986,Unavailable
 5834159 ,The yield of newly diagnosed HIV among all contacts aged 14+years old,SOC with POC CD4 for those testing HIV positive or SOC with POC CD4 and IPT for eligible household members,Standard of Care TB and HIV testing (SOC),No significant difference,"The yield of newly diagnosed HIV among all contacts aged 14+years old was 2.6% in the SoC arm (Table 3). This was higher in the PoC CD4 arm (3.7% prevalence ratio = 1.40; 95% CI: 0.85, 2.30) and the PoC CD4 + HH-IPT arm (3.4%, prevalence ratio = 1.29; 95% CI: 0.78, 2.15), but with no statistical evidence for an effect (p-values of 0.18 and 0.32, respectively).",46827:47244, 5834159 ,29499060,Unavailable
 5834159 ,HIV testing uptake,SOC with POC CD4 for those testing HIV positive or SOC with POC CD4 and IPT for eligible household members,Standard of Care TB and HIV testing (SOC),No significant difference,"HIV testing uptake was 34.7% in the SoC arm, 40.2% in the PoC CD4 arm (RR1.16, CI 0.99–1.36, p-value = 0.060) and 39.9% in the PoC CD4 + HH-IPT arm (RR = 1.15, CI 0.99–1.35, p-value = 0.075).",17536:17727, 5834159 ,29499060,Unavailable
 5834159 ,Linkage to care within 3 months,SOC with POC CD4 for those testing HIV positive or SOC with POC CD4 and IPT for eligible household members,Standard of Care TB and HIV testing (SOC),Significantly increased,"Linkage to care within 3 months was 30.8% in the SoC arm and 42.1% in the POC CD4 arms (RR 1.37; CI: 0.68–2.76, p-value = 0.382). 20/21 contacts (95.2%) initiated IPT in the PoC CD4 + HH-IPT arm, compared to 3/20 (15.0%) in the PoC CD4 arm (p = 0.004; p-value from Fisher’s exact test &lt; 0.001).",17728:18023, 5834159 ,29499060,Unavailable
 2367663 ,mean concentrations of malathion residue,"A 2-year, comprehensive intervention plan included intervention activities at the community, organizational, small group, and individual levels",control,No significant difference,"mean concentrations of malathion residue in house dust decreased from year 1 to year 4 in both intervention and control communities; however, there were no significant differences between communities after adjusting for year, p = 0.43.",42123:42375, 2367663 ,18470300,Unavailable
 2367663 ,azinphos-methyl residue concentrations,"A 2-year, comprehensive intervention plan included intervention activities at the community, organizational, small group, and individual levels",control,No significant difference,"For house dust, we saw a decrease in mean azinphos-methyl residue concentrations in both communities, but no significant differences between intervention and control communities after adjusting for year, p = 0.49.",41712:41943, 2367663 ,18470300,Unavailable
 2367663 ,Mean phosmet residue concentrations,"A 2-year, comprehensive intervention plan included intervention activities at the community, organizational, small group, and individual levels",control,No significant difference,"Mean phosmet residue concentrations increased in year 4, but there were no significant differences between communities after adjusting for year, p = 0.47.",41943:42114, 2367663 ,18470300,Unavailable
 3717762 ,Adverse effects,bimatoprost 0.03% preservative-free (PF),bimatoprost 0.03%,No significant difference,"AEs were reported for 40.5% (122/301) of bimatoprost PF and 44.1% (130/295) of bimatoprost patients (p=0.382), with ocular AEs reported for 31.9% and 34.9%, respectively (p=0.434).",33793:33974, 3717762 ,23743437,Unavailable
 3717762 ,"cup/disc ratio, best-corrected visual acuity at week 12 or visual field",bimatoprost 0.03% preservative-free (PF),bimatoprost 0.03%,No significant difference,"There were no statistically or clinically significant between-group differences for change from baseline in cup/disc ratio, best-corrected visual acuity at week 12 or visual field.",38184:38365, 3717762 ,23743437,Unavailable
 3717762 ,vital signs,bimatoprost 0.03% preservative-free (PF),bimatoprost 0.03%,No significant difference,There were no clinically significant between-group differences in vital signs.,38365:38443, 3717762 ,23743437,Unavailable
 3717762 ,intraocular pressure,bimatoprost 0.03% preservative-free (PF),bimatoprost 0.03%,No significant difference,The between-group difference in mean worse eye IOP was &lt;0.4 mm Hg at all time points and was not statistically or clinically significant (see online supplementary figure S2).,24786:24960, 3717762 ,23743437,Unavailable
 5747130 ,The mean procedure duration from skin incision to insertion of the tracheal cannula,optical guidance with a VivaSightTM-SL tube [VST],bronchoscopy,No significant difference,"The mean procedure duration from skin incision to insertion of the tracheal cannula did not differ significantly (n.s.) between the groups, being 14.7 ± 11.0 minutes in the VST group vs. 10.6 ± 8.2 minutes in the bronchoscopy group in the ITT analysis, and 10.0 ± 4.8 minutes vs. 10.6 ± 8.2 minutes (n.s.) in the PP analysis, respectively.",22651:22990, 5747130 ,29284503,Unavailable
 5747130 ,visualization,optical guidance with a VivaSightTM-SL tube [VST],bronchoscopy,No significant difference,"Noninferiority for visualization (the primary endpoint) could not be demonstrated in the VST group. Mean visualization scores were 5.9 (95% CIs for the mean 4.7–7.1) for the VST group vs. 4.0 (4.0–4.0) for the bronchoscopy group with a mean difference of 1.9 (0.7–3.1) in the ITT analysis and 5.4 (4.5–6.3) vs. 4.0 (4.0–4.0), mean difference 1.4 (0.5–2.3), in the PP analysis, respectively (see Fig. 2; lower values indicate better visualization).",23008:23512, 5747130 ,29284503,Unavailable
 5747130 ,Ventilation,optical guidance with a VivaSightTM-SL tube [VST],bronchoscopy,No significant difference,"ntilation was rated 2.8 (2.3–3.3) for the VST group vs. 5.0 (4.4–5.7) for the bronchoscopy group, mean difference −2.3 (−3.0 to −1.5) in the ITT analysis and 2.5 (2.1–2.9) vs. 5.0 (4.4–5.7), mean difference −2.5 (−3.2 to −1.8) in the PP analysis (see Fig. 2). An additional figure showing the ITT analysis is presented in Additional file 1. For score item A (identification of thyroid cartilage, cricoid cartilage, first to third tracheal cartilage) and item C (monitoring puncture: midline + level below first or second tracheal cartilage), we found no significant difference between the groups.",23514:24209, 5747130 ,29284503,Unavailable
 5747130 ,mean PaCO2,optical guidance with a VivaSightTM-SL tube [VST],bronchoscopy,Significantly decreased,"In the VST group, mean PaCO2 was lower than in the bronchoscopy group before (5.3 [5.0–5.7] vs. 7.6 [6.7–8.4] kPa, p &lt; 0.001, PP analysis) and after insertion of the tracheal cannula (5.9 [5.4–6.5] vs. 8.3 [7.2–9.5] kPa, p &lt; 0.001) (see Fig. 3).",25345:25665, 5747130 ,29284503,Unavailable
 5747130 ,pH values,optical guidance with a VivaSightTM-SL tube [VST],bronchoscopy,Significantly increased,"Conversely, pH values were higher in the VST group before puncture (7.44 [7.41–7.47] vs. 7.30 [7.27–7.34], p &lt; 0.001) (see Fig. 4) and after insertion of the tracheal cannula (7.40 [7.36–7.43] vs. 7.26 [7.22–7.30], p &lt; 0.001).",25345:25665, 5747130 ,29284503,Unavailable
 4987981 ,"Psoriasis Area and Severity Index (PASI), Erythema, Scaling and Induration (ESI) and Physician global assessment (PGA) scores",metformin or pioglitazone,placebo,Significantly decreased,"Statistically significant improvement was observed in PASI, ESI and PGA scores in pioglitazone (P values – PASI = 0.001, ESI = 0.002, PGA = 0.008) and metformin groups (P values – PASI = 0.001, ESI = 0.016, PGA = 0.012) as compared to placebo (Fig. 2).",24834:24980, 4987981 ,27531132,Unavailable
 4987981 ,percentage of patients achieving 75 % reduction in PASI and ESI scores,metformin or pioglitazone,placebo,Significantly increased,"Statistically significant difference in percentage of patients achieving 75 % reduction in PASI and ESI scores in metformin (p value – PASI = 0.001, ESI = 0.001) and pioglitazone groups (p value – PASI = 0.001, ESI = 0.001) (Fig. 4).",23557:23864, 4987981 ,27531132,Unavailable
 4987981 ,"FPG, total cholesterol and triglycerides levels",metformin or pioglitazone,placebo,Significantly decreased,"Statistically significant improvement is observed in FPG, total cholesterol and triglycerides levels (Table 2) in metformin and pioglitazone arms as compared to placebo.",23864:24075, 4987981 ,27531132,Unavailable
 4987981 ,IL-6 and TNF-α levels,metformin or pioglitazone,placebo,No significant difference,No significant change in the IL-6 and TNF-α levels among three groups (Fig. 5).Fig. 2,24834:24980, 4987981 ,27531132,Unavailable
 5642889 ,"the incidence of blood loss of ≥1,000 g",cooling the lower abdomen,the control,No significant difference,"There was no significant difference in the incidence of blood loss of ≥1,000 g between the two groups (7.4% vs. 7.6%, respectively, RR = 0.98, 95% CI = 0.55–1.78).",-1:-1, 5642889 ,29036203,Unavailable
 5642889 ,mean total blood loss (±SD) within 2 h,cooling the lower abdomen,the control,No significant difference,"There was no significant difference in the mean total blood loss (±SD) within 2 h between the intervention and control groups by per-protocol analysis (508.3 ± 314.8 g, n = 73 vs. 482.0 ± 311.4 g, n = 77, respectively).",49146:49399, 5642889 ,29036203,Unavailable
 5642889 ,incidence of blood loss of ≥500 g,cooling the lower abdomen,the control,No significant difference,"Also, there was no significant difference between the two groups regarding the incidence of blood loss of ≥500 g (45.2%, 33 of 73 vs. 35.1%, 27 of 77, RR = 1.18, 95% CI = 0.90–1.54),",49400:49583, 5642889 ,29036203,Unavailable
 5642889 ,the incidence of using therapeutic uterotonics,cooling the lower abdomen,the control,No significant difference,"the incidence of using therapeutic uterotonics (37.0%, 27 of 73 vs. 50.6%, 39 of 77, RR = 0.78, 95% CI = 0.58–1.04).",49696:49812, 5642889 ,29036203,Unavailable
 5840188 ,sustained virological response at 12 weeks (SVR12),sofosbuvir plus ledipasvir for 12 weeks,sofosbuvir plus oral weight-based ribavirin for 24 weeks,Significantly increased,Group I patients showed statistically significant (p&lt;0.05) higher SVR12 compared with group II patients (99% vs. 80%).,5919:6054, 5840188 ,29535545,Unavailable
 5840188 ,the frequencies of the side effects,sofosbuvir plus ledipasvir for 12 weeks,sofosbuvir plus oral weight-based ribavirin for 24 weeks,No significant difference,There was no statistical difference (p&gt;0.05%) between the studied groups regarding the frequencies of the side effects (26% vs. 29%).,6055:6208, 5840188 ,29535545,Unavailable
 5001793 ,Pain intensity in the PACU and morphine consumption,transversus abdominis plane block (TAP) or ilioinguinal and iliohypogastric nerve block (ILI+IHG),control,Significantly decreased,"Pain intensity in the PACU and morphine consumption was not significantly different between the TAP and ILI+IHG groups; however, they were significantly decreased when compared with the control group (Table 2).",27554:27819, 5001793 ,27487311,Unavailable
 5001793 ,Pain intensity in the PACU and morphine consumption,transversus abdominis plane block (TAP), ilioinguinal and iliohypogastric nerve block (ILI+IHG),No significant difference,Pain intensity in the PACU and morphine consumption was not significantly different between the TAP and ILI+IHG groups;,27554:27673, 5001793 ,27487311,Unavailable
 5001793 ,Morphine and dipyrone consumption following PACU discharge and up to 24 hours post-op,ilioinguinal and iliohypogastric nerve block (ILI+IHG),control or transversus abdominis plane block (TAP),Significantly decreased,Morphine and dipyrone consumption following PACU discharge and up to 24 hours post-op were significantly decreased in the ILI+IHG group compared with the other two groups.,33021:33192, 5001793 ,27487311,Unavailable
 5001793 ,Analgesic consumption during the 24 hours post-op,transversus abdominis plane block (TAP) or ilioinguinal and iliohypogastric nerve block (ILI+IHG),control,No significant difference,"Twenty-four hours after surgery, all evaluated parameters were similar.",6371:6442, 5001793 ,27487311,Unavailable
 3611743 ,WRAML-2 verbal learning,"glutamine, zinc, and vitamin A",placebo,Significantly increased,"However, children receiving combination glutamine, zinc, and vitamin A performed significantly better on WRAML-2 verbal learning than the placebo group, with mean age-adjusted scores of 9.28 (SD 3.41) and 7.28 (SD 3.34), respectively (p = 0.02).",24225:24487, 3611743 ,23644855,Unavailable
 5706695 ,knowledge about the taught words,definition method or context method ,control ,Significantly increased,"Regarding the effectiveness of the training methods, for the taught words at post-test1 both the definition group (b = 0.31, SE = 0.12, 95%CI [0.08, 0.53]) and the context group (b = 0.40, SE = 0.12, 95%CI [0.17, 0.62]) demonstrated significantly more knowledge about the taught words compared to the control group",74419:74801, 5706695 ,29186175,Unavailable
 5706695 ,knowledge about the taught words,definition method,context method,No significant difference,"Furthermore, there was no significant difference between the two training methods (b = 0.09, SE = 0.11, 95%CI [-0.14, 0.31]), suggesting that both training methods proved equally effective at improving vocabulary knowledge of the taught words.",74803:75080, 5706695 ,29186175,Unavailable
 5706695 ,vocabulary knowledge,definition method ,control ,Significantly increased,"At post-test 2 the definition group but not the context group demonstrated significantly more vocabulary knowledge than the control group (bdefiniton = 0.25, SE = 0.12, 95%CI [0.03, 0.48]; bcontext = 0.17, SE = 0.11, 95%CI [-0.05, 0.40]).",82047:82375, 5706695 ,29186175,Unavailable
 5706695 ,vocabulary knowledge,definition method ,context method ,No significant difference,"Despite this, the difference between the two training methods did not reach significance (b = -0.08, SE = 0.12, 95%CI [-0.30, 0.15]).",82376:82543, 5706695 ,29186175,Unavailable
 4550271 ,Community knowledge,provider or provider-school intervention,control,No significant difference,Community knowledge was marginally higher among households in the intervention arms but differences were not statistically significant.,63679:64088, 4550271 ,26309023,Unavailable
 4550271 ,treatment according to guidelines,provider or provider-school intervention,control,No significant difference,"Although clusters in the provider arm tended to have higher proportions of people treated according to guidelines (36% in provider, 23% control, 24% provider-school) there was no evidence of a statistically significant difference between the arms (p = 0.36) (Table 2).",63679:64088, 4550271 ,26309023,Unavailable
 4550271 ,the proportion of patients who tested positive and received (or were prescribed) an ACT,provider or provider-school intervention,control,No significant difference,"Less than half of febrile patients attending the facilities were tested for malaria and of those tested, the proportion of patients who tested positive and received (or were prescribed) an ACT was lower in the intervention arms, but these differences were not statistically significant (Table 2; Fig 3).",63679:64088, 4550271 ,26309023,Unavailable
 4710681 ,The hematologic toxicity,Pemetrexed (P) + Cisplatin (C) + Dalotuzumab-MK0646 (D),Pemetrexed (P) + Cisplatin (C),No significant difference,The hematologic toxicity was similar in both groups.,7811:7863, 4710681 ,26793618,Unavailable
 4710681 ,response rate,Pemetrexed (P) + Cisplatin (C) + Dalotuzumab-MK0646 (D),Pemetrexed (P) + Cisplatin (C),No significant difference,"PC + D had a similar response rate compared to PC, with a higher rate of hyperglycemia.",8037:8125, 4710681 ,26793618,Unavailable
 3948438 ,The incidence of coughing during emergence,propofol,control,Significantly decreased,"The incidence of coughing during emergence was significantly lower in the propofol group compared to the control group (60 vs 87%, P = 0.04).",15479:15620, 3948438 ,24624269,Unavailable
 3948438 ,The grade of coughing during emergence,propofol,control,Significantly decreased,The grade of coughing during emergence was also significantly lower in the propofol group than in the control group (P = 0.02) (Table 2).,15621:15797, 3948438 ,24624269,Unavailable
 3948438 ,The BIS value at the discontinuation of the anesthetic drugs,propofol,control,No significant difference,The BIS value at the discontinuation of the anesthetic drugs also did not show a significant difference between the groups (P = 0.25).,16341:16476, 3948438 ,24624269,Unavailable
 3948438 ,"mean arterial pressure, heart rate, and recovery time",propofol,control,No significant difference,"There were no significant differences in mean arterial pressure, heart rate, and recovery time during emergence between the two groups.",4521:4656, 3948438 ,24624269,Unavailable
 3978457 ,The mean improvement after 1 year,MTX + hydroxychloroquine + sulphasalazine + prednisone,MTX + adalimumab,No significant difference,"he mean improvement after 1 year was not significantly different between arms 1 and 2 (mean difference = 1.0, 95% CI = −2.8 to 4.7).",40603:40736, 3978457 ,24517212,Unavailable
 3540908 ,number of patients with ankylosing spondylitis in remission,etanercept 50 mg every other week, etanercept 50 mg weekly,No significant difference,"At the end of follow-up, 19 of 22 (86.3%) subjects in group 1 and 19 of 21 (90.4%) in group 2 were still in remission, with no significant difference between the two groups. The mean follow-up duration in group 1 and group 2 was 22 ± 1 months and 21 ± 1.6 months, respectively.",4540:4818, 3540908 ,23319853,Unavailable
 4707005 ,Success rates at various time points throughout follow-up,0.5 mg intravitreal ranibizumab for three to 14 days before Ahmed glaucoma valve implantation,Ahmed glaucoma valve implantation alone,No significant difference,"Success rates at various time points throughout follow-up (Table 3) were not significantly different between the two groups (P = 0.84, Fig. 1).Table 2",20147:20423, 4707005 ,26749079,Unavailable
 4707005 ,The number of anti-glaucoma medications,0.5 mg intravitreal ranibizumab for three to 14 days before Ahmed glaucoma valve implantation,Ahmed glaucoma valve implantation alone,No significant difference,"The number of anti-glaucoma medications used at various time points throughout follow-up in both groups declined significantly from baseline (ANOVA, α = 0.05). And the number of medications increased gradually in both groups with the passage of time. There was no significant difference at various time points between the two groups (Table 5).Table 5",25502:25922, 4707005 ,26749079,Unavailable
 4707005 ,"intraocular pressure, best corrected visual acuity, or postoperative complications",0.5 mg intravitreal ranibizumab for three to 14 days before Ahmed glaucoma valve implantation,Ahmed glaucoma valve implantation alone,No significant difference,"There were no significant differences in the two groups with respect to intraocular pressure, best corrected visual acuity, anti-glaucoma medications or postoperative complications at six months or 12 months.",5990:6198, 4707005 ,26749079,Unavailable
 3580400 ,hematocrit and glucose levels,Curcumin C3 Complex,placebo,No significant difference,Curcumin C3 Complex® was associated with lowered hematocrit and increased glucose levels that were clinically insignificant.,10399:10534, 3580400 ,23107780,Unavailable
 3580400 ,clinical or biomarker efficacy measures of Alzheimer disease,Curcumin C3 Complex,placebo,No significant difference,There were no differences between treatment groups in clinical or biomarker efficacy measures.,10535:10630, 3580400 ,23107780,Unavailable
 5814604 ,depressive symptoms score,afternoon engaged or morning engaged groups,unengaged group,Significantly increased,The unengaged group (n=102) had the highest depressive symptoms score compared with the afternoon engaged (n=65) and morning engaged (n=48) groups (overall P&lt;.001).,8045:8229, 5814604 ,29391341,Unavailable
 5814604 ,"body mass index, waist circumference, hip circumference",the moderate-to-vigorous physical activity (MVPA) evening peak group,the moderate-to-vigorous physical activity (MVPA) noon peak group,Significantly increased,"Based on a normalized version of the METs ≥3 data, the moderate-to-vigorous physical activity (MVPA) evening peak group (n=108) had a higher body mass index (P=.03), waist circumference (P=.02), and hip circumference (P=.03) than the MVPA noon peak group (n=61).",8230:8543, 5814604 ,29391341,Unavailable
 5818014 ,Survival estimates,arimoclomol 200 mg,placebo,No significant difference,"Survival estimates from the Cox proportional hazards model also favored arimoclomol compared to control, with an unadjusted hazard ratio (HR) of 0.67 (95% CI 0.29–1.48, p = 0.33);",46998:47194, 5818014 ,29367439,Unavailable
 5818014 ,Revised ALS Functional Rating Scale (ALSFRS-R) rate,arimoclomol 200 mg,placebo,No significant difference,"The Vonesh model, on the other hand, yielded a treatment difference of 0.77 ± 0.54 points/month (95% CI −0.33 to 1.86, p = 0.16) in ALSFRS-R rate of decline, whereas the direct effect of treatment on survival was not significant (p = 0.62).",50237:50512, 5818014 ,29367439,Unavailable
 4720464 ,Time of getting stool in the postoperative period after elective resection surgery on the colon and rectum,100 ml of instant coffee,100 ml of tea,Significantly decreased,Time of getting stool in the postoperative period after elective resection surgery on the colon and rectum is significantly shorter after drinking coffee for about 15h (p &lt;0.01).,4959:5137, 4720464 ,26843724,Unavailable
 4720464 ,the length of hospital stay,100 ml of instant coffee,100 ml of tea,Significantly decreased,"Also, the length of hospital stay was significantly shorter after drinking coffee (p &lt;0.01).",5138:5231, 4720464 ,26843724,Unavailable
 4720464 ,The incidence of postoperative complications,100 ml of instant coffee,100 ml of tea,Significantly decreased,The incidence of postoperative complications was significantly lower after consumption of coffee (p &lt;0.05).,5358:5465, 4720464 ,26843724,Unavailable
 5777927 ,binocular vision (BV),vision therapy (VT),no intervention,Significantly increased,"Post-vision therapy, the intervention group showed significant improvement in all the BV parameters (Wilcoxon signed rank test, p&nbsp;&lt;&nbsp;0.05) except negative fusional vergence.",5403:5593, 5777927 ,28599912,Unavailable
 5777927 ,"NPC break and recovery values, and near PFV break and recovery and monocular and binocular AF",vision therapy (VT),no intervention,Significantly increased,"Mann–Whitney U test revealed significant difference in NPC break and recovery values, and near PFV break and recovery and monocular and binocular AF between children with normal BV and NSBVA (p&nbsp;&lt;&nbsp;0.001).",29966:30204, 5777927 ,28599912,Unavailable
 3953523 ,100-mm Visual Analogue Scale,aceclofenac CR once daily,aceclofenac immediate release (IR) twice a day,No significant difference,"In the covariance analysis, the intergroup was not statistically significant when institutional difference was adjusted as a covariate (p=0.177) (Table 2).",18189:18383, 3953523 ,24639945,Unavailable
 3953523 ,Knee Injury and Osteoarthritis Outcome Score,aceclofenac CR once daily,aceclofenac immediate release (IR) twice a day,No significant difference,"Activities, whereas the control group demonstrated higher increase in the KOOS-quality of life; however, the intergroup differences were not statistically significant with regard to any of the four KOOS subscales. (p=0.367, p=0.138, p=0.870, and p=0.787, respectively) (Table 3).",20586:20905, 3953523 ,24639945,Unavailable
 3953523 ,Range of Motion,aceclofenac CR once daily,aceclofenac immediate release (IR) twice a day,No significant difference,"However, the intergroup difference in the ROM (-0.1°±7.6°; ROM of the experimental group-ROM of the control group) was not statistically significant (p=0.965) (Table 3).",21339:21548, 3953523 ,24639945,Unavailable
 3953523 ,Safety,aceclofenac CR once daily,aceclofenac immediate release (IR) twice a day,No significant difference,No significant intergroup differences were found in the numbers of adverse events and adverse drug reactions (Table 4).,22005:22163, 3953523 ,24639945,Unavailable
 5572237 ,walking speed,home-based stepping to music overlaid with an auditory metronome,used a regular metronome,Significantly increased,"There was no difference in walking speed between Assessments 4 and 5 (p = 0.272), indicating that walking speed improvements were maintained at follow-up (see Table 2 for full results).",27854:28095, 5572237 ,28878730,Unavailable
 5572237 ,Dynamic Gait Index,home-based stepping to music overlaid with an auditory metronome,used a regular metronome,Significantly increased,There were no differences in scores between Assessments 4 and 5 (p = 0.100).,38180:38274, 5572237 ,28878730,Unavailable
 4756994 ,postoperative VAS scores,local 20mL of levobupivacaine 0.25% infiltration to the trocar incisions before skin closure ,1g paracetamol was given to the patients intravenously 30 minutes before extubation and 5g paracetamol was given intravenoulsy in the 24 postoperative period //// 8mg lornoxicam i.v. was given 30 minutes before extubation and 8mg lornoxicam i.v. was given in the 24 postoperative period,No significant difference,"However, the reduction of postoperative VAS scores was in all times similar among the groups (repeated measured variance analysis, test, p = 0.466) (Table-2).",13274:13474, 4756994 ,26401858,Unavailable
 4756994 ,cumulative tramadol consumptions at 24th hours per kilogram,1g paracetamol was given to the patients intravenously 30 minutes before extubation and 5g paracetamol was given intravenoulsy in the 24 postoperative period //// 8mg lornoxicam i.v. was given 30 minutes before extubation and 8mg lornoxicam i.v. was given in the 24 postoperative period, local 20mL of levobupivacaine 0.25% infiltration to the trocar incisions before skin closure ,Significantly decreased,"The calculated cumulative tramadol consumptions at 24th hours per kilogram were 370.6 ± 121.6mg, 220.9 ± 92.5mg and 240.7 ± 110.4mg in groups 1, 2 and 3, respectively. We found significant differences in relation to tramadol consumption between groups 1 and 2 and groups 1 and 3 (one-way ANOVA test, p &lt; 0.001).",19555:19866, 4756994 ,26401858,Unavailable
 4756994 ,cumulative tramadol consumptions at 24th hours per kilogram,1g paracetamol was given to the patients intravenously 30 minutes before extubation and 5g paracetamol was given intravenoulsy in the 24 postoperative period ,8mg lornoxicam i.v. was given 30 minutes before extubation and 8mg lornoxicam i.v. was given in the 24 postoperative period,No significant difference,"Nevertheless, we did not find significant differences between groups 2 and 3 (one-way ANOVA test, p &gt; 0.05).",19867:19975, 4756994 ,26401858,Unavailable
 4756994 ,The Quality of Recovery Scale,1g paracetamol was given to the patients intravenously 30 minutes before extubation and 5g paracetamol was given intravenoulsy in the 24 postoperative period //// 8mg lornoxicam i.v. was given 30 minutes before extubation and 8mg lornoxicam i.v. was given in the 24 postoperative period, local 20mL of levobupivacaine 0.25% infiltration to the trocar incisions before skin closure ,No significant difference,The Quality of Recovery Scale scores did not significantly different among the groups (Table-3).,20583:20718, 4756994 ,26401858,Unavailable
 4756994 ,cumulative tramadol consumptions at 24th hours per kilogram,1g paracetamol was given to the patients intravenously 30 minutes before extubation and 5g paracetamol was given intravenoulsy in the 24 postoperative period //// 8mg lornoxicam i.v. was given 30 minutes before extubation and 8mg lornoxicam i.v. was given in the 24 postoperative period, local 20mL of levobupivacaine 0.25% infiltration to the trocar incisions before skin closure ,Significantly decreased,"The calculated cumulative tramadol consumptions at 24th hours per kilogram were 370.6 ± 121.6mg, 220.9 ± 92.5mg and 240.7 ± 110.4mg in groups 1, 2 and 3, respectively. We found significant differences in relation to tramadol consumption between groups 1 and 2 and groups 1 and 3 (one-way ANOVA test, p &lt; 0.001).",20095:20285, 4756994 ,26401858,Unavailable
 4913995 ,The mean change in the score of traditional perceptions of pregnant women,group sexual counseling,control,Significantly increased,"The mean change in the score of traditional perceptions of pregnant women in the intervention group (−3.42±2.08) was significantly different from that in the control group (−0.24±1.02, P&lt;0.0001).",24811:24989, 4913995 ,27366105,Unavailable
 4913995 ,The mean change in the score of sexual attitude,group sexual counseling,control,Significantly increased,"The mean change in the score of sexual attitude in the intervention group (11.66±5.10) was significantly greater than in the control group (−0.42±3.03, P=0.0001)",24811:24989, 4913995 ,27366105,Unavailable
 3658914 ,HbA1c levels,transglucosidase (TGD)  orally (300 or 900 mg/day) for 12 weeks,placebo,No significant difference,"In the placebo group, HbA1c levels were increased in 11 patients (69%) after the treatment; levels were higher but not significant than those in the TGD-treated group (14 [39%]; p = 0.07).",23349:23538, 3658914 ,23657005,Unavailable
 5977143 ,response times for the disposal of gas and stool,pyridostigmine,starch,Significantly decreased,"Regarding the first objective, in the Oral Pyridostigmin group, the mean response times for the disposal of gas and stool were 5.4 ± 4.7 h and 4.9 ± 3.4 h, respectively. Most of the participants 10 (50%) (disposal of stool) responded to treatment 4 h after the administration of oral pyridostigmine. In the starch group, the mean response times for the disposal of gas and stool were 32.4 ± 9.9 h and 36.2 ± 10.3 h, respectively. The results of t-test showed that there was a significant difference between the two groups and patients in the Oral Pyridostigmine group responded to treatment with much less time (p = 0.001) (Table 2).",16028:16749, 5977143 ,29734770,Unavailable
 5977143 ,frequency of response to treatment (disposal of gas or stool) in the 24-h period after the initiation of treatment,pyridostigmine,starch,Significantly increased,"Concerning the second objective, the frequency of treatment response (disposal of gas or stool) in the first 24 h after the commencement of treatment in the oral pyridostigmine group, 95% (n = 19) of the subjects had treatment response in the first 24 h. However, in the starch group, only 50% (n = 10) responded to treatment in the first 24 h such that the chi-square test showed a significant difference between the two groups (p = 0.001) (Table 3).",16756:17312, 5977143 ,29734770,Unavailable
 5989624 ,"TAG-34: 1+NH4, TAG-58: 0+NH4, TAG-64: 3+NH4, and TAG-64: 8+NH4), diacylglycerol DAG-38: 6+NH4, phosphatidylglycerols (PG-26: 0, PG-30: 2, and PG-40: 5), phosphatidylethanolamine PE-32: 2, lysophosphatidylethanolamine LPE-14: 1, lysophosphatidylinositol LPI-12: 0, and lysophosphatidylcholine LPC-16: 0.",fertilization/intracytoplasmic sperm injection (IVF/ICSI) with progestin-primed ovarian stimulation (PPOS),short-term protocol,Significantly increased,"Based on the OPLS-DA model, together with the p-value of the t test (p&lt;0.05) and a greater that 1.5-fold difference, significant augmentation in the levels of 12 lipids metabolites were observed in the PPOS groups compared with the short-term group. As detailed in Figure 3, those lipids included triacylglycerols (TAG-34: 1+NH4, TAG-58: 0+NH4, TAG-64: 3+NH4, and TAG-64: 8+NH4), diacylglycerol DAG-38: 6+NH4, phosphatidylglycerols (PG-26: 0, PG-30: 2, and PG-40: 5), phosphatidylethanolamine PE-32: 2, lysophosphatidylethanolamine LPE-14: 1, lysophosphatidylinositol LPI-12: 0, and lysophosphatidylcholine LPC-16: 0.",20637:21386, 5989624 ,29783268,Unavailable
 5362659 ,misled responses ,did not expect but received alcohol (reverse placebo),did not expect nor receive alcohol (control),Significantly increased,Bonferroni post-hoc tests showed that the control group provided significantly more misled responses than the reverse placebo group (p = .038).,29938:30099, 5362659 ,28214996,Unavailable
 5362659 ,misinformation items,did not expect but received alcohol (reverse placebo) or expected and received alcohol (alcohol group),did not expect nor receive alcohol (control),Significantly decreased,"However, for the misinformation items a significant difference was present between the alcohol and control group (p = .002), and between the reverse placebo and control group (p = .001), but not between the alcohol and reverse placebo group (p &gt; .999). Thus, the control group was significantly more likely to give a misled response to misleading items compared to the alcohol and reverse placebo group.2",30881:31372, 5362659 ,28214996,Unavailable
 3531529 ,the time to insertion,Proseal LMA (PLMA),"I-gel,",No significant difference,"Successful insertion and mechanical ventilation of both devices was achieved on the first attempt in all 30 patients, and the time to insertion was similar (26.4 ± 1.4 and 26.4 ± 0.8 for PLMA and I-gel, respectively).",13524:13741, 3531529 ,23277811,Unavailable
 3531529 ,leak volume and leak fraction,Proseal LMA (PLMA),"I-gel,",No significant difference,The differences in leak volume and leak fraction were insignificant between the groups.,13430:13517, 3531529 ,23277811,Unavailable
 3531529 ,Inspiratory tidal volume,Proseal LMA (PLMA),"I-gel,",No significant difference,Inspiratory tidal volume of both groups did not differ over time;,14236:14302, 3531529 ,23277811,Unavailable
 3531529 ,expiratory tidal volume,Proseal LMA (PLMA),"I-gel,",Significantly decreased,the expiratory tidal volume of the I-gel group at T1 was smaller than that of the PLMA group (P &lt; 0.05).,14311:14415, 3531529 ,23277811,Unavailable
 4650143 ,isometric mid thigh pull peak force,Alpha glycerylphosphorylcholine (A-GPC),placebo,Significantly increased,"The A-GPC treatment resulted in significantly greater isometric mid thigh pull peak force change from baseline (t = 1.76, p = 0.044) compared with placebo (A-GPC: 98.8. ± 236.9 N vs Placebo: −39.0 ± 170.9 N).",4705:4931, 4650143 ,26582972,Unavailable
 4650143 ,Upperbody Isometric Test force,Alpha glycerylphosphorylcholine (A-GPC),placebo,No significant difference,"For the upper body test the A-GPC treatment trended towards greater change from baseline force production (A-GPC: 50.9 ± 167.2 N Placebo: −14.9 ± 114.9 N) but failed to obtain statistical significance (t = 1.16, p = 0.127).",4931:5171, 4650143 ,26582972,Unavailable
 5791397 ,terms of transurethral access,transurethral nephroscope via resectoscope outer sheath,conventional percutaneous cystolithotripsy (PCCL) technique,No significant difference,No significant difference was found in terms of transurethral access no. between Group 1 and 2 (P = 0.643).,12633:12740, 5791397 ,29410893,Unavailable
 5791397 ,Operative time,transurethral nephroscope via resectoscope outer sheath,conventional percutaneous cystolithotripsy (PCCL) technique,No significant difference,Operative time was also similar in both groups (P = 0.428).,12741:12800, 5791397 ,29410893,Unavailable
 5791397 ,Duration of hospital stay,transurethral nephroscope via resectoscope outer sheath,conventional percutaneous cystolithotripsy (PCCL) technique,Significantly decreased,Duration of hospital stay was significantly higher in group 2 than group 1 (P = 0.000).,12801:12888, 5791397 ,29410893,Unavailable
 5827302 ,Subjective Units of Distress Scale (SUDS),Exercise,Control,No significant difference,"There were no significant differences between the exercise and control groups at baseline (Exercise Group=2.4±1.1 vs Control Group= 2.2±0.8, p=0.76), immediately after (Exercise group=3.8±0.8 vs Control Group= 2.6±1.8, p=0.21) and after 10 minutes of resting (Exercise group=1.6±0.5 vs Control group= 2.2±1.0; p=0.30).",31959:32328, 5827302 ,29515644,Unavailable
 5827302 ,Panic Disorder Severity Scale (PDSS),Exercise,Control,No significant difference,The results showed no significant group by time interaction (p=0.41) and no significant main effects for time (p=0.18) for PDSS.,32383:32511, 5827302 ,29515644,Unavailable
 5827302 ,Beck Anxiety Inventory (BAI),Exercise,Control,Significantly decreased,"Post-hoc analysis revealed a significantly decreased score in BAI in the exercise group post-intervention (M±SD= 29.6±7.4) compared to baseline (M±SD= 24.0±7.1, p=0.005) (Fig. 3).",32785:33015, 5827302 ,29515644,Unavailable
 5827302 ,Beck Depression Inventory-II (BDI-II),Exercise,Control,No significant difference,"Mann-Whitney’s U test showed no between-group differences for BDI-II (Exercise group=5.8±5.3 vs Control group= -0.6±2.8, p= 0.09). However, only the exercise group showed large effect size (1.06) within group. Descriptive data are seen in Table 2.",33940:34256, 5827302 ,29515644,Unavailable
 5827302 ,VO2max,Exercise,Control,Significantly increased,"In addition, VO2max was greater in the exercise group compared to the control group in post-intervention (Exercise group= 38.3±2.2 mL.kg-1.min-1 vs Control group= 32.3±2.7 mL.kg-1.min-1, p=0.005) (Fig. 6).",34742:35073, 5827302 ,29515644,Unavailable
 5836868 ,HbA1c level,alogliptin,placebo,Significantly decreased,"From baseline to the end of the study, there was a consistently significant relative reduction in HbA1c in the alogliptin group as compared with placebo in each baseline HbA1c category (Figure 1). The least‐squares mean difference in change from baseline between alogliptin and placebo was most pronounced for patients with HbA1c ≥ 9.0% (75 mmol/mol) at baseline (least‐squares mean difference −0.54% [6 mmol/mol], 95% CI −0.74%, −0.34%; P &lt; .001).",46321:46838, 5836868 ,28058763,Unavailable
 5836868 ,Hypoglycaemia,alogliptin,placebo,No significant difference,There were no significant differences in the rates of all reported hypoglycaemia or serious hypoglycaemia between the alogliptin and placebo groups for any category of baseline HbA1c value.,54502:54692, 5836868 ,28058763,Unavailable
 4588995 ,Pain scores,closure of the capsule,capsule was left open,No significant difference,Pain scores decreased from 6.4 to 2.4 in the closed capsule group and 6.3 to 2.2 in the control group.,6598:6728, 4588995 ,None,Unavailable
 4588995 ,Patient satisfaction,closure of the capsule,capsule was left open,No significant difference,Patient satisfaction was 8.3 for the closed capsule group compared to 8.5 for the control group.,6598:6728, 4588995 ,None,Unavailable
 4588995 ,PRO and VAS  measures,closure of the capsule,capsule was left open,No significant difference,"In comparing the two groups, there were no differences in magnitudes of score improvement for PRO measures, VAS, or satisfaction.",6598:6728, 4588995 ,None,Unavailable
 4391192 ,overall sleep quality,sleep with earplugs and eye masks,control,Significantly increased,The independent samples t-test showed subjective sleep quality in the intervention group was significantly higher than in the control group (P &lt;0.05).,25503:25741, 4391192 ,25881268,Unavailable
 4391192 ,Patients’ perceptions of nighttime noise,sleep with earplugs and eye masks,control,Significantly decreased,Patients’ perceptions of nighttime noise were significantly lower in the experimental group than in the control group (P &lt;0.05) (Table 2).Table 2,25503:25741, 4391192 ,25881268,Unavailable
 4391192 ,urinary melatonin levels and cortisol levels,sleep with earplugs and eye masks,control,No significant difference,Patients’ perceptions of nighttime noise were significantly lower in the experimental group than in the control group (P &lt;0.05) (Table 2).Table 2,25503:25741, 4391192 ,25881268,Unavailable
 3747867 ,Medication adherence,CASM plus DD-specific problem solving (CAPS),computer-assisted self-management (CASM),Significantly increased,"There was a significant A0–A12 treatment group effect, indicating that patients in CAPS had more improvement in medication adherence than those in CASM (P = 0.02) and Leap Ahead (P = 0.006).",28304:28529, 3747867 ,23735726,Unavailable
 3747867 ,HbA1c,CASM plus DD-specific problem solving (CAPS),computer-assisted self-management (CASM),No significant difference,No significant time or group main effects were found for log-transformed HbA1c.,28718:28808, 3747867 ,23735726,Unavailable
 5799985 ,clinical success,"mixture of metronidazole, ciprofloxacin, and minocycline (3MIX)-MP",conventional pulpectomy,No significant difference,"Although the difference in clinical success was not statistically significant,",5288:5366, 5799985 ,29430091,Unavailable
 1434781 ,The mean size of the posterior capsulorhexis,trypan blue dye,no dye,Significantly increased,The mean size of the posterior capsulorhexis was 4.6 ± 1.77 mm and 4.0 ± 0.93 mm in the group 1 and 2 respectively (p = 0.04) (Table 1).,11378:11553, 1434781 ,16539738,Unavailable
 1434781 ,The mean size of the anterior capsulorhexis,trypan blue dye,no dye,No significant difference,The mean size of the anterior capsulorhexis in group 1 and 2 was 5.9 ± 1.74 mm and 5.8 ± 0.92 mm respectively (p = 0.072).,11255:11378, 1434781 ,16539738,Unavailable
 4166058 ,severity of the mucosa injury,PMH7000,MR850,No significant difference,Fisher's exact test showed that there was no significant difference in the severity of the mucosa injury between the two groups (P value &gt;0.05).,17307:17468, 4166058 ,25250286,Unavailable
 4166058 ,The need for a second administration of nCPAP,PMH7000,MR850,No significant difference,"The need for a second administration of nCPAP in the MR850 group and PMH7000 group was three cases to one case, respectively, which when tested by Fisher's exact test, showed no significant difference (P value = 0.61) between the two groups.",17991:18250, 4166058 ,25250286,Unavailable
 4166058 ,chronic lung disease (CLD),PMH7000,MR850,No significant difference,"Among the 60 patients in both groups, seven cases were reported to have CLD, of which five cases were in the MR850 group and the two others were observed in the PMH7000 group; however, the difference between the two groups was not significant according to Fisher's exact test (P value = 0.42).",18250:18560, 4166058 ,25250286,Unavailable
 4166058 ,The mean and confidence interval of the duration of treatment,PMH7000,MR850,No significant difference,"The mean and confidence interval of the duration of treatment for both groups are shown in Figure 4 (at 25%, 50%, and 75%). The mean of the duration of treatment in the MR850 and PMH7000 groups are 5.3 ± 1.5 and 3.4 ± 1.3 days, respectively. The t-test showed no significant difference between the two groups (P value =0.36).",18790:19186, 4166058 ,25250286,Unavailable
 4166058 ,severity of the mucosa injury,PMH7000,MR850,Significantly decreased,"The difference in the levels of average temperature and humidity was significant (P value &lt;0.001).Conclusion:Although the records of temperature and RH in the PMH7000 system was lower than the records from the MR850 system,",4650:4936, 4166058 ,25250286,Unavailable
 5755650 ,The change of eGFR,perindopril and the L-type calcium antagonist amlodipine,perindopril and the T/L type calcium antagonist benidipine,No significant difference,The change of eGFR showed no significant difference between the amlodipine group (-1.58 ± 10.1 mL/min/1.73 m2) and the benidipine group (0.83 ± 13.2 mL/min/1.73 m2) (P = 0.170).,19279:19478, 5755650 ,29317956,Unavailable
 5755650 ,The absolute change of urinary albumin excretion,perindopril and the L-type calcium antagonist amlodipine,perindopril and the T/L type calcium antagonist benidipine,No significant difference,"The absolute change of urinary albumin excretion also showed no significant difference between patients with diabetes in the amlodipine group and the benidipine group (7.3 ± 106.1 mg/gCr vs. -19.8 ± 292.1 mg/gCr, P = 0.379).",22184:22408, 5755650 ,29317956,Unavailable
 5755650 ,systolic and diastolic blood pressure,perindopril and the L-type calcium antagonist amlodipine,perindopril and the T/L type calcium antagonist benidipine,No significant difference,SBP decreased from 145.8 ± 18.8 mm Hg to 128.2 ± 13.8 mm Hg in the amlodipine group and from 146.7 ± 15.6 mm Hg to 133.5 ± 12.9 mm Hg in the benidipine group.,18191:18350, 5755650 ,29317956,Unavailable
 3718642 ,The eGFR levels,everolimus regimen,mycophenolate mofetil (MMF) regimen,No significant difference,The eGFR levels were higher for the everolimus group through the study but the treatment comparisons did not show any statistically significant differences between the groups at any time point (Table 4; see also Additional file 2).,39160:39486, 3718642 ,23866828,Unavailable
 3718642 ,Composite efficacy failure event rates at month 12,everolimus regimen,mycophenolate mofetil (MMF) regimen,No significant difference,"Composite efficacy failure event rates at month 12 were identical in both groups (everolimus, 11.5% and MMF, 11.5%; Table 3).",32089:32254, 3718642 ,23866828,Unavailable
 3718642 ,"combined rate of death, graft loss and LTFU at month 12",everolimus regimen,mycophenolate mofetil (MMF) regimen,No significant difference,"The main secondary efficacy endpoint (combined rate of death, graft loss and LTFU) at month 12 was statistically non-inferior for everolimus (8.2%) versus MMF (4.9%).",38052:38218, 3718642 ,23866828,Unavailable
 3525562 ,self-esteem and self-efficacy scores,participated in a 6-month program of leadership training and service learning,did not participate in any training,No significant difference,"The intervention group was found to have improvements of both self-esteem (1.28) and self-efficacy (0.26) scores while the control group showed a decrease in both scores. However, the differences in these changes were not found to be statistically significant (p = 0.161 and 0.429, respectively).",31194:31491, 3525562 ,23272199,Unavailable
 2528216 ,Mean (SE) increase in duration of activities,tiotropium 18 μg daily,placebo,No significant difference,"The differences between groups were minor at week 4 prior to pulmonary rehabilitation (279 vs 253 minutes, Figure 3). Differences between groups were not statistically significant.",24619:24838, 2528216 ,18488436,Unavailable
 5984413 ,hits,Alpha Brain® nootropic supplement,placebo,No significant difference,"There was no statistically significant difference between Treatment and Placebo for hits (p = 0.69) (TreatmentPre 18.5 ± 1.5, TreatmentPost 19.4 ± 0.8, PlaceboPre 18.2 ± 2.9, PlaceboPost 19.4 ± 1.3) initial reaction time in seconds (p = 0.65) (TreatmentPre 1.65 ± 0.28, TreatmentPost 1.43 ± 0.28, PlaceboPre 1.59 ± 0.29, PlaceboPost 1.41 ± 0.21),",19355:19735, 5984413 ,29855372,Unavailable
 5984413 ,mean reaction time in seconds,Alpha Brain® nootropic supplement,placebo,No significant difference,"mean reaction time in seconds (p = 0.52) (TreatmentPre 1.60 ± 0.20, TreatmentPost 1.41 ± 0.16, PlaceboPre 1.61 ± 0.51, PlaceboPost 1.46 ± 0.56),",19736:19897, 5984413 ,29855372,Unavailable
 5984413 ,distance from center mass in centimeters,Alpha Brain® nootropic supplement,placebo,No significant difference,"distance from center mass in centimeters(p = 0.87) (TreatmentPre 11.28 ± 4.28, TreatmentPost 11.92 ± 4.23, PlaceboPre 10.52 ± 5.29, PlaceboPost 10.94 ± 4.64).",19901:20077, 5984413 ,29855372,Unavailable
 3659004 ,the difference in response after occlusion in blood flow between US-born Asians and Caucasians ,CoQ10,placebo,Significantly decreased,"As shown in Figure 4, the difference in response after occlusion in blood flow between US-born Asians and Caucasians (panel A) was eliminated after 2-week administration of Coq10 panel B (p&gt;0.05, ANOVA). The placebo group showed no change in their response (p&gt;0.05, ANOVA).",24486:24817, 3659004 ,23666274,Unavailable
 5333470 ,Postoperative visual analogue scale (VAS) pain scores,combining dexmedetomidine with sufentanil,sufentanil alone,Significantly increased,"Evaluation of pain score on VASR (a) and VASC (b) (Values represent means with 95% confidence interval) in the two groups. P &lt; 0.001 by General Linear Model analysis, subsequent comparison between the groups: asterisk = P &lt; 0.023 in VASR and P &lt; 0.02 in VASC after the post hoc analyses, dexmedetomidine group vs. control group",23768:24198, 5333470 ,28249614,Unavailable
 5333470 ,Ramsay sedation scale (RSS) score,combining dexmedetomidine with sufentanil,sufentanil alone,Significantly decreased,RSS scores was lower in the dexmedetomidine group than in the control group (Fig. 3. (a). P &lt; 0.035).Fig. 2,23505:23693, 5333470 ,28249614,Unavailable
 5333470 ,sufentanil consumption at 48 h postoperatively,combining dexmedetomidine with sufentanil,sufentanil alone,Significantly decreased,"Pair-simple comparisons (mean) showed a lower sufentanil consumption in the dexmedetomidine group than in the control group at 48 h postoperatively (Fig. 4. (a)). Total mean doses for each patient: 154 vs. 196 μg/sufentanil, P = 0.034).",24919:25212, 5333470 ,28249614,Unavailable
 5333470 ,Cumulative of meperidine supplementary doses at each time intervals after surgery,combining dexmedetomidine with sufentanil,sufentanil alone,Significantly decreased,Cumulative of meperidine supplementary doses at each time intervals after surgery was significantly lesser in the dexmedetomidine gourp than the control group (P = 0.002).,25918:26107, 5333470 ,28249614,Unavailable
 5333470 ,risk of PONV during the 6 to 48 h,combining dexmedetomidine with sufentanil,sufentanil alone,Significantly decreased,"With regard to the PONV (Fig. 3. (b)), comparison of the risk estimate by PONV scores ≥ 3, patients in the dexmedetomidine group had a significantly reduced risk of PONV during the 6 to 48 h compared with control group (odds ratio 0.184, 95% CI 0.09 to 0.38; P &lt; 0.001), and the incidences of PONV between the groups during 48 h was comparable (12% vs 33%).",26271:26684, 5333470 ,28249614,Unavailable
 5884508 ,Median weight loss,Biliopancreatic Diversion with Duodenal Switch (BPDS),Roux-en-Y Gastric Bypass (RYGB),Significantly increased,"Median weight loss at follow-up was 1.5-fold higher following BPDS relative to RYGB, resulting in respective median BMIs of 29.5 kg/m2 (21.7 to 36.7) after BPDS and 37.8 kg/m2 (34.1 to 45.7) after RYGB (p = 0.015).",14513:14749, 5884508 ,29617391,Unavailable
 5884508 ,fat:lean ratio,Biliopancreatic Diversion with Duodenal Switch (BPDS),Roux-en-Y Gastric Bypass (RYGB),Significantly decreased,The BPDS group had a lower fat:lean ratio compared to the RYGB group (p = 0.009).,14749:14831, 5884508 ,29617391,Unavailable
 5884508 ,total tissue,Biliopancreatic Diversion with Duodenal Switch (BPDS),Roux-en-Y Gastric Bypass (RYGB),Significantly increased,"Overall 24-hour TEE adjusted for total tissue was higher in the BPDS group, as were BMR, fasting EE and MAT (all p&lt;0.05).",14832:14954, 5884508 ,29617391,Unavailable
 4914313 ,overall survival (OS),UFT plus radiotherapy (RT) (A),capecitabine or UFT plus cetuximab plus RT (B),No significant difference,"1-year survival was 100% and 66.7% (p = 0.801, 95% CI: 29.1 - 100) in arms A and B respectively. OS in all registered patients (n = 17) was 15.3 months (95% CI: 13.0 - 17.5) and 64.7% (95% CI: 42.0 - 87.4) of the patients were alive at 1-year.",15830:16107, 4914313 ,26862857,Unavailable
 4914313 ,median progression free survival (PFS),UFT plus radiotherapy (RT) (A),capecitabine or UFT plus cetuximab plus RT (B),No significant difference,"After a median follow-up of 61.2 months, median progression free survival (PFS) was 10.4 months and 12.7 months, median OS was 15.8 months and 22.0 months in arms A and B respectively (p &gt; 0.05).",6678:6890, 4914313 ,26862857,Unavailable
 1065104 ,The dye content of each hemisphere,750 μmol/kg magnesium sulfate was given intramuscularly immediately after surgery.,equal volume of saline,Significantly decreased,"The dye content of each hemisphere was significantly lower in the magnesium-treated septic rats (left hemisphere, 0.00218 ± 0.0005; right hemisphere, 0.00199 ± 0.0007 [all results are means ± standard deviation]) than in control septic animals (left hemisphere, 0.00466 ± 0.0002; right hemisphere, 0.00641 ± 0.0003).",5804:6121, 1065104 ,15693962,Unavailable
 1065104 ,specific gravity,750 μmol/kg magnesium sulfate was given intramuscularly immediately after surgery.,equal volume of saline,Significantly increased,"In septic animals treated with magnesium sulfate, specific gravity was higher (left hemisphere, 1.0438 ± 0.0007; right hemisphere, 1.0439 ± 0.0004) than in the untreated septic animals (left hemisphere, 1.0429 ± 0.0009; right hemisphere, 1.0424 ± 0.0012), indicating less edema formation with the administration of magnesium.",6120:6446, 1065104 ,15693962,Unavailable
 5873829 ,clinical recovery at eight weeks,gluten-free diet (GFD),GFD with prednisolone (GFD+P),No significant difference,No significant differences were detected in clinical recovery at eight weeks;,5905:5984, 5873829 ,29600122,Unavailable
 5873829 ,improvement in histology by at least one grade at 12 months,gluten-free diet (GFD),GFD with prednisolone (GFD+P),No significant difference,"The proportion of patients with improvement in histology by at least one grade was higher in the GFD+P group at eight weeks, and there was no difference in overall histological improvement at 12 months after starting treatment.",6067:6294, 5873829 ,29600122,Unavailable
 5862001 ,Smoothness indexes and treatment-on-variability indexes,dual combination [DCCB + thiazide diuretic (TD)] or olmesartan dual combination (DCCB or TD) or triple combination therapy (DCCB+TD),placebo or angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) or dihydropyridine calcium channel blockers (DCCBs) or olmesartan ,Significantly increased,"Smoothness indexes and treatment-on-variability indexes were significantly (P = 0.0001) higher under olmesartan dual (1.53/1.22, 1.67/1.29, 2.05/1.59), olmesartan triple (2.47/1.85, 2.80/2.06, 3.64/2.67), or active control dual combination (1.70/1.26, 1.85/1.33, 2.29/1.65) than under monotherapies (control: 0.86/0.73, 0.80/0.65, 1.01/0.82; olmesartan: 1.02/0.86, 0.95/0.78, 1.23/1.00).",5695:6100, 5862001 ,29045341,Unavailable
 5862001 ,24-h blood pressure,olmesartan dual combination (olmesartan and DCCB),olmesartan dual combination (olmesartan and TD,No significant difference,"In addition, no difference in 24-h BP reduction was observed between patients treated with an olmesartan dual combination treatment including a dihydropyridine calcium-channel blocker [n = 540; SBP: −20.7 (−21.7, −19.8)/DBP: −12.4 (−12.9, −11.8) mmHg] or a thiazide diuretic [n = 97; SBP: −21.3 (−24.0, −18.7)/DBP: −12.5 (−14.2, −10.9) mmHg; P = 0.678 and P = 0.839 between treatments].",24680:25137, 5862001 ,29045341,Unavailable
 5735484 ,Time for the first analgesic request ,oral midazolam with oral clonidine and regional bupivacaine or oral midazolam and regional clonidine with bupivacaine,oral midazolam and regional bupivacaine,No significant difference,"Time for the first analgesic request was shorter in Group I (2.83 h) compared to Group II (4.43 h) and Group III (3.98 h), but there was no significant difference between the groups (P = 0.161) [Table 3].",16902:17163, 5735484 ,29284845,Unavailable
 5735484 ,parental separation and sedation score,oral midazolam with oral clonidine and regional bupivacaine ,oral midazolam and regional bupivacaine or oral midazolam and regional clonidine with bupivacaine,Significantly increased,Group II had best parental separation and sedation score when compared to other groups (P &lt; 0.05).,17879:17995, 5735484 ,29284845,Unavailable
 5819581 ,BCSS and CAT scores,the best pharmacological therapy (PT) and Intrapulmonary percussive ventilation (IPV)  ,PT group with high-frequency chest wall oscillation (HFCWO),Significantly increased,"Moreover, IPV patients showed an improvement in BCSS (p&lt;0.001) and CAT (p&lt;0.02) scores in comparison with HFCWO.",20402:20535, 5819581 ,29497290,Unavailable
 5819581 ,"TLC and TLC%, RV and RV%, and DLCO, MIP, and MEP",the best pharmacological therapy (PT) and Intrapulmonary percussive ventilation (IPV),PT group with high-frequency chest wall oscillation (HFCWO) ,Significantly increased,"However, in the group comparison analysis for the same variables between IPV group and HFCWO group, we observed a significant improvement in the IPV group in TLC and TLC% (p&lt;0.03), RV and RV% (p&lt;0.04), and DLCO, MIP, and MEP (p&lt;0.01).",20402:20535, 5819581 ,29497290,Unavailable
 5819581 ,"total cell count and neutrophil, lymphocyte, and macrophage counts in sputum samples",the best pharmacological therapy (PT) and Intrapulmonary percussive ventilation (IPV) or PT group with high-frequency chest wall oscillation (HFCWO) ,PT alone,Significantly increased,"A significant change in total cell count and neutrophil, lymphocyte, and macrophage counts in sputum samples were observed in the patients receiving either of the two treatments (IPV and HFCWO) compared to control group.",20181:20401, 5819581 ,29497290,Unavailable
 5819581 ,neutrophil count,"the best pharmacological therapy (PT) and Intrapulmonary percussive ventilation (IPV)  , ",PT group with high-frequency chest wall oscillation (HFCWO) ,Significantly increased,Only a slight significant change in neutrophil count was observed in the IPV group compared to HFCWO group (p&lt;0.05).,20402:20535, 5819581 ,29497290,Unavailable
 5819581 ,"mMRC, BCSS, and CAT scores",the best pharmacological therapy (PT) and Intrapulmonary percussive ventilation (IPV) or PT group with high-frequency chest wall oscillation (HFCWO) ,PT alone,Significantly increased,"Patients in both the IPV group and the HFCWO group showed a significant improvement in the tests of dyspnea and daily life and health status assessment (mMRC, BCSS, and CAT) compared to those in the control group.",18846:19059, 5819581 ,29497290,Unavailable
 5599826 ,eye open center of pressure-x (EO CoP-x),augmented reality (AR)-based otago exercise or yoga group ,self-exercise group ,Significantly decreased,"Regarding balance, eye open center of pressure-x (EO CoP-x) was significantly (p&lt;0.05) decreased in AR group and yoga group.",11613:11738, 5599826 ,28931993,Unavailable
 5599826 ,"eye close center of pressure (EC COP-x), eye open standard deviation-x (EO SD-x), and eye open height of ellipse (EO HoE)",augmented reality (AR)-based otago exercise ,self-exercise group or yoga group ,Significantly decreased,"However, eye close center of pressure (EC COP-x), eye open standard deviation-x (EO SD-x), and eye open height of ellipse (EO HoE) were only significantly decreased in the AR group.",11738:11920, 5599826 ,28931993,Unavailable
 5599826 ,morse fall scale,augmented reality (AR)-based otago exercise ,self-exercise group or yoga group ,Significantly increased,AR group also showed meaningfully (p&lt;0.05) improved results in morse fall scale.,11920:12001, 5599826 ,28931993,Unavailable
 5388709 ,"voluntary or electrically evoked isometric force production, or twitch electromechanical delay and time-to-peak tension",β-alanine (BA),placebo,No significant difference,"BA supplementation had no effect on voluntary or electrically evoked isometric force production, or twitch electromechanical delay and time-to-peak tension.",5921:6078, 5388709 ,28349262,Unavailable
 5388709 ,percentage change in fresh muscle HRT,β-alanine (BA),placebo,No significant difference,"Post hoc analysis showed that the percentage change in fresh muscle HRT was not significantly different between the BA (0 ± 9 ms; +1 ± 15%) and PLA group (+7 ± 10 ms; +12±15%) with a medium effect reported (P = 0.10, Cohen’s d = 0.7).",50115:50401, 5388709 ,28349262,Unavailable
 5388709 ,percentage change in fatigued muscle HRT,β-alanine (BA),placebo,Significantly decreased,"In fatigued muscle, post hoc analysis showed that the percentage change in fatigued muscle HRT was significantly different between the BA (−2.7 ± 16 ms; −2 ± 20%) and PLA group (12 ± 12 ms; 16 ± 17%) with a large effect reported (P = 0.03, Cohen’s d = 1.0).",50400:50709, 5388709 ,28349262,Unavailable
 2556743 ,amount of HES and the total amount of fluid,minimizing the variation in arterial pulse pressure (ΔPP) induced by mechanical ventilation.,control,Significantly increased,"During the surgical procedure, the amount of HES and the total amount of fluid (including crystalloid, HES, and blood products) was significantly greater in group I than in group C (Table 2).",21457:21688, 2556743 ,17822565,Unavailable
 2556743 ,"duration of mechanical ventilation, stay in the ICU, stay in hospital ",minimizing the variation in arterial pulse pressure (ΔPP) induced by mechanical ventilation.,control,Significantly decreased,"The median [interquartile range] duration of mechanical ventilation (1 [1 to 2] versus 5 [1 to 12] days, P &lt; 0.05), stay in the ICU (3 [2 to 4] versus 9 [4.5 to 15.5] days, P &lt; 0.01), and stay in hospital (7 [6 to 8.25] versus 17 [8 to 20] days, P &lt; 0.01) was significantly lower in group I than in group C (Figure 4). Over the study period (until hospital discharge), five patients died (on days 7, 11, 18, 19, and 26) in group C, whereas two patients died (on days 7 and 22) in group I (P = 0.171).",26669:27066, 2556743 ,17822565,Unavailable
 2556743 ,The number of patients with postoperative complications,minimizing the variation in arterial pulse pressure (ΔPP) induced by mechanical ventilation.,control,Significantly decreased,"The number of patients with postoperative complications is shown in Figure 3. Fewer patients developed complications in group I (7 patients (41%) versus 12 patients (75%), P = 0.049). The number of complications per patient was lower in group I than in group C (1.4 ± 2.1 per patient versus 3.9 ± 2.8 per patient, P = 0.015).",26669:27066, 2556743 ,17822565,Unavailable
 5966929 ,The proportion of accurate trials ,received four 30-min robot-based gestural training sessions,received the gestural training after the completion of research,Significantly increased,"The proportion of accurate trials with the participants with ASD in the intervention condition was greater than that for the participants with typical development, p &lt; .001, and for the participants with ASD in the wait-list control condition, p &lt; .001.",51634:51928, 5966929 ,29796238,Unavailable
 3499555 ,IncellDx positivity,mRNA testing,DNA testing,Significantly decreased,"IncellDx mRNA positivity was almost half of CLART2 DNA positivity (29.7% vs. 55.5, p&lt;0.001),",36520:36614, 3499555 ,23166611,Unavailable
 3499555 ,inadequate samples,mRNA testing,DNA testing,Significantly increased,"Furthermore, mRNA had significantly more inadequate samples (36 vs. 14, p = 0.007).",36866:36949, 3499555 ,23166611,Unavailable
 3499555 ,specificity and PPV ,mRNA testing,DNA testing,Significantly increased,"mRNA testing displayed similar NPV, slightly lower sensitivity but significantly higher specificity and PPV than DNA testing, except only when DNA positivity for either HPV16 or 18 was used.",7915:8105, 3499555 ,23166611,Unavailable
 5440036 ,The nausea severity,7.5 μg/kg palonosetron or 2.5 μg/kg palonosetron and 15 μg/kg droperidol ,"2.5 μg/kg palonosetron, ",Significantly decreased,"The nausea severity in Group P7.5 and Group P+D was significantly lower than that in Group P2.5 at 0–4 h (PP2.5–P7.5=0.0159, PP2.5–P+D=0.0003) and 24–48 h (PP2.5–P7.5=0.0032, PP2.5–P+D=0.0032), while the nausea score between Group P7.5 and Group P+D was similar (P=0.3580).",20119:20521, 5440036 ,28553076,Unavailable
 5440036 ,the vomiting scores,7.5 μg/kg palonosetron or 2.5 μg/kg palonosetron and 15 μg/kg droperidol ,"2.5 μg/kg palonosetron, ",No significant difference,No significant difference was found between the vomiting scores of each group.,19882:19960, 5440036 ,28553076,Unavailable
 5440036 ,The CR rate,2.5 μg/kg palonosetron,2.5 μg/kg palonosetron and 15 μg/kg droperidol ,Significantly decreased,"The CR rate of Group P2.5 was significantly lower than that of Group P+D at all time intervals, except for 4–72 h, and that of Group P7.5 at 24–72 h (Table 3).",20695:20906, 5440036 ,28553076,Unavailable
 5440036 ,The recovery time,7.5 μg/kg palonosetron or 2.5 μg/kg palonosetron and 15 μg/kg droperidol ,"2.5 μg/kg palonosetron, ",No significant difference,"The recovery time of Group P2.5, Group P7.5, and Group P+D was 33.32±8.36 min, 30.00±7.01 min, and 29.67±8.69 min, respectively. No significant difference was found between the three groups, in terms of recovery time (P=0.076).",20907:21151, 5440036 ,28553076,Unavailable
 4710520 ,The difference of IOP,"dorzolamide-timolol fixed combination (DTFC) and lubricant, and latanoprost for 4 weeks each","latanoprost, lubricant, and DTFC for 4 weeks each",No significant difference,The difference of IOP between the two treatments was 0.39 ± 0.21 mmHg (mean ± SE) and there was no statistically significant difference (p = 0.07).,25087:25235, 4710520 ,26756747,Unavailable
 4710520 ,Fluctuation in IOP,"dorzolamide-timolol fixed combination (DTFC) and lubricant, and latanoprost for 4 weeks each","latanoprost, lubricant, and DTFC for 4 weeks each",No significant difference,"Fluctuation in IOP was calculated for each visit, and there was no statistically significant difference between the two treatments (p = 0.65).",25869:26011, 4710520 ,26756747,Unavailable
 4710520 ,Diurnal systolic and diastolic BP,"dorzolamide-timolol fixed combination (DTFC) and lubricant, and latanoprost for 4 weeks each","latanoprost, lubricant, and DTFC for 4 weeks each",No significant difference,"Diurnal systolic and diastolic BP were lower in the DTFC than latanoprost group; however, the difference between the groups was not statistically significant (Table 3, Fig 3).",35723:36004, 4710520 ,26756747,Unavailable
 4710520 ,The heart rate,"dorzolamide-timolol fixed combination (DTFC) and lubricant, and latanoprost for 4 weeks each","latanoprost, lubricant, and DTFC for 4 weeks each",No significant difference,The HR showed no statistically significant difference between the groups (Table 4).,36005:36142, 4710520 ,26756747,Unavailable
 4710520 ,Diurnal OPP and DOPP,"dorzolamide-timolol fixed combination (DTFC) and lubricant, and latanoprost for 4 weeks each","latanoprost, lubricant, and DTFC for 4 weeks each",No significant difference,Diurnal OPP and DOPP also showed no statistically significant difference between the groups at all time points (Tables 5 and 6; Fig 4).,36513:36809, 4710520 ,26756747,Unavailable
 4360612 ,Six-month satisfaction rates,minimally invasive SI joint fusion with triangular titanium implants ,non-surgical management,Significantly increased,"Six-month satisfaction rates were higher in the surgery group compared to the NSM group (79.0 vs. 27.3% very satisfied, p&lt;.0001);",54700:54830, 4360612 ,25785242,Unavailable
 4360612 ,The mean number of adverse events per subject,minimally invasive SI joint fusion with triangular titanium implants ,non-surgical management,No significant difference,"The mean number of events per subject was slightly higher in the surgery group (1.3 vs. 1.0 events, p=0.1857).",55260:55371, 4360612 ,25785242,Unavailable
 4360612 ,number of patient exhibited pain improvement of ≥20 points,minimally invasive SI joint fusion with triangular titanium implants ,non-surgical management,Significantly increased,83% of the surgery group and 25% of the NSM group exhibited a pain improvement of ≥20 points (p&lt;.0001).,48243:48347, 4360612 ,25785242,Unavailable
 4360612 ,success rates,minimally invasive SI joint fusion with triangular titanium implants ,non-surgical management,Significantly increased,"By month 6, 83 of 102 SI joint fusion subjects (81.4%, 95% posterior credible interval [CI] 72.4-88.4%) and 11 of 46 NSM subjects (23.9%, 95% CI 12.6-38.8%) met the study's primary success endpoint. The difference in success rates was 56.6% (95% CI 41.4-70.0%) and the posterior probability that the success rate was higher in the SI joint fusion group was &gt;0.999.",44038:44403, 4360612 ,25785242,Unavailable
 4360612 ,number of patient that had ODI improvement of ≥15 points,minimally invasive SI joint fusion with triangular titanium implants ,non-surgical management,Significantly increased,75% of the surgery group vs. 27.3% of the NSM group had ODI improvement of ≥15 points (p&lt;.0001).,48626:48723, 4360612 ,25785242,Unavailable
 5852933 ,the shear bond strength of the composite resin with dentin,dentin pretreatment with 10% sodium ascorbate for 5 min (IIa) or 10 min (IIb),no dentin pretreatment done or dentin pretreatment with 6.5% proanthocyanidin (PA) for 5 min (IIIa) or 10 min (IIIb).,Significantly increased,"Mean difference was found to be maximum between Groups I and IIb and minimum between Groups IIIa and IIIb. All the between-group comparisons except between Groups IIIa and IIIb were significant statistically [Table 3]. On the basis of above evaluation, the following order of shear bond strength was observed in different groups/subgroups:IIb &gt; IIa &gt; IIIb ~ IIIa &gt; I” with “IIb &gt; IIa &gt; IIIb &gt; IIIa &gt; I”.",14518:15007, 5852933 ,29628645,Unavailable
 2365957 ,proportion of patients achieving HIV-1 RNA &lt; 50 copies/mL in the ITT,Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100),"atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg",No significant difference,"No significant differences (p &gt; 0.05) were noted between the FPV/r100 and ATV/r100 regimens at week 48 (Figure 1) regarding proportion of patients achieving HIV-1 RNA &lt; 50 copies/mL in the ITT: MD = F analysis (75% vs 83%) or ITT:observed analysis (89% vs 92%), nor in the proportion achieving &lt; 400 copies/mL in these analyses (79% vs 87%); 93% vs 96%).",21842:22255, 2365957 ,18373851,Unavailable
 2365957 ,magnitude of CD4+ count,Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100),"atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg",No significant difference,"CD4+ counts showed a similar pattern of increase over the course of the study in the FPV/r100 and ATV/r100 arms, with no statistically significant differences in magnitude of CD4+ count increase at any study visit (Figure 2).",23528:23790, 2365957 ,18373851,Unavailable
 2365957 ,Fasting total/LDL/HDL-cholesterol,Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100),"atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg",No significant difference,"Fasting total/LDL/HDL-cholesterol changes-from-baseline were also similar,",5679:5754, 2365957 ,18373851,Unavailable
 5066860 ,MRS score,"probiotics plus NUT for 4 weeks, followed by a 4-week treatment with probiotics plus placebo ","probiotics plus placebo over 4 weeks, followed by a 4-week treatment with probiotics plus NUT",Significantly decreased,"After the NUT period, participants showed a significant reduction in MRS score (18.4±5.4) in comparison to baseline (28.4±5) and the placebo period (28±5.2) (P&lt;0.0001 for both comparisons) (Figure 2).",18860:19128, 5066860 ,27785106,Unavailable
 5066860 ,high-density lipoprotein cholesterol plasma concentration,"probiotics plus NUT for 4 weeks, followed by a 4-week treatment with probiotics plus placebo ","probiotics plus placebo over 4 weeks, followed by a 4-week treatment with probiotics plus NUT",Significantly increased,increase in high-density lipoprotein cholesterol plasma concentration versus baseline and versus placebo (all P&lt;0.04).,5669:5808, 5066860 ,27785106,Unavailable
 5066860 ,triglycerides and total and low-density lipid (LDL)-cholesterol plasma levels,"probiotics plus NUT for 4 weeks, followed by a 4-week treatment with probiotics plus placebo ","probiotics plus placebo over 4 weeks, followed by a 4-week treatment with probiotics plus NUT",Significantly decreased,"In particular, at the end of the active-treatment period, we observed a significant reduction in triglycerides and total and low-density lipid (LDL)-cholesterol plasma levels, and an increase in HDL-cholesterol plasma concentration versus baseline and versus placebo (all P&lt;0.04).",19723:20022, 5066860 ,27785106,Unavailable
 5066860 ,MRS score,"probiotics plus NUT for 4 weeks, followed by a 4-week treatment with probiotics plus placebo ","probiotics plus placebo over 4 weeks, followed by a 4-week treatment with probiotics plus NUT",Significantly decreased,"After the NUT period, participants showed a significant reduction in MRS score (18.4±5.4) in comparison to baseline (28.4±5) and the placebo period (28±5.2) (P&lt;0.0001 for both comparisons) (Figure 2).",18860:19128, 5066860 ,27785106,Unavailable
 5066860 ,high-density lipoprotein cholesterol plasma concentration,"probiotics plus NUT for 4 weeks, followed by a 4-week treatment with probiotics plus placebo ","probiotics plus placebo over 4 weeks, followed by a 4-week treatment with probiotics plus NUT",Significantly increased,increase in high-density lipoprotein cholesterol plasma concentration versus baseline and versus placebo (all P&lt;0.04).,5669:5808, 5066860 ,27785106,Unavailable
 5066860 ,triglycerides and total and low-density lipid (LDL)-cholesterol plasma levels,"probiotics plus NUT for 4 weeks, followed by a 4-week treatment with probiotics plus placebo ","probiotics plus placebo over 4 weeks, followed by a 4-week treatment with probiotics plus NUT",Significantly decreased,"In particular, at the end of the active-treatment period, we observed a significant reduction in triglycerides and total and low-density lipid (LDL)-cholesterol plasma levels, and an increase in HDL-cholesterol plasma concentration versus baseline and versus placebo (all P&lt;0.04).",19723:20022, 5066860 ,27785106,Unavailable
 4360719 ,"CRQ dyspnoea score, the ESWT distance between the two groups, BMI, body fat EQ5D, MET-minutes, activity rating, HADS, exacerbations or admissions",2 h (1 h individually tailored exercise training and 1 h education programme) every 3 months for 1 year.,standard care,No significant difference,"No statistically significant differences were detected between the intervention and control groups for the CRQ dyspnoea score (0.19 (−0.26 to 0.64) units) or other domains of the CRQ, the ESWT distance between the two groups (109.1 (−100.1 to 318.2) metres), BMI, body fat EQ5D, MET-minutes, activity rating, HADS, exacerbations or admissions (table 2).",29934:30345, 4360719 ,25762226,Unavailable
 4210953 ,"PHQ, GAD, or WSAS scores",short message service (SMS),control,No significant difference,"Intervention and control groups did not differ significantly on their intake PHQ, GAD, or WSAS scores, suggesting similar levels of psychological distress.",28114:28269, 4210953 ,25295667,Unavailable
 4210953 ,"treatment completion, treatment length, number of sessions attended, or DNA rate",short message service (SMS),control,No significant difference,"Regarding attendance, there were no statistically significant differences between intervention and control groups on treatment completion, treatment length, number of sessions attended, or DNA rate.",29267:29466, 4210953 ,25295667,Unavailable
 3258215 ,the frequency of providing EAFD and EASD of statins in community pharmacies,intensive support for the implementation,a written manual on the implementation of EAFD and EASD ,No significant difference,"In the intervention group a total of 72 of 469 new statin users (15.4%) received education and 49 of 393 patients with a second statin prescription (12.5%) compared to 78 of 402 new users (19.4%, P = 0.944) and 35 of 342 patients with a second prescription (10.2%, P = 0.579) in the control group.",5191:5522, 3258215 ,22087850,Unavailable
 4769147 ,"rates of exclusive as well as any breastfeeding at discharge, 3 months and 6 months of infants’ age ","controlled limited formula (CLF) intervention (10 ml formula by syringe after each breastfeeding, discontinued at onset of lactation) ","control group (standard approach, SA).",No significant difference,"We found no evidence of difference between treatment groups in the rates of exclusive as well as any breastfeeding at discharge (p-value 0.2 and &gt;0.99 respectively), 3 months (p-value 0.12 and 0.10) and 6 months of infants’ age (p-value 0.45 and 0.34 respectively).",11235:11500, 4769147 ,26918700,Unavailable
 4769147 ,maximal body weight loss,"controlled limited formula (CLF) intervention (10 ml formula by syringe after each breastfeeding, discontinued at onset of lactation) ","control group (standard approach, SA).",Significantly decreased,"Although there was no statistically significant difference in birth weights or weights at enrolment between the intervention groups, there was a significant difference in the maximal body weight loss (expressed in percent—minus 7.3% in CLF group and minus 8.4% in control group respectively, p = 0.002).",47801:48104, 4769147 ,26918700,Unavailable
 4769147 ,Levels of bilirubin above 200 umol/l,"controlled limited formula (CLF) intervention (10 ml formula by syringe after each breastfeeding, discontinued at onset of lactation) ","control group (standard approach, SA).",Significantly decreased,"Llevels of bilirubin above 200 umol/l were found in 8 cases (16%) in the CLF group and in 18 cases (36%) in the control group. This difference is statistically significant (p-value 0.02),",49129:49317, 4769147 ,26918700,Unavailable
 3659156 ,blood pressure values,"hemodynamic, in which treatment choice considered impedance cardiography results",empiric,Significantly decreased,"All final blood pressure values were lower in the hemodynamic group, significantly for office systolic blood pressure (empiric vs. hemodynamic: 136.1 vs. 131.6 mmHg; p=0.036) and diastolic blood pressure (87.0 vs. 83.7 mmHg; p=0.013), as well as night-time systolic blood pressure (121.3 vs. 117.2 mmHg; p=0.023) and diastolic blood pressure (71.9 vs. 68.4 mmHg; p=0.007).",5190:5648, 3659156 ,23558598,Unavailable
 3770450 ,Serum P1NP,2-hour session of Thai traditional massage twice a week for 4 weeks,"4-week control period after a 2-week washout, or vice versa",Significantly increased,"Serum P1NP increased significantly after Thai traditional massage (P &lt;0.01),",3866:3960, 3770450 ,23530566,Unavailable
 3770450 ,serum osteocalcin or CTX,2-hour session of Thai traditional massage twice a week for 4 weeks,"4-week control period after a 2-week washout, or vice versa",No significant difference,while there was no change in serum osteocalcin or CTX.,3960:4015, 3770450 ,23530566,Unavailable
 3611074 ,median preoperative anxiety score in the pediatric ward and in the operating room,1 mg/kg ketorolac,control,No significant difference,"There was no significant difference in the median preoperative anxiety score using mYAS between two groups in the pediatric ward (median: 23.3 and range: 23.3-23.3 in the control group vs. median 23.3 and range: 23.3-30.0 in the ketorolac group, P = 0.178) and in the operating room (median: 31.7 and range: 25.0-41.7 in the control group vs. median: 31.7 and range: 27.5-47.5 in the ketorolac group, P = 0.447).",15459:15871, 3611074 ,23560190,Unavailable
 3611074 ,"the incidence of EA  at 5, 20 min ",1 mg/kg ketorolac,control,No significant difference,"There was no significant difference in the incidence of EA between control groups and the ketorolac group at 5 min (one patient, 3% vs. four patients, 10%, P = 0.360) and at 20 min (16 patients, 41 % vs 11 patients, 27%, P = 0.269).",16016:16249, 3611074 ,23560190,Unavailable
 3611074 ,The total number of patients displaying EA,1 mg/kg ketorolac,control,No significant difference,The total number of patients displaying EA was 16 (41%) in the control group and 13 (32%) in the ketorolac group (P = 0.526) (Fig. 1).,16249:16421, 3611074 ,23560190,Unavailable
 3611074 ,the number of children who received fentanyl for analgesia after 20 min in the PACU,1 mg/kg ketorolac,control,Significantly decreased,"There was a significant difference in the number of children who received fentanyl for analgesia after 20 min in the PACU when comparing the control group (13/39, 33%) to the ketorolac group (5/41, 12%) (P = 0.046).",16833:17048, 3611074 ,23560190,Unavailable
 5654748 ,"average number of days per week with a step entry, average time per week on the website and average number of website visits per week",Web 2.0-based intervention on physical activity behaviour,10 000 Steps programme,Significantly increased,"The Web 2.0 group had significantly higher average number of days per week with a step entry, average time per week on the website and average number of website visits per week at 0–3, 3–12 and 12–18 months compared with the Web 1.0 group (table 4).",39607:39914, 5654748 ,28049624,Unavailable
 5654748 ,average number of days per week with a step comment at 0–3 months;,Web 2.0-based intervention on physical activity behaviour,10 000 Steps programme,Significantly increased,The Web 2.0 group had a significantly greater average number of days per week with a step comment in comparison with the Web 1.0 group at 0–3 months;,39915:40065, 5654748 ,28049624,Unavailable
 5654748 ,average number of days per week with a step comment at 3–12 and 12–18 months.,Web 2.0-based intervention on physical activity behaviour,10 000 Steps programme,No significant difference,"The Web 2.0 group had a significantly greater average number of days per week with a step comment in comparison with the Web 1.0 group at 0–3 months; however, this was no longer statistically significant at 3–12 and 12–18 months.",39915:40144, 5654748 ,28049624,Unavailable
 4768925 ,The NIHSS score and levels of ACTH and COR,intravenous drips of butylphthalide,control,Significantly decreased,The NIHSS score and levels of ACTH and COR of the treatment group were significantly lower than those of the control group (p&lt;0.05).,4592:4725, 4768925 ,26955446,Unavailable
 3622018 ,sleep disturbance symptoms,Mind–Body Bridging (MBB) and Mindfulness Meditation (MM) ,sleep hygiene education (SHE),Significantly decreased,"Mixed effects model analysis revealed that mean sleep disturbance symptoms in the MBB (p = .0029) and MM (p = .0499) groups were lower than in the SHE group, indicating that both mind–body interventions improved sleep.",4480:4732, 3622018 ,23338490,Unavailable
 3622018 ,"overall levels of mindfulness, self-compassion, well-being",Mind–Body Bridging (MBB) ,sleep hygiene education (SHE),Significantly increased,"In addition, compared with the SHE group, the MBB group showed reductions in self-reported depression symptoms (p = .040) and improvements in overall levels of mindfulness (p = .018), self-compassion (p = .028), and well-being (p = .019) at postintervention.",4732:5059, 3622018 ,23338490,Unavailable
 3622018 ,self-reported depression symptoms,Mind–Body Bridging (MBB) ,sleep hygiene education (SHE),Significantly decreased,"In addition, compared with the SHE group, the MBB group showed reductions in self-reported depression symptoms (p = .040)",4732:4872, 3622018 ,23338490,Unavailable
 3622018 ,Positive and Negative Affect,Mind–Body Bridging (MBB)  and Mindfulness Meditation (MM) ,sleep hygiene education (SHE),No significant difference,"However, the ANCOVA indicated that the groups did not statistically differ from one another for negative (p = .612) and positive affect (p = .278) (see Table 7 for unadjusted means and standard deviations of PANAS scores).",83005:83302, 3622018 ,23338490,Unavailable
 5055753 ,The percentages of patients in the calm and sedated scale,0.2 mg oral clonidine ,2 mg oral midazolam,Significantly increased,"The percentages of patients in the calm and sedated scale were significantly higher in the clonidine group (35 and 42.5%, respectively), compared to the midazolam group (17.5 and 17.5%, respectively) (P = 0.042, 0.029; respectively).",18414:18648, 5055753 ,27761415,Unavailable
 5055753 ,the percentages of patients in the agitated and heavily sedated,0.2 mg oral clonidine ,2 mg oral midazolam,Significantly decreased,"In addition, the percentages of patients in the agitated and heavily sedated group were significantly higher in the midazolam group, compared to this in the clonidine group (P = 0.002 and 0.014; respectively) (Figure 1).",18648:18911, 5055753 ,27761415,Unavailable
 5055753 ,The mean ± SD of intraoperatively administered fentany,0.2 mg oral clonidine ,2 mg oral midazolam,Significantly decreased,The mean ± SD of intraoperatively administered fentanyl in the clonidine group (105 ± 30.8) was significantly lower than in the midazolam group (165 ± 34.5) (P = 0.0018) (Figure 2).,19296:19520, 5055753 ,27761415,Unavailable
 5055753 ,Mean ± SD of heart rate,0.2 mg oral clonidine ,2 mg oral midazolam,No significant difference,"Mean ± SD of heart rate in the clonidine group was lower than that for the midazolam group, at 0 (P = 0.51), 30 (P = 0.24), 60 (P = 0.32), 90 (P = 0.088), 120 (P = 0.072), and 180 (P = 0.095) minutes, but it was not significant at these time points (Figure 3).",19892:20195, 5055753 ,27761415,Unavailable
 5055753 ,VAS scores at one and two hours after operation,0.2 mg oral clonidine ,2 mg oral midazolam,Significantly decreased,"VAS scores were significantly lower at one (P = 0.01) and two hours (P = 0.001) after operation in the clonidine group, compared to the midazolam group.",5459:5611, 5055753 ,27761415,Unavailable
 4815896 ,MMP-8 levels,Low-dose methylprednisolone therapy ,placebo,Significantly increased,"On day 7, reduction in MMP-8 levels (p = 0.0016) occurred in the MPT group,",9656:9749, 4815896 ,27066464,Unavailable
 4815896 ,soluble intercellular adhesion molecule-1 (sICAM-1),Low-dose methylprednisolone therapy ,placebo,Significantly decreased,whereas increases in sICAM-1 levels (p = 0.0005) occurred in the placebo group (no increases in sICAM-1 in the MPT group).,9750:9890, 4815896 ,27066464,Unavailable
 4815896 ,sRAGE levels,Low-dose methylprednisolone therapy ,placebo,No significant difference,sRAGE levels decreased in both MPT and placebo groups (p &lt; 0.0001) from day 0 to day 7.,9890:9995, 4815896 ,27066464,Unavailable
 2826289 ,the Patient Pain Assessment score ,"Bacillus coagulans GBI-30, 6086",placebo,No significant difference,"Subjects who received Bacillus coagulans GBI-30, 6086 experienced borderline statistically significant improvement in the Patient Pain Assessment score (P = .052",4237:4432, 2826289 ,20067641,Unavailable
 2826289 ,Pain Scale ,"Bacillus coagulans GBI-30, 6086",placebo,Significantly decreased,"Subjects who received Bacillus coagulans GBI-30, 6086 experienced borderline statistically significant improvement in the Patient Pain Assessment score (P = .052) and statistically significant improvement in Pain Scale (P = .046) vs placebo.",4237:4530, 2826289 ,20067641,Unavailable
 2826289 ,physician global assessment or physician assessment of painful and swollen joints,"Bacillus coagulans GBI-30, 6086",placebo,No significant difference,There were no significant differences in the physician global assessment or physician assessment of painful and swollen joints.,17196:17324, 2826289 ,20067641,Unavailable
 2826289 ,the ability to walk 2 miles and the ability to reach,"Bacillus coagulans GBI-30, 6086",placebo,No significant difference,"For the HAQ individual disability scores, the ability to walk 2 miles was marginally significant (P = .072) and the ability to reach was not quite significant (P = .11) (Table 2).",17324:17585, 2826289 ,20067641,Unavailable
 4218766 ,risk of 1-year CV morbidity and mortality ,zofenopril 60 mg/day,placebo,Significantly decreased,"In either men or women zofenopril treatment was associated with a significantly larger reduction in the risk of 1-year CV morbidity and mortality and an improved survival as compared to placebo [odds ratio and 95% confidence interval for men: 0.61 (0.48, 0.78), p = 0.0001; women: 0.60 (0.43, 0.86), p = 0.005) ( Figure 3 and 4 ).",37012:37475, 4218766 ,25364906,Unavailable
 3575612 ,adverse drug reactions,pterostilbene 125 mg twice daily or pterostilbene 50 mg twice daily or pterostilbene 50 mg + grape extract (GE) 100 mg twice daily  ,matching placebo twice daily for 6–8 weeks.,No significant difference,"There was no biochemical ADRs on liver, kidney, or glucose markers (See Figure 1). There were no statistically significant self-reported ADRs versus placebo (see Table 2). There were no major ADRs (e.g., hospitalization, new-onset disease, infection, or death).",12972:13314, 3575612 ,23431291,Unavailable
 3575612 ,bicarbonate ,pterostilbene 125 mg twice daily ,matching placebo twice daily for 6–8 weeks.,Significantly decreased,There was a significant 3.6% reduction in bicarbonate in the high-dose group versus placebo (P = 0.02) with a similar trend in both low-dose groups.,13314:13480, 3575612 ,23431291,Unavailable
 3575612 ,BUN,pterostilbene 50 mg twice daily or pterostilbene 50 mg + grape extract (GE) 100 mg twice daily  ,matching placebo twice daily for 6–8 weeks.,No significant difference,"The combination of grape extract and low-dose pterostilbene decreased BUN by 7.1% from baseline (P = 0.01), but this reduction was not significant when compared to placebo (P = 0.20).",13480:13698, 3575612 ,23431291,Unavailable
 4525725 ,The mean number of topics discussed,tailored health risk feedback,generic health risk feedback,No significant difference,"The mean number of topics discussed did not differ between those who received the generic (M = 2.87, SD = 2.39) versus the tailored feedback (M = 2.83, SD = 2.28; t(85) = 0.08, p = .94).",28796:29085, 4525725 ,26243144,Unavailable
 4525725 ,the average number of additional actions related to survey health risks taken by the GP,tailored health risk feedback,generic health risk feedback,No significant difference,"There was also no difference in the average number of additional actions related to survey health risks taken by the GP (such as help plan changes to lifestyle, gave me information, organised a follow up appointment) between participants who received the generic versus tailored feedback (t(85) = 0.85, p = .40).",29085:29431, 4525725 ,26243144,Unavailable
 4525725 ,participants who show report to their GP,tailored health risk feedback,generic health risk feedback,Significantly increased,"Significantly more participants who received the tailored feedback reported showing this to their GP than those who received the generic feedback, Fisher’s exact χ2(2, N = 70) = 7.30, p = .03.Table 2",27454:27744, 4525725 ,26243144,Unavailable
 4525725 ,Participants who agree that the feedback was ‘relevant to me’ ,tailored health risk feedback,generic health risk feedback,Significantly increased,"Participants were significantly more likely to agree that the tailored feedback was ‘relevant to me’ compared to the generic feedback, Fisher’s exact: χ2(1, N = 87) = 5.22, p = .03,",26473:26717, 4525725 ,26243144,Unavailable
 5799986 ,extruded debris,EndoIrrigator Plus,conventional syringe or PUI,Significantly decreased,Tukey's multiple post hoc tests revealed that EndoIrrigator Plus group extruded significantly less debris than PUI and conventional syringe irrigation groups (P &lt; 0.05).,13745:13948, 5799986 ,29430092,Unavailable
 5799986 ,extruded debris,PUI,conventional syringe ,Significantly decreased,"In addition, PUI group extruded significantly less debris than conventional syringe irrigation group (P &lt; 0.05) [Table 2].",13949:14133, 5799986 ,29430092,Unavailable
 5827507 ,Dentinal hypersensitivity (DH),"combined 5% KNO3 and the diode laser or  gallium-aluminum-arsenide diode laser (62.2 J/cm2, wavelength - 980 nm, noncontact pulse mode, and power wattage - 0.5 W);",5% potassium nitrate (KNO3) ,Significantly decreased,A significant reduction in DH was observed for Group 3 (GaAlA laser diode and 5% KNO3) and Group 2 (GaAlA laser diode) than Group 1 (5% KNO3).,14778:14942, 5827507 ,29491586,Unavailable
 4170701 ,"ESR, CRP, Hb, grip strength, BAS-G, BASFI, and BASDAI, either at baseline or after 3-month exercise",combined home exercise (COMB),range-of-motion home exercise (ROM),No significant difference,"On the follow-up of disease activity and functional ability, no significant statistical difference was found between the two groups in ESR, CRP, Hb, grip strength, BAS-G, BASFI, and BASDAI, either at baseline or after 3-month exercise (Table 5).",28810:29097, 4170701 ,25276785,Unavailable
 4170701 ,variables of pulmonary function test,combined home exercise (COMB),range-of-motion home exercise (ROM),No significant difference,"Either at baseline or after 3-month exercise, no significant difference was observed between the two groups in terms of variables of pulmonary function test.",28263:28421, 4170701 ,25276785,Unavailable
 5815237 ,CHI3L1 concentration decline,inhaled nitric oxide (iNO),placebo,Significantly decreased,"The baseline (day 1) CHI3L1 concentration (estimate, 95% CI 213 ng/mL, 176–259) decreased by 34% per day (95% CI 31–38) in the placebo group and 29% per day (95% CI 25–33) in the iNO group (p = 0.007) (Fig. 2).Fig. 2",40473:40750, 5815237 ,29448936,Unavailable
 5777419 ,the total cultivable microbiota,probiotic or antibiotic,placebo ,No significant difference,"At microbiological level, the total cultivable microbiota decreased significantly in the probiotic and antibiotic groups. In the placebo group, the prevalence of subjects with P. gingivalis decreased. However, there were no significant differences between groups.",47680:47960, 5777419 ,29364340,Unavailable
 5777419 ,"attachment gain, reduction of PPD, and reduction of plaque",probiotic or antibiotic,placebo ,No significant difference,"In the probiotic group, we observed attachment gain, reduction of PPD, and reduction of plaque, which was not significant when compared with the other groups.",48169:48327, 5777419 ,29364340,Unavailable
 3881817 ,Specimens not leaking,irrigation with a final application of EC40TM,irrigation with 10 mL 2.0% chlorhexidine (CHX),No significant difference,EC40TM exhibited a similar behaviour to 2% CHX.,20399:20457, 3881817 ,23559116,Unavailable
 3881817 ,Specimens not leaking,irrigation with a final application of EC40TM,without final irrigation or irrigation with the combination (1:1) of 0.2% CHX + 0.1% cetrimide (CTR).,Significantly increased,EC40TM had significant differences when compared to the 2.5% NaOCl group and the group 0.2% CHX + 0.1% CTR.,20611:20730, 3881817 ,23559116,Unavailable
 3881817 ,Specimens not leaking,without final irrigation,irrigation with 10 mL 2.0% chlorhexidine (CHX) or irrigation with the combination (1:1) of 0.2% CHX + 0.1% cetrimide (CTR).,No significant difference,No significant differences were observed between the group without final irrigation and the 2% CHX group or 0.2% CHX + 0.1% CTR.,5851:5979, 3881817 ,23559116,Unavailable
 4717613 ,reduction of the albumin levels,"preoperative nutrition program with immune modulating formulae (enriched with arginine, omega-3 fatty acids and nucleotides)",normal diet,Significantly decreased,"With respect to thoracotomy and VATS, the change in albumin levels of the patients who underwent thoracotomy was 0.58 ± 0.33 in G1 and 1.04 ± 0.31 in G2 (p &lt; 0.001). The change in albumin levels of the patients who underwent VATS was 0.65 ± 0.27 in G1 and 1.15 ± 0.44 in G2 (p = 0.005) (Table 2).Fig. 1",20737:21142, 4717613 ,26782276,Unavailable
 4717613 ,complication development rate,"preoperative nutrition program with immune modulating formulae (enriched with arginine, omega-3 fatty acids and nucleotides)",normal diet,Significantly decreased,"Of the 27 patients in the control group, 12 (44.4 %) developed complications. Of these 12 patients, 7 (58.33 %) had prolonged air leak, 3 (25.0 %) had atelectasis requiring bronchoscopy, 1 (8.33 %) had pneumonia and 1 (8.33 %) had cardiac arhythmia. On the other hand, in G1, of the 31 patients only 6 (19.4 %) developed complications; 4 (66.67 %) had prolonged air leak, 1 (16.67 %) had atelectasis requiring bronchoscopy and 1 (16.67 %) had pneumonia (Fig. 2). There was a statistical difference between the two groups with respect to complication development rates (p = 0.049)",22673:23308, 4717613 ,26782276,Unavailable
 4717613 ,The mean tube drainage times,"preoperative nutrition program with immune modulating formulae (enriched with arginine, omega-3 fatty acids and nucleotides)",normal diet,Significantly decreased,The mean tube drainage times were 6 (42–1)/day in the control group and 4 (15–2)/day in the nutrition group (p = 0.019) (Fig. 3).Fig. 2,23310:23523, 4717613 ,26782276,Unavailable
 5845721 ,number of days the nurses wore the activity monitor,individual or friend ,team,No significant difference,No significant differences in the number of days the nurses wore the activity monitor were observed between intervention groups (p &gt; 0.05).,33338:33497, 5845721 ,29559917,Unavailable
 5845721 , Weekly moderate-to-vigorous intensity PA (MVPA) levels,individual or friend ,team,No significant difference,"No significant differences in MVPA levels were observed between intervention groups (F = 1.199, df = 9.654, p = 0.292, η2 = 0.034; see Figure 3).",37161:37295, 5845721 ,29559917,Unavailable
 5845721 ,daily steps,individual or friend ,team,No significant difference,"No significant differences in daily steps were observed between intervention groups (F = 1.146, df = 7.819, p = 0.333, η2 = 0.032; see Figure 5).",34746:34975, 5845721 ,29559917,Unavailable
 5845721 ,cardiovascular health indicators,individual or friend ,team,No significant difference,No significant differences in changes in cardiovascular health indicators were observed between groups (p &gt; 0.05).,37161:37295, 5845721 ,29559917,Unavailable
 3494227 ,"depression, anxiety, and worry symptoms",mindfulness based stress reduction program,control,Significantly decreased,"After adjusting for pre-intervention scores, there was significant difference between the two groups on pre-test and post-intervention scores on the depression [F (126.04, P=.000], anxiety [F (102.74), P=.000] and worry symptoms [F (308.29), P=.000].",15206:15558, 3494227 ,23308349,Unavailable
 1522015 ,The mean log retinal area,lutein supplementation (10 mg/d for 12 wks followed by 30 mg/d) for the first 24 weeks and then placebo for the following 24 weeks,placebo (24 weeks) was administered prior to lutein,Significantly increased,"The mean log retinal area when the participants were on lutein was 0.018 higher (95% CI: 0.001, 0.036, p value: 0.038) than when they received placebo, but the visual field deteriorated throughout the study (change per week: -0.2%, 95% CI: -0.003, -0.001, p value&lt; 0.001).",35229:35502, 1522015 ,16759390,Unavailable
 1522015 ,the average log CS at normal illumination,lutein supplementation (10 mg/d for 12 wks followed by 30 mg/d) for the first 24 weeks and then placebo for the following 24 weeks,placebo (24 weeks) was administered prior to lutein,No significant difference,"In this model, the average log CS at normal illumination was slightly (0.017 unit, 95% CI -0.014, 0.049, p value: 0.30) higher when participants were on lutein than when they were receiving placebo.",37896:38095, 1522015 ,16759390,Unavailable
 1913939 ,change in weight,the Web-based condition,condition that provided print materials on the same topics,No significant difference,The ANCOVA analyses for reported weight indicated that there was no significant differential change in weight between the two groups.,44255:44389, 1913939 ,17581811,Unavailable
 1913939 ,Physical Activity,the Web-based condition,condition that provided print materials on the same topics,No significant difference,The ANCOVA to test differential change between the Web group and the print group detected no differences between the two groups on the five measures of physical activity.,47798:47969, 1913939 ,17581811,Unavailable
 1913939 ,Attitudes Toward a Healthful Diet*,the Web-based condition,condition that provided print materials on the same topics,Significantly increased,"Attitudes Toward a Healthful Diet*	3.835 (0.395)	3.711 (0.434)	7.104 (1,415)	.008",37219:37439, 1913939 ,17581811,Unavailable
 1913939 ,Dietary Stage of Change,the Web-based condition,condition that provided print materials on the same topics,Significantly decreased,"Dietary Stage of Change† 1.902 (0.902) 2.149 (0.921) 6.487 (1,408) .01",44750:44910, 1913939 ,17581811,Unavailable
 1913939 ,Stress Management,the Web-based condition,condition that provided print materials on the same topics,No significant difference,The ANCOVA to test differential change between the Web group and the print group detected no differences between the two groups on the three measures of stress.,44750:44910, 1913939 ,17581811,Unavailable
 3616693 ,The survival period of the bleb,membrane containing MMC treatment ,glaucoma filtration operation with no implantation of chitosan membrane (as control) // or drug-free chitosan membrane implantation (blank/placebo group) // or membrane containing 5-FU treatment (5-FU group) ,Significantly increased,The survival period of the bleb in the MMC group was significantly prolonged compared with the other three groups (P &lt; 0.01); 35% of blebs had disappeared at day 10 after operation.,17336:17534, 3616693 ,23576864,Unavailable
 3616693 ,IOP-decrease period,membrane containing MMC treatment ,glaucoma filtration operation with no implantation of chitosan membrane (as control) // or drug-free chitosan membrane implantation (blank/placebo group) // or membrane containing 5-FU treatment (5-FU group) ,Significantly increased,"A significant decrease in IOPs occurred immediately after operation and lasted to day 28 postoperation in the MMC group (F = 26.866, P &lt; 0.01), whereas IOPs reached their lowest level on day 3 and achieved a general equilibrium point at day 14 postoperation in both the 5-FU (F = 13.467, P &lt; 0.01) and control (F = 6.567, P &lt; 0.01) groups. In the blank/placebo group, IOPs began to increase at day 3 after operation and reached preoperation level at day 7 (F = 11.426, P &lt; 0.01). Intergroup comparisons showed that the MMC group had the longest sustained IOP-decrease period, followed by the 5-FU and control groups.",18149:18911, 3616693 ,23576864,Unavailable
 4756971 ,The average VAS pain at 1 and 4 hours,peritubal analgesic infiltration ,control ,Significantly decreased,"The average VAS pain at 1 and 4 hours after the operation in the study group was 4.64±2.73 and 3.41±2.28 compared with 7.11±2.33 and 4.40±2.21 in the control group (P≤0.001 and 0.026), respectively.",10569:10768, 4756971 ,26689520,Unavailable
 4756971 ,"The postoperative VAS pain at 12, 24 and 48 hours",peritubal analgesic infiltration ,control ,No significant difference,"The postoperative VAS pain at 12, 24 and 48 hours were not significant different between both groups (Figure-3).",10768:10919, 4756971 ,26689520,Unavailable
 4756971 ,Doses of morphine usage for controlling postoperative pain,peritubal analgesic infiltration ,control ,Significantly decreased,"Doses of morphine usage for controlling postoperative pain was 4.43±2.78mg in study group and 7.52±5.12mg in control group (P=0.002, Table-2).",10919:11102, 4756971 ,26689520,Unavailable
 4756971 ,The first analgesic demand (minutes),peritubal analgesic infiltration ,control ,Significantly increased,"The first analgesic demand was longer in study group compared with the control group (97.00±87.74 min VS 55.10±60.50mg, P=0.007) (Table-2).",11102:11281, 4756971 ,26689520,Unavailable
 1201139 ,response rate,receive a five-pound voucher (redeemable at many high street shops) with their mailed questionnaire,control,Significantly increased,"Inclusion of the voucher with the second questionnaire resulted in a 11.7% (95% CI 4.7% to 18.6%) improvement in the response rate between the two groups (χ2 = 10.6, P = 0.001).",10268:10456, 1201139 ,16109160,Unavailable
 3409545 ,"salivary cortisol, negative affect, positive affect, and pain",20 minutes of Swedish Massage Therapy to the lower extremities,"20 minute Reflexology, using highly specified protocols",No significant difference,"According to between-group  t-tests, no significantly greater improvement in outcomes resulted when the two treatment conditions were compared.",18010:18170, 3409545 ,22888364,Unavailable
 5822856 ,Berg Balance Scale (BBS) and the Timed Up and Go test (TUG),flat insoles or textured insoles ,without insoles,Significantly increased,"Outcome measures (BBS and TUG) before and after intervention are shown in Table 2 and Figure 3. A significant improvement was noted after 4 weeks in both G1 and G2 (p&lt;0.0001), but not in CG (p=0.14 and p=0.64 for BBS and TUG, respectively) (Figure 3)",19809:20259, 5822856 ,29497286,Unavailable
 5822856 ,Berg Balance Scale (BBS) and the Timed Up and Go test (TUG),flat insoles, textured insoles ,No significant difference,No difference could be noted between G1 and G2.,20261:20308, 5822856 ,29497286,Unavailable
 5822856 ,Insole wearing time,flat insoles, textured insoles ,No significant difference,"Insole wearing time was 6 h/day (±2.4, 2.2–12) in G1 and 6.2 h/day (±2.7, 1.9–12) in G2. No significant difference was found between groups (p=0.91).",20436:20604, 5822856 ,29497286,Unavailable
 3695249 ,number of patients requested disconnection of the IV-PCA pumps because of intractable nausea and/or vomiting after surgery mostly within 12 h,intravenous 75 µg palonosetron ,intravenous 4 mg ondansetron or 0.3 mg ramosetron ,Significantly decreased,"Six patients (17.1%) in the ondansetron group, 5 (14.3%) in the ramosetron group, and none (0%) in the palonosetron group (P = 0.041) requested disconnection of the IV-PCA pumps because of intractable nausea and/or vomiting after surgery mostly within 12 h.",16535:16792, 3695249 ,23814652,Unavailable
 3695249 ,Pain scores and the total amounts of fentanyl administered via IV-PCA,intravenous 75 µg palonosetron ,intravenous 4 mg ondansetron or 0.3 mg ramosetron ,No significant difference,Pain scores and the total amounts of fentanyl administered via IV-PCA were similar in the three groups during 48 h after surgery (Fig. 2).,16799:16974, 3695249 ,23814652,Unavailable
 3695249 ,the time to use a rescue emetic,intravenous 75 µg palonosetron ,intravenous 4 mg ondansetron or 0.3 mg ramosetron ,Significantly increased,"Patients who were given the rescue antiemetic were censored and Kaplan-Meier analysis of the interval to first rescue antiemetic showed a significant intergroup difference (Fig. 1) between the palonosetron and ondansetron (P &lt; 0.001), palonosetron and ramosetron (P &lt; 0.001), and ondansetron and ramosetron (P = 0.042) groups. Thus, the order of prophylactic efficacy in prolonging the time to use a rescue emetic was palonosetron, ramosetron, and ondansetron.",16025:16522, 3695249 ,23814652,Unavailable
 3695249 ,The number of nausea-free patients,intravenous 75 µg palonosetron ,intravenous 4 mg ondansetron or 0.3 mg ramosetron ,Significantly increased,The number of nausea-free patients was greater in the palonosetron group than in the other 2 groups during the 48 h study period (Table 2).,15467:15646, 3695249 ,23814652,Unavailable
 4649576 ,the severity of nausea and vomiting,vitamin B6 or ginger,placebo,No significant difference,"Comparison of the severity of nausea and vomiting during the treatment days did not show significant difference between the three groups; however, the severity of nausea in placebo group was higher than that of the ginger and vitamin B6 groups during the treatment [Table 3].",13621:13935, 4649576 ,26664238,Unavailable
 4173571 ,required rescue antiemetic (RAE),single dose of dexamethasone 8 mg with granisetron 1 mg or  with ondansetron 4 mg,single dose of dexamethasone 8 mg with normal saline 2 ml,Significantly decreased,"Only 12% and 20% patients in Group G and O respectively required RAE, as compared to 52% patients in Group D; P = 0.004.",16528:16674, 4173571 ,25886108,Unavailable
 4173571 ,A complete response (no PONV or RAE requirement),single dose of dexamethasone 8 mg with granisetron 1 mg or  with ondansetron 4 mg,single dose of dexamethasone 8 mg with normal saline 2 ml,Significantly increased,"A complete response (no PONV or RAE requirement) occurred in 88%, 76% and 44% in Group G, O and D respectively; P = 0.002.",14632:14772, 4173571 ,25886108,Unavailable
 4173571 ,Post-operative vomiting,single dose of dexamethasone 8 mg with granisetron 1 mg or  with ondansetron 4 mg,single dose of dexamethasone 8 mg with normal saline 2 ml,Significantly decreased,"Post-operative vomiting was observed in 8%, 12% and 48% of patients in group G, O and D; P = 0.001 [Table 4].",14772:14938, 4173571 ,25886108,Unavailable
 4173571 ,Excessive vomiting (more than equal to two) and frequent RAE (more than equal to two),single dose of dexamethasone 8 mg with granisetron 1 mg or  with ondansetron 4 mg,single dose of dexamethasone 8 mg with normal saline 2 ml,Significantly decreased,"Excessive vomiting (more than equal to two) and frequent RAE (more than equal to two) were observed in 0%, 4% and 20% of patients in group G, O and D respectively; P = 0.003.",15173:15365, 4173571 ,25886108,Unavailable
 4173571 ,Post-operative sedation,single dose of dexamethasone 8 mg with granisetron 1 mg or  with ondansetron 4 mg,single dose of dexamethasone 8 mg with normal saline 2 ml,No significant difference,"Post-operative sedation (Grade 2 and 3) was observed in 20%, 44% and 20% of patients in Group G, O and D respectively; P = 0.092.",16528:16674, 4173571 ,25886108,Unavailable
 5827476 ,duration of analgesia,20 ml of 0.5% (100 mg) bupivacaine was added to 480 ml of normal saline for intraperitoneal irrigation during and after surgery,intraperitoneal irrigation was done with 500 ml of normal saline,Significantly increased,DOA in Group S were 0.06 ± 0.172 h (3.6 ± 10.32 min) and that in Group B was 19.35 ± 8.64 h (P = 0.00).,13700:13820, 5827476 ,29491515,Unavailable
 5827476 ,Cumulative requirement of tramadol in 24 h ,20 ml of 0.5% (100 mg) bupivacaine was added to 480 ml of normal saline for intraperitoneal irrigation during and after surgery,intraperitoneal irrigation was done with 500 ml of normal saline,Significantly decreased,Cumulative requirement of tramadol in 24 h in Group S was 123.33 ± 43.01 mg which was significantly higher (P = 0.00) than Group B (23.33 ± 43.01 mg) [Table 2].,13821:14037, 5827476 ,29491515,Unavailable
 5827476 ,numeric pain rating scale (NRS),20 ml of 0.5% (100 mg) bupivacaine was added to 480 ml of normal saline for intraperitoneal irrigation during and after surgery,intraperitoneal irrigation was done with 500 ml of normal saline,Significantly decreased,"At extubation, patients of Group S reported significantly higher NRS score as compared to Group B (P = 0.0) [Table 2].",14303:14477, 5827476 ,29491515,Unavailable
 5827476 ,Incidence of shoulder pain or nausea and vomiting,20 ml of 0.5% (100 mg) bupivacaine was added to 480 ml of normal saline for intraperitoneal irrigation during and after surgery,intraperitoneal irrigation was done with 500 ml of normal saline,No significant difference,"Incidence of shoulder pain was 20%, while that of nausea and vomiting was 16.66% in both the groups [Table 3] (P &gt; 0.05).",15012:15190, 5827476 ,29491515,Unavailable
 5860698 ,number of CVD events,CVD risk strategy,SBP strategy,Significantly decreased,"Areas under the curve comparing the two treatment strategies throughout the range of possible thresholds for CVD risk and SBP demonstrated that, on average, a greater number of CVD events would be avoided for a given number of persons treated with the CVD risk strategy compared with the SBP strategy (area under the curve 0.71 [95% CI 0.70–0.72] for the CVD risk strategy versus 0.54 [95% CI 0.53–0.55] for the SBP strategy) (Fig 1).",60704:61190, 5860698 ,29558462,Unavailable
 3793517 ,Eradication rate,sequential eradication therapy,standard eradication therapy,No significant difference,"Six weeks after completion of therapy, H. pylori test on 14C-UBT was negative in 5 (55.6%) of nine patients in the standard and in 4 (57.1%) of 7 patients in the sequential groups. This eradication rate although slightly higher with sequential therapy, it is non-significant (P = 0.949) [Table 1].",14273:14655, 3793517 ,24130381,Unavailable
 3793517 ,serum ferritin,sequential eradication therapy,standard eradication therapy,No significant difference,"Between the two groups, serum ferritin before therapy was quite different, however that difference was non-significant. After therapy, the difference between both groups was also non-significant [Figure 2].",15129:15372, 3793517 ,24130381,Unavailable
 4687062 ,Troponin release,bone marrow mononuclear cell (BMMNC) transplantation,saline,No significant difference,"At 2 days, mean TnI concentration increased in both study groups (mean TnI control group, 3.0 SD 2.0; BMMNC group mean TnI, 3.3 SD 1.9) (Fig 1B). The difference between the groups was not statistically significant (p = 0.71).",35869:36146, 4687062 ,26690350,Unavailable
 4687062 ,The mean absolute change of the global LVEF,bone marrow mononuclear cell (BMMNC) transplantation,saline,No significant difference,"The mean absolute change of the global LVEF was higher in the BMMNC group (placebo 1.1 SD 10.2 vs. BMMNC 9.5 SD 16.0) (Fig 1C). In comparison to the previous study, due to a patient dropout rate and high variation, the difference was not statistically significant (p = 0.15).",36402:36730, 4687062 ,26690350,Unavailable
 4687062 ,cytokines,bone marrow mononuclear cell (BMMNC) transplantation,saline,No significant difference,Control mean ±SD	BMMNC mean ±SD	P-valueIL-1b † 	0.5 ±0.2	0.5 ±0.4	0.60IL-1ra † 	35.3 ±47.3	21.7 ±24.2	0.38IL-2 † 	4.9 ±6.6	2.7 ±2.2	0.27IL-4 † 	4.5 ±2.7	4. ±1.9	0.09IL-5 † 	1.9 ±1.2	1.7 ±0.9	0.56IL-6 † 	4.9 ±3.2	5.7 ±4.7	0.58IL-7 † 	2.4 ±2.1	1.9 ±0.9	0.42IL-8 † 	6.0 ±5.0	4.9 ±3.6	0.53IL-9 † 	2.7 ±2.1	2.5 ±1.9	0.83IL-10 † 	11.9 ±22.7	2.6 ±8.4	0.13IL-12 † 	25.3 ±32.3	11.0 ±5.3	0.11IL-13 † 	6.6 ±7.2	3.9 ±1.2	0.18IL-15 † 	6.1 ±0.9	6.9 ±3.1	0.37IL-17 † 	2.4 ±2.1	1.9 ±0.9	0.29Eotaxin	15.6 ±10.6	16.7 ±9.6	0.77Fibroblast growth factor (FGF)basic † 	8.4 ±14.3	4.5 ±5.8	0.35Granulocyte growth stimulating factor (G-CSF) † 	14.5 ±13.3	12.2 ±8.4	0.59Granulocyte-macrophage colony stimulating factor (Gm-CSF) † 	11.8 ±1.2	11.8 ±1.2	1.00Interferon-γ (IFNγ) † 	17.3 ±25.5	13.3 ±19.4	0.65IP-10	140.9 ±37.7	151.1 ±59.1	0.61MCP-1/MCAF † 	9.6 ±8.7	12.0 ±14.7	0.62MIP-1a † 	1.7 ±1.7	1.5 ±1.0	0.69MIP-1β	18.1 ±10.6	15.8 ±5.7	0.47RANTES* 	21081.0 ±9016.9	22284.6 ±6016.4	0.68Tumor necrose factor-α (TNF-α) † 	5.7 ±4.1	5.7 ±5.0	0.99Vascular endothelial growth factor (VEGF) † 	48.0 ±102.1	23.3 ±15.8	0.38,NaN:46670, 4687062 ,26690350,Unavailable
 3664406 ,transepidermal water loss.,bathing with a wash product ,bathing with water alone,No significant difference,"Wash was noninferior to water alone in terms of TEWL (intention-to-treat analysis: 95% confidence interval [CI] for difference [wash–water, adjusted for family history of eczema, neonate state, and baseline] −1.24, 1.07; per protocol analysis: 95% CI −1.42, 1.09).",6080:6345, 3664406 ,23421327,Unavailable
 3664406 ,skin surface pH,bathing with a wash product ,bathing with water alone,No significant difference,"No significant differences were found in the pH measurements at 14 days, as well as no significant difference in TEWL at 28 days.",58265:58390, 3664406 ,23421327,Unavailable
 3664406 ,satisfaction scores,bathing with a wash product ,bathing with water alone,No significant difference,"There were no differences in overall satisfaction scores, as assessed by a 10-cm visual analog scale.",58767:58868, 3664406 ,23421327,Unavailable
 3664406 ,left their neonate smelling good,bathing with a wash product ,bathing with water alone,Significantly increased,Mothers were more likely to state that using a bathing product left their neonate smelling good (p &lt; .001).,58265:58390, 3664406 ,23421327,Unavailable
 4113172 ,CRP,lifestyle or metformin,placebo,Significantly decreased,"In both ILS and metformin groups, CRP values at EOS were significantly lower than the corresponding placebo group values.",25095:25217, 4113172 ,24824548,Unavailable
 4113172 ,Fibrinogen,lifestyle or metformin,placebo,No significant difference,"Fibrinogen levels fell significantly in the ILS group at 1 year compared with those in the placebo and metformin groups but showed no differences between groups at EOS, as both placebo and metformin groups showed a fall in levels.",25570:25800, 4113172 ,24824548,Unavailable
 4113172 ,tissue plasminogen activator (tPA),lifestyle or metformin,placebo,Significantly decreased,tPA levels fell by 22% at 1 year in the ILS group and by 18% in the metformin group versus 7% in the placebo group and then rose similarly in both intervention groups at EOS to levels that were still significantly lower than the corresponding placebo value.,25261:25518, 4113172 ,24824548,Unavailable
 3757635 ,The medians of the VAS values,autologous cryoprecipitate,absorbable sutures,Significantly decreased,"The medians of the VAS values were significantly lower when glue was used (P &lt; 0.05) [Table 2, Figure 1].",15799:16000, 3757635 ,24014989,Unavailable
 3757635 ,The median surgical time,autologous cryoprecipitate,absorbable sutures,Significantly decreased,The median surgical time was 11 min (range 9-15) for the glue group and 21 min (range 12-28) for the suture group (P &lt;0.05) [Table 1].,16492:16686, 3757635 ,24014989,Unavailable
 3757635 ,intraoperative or post-operative complications,autologous cryoprecipitate,absorbable sutures,No significant difference,No significant intraoperative or post-operative complications were noted.,4040:4113, 3757635 ,24014989,Unavailable
 3687098 ,adverse event of constipation,sitagliptin 100 mg/day,comparator agent,Significantly increased,The incidence rate of the adverse event of constipation was higher in the sitagliptin group (2.3) than in the non-exposed group (1.8).,37392:37526, 3687098 ,23700194,Unavailable
 3687098 ,The incidence rates of malignancy,sitagliptin 100 mg/day,comparator agent,No significant difference,"The incidence rates of malignancy were similar for the two groups: 0.90 per 100 patient-years in the sitagliptin group and 0.93 per 100 patient-years in the non-exposed group [between-group difference of −0.05 (95% CI −0.41, 0.30)].",29304:29536, 3687098 ,23700194,Unavailable
 3687098 ,The incidence rates of pancreatitis,sitagliptin 100 mg/day,comparator agent,No significant difference,"For the composite endpoint of pancreatitis (which included the MedDRA terms “pancreatitis” and “pancreatitis acute”), the incidence rates were similar for both groups (Table 4), with a difference in rate of −0.0 (95% CI −0.2, 0.1).",45662:45934, 3687098 ,23700194,Unavailable
 3687098 ,The incidence of the composite endpoint of rash,sitagliptin 100 mg/day,comparator agent,Significantly increased,The incidence of the composite endpoint of rash was higher in the sitagliptin group compared with the non-exposed group (Table 4). The difference in the composite endpoint was primarily related to a higher incidence of the individual terms “rash” and “rash macular”.,46831:47138, 3687098 ,23700194,Unavailable
 1578575 ,"the mean percentage of nuclei stained by Ki-67 (MIB-1) , estrogen receptor (1D5) and progesterone receptor positivity (PgR 636)",tamoxifen/10 mg/day for 14 days,control group-without medication,Significantly decreased,"In Group A (control), there was no statistically significant reduction in Ki-67 (MIB-1) (p = 0.627), estrogen receptor (1D5) (p = 0.296) and progesterone receptor positivity (PgR 636) (p = 0.381).In Group B (tamoxifen 10 mg/day), the mean percentage of nuclei stained by Ki-67 (MIB-1) was 24.69% before and 10.43% after tamoxifen treatment. Mean percentage of nuclei stained by estrogen receptor (1D5) was 59.53% before and 25.99% after tamoxifen treatment. Mean percentage of nuclei stained by progesterone receptor (PgR 636), was 59.34 before and 29.59% after tamoxifen treatment. A statistically significant reduction was found with the three markers (p &lt; 0.001).",4483:5157, 1578575 ,16972993,Unavailable
 4265717 ,urogenital distress inventory (UDI) and the incontinence impact questionnaire (IIQ) scores,undergoing office evaluation with a preoperative urodynamic work-up,undergoing office evaluation,Significantly decreased,"At 6 months, a 70% reduction in UDI and IIQ scores was significant in the urodynamic testing group at 86.7% and 73.3%, respectively, compared with only 60.0% and 46.7%, respectively, in the office evaluation only group (p=0.001 and p=0.001).",20762:20936, 4265717 ,25512817,Unavailable
 4265717 ,rate of positive provocative stress test,undergoing office evaluation with a preoperative urodynamic work-up,undergoing office evaluation,Significantly decreased,"At 1 year, the urodynamic testing group had a 3.3% rate of positive provocative stress test compared with 13.3% in the office evaluation only group (p&lt;0.001).",20393:20551, 4265717 ,25512817,Unavailable
 4265717 ,treatment outcomes with stratified preoperative values for VLPP and MUCP at both 6 and 12 months,undergoing office evaluation with a preoperative urodynamic work-up,undergoing office evaluation,No significant difference,No significant differences (p-values insignificant) were seen when comparing treatment outcomes with stratified preoperative values for VLPP and MUCP at both 6 and 12 months.,20762:20936, 4265717 ,25512817,Unavailable
 3590692 ,"mean scores of depression, anxiety and stress",combined medical-relaxation therapy,usual medical therapy,Significantly decreased,"However, after 4 weeks of relaxation, the mean scores of depression, anxiety and stress were significantly different between the two groups (p &lt; 0.05) (Table 1).",15780:15986, 3590692 ,23493112,Unavailable
 3781573 ,incidence rate of diabetic peripheral neuropathy (DPN),insulin-sensitizing (IS) treatment,insulin-providing (IP) treatment,Significantly decreased,"Among the 1,075 participants with no DPN at entry, the 4-year cumulative incidence rate of DPN was significantly lower in the IS strategy group (66%) than in the IP strategy group (72%) (P = 0.02) (Fig. 1A).",23191:23469, 3781573 ,23757426,Unavailable
 3781573 ,HbA1c,insulin-sensitizing (IS) treatment,insulin-providing (IP) treatment,Significantly decreased,"HbA1c was significantly lower in the IS strategy arm than in the IP strategy arm, and this difference was maintained through study end (7.1 ± 1.4 vs. 7.6 ± 1.4% in IS vs. IP at year 4, P &lt; 0.01).",22015:22240, 3781573 ,23757426,Unavailable
 4588430 ,mean consultation time,telephone consultation,face-to-face consultation,Significantly decreased,"There was a statistically significant lower mean consultation time for telephone consultations across all available follow-up compared to face-to-face consultation. Mean consultation times were 9.8 min (IQR 8 to 12.3) for telephone consultation, and 14.3 min (11.6 to 17.0) for face-to-face consultation with an estimated reduction (95% CI) of 4.3 (2.8 to 5.7) min in consultation times (p &lt; 0.001).",24367:24766, 4588430 ,26501125,Unavailable
 4588430 ,NHS costs,telephone consultation,face-to-face consultation,Significantly decreased,"Estimates of NHS costs for the intervention (including staff costs and telephone costs) showed that telephone consultation had a mean cost of UK£35.41 per patient consultation compared with £51.12 for face–face consultation, difference £15.71 (95% CI 11.8–19.6; P &lt; 0.001).",25013:25286, 4588430 ,26501125,Unavailable
 4588430 ,QOL score,telephone consultation,face-to-face consultation,No significant difference,The complier-adjusted analysis of QOL scores showed similar conclusions when there was at least minimal consultation participation (as defined previously); the efficacy-based treatment effect estimate (95% CI) was 4.8 (− 4.1 to 13.6) points; p = 0.285.,23337:23589, 4588430 ,26501125,Unavailable
 4162033 ,ALT/AST changes,atorvastatin (40 mg/d),atorvastatin (5 mg/d),No significant difference,there was found no significant relation between different dosages of statin and ALT/AST changes over the study period; and the enzymes fluctuations in all age groups remained in normal range.,12846:13038, 4162033 ,25221771,Unavailable
 3525031 ,Pain severity,0.7 mg/kg pethidine every 6 hour IM,0.07 mg/kg oral methadone every 6 hour.,No significant difference,"Pain severity in methadone group at 6, 12, 18 and 24 hour post operation were 6.4 ± 0.9, 3.4 ± 0.8, 1.9 ± 1.1, 0.5 ± 0.5 (p &lt; 0.05) and for patients in pethidine group were 6.6 ± 0.8, 3.4 ± 0.9, 2.1 ± 1.0 and 0.5 ± 0.5 (p &lt; 0.05), respectively (Mean ± SD). Between groups differences in each follow up time were not statistically significant.",4490:4833, 3525031 ,23264787,Unavailable
 3525031 ,terms of complications and supplementary analgesic use,0.7 mg/kg pethidine every 6 hour IM,0.07 mg/kg oral methadone every 6 hour.,No significant difference,There was no difference between groups in terms of complications and supplementary analgesic use.,4833:4930, 3525031 ,23264787,Unavailable
 4757000 ,mean daily pad usage,transobturator midurethral sling (TOS) ,single-incision sling,No significant difference,"Preoperatively, mean daily pad usage was calculated as 4.45±0.82 (3–6) in the TOS group, and 4.25±0.78 (3–6) in the single-incision sling group (p=0.495).",16789:17096, 4757000 ,26401864,Unavailable
 4757000 ,subjective cure rates,transobturator midurethral sling (TOS) ,single-incision sling,No significant difference,"therefore subjective cure rates were calculated as 75% and 55%, respectively (p=0.190) (Table-2).",17258:17394, 4757000 ,26401864,Unavailable
 4757000 ,scores achieved in ICIQ-SF,transobturator midurethral sling (TOS) ,single-incision sling,Significantly increased,"The comparison of scores achieved in ICIQ-SF administered before and 6 months after the surgery revealed that the patients in the TOS group showed significantly better improvement when compared to patients in the single-incision sling group (76.20% versus 64.10%, p=0.001).",19425:19698, 4757000 ,26401864,Unavailable
 4757000 ,scores achieved in I–QOL,transobturator midurethral sling (TOS) ,single-incision sling,Significantly increased,"Similarly, the comparison of scores achieved in I–QOL administered before and 6 months after the surgery revealed that the patients in the TOS group showed significantly better improvement (81.31% versus 69.28%, p=0.001) (Table-3).",19698:19969, 4757000 ,26401864,Unavailable
 4757000 ,Mean operation time,transobturator midurethral sling (TOS) ,single-incision sling,Significantly increased,Mean operation time was 24.25±3.41 (18–28) minutes in the TOS group and 16.30±1.65 (14–20) minutes in the single-incision sling group (p&lt;0.05).,22318:22462, 4757000 ,26401864,Unavailable
 5873437 ,mortality,3‐5 days of continuous ELAD treatment plus SOC ,standard of care (SOC) only,No significant difference,"In the subgroup of the study population that presented with age &lt;46.9 years (n = 101), ELAD (n = 43) was associated with lower mortality compared with the control group (n = 58): 32.6% versus 44.8% (HR, 0.63; P = 0.17).",79188:79427, 5873437 ,29171941,Unavailable
 5873437 ,Lille score,3‐5 days of continuous ELAD treatment plus SOC ,standard of care (SOC) only,No significant difference,Lille score calculation over that period showed 74.7% were responders (Lille &lt; 0.45) in the ELAD group versus 47% in the control group (P &lt; 0.01).,82441:82607, 5873437 ,29171941,Unavailable
 5873437 ,IL1Ra levels,3‐5 days of continuous ELAD treatment plus SOC ,standard of care (SOC) only,Significantly increased,"Also, in the Wilcoxon signed rank test, IL1Ra levels were elevated compared with baseline significantly at study day 3, 5, and 7 in ELAD patients (P &lt; 0.05), but not in controls.",84015:84214, 5873437 ,29171941,Unavailable
 5873437 ,positive postdischarge PEth,3‐5 days of continuous ELAD treatment plus SOC ,standard of care (SOC) only,Significantly decreased,Fewer ELAD subjects had positive postdischarge PEth than controls (28% versus 52%; P &lt; 0.05).,81535:81646, 5873437 ,29171941,Unavailable
 5440059 ,urinary incontinence (UI) ,"usual care plus management by health professionals, with need-based referrals",usual care (UC) only,No significant difference,"Using a one-sided Fisher’s exact test, no statistically significant differences between groups for UI at midpoint (.125, CI = [0.00, 0.360], p = .247) or final assessment (.25, CI = [0.00, 0.515], p = .068) were found.",28156:28392, 5440059 ,28567437,Unavailable
 5440059 ,presence of nocturia,"usual care plus management by health professionals, with need-based referrals",usual care (UC) only,No significant difference,"There were no statistically significant differences between groups for the presence of nocturia at midpoint (.042, CI = [0.00, 0.262], p = .500) or final assessment (.083, CI = [0.00, 0.293], p = .350).",28156:28392, 5440059 ,28567437,Unavailable
 3695250 ,The total amount of fentanyl consumption during the 48 h after surgery,ketamine infusion of 2 µg/kg/min following bolus 0.5 mg/kg ,saline infusion following bolus of saline or ketamine infusion of 1 µg/kg/min following bolus 0.5 mg/kg,Significantly decreased,The total amount of fentanyl consumption was significantly lower in the K2 group (474 µg) compared to the control group (826 µg) and the K1 group (756 µg) during the 48 h after surgery (P &lt; 0.05) (Table 2).,13176:13424, 3695250 ,23814653,Unavailable
 3695250 ,"VAS scores for pain at rest or with movement at 1, 6, 24 and 48 h postoperatively",ketamine infusion of 2 µg/kg/min following bolus 0.5 mg/kg ,saline infusion following bolus of saline or ketamine infusion of 1 µg/kg/min following bolus 0.5 mg/kg,No significant difference,"VAS scores for pain at rest or with movement at 1, 6, 24 and 48 h postoperatively were similar among the three groups (Table 2).",13431:13598, 3695250 ,23814653,Unavailable
 3695250 ,The patient satisfaction rate,ketamine infusion of 2 µg/kg/min following bolus 0.5 mg/kg ,saline infusion following bolus of saline or ketamine infusion of 1 µg/kg/min following bolus 0.5 mg/kg,No significant difference,The patient satisfaction rate was similar among the three groups (Table 4).,13833:13947, 3695250 ,23814653,Unavailable
 3695250 ,The incidence of adverse events,ketamine infusion of 2 µg/kg/min following bolus 0.5 mg/kg ,saline infusion following bolus of saline or ketamine infusion of 1 µg/kg/min following bolus 0.5 mg/kg,No significant difference,"The incidence of adverse events such as nausea, vomiting, dizziness, headache, and sedation were comparable among the groups (Table 3).",13658:13833, 3695250 ,23814653,Unavailable
 5030453 ,functional activity,patients used the mobile app and reviewed the reported data with the treating physician at scheduled visits (C),eceived regular physician support (A) or patients were instructed to use the mobile app without physician review (B),No significant difference,"However, within the three groups differences in the reported functional activity at the three visits did not reach statistical significance, irrespective of whether current or worst daily functional activity was analyzed.",31574:31796, 5030453 ,27601354,Unavailable
 5030453 ,concentration issues,patients were instructed to use the mobile app without physician review (B),eceived regular physician support (A),Significantly decreased,"During the second visit, only group B reported significantly fewer concentration issues than group A (P=.006).",34192:34319, 5030453 ,27601354,Unavailable
 5030453 ,number of patient confirmed use of the Internet for obtain further information about their disease,patients were instructed to use the mobile app without physician review (B) or patients used the mobile app and reviewed the reported data with the treating physician at scheduled visits (C),eceived regular physician support (A),Significantly increased,"At the third visit, significantly more patients in groups B (64.29% P=.04) and C (70.73%, P=.007) confirmed use of the Internet for this purpose compared with group A (41.46%).",34962:35172, 5030453 ,27601354,Unavailable
 2797956 ,percentage of time between 4.4 and 6.6 mmol/l,Two-day closed-loop therapy (except for a 15-min premeal manual bolus),1-day control phase with intraperitoneal open-loop insulin delivery,Significantly increased,"A significantly higher percentage of time was spent between 4.4 and 6.6 mmol/l during closed-loop versus control phases (39.1 ± 4.5 vs. 27.7 ± 6.2%, P = 0.05),",27497:27673, 2797956 ,19846796,Unavailable
 2797956 ,plasma insulin peak levels,Two-day closed-loop therapy (except for a 15-min premeal manual bolus),1-day control phase with intraperitoneal open-loop insulin delivery,Significantly decreased,"However, for closed-loop phases, plasma insulin peak levels were significantly lower (29.7 ± 2.9 vs. 51.5 ± 8.4 mIU/l, P = 0.017)",28794:28941, 2797956 ,19846796,Unavailable
 2797956 ,mean blood glucose levels,Two-day closed-loop therapy (except for a 15-min premeal manual bolus),1-day control phase with intraperitoneal open-loop insulin delivery,Significantly decreased,"Better closed-loop glucose control came from the time periods excluding the two early postprandial hours with a higher percentage of time in the 4.4–6.6 mmol/l range (46.3 ± 5.3 vs. 28.6 ± 7.4, P = 0.025) and lower mean blood glucose levels (6.9 ± 0.3 vs. 7.9 ± 0.6 mmol/l, P = 0.036). T",5207:5528, 2797956 ,19846796,Unavailable
 31579 ,"mean pulmonary artery pressure, pulmonary vascular resistance index and central venous pressure ",inhalation of nitric oxide (NO) (20 ppm for 1 hour) ,atrial natriuretic peptide (ANP)  infusion (10 ng/kg/min for 1 hour),Significantly decreased,"Despite an approximate 50% increase in mixed venous ANP plasma concentration (from 86 ± 21 to 123 ± 33 ng/l, P &lt; 0.05) during ANP infusion, there were no changes in mean pulmonary artery pressure, pulmonary vascular resistance index, extravascular lung water index, or in pulmonary gas exchange. NO inhalation, in contrast, lowered mean pulmonary artery pressure (from 26 ± 1.9 to 23.9 ± 1.7 mmHg, P &lt; 0.01), pulmonary vascular resistance index (from 314 ± 37 to 273 ± 32 dynes/cm5/m2, P &lt; 0.05) and central venous pressure (from 8.2 ± 1.2 to 7.3 ± 1.1 mmHg, P &lt; 0.02).",4107:4775, 31579 ,11353932,Unavailable
 4733105 ,task accuracy or reaction time,trained in a vehicle with a newly developed onboard cognitive training program (V) or trained with a similar program but on a personal computer (P) ,trained to solve a crossword puzzle (C),No significant difference,"There was no significant effect of training group either on task accuracy or reaction time (P = 0.723 and P = 0.200, respectively).",44362:44563, 4733105 ,26855826,Unavailable
 4733105 ,high‐gamma power in the left thalamus from 0 to 100 msec and from 200 to 300 msec in the nontarget condition.,trained in a vehicle with a newly developed onboard cognitive training program (V) or trained with a similar program but on a personal computer (P) ,trained to solve a crossword puzzle (C),Significantly increased,"In addition, Groups V and P showed increased high‐gamma power compared to Group C (which exhibited decreased high‐gamma power) in the left thalamus from 0 to 100 msec and from 200 to 300 msec in the nontarget condition.",50084:50304, 4733105 ,26855826,Unavailable
 3511174 ,improvements in AHA and Melbourne,Botulinum Toxin-A (BoNT-A) treatment (B),BoNT-A plus eight weeks resistance training (BT),No significant difference,"Both groups had very small improvements in AHA and Melbourne two months after BoNT-A injections, without differences between groups.",5096:5228, 3511174 ,22747635,Unavailable
 3511174 ,The muscle tone,Botulinum Toxin-A (BoNT-A) treatment (B),BoNT-A plus eight weeks resistance training (BT),No significant difference,"The muscle tone results, measured as resistance to passive elbow extension and forearm supination, are shown in Figure 3. In both groups there was only a small, non-significant decrease or no change in elbow flexor muscle tone from Baseline to Post 2 and Post 5 months, with no between-group differences in treatment effect.",29638:29999, 3511174 ,22747635,Unavailable
 3511174 ,Forearm supination resistance,Botulinum Toxin-A (BoNT-A) treatment (B),BoNT-A plus eight weeks resistance training (BT),Significantly decreased,"Forearm supination resistance decreased in both groups, but considerably more so in group B (p = .043), resulting in a significant difference in treatment effect between the groups (p = .047).",30000:30226, 3511174 ,22747635,Unavailable
 3511174 ,muscle strength in injected muscles nd non-injected muscles,Botulinum Toxin-A (BoNT-A) treatment (B),BoNT-A plus eight weeks resistance training (BT),No significant difference,"There were significant, or close to significant, short-term treatment effects in favour of group BT for muscle strength in injected muscles (elbow flexion strength, p = .08) and non-injected muscles (elbow extension and supination strength, both p = .05), without concomitant increases in muscle tone.",5229:5565, 3511174 ,22747635,Unavailable
 4358417 ,body weight and BMI,100 mg of rosehip extract ,placebo,Significantly decreased,the decreases in the body weight and BMI were significantly larger at W12 in the rosehip group than in the placebo group.,20678:20801, 4358417 ,25834460,Unavailable
 4358417 ,the abdominal total fat area,100 mg of rosehip extract ,placebo,Significantly decreased,"However, at W12, the abdominal total fat area in the rosehip group was significantly lower than that at W0, where the decrease was significantly larger than that in the placebo group. In contrast, there was no significant intragroup variation in the abdominal subcutaneous fat area, but the decrease in this area in the rosehip group at W12 was significantly larger than that in the placebo group.",21155:21553, 4358417 ,25834460,Unavailable
 4358417 ,the abdominal subcutaneous fat area,100 mg of rosehip extract ,placebo,Significantly decreased,"Moreover, the abdominal subcutaneous fat area was significantly lower in the rosehip group than in the placebo group at week 12 after the initiation of intake (P&lt;0.05).",5414:5602, 4358417 ,25834460,Unavailable
 5789502 ,"heart rates at 5, 10, and 15 min",dexmedetomidine 0.30 μg/kg (Group D0.3) ,dexmedetomidine 0.15 μg/kg (Group D0.15),Significantly decreased,"However, HRs were significantly lower in Group D0.3 when compared to Group D0.15 at 5, 10, and 15 min [Figure 2].",13550:13722, 5789502 ,29416453,Unavailable
 5789502 ,Pain scores,dexmedetomidine 0.30 μg/kg (Group D0.3) ,dexmedetomidine 0.15 μg/kg (Group D0.15),Significantly decreased,Pain scores were significantly lower in Group D0.3 compared to Group D0.15 at all time intervals postoperatively.,14734:14870, 5789502 ,29416453,Unavailable
 5789502 ,The time to discharge,dexmedetomidine 0.30 μg/kg (Group D0.3) ,dexmedetomidine 0.15 μg/kg (Group D0.15),No significant difference,The time to discharge was 31.48 ± 18.7 min in Group D0.15 and 20.96 ± 10.96 min in D0.3 groups using modified Aldrete Score[9](9/10). The groups were comparable with time to discharge (P = 0.071).,16837:17112, 5789502 ,29416453,Unavailable
 5561588 ,time to maximum block,endotracheal intubation after onset of the neuromuscular block at the adductor pollicis muscle (A)  ,endotracheal intubation after onset at the trapezius muscle (B),Significantly increased,"Following injection of rocuronium, maximum block was recorded slightly later at the adductor pollicis muscle compared to the trapezius muscle: 2.8 ± 1.1 versus 2.5 ± 1.1 min, respectively, (mean ± SD; P = 0.006).",22334:22577, 5561588 ,28818054,Unavailable
 3635594 ,"erythrocyte acetylcholinesterase (AChE),  percent AChE","methanesulfonyl fluoride (MSF, SNX-001)",placebo,Significantly decreased,"As expected, MSF treatment accumulated significant AChE inhibition as compared with control (F(1,8) = 212.000, P &lt; 0.001), there were significant differences in the percent AChE inhibition in different tissues (F(3,24) = 15.910, P &lt; 0.01),",31967:32300, 3635594 ,23116458,Unavailable
 5769191 ,rate of pregnancy,"in addition to their routine treatment, received auriculotherapy for 8–10 sessions during menstrual cycle.",routine treatments,No significant difference,"The results also revealed that despite the higher rate of pregnancy in the intervention group than the control group, the difference was not significant;",20291:20445, 5769191 ,29344039,Unavailable
 5769191 ,the frequency of clinical pregnancy,"in addition to their routine treatment, received auriculotherapy for 8–10 sessions during menstrual cycle.",routine treatments,Significantly increased,the frequency of clinical pregnancy in the intervention group was significantly higher than the control group [Table 2].,20454:20613, 5769191 ,29344039,Unavailable
 1208905 ,score at follow-up,receive a single session of true acupuncture,receive a single session of placebo acupuncture,No significant difference,"For all analyses, patients receiving true acupuncture reported slightly higher scores at follow-up, approximately equivalent to 10% of baseline. Patients in both groups improved, but no important differences between groups emerged.",27921:28153, 1208905 ,16109163,Unavailable
 1208905 ,Breathlessness,receive a single session of true acupuncture,receive a single session of placebo acupuncture,No significant difference,Outcome did not differ by point prescription in either the subgroup analysis (Table 4) or by including prescription and prescription by group interaction in the ANCOVA model.,31035:31248, 1208905 ,16109163,Unavailable
 3931289 ,time to first pulmonary exacerbation,esomeprazole 40 mg twice daily,placebo,No significant difference,There was no significant difference in time to first pulmonary exacerbation between the esomeprazole and placebo groups (log rank test p = 0.3169) (Figure 2).,22080:22275, 3931289 ,24528942,Unavailable
 3931289 ,exacerbation rate,esomeprazole 40 mg twice daily,placebo,No significant difference,"Similarly, there was no significant difference between groups in exacerbation rate during the study period (2.04 exacerbations per person year in esomeprazole group 95% CI (1.33, 4.14) compared with 0.59 exacerbations per person year in placebo group (95% CI (0.19, 1.82), p = 0.07.",22276:22559, 3931289 ,24528942,Unavailable
 3931289 ,change in FEV1 percent or FVC percent,esomeprazole 40 mg twice daily,placebo,No significant difference,"There was no significant change in FEV1 percent predicted or FVC percent predicted in either group over the study period, p = 0.23 and 0.58, respectively, and there was no difference between groups in change in FEV1 or FVC percent predicted from baseline to end of study (Figure 3).",22559:22900, 3931289 ,24528942,Unavailable
 3931289 ,GSAS and CFQ-R score,esomeprazole 40 mg twice daily,placebo,No significant difference,"GSAS and CFQ-R score did not change significantly over the study period (p = 0.27 and 0.32, respectively) and there was no difference in change in scores between the two treatment groups.",22901:23088, 3931289 ,24528942,Unavailable
 5866733 ,"Serum AST, ALT, ALP, CK-MB, and TnI levels",n-acetylcysteine for 7 days before the operation,nothing,No significant difference,"Serum AST, ALT, ALP, CK-MB, and TnI levels demonstrated no significant difference between the 2 groups at any of the 4 measurement time points (preoperative, during cardiopulmonary bypass, 24th postoperative hour, and 48th postoperative hour) (p&gt;0.05) (Table 2).",14481:14827, 5866733 ,29540661,Unavailable
 5866733 ,Serum BUN level after cardiopulmonary bypass ,n-acetylcysteine for 7 days before the operation,nothing,No significant difference,"Serum BUN levels demonstrated no significant difference in the preoperative period (17.6±4.99 vs. 18.6±4.72, for Group 1 and 2, respectively, p&gt;0.05) and after cardiopulmonary bypass (17.1±4.61 vs. 19.6±8.56, for Group 1 and 2, respectively, p&gt;0.05)",15606:15893, 5866733 ,29540661,Unavailable
 5866733 ,ammonia (NH3) after cardiopulmonary bypass and at 24th hour and at 48th hour,n-acetylcysteine for 7 days before the operation,nothing,Significantly decreased,"whereas the differences in NH3 levels were significant after cardiopulmonary bypass (37.8±10.26 vs. 47.0±14.57, for Group 1 and 2, respectively, p&lt;0.05, unpaired t test), at 24th hour (39.0±8.80 vs. 55.4±19.64, for Group 1 and 2, respectively, p&lt;0.05, unpaired t test) and at 48th hour (40.1±8.44 vs. 53.2±20.15, for Group 1 and 2, respectively, p&lt;0.05, unpaired t test) (Figure 1).",15606:15893, 5866733 ,29540661,Unavailable
 5866733 ,Serum BUN level at 24th and 48 postoperative hour ,n-acetylcysteine for 7 days before the operation,nothing,No significant difference,"whereas the differences were significant at 24th postoperative hour (18.7±4.36 vs. 24.4±9.52, for Group 1 and 2, respectively, p&lt;0.05) and 48th postoperative hour (19.8±5.42 vs. 24.9±10.90, for Group 1 and 2, respectively, p&lt;0.05) (Figure 2).",15892:16258, 5866733 ,29540661,Unavailable
 5866733 ,Lactate levels at 24th and 48th,n-acetylcysteine for 7 days before the operation,nothing,Significantly increased,Lactate levels at 24th and 48th postoperative hours were significantly higher in Group 1 when compared to Group 2 (p&lt;0.05) (Figure 3).,16258:16474, 5866733 ,29540661,Unavailable
 3664374 ,percentage of nr-axSpA patients achieved the primary endpoint of ASAS40 response at week 12,adalimumab,placebo,Significantly increased,"A significantly greater percentage of nr-axSpA patients treated with adalimumab achieved the primary endpoint of ASAS40 response at week 12 (33/91, 36%) compared with patients treated with placebo (14/94, 15%; p&lt;0.001, NRI; figure 2A).",34529:34843, 3664374 ,22772328,Unavailable
 3664374 ,number of patients who had BASFI &lt;2 at week 12,adalimumab,placebo,Significantly increased,"Based on the BASFI component of the ASAS partial remission criteria, 33% of patients (25/75) had BASFI &lt;2 at week 12 in the adalimumab group compared with 11% (9/79) in the placebo group (p=0.001) among patients with BASFI ≥2 at baseline.",39863:40102, 3664374 ,22772328,Unavailable
 3636850 ,The mean Streptococcus mutans and Lactobacillus,fluoridated dentifrices,non-fluoridated dentifrices,Significantly decreased,"The mean Streptococcus mutans and Lactobacillus was found to be significantly lower in the fluoridated group at 3, 6, and 12 months time interval (P &lt; 0.05).",11464:11638, 3636850 ,23633797,Unavailable
 3636850 ,The OHI-S,fluoridated dentifrices,non-fluoridated dentifrices,Significantly decreased,The OHI-S was found to be significantly low in the fluoridated group at the 12 months time interval (P &lt; 0.05).,10439:10567, 3636850 ,23633797,Unavailable
 3636850 ,mean DMFT and deft,fluoridated dentifrices,non-fluoridated dentifrices,No significant difference,Difference in mean DMFT and deft between fluoridated group and non-fluoridated group was not found to be statistically significant at any time intervals.,10921:11074, 3636850 ,23633797,Unavailable
 5827042 ,treatment failure,the combination of fentanyl-midazolam,dexmedetomidine-fentanyl,Significantly decreased,"Out of the 9 patients who experienced treatment failure, 8 (88.90%) patients were in dexmedetomidine group and 1 (11.10%) was in the midazolam group (p = 0.029).",15203:15397, 5827042 ,29503835,Unavailable
 5827042 ,time to recovery,the combination of fentanyl-midazolam,dexmedetomidine-fentanyl,Significantly decreased,"Mean pain score at the time of reduction was not significantly different between the 2 groups from a clinical point of view; however, dexmedetomidine group had a significantly shorter time to recovery (p &lt; 0.001).",15203:15397, 5827042 ,29503835,Unavailable
 3606612 ,hemoglobin,11 mg of Heme Iron Polypeptide (HIP) orally 3 times per day,IV iron sucrose 200 mg monthly ,No significant difference,There was no difference in the Hb in the HIP group was 117 g/L and 113 g/L in the IV sucrose group at 6 months (p = 0.37; Table 3).,20267:20438, 3606612 ,23514036,Unavailable
 3606612 ,TSAT,11 mg of Heme Iron Polypeptide (HIP) orally 3 times per day,IV iron sucrose 200 mg monthly ,No significant difference,"Among iron indices, the TSAT at 6 months was also similar in both the groups {21.5%(17–29) in HIP and 21.5% (17–27) in IV sucrose; p = 0.82},",20438:20579, 3606612 ,23514036,Unavailable
 3606612 ,serum ferritin,11 mg of Heme Iron Polypeptide (HIP) orally 3 times per day,IV iron sucrose 200 mg monthly ,Significantly decreased,whereas serum ferritin was significantly higher in the IV iron sucrose group compared to HIP group {85.5 ug/L (44–104) in HIP and 244 ug/L (71.5-298); p = 0.004}.,20579:20742, 3606612 ,23514036,Unavailable
 3606612 ,adverse effects,11 mg of Heme Iron Polypeptide (HIP) orally 3 times per day,IV iron sucrose 200 mg monthly ,No significant difference,Overall adverse effects are similar between both the groups (Table 4).,25796:25905, 3606612 ,23514036,Unavailable
 5745479 ,proportion of any AE,amoxicillin,placebo,Significantly increased,"For the whole cohort, at the end of week one, a significantly higher proportion of any AE (diarrhoea or nausea or rash) was reported in the amoxicillin group compared to placebo (OR = 1.31, 95% CI 1.05–1.64) (Table 1).",12318:12598, 5745479 ,29236038,Unavailable
 5745479 ,diarrhoea,amoxicillin,placebo,Significantly increased,"Analysing each specific AE, diarrhoea was present significantly more often among patients in the amoxicillin group, compared to those in the placebo group (OR 1.43 CI 1.08–1.90, Table 2) (NNH: 29).",13473:13732, 5745479 ,29236038,Unavailable
 5745479 ,Nausea,amoxicillin,placebo,No significant difference,Nausea was not associated with amoxicillin treatment for either the whole cohort or any subgroup of patients (Table 3).,14127:14308, 5745479 ,29236038,Unavailable
 5745479 ,rash in males,amoxicillin,placebo,Significantly increased,Subgroup analysis showed rash was significantly more often reported in males prescribed amoxicillin (interaction term 3.72 95% CI 1.22–11.36; OR of amoxicillin in males 2.79 (95% CI 1.08–7.22).,7387:7580, 5745479 ,29236038,Unavailable
 4753023 ,The mean Hb concentration,one ferrous sulfate tablet containing 50 mg of elemental iron daily,placebo,Significantly increased,The mean Hb concentration was 12.05 ± 0.9 in the experimental and 11.94 ± 0.6 in the placebo group; this different was significant (P = 0.03),15431:15572, 4753023 ,26889391,Unavailable
 4753023 ,the mean of birth weight,one ferrous sulfate tablet containing 50 mg of elemental iron daily,placebo,No significant difference,but there was not significant different between 2 groups in the mean of birth weight (P = 0.2) (; Table 2).,15573:15725, 4753023 ,26889391,Unavailable
 4753023 ,ferritin,one ferrous sulfate tablet containing 50 mg of elemental iron daily,placebo,Significantly increased,"There were statistically significant differences between the two groups in Hb (p = 0/03) and ferritin (p = 0/04) levels at the end of pregnancy, but the incidence of anemia exhibited no difference in either group (p &lt; 0/001).",4491:4716, 4753023 ,26889391,Unavailable
 3714385 ,"HOMA-IR before induction of anaesthesia, 60 min after the start of surgery, and at the start of skin closure",remifentanil at infusion rates of 0.1 μg·kg-1·min-1 (L),remifentanil at infusion rates of 0.5 μg·kg-1·min-1 (H),No significant difference,"HOMA-IR varied within normal limits before induction of anaesthesia, 60 min after the start of surgery, and at the start of skin closure, with no significant differences between the 2 groups.",18720:18911, 3714385 ,23869185,Unavailable
 3714385 ,HOMA-β values at 60 min after the start of surgery and skin closure,remifentanil at infusion rates of 0.1 μg·kg-1·min-1 (L),remifentanil at infusion rates of 0.5 μg·kg-1·min-1 (H),No significant difference,"HOMA-β values at 60 min after the start of surgery and skin closure were significantly lower in Group L than in the Group H, but significant difference was not noted.",19096:19262, 3714385 ,23869185,Unavailable
 3714385 ,3-MH/Cr values,remifentanil at infusion rates of 0.1 μg·kg-1·min-1 (L),remifentanil at infusion rates of 0.5 μg·kg-1·min-1 (H),No significant difference,There were no significant differences in the 3-MH/Cr values between the 2 groups at any time point.,5302:5401, 3714385 ,23869185,Unavailable
 3751503 ,IKDC or KT-1000 results,aseptic bone-patellar tendon-bone (BTB) allografts,BioCleanse-sterilized allografts,No significant difference,. IKDC or KT-1000 results were not significantly different between groups at any time point.,5253:5345, 3751503 ,23203337,Unavailable
 3751503 ,Active flexion ROM,aseptic bone-patellar tendon-bone (BTB) allografts,BioCleanse-sterilized allografts,No significant difference,Active flexion ROM significantly improved from pre-op to 24-month follow-up (P &lt; 0.0001) with no difference between groups at any time point.,5346:5508, 3751503 ,23203337,Unavailable
 3751503 ,Active extension ROM,aseptic bone-patellar tendon-bone (BTB) allografts,BioCleanse-sterilized allografts,No significant difference,Active extension ROM did not differ significantly between the two groups.,5508:5581, 3751503 ,23203337,Unavailable
 5319516 ,triglycerides,zhibitai 480 mg + atorvastatin 10 mg (ZA10 group),atorvastatin 20 mg (A20 group) or atorvastatin 40 mg (A40 group),No significant difference,There were no differences in TG levels among the 3 groups at 8 weeks (P &gt; 0.05) (Table 2).,20452:20598, 5319516 ,28207527,Unavailable
 5319516 ,cardiotrophin-1 (CT-1) and high sensitivity-C reactive protein (hs-CRP),zhibitai 480 mg + atorvastatin 10 mg (ZA10 group),atorvastatin 20 mg (A20 group) or atorvastatin 40 mg (A40 group),No significant difference,"CT-1 levels were decreased significantly after 4 and 8 weeks of treatment in all 3 groups compared with baseline (P &lt; 0.01), and the resulting levels were similar among all 3 groups (P &gt; 0.05). hs-CRP levels were also decreased significantly after 4 and 8 weeks in the 3 groups compared with baseline (P &lt; 0.05), without difference among the 3 groups (P &gt; 0.05) (Table 3).",20452:20598, 5319516 ,28207527,Unavailable
 5319516 ,creatine kinase,zhibitai 480 mg + atorvastatin 10 mg (ZA10 group),atorvastatin 20 mg (A20 group) or atorvastatin 40 mg (A40 group),No significant difference,There was no significant difference in CK between the three groups before and after treatment (Table 4).,20452:20598, 5319516 ,28207527,Unavailable
 5976302 ,stair ascent time,arch support insoles for 12 weeks,did not wear the insoles,Significantly increased,"Objective physical activity tests revealed that compared with the control group, the treatment group exhibited significant improvement in stair ascent time (−2.1, effect size: −0.33, P = .015) (Fig. 3).",27959:28215, 5976302 ,29768332,Unavailable
 5976302 ,transfer and basic mobility measured by PODCI and physical health assessed by PedsQL ,arch support insoles for 12 weeks,did not wear the insoles,Significantly increased,"Compared to the control group, statistically significant improvement of the treatment group was noted in transfer and basic mobility measured by PODCI (10.6, effect size: 0.76, P = .048) and physical health assessed by PedsQL (12, effect size: 0.59, P = .011) at the 12-week follow-up.",28216:28535, 5976302 ,29768332,Unavailable
 5976302 ,physical health by PedsQL,arch support insoles for 12 weeks,did not wear the insoles,Significantly increased,"For efficiency analysis, the efficiency was statistically higher in the treatment group than in the control group for physical health by PedsQL (10.3% vs −38.9%, P = .035, and P &lt; .001 by ANCOVA);",28944:29176, 5976302 ,29768332,Unavailable
 5516151 ,time to death or graft loss,belatacept  (more intense [MI] or less intense [LI]),cyclosporine,No significant difference,Hazard ratios (HRs) comparing time to death or graft loss were 0.915 (95% confidence interval [CI] 0.625–1.339; p = 0.65) for belatacept MI versus cyclosporine and 0.927 (95% CI 0.634–1.356; p = 0.70) for belatacept LI versus cyclosporine.,9413:9913, 5516151 ,27130868,Unavailable
 5516151 ,Mean estimated GFR (eGFR),belatacept  (more intense [MI] or less intense [LI]),cyclosporine,Significantly increased,"Mean estimated GFR (eGFR) plus or minus standard error at 7 years was 53.9 ± 1.9, 54.2 ± 1.9, and 35.3 ± 2.0 mL/min per 1.73 m2 for belatacept MI, belatacept LI and cyclosporine, respectively (p &lt; 0.001 for overall treatment effect).",9913:10404, 5516151 ,27130868,Unavailable
 5516151 ,Acute rejection rates and safety profiles,belatacept  (more intense [MI] or less intense [LI]),cyclosporine,No significant difference,Acute rejection rates and safety profiles of belatacept‐ and cyclosporine‐based treatment were similar.,10983:11086, 5516151 ,27130868,Unavailable
 3664320 ,Median progression-free survival,axitinib,sorafenib,Significantly increased,"In the Japanese subgroup analysis, IRC-assessed median PFS with axitinib was 12.1 months (95% CI 8.6 to not estimable) compared with 4.9 months (95% CI 2.8–6.6) with sorafenib (HR 0.390; 95% CI 0.130–1.173; P = 0.0401, stratified one-sided log-rank test) (Fig. 1B, Table 3).",35869:36249, 3664320 ,23630366,Unavailable
 3664320 ,The objective response rate,axitinib,sorafenib,Significantly increased,"IRC-assessed ORR was significantly higher with axitinib than that with sorafenib in Japanese patients (52.0 vs. 3.4%, respectively, P = 0.0001) (Fig. 3, Table 4).",41952:42221, 3664320 ,23630366,Unavailable
 1550956 ,protein C levels,treatment with drotrecogin alfa (activated) (DrotAA),placebo,Significantly increased,DrotAA treatment improved protein C levels by day 1 compared with placebo (P = 0.008),6382:6484, 1550956 ,16780598,Unavailable
 1550956 ,protein S and antithrombin III,"treatment with drotrecogin alfa (activated) (DrotAA) in  severe deficiency, protein C levels ≤ 40% of normal protein C activity (n = 615, 39% of patients); deficient, protein C levels 41–80% of normal protein C activity (n = 764, 48.5% of patients);","treatment with drotrecogin alfa (activated) (DrotAA) in  &gt;80% of normal protein C activity (n = 195, 12.4% of patients)",No significant difference,"There was no significant difference between treatment groups in day 1 levels or the day 1 change in two other markers of coagulation, protein S (P = 0.41 and P = 0.59, respectively) and antithrombin III (P = 0.61 and P = 0.88, respectively).",21781:22033, 1550956 ,16780598,Unavailable
 3258705 ,The mean duration of infertility,"oestradiol group, 2 mg of oestradiol valerate was initiated orally with progesterone",the control group received vaginal administration of progesterone supplementation alone starting on the day after oocyte retrieval and continued until the tenth week if the chemical pregnancy test was positive,No significant difference,"The mean duration of infertility was 5.98 ±0.55 years in the control group and 7.81 ±1.37 years in the oestradiol group, but this difference was not statistically significant (P &gt; 0.05).",14160:14363, 3258705 ,22291742,Unavailable
 3258705 ,luteinizing hormone (LH),"oestradiol group, 2 mg of oestradiol valerate was initiated orally with progesterone",the control group received vaginal administration of progesterone supplementation alone starting on the day after oocyte retrieval and continued until the tenth week if the chemical pregnancy test was positive,No significant difference,There were no significant differences between the two groups in LH levels measured on different days.,14364:14466, 3258705 ,22291742,Unavailable
 3258705 ,serum level of progesterone and oestradiol,"oestradiol group, 2 mg of oestradiol valerate was initiated orally with progesterone",the control group received vaginal administration of progesterone supplementation alone starting on the day after oocyte retrieval and continued until the tenth week if the chemical pregnancy test was positive,No significant difference,"Although the serum level of progesterone and oestradiol on different days in the oestradiol group was higher than that of the control group, these differences were not statistically significant (P &gt; 0.05) (Table II).",14466:14745, 3258705 ,22291742,Unavailable
 3258705 ,"The mean number of retrieved oocytes, number of transferred embryos, and chemical and clinical pregnancy rate","oestradiol group, 2 mg of oestradiol valerate was initiated orally with progesterone",the control group received vaginal administration of progesterone supplementation alone starting on the day after oocyte retrieval and continued until the tenth week if the chemical pregnancy test was positive,No significant difference,"The mean number of retrieved oocytes, number of transferred embryos, and chemical and clinical pregnancy rate did not significantly differ between the two groups (Table III).",14744:14959, 3258705 ,22291742,Unavailable
 5827507 ,Dentinal hypersensitivity (DH),combined 5% KNO3 and the diode laser,1-5% potassium nitrate (KNO3),Significantly decreased,A significant reduction in DH was observed for Group 3 (GaAlA laser diode and 5% KNO3) and Group 2 (GaAlA laser diode) than Group 1 (5% KNO3).,14778:14943, 5827507 ,29491586,Unavailable
 5827507 ,Dentinal hypersensitivity (DH), gallium-aluminum-arsenide diode laser,1-5% potassium nitrate (KNO3),Significantly decreased,A significant reduction in DH was observed for Group 3 (GaAlA laser diode and 5% KNO3) and Group 2 (GaAlA laser diode) than Group 1 (5% KNO3).,14778:14943, 5827507 ,29491586,Unavailable
 4588672 , mini-Communicative Abilities Log (mini-CAL) score at 12 weeks,constraint-induced aphasia therapy (CIAT),no intervention,Significantly increased,"Patients who received CIAT scored higher on the mini-CAL at 12 weeks after intervention compared to the control group (Mean 31 vs. 23; difference=8, 95% CI 1.3 to 13.5, p=0.019)",26350:26544, 4588672 ,26399192,Unavailable
 4588672 , the Semantic Fluency Test (SFT) score,constraint-induced aphasia therapy (CIAT),no intervention,No significant difference,"The SFT was marginally higher 2 weeks after intervention in CIAT patients than controls (Mean 21 vs. 12; difference 9, 95% CI −0.3 to 17.8, p=0.058). This difference was not sustained at twelve weeks after intervention.",26546:26782, 4588672 ,26399192,Unavailable
 4951149 ,faecal consistency,low-fibre Western-style diet (WSD) ,healthy-carbohydrate diet (HCD),Significantly increased,The faecal consistency differed significantly (P = 0.02) between the two interventions. Six subjects reported constipation during the WSD compared with one subject during the HCD.,52398:52595, 4951149 ,27434092,Unavailable
 4951149 ,number of observed species (alpha-diversity) in the stools ,healthy-carbohydrate diet (HCD), low-fibre Western-style diet (WSD) ,Significantly decreased,The number of observed species (alpha-diversity) was significantly lower in the stools collected after the HCD (an average of 615 species) compared with those collected after the WSD (675 species) (P &lt; 0.0001).,65538:65766, 4951149 ,27434092,Unavailable
 3560577 ,The mean time for pH &gt;4 and pH &gt;6,Lansoprazole 30 mg intravenously ,pantoprazole 40 mg intravenously ,No significant difference,"The mean time for pH &gt;4 and pH &gt;6 with lansoprazole was shorter than with pantoprazole on day 1, but the difference was not statistically significant (109.61±32.15 min vs. 153.42±29.36 min, P=0.3304 for pH 4; and 211.93±39.18 min vs. 288.43±35.79 min, P=0.1706 for pH 6).",20468:20813, 3560577 ,22293876,Unavailable
 3681405 ,The median survival time (MST) for patients with non-small cell lung cancer (NSCLC),preoperative chemotherapy plus surgery,surgery-alone arm,Significantly decreased,"The median survival time (MST) was 45.42 months in the preoperative chemotherapy arm and 57.59 months in the surgery-alone arm (log-rank P = 0.016), with a HR of death of 1.67 (95% CI, 1.43–1.96).",15738:15892, 3681405 ,23776338,Unavailable
 3681405 ,The MST of stage II non-small cell lung cancer (NSCLC),preoperative chemotherapy plus surgery,surgery-alone arm,Significantly decreased,The MST of stage II NSCLC was 40.86 months in the preoperative chemotherapy arm and 80.81 months in the primary surgery arm (log-rank P = 0.044).,15738:15892, 3681405 ,23776338,Unavailable
 3681405 ,survival rates of stage I and stage IIIA non-small cell lung cancer (NSCLC),preoperative chemotherapy plus surgery,surgery-alone arm,No significant difference,"There were not significant differences between the two arms in the survival rates of stage I and stage IIIA NSCLC (log-rank P = 0.734; log-rank P = 0.051, respectively).",15738:15892, 3681405 ,23776338,Unavailable
 3681405 ,Progression-free survival for patients with non-small cell lung cancer (NSCLC),preoperative chemotherapy plus surgery,surgery-alone arm,No significant difference,The median PFS time was 42.21 months in the preoperative chemotherapy arm and 45.67 months in the surgery-alone arm (log-rank P = 0.38).,15738:15892, 3681405 ,23776338,Unavailable
 3685700 ,hunger, total sleep deprivation (TSD) + six yogurt probes with varying sucrose concentrations (2–29 %),sleep (permitted between 22:30 and 06:30&nbsp;h)+ six orally presented yogurt probes with varying sucrose concentrations (2–29 %),No significant difference,"However, no significant differences between the TSD and sleep conditions were observed when the change in hunger before (i.e., 08:00&nbsp;h) and after the preload (i.e., 08:30&nbsp;h) was analyzed (TSD vs. Sleep, −37 ± 6 vs. −36 ± 5&nbsp;mm).",16064:16292, 3685700 ,23807868,Unavailable
 3685700 ,ratings of sweet intensity or pleasantness of the yogurt samples with varying sucrose concentrations, total sleep deprivation (TSD) + six yogurt probes with varying sucrose concentrations (2–29 %),sleep (permitted between 22:30 and 06:30&amp;nbsp;h)+ six orally presented yogurt probes with varying sucrose concentrations (2–29 %),No significant difference,"As indicated by repeated measures ANOVA, ratings of sweet intensity or pleasantness of the yogurt samples with varying sucrose concentrations did not significantly (i.e., p &lt; 0.05) differ between conditions",17266:17473, 3685700 ,23807868,Unavailable
 3685700 ,Plasma glucose measurements, total sleep deprivation (TSD) + six yogurt probes with varying sucrose concentrations (2–29 %),sleep (permitted between 22:30 and 06:30&amp;amp;nbsp;h)+ six orally presented yogurt probes with varying sucrose concentrations (2–29 %),No significant difference,"Plasma glucose measurements did not differ between the TSD and sleep conditions (TSD vs Sleep, 5.4 ± 0.5 vs. 5.3 ± 0.4&nbsp;mmol/l).",18840:18968, 3685700 ,23807868,Unavailable
 3685700 ,Plasma concentrations of total ghrelin, total sleep deprivation (TSD) + six yogurt probes with varying sucrose concentrations (2–29 %),sleep (permitted between 22:30 and 06:30&amp;amp;amp;nbsp;h)+ six orally presented yogurt probes with varying sucrose concentrations (2–29 %),Significantly increased,"Plasma concentrations of total ghrelin were higher after TSD than after a night of sleep (TSD vs. Sleep, 442 ± 61 vs. 390 ± 44&nbsp;pg/ml, p = 0.04).",18968:19112, 3685700 ,23807868,Unavailable
 5737953 ,The median time to complete encrustation/epithelialization,lip balm with propolis special extract GH 2002 ,lip balm with aciclovir cream,Significantly decreased,"The median time to complete encrustation/epithelialization was 4.0 days with propolis (average 4.41 [1.63] days), and 5.0 days with aciclovir (average 5.54 [1.87]). The superiority of propolis was highly significant (P &lt; 0.0001; Mann-Whitney U test modified for superiority testing with a threshold 0.5 days; Figure 4).Figure 4",22281:22708, 5737953 ,29276548,Unavailable
 5737953 ,pain reduction,lip balm with propolis special extract GH 2002 ,lip balm with aciclovir cream,Significantly decreased,The difference of 8 mm on a visual analogue scale in favor of propolis extract GH 2002 was statistically significant (P &lt; 0.001 based on Mann-Whitney U test).Figure 5,23706:23933, 5737953 ,29276548,Unavailable
 5737953 ,severe tension and swelling,lip balm with propolis special extract GH 2002 ,lip balm with aciclovir cream,Significantly decreased,"Overall, patients in the aciclovir group had more severe tension and swelling than patients in the group using propolis (P = 0.042 based on Mann-Whitney U test; data not shown).",24583:24794, 5737953 ,29276548,Unavailable
 5737953 ,itching or burning,lip balm with propolis special extract GH 2002 ,lip balm with aciclovir cream,Significantly decreased,"For the further visits on Days 2 to 5 there was a significant difference in favor of propolis, reaching 89% versus 66% free of itching or burning (Figure 6), and 94% versus 74% free of tension and swelling (Figure 7) at Day 5 for propolis versus aciclovir (P &lt; 0.001 based on Mann-Whitney U test).",24812:25226, 5737953 ,29276548,Unavailable
 5737953 ,"assessment of global efficacy by the physicians ""good"" to ""very good""""",lip balm with propolis special extract GH 2002 ,lip balm with aciclovir cream,Significantly increased,"Differences were statistically significant at all visits on Days 2, 3, 4, and 5 (ITT group P &lt; 0.0001 based on Mann-Whitney U test). Results for the PP group were practically identical, with 94.7% and 69.0% of ratings as “good” and “very good” on Day 5 for propolis and aciclovir, respectively.Figure 8",26253:26615, 5737953 ,29276548,Unavailable
 4354432 ,Mean plasma concentration–time curves for R- and S-warfarin,lobeglitazone (0.5 mg) for 1–12 days with warfarin (25 mg),warfarin (25 mg) alone,No significant difference,"Mean plasma concentration–time curves for R- and S-warfarin following administration of warfarin alone and when combined with lobeglitazone are shown in Figure 1. Cmax, Tmax, and t1/2 for R- and S-warfarin did not differ significantly between the two treatments (Table 1).",17751:18274, 4354432 ,25767371,Unavailable
 4354432 ,findings for vital signs or physical examination results,lobeglitazone (0.5 mg) for 1–12 days with warfarin (25 mg),warfarin (25 mg) alone,No significant difference,No clinically significant findings for vital signs or physical examination results were observed.,21527:21624, 4354432 ,25767371,Unavailable
 3558647 ,The best time to laryngoscopy,Rocuronium 0.9 mg/kg (R group),cisatracurium 0.15 mg/kg (C group),Significantly decreased,The best time to laryngoscopy was predicted by measuring TOF and was found to be significantly longer in the C group (197 ± 53 s) than in the R group (102 ± 49 s) (P value &lt; 0.05).,5343:5523, 3558647 ,23372884,Unavailable
 3476989 ,The pain level in the active side of the shoulder/neck,coffee (1/2 -1 cup) on average 1 h 18 min before start,abstained from coffee intake,Significantly decreased,"The pain increase in the active side of the shoulder/neck was significantly lower for the coffee consumers than for the abstainers (see Table 1; β5),",10726:10914, 3476989 ,22943590,Unavailable
 3770494 ,recalled the last five words,methylphenidate (MPH) 20 mg,placebo,No significant difference,"There was, however, no difference between the real MPH and placebo groups.",25486:25560, 3770494 ,24039459,Unavailable
 3770494 ,anger and fatigue,methylphenidate (MPH) 20 mg,placebo,Significantly increased,Participants whose treatment assumption after final free recall was MPH showed significantly more anger (P = 0.031) and fatigue (P = 0.036) than those who answered placebo.,27807:28013, 3770494 ,24039459,Unavailable
 4161875 ,daily nursing workload for glucose control,intervention group these data were used to feed a computerized glucose regulation algorithm,continuous glucose monitoring (CGM) data were blinded in the control group,Significantly decreased,significant reduction in daily nursing workload for glucose control was found in the intervention group (17 versus 36&nbsp;minutes; P &lt;0.001).,6297:6441, 4161875 ,25139609,Unavailable
 4161875 ,Mean daily costs per patient,intervention group these data were used to feed a computerized glucose regulation algorithm,continuous glucose monitoring (CGM) data were blinded in the control group,Significantly decreased,"Mean daily costs per patient were significantly reduced with EUR 12 (95% CI −32 to −18, P = 0.02) in the intervention group.",6297:6441, 4161875 ,25139609,Unavailable
 4710815 ,incidence of cardiac disorders,"Respimat 2.5 µg (R 2.5),  Respimat 5 µg(R5)",HandiHaler 18 µg (HH18),Significantly decreased,"Although the incidence of cardiac disorders was higher in the HandiHaler group (n=5 vs 2), the very small number of cardiac deaths, the small absolute risk difference and the wide CIs around the HRs, do not indicate any significant difference (table 2).",33037:33347, 4710815 ,26715479,Unavailable
 4710815 ,number of cardiac deaths,"Respimat 2.5 µg (R 2.5),  Respimat 5 µg(R5)",HandiHaler 18 µg (HH18),No significant difference,"the very small number of cardiac deaths, the small absolute risk difference and the wide CIs around the HRs, do not indicate any significant difference (table 2).",33128:33347, 4710815 ,26715479,Unavailable
 4710815 ,"cardiac arrhythmia  or cardiac history defined as history of MI, ischaemic heart disease/coronary artery disease, cardiac arrhythmia or heart failure","Respimat 2.5 µg (R 2.5),  Respimat 5 µg(R5)",HandiHaler 18 µg (HH18),No significant difference,"No significant treatment interactions were observed for either Respimat dose compared with HandiHaler in the subgroups of patients with baseline cardiac arrhythmia (Respimat 2.5 µg: HR 1.03; 95% CI 0.58 to 1.84; 5 µg: HR 0.83; 95% CI 0.44 to 1.56) or cardiac history defined as history of MI, ischaemic heart disease/coronary artery disease, cardiac arrhythmia or heart failure (Respimat 2.5 µg: HR 1.01; 95% CI 0.65 to 1.57; 5 µg: HR 0.93; 95% CI 0.59 to 1.46) (see E-figure 2a, b).",41675:42158, 4710815 ,26715479,Unavailable
 4710815 ,"safety,The risk of exacerbation and major adverse cardiovascular (CV) events (MACEs)","Respimat 2.5 µg (R 2.5),  Respimat 5 µg(R5)",HandiHaler 18 µg (HH18),No significant difference,"For the secondary safety end points of time to first MACE, there was no significant difference between the Respimat and HandiHaler groups (table 4 and E-figure 4a, b).",53504:53729, 4710815 ,26715479,Unavailable
 3747889 ,carotid intima-media thickness (CIMT),insulin glargine and n-3 polyunsaturated fatty acid (n-3FA) supplements,standard glycemic care and double-blind therapy with a 1-g capsule of n-3FA;  ,No significant difference,"Compared with standard care, insulin glargine reduced the primary CIMT outcome, but the difference was not statistically significant (difference = 0.0030 ± 0.0021 mm/year; P = 0.145)",7843:8042, 3747889 ,23564916,Unavailable
 3747889 ,change in maximum CIMT for the common carotid and the common carotid plus bifurcation,insulin glargine and n-3 polyunsaturated fatty acid (n-3FA) supplements,standard glycemic care and double-blind therapy with a 1-g capsule of n-3FA;  ,Significantly decreased,"significantly reduced the secondary CIMT outcomes (differences of 0.0033 ± 0.0017 mm/year [P = 0.049] and 0.0045 ± 0.0021 mm/year [P = 0.032], respectively)",8239:8351, 3747889 ,23564916,Unavailable
 3747889 ,"carotid intima-media thickness (CIMT), change in maximum CIMT for the common carotid and the common carotid plus bifurcation",insulin glargine and n-3 polyunsaturated fatty acid (n-3FA) supplements,placebo,No significant difference,There were no differences in the primary and secondary outcomes between the n-3FA supplement and placebo groups.,8239:8351, 3747889 ,23564916,Unavailable
 3666925 ,postoperative peak cTnI release,morphine (0.1 mg/kg) injected via a cardioplegia needle into the aortic root,control group (the same protocol was performed as in the postconditioning group except that patients received the same volume of saline instead,Significantly decreased,"Morphine-induced postconditioning reduced postoperative peak cTnI release as compared to the control group (0.57 ± 0.15 versus 0.75 ± 0.20 ng/mL, p&lt;0.0001).",5363:5520, 3666925 ,23577699,Unavailable
 3666925 ,peak inotropic score ; duration of mechanical ventilation as well as ICU stay,morphine (0.1 mg/kg) injected via a cardioplegia needle into the aortic root,control group (the same protocol was performed as in the postconditioning group except that patients received the same volume of saline instead,Significantly decreased,"Morphine-induced postconditioned patients had lower peak inotropic score (5.7 ± 2.4 versus 8.4 ± 3.6, p&lt;0.0001) and shorter duration of mechanical ventilation as well as ICU stay (20.6 ± 6.8 versus 28.5 ± 8.3 hours, p&lt;0.0001 and 40.4 ± 10.3 versus 57.8 ± 15.2 hours, p&lt;0.0001, respectively)",5520:5810, 3666925 ,23577699,Unavailable
 3666925 ,left ventricular ejection fraction; cardiac output,morphine (0.1 mg/kg) injected via a cardioplegia needle into the aortic root,control group (the same protocol was performed as in the postconditioning group except that patients received the same volume of saline instead,Significantly increased,"while higher left ventricular ejection fraction as well as cardiac output (0.57±0.15 versus 0.51±0.13, p=0.0467 and 1.39 ± 0.25 versus 1.24 ± 0.21 L/min, p=0.0029, respectively) as compared to the control group during the first postoperative 24 hours.",5811:6063, 3666925 ,23577699,Unavailable
 5725027 ,quality of recovery (QoR),group D received dexmedetomidine 0.04 ug/(kg·h) plus sufentanil 0.02 ug/(kg·h),control group S received sufentanil 0.04 ug/(kg·h) ,Significantly increased,"The QoR-15 scores were significantly higher in the group D than in the group S on postoperative day (POD) 1, 2, 3 and 5 (P &lt; 0.05).",5030:5162, 5725027 ,29245985,Unavailable
 5725027 ,The pressing times of analgesic pump and rescue tramadol,group D received dexmedetomidine 0.04 ug/(kg·h) plus sufentanil 0.02 ug/(kg·h),control group S received sufentanil 0.04 ug/(kg·h) ,No significant difference,The pressing times of analgesic pump and rescue tramadol were not significantly different between the two groups (P &gt; 0.05).,5299:5423, 5725027 ,29245985,Unavailable
 5725027 ,incidence of nausea,group D received dexmedetomidine 0.04 ug/(kg·h) plus sufentanil 0.02 ug/(kg·h),control group S received sufentanil 0.04 ug/(kg·h) ,Significantly decreased,reduced incidence of nausea within 48 h after surgery in the group D (P &lt; 0.05; Table 5).,44851:44982, 5725027 ,29245985,Unavailable
 5725027 ,Vomiting,group D received dexmedetomidine 0.04 ug/(kg·h) plus sufentanil 0.02 ug/(kg·h),control group S received sufentanil 0.04 ug/(kg·h) ,No significant difference,There were no differences between the two groups in the incidence of postoperative adverse effects with the exception of reduced incidence of nausea within 48 h after surgery in the group D (P &lt; 0.05; Table 5).,44730:44982, 5725027 ,29245985,Unavailable
 2365983 ,Median operating time,total laparoscopic restorative proctocolectomy,hand-assisted laparoscopic restorative proctocolectomy and open restorative proctocolectomy,Significantly decreased,"Morbidity and reoperation rates in the total laparoscopic, hand-assisted laparoscopic, and open groups were comparable (29 vs. 20 vs. 23 percent and 17 vs.10 vs. 13 percent, respectively).",4708:4967, 2365983 ,18301949,Unavailable
 2365983 ,Morbidity and reoperation rates,total laparoscopic restorative proctocolectomy,"hand-assisted laparoscopic restorative proctocolectomy, and open restorative proctocolectomy",Significantly decreased,"There was a statistically significant shorter period to oral intake in the TLRP group compared with both other groups (time to resumption of liquid diet, 3 vs. 5 vs. 5&nbsp;days and normal diet 5 vs. 6 vs. 7&nbsp;days in the TLRP, HAL-RP, and ORP groups, respectively; P = 0.004 and P = 0.018, respectively).",23269:23476, 2365983 ,18301949,Unavailable
 2365983 ,daily and total morphine requirement,total laparoscopic restorative proctocolectomy,hand-assisted laparoscopic restorative proctocolectomy and open restorative proctocolectomy,Significantly decreased,"Although daily and total morphine requirement in the TLRP was lower compared with the HAL-RP and ORP groups, this difference was not statistically significant (Fig.&nbsp;1).",23269:23476, 2365983 ,18301949,Unavailable
 2365983 ,costs,total laparoscopic restorative proctocolectomy,hand-assisted laparoscopic restorative proctocolectomy ,No significant difference,"Total costs were 1864 euros less in the TLRP compared with the HAL-RP group. This difference, which was not statistically significant, can be explained by the shorter hospital stay in the TLRP group. Table&nbsp;3",26113:26350, 2365983 ,18301949,Unavailable
 2365983 ,daily and total morphine requirement,total laparoscopic restorative proctocolectomy,hand-assisted laparoscopic restorative proctocolectomy and open restorative proctocolectomy,Significantly decreased,"Although daily and total morphine requirement in the TLRP was lower compared with the HAL-RP and ORP groups, this difference was not statistically significant (Fig.&nbsp;1).",24216:24369, 2365983 ,18301949,Unavailable
 5807510 ,the rate of genetic diagnosis within 28 days,rWGS plus standard genetic tests,standard genetic tests alone,Significantly increased,"Nevertheless, intention to treat analysis showed the rate of genetic diagnosis within 28 days of enrollment (the primary end-point) to be higher in cases (31%, 10 of 32) than controls (3%, 1 of 33; difference, 28% [95% CI, 10–46%]; p = 0.003).",9939:10200, 5807510 ,29449963,Unavailable
 5807510 ,the rate of neonatal diagnosis,rWGS plus standard genetic tests,standard genetic tests alone,Significantly increased,"Among infants enrolled in the first 25 days of life, the rate of neonatal diagnosis was higher in cases (32%, 7 of 22) than controls (0%, 0 of 23; difference, 32% [95% CI, 11–53%];p = 0.004).",10200:10408, 5807510 ,29449963,Unavailable
 5807510 ,Median age at diagnosis and median time to diagnosis,rWGS plus standard genetic tests,standard genetic tests alone,Significantly decreased,"Median age at diagnosis (25 days [range 14–90] in cases vs. 130 days [range 37–451] in controls) and median time to diagnosis (13 days [range 1–84] in cases, vs. 107 days [range 21–429] in controls) were significantly less in cases than controls (p = 0.04).",10409:10684, 5807510 ,29449963,Unavailable
 4364332 ,positive response to the first invitation letter,trial invitation letter containing an incentive offer of £100,standard trial invitation letter,Significantly increased,"The £100 incentive offer increased positive response to the first invitation letter from 24.7% to 31.6%, an increase of 6.9% (P &lt; 0.05).",5155:5309, 4364332 ,25888477,Unavailable
 5842245 ,GSI from Symptoms Checklist-90 or PSS Perceived Stress Scale-14 or PSQI Pittsburgh Sleep Quality Index,Music therapy intervention (iMT),"The iMBI (In Swedish: Mindfulness Grundkurs 2.0 from Mindfulnesscenter AB, Sweden)",No significant difference,Table 1 shows the comparisons between those who logged in and completed at least one session and those who did not log into the self-help programmes. No significant difference in any of the scales was found between those who logged in and completed at least one session and those who did not log into the self-help programmes.Table 1,30226:30629, 5842245 ,28776094,Unavailable
 5863299 ,Circulating nitric oxide levels,Danhong injection combined with Naoxintong capsule for 12 weeks,placebo,Significantly increased,"At 12 weeks of treatment the level of NO had significantly elevated in both groups, but the change in the treatment group was obviously larger than that in the control group (P &lt; 0.05).",28501:28625, 5863299 ,29707035,Unavailable
 5863299 ,Circulating levels of endothelin-1 (ET-1) and von Willebrand factor (VWF),Danhong injection combined with Naoxintong capsule for 12 weeks,placebo,Significantly decreased,"At 12 weeks of treatment, the ET-1 and VWF levels of both groups were significantly lower than at the baseline, but the decrease in the treatment group was significantly less than that of the control.",28501:28625, 5863299 ,29707035,Unavailable
 5863299 , left ventricular ejection fraction,Danhong injection combined with Naoxintong capsule for 12 weeks,placebo,Significantly increased,"It was surprising that, at 12 weeks of treatment, the LVEF of both groups were less than those at 7 weeks, but the LVEF remained significantly higher in the treatment group than the control group.",28501:28625, 5863299 ,29707035,Unavailable
 5863299 ,The overall response rate,Danhong injection combined with Naoxintong capsule for 12 weeks,placebo,Significantly increased,The overall response rate of the treatment group (86.44%) was significantly higher than that of the control group (70.96%).,28501:28625, 5863299 ,29707035,Unavailable
 5659607 ,risk of asthma/recurrent wheeze,"vitamin D3 (4,000 IU/d)",control,Significantly decreased,"A combined analysis of the calculated odds-ratios from the separate trials showed a significant 26% reduced risk of asthma/recurrent wheeze in the vitamin D vs. control group: OR = 0.74 (95% CI, 0.57 to 0.96), p = 0.02 (Fig 2A and Table 3),",42675:43021, 5659607 ,29077711,Unavailable
 5741948 ,adjusted health and social care costs,treatment as usual with an integrated health promotion intervention (IMPaCT),standard community mental health team care (treatment as usual),No significant difference,"There were no differences in adjusted health and social care costs (£95, 95% CI -£1410 to £1599)",13920:14017, 5741948 ,29273021,Unavailable
 5741948 ,societal costs,treatment as usual with an integrated health promotion intervention (IMPaCT),standard community mental health team care (treatment as usual),No significant difference,"There were no differences in adjusted health and social care costs (£95, 95% CI -£1410 to £1599) or societal costs (£675, 95% CI -£1039 to £2388) between the intervention and control arms.",13921:14110, 5741948 ,29273021,Unavailable
 5741948 ,"SF-36 mental component or SF-36 physical component  or , QALYs estimated from the SF-36 or QALYs estimated from the EQ-5D-3 L (",treatment as usual with an integrated health promotion intervention (IMPaCT),standard community mental health team care (treatment as usual),No significant difference,"Similarly, there were no differences between the groups in the SF-36 mental component (−0.80, 95% CI -3.66 to 2.06), SF-36 physical component (−0.68, 95% CI -3.01 to 1.65), QALYs estimated from the SF-36 (−0.00, −0.01 to 0.00) or QALYs estimated from the EQ-5D-3 L (0.00, 95% CI -0.01 to 0.02).",14110:14404, 5741948 ,29273021,Unavailable
 4734805 ,The central retinal thickness,bromfenac 0.09% ophthalmic solution,nepafenac 0.1%,No significant difference,"The central retinal thickness did not show significant changes after treatment when compared to baseline as follows: in the bromfenac group (247.2±32.9 vs 252.0±24.9 μm; P=0.958) and in nepafenac group (250.8±34 vs 264.0±34.1 μm; P=0.137), respectively.",5727:6015, 4734805 ,26869758,Unavailable
 3656395 ,"diabetes outcome measures (HbA1c, blood pressure, cholesterol, BMI).",a comprehensive programme,usual care,No significant difference,"Table II shows that compared with usual care the comprehensive programme did not result in statistically significant improvements in the diabetes outcome measures (HbA1c, blood pressure, cholesterol, BMI).",30655:30868, 3656395 ,23659710,Unavailable
 5850768 ,Immunogenicity,3 mg/kg of SB2 ,3 mg/kg of infliximab,No significant difference,Immunogenicity was comparable between SB2 and INF with no statistically significant difference.,32993:33088, 5850768 ,28957563,Unavailable
 5850768 ,The overall efficacy,3 mg/kg of SB2 ,3 mg/kg of infliximab,No significant difference,The overall efficacy did not differ from what had been observed at week 30 (ACR20 responses in PPS: 64.1% in SB2 and 66.0% in INF; ACR20 responses in FAS: 63.6% in SB2 and 65.3% in INF).,25037:25224, 5850768 ,28957563,Unavailable
 5850768 ,the safety profile,3 mg/kg of SB2 ,3 mg/kg of infliximab,No significant difference,"In summary, the safety profile of SB2 remained relatively consistent with previously reported data (up to 30 weeks) and was comparable to that of INF. Table 1",27811:28052, 5850768 ,28957563,Unavailable
 3643086 ,"temporal variation of biomarker levels (IL-6, VCAM-1, ET-1)",atorvastatin 80 mg/day,placebo,No significant difference,"No significant difference was observed on the temporal variation of biomarker levels (IL-6, VCAM-1, ET-1) between treatment and control groups.",5911:6054, 3643086 ,None,Unavailable
 3643086 ,intrahospital mortality rate,atorvastatin 80 mg/day,placebo,No significant difference,The intrahospital mortality rate was 26% in the statin group and 45% in the placebo group (P = 0.17).,6055:6173, 3643086 ,None,Unavailable
 5866333 ,growth hormone (GH),sitagliptin,placebo,Significantly increased,"Sitagliptin enhanced stimulated GH secretion (P&lt;0.01 versus placebo, for 30&nbsp;minutes) and free insulin–like growth factor‐1 (P&lt;0.001 versus placebo, after adjustment for baseline) in women.",7610:7887, 5866333 ,29478970,Unavailable
 5866333 ,Vasodilation and tissue plasminogen activator (tPA) activity in women,sitagliptin,placebo,Significantly increased,"Vasodilation and tPA increased in all patients, but sitagliptin enhanced vasodilation (P=0.01 versus placebo) and increased tPA (P&lt;0.001) in women only.",7888:8182, 5866333 ,29478970,Unavailable
 5866333 ,"free insulin–like growth factor‐1, GH",sitagliptin,placebo,Significantly increased,"GHR blockade decreased free insulin–like growth factor‐1 (P=0.04 versus sitagliptin alone) and increased stimulated GH (P&lt;0.01), but decreased vascular resistance (P=0.01) such that nadir vascular resistance correlated inversely with GH (r s=−0.90, P&lt;0.001).",8220:8698, 5866333 ,29478970,Unavailable
 5866333 ,vascular resistance,sitagliptin,placebo,Significantly decreased,"GHR blockade decreased free insulin–like growth factor‐1 (P=0.04 versus sitagliptin alone) and increased stimulated GH (P&lt;0.01), but decreased vascular resistance (P=0.01) such that nadir vascular resistance correlated inversely with GH (r s=−0.90, P&lt;0.001).",8220:8698, 5866333 ,29478970,Unavailable
 3680603 ,Cardiac markers (isoenzyme creatine kinase with muscle and brain subunits [CK-MB] or troponin-I) and the brain natriuretic peptide,"5,000 U/kg ulinastatin",normal saline,No significant difference,"Cardiac markers (isoenzyme creatine kinase with muscle and brain subunits [CK-MB] or troponin-I) and the brain natriuretic peptide level were significantly higher in both groups than the respective preoperative values (p&lt;0.05), but there were no significant differences between the two groups.",14854:15147, 3680603 ,23772405,Unavailable
 3680603 ,"fibrinogen, creatinine, lactate, and aspartate aminotransferase (AST)","5,000 U/kg ulinastatin",normal saline,No significant difference,"There were no statistical differences between fibrinogen, creatinine, lactate, and aspartate aminotransferase (AST) in the two groups (Table 3).",15148:15334, 3680603 ,23772405,Unavailable
 3680603 ,"duration of mechanical ventilator support, ICU stay, chest tube drainage for postoperative 6 hours, chest tube indwelling time, hospital stay, transfusion amounts, or postoperative complications","5,000 U/kg ulinastatin",normal saline,No significant difference,"Among the postoperative outcomes, no statistical significant differences were observed between the two groups in the duration of mechanical ventilator support, ICU stay, chest tube drainage for postoperative 6 hours, chest tube indwelling time, hospital stay, transfusion amounts, or postoperative complications (p&gt;0.05) (Table 4).",15335:15708, 3680603 ,23772405,Unavailable
 3634976 ,quadrivalent meningococcal serogroups A -  vaccine response (VR) rate,"MenACWY-TT, Nimenrix™","GlaxoSmithKline, Belgium",Significantly increased,A MenACWY-TT 175 134 76.6* [69.6; 82.6] 119 93 78.2 [69.6; 85.2] 56 41 73.2 [59.7; 84.2]MenPS 60 55 91.7 [81.6; 97.2] 37 37 100 [90.5; 100] 23 18 78.3 [56.3; 92.5],27188:27925, 3634976 ,23494214,Unavailable
 5805261 ,"number of ablation, ablation time, and energy delivery",switching bipolar (SB) radiofrequency ablation (RFA),switching monopolar (SM) separable clustered (SC) electrodes,Significantly decreased,"In the SB-RFA group, less number of ablations were required (1.72±0.70 vs. 2.31±1.37, P = 0.039), the ablation time was shorter (10.9±3.9 vs.14.3±5.0 min, p = 0.004), and energy delivery was smaller (13.1±6.3 vs.23.4±12.8 kcal, p&lt;0.001) compared to SM-RFA.",15524:15832, 5805261 ,29420589,Unavailable
 5805261 ,Ablation volume,switching bipolar (SB) radiofrequency ablation (RFA),switching monopolar (SM) separable clustered (SC) electrodes,No significant difference,"Ablation volume was not significantly different between SB-RFA and SM-RFA groups (61.8±24.3 vs.54.9±23.7 cm3, p = 0.229).",15832:15984, 5805261 ,29420589,Unavailable
 5805261 ,free survival rates,switching bipolar (SB) radiofrequency ablation (RFA),switching monopolar (SM) separable clustered (SC) electrodes,No significant difference,The 1-year and 2-year LTP free survival rates were 93.9% and 84.3% in the SB-RFA group and 94.4% and 88.4% in the SM-RFA group (p = 0.687).,16111:16267, 5805261 ,29420589,Unavailable
 3668104 ,bispectral index (BIS) at 90 min," Group B dexmedetomidine 0.2 µg/kg/hr,  Group C dexmedetomidine 0.4 µg/kg/hr",Group A - normal saline,Significantly increased,"Group A was significantly different compared to Group B and C (P &lt; 0.05): at 90 min (Group A: 86.5 ± 9.2 min, Group B: 85.1 ± 9.6 min, and Group C: 71.7 ± 11.6 min);",13766:13895, 3668104 ,23741565,Unavailable
 3668104 ,bispectral index (BIS),Group C dexmedetomidine 0.4 µg/kg/hr,"Group A - normal saline, dexmedetomidine 0.2 µg/kg/hr - Group B",Significantly decreased,Groups A and B showed significant differences compared to Group C (P &lt; 0.05) (Fig. 2).,13766:13895, 3668104 ,23741565,Unavailable
 3668104 ,heart rate and mean arterial pressure,Group C dexmedetomidine 0.4 µg/kg/hr,"Group A - normal saline, dexmedetomidine 0.2 µg/kg/hr - Group B",No significant difference,"The heart rate and mean arterial pressure showed a decrease, but there were no significant differences among the three groups (Fig. 3).",13902:14074, 3668104 ,23741565,Unavailable
 3668104 ,"post anesthetic care unit (PACU), modified aldrete score (MAS) for 30 min"," Group B dexmedetomidine 0.2 µg/kg/hr,  Group C dexmedetomidine 0.4 µg/kg/hr",Group A - normal saline,Significantly decreased,"In the PACU, MAS was significantly high for 30 min in Group A compared to Group B and C (P &lt; 0.05) (Fig. 4).",14081:14229, 3668104 ,23741565,Unavailable
 3702091 ,"anxiety by 27%, depression by 37%  and C-reactive proteins",strength and endurance training,experimental and control,Significantly decreased,"Also, the strength and endurance training had reduced the anxiety by 27% (P = .0001), depression by 37% (P = .0001) and C-reactive proteins by 20% (P = 0.0001), in the subjects.",5250:5478, 3702091 ,23833584,Unavailable
 5985618 ,Mean rank of pain score,temperature-controlled radiofrequency (TC-RF) tonsil ablation - Group A,CO2-laser cryptolysis (CO2-LC) - Group B,Significantly increased,"Pain levels in Group A were greater than in Group B at all time points, and the differences between the two groups were statistically significant (P&lt;0.05).",18775:18930, 5985618 ,None,Unavailable
 5985618 ,The amount of bleeding,temperature-controlled radiofrequency (TC-RF) tonsil ablation - Group A,CO2-laser cryptolysis (CO2-LC) - Group B,Significantly increased,The amount of bleeding in the LC group was found to be significantly less than in the RF group (P&lt;0.05).,4503:4609, 5985618 ,None,Unavailable
 5985618 ,duration of procedure,temperature-controlled radiofrequency (TC-RF) tonsil ablation - Group A,CO2-laser cryptolysis (CO2-LC) - Group B,No significant difference,No significant difference was found between the groups regarding duration of procedure (P=0.157).,4609:4706, 5985618 ,None,Unavailable
 3641305 ,INH-related drug-induced liver injury,STD-treatment: approx. 5&nbsp;mg/kg of isoniazid for all),NAT2 genotype-guided treatment (PGx-treatment),Significantly increased,"The incidence of combined unfavorable events, defined by early therapeutic failure or INH-related drug-induced liver injury, was significantly lower in the combined population of rapid and slow acetylators; 17.0&nbsp;% in the PGx-treatment and 48.1&nbsp;% in the STD-treatment (relative risk; 0.354 [95%CI: 0.177, 0.707], p = 0.001 (Table&nbsp;3c)).",38739:39132, 3641305 ,23150149,Unavailable
 3641305 ,combined unfavorable events,STD-treatment: approx. 5&amp;nbsp;mg/kg of isoniazid for all),NAT2 genotype-guided treatment (PGx-treatment),Significantly increased,"the combined unfavorable events were 20.5&nbsp;% (16/78 patients) in PGx-guided therapy and 42.9&nbsp;% (33/77 patients) in the empirical therapy (relative risk; 0.479 [95%CI: 0.288, 0.795], p = 0.003) (Fig.&nbsp;2).Fig. 2",39584:39870, 3641305 ,23150149,Unavailable
 2836833 ,Fecal fat loss,1500 mg calcium,500 mg calcium,Significantly increased,Fecal fat loss expressed as percent of fat intake was significantly higher with 1500 mg (high-Ca) compared to 500 mg (low-Ca) calcium intake per day (mean: 3.0%; the 95% CI: 2.3 to 3.7%; P &lt;0.001) independent of calcium source and lactose digestion status.,4734:5007, 2836833 ,19823185,Unavailable
 2836833 ,Urinary calcium excretion,1500 mg calcium,500 mg calcium,Significantly increased,Urinary calcium excretion (Table 4) was significantly higher in high-Ca than low-Ca (128.3± 57.9 and 146.4 ± 77.9 mg/day−1; the 95% CI for difference: 3.8 to 31.1 mg/day; P = 0.014).,23974:24224, 2836833 ,19823185,Unavailable
 2836833 ,weight loss,1500 mg calcium,500 mg calcium,No significant difference,"After following an energy restricted diet for 12 weeks (Table 1), there were no significant differences in weight loss between dairy and nondairy diets (8.5 ± 2.7 and 7.2 ± 2.8 kg, P = 0.116).",24465:24713, 2836833 ,19823185,Unavailable
 2836833 ,systolic or diastolic blood pressure,1500 mg calcium,500 mg calcium,No significant difference,Diet had no significant effect on either systolic or diastolic blood pressure (Table 7).,26288:26415, 2836833 ,19823185,Unavailable
 5789501 ,range of motion and SPADI at 4-week,anatomical landmark-guided (LMG) technique,Suprascapular nerve block (SSNB) using the ultrasound guidance,No significant difference,"Both the groups showed statistically similar improvement of VAS, range of motion and SPADI at 4-week (P &gt; 0.05) follow-up.",4830:4973, 5789501 ,29416452,Unavailable
 4748460 ,"visual analogue pain score (VAS), the Knee Osteoarthritis Outcome Score (KOOS), Knee Quality of Life (KQoL) scale, maximum hopping distance and number of knee bends",photo-activated (PA) platelet-rich plasma (PRP),hyaluronic acid (HA),No significant difference,"After controlling for baseline values, there were no significant between-group differences at either time-point.",6212:6324, 4748460 ,26861957,Unavailable
 4028193 ,Depression (Beck Depression Inventory II; BDI-II),Internet-based computerized cognitive behavior therapy (iCBT) program in Manga format,control,No significant difference,No significant difference was observed in the remission based on BDI-II between the intervention and control groups: relative risk (RR) of having subthreshold depression in the intervention group were 0.79 (p = 0.22) at the 3-month follow-up and 0.77 (p = 0.20) at the 6-month follow-up;,70681:70968, 4028193 ,24844530,Unavailable
 4028193 ,Kessler's psychological distress scale (K6),Internet-based computerized cognitive behavior therapy (iCBT) program in Manga format,control,No significant difference,"The probability of the remission based on K6 was not significantly different between the groups at the 3-month follow-up (RR = 1.02, p = 0.94) and was marginally significantly higher in the intervention group than in the control group at the 6-month follow-up (RR = 0.63, p = 0.06); the NNTs were -279 at the 3-month follow-up and 12 at the 6-month follow-up.",71098:71457, 4028193 ,24844530,Unavailable
 1936417 ,satisfied with labor and delivery,group in which support was permitted,group in which there was no support,Significantly increased,"Overall, the women in the support group were more satisfied with labor (median 88.0 versus 76.0, p &lt; 0.0001) and delivery (median 91.4 versus 77.1, p &lt; 0.0001).",4525:4685, 1936417 ,17612408,Unavailable
 5732507 ,infant HIV status at 6&nbsp;weeks and at 12&nbsp;months,enhanced intervention (EI) condition of SC PMTCT plus the “Protect Your Family” intervention prevention of mother-to-child-transmission (PMTCT) of HIV,standard care (SC) condition plus time-equivalent attention-control on disease prevention,No significant difference,"There were no significant differences between SC and EI on infant HIV status at 6&nbsp;weeks and at 12&nbsp;months, and no differences in maternal adherence at 32&nbsp;weeks, reported infant adherence at 6&nbsp;weeks, or PMTCT and HIV knowledge by study condition over time.",9679:9933, 5732507 ,29248014,Unavailable
 5844532 ,improved cross-sectional area (CSA),RGTA® (OTR4131)—Equitend®,placebo,Significantly increased,"After 4 months, the number of Equitend® treated horses with an improved CSA was significantly higher than the placebo-treated horses (p = 0.03571).",19116:19274, 5844532 ,29522564,Unavailable
 5844532 ,"pre-injury performance level, racing in, and winning",RGTA® (OTR4131)—Equitend®,placebo,Significantly increased,"The Equitend® group returned to their pre-injury performance level, racing in, and winning, significantly more races than the placebo group (p = 0.01399 and 0.0421, respectively).",19275:19466, 5844532 ,29522564,Unavailable
 5844532 ,recurrence,RGTA® (OTR4131)—Equitend®,placebo,Significantly decreased,"Furthermore, recurrence was significantly higher in the placebo group than in the Equitend® group (71.4% vs 16.6%, p = 0.02442).",19466:19605, 5844532 ,29522564,Unavailable
 2699714 ,A1C level,etanercept therapy,placebo,Significantly decreased,A1C at week 24 was lower in the etanercept group (5.91 ± 0.5%) compared with that in the placebo group (6.98 ± 1.2%; P &lt; 0.05) with a higher percent decrease from baseline than in the placebo group (etanercept 0.41 ± 0.1 vs. placebo 0.18 ± 0.21; P &lt; 0.01).,5306:5600, 2699714 ,19366957,Unavailable
 2699714 ,C-peptide,etanercept therapy,placebo,Significantly increased,The percent change in C-peptide area under the curve from baseline to week 24 showed a 39% increase in the etanercept group and a 20% decrease in the placebo group (P &lt; 0.05).,5600:5795, 2699714 ,19366957,Unavailable
 2699714 ,insulin dose,etanercept therapy,placebo,Significantly decreased,From baseline to week 24 insulin dose decreased 18% in the etanercept group compared with a 23% increase in the placebo group (P &lt; 0.05).,5796:5953, 2699714 ,19366957,Unavailable
 2921405 ,diarrhea,2.4 g/day of prebiotic oligosaccharide and 1.9×107 colony forming unit (c.f.u)/day of probiotic Bifidobacterium lactis HN019,control milk,No significant difference,"Overall, there was no effect of prebiotic and probiotic on diarrhea (6% reduction, 95% Confidence Interval [CI]: −1 to 12%; p = 0.08).",6932:7066, 2921405 ,20730056,Unavailable
 2921405 ,dysentery episodes,2.4 g/day of prebiotic oligosaccharide and 1.9×107 colony forming unit (c.f.u)/day of probiotic Bifidobacterium lactis HN019,control milk,Significantly decreased,Incidence of dysentery episodes was reduced by 21% (95% CI: 0 to 38%; p = 0.05).,7067:7147, 2921405 ,20730056,Unavailable
 2921405 ,"Incidence of pneumonia, severe acute lower respiratory infection (ALRI)",2.4 g/day of prebiotic oligosaccharide and 1.9×107 colony forming unit (c.f.u)/day of probiotic Bifidobacterium lactis HN019,control milk,Significantly decreased,Incidence of pneumonia was reduced by 24% (95% CI: 0 to 42%; p = 0.05) and severe acute lower respiratory infection (ALRI) by 35% (95% CI: 0 to 58%; p = 0.05).,7147:7307, 2921405 ,20730056,Unavailable
 2921405 ,days with severe illness and high fever,2.4 g/day of prebiotic oligosaccharide and 1.9×107 colony forming unit (c.f.u)/day of probiotic Bifidobacterium lactis HN019,control milk,Significantly decreased,"Compared to children in Co group, children in PP group had 16% (95% CI: 5 to 26%, p = 0.004) and 5% (95% CI: 0 to 10%; p = 0.05) reduction in days with severe illness and high fever respectively.",7308:7503, 2921405 ,20730056,Unavailable
 4177066 ,importance of early reading aloud and of infant socialization,Early video administered  to first-time parents in modifying parental knowledge,Late video administered to first-time parents in modifying parental knowledge,Significantly increased,"In particular, a statistically significant difference between groups in favor of the early group was found for the acquisition of new knowledge regarding the importance of early reading aloud (p &lt; 0.001) and of infant socialization (p = 0.01, Fisher exact test).",25009:25271, 4177066 ,25193490,Unavailable
 4177066 ,"the acquisition of positive attitudes towards early reading aloud, early exposure to music and parental socialization",Early video administered  to first-time parents in modifying parental knowledge,Late video administered to first-time parents in modifying parental knowledge,Significantly decreased,"Conversely, a significant difference between groups in favor of the late intervention group was found for the acquisition of positive attitudes towards early reading aloud (p &lt; 0.01), early exposure to music (p &lt; 0.001) and parental socialization (p = 0.03, Fisher exact test).",25272:25549, 4177066 ,25193490,Unavailable
 3474778 ,The quality of water,high-performance water filter and jerry cans for safe storage,control,Significantly increased,"The quality of water stored in intervention households was significantly better than in control households (3 vs. 181 TTC/100 mL, respectively, p&lt;0.001).",7142:7318, 3474778 ,23082124,Unavailable
 3474778 ,Diarrhea longitudinal prevalence in children &lt;2 years,high-performance water filter and jerry cans for safe storage,control,Significantly decreased,"Diarrhea longitudinal prevalence in children &lt;2 years was 13.6% (72/530) in the control arm and 6.6% (40/608) in the intervention arm, representing a 53% reduction (longitudinal prevalence ratio, LPR = 0.47, 95% CI: 0.30–0.73, p = 0.001) (Table 3 and Figure 3).",59981:60368, 3474778 ,23082124,Unavailable
 3474778 ,For all household members,high-performance water filter and jerry cans for safe storage,control,Significantly decreased,"For all household members, diarrhea longitudinal prevalence was 3.5% (101/2906) in the control group and 1.6% (50/3168) in the intervention (LPR = 0.46, 95% CI: 0.30–0.70, p&lt;0.001).",60547:60746, 3474778 ,23082124,Unavailable
 3474778 ,Weight-for-age z-scores (WAZ),high-performance water filter and jerry cans for safe storage,control,No significant difference,"There was no evidence of a difference between the intervention and control groups in mean WAZ scores (−1.21 vs. −1.24, respectively, p = 0.92).",66637:66798, 3474778 ,23082124,Unavailable
 1065065 ,"cytokines, duration of ventilation and length of intensive care unit stay, and inspired fractional oxygen/arterial oxygen tension ratio",lornoxicam (8 mg administered intravenously every 12 hours for six doses),placebo,No significant difference,"No significant differences were found between the intravenous lornoxicam and placebo groups in major cytokines, duration of ventilation and length of intensive care unit stay, and inspired fractional oxygen/arterial oxygen tension ratio (P &gt; 0.05).",4569:4834, 1065065 ,15566594,Unavailable
 5093191 ,"6-min walk distance, leg strength, chest strength , 30-s sit-to-stand result , and reach distance",exercise&nbsp;training intervention,provide usual care,Significantly increased,"Compared to the control condition, men in the intervention significantly improved their 6-min walk distance (M diff = 49.98&nbsp;m, p adj = 0.001), leg strength (M diff = 21.82&nbsp;kg, p adj = 0.001), chest strength (M diff = 6.91&nbsp;kg, p adj = 0.001), 30-s sit-to-stand result (M diff = 3.38 reps, p adj = 0.001), and reach distance (M diff = 4.8&nbsp;cm, p adj = 0.024).",4872:5509, 5093191 ,27098346,Unavailable
 5093191 ,resting heart rate,exercise&amp;nbsp;training intervention,provide usual care,Significantly decreased,"A significant difference (unadjusted for multiplicity) in favour of men in the intervention was also found for resting heart rate (M diff = −3.76 beats/min, p = 0.034).",5509:5722, 5093191 ,27098346,Unavailable
 3672718 ,RFS (relapse free survival) and OS (overall survival),"epirubicin (E) containing chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF)","cyclophosphamide, methotrexate and fluorouracil (CMF) treatment.",No significant difference,In patients with TIMP-1 immunoreactivity there is a trend towards an increase in RFS (HR = 0.48; 95% CI: 0.24 to 0.93; Figure 2A) and OS (HR = 0.46; 95% CI: 0.21 to 1.00) in patients treated with E-CMF compared to CMF alone.,26481:26742, 3672718 ,23570501,Unavailable
 4733100 ,Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire at 12 months,"expert system-based, print-delivered physical activity intervention",control,Significantly increased,"Compared to the attention control, intervention participants had significantly increased odds of meeting the U.S. recommended guideline of ≥&nbsp;150&nbsp;min/week of at least moderate-intensity physical activity at 12&nbsp;months for the modified CHAMPS (odds ratio [OR]&nbsp;=&nbsp;2.86; 95% CI: 1.03–7.96; p&nbsp;=&nbsp;0.04)",5472:5765, 4733100 ,26844197,Unavailable
 4733100 ,Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire at 6 months,"expert system-based, print-delivered physical activity intervention",control,No significant difference,"Compared to the attention control, intervention participants had significantly increased odds of meeting the U.S. recommended guideline of ≥&nbsp;150&nbsp;min/week of at least moderate-intensity physical activity at 12&nbsp;months for the modified CHAMPS (odds ratio [OR]&nbsp;=&nbsp;2.86; 95% CI: 1.03–7.96; p&nbsp;=&nbsp;0.04) but not at 6&nbsp;months (OR&nbsp;=&nbsp;1.54; 95% CI: 0.56–4.23; p&nbsp;=&nbsp;0.40).",5472:5828, 4733100 ,26844197,Unavailable
 4733100 ,moderate-equivalent physical activity at 6&nbsp;months,"expert system-based, print-delivered physical activity intervention",control,Significantly increased,"Based on accelerometer data, intervention participants had significantly increased odds of meeting ≥&nbsp;150&nbsp;min/week of moderate-equivalent physical activity at 6&nbsp;months (OR&nbsp;=&nbsp;6.26; 95% CI: 1.26–31.22; p&nbsp;=&nbsp;0.03)",5828:6036, 4733100 ,26844197,Unavailable
 4733100 ,moderate-equivalent physical activity at 12 months,"expert system-based, print-delivered physical activity intervention",control,No significant difference,"Based on accelerometer data, intervention participants had significantly increased odds of meeting ≥&nbsp;150&nbsp;min/week of moderate-equivalent physical activity at 6&nbsp;months (OR&nbsp;=&nbsp;6.26; 95% CI: 1.26–31.22; p&nbsp;=&nbsp;0.03) and borderline significantly increased odds at 12&nbsp;months (OR&nbsp;=&nbsp;4.73; 95% CI: 0.98–22.76; p&nbsp;=&nbsp;0.053).",5827:6137, 4733100 ,26844197,Unavailable
 1065070 ,extravascular lung water (EVLW),oleic acid 0.06 ml/kg intravenously over 30 min. , Sham operation; Escherichia coli lipopolysaccharide 15 ng/kg per min intravenously for 6 hours,Significantly increased,"At the end of experiment, values for EVLWST (mean ± standard error) were 8.9 ± 0.6, 11.8 ± 1.0 and 18.2 ± 0.9 ml/kg in the sham-operated, lipopolysaccharide and oleic acid groups, respectively (P &lt; 0.05).",4367:4599, 1065070 ,15566591,Unavailable
 1065070 ,postmortem gravimetric extravascular lung water  (EVLWG),oleic acid 0.06 ml/kg intravenously over 30 min. , Sham operation; Escherichia coli lipopolysaccharide 15 ng/kg per min intravenously for 6 hours,Significantly increased,"As shown in Fig. 5, EVLWIG in the OA group increased by 4.7 ml/kg and 5.6 ml/kg relative to the LPS and the sham-operated groups, amounting to increments by 65% and 90%, respectively (P = 0.001).",18091:18351, 1065070 ,15566591,Unavailable
 5976899 ,"range of motion (ROM), kinesiophobia, depression, and quality of life (QoL)",traditional physiotherapy-Mulligan mobilization (TPMM) group,traditional physiotherapy (TP) group,Significantly increased,"When comparing effects of these two treatment programs, it was observed that the TPMM group had a better outcome (p &lt; 0.05) in terms of ROM, kinesiophobia, depression, and QoL.",4258:4454, 5976899 ,29861800,Unavailable
 5976899 ,"pain, Neck Disability Index (NDI), right/left neck rotation, left lateral flexion ROM, and mental health subcategory of SF-36",traditional physiotherapy-Mulligan mobilization (TPMM) group,traditional physiotherapy (TP) group,No significant difference,"Comparing the gains of the participants in the two groups indicated that pain, NDI, right/left neck rotation, left lateral flexion ROM, and mental health subcategory of SF-36 had similar improvement rate in both groups (p &gt; 0.05) (Table 3).",18570:18871, 5976899 ,29861800,Unavailable
 3775760 ,area under the curve (AUC) for Rev,12 mg Opal-HIV-Gag(c) group,placebo,No significant difference,"There was an apparent response in area under the curve (AUC) for Rev (p = 0.012 before correction for multiple tests) for the 12 mg Opal-HIV-Gag(c) group compared with pooled placebo participants (n = 8) (data not shown; these data are described more fully in a separate manuscript), but this was not significant after Bonferroni correction for multiple tests.",28804:29164, 3775760 ,24069230,Unavailable
 4644318 ,Effective pain relief,"fluoroscopically guided epidural injection, through the Parasagittal interlaminar (PIL)","fluoroscopically guided epidural injection, through including transforaminal (TF)",No significant difference,"Effective pain relief [numeric rating scale (NRS) &lt; 3] was observed in 77.3% (95% CI: 67‒90.5%) of patients in PIL group and 74.2% (95% CI: 62.4 - 89.4%) of patients in the TF group (P = 0.34), at 4 weeks.",5300:5505, 4644318 ,26587400,Unavailable
 4644318 ,effective pain relief [numerical rating scale (NRS),"fluoroscopically guided epidural injection, through the Parasagittal interlaminar (PIL)","fluoroscopically guided epidural injection, through including transforaminal (TF)",No significant difference,"Mean NRS score was not significantly different between the PIL group compared to the TF group, at 4 weeks (P = 0.19).",5505:5623, 4644318 ,26587400,Unavailable
 4644318 ,Number of patients with improved disability,"fluoroscopically guided epidural injection, through the Parasagittal interlaminar (PIL)","fluoroscopically guided epidural injection, through including transforaminal (TF)",No significant difference,"Number of patients with improved disability (measured by ODI &lt; 20%) was not significantly different in PIL group (78% of cases) compared to the TF group (76% of cases), at 4 weeks (P = 0.21).",5624:5816, 4644318 ,26587400,Unavailable
 4644318 ,adverse effects,"fluoroscopically guided epidural injection, through the Parasagittal interlaminar (PIL)","fluoroscopically guided epidural injection, through including transforaminal (TF)",No significant difference,There were no adverse effects observed in any of our patients.,5815:5878, 4644318 ,26587400,Unavailable
 5891985 ,fasting total cholesterol (TC) and low density lipoprotein cholesterin (LDL-C),liraglutide,metformin,No significant difference,"However, in the present study, there were no significant differences between 120&nbsp;min values and fasting values in ΔTC and ΔLDL-C with respect to metformin treatment. Furthermore, no significant differences were found in plasma lipids and lipoprotein after liraglutide treatment compared with the basal values (shown in Additional file 1: Table S1).",25148:25539, 5891985 ,29636047,Unavailable
 5891985 ,"waist circumference, and body weight ,  BMI",liraglutide,metformin,No significant difference,"Metformin treatment also showed a slight downtrend in BW and BMI, although the difference was not significant (shown in Additional file 1: Table S2).",25853:26046, 5891985 ,29636047,Unavailable
 5891985 ,plasma insulin level (area under the curve (AUCins),liraglutide,metformin,No significant difference,"The differences in AUCins (ΔAUCins) before and after liraglutide treatment (738 [451, 1118] vs 594 [357, 1216]&nbsp;mIU/L, P = 0.014) were remarkably enhanced compared to that in metformin therapy, but differences in ΔI30/ΔG30 before and after liraglutide treatment (6.01 [1.79, 28.46] vs − 2.62 [− 14.85, 8.76], P = 0.065) were not significant between the two groups (Table&nbsp;2).",26712:27127, 5891985 ,29636047,Unavailable
 5891985 ,non-esterified fatty acids (NEFA),liraglutide,metformin,No significant difference,There were no significant changes in fasting non-esterified free fatty acids after liraglutide and metformin treatment.Fig.&nbsp;1,29912:30059, 5891985 ,29636047,Unavailable
 5891985 ,soluble vascular cell adhesion molecule-1 (sVCAM-1) levels,liraglutide,metformin,Significantly decreased,"Compared to metformin therapy, the levels of sVCAM-1 were remarkably suppressed after 8-week liraglutide treatment (382 ± 131 vs 503 ± 182&nbsp;ng/ml, P = 0.046) (Fig.&nbsp;2, Table&nbsp;2).",30738:31010, 5891985 ,29636047,Unavailable
 4590915 ,"total urine volume (TUV), and glomerular filtration rate (GFR)","Group II (Rhubarb) received conservative management along with Rhubarb capsule (350 mg, thrice daily)",Group I (Control) was given conservative management,Significantly decreased,"As compared to control group, Rhubarb group showed significant (P &lt; 0.05) reduction in both systolic and diastolic blood pressure after 12 weeks of treatment (Table 1).",14432:14661, 4590915 ,26464863,Unavailable
 4590915 ,serum potassium,"Group II (Rhubarb) received conservative management along with Rhubarb capsule (350 mg, thrice daily)",Group I (Control) was given conservative management,Significantly decreased,There was decrease in serum potassium in both the groups which was significant (P &lt; 0.05) in Rhubarb group as compared to control.,15317:15467, 4590915 ,26464863,Unavailable
 4590915 ,"serum calcium, TUV, GFR","Group II (Rhubarb) received conservative management along with Rhubarb capsule (350 mg, thrice daily)",Group I (Control) was given conservative management,Significantly increased,"There was significant increase in serum calcium (P &lt; 0.01), decrease in TUP (P &lt; 0.05), increase in TUV (P &lt; 0.001), and increase in GFR (P &lt; 0.001) after 12 weeks of treatment in Rhubarb group as compared to control group (Table 2).",15468:15825, 4590915 ,26464863,Unavailable
 4590915 ,total urine protein (TUP),"Group II (Rhubarb) received conservative management along with Rhubarb capsule (350 mg, thrice daily)",Group I (Control) was given conservative management,Significantly decreased,"There was significant increase in serum calcium (P &lt; 0.01), decrease in TUP (P &lt; 0.05), increase in TUV (P &lt; 0.001), and increase in GFR (P &lt; 0.001) after 12 weeks of treatment in Rhubarb group as compared to control group (Table 2).",15468:15825, 4590915 ,26464863,Unavailable
 3661555 ,Return-to-work rates,work support intervention aimed at enhancing return-to-work,usual care,No significant difference,Return-to-work rates were 86% and 83% (p = 0.6) for the intervention group and control group when excluding 8 patients who died or with a life expectancy of months at follow-up.,7509:7686, 3661555 ,23717406,Unavailable
 3661555 ,Median time from initial sick leave to partial return-to-work,work support intervention aimed at enhancing return-to-work,usual care,No significant difference,Median time from initial sick leave to partial return-to-work was 194 days (range 14–435) versus 192 days (range 82–465) (p = 0.90) with a hazard ratio of 1.03 (95% CI 0.64–1.6).,7687:7865, 3661555 ,23717406,Unavailable
 3661555 ,Quality of life and work ability,work support intervention aimed at enhancing return-to-work,usual care,No significant difference,Quality of life and work ability improved statistically over time but did not differ statistically between groups.,7866:7981, 3661555 ,23717406,Unavailable
 3661555 ,Work functioning and costs,work support intervention aimed at enhancing return-to-work,usual care,No significant difference,Work functioning and costs did not differ statistically between groups.,7981:8052, 3661555 ,23717406,Unavailable
 5435086 ,the number of high use days without medical review within 48 h,budesonide/formoterol inhaler,budesonide/formoterol with salbutamol,Significantly decreased,"In the SMART regimen, the number of high use days without medical review within 48 h was approximately half of that in the Standard regimen; relative rate (95% CI) 0·49 (0·31 to 0·75), P = 0·001 (Fig.&nbsp;1, Table&nbsp;2a).",23854:24166, 5435086 ,28496190,Unavailable
 5435086 ,relative rate,budesonide/formoterol inhaler,budesonide/formoterol with salbutamol,Significantly increased,"There was a total of 35 and 66 severe exacerbations in the SMART and Standard groups respectively; relative rate (95% CI) 0·54 (0·36 to 0·82), P = 0·004",25931:26100, 5435086 ,28496190,Unavailable
 5244530 ,"depression severity reduction, remission rate, change in quality of life, psychological well-being, sedative prescriptions, sick leave",person-centred  general practitioners (GP) consultations,treatment as usual (TAU),No significant difference,"There were no significant differences between the intervention and control group in depression severity reduction or remission rate, change in quality of life, psychological well-being, sedative prescriptions, or sick leave during the whole 12-month follow-up.",8377:8637, 5244530 ,28103816,Unavailable
 5244530 ,continued antidepressants until the 6&nbsp;month,person-centred  general practitioners (GP) consultations,treatment as usual (TAU),Significantly increased,"However, significantly more patients in the intervention group continued antidepressants until the 6&nbsp;month follow-up (86/125 vs 78/133, p &lt; 0.05).",8638:8801, 5244530 ,28103816,Unavailable
 3364614 ,LF/HF ratio,blue laser light,control reasons the laser,No significant difference,"The evaluation parameter LF/HF ratio (low frequency/high frequency ratio) from the HRV spectral analysis showed a very slight increase during stimulation, however it was not significant.",17956:18286, 3364614 ,22666700,Unavailable
 3717757 ,HR genotype persistence,HPV-16/18 vaccine,placebo (Al(OH)3 control),No significant difference,"HR genotype persistence was 30.4% (7/23) and 27.0% (17/63) in the control and vaccine arms, respectively (p=0.75).",44168:44282, 3717757 ,23486859,Unavailable
 3717757 ,LR genotype persistent,HPV-16/18 vaccine,placebo (Al(OH)3 control),No significant difference,"LR genotype persistent infections were non-significantly higher in the control (36.4%, 12/33) compared with the vaccine arm (22.1%, 15/68; p=0.13).",44283:44430, 3717757 ,23486859,Unavailable
 3724383 ,stool frequency,"synbiotic (Lactol®, composed of Lactobacillus Sporogenes, 1 Tab/20 kg/d) plus mineral oil (Paraffin 1 ml/kg/d)",mineral oil alone,Significantly increased,"After the treatment, stool frequency increased in both groups (P &lt; 0.001), with greater increase in synbiotic + mineral oil group (P = 0.001).",4553:4732, 3724383 ,23914206,Unavailable
 3724383 ,"Straining at defecation, incomplete evacuation, and soiling","synbiotic (Lactol®, composed of Lactobacillus Sporogenes, 1 Tab/20 kg/d) plus mineral oil (Paraffin 1 ml/kg/d)",mineral oil alone,Significantly decreased,"Straining at defecation, incomplete evacuation, and soiling decreased in both groups (P &lt; 0.001), but more decrease was seen in the synbiotic + mineral oil group (P &lt; 0.05).",4868:5081, 3724383 ,23914206,Unavailable
 3724383 ,better global improvement,"synbiotic (Lactol®, composed of Lactobacillus Sporogenes, 1 Tab/20 kg/d) plus mineral oil (Paraffin 1 ml/kg/d)",mineral oil alone,Significantly increased,"Finally, there was a better global improvement in the synbiotic + mineral oil group (P &lt; 0.05).",5082:5198, 3724383 ,23914206,Unavailable
 3724383 ,severe side-effects,"synbiotic (Lactol®, composed of Lactobacillus Sporogenes, 1 Tab/20 kg/d) plus mineral oil (Paraffin 1 ml/kg/d)",mineral oil alone,No significant difference,No severe side-effects were observed in any group.,5198:5248, 3724383 ,23914206,Unavailable
 4218764 ,The cumulative sufentanil consumption,"10-mL bolus of 0.2% ropivacaine before emergence, followed by a continuous infusion of 6 mL/h for 24 hours (PVB group)",saline at the same scheme of administration,Significantly decreased,The cumulative sufentanil consumption in the PVB group (54.3 ± 12.1 μg) at 24 postoperative hours was more than 20% less than that of the control group (68.1 ± 9.9 μg) (P &lt; 0.001).,5891:6132, 4218764 ,25304475,Unavailable
 4218764 ,pain scores (numerical rating scale),"10-mL bolus of 0.2% ropivacaine before emergence, followed by a continuous infusion of 6 mL/h for 24 hours (PVB group)",saline at the same scheme of administration,Significantly decreased,"There was also a significant difference in pain scores (numerical rating scale) between groups, where the PVB group had lower scores than did the control group at rest and with coughing for the first 24 hours (P &lt; 0.001).",5891:6132, 4218764 ,25304475,Unavailable
 3664327 ,"effect on empathic concern,  personal distress ratings",empathy scenario and recorded self-reports of empathic reactions to the scenario,computerized implicit perspective taking task,No significant difference,"The MANOVA showed that OT (vs. placebo) had no effect on empathic concern, F(1, 90) = 0.16, p = 0.69, or personal distress ratings, F(1, 90) = 0, p = 0.99.",34285:34531, 3664327 ,23754995,Unavailable
 4210722 ,vaccination certificates were submitted, a separate reminder card 4 days before the appointment (IG3),no further reminder (IG1); reminder card together with the appointment letter (IG2);,Significantly increased,"In Hamburg, significantly more vaccination certificates were submitted by the group which received the reminder card separately 4 days before the examination (IG3) compared to IG1 and IG2 (p = 0.04).",6454:6670, 4210722 ,25293888,Unavailable
 4210722 ,use of a reminder card, a separate reminder card 4 days before the appointment (IG3); reminder card together with the appointment letter (IG2);,no further reminder (IG1); ,No significant difference,"Overall, the use of a reminder card had a positive but not significant effect as 89 % (185/209) of participants who received the reminder card submitted vaccination data versus 81 % (84/104) of participants who did not receive any reminder card (p = 0.06).",6818:7091, 4210722 ,25293888,Unavailable
 3634264 ,flow mediated dilation,1500 mg/dialysis interval (every other day) oral L-carnitine,placebo,No significant difference,"This study showed that after one month of L-carnitine or placebo therapy there was no significant improvement in flow mediated dilation (p = 0.80 and p = 0.59, respectively)",4849:5022, 3634264 ,23626603,Unavailable
 3634264 ,carotid intima-media thickness,1500 mg/dialysis interval (every other day) oral L-carnitine,placebo,No significant difference,"decrease in carotid intima-media thickness (p = 0.12 and p = 0.50, respectively).",5026:5107, 3634264 ,23626603,Unavailable
 5988794 ,"SF-12(12-item Short Form Health Survey), EQ-5D-5L scores at 6 or 12 months",hip arthroscopy,personalised hip therapy,No significant difference,There were no significant between-group differences in SF-12 or EQ-5D-5L scores at 6 or 12 months after randomisation (table 2).Figure 2,55476:55675, 5988794 ,None,Unavailable
 5988794 ,International Hip Outcome Tool (iHOT-33),hip arthroscopy,personalised hip therapy,No significant difference,In a post-hoc analysis there was no significant difference in iHOT-33 at 12 months for patients in the hip arthroscopy group who were treated within 6 months of randomisation versus those treated 6 months or more after randomisation (0·9 [95% CI −10·7 to 8·8]).,64848:65110, 5988794 ,None,Unavailable
 5822859 ,FO pulsatility index (FOPI)," group II (adequate growth and maternal hypertension),", and group III (normal controls); group I (IUGR);,Significantly increased,"Mean FOPI in IUGR fetuses (n = 15) was 3.70 ± 0.99 (3.15–4.26); in the group II (n = 12), it was 2.84 ± 0.69 (2.40–3.28), and in the group III (n = 13), it was 2.77 ± 0.44 (2.50–3.04) (p=0.004).",6511:6773, 5822859 ,29581724,Unavailable
 4745915 ,cortisol concentration,12-week combined exercise program,sedentary control group,No significant difference,"Although no difference in the cortisol concentration between the patient groups in the course of the 12-week time period could be detected, cortisol levels significantly increased in the trained group after the 12-week combined exercise program (P = 0.047, Table 2), while no change was observed in the sedentary control group.",31250:31635, 4745915 ,26903712,Unavailable
 4745915 ,absolute number of CD80+ and CD86+ cDC,12-week combined exercise program,sedentary control group,No significant difference,"In addition, no differences in the course of the 12-week time period could be detected between the patient groups for the absolute number of CD80+ and CD86+ cDC, although CD86+ cDC significantly decreased after 12 weeks in the sedentary control group (P = 0.022; Figure 2(d)).",35077:35442, 4745915 ,26903712,Unavailable
 4745915 ,"absolute number of CD62L+, CCR5+, and CCR7+ cDC",12-week combined exercise program,sedentary control group,No significant difference,"No differences regarding the absolute number of CD62L+, CCR5+, and CCR7+ cDC could be detected between the groups in the course of the 12-week time period,",36266:36456, 4745915 ,26903712,Unavailable
 4745915 ,"CCR5+ and CD86+ pDC, secreted amount of IL-6, IL-12p70, TNF-α, IFN-α, caspase-1, and MMP-9",12-week combined exercise program,sedentary control group,No significant difference,"No significant differences could be detected for the fold change of CCR5+ and CD86+ pDC nor for the secreted amount of IL-6, IL-12p70, TNF-α, IFN-α, caspase-1, and MMP-9 upon IQ stimulation between trained and sedentary MS patients after 12 weeks (Tables 3 and 4).",39658:40060, 4745915 ,26903712,Unavailable
 5777424 ,tooth sensitivity risk,Etodolac (400 mg),placebo,No significant difference,The treatment that patients received prior to the bleaching procedure did not affect the risk to sensitivity at any of the moments of evaluation (during and immediately after: p=1.0; after 24 hours: p=0.683).,26881:27089, 5777424 ,29412363,Unavailable
 5777424 ,bleaching effectiveness,Etodolac (400 mg),placebo,No significant difference,"In regards to bleaching effectiveness, the bleaching procedure carried out in this study was able to significantly reduce the shade scores from the bleach guide, while the second session resulted in additional bleaching effect (Figure 4). The sequence of treatment did not affect bleaching effectiveness.",35220:35561, 5777424 ,29412363,Unavailable
 3682309 ,"Duration RRT prescribed, hrs",continuous venovenous hemofiltration [CVVH],continuous venovenous hemodialysis [CVVHD],No significant difference,"Duration RRT prescribed, hrs	146 ± 240	145 ± 156	0.88",30348:30464, 3682309 ,23095370,Unavailable
 3682309 ,Duration RRT received,continuous venovenous hemofiltration [CVVH],continuous venovenous hemodialysis [CVVHD],No significant difference,"Duration RRT received, hrs	130 ± 222	128 ± 142	0.87",30495:30609, 3682309 ,23095370,Unavailable
 3682309 ,Mean RRT dose,continuous venovenous hemofiltration [CVVH],continuous venovenous hemodialysis [CVVHD],No significant difference,"Mean RRT dose, mL/kg/hr	33.6 ± 7.4	34.7 ± 4.4	0.50",31104:31217, 3682309 ,23095370,Unavailable
 3682309 ,"Prescribed dose delivered, %",continuous venovenous hemofiltration [CVVH],continuous venovenous hemodialysis [CVVHD],No significant difference,"Prescribed dose delivered, %	84.7 ± 16.3	87.8 ± 13.7	0.73",31248:31368, 3682309 ,23095370,Unavailable
 3682309 ,"Net ultrafiltration, L/day",continuous venovenous hemofiltration [CVVH],continuous venovenous hemodialysis [CVVHD],No significant difference,"Net ultrafiltration, L/day	1.7 ± 2.2	0.8 ± 4.1	0.98",31399:31513, 3682309 ,23095370,Unavailable
 3751568 ,child-reported maximal knee pain,physiotherapist-prescribed exercise programme,no treatment,Significantly decreased,"Significant improvements in child-reported maximal knee pain were found following treatment, regardless of group allocation with a mean 14.5 mm reduction on the visual analogue scale (95% CI 5.2 – 23.8 mm, p=0.003).",5809:6025, 3751568 ,23941143,Unavailable
 3751568 ,"overall psychosocial health, specifically self-esteem, mental health and behaviour",physiotherapist-prescribed exercise programme,no treatment,Significantly increased,"Significant differences between treatment groups were noted for parent-reported overall psychosocial health (p=0.009), specifically self-esteem (p=0.034), mental health (p=0.001) and behaviour (p=0.019), in favour of exercising into the hypermobile range (n=11) compared to neutral only (n=14).",6024:6319, 3751568 ,23941143,Unavailable
 3751568 ,adverse events,physiotherapist-prescribed exercise programme,no treatment,No significant difference,No other differences were found between groups and no adverse events occurred.,6432:6511, 3751568 ,23941143,Unavailable
 1849920 ,number of restored surfaces,amalgam group,composite group (0.9 vs. 0.6 μg/g creatinine),No significant difference,"At the end of the follow-up period, the number of restored surfaces in place ranged from 0 to 36 in both treatment groups, and the mean values did not differ significantly (p = 0.16).",21128:21330, 1849920 ,17431496,Unavailable
 1849920 ,cumulative number of restored surfaces,amalgam group,composite group (0.9 vs. 0.6 μg/g creatinine),No significant difference,The amalgam and composite groups also did not differ significantly in the cumulative number of restored surfaces over the trial (p = 0.10).,21330:21486, 1849920 ,17431496,Unavailable
 1849920 ,mean urinary mercury concentration,amalgam group 0.9 ,composite group 0.6 μg/g ,No significant difference,"At the end of the 5-year follow-up period, the mean urinary mercury concentration was significantly greater among children in the amalgam group (0.9; range, 0.1–5.7 μg/g creatinine) than among children in the composite group (0.6; range, 0.1–2.9 μg/g creatinine) (p &lt; 0.001).",21561:21853, 1849920 ,17431496,Unavailable
 3646875 ,similarity of the students’ ontology artefacts compared with gold standard ontologies developed by the authors before the experiment; secondary outcome was the intra-group similarity of group members’ ontologies,training on different topics in ontology development,untrained group,No significant difference,the ontologies developed after specific training were only slightly but not significantly closer to the gold standard ontologies than the ontologies developed without prior specific training;,7568:7759, 3646875 ,23667440,Unavailable
 5769202 ,"refractive errors, visual acuity",Bates eye exercise therapy,Trataka Yoga Kriya,No significant difference,Results obtained revealed that both Bates exercises and Trataka Yoga Kriya were not significantly effective in reducing refractive errors and in improving visual acuity (P value of refractive error in right eye: 0.4250; left eye: 0.4596; P value of visual acuity in right eye: 0.5691; left eye: 0.8952).,5002:5357, 5769202 ,29343934,Unavailable
 5850179 ,major adverse cardiovascular event,morphine,no‐morphine,No significant difference,"There was no significant difference in major adverse cardiovascular events between patients who received morphine compared with those who did not (26.2% versus 22.0%, respectively; P=0.15).",20034:20240, 5850179 ,29440010,Unavailable
 5850179 ,The all‐cause mortality,morphine,no‐morphine,No significant difference,The all‐cause mortality was 5.3% in the morphine group versus 5.8% in the no‐morphine group (P=0.89).,20241:20359, 5850179 ,29440010,Unavailable
 5850179 ,infarct size,morphine,no‐morphine,No significant difference,There was no difference between groups in infarct size as assessed by the creatine kinase peak after primary percutaneous coronary intervention (4023±118 versus 3903±149&nbsp;IU/L; P=0.52).,20360:20561, 5850179 ,29440010,Unavailable
 4990415 ,weight and BMI,Group Support Lifestyle Modification (GSLiM),dietary counseling,No significant difference,"During follow up, there was an insignificant increase in weight and BMI.",129318:129391, 4990415 ,27537687,Unavailable
 4990415 ,"Systolic blood pressure, Diastolic blood pressure",Group Support Lifestyle Modification (GSLiM),dietary counseling,No significant difference,"Table 6 summarises obesity and cardiovascular measures from baseline to 12th week, 13th to 24th week, baseline to 24th week and from 25th week to 36th week. No other significant mean difference between groups observed at any of the time intervals.",68403:68724, 4990415 ,27537687,Unavailable
 4990415 ,Negative emotions,Group Support Lifestyle Modification (GSLiM),dietary counseling,Significantly decreased,"Negative emotions, mean (sd) 2.02 (0.57)b 0.07 (0.47) 1.51 (0.004, 3.02)c 0.020 0.049",96378:97072, 4990415 ,27537687,Unavailable
 4990415 ,Physical Discomfort,Group Support Lifestyle Modification (GSLiM),dietary counseling,Significantly decreased,"Physical Discomfort, mean (sd)	1.41 (0.48)c	0.36 (0.44)	1.31 (0.05, 2.56)c	0.022	0.041",96378:97072, 4990415 ,27537687,Unavailable
 4990415 ,Total WEL score,Group Support Lifestyle Modification (GSLiM),dietary counseling,Significantly increased,"Total WEL score	-1.77 (1.45)	0.45 (1.19)	8.76 (3.05, 17.47)b	0.045	0.003",106013:106576, 4990415 ,27537687,Unavailable
 1174954 ,"Western Ontario and McMaster Universities (WOMAC) OA index, particularly of physical function, patient global assessment ",risedronate 15 mg,placebo,Significantly increased,"Those receiving risedronate at 15 mg showed improvement of the WOMAC index, particularly of physical function, significant improvement of the patient global assessment (P &lt; 0.001)",5630:5957, 1174954 ,15899049,Unavailable
 1174954 ,joint-space width,risedronate 5 mg ,risedronate 15 mg,No significant difference,Eight percent (n = 7) of patients receiving placebo and 4% (n = 4) of patients receiving 5 mg risedronate exhibited detectable progression of disease (joint-space width ≥ 25% or ≥ 0.75 mm) versus 1% (n = 1) of patients receiving 15 mg risedronate (P = 0.067).,5630:5957, 1174954 ,15899049,Unavailable
 1174954 ,cartilage degradation and bone resorption,"risedronate 5 mg, risedronate 15 mg",placebo,No significant difference,"At 1 year, the mean decreases in the groups receiving risedronate at 15 mg and 5 mg were 29.1% ± 2.6 and 19.5% ± 2.5, respectively, compared with a mean decrease of 2.7% ± 2.5 in the placebo group (P &lt; 0.001).",26626:26855, 1174954 ,15899049,Unavailable
 5096778 ,the number of capsules returned,ibudilast (40 mg twice daily),placebo,No significant difference,There was no treatment group difference (P=0.6) with the number of capsules returned (placebo vs ibudilast [mean {SD}: 2.4 {2.4} vs 7.7 {15.6}]).,23016:23178, 5096778 ,27826212,Unavailable
 5096778 , frequency of moderate to severe headaches 5-8 weeks,ibudilast (40 mg twice daily),placebo,Significantly decreased,"However, irrespective of treatments, in treatment weeks 5–8 of each block, there was a significant reduction (P=0.02) in the frequency of moderate to severe headaches (Figure 3).",24212:24454, 5096778 ,27826212,Unavailable
 5096778 ,headache index,ibudilast (40 mg twice daily),placebo,Significantly decreased,"However, in treatment weeks 5–8, there was a significant reduction in the headache index (P=0.003) (Figure 4).",24781:24955, 5096778 ,27826212,Unavailable
 5096778 ,frequency intake of symptomatic medication,ibudilast (40 mg twice daily),placebo,No significant difference,"however, no treatment differences were detected (P=1) in either treatment weeks 1–4 (mean difference −0.5, 95% CI −11.2 to 10.2) or treatment weeks 5–8 (mean difference 0.5, 95% CI −10.2 to 11.2) (Figure 5B).",25476:25748, 5096778 ,27826212,Unavailable
 5739620 ,time to the onset of skin toxicity,erythromycin ointment 2% followed by doxycycline,r doxycycline 100 mg b.i.d.,No significant difference,"n the doxycycline arm median time was 43 days (day one of cycle 4), in the erythromycin arm median time was 29 days (day one of cycle 3) without statistical significance in the corresponding logrank test (P =.68).",23301:23548, 5739620 ,29285233,Unavailable
 5739620 ,appearance of a moderate to severe skin toxicity,erythromycin ointment 2% followed by doxycycline,r doxycycline 100 mg b.i.d.,No significant difference,An obvious difference between both arms appeared on day 15 (day one of cycle 2) and this remained discernible thereafter indicating a clear trend towards superior efficacy of the standard arm using doxycycline (P =.069).,26995:27249, 5739620 ,29285233,Unavailable
 5739620 ,adverse events,erythromycin ointment 2% followed by doxycycline,r doxycycline 100 mg b.i.d.,No significant difference,"Eleven out of 41 patients (26.8%) treated within the doxycycline arm, and 7/39 patients (17.9%) in the erythromycin arm reported SAE (P =.34).",41359:41535, 5739620 ,29285233,Unavailable
 5878866 ,The mean pain intensity score,transcutaneous electrical nerve stimulation (TENS),50 mg of fentanyl,No significant difference,The mean pain intensity score was 9.02 ± 1.32 in the TENS group and 8.95 ± 1.33 in the fentanyl group at baseline (P = 0.80).,6055:6197, 5878866 ,29743962,Unavailable
 5878866 ,overall pain scores,transcutaneous electrical nerve stimulation (TENS),50 mg of fentanyl,No significant difference,"Repeated measures analysis of variance indicated that there was no significant difference on overall pain scores between the two treatment groups adjusted for age, BMI, total analgesia used, and baseline pain score (F (1, 74) = 1.44, P = 0.23).",6198:6476, 5878866 ,29743962,Unavailable
 5878866 ,The use of analgesic drugs,transcutaneous electrical nerve stimulation (TENS),50 mg of fentanyl,Significantly decreased,The use of analgesic drugs in the TENS group was significantly higher than the fentanyl group (P = 0.01).,6477:6600, 5878866 ,29743962,Unavailable
 5878866 ,nausea/vomiting,transcutaneous electrical nerve stimulation (TENS),50 mg of fentanyl,No significant difference,"In addition, we found that nine patients (22.5%) complained of nausea/vomiting in the TENS group compared to thirteen patients (32.5%) in the fentanyl group (P = 0.31).",6600:6785, 5878866 ,29743962,Unavailable
 2797957 ,mean change TPS,Sativex,placebo,No significant difference,There was no significant difference in mean change TPS between Sativex and placebo (P = 0.40; SEM 9.5; 95% CI −11.3 to 27.8) at end point.,8406:8562, 2797957 ,19808912,Unavailable
 2797957 ,"mean change in superficial , deep, and muscular  pain",Sativex,placebo,No significant difference,"Similarly, there was no difference in mean change in superficial (P = 0.72; 9.1; −15.3 to 21.93), deep (P = 0.38; 10.5; −12.2 to 30.8), and muscular (P = 0.26; 10.3; −9.15 to 33.0) pain VAS. Differences in NPS did not reach statistical significance (P = 0.62; 7.8; −20.1 to 12.1).",8562:8910, 2797957 ,19808912,Unavailable
 2797957 ,"sensory scale, affective scale, and present pain intensity",Sativex,placebo,No significant difference,"The McGill pain questionnaire showed no difference in sensory scale (P = 0.65; SEM 3.3; 95% CI −5.39 to 8.44), affective scale (P = 0.81; 1.3; −3.0 to 2.4), VAS (P = 0.24; 1.0; −0.91 to 3.4), and present pain intensity (P = 0.57; 0.53; −0.79 to 1.4) between study cohorts.",21487:21827, 2797957 ,19808912,Unavailable
 4390525 ,saphenous nerve lesion,"G1-group after proximal stripping without invagination, G2-group after proximal stripping with invagination","G3-group after distal stripping without invagination, G4-group after distal stripping with invagination",No significant difference,Best results of treatment were observed in group G4 (distal stripping with vein invagination) where no statistically significant consequences of nerve injury were detected.,20027:20200, 4390525 ,24906907,Unavailable
 4390525 ,saphenous nerve sensory perception abnormalities,G1-group after proximal stripping without invagination, G4-group after distal stripping with invagination,Significantly increased,The best results of saphenous nerve regeneration were observed in G4 (one out of 20 patients – 5% in both IC–SD and FvF studies) and the worst in G1 (seven out of 20 patients – 35% in IC–SD examinations and nine out of 20 patients – 45% in FvF studies) groups.,30321:30581, 4390525 ,24906907,Unavailable
 4627615 ,25(OH)D concentration,buccal spray;,control,Significantly increased,"When control group in healthy subjects was compared with their corresponding treatment groups, it was found that the difference of mean between control group and buccal spray group was 7.47 (95&nbsp;% CI, 5.27, 9.67) which was significant (p &lt; 0.05)",28085:28329, 4627615 ,26514332,Unavailable
 4627615 ,25(OH)D concentration, soft gelatin capsule,control,Significantly increased,"and the same between control group and soft gelatin capsule group was 3.53 (95&nbsp;% CI, 1.79, 5.28) which was also statistically significant (p &lt; 0.05).",28330:28481, 4627615 ,26514332,Unavailable
 4627615 ,adverse event, soft gelatin capsule,control,No significant difference,No adverse event reported after administration of the buccal spray or soft gelatin capsule formulations of vitamin D3 during entire study period in healthy or patients with malabsorption disease and hence the product is considered safe.,36743:36990, 4627615 ,26514332,Unavailable
 4736250 ,self-reported moderate intensity MET,screened for metabolic syndrome,control group,Significantly increased,"After controlling for potential confounders, the intervention group achieved a marginally significant improvement in the self-reported moderate intensity MET minutes per week (p = 0.049) relative to the control group.",28906:29141, 4736250 ,26830197,Unavailable
 4736250 ,"fibre intake score, fat intake score, fruit intake, and vegetable intake",screened for metabolic syndrome,control group,Significantly increased,"Significant differences were observed between groups at post-test for the fibre intake score (p = 0.004), fat intake score (p &lt; 0.001), fruit intake (p = 0.001), and vegetable intake (p &lt; 0.001).",34571:34837, 4736250 ,26830197,Unavailable
 5753932 ,maximum voluntary contraction force; stabilized body temperature,body-weight supported treadmill cool (16°C),body-weight supported treadmill room (21°C),Significantly increased,Exercise in cooler room temperature increased maximum voluntary contraction force (p = 0.010) and stabilized body temperature (p = 0.011) compared to standard room temperature.,5926:6137, 5753932 ,29318030,Unavailable
 4105274 ,knee flexion range of motion,With gabapentin,Without gabapentin,No significant difference,"The lower and upper 95% CIs were −11 and 0.25, P-value was 0.068, and the difference between the two treatment arms was not statistically significant.",25904:26072, 4105274 ,25053894,Unavailable
 4889182 ,number of page views in the social media group,social media exposure,no social media exposure (control),No significant difference,"Examining 7‐day page views (Table&nbsp;3), there was similarly no difference in number of page views in the social media group (330.5) compared with the control group (268; P=0.17).",34447:34699, 4889182 ,27121850,Unavailable
 3398966 ,Mortality,the HQP model of community-based nurse care management.,the usual care afforded to traditional Medicare beneficiaries,Significantly decreased,"Overall, 86 (9.9%) intervention participants and 111 (12.9%) control participants died during the study period, representing a 25% lower relative risk of death (unadjusted hazard ratio [HR] 0.75 [95% CI 0.57–1.00], p = 0.047) among the intervention group.",84919:85192, 3398966 ,22815653,Unavailable
